course_id,course_code,course_name,test_id,ques_id,sequence,question_text,question_answer_id,answer_sequence,answer_text,correct
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59829,0,This low-level disinfectant is incompatible with soap,198497,0,"a.	Alcohol",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59829,0,This low-level disinfectant is incompatible with soap,198498,1,"b.	Phenol",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59829,0,This low-level disinfectant is incompatible with soap,198499,2,"c.	Quaternary ammonium compounds",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59829,0,This low-level disinfectant is incompatible with soap,198500,3,"d.	Ortho-phthalaldehyde",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59830,1,"When using glutaraldehyde, technicians should always wear latex gloves for protection",198501,0,TRUE,0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59830,1,"When using glutaraldehyde, technicians should always wear latex gloves for protection",198502,1,FALSE,1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59831,2,When using high-level disinfectants it is important to remember they may be deactivated by,198503,0,"a.	Alkylation",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59831,2,When using high-level disinfectants it is important to remember they may be deactivated by,198504,1,"b.	Organic matter",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59831,2,When using high-level disinfectants it is important to remember they may be deactivated by,198505,2,"c.	Oxidation",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59831,2,When using high-level disinfectants it is important to remember they may be deactivated by,198506,3,"d.	All the above",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59832,3,In an automated washer the key source of disinfection is,198507,0,"a.	Hydrogen peroxide",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59832,3,In an automated washer the key source of disinfection is,198508,1,"b.	Water temperature",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59832,3,In an automated washer the key source of disinfection is,198509,2,"c.	Heat",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59832,3,In an automated washer the key source of disinfection is,198510,3,"d.	Disinfecting detergent",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59833,4,The use of test strips to test the minimum effective concentration in high-level disinfection solutions is required,198511,0,"a.	Weekly, preferably daily",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59833,4,The use of test strips to test the minimum effective concentration in high-level disinfection solutions is required,198512,1,"b.	Daily",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59833,4,The use of test strips to test the minimum effective concentration in high-level disinfection solutions is required,198513,2,"c.	Each time the solution will be used",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59833,4,The use of test strips to test the minimum effective concentration in high-level disinfection solutions is required,198514,3,"d.	Only when manual soaking systems are used",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59834,5,"The use of heat to kill all microorganisms, except spores, is called",198515,0,"a.	Sterilization",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59834,5,"The use of heat to kill all microorganisms, except spores, is called",198516,1,"b.	Thermal disinfection",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59834,5,"The use of heat to kill all microorganisms, except spores, is called",198517,2,"c.	High-level disinfection",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59834,5,"The use of heat to kill all microorganisms, except spores, is called",198518,3,"d.	Mechanical disinfection",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59835,6,These chemicals are used on animate (living tissue) to slow the growth of microorganisms,198519,0,"a.	Glutaraldehydes",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59835,6,These chemicals are used on animate (living tissue) to slow the growth of microorganisms,198520,1,"b.	Disinfectants",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59835,6,These chemicals are used on animate (living tissue) to slow the growth of microorganisms,198521,2,"c.	Halogens",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59835,6,These chemicals are used on animate (living tissue) to slow the growth of microorganisms,198522,3,"d.	Antiseptics",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59836,7,Items that are introduced directly into the bloodstream or other normally sterile areas of the body are classified as,198523,0,"a.	Critical items",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59836,7,Items that are introduced directly into the bloodstream or other normally sterile areas of the body are classified as,198524,1,"b.	Semi-critical items",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59836,7,Items that are introduced directly into the bloodstream or other normally sterile areas of the body are classified as,198525,2,"c.	Non-critical items",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59836,7,Items that are introduced directly into the bloodstream or other normally sterile areas of the body are classified as,198526,3,"d.	Equipment",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59837,8,The process by which all forms of microorganisms are completely destroyed is,198527,0,"a.	High-level disinfection",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59837,8,The process by which all forms of microorganisms are completely destroyed is,198528,1,"b.	Thermal disinfection",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59837,8,The process by which all forms of microorganisms are completely destroyed is,198529,2,"c.	Sterilization",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59837,8,The process by which all forms of microorganisms are completely destroyed is,198530,3,"d.	Chemical disinfection",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59838,9,Iodophors are a member of this chemical family,198531,0,"a.	Halogens",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59838,9,Iodophors are a member of this chemical family,198532,1,"b.	Quaternary ammonium compounds",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59838,9,Iodophors are a member of this chemical family,198533,2,"c.	Alcohol",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59838,9,Iodophors are a member of this chemical family,198534,3,"d.	Phenolics",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59839,10,Phenolics are classified as,198535,0,"a.	Intermediate to low-level disinfectants",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59839,10,Phenolics are classified as,198536,1,"b.	Intermediate to high-level disinfectants",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59839,10,Phenolics are classified as,198537,2,"c.	High-level disinfectants",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59839,10,Phenolics are classified as,198538,3,"d.	Sterilants",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59840,11,Which of the following are classified as high-level disinfectants?,198539,0,"a.	Glutaraldehyde and phenolics",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59840,11,Which of the following are classified as high-level disinfectants?,198540,1,"b.	Glutaraldehyde and ortho-phthalaldehydes",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59840,11,Which of the following are classified as high-level disinfectants?,198541,2,"c.	Quaternary ammonium compounds and phenolics",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59840,11,Which of the following are classified as high-level disinfectants?,198542,3,"d.	Halogens and ortho-phthaladehydes",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59841,12,Thermal disinfection is accomplished using,198543,0,"a.	Heated chemicals",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59841,12,Thermal disinfection is accomplished using,198544,1,"b.	Heated glutaraldehyde",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59841,12,Thermal disinfection is accomplished using,198545,2,"c.	Prolonged high pressure steam",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59841,12,Thermal disinfection is accomplished using,198546,3,"d.	Heat",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59842,13,How long must alcohol remain in wet contact with an item to achieve a reasonable level of disinfection?,198547,0,"a.	One to two minutes",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59842,13,How long must alcohol remain in wet contact with an item to achieve a reasonable level of disinfection?,198548,1,"b.	Two to three minutes",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59842,13,How long must alcohol remain in wet contact with an item to achieve a reasonable level of disinfection?,198549,2,"c.	Five to 10 minutes",1
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59842,13,How long must alcohol remain in wet contact with an item to achieve a reasonable level of disinfection?,198550,3,"d.	10 to 20 minutes",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59843,14,Which if the following would be the best choice for high-level disinfection of instruments?,198551,0,"a.	Phenolics",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59843,14,Which if the following would be the best choice for high-level disinfection of instruments?,198552,1,"b.	Chlorine",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59843,14,Which if the following would be the best choice for high-level disinfection of instruments?,198553,2,"c.	Iodophors",0
8710,Elearning-0000-157,SPD INTERNSHIP CHAPTER 9 - DISINFECTION,n13407,59843,14,Which if the following would be the best choice for high-level disinfection of instruments?,198554,3,"d.	Ortho-phthalaldehydes",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59844,0,Microgrind or supercut scissors are usually identified with a black handle.,198555,0,TRUE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59844,0,Microgrind or supercut scissors are usually identified with a black handle.,198556,1,FALSE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59845,1,Stainless steel jaw needle holders last longer than tungsten carbide jaw needle holders.,198557,0,TRUE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59845,1,Stainless steel jaw needle holders last longer than tungsten carbide jaw needle holders.,198558,1,FALSE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59846,2,The place where the two parts of a ring handled instrument meet and pivot is called the box lock.,198559,0,TRUE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59846,2,The place where the two parts of a ring handled instrument meet and pivot is called the box lock.,198560,1,FALSE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59847,3,Instruments are heat treated to give their surface a mirror (shiny) finish.,198561,0,TRUE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59847,3,Instruments are heat treated to give their surface a mirror (shiny) finish.,198562,1,FALSE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59848,4,Tissue forceps have teeth.,198563,0,TRUE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59848,4,Tissue forceps have teeth.,198564,1,FALSE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59849,5,During instruments manufacturer the process of passivation helps build a protective chromium oxide layer on each instrument's surface.,198565,0,TRUE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59849,5,During instruments manufacturer the process of passivation helps build a protective chromium oxide layer on each instrument's surface.,198566,1,FALSE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59850,6,The part of a hemostat that locks and holds it in position is called the box lock.,198567,0,TRUE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59850,6,The part of a hemostat that locks and holds it in position is called the box lock.,198568,1,FALSE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59851,7,"After applying instrument identification tape, instruments should be autoclaved to help the tape bond to the instrument.",198569,0,TRUE,1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59851,7,"After applying instrument identification tape, instruments should be autoclaved to help the tape bond to the instrument.",198570,1,FALSE,0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59852,8,Instrument marking tape should be wrapped approximately __________ around the instrument.,198571,0,"a.	1.5 times",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59852,8,Instrument marking tape should be wrapped approximately __________ around the instrument.,198572,1,"b.	Two times",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59852,8,Instrument marking tape should be wrapped approximately __________ around the instrument.,198573,2,"c.	2.5 times",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59852,8,Instrument marking tape should be wrapped approximately __________ around the instrument.,198574,3,"d.	Three times",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59853,9,An osteotome is,198575,0,"a.	Used to cut or shave bone",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59853,9,An osteotome is,198576,1,"b.	A retractor",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59853,9,An osteotome is,198577,2,"c.	A hemostatic forceps",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59853,9,An osteotome is,198578,3,"d.	Used to dissect soft tissue",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59854,10,The purpose of a suction stylet is to,198579,0,"a.	Unclog the suction during surgery",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59854,10,The purpose of a suction stylet is to,198580,1,"b.	Clean the suction in the decontamination area",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59854,10,The purpose of a suction stylet is to,198581,2,"c.	Facilitate the sterilization process",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59854,10,The purpose of a suction stylet is to,198582,3,"d.	Provide a measuring guide for the surgeon",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59855,11,Kerrison/laminectomy rongeurs should be tested using,198583,0,"a.	Tissue paper",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59855,11,Kerrison/laminectomy rongeurs should be tested using,198584,1,"b.	A plastic dowel rod",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59855,11,Kerrison/laminectomy rongeurs should be tested using,198585,2,"c.	Rubber testing material",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59855,11,Kerrison/laminectomy rongeurs should be tested using,198586,3,"d.	An index card",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59856,12,Scissors with tungsten carbide cutting edges are usually identified by,198587,0,"a.	Black handles",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59856,12,Scissors with tungsten carbide cutting edges are usually identified by,198588,1,"b.	Silver handles",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59856,12,Scissors with tungsten carbide cutting edges are usually identified by,198589,2,"c.	Gold handles",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59856,12,Scissors with tungsten carbide cutting edges are usually identified by,198590,3,"d.	The letters ""TC""ù",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59857,13,The best way to clean a suction lumen is,198591,0,"a.	Using running warm water",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59857,13,The best way to clean a suction lumen is,198592,1,"b.	Using the proper sized brush",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59857,13,The best way to clean a suction lumen is,198593,2,"c.	Soaking in an enzyme solution for three minutes",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59857,13,The best way to clean a suction lumen is,198594,3,"d.	Using the appropriate stylet",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59858,14,To properly test the sharpness of scissors four inches or less use,198595,0,"a.	Yellow test material",1
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59858,14,To properly test the sharpness of scissors four inches or less use,198596,1,"b.	Red test material",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59858,14,To properly test the sharpness of scissors four inches or less use,198597,2,"c.	An index cart",0
8890,Elearning-0000-177,SPD INTERNSHIP CHAPTER 10  SURGICAL INSTRUMENTATION,n13408,59858,14,To properly test the sharpness of scissors four inches or less use,198598,3,"d.	Orange test material",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59861,0,The first step to inspect the insulation of a laparoscopic instrument is to,198603,0,"a.	Check the collar at the distal tip",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59861,0,The first step to inspect the insulation of a laparoscopic instrument is to,198604,1,"b.	Try to slide the insulation back",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59861,0,The first step to inspect the insulation of a laparoscopic instrument is to,198605,2,"c.	Check the handle for chipping or cracking",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59861,0,The first step to inspect the insulation of a laparoscopic instrument is to,198606,3,"d.	Visually check the instrument's shaft",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59862,1,Which of the following steps happens first when processing flexible endoscopes?,198607,0,"a.	Leak-testing",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59862,1,Which of the following steps happens first when processing flexible endoscopes?,198608,1,"b.	High-level disinfecting/sterilizing",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59862,1,Which of the following steps happens first when processing flexible endoscopes?,198609,2,"c.	Manual cleaning",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59862,1,Which of the following steps happens first when processing flexible endoscopes?,198610,3,"d.	Drying",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59863,2,Which of the following should be used to thoroughly rinse (remove) all traces of disinfectant from an endoscope's channels?,198611,0,"a.	Forced air",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59863,2,Which of the following should be used to thoroughly rinse (remove) all traces of disinfectant from an endoscope's channels?,198612,1,"b.	Water containing approved sterilant",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59863,2,Which of the following should be used to thoroughly rinse (remove) all traces of disinfectant from an endoscope's channels?,198613,2,"c.	Treated water",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59863,2,Which of the following should be used to thoroughly rinse (remove) all traces of disinfectant from an endoscope's channels?,198614,3,"d.	A heated glutaraldehyde",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59864,3,The purpose of using a decontamination battery or hose when cleaning powered surgical instruments is,198615,0,"a.	To keep fluid from entering the unit",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59864,3,The purpose of using a decontamination battery or hose when cleaning powered surgical instruments is,198616,1,"b.	To keep functioning batteries and cords clean",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59864,3,The purpose of using a decontamination battery or hose when cleaning powered surgical instruments is,198617,2,"c.	To prevent electrical shock",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59864,3,The purpose of using a decontamination battery or hose when cleaning powered surgical instruments is,198618,3,"d.	To test the unit while cleaning",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59865,4,Endoscopes are often processed in a mechanical unit called,198619,0,"a.	An ultrasonic cleaner",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59865,4,Endoscopes are often processed in a mechanical unit called,198620,1,"b.	A washer-decontaminator",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59865,4,Endoscopes are often processed in a mechanical unit called,198621,2,"c.	A flush-pulse endoscope reprocessor",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59865,4,Endoscopes are often processed in a mechanical unit called,198622,3,"d.	An automatic endoscope reprocessor",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59866,5,The endoscope that would be dispensed for a procedure that required visualization of the lower part of the large intestine would be a,198623,0,"a.	Colonoscope",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59866,5,The endoscope that would be dispensed for a procedure that required visualization of the lower part of the large intestine would be a,198624,1,"b.	Sigmoidoscope",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59866,5,The endoscope that would be dispensed for a procedure that required visualization of the lower part of the large intestine would be a,198625,2,"c.	Gastroscope",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59866,5,The endoscope that would be dispensed for a procedure that required visualization of the lower part of the large intestine would be a,198626,3,"d.	Ureteroscope",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59867,6,Loaner instruments should,198627,0,"a.	Be decontaminated if they appear soiled upon arrival",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59867,6,Loaner instruments should,198628,1,"b.	Be sterilized using a low temperature process",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59867,6,Loaner instruments should,198629,2,"c.	Be decontaminated before use",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59867,6,Loaner instruments should,198630,3,"d.	Should not be used",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59868,7,Information regarding cleaning processes for endoscope should be provided by,198631,0,"a.	The Society of Gastroenterology Nurses and Associates",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59868,7,Information regarding cleaning processes for endoscope should be provided by,198632,1,"b.	The Association for Professionals in Infection Control and Epidemiology",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59868,7,Information regarding cleaning processes for endoscope should be provided by,198633,2,"c.	The instrument manufacturer",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59868,7,Information regarding cleaning processes for endoscope should be provided by,198634,3,"d.	The Operating Room staff",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59869,8,Which of the following statements about endoscopes is true?,198635,0,"a.	Not all endoscopes can be processed in an automatic endoscope reprocessor",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59869,8,Which of the following statements about endoscopes is true?,198636,1,"b.	Ultrasonic cleaning is the process of choice for endoscopes",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59869,8,Which of the following statements about endoscopes is true?,198637,2,"c.	Flexible endoscopes are not easily damaged",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59869,8,Which of the following statements about endoscopes is true?,198638,3,"d.	All endoscopes should be steam sterilized",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59870,9,Electronic testing of laparoscopic insulation should be done,198639,0,"a.	In the decontamination area prior to cleaning",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59870,9,Electronic testing of laparoscopic insulation should be done,198640,1,"b.	In the clean assembly area prior to set assembly",1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59870,9,Electronic testing of laparoscopic insulation should be done,198641,2,"c.	At the factory or onsite repair unit",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59870,9,Electronic testing of laparoscopic insulation should be done,198642,3,"d.	In the Operating Room at the end of the procedure",0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59871,10,Loaner instrumentation can cause receiving challenges.,198643,0,a. True,1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59871,10,Loaner instrumentation can cause receiving challenges.,198644,1,b. False,0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59872,11,Flexible endoscopes that fail a leak test may continue to be used until the break/hole impacts the scope's function.,198645,0,a. True,0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59872,11,Flexible endoscopes that fail a leak test may continue to be used until the break/hole impacts the scope's function.,198646,1,b. False,1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59873,12,All flexible endoscopes have internal channels.,198647,0,a. True,0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59873,12,All flexible endoscopes have internal channels.,198648,1,b. False,1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59874,13,"After use, loaner instrumentation must be decontaminated before it is shipped out.",198649,0,a. True,1
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59874,13,"After use, loaner instrumentation must be decontaminated before it is shipped out.",198650,1,b. False,0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59875,14,The biggest advantage to battery-powered surgical instruments is that they can be immersed for cleaning.,198651,0,a. True,0
9855,Questions-0000-146,SPD INTERNSHIP CHAPTER 11 - COMPLEX SURGICAL INSTRUMENTS,n13411,59875,14,The biggest advantage to battery-powered surgical instruments is that they can be immersed for cleaning.,198652,1,b. False,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59876,0,The U.S. Food and Drug Administration classifies sterilization packaging as a,198653,0,"a.	Class I Medical Device",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59876,0,The U.S. Food and Drug Administration classifies sterilization packaging as a,198654,1,"b.	Class II Medical Device",1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59876,0,The U.S. Food and Drug Administration classifies sterilization packaging as a,198655,2,"c.	Class III Medical Device",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59876,0,The U.S. Food and Drug Administration classifies sterilization packaging as a,198656,3,"d.	Class IV Medical Device",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59877,1,Which of the following is NOT an acceptable sterilization packaging material?,198657,0,"a.	Muslin",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59877,1,Which of the following is NOT an acceptable sterilization packaging material?,198658,1,"b.	Barrier cloth",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59877,1,Which of the following is NOT an acceptable sterilization packaging material?,198659,2,"c.	Canvas",1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59877,1,Which of the following is NOT an acceptable sterilization packaging material?,198660,3,"d.	Twills",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59878,2,Count sheets,198661,0,"a.	Describe each instrument in detail",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59878,2,Count sheets,198662,1,"b.	Are used only for Operating Room trays and large procedure packs",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59878,2,Count sheets,198663,2,"c.	Provide a detailed  list of tray contents",1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59878,2,Count sheets,198664,3,"d.	Include manufacturer's Instructions for Use information",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59879,3,"When arranging paper/plastic pouches in the sterilizer, the pouches should be arranged",198665,0,"a.	Paper-to-plastic",1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59879,3,"When arranging paper/plastic pouches in the sterilizer, the pouches should be arranged",198666,1,"b.	Paper-to-paper",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59879,3,"When arranging paper/plastic pouches in the sterilizer, the pouches should be arranged",198667,2,"c.	Plastic-to-plastic",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59879,3,"When arranging paper/plastic pouches in the sterilizer, the pouches should be arranged",198668,3,"d.	Flat",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59880,4,The relative humidity of the Central Service prep and pack area should be,198669,0,"a.	Less than 75%",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59880,4,The relative humidity of the Central Service prep and pack area should be,198670,1,"b.	30% to 60%",1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59880,4,The relative humidity of the Central Service prep and pack area should be,198671,2,"c.	40% to 80%",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59880,4,The relative humidity of the Central Service prep and pack area should be,198672,3,"d.	Less than 35%",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59881,5,Some plastics including formulations of spun-bonded polyolefin are intended for use solely in these sterilization processes,198673,0,"a.	Steam",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59881,5,Some plastics including formulations of spun-bonded polyolefin are intended for use solely in these sterilization processes,198674,1,"b.	Ozone and hydrogen peroxide",1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59881,5,Some plastics including formulations of spun-bonded polyolefin are intended for use solely in these sterilization processes,198675,2,"c.	Liquid",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59881,5,Some plastics including formulations of spun-bonded polyolefin are intended for use solely in these sterilization processes,198676,3,"d.	Gravity",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59882,6,When placing hinged instruments in an instrument tray,198677,0,"a.	Lock the handles to prevent damage during sterilization",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59882,6,When placing hinged instruments in an instrument tray,198678,1,"b.	Arrange the instruments in alphabetical order",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59882,6,When placing hinged instruments in an instrument tray,198679,2,"c.	Arrange the instruments in the order of their use",0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59882,6,When placing hinged instruments in an instrument tray,198680,3,"d.	Unlock the handles and open the instruments",1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59883,7,Gauze squares are the wicking material of choice for instrument sets.,198681,0,A. True,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59883,7,Gauze squares are the wicking material of choice for instrument sets.,198682,1,b. False,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59884,8,Temperatures in a sterile storage area should be 55 ∞F to 60 ∞F.,198683,0,a. True,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59884,8,Temperatures in a sterile storage area should be 55 ∞F to 60 ∞F.,198684,1,b. False,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59885,9,"When placing instruments in a peel pack, the tips should always face the plastic side of the pack.",198685,0,a. True,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59885,9,"When placing instruments in a peel pack, the tips should always face the plastic side of the pack.",198686,1,b. False,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59886,10,All rigid sterilization containers have tamper-evident seals.,198687,0,a. True,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59886,10,All rigid sterilization containers have tamper-evident seals.,198688,1,b. False,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59887,11,Cellulose materials cannot be processed within ozone sterilizers,198689,0,a. True,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59887,11,Cellulose materials cannot be processed within ozone sterilizers,198690,1,b. False,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59888,12,Reusable textile packaging requires less labor than disposable packaging.,198691,0,a. True,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59888,12,Reusable textile packaging requires less labor than disposable packaging.,198692,1,b. False,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59889,13,Using latex tubing to protect delicate instrumentation is the process of choice for items to be steam sterilized.,198693,0,a. True,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59889,13,Using latex tubing to protect delicate instrumentation is the process of choice for items to be steam sterilized.,198694,1,b. False,1
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59890,14,While the outside of all instruments must be dry before sterilization it is important to ensure all lumens are kept moist for sterilization.,198695,0,a. True,0
9856,Questions-0000-147,SPD INTERNSHIP CHAPTER 12 - ASSEMBLY AND PACKAGING,n13412,59890,14,While the outside of all instruments must be dry before sterilization it is important to ensure all lumens are kept moist for sterilization.,198696,1,b. False,1
9317,Elearning-0000-565,FY2021 LUNG CANCER DSC_CHEROKEE,n13413,59891,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 LUNG CANCER DSC_CHEROKEE CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",198697,0,TRUE,1
9317,Elearning-0000-565,FY2021 LUNG CANCER DSC_CHEROKEE,n13413,59891,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 LUNG CANCER DSC_CHEROKEE CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",198698,1,FALSE,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59893,0,Patient safety is a team effort and patient's should been at an arm's length and remain within line of sight at all times.,198701,0,a. True,1
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59893,0,Patient safety is a team effort and patient's should been at an arm's length and remain within line of sight at all times.,198702,1,b. False,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59894,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198703,0,"a. Observe your patient for dizziness, lightheadedness and changes in condition and report it to the RN",0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59894,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198704,1,b. Confirm the patient is wearing anti-slip socks,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59894,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198705,2,"c. Utilize assistive devices, if indicated",0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59894,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198706,3,"d. Ensure the patient's tubes, lines and catheters are out of the way",0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59894,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198707,4,e. All of the above,1
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59895,2,Risk factors for falls include,198708,0,A. Orthostatic hypotension,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59895,2,Risk factors for falls include,198709,1,B. Medications,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59895,2,Risk factors for falls include,198710,2,C. Lines/ tubes/ drains/ catheters,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59895,2,Risk factors for falls include,198711,3,D. Pain,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59895,2,Risk factors for falls include,198712,4,E. Motor/ Sensory Impairment,0
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59895,2,Risk factors for falls include,198713,5,F. All of the above,1
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59896,3,Gait belts are a good tool to use to help support the patient and staff member when standing and ambulating a patient?,198714,0,a. True,1
9688,Elearning-0000-902,FALL PREVENTION IN SURGICAL SERVICES FOR ANCILLARY STAFF,n13415,59896,3,Gait belts are a good tool to use to help support the patient and staff member when standing and ambulating a patient?,198715,1,b. False,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59897,0,Patient safety is a team effort and patient's should been at an arm's length and remain within line of sight at all times.,198716,0,a. True,1
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59897,0,Patient safety is a team effort and patient's should been at an arm's length and remain within line of sight at all times.,198717,1,b. False,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59898,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198718,0,"a. Reassess your patient for dizziness, lightheadedness and changes in condition",0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59898,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198719,1,b. Confirm the patient is wearing anti-slip socks,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59898,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198720,2,"c. Utilize assistive devices, if indicated.",0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59898,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198721,3,"d. Ensure the patient's tubes, lines and catheters are out of the way",0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59898,1,"You assist your patient to a sitting position on the side of the stretcher. Prior to standing the patient, you should:",198722,4,e. All of the above,1
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59899,2,Your patient received a PNB for a knee arthroscopy. You are assessing motor and sensory impairments prior to moving the patient to the next phase of care. You ask the patient to raise their leg straight off of the bed and hold it. The patient is able to raise their leg with their knee bent and is able to hold it for 2 seconds. Which of the following actions is most appropriate?,198723,0,"a. Move forward with standing and ambulating the patient, this is a normal finding",0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59899,2,Your patient received a PNB for a knee arthroscopy. You are assessing motor and sensory impairments prior to moving the patient to the next phase of care. You ask the patient to raise their leg straight off of the bed and hold it. The patient is able to raise their leg with their knee bent and is able to hold it for 2 seconds. Which of the following actions is most appropriate?,198724,1,b. Have 3 staff members present when standing the patient incase the patient's knee buckles,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59899,2,Your patient received a PNB for a knee arthroscopy. You are assessing motor and sensory impairments prior to moving the patient to the next phase of care. You ask the patient to raise their leg straight off of the bed and hold it. The patient is able to raise their leg with their knee bent and is able to hold it for 2 seconds. Which of the following actions is most appropriate?,198725,2,"c. The patient failed the straight leg raise test indicating their quad strength may not support them when standing, continue to assess the patient for return of motor strength.",1
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59899,2,Your patient received a PNB for a knee arthroscopy. You are assessing motor and sensory impairments prior to moving the patient to the next phase of care. You ask the patient to raise their leg straight off of the bed and hold it. The patient is able to raise their leg with their knee bent and is able to hold it for 2 seconds. Which of the following actions is most appropriate?,198726,3,d. Call Anesthesia and the surgeon to report the findings,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59900,3,Risk factors for falls include,198727,0,a. Orthostatic hypotension,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59900,3,Risk factors for falls include,198728,1,b. Medications,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59900,3,Risk factors for falls include,198729,2,c. Lines/ tubes/ drains/ catheters,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59900,3,Risk factors for falls include,198730,3,d. Pain,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59900,3,Risk factors for falls include,198731,4,e. Motor/ Sensory Impairment,0
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59900,3,Risk factors for falls include,198732,5,f. All of the above,1
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59901,4,It is required to document environmental safety measures taken to reduce the risk of patient falls?,198733,0,a. True,1
9687,Elearning-0000-901,FALL PREVENTION IN SURGICAL SERVICES FOR NURSES,n13416,59901,4,It is required to document environmental safety measures taken to reduce the risk of patient falls?,198734,1,b. False,0
9521,Elearning-0000-750,C-374 VERSION 4.0,n13418,59909,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",198760,0,TRUE,1
9521,Elearning-0000-750,C-374 VERSION 4.0,n13418,59909,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",198761,1,FALSE,0
9658,Elearning-0000-875,FY2021 SURGICAL SERVICES: MURPHY DRIP / CONTINUOUS BLADDER IRRIGATION,n13452,59915,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the MURPHY DRIP / CONTINUOUS BLADDER IRRIGATION CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",198781,0,TRUE,1
9658,Elearning-0000-875,FY2021 SURGICAL SERVICES: MURPHY DRIP / CONTINUOUS BLADDER IRRIGATION,n13452,59915,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the MURPHY DRIP / CONTINUOUS BLADDER IRRIGATION CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",198782,1,FALSE,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59919,0,Please list the location for this activity.,198789,0,Atlanta,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59919,0,Please list the location for this activity.,198790,1,Forsyth,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59919,0,Please list the location for this activity.,198791,2,Cherokee,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59919,0,Please list the location for this activity.,198792,3,Other,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59920,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",198793,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59920,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",198794,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59920,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",198795,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59920,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",198796,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59920,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",198797,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59921,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",198798,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59921,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",198799,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59921,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",198800,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59921,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",198801,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59921,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",198802,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59922,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",198803,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59922,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",198804,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59922,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",198805,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59922,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",198806,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59922,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",198807,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59923,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",198808,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59923,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",198809,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59923,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",198810,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59923,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",198811,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59923,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",198812,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59924,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",198813,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59924,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",198814,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59924,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",198815,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59924,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",198816,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59924,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",198817,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59925,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",198818,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59925,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",198819,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59925,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",198820,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59925,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",198821,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59925,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",198822,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59926,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",198823,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59926,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",198824,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59926,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",198825,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59926,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",198826,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59926,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",198827,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59927,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",198828,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59927,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",198829,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59927,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",198830,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59927,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",198831,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59927,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",198832,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59928,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",198833,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59928,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",198834,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59928,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",198835,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59928,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",198836,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59928,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",198837,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59929,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",198838,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59929,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",198839,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59929,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",198840,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59929,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",198841,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59929,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",198842,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59930,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",198843,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59930,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",198844,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59930,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",198845,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59930,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",198846,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59930,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",198847,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59931,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",198848,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59931,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",198849,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59931,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",198850,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59931,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",198851,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59931,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",198852,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59932,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,198853,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59932,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,198854,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59932,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,198855,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59932,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,198856,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59932,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,198857,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59933,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",198858,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59933,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",198859,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59933,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",198860,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59933,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",198861,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59933,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",198862,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59934,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",198863,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59934,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",198864,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59934,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",198865,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59934,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",198866,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59934,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",198867,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59935,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,198868,0,Strongly Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59935,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,198869,1,Agree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59935,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,198870,2,No Opinion,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59935,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,198871,3,Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59935,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,198872,4,Strongly Disagree,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59936,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,198873,0,Excellent,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59936,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,198874,1,Very Good,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59936,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,198875,2,Good,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59936,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,198876,3,Fair,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59936,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,198877,4,Poor,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59937,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Suzanne Richter RN, CPST</ol>",198878,0,Excellent,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59937,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Suzanne Richter RN, CPST</ol>",198879,1,Very Good,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59937,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Suzanne Richter RN, CPST</ol>",198880,2,Good,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59937,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Suzanne Richter RN, CPST</ol>",198881,3,Fair,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59937,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Suzanne Richter RN, CPST</ol>",198882,4,Poor,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59938,19,"Overall, this activity was:",198883,0,Excellent,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59938,19,"Overall, this activity was:",198884,1,Very Good,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59938,19,"Overall, this activity was:",198885,2,Good,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59938,19,"Overall, this activity was:",198886,3,Fair,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59938,19,"Overall, this activity was:",198887,4,Poor,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59939,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",198888,0,Yes,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59939,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",198889,1,No,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59939,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",198890,2,N/A,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59942,23,How would you improve this class?,198891,0,Reduce content covered in class,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59942,23,How would you improve this class?,198892,1,Increase content covered in class,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59942,23,How would you improve this class?,198893,2,Update content covered in class,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59942,23,How would you improve this class?,198894,3,Improve the instructional methods,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59942,23,How would you improve this class?,198895,4,Make course activities more stimulating,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59942,23,How would you improve this class?,198896,5,Slow the pace of the class,0
9931,Questions-0000-65,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 3.12.21,n13455,59942,23,How would you improve this class?,198897,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59970,0,Please list the location for this activity.,199002,0,Atlanta,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59970,0,Please list the location for this activity.,199003,1,Cherokee,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59970,0,Please list the location for this activity.,199004,2,Forsyth,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59970,0,Please list the location for this activity.,199005,3,Other,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59971,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the importance of self-assessment and discuss barriers to providing compassionate bereavement care.</ol>",199006,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59971,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the importance of self-assessment and discuss barriers to providing compassionate bereavement care.</ol>",199007,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59971,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the importance of self-assessment and discuss barriers to providing compassionate bereavement care.</ol>",199008,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59971,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the importance of self-assessment and discuss barriers to providing compassionate bereavement care.</ol>",199009,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59971,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the importance of self-assessment and discuss barriers to providing compassionate bereavement care.</ol>",199010,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59972,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss positive ways to communicate with grieving families.</ol>",199011,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59972,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss positive ways to communicate with grieving families.</ol>",199012,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59972,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss positive ways to communicate with grieving families.</ol>",199013,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59972,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss positive ways to communicate with grieving families.</ol>",199014,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59972,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss positive ways to communicate with grieving families.</ol>",199015,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59973,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,199016,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59973,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,199017,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59973,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,199018,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59973,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,199019,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59973,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,199020,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59974,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the care of the family experiencing a perinatal loss.</OL>,199021,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59974,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the care of the family experiencing a perinatal loss.</OL>,199022,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59974,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the care of the family experiencing a perinatal loss.</OL>,199023,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59974,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the care of the family experiencing a perinatal loss.</OL>,199024,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59974,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the care of the family experiencing a perinatal loss.</OL>,199025,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59975,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",199026,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59975,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",199027,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59975,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",199028,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59975,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",199029,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59975,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",199030,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59976,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of comfort as it relates to providing care and support to families experiencing perinatal loss.</OL>,199031,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59976,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of comfort as it relates to providing care and support to families experiencing perinatal loss.</OL>,199032,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59976,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of comfort as it relates to providing care and support to families experiencing perinatal loss.</OL>,199033,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59976,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of comfort as it relates to providing care and support to families experiencing perinatal loss.</OL>,199034,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59976,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of comfort as it relates to providing care and support to families experiencing perinatal loss.</OL>,199035,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59977,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",199036,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59977,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",199037,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59977,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",199038,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59977,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",199039,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59977,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",199040,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59978,8,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,199041,0,Strongly Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59978,8,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,199042,1,Agree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59978,8,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,199043,2,No Opinion,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59978,8,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,199044,3,Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59978,8,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,199045,4,Strongly Disagree,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59979,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Petersen, RNC, MS</ol>",199046,0,Excellent,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59979,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Petersen, RNC, MS</ol>",199047,1,Very Good,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59979,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Petersen, RNC, MS</ol>",199048,2,Good,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59979,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Petersen, RNC, MS</ol>",199049,3,Fair,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59979,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Petersen, RNC, MS</ol>",199050,4,Poor,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59980,10,"Overall, this activity was:",199051,0,Excellent,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59980,10,"Overall, this activity was:",199052,1,Very Good,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59980,10,"Overall, this activity was:",199053,2,Good,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59980,10,"Overall, this activity was:",199054,3,Fair,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59980,10,"Overall, this activity was:",199055,4,Poor,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59981,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",199056,0,Yes,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59981,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",199057,1,No,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59981,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",199058,2,N/A,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59984,14,How would you improve this class?,199059,0,Reduce content covered in class,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59984,14,How would you improve this class?,199060,1,Increase content covered in class,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59984,14,How would you improve this class?,199061,2,Update content covered in class,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59984,14,How would you improve this class?,199062,3,Improve the instructional methods,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59984,14,How would you improve this class?,199063,4,Make course activities more stimulating,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59984,14,How would you improve this class?,199064,5,Slow the pace of the class,0
9874,Questions-0000-163,TOUGH TALK: NAVIGATING DIFFICULT TOPICS IN PERINATAL LOSS (EVALUATION SURVEY 1.0) ONLINE - 3.16.21,n13457,59984,14,How would you improve this class?,199065,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59987,0,Do you complete a pre-clean at the bedside prior to bringing down the scope to GI Lab to process?,199066,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59987,0,Do you complete a pre-clean at the bedside prior to bringing down the scope to GI Lab to process?,199067,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59988,1,PPE is not required in the GI Lab during processing of scope,199068,0,TRUE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59988,1,PPE is not required in the GI Lab during processing of scope,199069,1,FALSE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59989,2,The first step to processing the scope is?,199070,0,Wiping it down with a lint free cloth,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59989,2,The first step to processing the scope is?,199071,1,Submerging it in water,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59989,2,The first step to processing the scope is?,199072,2,Perform leak test,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59990,3,5 gallons of water in the sink is required to process a scope,199073,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59990,3,5 gallons of water in the sink is required to process a scope,199074,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59991,4,Once scope is submerged in water no bubbles are to be seen to pass the leak test,199075,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59991,4,Once scope is submerged in water no bubbles are to be seen to pass the leak test,199076,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59992,5,How much enzymatic solution is required to be placed in the 5 gallons of water in the sink to clean the scope,199077,0,A. 25cc,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59992,5,How much enzymatic solution is required to be placed in the 5 gallons of water in the sink to clean the scope,199078,1,B. 50cc,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59992,5,How much enzymatic solution is required to be placed in the 5 gallons of water in the sink to clean the scope,199079,2,C. 75cc,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59992,5,How much enzymatic solution is required to be placed in the 5 gallons of water in the sink to clean the scope,199080,3,D. 100cc,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59993,6,Tap water and enzymatic solution is what is in the two large canisters used during the cleaning process with the Scope Buddy,199081,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59993,6,Tap water and enzymatic solution is what is in the two large canisters used during the cleaning process with the Scope Buddy,199082,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59994,7,"When using the Scope Buddy, clean water is siphoned before the enzymatic solution",199083,0,TRUE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59994,7,"When using the Scope Buddy, clean water is siphoned before the enzymatic solution",199084,1,FALSE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59995,8,You must dry the scope prior to placing it in the washer,199085,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59995,8,You must dry the scope prior to placing it in the washer,199086,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59996,9,During ATP when do you cut the brush?,199087,0,A. Once you have entered and exited the scope,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59996,9,During ATP when do you cut the brush?,199088,1,B. Never cut the brush,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59996,9,During ATP when do you cut the brush?,199089,2,C. There is no brush in ATP,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59997,10,Digital read out on ATP should be less than what to be considered an acceptable level?,199090,0,A. Less than 500,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59997,10,Digital read out on ATP should be less than what to be considered an acceptable level?,199091,1,B. Less than 1000,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59997,10,Digital read out on ATP should be less than what to be considered an acceptable level?,199092,2,C. Less than 100,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59997,10,Digital read out on ATP should be less than what to be considered an acceptable level?,199093,3,D. Less than 1,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59998,11,If the digital read out on ATP is higher than the acceptable range you must then do what?,199094,0,A. Wipe the scope down with a lint free cloth,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59998,11,If the digital read out on ATP is higher than the acceptable range you must then do what?,199095,1,B. Run the scope in the washer,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,59998,11,If the digital read out on ATP is higher than the acceptable range you must then do what?,199096,2,C. Redo all steps to processing the scope prior to ATP,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60000,12,What is the required information for the new washer to run?,199100,0,A. Scan Scope,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60000,12,What is the required information for the new washer to run?,199101,1,B. Scan Badge,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60000,12,What is the required information for the new washer to run?,199102,2,C. Scan Scope and Badge,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60001,13,The testing strip of paper is printed after the washer has completed the cleaning cycle,199103,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60001,13,The testing strip of paper is printed after the washer has completed the cleaning cycle,199104,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60003,14,You should never touch a scope with your bare hands,199107,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60003,14,You should never touch a scope with your bare hands,199108,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60004,15,It is OK for the clean scope to touch another clean scope in the scope cabinet,199109,0,TRUE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60004,15,It is OK for the clean scope to touch another clean scope in the scope cabinet,199110,1,FALSE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60005,16,After hours and on weekends bronchoscopes should be cleaned by RT department.,199111,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60005,16,After hours and on weekends bronchoscopes should be cleaned by RT department.,199112,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60006,17,A cap for cleaning is not necessary on the high definition scope,199113,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60006,17,A cap for cleaning is not necessary on the high definition scope,199114,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60007,18,The high definition bronchoscopes do have built in leak test ports,199115,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60007,18,The high definition bronchoscopes do have built in leak test ports,199116,1,FALSE,0
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60008,19,On the new washer you should make sure fluids are sufficient before starting wash,199117,0,TRUE,1
9926,Questions-0000-60,FY2021 HLD BRONCHOSCOPE CLEANING TEST,n13458,60008,19,On the new washer you should make sure fluids are sufficient before starting wash,199118,1,FALSE,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60009,0,Which of the following are correct?,199119,0,a. The small bowel feeding tube can be inserted by any nurse who has completed the competency.,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60009,0,Which of the following are correct?,199120,1,b. The small bowel feeding tube can be inserted by interventional radiology only.,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60009,0,Which of the following are correct?,199121,2,c. The small bowel feeding tube can be inserted by interventional radiology and by the rapid response team utilizing the CorTrak system.,1
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60009,0,Which of the following are correct?,199122,3,d. The rapid response nurse can choose whether she inserts the small bowel feeding tube with the CorTrak device or not based on her assessment.,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60010,1,The patient's head of bed should be elevated at all times during the administration of tube feeding.,199123,0,TRUE,1
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60010,1,The patient's head of bed should be elevated at all times during the administration of tube feeding.,199124,1,FALSE,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60011,2,Ms. Jones is receiving tube feeding at 45 ml per hour via a small bowel feeding tube. The MRI technologist calls to tell you that they are on the way to take your patient down to MRI. What should your response be?,199125,0,a. Ms. Jones is receiving tube feeding and it must be stopped for 1 hour before she can lay flat. Please let me know what time I should turn the tube feeding off so that we can time it for one hour before you come to get her.,1
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60011,2,Ms. Jones is receiving tube feeding at 45 ml per hour via a small bowel feeding tube. The MRI technologist calls to tell you that they are on the way to take your patient down to MRI. What should your response be?,199126,1,b. I will turn her tube feeding off now and then you can come and get her since she is only receiving 45 ml per hour of tube feeding.,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60011,2,Ms. Jones is receiving tube feeding at 45 ml per hour via a small bowel feeding tube. The MRI technologist calls to tell you that they are on the way to take your patient down to MRI. What should your response be?,199127,2,"c. I am going on my lunch break now, you can come and get her whenever it is convenient for you but you will need to bring additional transporter to take the tube feeding down with you as well.",0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60012,3,Documentation of the cm marking on the tube should be done:,199128,0,a. Once a shift,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60012,3,Documentation of the cm marking on the tube should be done:,199129,1,b. Twice a shift,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60012,3,Documentation of the cm marking on the tube should be done:,199130,2,c. Every 4 hours,1
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60012,3,Documentation of the cm marking on the tube should be done:,199131,3,d. Every 12 hours,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60013,4,The Centimeter marking on the tube is at the 50 cm mark. When you chart this you realize that the last time it was charted it was at the 76 cm mark. What should you do?,199132,0,a. No action is required since the patient is not coughing and not having any s/s of aspiration.,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60013,4,The Centimeter marking on the tube is at the 50 cm mark. When you chart this you realize that the last time it was charted it was at the 76 cm mark. What should you do?,199133,1,b. Turn off the tube feeding and notify the MD immediately,1
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60013,4,The Centimeter marking on the tube is at the 50 cm mark. When you chart this you realize that the last time it was charted it was at the 76 cm mark. What should you do?,199134,2,c. Turn off the tube feeding and notify the rapid response team to come back and re-insert the tube back to the 76 cm mark.,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60013,4,The Centimeter marking on the tube is at the 50 cm mark. When you chart this you realize that the last time it was charted it was at the 76 cm mark. What should you do?,199135,3,"d. Notify the MD, but do not turn off the tube feeding as the patient may become dehydrated.",0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60014,5,Once the radiologist calls and tell you the tube is in the stomach you can begin tube feeding.,199136,0,TRUE,0
9422,Elearning-0000-660,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: NURSES,n13459,60014,5,Once the radiologist calls and tell you the tube is in the stomach you can begin tube feeding.,199137,1,FALSE,1
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29172,0,Which of the following describes a small bowel feeding tube?,88880,0,a. Frequently weighted,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29172,0,Which of the following describes a small bowel feeding tube?,88881,1,b. Goes through the patient's nose into the stomach,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29172,0,Which of the following describes a small bowel feeding tube?,88882,2,c. Stylet to assist with placement,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29172,0,Which of the following describes a small bowel feeding tube?,88883,3,d. Dobhoff,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29172,0,Which of the following describes a small bowel feeding tube?,88884,4,"e. A, C & D",1
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29172,0,Which of the following describes a small bowel feeding tube?,88885,5,f. All of the above,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29173,1,"You are called to the room of one of your patients who had a small bowel feeding tube placed within the last few hours.  The patient states they need to go to the bathroom and are now not able to get up by themselves, although they were able to do so prior to the tube being placed.  Which of the following will you do FIRST?",88886,0,"a.	Disconnect the tube and help them to the bathroom, since you were able to do so before the tube was placed",0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29173,1,"You are called to the room of one of your patients who had a small bowel feeding tube placed within the last few hours.  The patient states they need to go to the bathroom and are now not able to get up by themselves, although they were able to do so prior to the tube being placed.  Which of the following will you do FIRST?",88887,1,"b.	Check the orders to verify presence of an ambulation order",0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29173,1,"You are called to the room of one of your patients who had a small bowel feeding tube placed within the last few hours.  The patient states they need to go to the bathroom and are now not able to get up by themselves, although they were able to do so prior to the tube being placed.  Which of the following will you do FIRST?",88888,2,"c.	Notify the nurse",1
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29173,1,"You are called to the room of one of your patients who had a small bowel feeding tube placed within the last few hours.  The patient states they need to go to the bathroom and are now not able to get up by themselves, although they were able to do so prior to the tube being placed.  Which of the following will you do FIRST?",88889,3,"d.	Get a bedpan, since they are no longer able to get out of bed",0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29174,2,It is not necessary for you to include presence of a small bowel feeding tube during hand off communication.,88890,0,TRUE,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29174,2,It is not necessary for you to include presence of a small bowel feeding tube during hand off communication.,88891,1,FALSE,1
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29175,3,"Upon arrival to your patient's room, you note the patient to be agitated and breathing fast.  Their vital signs are as follows:  Temp - 97.0; HR 123; RR 36; BP 148/82.  Which of the following will you do FIRST?",88892,0,a. Offer the patient a warm blanket in attempt to make them more comfortable,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29175,3,"Upon arrival to your patient's room, you note the patient to be agitated and breathing fast.  Their vital signs are as follows:  Temp - 97.0; HR 123; RR 36; BP 148/82.  Which of the following will you do FIRST?",88893,1,b. Notify the nurse,1
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29175,3,"Upon arrival to your patient's room, you note the patient to be agitated and breathing fast.  Their vital signs are as follows:  Temp - 97.0; HR 123; RR 36; BP 148/82.  Which of the following will you do FIRST?",88894,2,c. Ask their family member to leave; it appears they need more rest,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29175,3,"Upon arrival to your patient's room, you note the patient to be agitated and breathing fast.  Their vital signs are as follows:  Temp - 97.0; HR 123; RR 36; BP 148/82.  Which of the following will you do FIRST?",88895,3,d. Change the TV channel; that TV show must be agitating the patient,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29176,4,"While rounding on your patient you note they are sleeping quietly, vital signs are stable, and their pump for their feeding tube is alarming.  Which of the following will you do FIRST?",88896,0,a. Silence the alarm,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29176,4,"While rounding on your patient you note they are sleeping quietly, vital signs are stable, and their pump for their feeding tube is alarming.  Which of the following will you do FIRST?",88897,1,b. Turn off the pump,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29176,4,"While rounding on your patient you note they are sleeping quietly, vital signs are stable, and their pump for their feeding tube is alarming.  Which of the following will you do FIRST?",88898,2,c. Ignore the alarm,0
8895,Elearning-0000-181,FY2021 SMALL BOWEL FEEDING TUBE EDUCATION: TECHS,n6015,29176,4,"While rounding on your patient you note they are sleeping quietly, vital signs are stable, and their pump for their feeding tube is alarming.  Which of the following will you do FIRST?",88899,3,d. Notify the nurse,1
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60015,0,"Scenario:<br>  Patient admitted with failure to thrive with a history of opioid induced constipation taking laxatives at home. During stay, patient received three doses of miralax and bisacodyl suppository. Patient admitted on 5/1. On 5/4, day four of admission, patient reported loose stools. MD ordered C.Diff test. Specimen sent and tested positive for C.Diff. Patient had no reoccurrence of loose stools.<br>  Should have questioned the MD's order to send a stool specimen for C.Diff based on medications given above?",199138,0,TRUE,1
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60015,0,"Scenario:<br>  Patient admitted with failure to thrive with a history of opioid induced constipation taking laxatives at home. During stay, patient received three doses of miralax and bisacodyl suppository. Patient admitted on 5/1. On 5/4, day four of admission, patient reported loose stools. MD ordered C.Diff test. Specimen sent and tested positive for C.Diff. Patient had no reoccurrence of loose stools.<br>  Should have questioned the MD's order to send a stool specimen for C.Diff based on medications given above?",199139,1,FALSE,0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60016,1,"Scenario:<br>  Patient admitted with failure to thrive with a history of opioid induced constipation taking laxatives at home. During stay, patient received three doses of miralax and bisacodyl suppository. Patient admitted on 5/1. On 5/4, day four of admission, patient reported loose stools. MD ordered C.Diff test. Specimen sent and tested positive for C.Diff. Patient had no reoccurrence of loose stools.<br>  What process would have potentially stopped the specimen from being sent?",199140,0,"a.	C.Diff specimen log",0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60016,1,"Scenario:<br>  Patient admitted with failure to thrive with a history of opioid induced constipation taking laxatives at home. During stay, patient received three doses of miralax and bisacodyl suppository. Patient admitted on 5/1. On 5/4, day four of admission, patient reported loose stools. MD ordered C.Diff test. Specimen sent and tested positive for C.Diff. Patient had no reoccurrence of loose stools.<br>  What process would have potentially stopped the specimen from being sent?",199141,1,"b.	Using  appropriate C.Diff testing algorithm",0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60016,1,"Scenario:<br>  Patient admitted with failure to thrive with a history of opioid induced constipation taking laxatives at home. During stay, patient received three doses of miralax and bisacodyl suppository. Patient admitted on 5/1. On 5/4, day four of admission, patient reported loose stools. MD ordered C.Diff test. Specimen sent and tested positive for C.Diff. Patient had no reoccurrence of loose stools.<br>  What process would have potentially stopped the specimen from being sent?",199142,2,"c.	Both A&B",1
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60017,2,"Scenario:<br>  75 yo female admitted through the ED. She states that she has been having diarrhea at home off and on for the last week. She describes her ""diarrhea""ù as loose stools that she had once or twice a day 3 times last week. A c-diff test is ordered on admission. 3 days after admission there is no documentation of a stool. Per NSH policy the lab cancelled the order for the specimen after 2 days. The next day she was given miralax due to constipation. She had two liquid stools on the day the miralax was ordered.<br>  The nurse should:",199143,0,"A.	Send the stool for c-diff testing and place patient on modified contact isolation.",0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60017,2,"Scenario:<br>  75 yo female admitted through the ED. She states that she has been having diarrhea at home off and on for the last week. She describes her ""diarrhea""ù as loose stools that she had once or twice a day 3 times last week. A c-diff test is ordered on admission. 3 days after admission there is no documentation of a stool. Per NSH policy the lab cancelled the order for the specimen after 2 days. The next day she was given miralax due to constipation. She had two liquid stools on the day the miralax was ordered.<br>  The nurse should:",199144,1,"B.	After discovering that the test had been cancelled by the lab, call the MD for a new order",0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60017,2,"Scenario:<br>  75 yo female admitted through the ED. She states that she has been having diarrhea at home off and on for the last week. She describes her ""diarrhea""ù as loose stools that she had once or twice a day 3 times last week. A c-diff test is ordered on admission. 3 days after admission there is no documentation of a stool. Per NSH policy the lab cancelled the order for the specimen after 2 days. The next day she was given miralax due to constipation. She had two liquid stools on the day the miralax was ordered.<br>  The nurse should:",199145,2,"C.	No actions are required, this would be considered an expected result after receiving the miralax.",1
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60018,3,The c-diff log is required to be completed prior to sending any stool for c-diff testing.,199146,0,TRUE,1
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60018,3,The c-diff log is required to be completed prior to sending any stool for c-diff testing.,199147,1,FALSE,0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60019,4,"Scenario:<br>  Your patient was admitted for cellulitis and was transferred from a nursing home. She is independently ambulatory, alert and oriented.  She is on IV Levaquin and has received 4 doses. During your morning assessment your patient states she had a loose stool during the night. <br>  What is your next step:",199148,0,A. No actions needed she has only had one loose stool,0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60019,4,"Scenario:<br>  Your patient was admitted for cellulitis and was transferred from a nursing home. She is independently ambulatory, alert and oriented.  She is on IV Levaquin and has received 4 doses. During your morning assessment your patient states she had a loose stool during the night. <br>  What is your next step:",199149,1,B. Place stool collection cup in room and instruct patient to notify you if she has any additional stools.,0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60019,4,"Scenario:<br>  Your patient was admitted for cellulitis and was transferred from a nursing home. She is independently ambulatory, alert and oriented.  She is on IV Levaquin and has received 4 doses. During your morning assessment your patient states she had a loose stool during the night. <br>  What is your next step:",199150,2,"C. Continue to monitor for signs and symptoms of C-Diff such as 3 or more stools per day, abdominal pain, bloating etc. while recognizing that this patient is at high risk for C-Diff due to antibiotic and nursing home transfer.",1
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60020,5,It is acceptable to chart x4 at the end of the shift if a patient has had 4 stools during the shift.,199151,0,TRUE,0
9297,Elearning-0000-547,FY2021 C. DIFF ANNUAL EDUCATION: PATIENT CARE,n13460,60020,5,It is acceptable to chart x4 at the end of the shift if a patient has had 4 stools during the shift.,199152,1,FALSE,1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60021,0,The process by which instruments are steam sterilized for immediate use is called,199153,0,"a.	Emergency sterilization",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60021,0,The process by which instruments are steam sterilized for immediate use is called,199154,1,"b.	Immediate use steam sterilization",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60021,0,The process by which instruments are steam sterilized for immediate use is called,199155,2,"c.	Core sterilization",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60021,0,The process by which instruments are steam sterilized for immediate use is called,199156,3,"d.	Rapid reprocessing",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60022,1,Items to be disinfected or sterilized at the point of use must be,199157,0,"a.	Properly cleaned per Manufacturer's Instructions for Use",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60022,1,Items to be disinfected or sterilized at the point of use must be,199158,1,"b.	Semi-critical devices",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60022,1,Items to be disinfected or sterilized at the point of use must be,199159,2,"c.	non-critical devices",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60022,1,Items to be disinfected or sterilized at the point of use must be,199160,3,"d.	heat sensitive",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60023,2,The best way to transport items that have been processed using immediate use steam sterilization at the point of use,199161,0,"a.	covered with a sterile towel",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60023,2,The best way to transport items that have been processed using immediate use steam sterilization at the point of use,199162,1,"b.	in a rigid container designed for immediate use steam sterilization",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60023,2,The best way to transport items that have been processed using immediate use steam sterilization at the point of use,199163,2,"c.	in a covered mesh bottom tray",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60023,2,The best way to transport items that have been processed using immediate use steam sterilization at the point of use,199164,3,"d.	in a kraft paper bag",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60024,3,Before an item can be placed in a liquid chemical sterile processing system they must be,199165,0,"a.	heated",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60024,3,Before an item can be placed in a liquid chemical sterile processing system they must be,199166,1,"b.	filled with air",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60024,3,Before an item can be placed in a liquid chemical sterile processing system they must be,199167,2,"c.	sterilized",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60024,3,Before an item can be placed in a liquid chemical sterile processing system they must be,199168,3,"d.	cleaned",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60025,4,Which of the following statements about immediate use steam sterilization is true?,199169,0,"a.	It is the sterilization method of choice for mental instruments",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60025,4,Which of the following statements about immediate use steam sterilization is true?,199170,1,"b.	It is recommended to be used as a primary sterilization process by the Association for the Advancement of Medical Instrumentation and the Association of periOperative Registered Nurses",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60025,4,Which of the following statements about immediate use steam sterilization is true?,199171,2,"c.	It reduces turnaround time because cleaning is not required",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60025,4,Which of the following statements about immediate use steam sterilization is true?,199172,3,"d.	It should be used only when there is not time to process items using the wrapped method",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60026,5,Both the Association of periOperative Registered Nurses and The Joint Commission recommend that,199173,0,"a.	The use of immediate use steam sterilization be minimized or decreased",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60026,5,Both the Association of periOperative Registered Nurses and The Joint Commission recommend that,199174,1,"b.	Immediate use steam sterilization be performed in only one sterilizer per facility",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60026,5,Both the Association of periOperative Registered Nurses and The Joint Commission recommend that,199175,2,"c.	Healthcare facilities get U.S. Food and Drug Administration approval for immediate use steam sterilization",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60026,5,Both the Association of periOperative Registered Nurses and The Joint Commission recommend that,199176,3,"d.	Only Central Service technicians operate immediate use steam sterilizers",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60027,6,Implantable devices,199177,0,"a.	Should be immediate use steam sterilization in extended cycles",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60027,6,Implantable devices,199178,1,"b.	Should only be sterilized using ethylene oxide",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60027,6,Implantable devices,199179,2,"c.	Should not be immediate use steam sterilization sterilized unless there is a tracking system in place to trace the item to a patient",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60027,6,Implantable devices,199180,3,"d.	Require double cycle sterilization to ensure sterility",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60028,7,"When transporting items that have been immediate use steam sterilized, it is required that",199181,0,"a.	They be transported in a metal container",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60028,7,"When transporting items that have been immediate use steam sterilized, it is required that",199182,1,"b.	They be transported to the patient area within five minutes of the completion of the sterilization cycle",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60028,7,"When transporting items that have been immediate use steam sterilized, it is required that",199183,2,"c.	They be allow to properly cooled before transport",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60028,7,"When transporting items that have been immediate use steam sterilized, it is required that",199184,3,"d.	They be transported in such a manner that reduces the potential for contamination",1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60029,8,"When sterilizing items at the point-of-use, an abbreviated cleaning procedure may be used due to the urgent need for the instruments.",199185,0,TRUE,0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60029,8,"When sterilizing items at the point-of-use, an abbreviated cleaning procedure may be used due to the urgent need for the instruments.",199186,1,FALSE,1
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60030,9,Immediate use steam sterilization documentation should include,199187,0,"a.	The name of the patient for which the items were sterilized",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60030,9,Immediate use steam sterilization documentation should include,199188,1,"b.	Sterilizer number and cycle",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60030,9,Immediate use steam sterilization documentation should include,199189,2,"c.	Name of the instrument sterilized",0
8889,Elearning-0000-176,SPD INTERNSHIP CHAPTER 13 - POINT-OF-USE PROCESSING,n13461,60030,9,Immediate use steam sterilization documentation should include,199190,3,"d.	All the above",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60031,0,"When loading a steam sterilizer, basins should be",199191,0,"a.	Placed in an upright position",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60031,0,"When loading a steam sterilizer, basins should be",199192,1,"b.	Loaded first",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60031,0,"When loading a steam sterilizer, basins should be",199193,2,"c.	Placed on edge",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60031,0,"When loading a steam sterilizer, basins should be",199194,3,"d.	Placed in a wire basket",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60032,1,The higher the bioburden on an object,199195,0,"a.	The more difficult it will be to sterilize",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60032,1,The higher the bioburden on an object,199196,1,"b.	The less time it will take to sterilize it",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60032,1,The higher the bioburden on an object,199197,2,"c.	The more biological tests will be needed in the load",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60032,1,The higher the bioburden on an object,199198,3,"d.	The longer it will take to cool after sterilization",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60033,2,"When combining loads, hard goods should be placed on the top shelves to allow for more efficient removal of the condensate",199199,0,TRUE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60033,2,"When combining loads, hard goods should be placed on the top shelves to allow for more efficient removal of the condensate",199200,1,FALSE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60034,3,The steam sterilization process can be affected by the design of the medical device being sterilized,199201,0,TRUE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60034,3,The steam sterilization process can be affected by the design of the medical device being sterilized,199202,1,FALSE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60035,4,Central Service technicians need to understand the anatomy of a steam sterilizer to,199203,0,"a.	Know how to properly clean the chamber",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60035,4,Central Service technicians need to understand the anatomy of a steam sterilizer to,199204,1,"b.	Understand how the sterilizer operates",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60035,4,Central Service technicians need to understand the anatomy of a steam sterilizer to,199205,2,"c.	Understand how to test the thermostatic trap",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60035,4,Central Service technicians need to understand the anatomy of a steam sterilizer to,199206,3,"d.	Know how to properly maintain the jacket",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60036,5,The weakest part of a steam sterilizer is the,199207,0,"a.	Jacket",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60036,5,The weakest part of a steam sterilizer is the,199208,1,"b.	Gasket",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60036,5,The weakest part of a steam sterilizer is the,199209,2,"c.	Door",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60036,5,The weakest part of a steam sterilizer is the,199210,3,"d.	Thermostatic valve",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60037,6,Three of the main phases of a terminal steam sterilizer cycle are,199211,0,"a.	Gravity, exposure and exhaust",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60037,6,Three of the main phases of a terminal steam sterilizer cycle are,199212,1,"b.	Pre-vacuum, exposure and exhaust",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60037,6,Three of the main phases of a terminal steam sterilizer cycle are,199213,2,"c.	Exposure, exhaust and dry",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60037,6,Three of the main phases of a terminal steam sterilizer cycle are,199214,3,"d.	Conditioning, exposure and exhaust",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60038,7,The most common reason for steam sterilization failure is,199215,0,"a.	Lack of steam contact with the instrument",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60038,7,The most common reason for steam sterilization failure is,199216,1,"b.	Insufficient temperature",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60038,7,The most common reason for steam sterilization failure is,199217,2,"c.	Inadequate exposure time",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60038,7,The most common reason for steam sterilization failure is,199218,3,"d.	Drying issues",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60039,8,The coolest place in a steam sterilizer is the,199219,0,"a.	Gasket",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60039,8,The coolest place in a steam sterilizer is the,199220,1,"b.	Thermostatic trap",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60039,8,The coolest place in a steam sterilizer is the,199221,2,"c.	Jacket",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60039,8,The coolest place in a steam sterilizer is the,199222,3,"d.	Chamber",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60040,9,Steam flush pressure pulse sterilizers are a type of gravity sterilizers,199223,0,TRUE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60040,9,Steam flush pressure pulse sterilizers are a type of gravity sterilizers,199224,1,FALSE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60041,10,Factors that can cause sterilant contact failure with the instrument are,199225,0,"a.	Cleaning, loosely packed load",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60041,10,Factors that can cause sterilant contact failure with the instrument are,199226,1,"b.	Conditioning, size and weight of the instrument",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60041,10,Factors that can cause sterilant contact failure with the instrument are,199227,2,"c.	Solid bottom containers, exposure time",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60041,10,Factors that can cause sterilant contact failure with the instrument are,199228,3,"d.	Crowded loads, clogged drain strainer",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60042,11,One of the most frequent causes of a clogged drain screen is,199229,0,"a.	Tape",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60042,11,One of the most frequent causes of a clogged drain screen is,199230,1,"b.	Wrapper particles",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60042,11,One of the most frequent causes of a clogged drain screen is,199231,2,"c.	Poor steam quality",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60042,11,One of the most frequent causes of a clogged drain screen is,199232,3,"d.	Malfunctioning baffle plate",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60043,12,Peel pouches should be placed _______________________________________ for sterilization,199233,0,"a.	On edge, paper to plastic",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60043,12,Peel pouches should be placed _______________________________________ for sterilization,199234,1,"b.	On edge, plastic to plastic",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60043,12,Peel pouches should be placed _______________________________________ for sterilization,199235,2,"c.	Placed flat with the plastic side up",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60043,12,Peel pouches should be placed _______________________________________ for sterilization,199236,3,"d.	Placed flat with the paper side up",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60044,13,Items with a standard steam sterilization cycle recommended by the manufacturer can be damaged if run in an extended cycle.,199237,0,TRUE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60044,13,Items with a standard steam sterilization cycle recommended by the manufacturer can be damaged if run in an extended cycle.,199238,1,FALSE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60045,14,How frequently should a sterilizer's strainer be removed and cleaned?,199239,0,"a.	Daily",1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60045,14,How frequently should a sterilizer's strainer be removed and cleaned?,199240,1,"b.	After each use",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60045,14,How frequently should a sterilizer's strainer be removed and cleaned?,199241,2,"c.	Once weekly",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60045,14,How frequently should a sterilizer's strainer be removed and cleaned?,199242,3,"d.	Only when the machine's operating control gauge indicates cleaning is necessary",0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60046,15,Immediate use steam sterilization is the process to sterilize trays for future use.,199243,0,TRUE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60046,15,Immediate use steam sterilization is the process to sterilize trays for future use.,199244,1,FALSE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60047,16,Wood products should be sterilized in an extended steam cycle.,199245,0,TRUE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60047,16,Wood products should be sterilized in an extended steam cycle.,199246,1,FALSE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60049,18,When water is seen on the outside of a pack after sterilization the pack is considered safe to use if all other packs in the load are dry.,199249,0,TRUE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60049,18,When water is seen on the outside of a pack after sterilization the pack is considered safe to use if all other packs in the load are dry.,199250,1,FALSE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60050,19,Packs that are improperly packaged or loaded on the sterilizer cart frequently become wet packs.,199251,0,TRUE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60050,19,Packs that are improperly packaged or loaded on the sterilizer cart frequently become wet packs.,199252,1,FALSE,0
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60227,20,After sterilization the load contents may take two hours or more to cool.,199913,0,TRUE,1
8888,Elearning-0000-175,SPD INTERNSHIP CHAPTER 14 - HIGH-TEMPERATURE STERILIZATION,n13462,60227,20,After sterilization the load contents may take two hours or more to cool.,199914,1,FALSE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60070,0,Woven reusable fabrics are the packaging products of choice for ozone sterilization,199326,0,TRUE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60070,0,Woven reusable fabrics are the packaging products of choice for ozone sterilization,199327,1,FALSE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60071,1,Ethylene kills microorganisms by a process called oxidation,199328,0,TRUE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60071,1,Ethylene kills microorganisms by a process called oxidation,199329,1,FALSE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60072,2,"Ethylene oxide, hydrogen peroxide and ozone sterilization process must all be monitored using chemical, physical and biological monitors.",199330,0,TRUE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60072,2,"Ethylene oxide, hydrogen peroxide and ozone sterilization process must all be monitored using chemical, physical and biological monitors.",199331,1,FALSE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60073,3,"Ethylene oxide, hydrogen peroxide and ozone sterilization can all use the same packaging materials.",199332,0,TRUE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60073,3,"Ethylene oxide, hydrogen peroxide and ozone sterilization can all use the same packaging materials.",199333,1,FALSE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60074,4,Lumens should be moist when using hydrogen peroxide as a sterilizing agent,199334,0,TRUE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60074,4,Lumens should be moist when using hydrogen peroxide as a sterilizing agent,199335,1,FALSE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60075,5,Ethylene oxide is a toxic gas,199336,0,TRUE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60075,5,Ethylene oxide is a toxic gas,199337,1,FALSE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60076,6,"7.	Cellulose-containing packaging materials are not compatible with hydrogen peroxide sterilization.",199338,0,TRUE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60076,6,"7.	Cellulose-containing packaging materials are not compatible with hydrogen peroxide sterilization.",199339,1,FALSE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60077,7,Information about device's compatibility with a specific sterilization process should be obtained from the device's manufacturer.,199340,0,TRUE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60077,7,Information about device's compatibility with a specific sterilization process should be obtained from the device's manufacturer.,199341,1,FALSE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60078,8,An extended aeration cycle is required for items sterilized in ozone sterilization processes.,199342,0,TRUE,0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60078,8,An extended aeration cycle is required for items sterilized in ozone sterilization processes.,199343,1,FALSE,1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60079,9,Permissible exposure levels for low-temperature sterilization methods are established by the,199344,0,"a.	U.S. Food and Drug Administration",0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60079,9,Permissible exposure levels for low-temperature sterilization methods are established by the,199345,1,"b.	Centers for Disease Control",0
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60079,9,Permissible exposure levels for low-temperature sterilization methods are established by the,199346,2,"c.	Occupational Safety and Health Administration",1
8882,Elearning-0000-174,SPD INTERNSHIP CHAPTER 15 - LOW-TEMPERATURE STERILIZATION,n13466,60079,9,Permissible exposure levels for low-temperature sterilization methods are established by the,199347,3,"d.	Environmental Protection Agency",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60119,0,The relative humidity of the Central Service sterile storage areas should be,199489,0,"a.	Less than 70%",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60119,0,The relative humidity of the Central Service sterile storage areas should be,199490,1,"b.	Less than 60%",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60119,0,The relative humidity of the Central Service sterile storage areas should be,199491,2,"c.	Less than 50%",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60119,0,The relative humidity of the Central Service sterile storage areas should be,199492,3,"d.	Less than 35%",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60120,1,Temperatures in a sterile storage area should be 64 ∞ to 75 ∞F.,199493,0,TRUE,0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60120,1,Temperatures in a sterile storage area should be 64 ∞ to 75 ∞F.,199494,1,FALSE,1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60121,2,"Because of event-related shelf-life, stock rotation is no longer necessary.",199495,0,TRUE,0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60121,2,"Because of event-related shelf-life, stock rotation is no longer necessary.",199496,1,FALSE,1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60122,3,The sterile storage process starts,199497,0,"a.	When items are received in the decontamination area",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60122,3,The sterile storage process starts,199498,1,"b.	After items are sterilized and cooled",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60122,3,The sterile storage process starts,199499,2,"c.	When the sterilizer door is opened",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60122,3,The sterile storage process starts,199500,3,"d.	When items are placed into the sterilizer",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60123,4,Sterile storage areas should,199501,0,"a.	Have positive airflow and at least 10 air exchanges per hour",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60123,4,Sterile storage areas should,199502,1,"b.	Have positive airflow and at least four air exchanges per hour",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60123,4,Sterile storage areas should,199503,2,"c.	Have negative airflow and at least 10 air exchanges per hour",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60123,4,Sterile storage areas should,199504,3,"d.	Have negative airflow and at least four air exchanges per hour",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60124,5,Temperature and humidity levels in the sterile storage area should be checked and recorded at least weekly,199505,0,TRUE,0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60124,5,Temperature and humidity levels in the sterile storage area should be checked and recorded at least weekly,199506,1,FALSE,1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60125,6,The shelving system of choice for the sterile storage area is,199507,0,"a.	Closed",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60125,6,The shelving system of choice for the sterile storage area is,199508,1,"b.	Semi closed",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60125,6,The shelving system of choice for the sterile storage area is,199509,2,"c.	Open",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60125,6,The shelving system of choice for the sterile storage area is,199510,3,"d.	Tracked",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60126,7,Trays which overhang shelving,199511,0,"a.	Can become contaminated",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60126,7,Trays which overhang shelving,199512,1,"b.	Are ok for rigid containers, but not for flat wrapped trays",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60126,7,Trays which overhang shelving,199513,2,"c.	Is the appropriate way to store trays as it allows for the use of proper body mechanics when lifting heavy trays",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60126,7,Trays which overhang shelving,199514,3,"d.	None of the above",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60127,8,The type of shelving that leaves packaging the most vulnerable is,199515,0,"a.	Open",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60127,8,The type of shelving that leaves packaging the most vulnerable is,199516,1,"b.	Closed",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60127,8,The type of shelving that leaves packaging the most vulnerable is,199517,2,"c.	Semi closed",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60127,8,The type of shelving that leaves packaging the most vulnerable is,199518,3,"d.	Tracked",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60128,9,The bottom shelf of any sterile storage system should be,199519,0,"a.	Solid and eight to 10 inches from the floor",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60128,9,The bottom shelf of any sterile storage system should be,199520,1,"b.	Solid and two to four inches from the floor",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60128,9,The bottom shelf of any sterile storage system should be,199521,2,"c.	Cleaned weekly",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60128,9,The bottom shelf of any sterile storage system should be,199522,3,"d.	Wire and eight to 10 inches from the floor",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60129,10,Sterile trays should,199523,0,"a.	Not be touched until they are properly cooled",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60129,10,Sterile trays should,199524,1,"b.	Be lifted not dragged off the sterilizer cart",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60129,10,Sterile trays should,199525,2,"c.	Be checked to be sure the chemical indicators have turned the appropriate color",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60129,10,Sterile trays should,199526,3,"d.	All of the above",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60130,11,Wrapped trays should not be stacked because,199527,0,"a.	The tray contents may be damaged",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60130,11,Wrapped trays should not be stacked because,199528,1,"b.	It can cause holes in the wrapper of the bottom tray",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60130,11,Wrapped trays should not be stacked because,199529,2,"c.	It will cause the shelving to bend",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60130,11,Wrapped trays should not be stacked because,199530,3,"d.	They will be more difficult to rotate",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60131,12,Outside shipping containers,199531,0,"a.	Should be removed prior to placing the items in storage",1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60131,12,Outside shipping containers,199532,1,"b.	May be stored in the sterile storage area as long as they are not stored near the in-house sterilized items",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60131,12,Outside shipping containers,199533,2,"c.	Make good storage containers to help keep items from falling from the shelves",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60131,12,Outside shipping containers,199534,3,"d.	All the above",0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60132,13,Event-related shelf life means items are safe until opened for use.,199535,0,TRUE,0
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60132,13,Event-related shelf life means items are safe until opened for use.,199536,1,FALSE,1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60133,14,Sterilized packages may be jeopardized due to storage practices.,199537,0,TRUE,1
8872,Elearning-0000-173,SPD INTERNSHIP CHAPTER 16 - STERILE STORAGE AND TRANSPORT,n13469,60133,14,Sterilized packages may be jeopardized due to storage practices.,199538,1,FALSE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60104,0,A Bronch Wash is any volume less than 20ml,199449,0,TRUE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60104,0,A Bronch Wash is any volume less than 20ml,199450,1,FALSE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60105,1,A Bronchial Alveolar Lavage is any volume 20ml or greater,199451,0,TRUE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60105,1,A Bronchial Alveolar Lavage is any volume 20ml or greater,199452,1,FALSE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60106,2,What do you need to be aware of before giving Phenylephrine,199453,0,1. It can decrease blood pressure,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60106,2,What do you need to be aware of before giving Phenylephrine,199454,1,2. It can increase blood pressure,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60106,2,What do you need to be aware of before giving Phenylephrine,199455,2,3. It can cause a fast/irregular heartbeat,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60106,2,What do you need to be aware of before giving Phenylephrine,199456,3,4. It can increase the blood pressure and cause a fast/irregular heartbeat.,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60107,3,Correct mixture for Phenylephrine is,199457,0,1. 10ml mixed with 1ml of 0.9% Sodium Chloride,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60107,3,Correct mixture for Phenylephrine is,199458,1,2. 1ml mixed with 9ml of 0.9% Sodium Chloride,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60107,3,Correct mixture for Phenylephrine is,199459,2,3. 1ml mixed with 9ml of 0.9% Sodium Bicarb,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60108,4,What is the best way to achieve hemostasis in the lung,199460,0,1. CPAP,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60108,4,What is the best way to achieve hemostasis in the lung,199461,1,2. Iced normal saline lavage,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60108,4,What is the best way to achieve hemostasis in the lung,199462,2,3. Hold pressure with the bronchoscope,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60109,5,"When prepping nares for a bronchoscopy, what % viscous lidocaine should be used",199463,0,1. 10%,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60109,5,"When prepping nares for a bronchoscopy, what % viscous lidocaine should be used",199464,1,2. 1%,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60109,5,"When prepping nares for a bronchoscopy, what % viscous lidocaine should be used",199465,2,3. 5%,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60109,5,"When prepping nares for a bronchoscopy, what % viscous lidocaine should be used",199466,3,4. 2%,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60110,6,"When prepping a patient for a bronchoscopy, with platelets less than 50, you should prep the mouth instead of the nares",199467,0,TRUE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60110,6,"When prepping a patient for a bronchoscopy, with platelets less than 50, you should prep the mouth instead of the nares",199468,1,FALSE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60111,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,199469,0,1. Formaldehyde,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60111,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,199470,1,2. Alcohol,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60111,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,199471,2,3. Peroxide,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60111,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,199472,3,4. Hairspray,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60112,8,You should always wear gloves when touching a bronchoscope?,199473,0,TRUE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60112,8,You should always wear gloves when touching a bronchoscope?,199474,1,FALSE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60113,9,The Medication sheet should be:,199475,0,1. Signed and dated only,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60113,9,The Medication sheet should be:,199476,1,2. Noted and timed only,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60113,9,The Medication sheet should be:,199477,2,"3. Signed, dated, timed, and noted",1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60113,9,The Medication sheet should be:,199478,3,4. None of the above,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60114,10,The bedside pre-clean of the bronchoscope can be done after you take the samples to the lab,199479,0,TRUE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60114,10,The bedside pre-clean of the bronchoscope can be done after you take the samples to the lab,199480,1,FALSE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60115,11,The enzymatic sponge is utilized during the bedside pre-clean,199481,0,TRUE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60115,11,The enzymatic sponge is utilized during the bedside pre-clean,199482,1,FALSE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60116,12,You should transport a bronchoscope in a closed bin,199483,0,TRUE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60116,12,You should transport a bronchoscope in a closed bin,199484,1,FALSE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60117,13,It is ok if a clean bronchoscope touches another clean bronchoscope while stored in gi lab,199485,0,TRUE,0
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60117,13,It is ok if a clean bronchoscope touches another clean bronchoscope while stored in gi lab,199486,1,FALSE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60118,14,Physicians are responsible for placing bronch orders in to cerner,199487,0,TRUE,1
9925,Questions-0000-59,FY2021 ANNUAL BRONCHOSCOPY TEST,n13468,60118,14,Physicians are responsible for placing bronch orders in to cerner,199488,1,FALSE,0
9524,Elearning-0000-753,C369 VERSION 4.0,n13471,60154,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",199621,0,TRUE,1
9524,Elearning-0000-753,C369 VERSION 4.0,n13471,60154,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",199622,1,FALSE,0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60217,0,Formal training should occur,199877,0,"a.	For new employees",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60217,0,Formal training should occur,199878,1,"b.	At least monthly",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60217,0,Formal training should occur,199879,2,"c.	For employees who move to a new positions",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60217,0,Formal training should occur,199880,3,"d.	For new employees and those who move to new position",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60218,1,Monitoring records must be,199881,0,"a.	Accurate",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60218,1,Monitoring records must be,199882,1,"b.	Legible",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60218,1,Monitoring records must be,199883,2,"c.	Complete",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60218,1,Monitoring records must be,199884,3,"d.	All the above",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60219,2,Sterilizer load records should contain,199885,0,"a.	Items and quantity sterilized",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60219,2,Sterilizer load records should contain,199886,1,"b.	Type of packaging used in the load",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60219,2,Sterilizer load records should contain,199887,2,"c.	Preventative maintenance dates",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60219,2,Sterilizer load records should contain,199888,3,"d.	All the above",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60220,3,External indicators can prove an item is sterile when the sterilization cycle is complete,199889,0,TRUE,0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60220,3,External indicators can prove an item is sterile when the sterilization cycle is complete,199890,1,FALSE,1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60221,4,Temperature and humidity levels need to be monitored and recorded,199891,0,"a.	Weekly, preferably daily",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60221,4,Temperature and humidity levels need to be monitored and recorded,199892,1,"b.	For each shift",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60221,4,Temperature and humidity levels need to be monitored and recorded,199893,2,"c.	At least daily",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60221,4,Temperature and humidity levels need to be monitored and recorded,199894,3,"d.	At least monthly",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60222,5,The U.S. Food and Drug Administration Class II chemical indicator that is run daily in dynamic air removal sterilizers is called a,199895,0,"a.	Process challenge device",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60222,5,The U.S. Food and Drug Administration Class II chemical indicator that is run daily in dynamic air removal sterilizers is called a,199896,1,"b.	External chemical indicator",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60222,5,The U.S. Food and Drug Administration Class II chemical indicator that is run daily in dynamic air removal sterilizers is called a,199897,2,"c.	Biological indicator",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60222,5,The U.S. Food and Drug Administration Class II chemical indicator that is run daily in dynamic air removal sterilizers is called a,199898,3,"d.	Bowie-Dick test",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60223,6,One type of formal monitoring is monitoring the department temperature and humidity levels,199899,0,TRUE,1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60223,6,One type of formal monitoring is monitoring the department temperature and humidity levels,199900,1,FALSE,0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60224,7,A physical monitor on a washer-disinfector is the,199901,0,"a.	Thermostatic valve",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60224,7,A physical monitor on a washer-disinfector is the,199902,1,"b.	Printout",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60224,7,A physical monitor on a washer-disinfector is the,199903,2,"c.	Biological test",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60224,7,A physical monitor on a washer-disinfector is the,199904,3,"d.	All the above",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60225,8,Cart washer screens should be cleaned at least,199905,0,"a.	Daily",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60225,8,Cart washer screens should be cleaned at least,199906,1,"b.	During each shift",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60225,8,Cart washer screens should be cleaned at least,199907,2,"c.	Weekly, preferably daily",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60225,8,Cart washer screens should be cleaned at least,199908,3,"d.	Monthly",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60226,9,A biological indicator is called positive when,199909,0,"a.	The incubation process is complete",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60226,9,A biological indicator is called positive when,199910,1,"b.	There is no growth in the ampule after incubation",0
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60226,9,A biological indicator is called positive when,199911,2,"c.	There is growth in the ampule after incubation",1
8861,Elearning-0000-172,SPD INTERNSHIP CHAPTER 17 - MONITORING AND RECORDKEEPING FOR CENTRAL,n13475,60226,9,A biological indicator is called positive when,199912,3,"d.	Prior to sterilization",0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60254,0,Quality requires the efforts and participation of everyone in the healthcare facility.,200021,0,TRUE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60254,0,Quality requires the efforts and participation of everyone in the healthcare facility.,200022,1,FALSE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60255,1,A failure mode and effects analysis tried to predict failures before they occur.,200023,0,TRUE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60255,1,A failure mode and effects analysis tried to predict failures before they occur.,200024,1,FALSE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60256,2,The International Standards Organization uses routine and unannounced inspections to monitor standards in healthcare facilities.,200025,0,TRUE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60256,2,The International Standards Organization uses routine and unannounced inspections to monitor standards in healthcare facilities.,200026,1,FALSE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60257,3,Quality processes are limited to administration and the risk management department.,200027,0,TRUE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60257,3,Quality processes are limited to administration and the risk management department.,200028,1,FALSE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60258,4,Quality management is patient focused.,200029,0,TRUE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60258,4,Quality management is patient focused.,200030,1,FALSE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60259,5,Providing quality products and services directly impacts patient outcomes.,200031,0,TRUE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60259,5,Providing quality products and services directly impacts patient outcomes.,200032,1,FALSE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60260,6,Customer surveys are ineffective tools in establishing Central Service quality processes.,200033,0,TRUE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60260,6,Customer surveys are ineffective tools in establishing Central Service quality processes.,200034,1,FALSE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60261,7,"If everyone develops a quality-driven focus, written policies and procedures are not necessary in the Central Service department.",200035,0,TRUE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60261,7,"If everyone develops a quality-driven focus, written policies and procedures are not necessary in the Central Service department.",200036,1,FALSE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60262,8,A root cause analysis is a proactive approach to quality.,200037,0,TRUE,0
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60262,8,A root cause analysis is a proactive approach to quality.,200038,1,FALSE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60263,9,Not following established policies and procedures will result in a lower quality program.,200039,0,TRUE,1
8850,Elearning-0000-171,SPD INTERNSHIP CHAPTER 18 - QUALITY ASSURANCE,n13478,60263,9,Not following established policies and procedures will result in a lower quality program.,200040,1,FALSE,0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60285,0,Which of the following systems provides supplies and instruments for individual surgical procedures?,200125,0,"a.	Exchange cart",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60285,0,Which of the following systems provides supplies and instruments for individual surgical procedures?,200126,1,"b.	Periodic automated replenishment system",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60285,0,Which of the following systems provides supplies and instruments for individual surgical procedures?,200127,2,"c.	Case cart",1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60285,0,Which of the following systems provides supplies and instruments for individual surgical procedures?,200128,3,"d.	Requisition",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60286,1,The inventory system that stocks supplies by established stock levels is called,200129,0,"a.	A periodic automated replenishment system",1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60286,1,The inventory system that stocks supplies by established stock levels is called,200130,1,"b.	Case cart",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60286,1,The inventory system that stocks supplies by established stock levels is called,200131,2,"c.	An ADT system",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60286,1,The inventory system that stocks supplies by established stock levels is called,200132,3,"d.	Exchange system",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60287,2,The inventory system that uses two identical carts to facilitate supply replenishment is called the,200133,0,"a.	Case cart system",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60287,2,The inventory system that uses two identical carts to facilitate supply replenishment is called the,200134,1,"b.	Exchange cart system",1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60287,2,The inventory system that uses two identical carts to facilitate supply replenishment is called the,200135,2,"c.	Periodic automated replenishment system",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60287,2,The inventory system that uses two identical carts to facilitate supply replenishment is called the,200136,3,"d.	Requisition system",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60288,3,Automated supply replenishment systems are,200137,0,"a.	No longer used",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60288,3,Automated supply replenishment systems are,200138,1,"b.	Used only in surgery",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60288,3,Automated supply replenishment systems are,200139,2,"c.	Difficult to manage",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60288,3,Automated supply replenishment systems are,200140,3,"d.	Computerized",1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60289,4,The movement of supplies throughout the healthcare facility is called,200141,0,"a.	Distribution",1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60289,4,The movement of supplies throughout the healthcare facility is called,200142,1,"b.	Inventory management",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60289,4,The movement of supplies throughout the healthcare facility is called,200143,2,"c.	Case cart system",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60289,4,The movement of supplies throughout the healthcare facility is called,200144,3,"d.	Procurement",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60290,5,Operational supplies are supplies that are dispensed for patient care,200145,0,TRUE,0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60290,5,Operational supplies are supplies that are dispensed for patient care,200146,1,FALSE,1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60291,6,Supplies such as disposable wraps are called,200147,0,"a.	Consumable",1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60291,6,Supplies such as disposable wraps are called,200148,1,"b.	Capital supplies",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60291,6,Supplies such as disposable wraps are called,200149,2,"c.	Patient care supplies",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60291,6,Supplies such as disposable wraps are called,200150,3,"d.	Non-refundable supplies",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60292,7,Capital equipment items are,200151,0,"a.	Usually used for patient care",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60292,7,Capital equipment items are,200152,1,"b.	Items with a lower purchase cost",0
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60292,7,Capital equipment items are,200153,2,"c.	Items with a higher purchase count",1
8839,Elearning-0000-170,SPD INTERNSHIP CHAPTER 19 - MANAGING INVENTORY WITHIN THE CENTRAL SERVICE DEPARTMENT,n13480,60292,7,Capital equipment items are,200154,3,"d.	Purchased, stored, consumed and recorded",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60293,0,T/F Anticoagulants are HIGH risk medications that are more likely to cause patient harm then most other classes of medications,200155,0,TRUE,1
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60293,0,T/F Anticoagulants are HIGH risk medications that are more likely to cause patient harm then most other classes of medications,200156,1,FALSE,0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60294,1,T/F The Joint Commission created National Patient Safety Goal 03.05.01 to reduce the likelihood of patient harm associated with the use of anticoagulant therapy.,200157,0,TRUE,1
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60294,1,T/F The Joint Commission created National Patient Safety Goal 03.05.01 to reduce the likelihood of patient harm associated with the use of anticoagulant therapy.,200158,1,FALSE,0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60295,2,Reversal agents may be used to reverse the effects of anticoagulants to:,200159,0,"a.	Reduce the risk of bleeding during scheduled surgeries or procedures",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60295,2,Reversal agents may be used to reverse the effects of anticoagulants to:,200160,1,"b.	Treatment of minor or moderate bleeding in a patient on anticoagulant therapy",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60295,2,Reversal agents may be used to reverse the effects of anticoagulants to:,200161,2,"c.	Treatment of major, or life-threatening bleeding in a patient on anticoagulant therapy",1
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60295,2,Reversal agents may be used to reverse the effects of anticoagulants to:,200162,3,"d.	Treatment of patients with elevated INR, anti-Xa, or aPTT who are not actively bleeding",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60295,2,Reversal agents may be used to reverse the effects of anticoagulants to:,200163,4,"e.	All of the above",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60296,3,Which of the following statements are true regarding the use of anticoagulants in the perioperative setting?,200164,0,"a.	Special consideration should be taken to appropriately time the last dose prior to, and the first dose after a procedure.",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60296,3,Which of the following statements are true regarding the use of anticoagulants in the perioperative setting?,200165,1,"b.	The use of therapeutic anticoagulation is generally contraindicated in patients with an epidural.",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60296,3,Which of the following statements are true regarding the use of anticoagulants in the perioperative setting?,200166,2,"c.	Pharmacy and Pain Service should be contacted prior to administering any anticoagulant to a patient with an epidural.",0
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60296,3,Which of the following statements are true regarding the use of anticoagulants in the perioperative setting?,200167,3,"d.	All of the above",1
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60297,4,T/F Northside Hospital Policy & Procedures on anticoagulant therapy as well as evidence-based guidelines and references may be found on Lucidoc,200168,0,TRUE,1
9125,Elearning-0000-390,FY2021 NPSG 03.05.01 SAFE USE OF ANTICOAGULANT THERAPY,n13481,60297,4,T/F Northside Hospital Policy & Procedures on anticoagulant therapy as well as evidence-based guidelines and references may be found on Lucidoc,200169,1,FALSE,0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60298,0,Technicians in the ______________________________ department perform safety inspections and functional tests on equipment.,200170,0,"a.	Materials Management",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60298,0,Technicians in the ______________________________ department perform safety inspections and functional tests on equipment.,200171,1,"b.	Infection control",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60298,0,Technicians in the ______________________________ department perform safety inspections and functional tests on equipment.,200172,2,"c.	Biomedical/Clinical Engineering",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60298,0,Technicians in the ______________________________ department perform safety inspections and functional tests on equipment.,200173,3,"d.	Facilities and maintenance",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60299,1,"When patient equipment enters a healthcare facility, it must be safety checked by a _____________________________ before it is cleared for patient use.",200174,0,"a.	Biomedical technician",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60299,1,"When patient equipment enters a healthcare facility, it must be safety checked by a _____________________________ before it is cleared for patient use.",200175,1,"b.	infection control committee member",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60299,1,"When patient equipment enters a healthcare facility, it must be safety checked by a _____________________________ before it is cleared for patient use.",200176,2,"c.	Central Service technician",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60299,1,"When patient equipment enters a healthcare facility, it must be safety checked by a _____________________________ before it is cleared for patient use.",200177,3,"d.	Central Service director",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60300,2,Which of the following requires that preventative maintenance standards be established for medical equipment?,200178,0,"a.	Occupational Safety and Health Administration",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60300,2,Which of the following requires that preventative maintenance standards be established for medical equipment?,200179,1,"b.	The Joint Commission",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60300,2,Which of the following requires that preventative maintenance standards be established for medical equipment?,200180,2,"c.	Association for the Advancement of Medical Instrumentation",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60300,2,Which of the following requires that preventative maintenance standards be established for medical equipment?,200181,3,"d.	National Institute for Occupational Safety and Health",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60301,3,"All patient care equipment that was dispensed for use must be Considered ______________________ and handled as such, regardless of its appearance.",200182,0,"a.	sterile",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60301,3,"All patient care equipment that was dispensed for use must be Considered ______________________ and handled as such, regardless of its appearance.",200183,1,"b.	clean",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60301,3,"All patient care equipment that was dispensed for use must be Considered ______________________ and handled as such, regardless of its appearance.",200184,2,"c.	contaminated",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60301,3,"All patient care equipment that was dispensed for use must be Considered ______________________ and handled as such, regardless of its appearance.",200185,3,"d.	visibly soiled",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60302,4,Which of the following common items of patient care equipment limits the development of deep vein thrombosis and peripheral edema in immobile patients?,200186,0,"a.	Respirator",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60302,4,Which of the following common items of patient care equipment limits the development of deep vein thrombosis and peripheral edema in immobile patients?,200187,1,"b.	Intermittent suction device",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60302,4,Which of the following common items of patient care equipment limits the development of deep vein thrombosis and peripheral edema in immobile patients?,200188,2,"c.	Sequential compression device",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60302,4,Which of the following common items of patient care equipment limits the development of deep vein thrombosis and peripheral edema in immobile patients?,200189,3,"d.	Defibrillator",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60306,5,Disposable components such as pads and tubing on patient care equipment should be,200200,0,"a.	discarded at the point-of-use",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60306,5,Disposable components such as pads and tubing on patient care equipment should be,200201,1,"b.	be reprocessed for re-use",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60306,5,Disposable components such as pads and tubing on patient care equipment should be,200202,2,"c.	discarded during preventive maintenance",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60306,5,Disposable components such as pads and tubing on patient care equipment should be,200203,3,"d.	removed in the biomedical engineering department",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60307,6,Equipment should be inspected for obvious hazards such as cracked or frayed electrical cords,200204,0,"a.	only by trained biomedical engineering technicians",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60307,6,Equipment should be inspected for obvious hazards such as cracked or frayed electrical cords,200205,1,"b.	only during preventative maintenance activities",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60307,6,Equipment should be inspected for obvious hazards such as cracked or frayed electrical cords,200206,2,"c.	only when there are complaints from user department personnel",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60307,6,Equipment should be inspected for obvious hazards such as cracked or frayed electrical cords,200207,3,"d.	whenever the equipment is inspected in Central Service",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60308,7,"If an equipment malfunction causes harm to patients, it should be",200208,0,"a.	discarded immediately",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60308,7,"If an equipment malfunction causes harm to patients, it should be",200209,1,"b.	sent to the manufacturer for repairs",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60308,7,"If an equipment malfunction causes harm to patients, it should be",200210,2,"c.	sequestered for inspection by Occupational Safety and Health Administration personnel",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60308,7,"If an equipment malfunction causes harm to patients, it should be",200211,3,"d.	returned immediately to the biomedical department",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60309,8,Patient care equipment should be stored in a __________________________________ condition.,200212,0,"a.	""ready to dispense""ù",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60309,8,Patient care equipment should be stored in a __________________________________ condition.,200213,1,"b.	""ready to clean""ù",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60309,8,Patient care equipment should be stored in a __________________________________ condition.,200214,2,"c.	""ready to inspect""ù",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60309,8,Patient care equipment should be stored in a __________________________________ condition.,200215,3,"d.	""ready to sterilize""ù",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60310,9,Patient care equipment is typically stored,200216,0,"a.	in the Biomedical engineering department",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60310,9,Patient care equipment is typically stored,200217,1,"b.	in patient units",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60310,9,Patient care equipment is typically stored,200218,2,"c.	in the Central Service department",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60310,9,Patient care equipment is typically stored,200219,3,"d.	in sterile storage areas of the Materiel Management department",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60311,10,"The ________________________ requires that the healthcare facility report malfunctions of medical devices that have contributed to patient injury, illness and/or death to the manufacturer and the U.S. Food and Drug Administration.",200220,0,"a.	Occupational Safety and Health Administration Patient Safety Act",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60311,10,"The ________________________ requires that the healthcare facility report malfunctions of medical devices that have contributed to patient injury, illness and/or death to the manufacturer and the U.S. Food and Drug Administration.",200221,1,"b.	Safe Medical Devices Act",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60311,10,"The ________________________ requires that the healthcare facility report malfunctions of medical devices that have contributed to patient injury, illness and/or death to the manufacturer and the U.S. Food and Drug Administration.",200222,2,"c.	Environmental Protection Agency  Patient Security Act",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60311,10,"The ________________________ requires that the healthcare facility report malfunctions of medical devices that have contributed to patient injury, illness and/or death to the manufacturer and the U.S. Food and Drug Administration.",200223,3,"d.	U.S. Food and Drug Administration Equipment Notification Act",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60312,11,Which of the following statements is correct?,200224,0,"a.	Patient care equipment tracking requires a computer",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60312,11,Which of the following statements is correct?,200225,1,"b.	Patient care equipment should only be tracked if it has a value in excess of an amount specified by the facility",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60312,11,Which of the following statements is correct?,200226,2,"c.	Tracking patient care equipment can prevent equipment shortages",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60312,11,Which of the following statements is correct?,200227,3,"d.	Patient care equipment must only be tracked if its usage will be charged to patients",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60313,12,Equipment leasing and rental differ in that,200228,0,"a.	leasing involves purchase; rental does not require ownership",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60313,12,Equipment leasing and rental differ in that,200229,1,"b.	equipment rental is usually done on a shorter-term basis than equipment leasing",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60313,12,Equipment leasing and rental differ in that,200230,2,"c.	equipment leasing involves the most expensive equipment; equipment rental involves less expensive equipment",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60313,12,Equipment leasing and rental differ in that,200231,3,"d.	equipment leasing is an operating expense; equipment rental does not have cost implications",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60314,13,Preventative maintenance is,200232,0,"a.	performed when a piece of equipment injures a patient",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60314,13,Preventative maintenance is,200233,1,"b.	designed to identify potential problems before they occur",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60314,13,Preventative maintenance is,200234,2,"c.	performed when a user unit notices a problem",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60314,13,Preventative maintenance is,200235,3,"d.	done by Central Services before equipment is dispensed",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60315,14,The decision to use reusable or disposable instruments in procedure tray is determined by,200236,0,"a.	where the instruments will be used",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60315,14,The decision to use reusable or disposable instruments in procedure tray is determined by,200237,1,"b.	the Infection Prevention department",0
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60315,14,The decision to use reusable or disposable instruments in procedure tray is determined by,200238,2,"c.	several factors including physician preference, storage and cost",1
8816,Elearning-0000-168,SPD INTERNSHIP CHAPTER 20 - THE ROLE OF CENTRAL SERVICE IN ANCILLARY DEPARTMENT SUPPORT,n13482,60315,14,The decision to use reusable or disposable instruments in procedure tray is determined by,200239,3,"d.	amount of items to be used and delivery schedule",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60316,0,"In addition to providing financial and operational management, information technology and systems are used to help ensure patient safety.",200240,0,TRUE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60316,0,"In addition to providing financial and operational management, information technology and systems are used to help ensure patient safety.",200241,1,FALSE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60317,1,Information technology us often the cornerstone of initiatives to transform healthcare.,200242,0,TRUE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60317,1,Information technology us often the cornerstone of initiatives to transform healthcare.,200243,1,FALSE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60318,2,Which of the following is NOT a result of computer integration?,200244,0,"a.	Eliminating redundant entry of information",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60318,2,Which of the following is NOT a result of computer integration?,200245,1,"b.	Promotes efficiency",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60318,2,Which of the following is NOT a result of computer integration?,200246,2,"c.	Automatically provides critical update to industry standards",1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60318,2,Which of the following is NOT a result of computer integration?,200247,3,"d.	Reduced inaccurate and conflicting information",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60319,3,Patient census information used in Central Service is obtained from the electronic health record.,200248,0,TRUE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60319,3,Patient census information used in Central Service is obtained from the electronic health record.,200249,1,FALSE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60320,4,Computer supply chain management systems are used to monitor facility assets.,200250,0,TRUE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60320,4,Computer supply chain management systems are used to monitor facility assets.,200251,1,FALSE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60321,5,Tracking individual instruments is important to help ensure specific instruments are kept with a specific set.,200252,0,TRUE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60321,5,Tracking individual instruments is important to help ensure specific instruments are kept with a specific set.,200253,1,FALSE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60322,6,"Which of the following is NOT a reason for tracking supplies, equipment and instruments?",200254,0,"a.	Monitoring item use",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60322,6,"Which of the following is NOT a reason for tracking supplies, equipment and instruments?",200255,1,"b.	Ensuring that items can be quickly located",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60322,6,"Which of the following is NOT a reason for tracking supplies, equipment and instruments?",200256,2,"c.	Meeting Centers for Disease Control and Occupational Safety and Health Administration requirements",1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60322,6,"Which of the following is NOT a reason for tracking supplies, equipment and instruments?",200257,3,"d.	Assisting with quality processes",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60323,7,Which of the following tracking methods provides real-time information?,200258,0,"a.	Radio frequency identification tags",1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60323,7,Which of the following tracking methods provides real-time information?,200259,1,"b.	Laser-etched bar codes",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60323,7,Which of the following tracking methods provides real-time information?,200260,2,"c.	Standard bar codes",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60323,7,Which of the following tracking methods provides real-time information?,200261,3,"d.	Dot matrix applications",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60324,8,Point-of-use computing,200262,0,"a.	is impossible in Central Service because of infection control requirements",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60324,8,Point-of-use computing,200263,1,"b.	provides no benefit to the Central Service department",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60324,8,Point-of-use computing,200264,2,"c.	moves computers into Central Service work areas",1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60324,8,Point-of-use computing,200265,3,"d.	eliminates data entry jobs",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60325,9,Which of the following is NOT a feature of an instrument tracking system?,200266,0,"a.	Productivity information",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60325,9,Which of the following is NOT a feature of an instrument tracking system?,200267,1,"b.	Financial data",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60325,9,Which of the following is NOT a feature of an instrument tracking system?,200268,2,"c.	Quality assurance information",0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60325,9,Which of the following is NOT a feature of an instrument tracking system?,200269,3,"d.	Product updates and recall information",1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60326,10,"Computerized tracking systems are fast, but manual tracking systems are more effective for tracking.",200270,0,TRUE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60326,10,"Computerized tracking systems are fast, but manual tracking systems are more effective for tracking.",200271,1,FALSE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60327,11,"Once a tracking system is implemented, there is generally no need to update system information.",200272,0,TRUE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60327,11,"Once a tracking system is implemented, there is generally no need to update system information.",200273,1,FALSE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60328,12,"At this time, tracking systems are unable to track worker productivity information.",200274,0,TRUE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60328,12,"At this time, tracking systems are unable to track worker productivity information.",200275,1,FALSE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60329,13,Tracking systems can help manage preventative maintenance schedules.,200276,0,TRUE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60329,13,Tracking systems can help manage preventative maintenance schedules.,200277,1,FALSE,0
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60330,14,Most Central Service departments employ some sort of automated information management system.,200278,0,TRUE,1
8805,Elearning-0000-167,SPD INTERNSHIP CHAPTER 21 - THE ROLE OF INFORMATION TECHNOLOGY IN CENTRAL SERVICE,n13484,60330,14,Most Central Service departments employ some sort of automated information management system.,200279,1,FALSE,0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60331,0,Risk management programs are designed to prevent accidents and injury.,200280,0,TRUE,1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60331,0,Risk management programs are designed to prevent accidents and injury.,200281,1,FALSE,0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60332,1,Which of the following is NOT a component of risk management?,200282,0,"a.	Injury prevention",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60332,1,Which of the following is NOT a component of risk management?,200283,1,"b.	Claims management",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60332,1,Which of the following is NOT a component of risk management?,200284,2,"c.	Staff management",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60332,1,Which of the following is NOT a component of risk management?,200285,3,"d.	Risk assessment",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60333,2,Which of the following is NOT considered one of the three occupational hazards?,200286,0,"a.	Physical hazards",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60333,2,Which of the following is NOT considered one of the three occupational hazards?,200287,1,"b.	Ergonomic hazards",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60333,2,Which of the following is NOT considered one of the three occupational hazards?,200288,2,"c.	Biological hazards",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60333,2,Which of the following is NOT considered one of the three occupational hazards?,200289,3,"d.	Chemical hazards",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60334,3,Information about chemical or hazardous substances must be available to all employees.,200290,0,TRUE,1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60334,3,Information about chemical or hazardous substances must be available to all employees.,200291,1,FALSE,0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60335,4,"Healthcare facilities are required by the ________________ to provide adequate ventilation systems, personal protective equipment and safe work operating procedures?",200292,0,"a.	Environmental Protection Agency",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60335,4,"Healthcare facilities are required by the ________________ to provide adequate ventilation systems, personal protective equipment and safe work operating procedures?",200293,1,"b.	U.S. Food and Drug Administration",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60335,4,"Healthcare facilities are required by the ________________ to provide adequate ventilation systems, personal protective equipment and safe work operating procedures?",200294,2,"c.	Occupational Safety and Health Administration",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60335,4,"Healthcare facilities are required by the ________________ to provide adequate ventilation systems, personal protective equipment and safe work operating procedures?",200433,3,d. Centers for Medicare and Medicaid Services,0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60336,5,Time weighted average is the amount of a substance a person can be exposed to over an eight-hour day.,200295,0,TRUE,1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60336,5,Time weighted average is the amount of a substance a person can be exposed to over an eight-hour day.,200296,1,FALSE,0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60337,6,The process of changing work or working conditions to reduce physical stress is,200297,0,"a.	called ergonomics",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60337,6,The process of changing work or working conditions to reduce physical stress is,200298,1,"b.	an employee injury reduction plan",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60337,6,The process of changing work or working conditions to reduce physical stress is,200299,2,"c.	the Occupational Safety and Health Administration Workers' Rights Program",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60337,6,The process of changing work or working conditions to reduce physical stress is,200300,3,"d.	the Occupational Safety and Health Administration Risk Management Program",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60338,7,The key to working safely is keeping the work area organized.,200301,0,TRUE,0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60338,7,The key to working safely is keeping the work area organized.,200302,1,FALSE,1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60339,8,When a technician cannot see what is in a sink or basin they should,200303,0,"a.	drain the sink or basin",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60339,8,When a technician cannot see what is in a sink or basin they should,200304,1,"b.	use a sponge forceps to grasp items",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60339,8,When a technician cannot see what is in a sink or basin they should,200305,2,"c.	have someone help determine what is in the sink or basin",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60339,8,When a technician cannot see what is in a sink or basin they should,200306,3,"d.	all the above",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60340,9,Which of the following is NOT required for sharps safety?,200307,0,"a.	Dispose of all single use sharps in an appropriate container",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60340,9,Which of the following is NOT required for sharps safety?,200308,1,"b.	Sharp ends should be pointed away from anyone's body during transport",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60340,9,Which of the following is NOT required for sharps safety?,200309,2,"c.	Wash all disposable sharps before discarding them",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60340,9,Which of the following is NOT required for sharps safety?,200310,3,"d.	All the above",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60341,10,The level of exposure to a harmful substance when an employer must take required precautions to protect the worker.,200311,0,"a.	Time weighted average",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60341,10,The level of exposure to a harmful substance when an employer must take required precautions to protect the worker.,200312,1,"b.	Short-term excursion limit",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60341,10,The level of exposure to a harmful substance when an employer must take required precautions to protect the worker.,200313,2,"c.	Permissible exposure limit",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60341,10,The level of exposure to a harmful substance when an employer must take required precautions to protect the worker.,200314,3,"d.	Action level",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60342,11,Ergonomic injuries,200315,0,"a.	are not a concern for Central Service employees",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60342,11,Ergonomic injuries,200316,1,"b.	are rare in today's work environment",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60342,11,Ergonomic injuries,200317,2,"c.	are a risk factor for persons who perform repetitive or physical work",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60342,11,Ergonomic injuries,200318,3,"d.	happen only in the office setting",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60343,12,Secondary containers of chemicals,200319,0,"a.	must be labeled with a copy of the original manufacturer's label or a generic label that identifies hazard warnings and directions",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60343,12,Secondary containers of chemicals,200320,1,"b.	must be labeled with a permanent marker and must state the chemical's name and designated storage location",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60343,12,Secondary containers of chemicals,200321,2,"c.	secondary containers of chemicals are not allowed in healthcare facilities",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60343,12,Secondary containers of chemicals,200322,3,"d.	there are no restrictions for secondary container labels at this time",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60344,13,Safety data sheets are provided by the,200323,0,"a.	Occupational Safety and Health Administration",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60344,13,Safety data sheets are provided by the,200324,1,"b.	U.S. Food and Drug Administration",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60344,13,Safety data sheets are provided by the,200325,2,"c.	Risk Management department",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60344,13,Safety data sheets are provided by the,200326,3,"d.	Product manufacturer",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60345,14,A molecular reaction that creates an uncontrolled release of energy is called,200327,0,"a.	combustion",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60345,14,A molecular reaction that creates an uncontrolled release of energy is called,200328,1,"b.	polymerization",1
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60345,14,A molecular reaction that creates an uncontrolled release of energy is called,200329,2,"c.	vapor density",0
8794,Elearning-0000-166,SPD INTERNSHIP CHAPTER 22 - SAFETY AND RISK MANAGEMENT FOR CENTRAL SERVICE,n13485,60345,14,A molecular reaction that creates an uncontrolled release of energy is called,200330,3,"d.	fire",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60346,0,Which of the following is an example of communication?,200331,0,"a.	Spoken word",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60346,0,Which of the following is an example of communication?,200332,1,"b.	Written word",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60346,0,Which of the following is an example of communication?,200333,2,"c.	Non-verbal expressions",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60346,0,Which of the following is an example of communication?,200334,3,"d.	All the above",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60347,1,Central Service technicians who do not think they are being treated appropriately by their employer should,200335,0,"a.	find another job",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60347,1,Central Service technicians who do not think they are being treated appropriately by their employer should,200336,1,"b.	discuss the problem with their workplace peers",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60347,1,Central Service technicians who do not think they are being treated appropriately by their employer should,200337,2,"c.	discuss the situation with their supervisor",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60347,1,Central Service technicians who do not think they are being treated appropriately by their employer should,200338,3,"d.	accept the situation as ""the way things are done""ù at the facility",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60348,2,"Behavior relating to what is ""right""ù and ""wrong""ù relative to the standards of professional conduct are called",200339,0,"a.	ethical behavior",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60348,2,"Behavior relating to what is ""right""ù and ""wrong""ù relative to the standards of professional conduct are called",200340,1,"b.	moral behavior",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60348,2,"Behavior relating to what is ""right""ù and ""wrong""ù relative to the standards of professional conduct are called",200341,2,"c.	legal behavior",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60348,2,"Behavior relating to what is ""right""ù and ""wrong""ù relative to the standards of professional conduct are called",200342,3,"d.	personal behavior",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60349,3,A step in communication that occurs when a listener asks a question is called,200343,0,"a.	stereotyping",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60349,3,A step in communication that occurs when a listener asks a question is called,200344,1,"b.	feedback",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60349,3,A step in communication that occurs when a listener asks a question is called,200345,2,"c.	communication looping",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60349,3,A step in communication that occurs when a listener asks a question is called,200346,3,"d.	halo interpretation",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60350,4,This process allows a person to understand someone else's needs,200347,0,"a.	Communication",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60350,4,This process allows a person to understand someone else's needs,200348,1,"b.	Human relations",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60350,4,This process allows a person to understand someone else's needs,200349,2,"c.	Feedback",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60350,4,This process allows a person to understand someone else's needs,200350,3,"d.	Moral behavior",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60351,5,"When speaking, one should",200351,0,"a.	be influenced by the listener's emotions",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60351,5,"When speaking, one should",200352,1,"b.	concentrate on the listener rather than oneself",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60351,5,"When speaking, one should",200353,2,"c.	concentrate on oneself rather than the listener",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60351,5,"When speaking, one should",200354,3,"d.	use technical jargon to impress the listener",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60352,6,Which of the following basic listening tactics is most useful?,200355,0,"a.	Try to listen only for specific facts",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60352,6,Which of the following basic listening tactics is most useful?,200356,1,"b.	Ignore any non-verbal communication ""sent""ù by the speaker",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60352,6,Which of the following basic listening tactics is most useful?,200357,2,"c.	Focus on the delivery of the message rather than its content",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60352,6,Which of the following basic listening tactics is most useful?,200358,3,"d.	None of the above",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60353,7,The ability to use information gained from words or body language to interact with others,200359,0,"a.	Communication",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60353,7,The ability to use information gained from words or body language to interact with others,200360,1,"b.	Human relations",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60353,7,The ability to use information gained from words or body language to interact with others,200361,2,"c.	Teamwork",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60353,7,The ability to use information gained from words or body language to interact with others,200362,3,"d.	Mentoring",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60354,8,Which of the following is the most important factor necessary for teamwork?,200363,0,"a.	Attitude",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60354,8,Which of the following is the most important factor necessary for teamwork?,200364,1,"b.	Prompt",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60354,8,Which of the following is the most important factor necessary for teamwork?,200365,2,"c.	Loyalty",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60354,8,Which of the following is the most important factor necessary for teamwork?,200366,3,"d.	Cooperation",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60355,9,Which of the following statement is correct?,200367,0,"a.	Informal work groups are ""bad""ù for the organization",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60355,9,Which of the following statement is correct?,200368,1,"b.	Informal work groups develop an informal communication system called the grapevine",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60355,9,Which of the following statement is correct?,200369,2,"c.	A task group is an example of an informal group",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60355,9,Which of the following statement is correct?,200370,3,"d.	Employees can only be members of one formal group at a time",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60356,10,A group of employees from different departments within the healthcare facility that work together to solve operating problems is called a,200371,0,"a.	decision-making team",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60356,10,A group of employees from different departments within the healthcare facility that work together to solve operating problems is called a,200372,1,"b.	multi-dimensional team",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60356,10,A group of employees from different departments within the healthcare facility that work together to solve operating problems is called a,200373,2,"c.	cross-functional team",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60356,10,A group of employees from different departments within the healthcare facility that work together to solve operating problems is called a,200374,3,"d.	management/sub-management team",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60357,11,Which of the following is true about a valuing diversity effort?,200375,0,"a.	It ""happens""ù because top-level officials require it",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60357,11,Which of the following is true about a valuing diversity effort?,200376,1,"b.	It occurs because a Central Service director desires it",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60357,11,Which of the following is true about a valuing diversity effort?,200377,2,"c.	It is a ""program""ù in which a committee ""decides what to do""ù",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60357,11,Which of the following is true about a valuing diversity effort?,200378,3,"d.	None of the above",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60358,12,Coaching is an example of,200379,0,"a.	informal communication",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60358,12,Coaching is an example of,200380,1,"b.	discipline",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60358,12,Coaching is an example of,200381,2,"c.	formal communication",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60358,12,Coaching is an example of,200382,3,"d.	Mentoring",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60359,13,Knowing what is expected and consistently meeting those expectations is a part of,200383,0,"a.	effective communications",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60359,13,Knowing what is expected and consistently meeting those expectations is a part of,200384,1,"b.	ethical behavior",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60359,13,Knowing what is expected and consistently meeting those expectations is a part of,200385,2,"c.	job success",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60359,13,Knowing what is expected and consistently meeting those expectations is a part of,200386,3,"d.	professional behavior",1
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60360,14,When Central Service technicians have internet access at work,200387,0,"a.	it should be used for work-related purposes only",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60360,14,When Central Service technicians have internet access at work,200388,1,"b.	it may be used for any purposes as long as it doesn't interfere with work",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60360,14,When Central Service technicians have internet access at work,200389,2,"c.	it should only be used during break time",0
8784,Elearning-0000-165,SPD INTERNSHIP CHAPTER 23 - SUCCESS THROUGH COMMUNICATION,n13486,60360,14,When Central Service technicians have internet access at work,200390,3,"d.	they should follow the facility's policy",1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60361,0,Which of the following is an open-ended question?,200391,0,"a.	""How long have you worked here?""ù",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60361,0,Which of the following is an open-ended question?,200392,1,"b.	""Do you like your job?""ù",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60361,0,Which of the following is an open-ended question?,200393,2,"c.	""What problems do you most frequently encounter on the job?""ù",1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60361,0,Which of the following is an open-ended question?,200394,3,"d.	""What is the name of Central Service director?""ù",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60362,1,Personal development improves employability skills.,200395,0,TRUE,1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60362,1,Personal development improves employability skills.,200396,1,FALSE,0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60363,2,"When setting personal goals, set goals that are",200397,0,"a.	quickly attainable",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60363,2,"When setting personal goals, set goals that are",200398,1,"b.	attainable within five years then set new goals",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60363,2,"When setting personal goals, set goals that are",200399,2,"c.	attainable, then build on those successes",1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60363,2,"When setting personal goals, set goals that are",200400,3,"d.	specific to the current position and education",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60364,3,Professional development provides the information and experience needed for career progress.,200401,0,TRUE,1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60364,3,Professional development provides the information and experience needed for career progress.,200402,1,FALSE,0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60365,4,A technician teaching others increases their own understanding of the standards.,200403,0,TRUE,1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60365,4,A technician teaching others increases their own understanding of the standards.,200404,1,FALSE,0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60366,5,Planning and reviewing goals will identify activities to help meet those goals,200405,0,TRUE,1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60366,5,Planning and reviewing goals will identify activities to help meet those goals,200406,1,FALSE,0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60367,6,Resources found online have already been determined to be valid before they are posted online,200407,0,TRUE,0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60367,6,Resources found online have already been determined to be valid before they are posted online,200408,1,FALSE,1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60368,7,Steps toward attaining professional goals in Central Service include,200409,0,"a.	obtaining certification",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60368,7,Steps toward attaining professional goals in Central Service include,200410,1,"b.	attending educational conferences",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60368,7,Steps toward attaining professional goals in Central Service include,200411,2,"c.	participating in professional groups",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60368,7,Steps toward attaining professional goals in Central Service include,200412,3,"d.	all the above",1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60369,8,One important step in preparing for an interview is,200413,0,"a.	reviewing the certification exam questions",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60369,8,One important step in preparing for an interview is,200414,1,"b.	developing a written response to application questions",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60369,8,One important step in preparing for an interview is,200415,2,"c.	anticipating possible interview questions",1
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60369,8,One important step in preparing for an interview is,200416,3,"d.	all the above",0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60370,9,On the job relationships do NOT change when one team member has been promoted,200417,0,TRUE,0
8779,Elearning-0000-164,SPD INTERNSHIP CHAPTER 24 - PERSONAL AND PROFESSIONAL DEVELOPMENT FOR CENTRAL SERVICES,n13487,60370,9,On the job relationships do NOT change when one team member has been promoted,200418,1,FALSE,1
9310,Elearning-0000-559,FY2021 PHARMACY HEART FAILURE EDUCATION,n13483,60305,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",200198,0,TRUE,1
9310,Elearning-0000-559,FY2021 PHARMACY HEART FAILURE EDUCATION,n13483,60305,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",200199,1,FALSE,0
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60371,0,Bone flap will be placed in the abdomen following a craniectomy.   True or False?,200419,0,TRUE,1
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60371,0,Bone flap will be placed in the abdomen following a craniectomy.   True or False?,200420,1,FALSE,0
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60372,1,"Seizures, CVA, and increased ICP can be complications of craniotomy or craniectomy. True or False",200421,0,TRUE,1
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60372,1,"Seizures, CVA, and increased ICP can be complications of craniotomy or craniectomy. True or False",200422,1,FALSE,0
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60373,2,Normal ICP is 15-25. True or False,200423,0,TRUE,0
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60373,2,Normal ICP is 15-25. True or False,200424,1,FALSE,1
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60374,3,"Pain, Hypoxia, and Increased BP can cause elevation of ICP.  True or False",200425,0,TRUE,1
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60374,3,"Pain, Hypoxia, and Increased BP can cause elevation of ICP.  True or False",200426,1,FALSE,0
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60375,4,EVD does not have to be clamped prior to mobilization of patient following craniotomy or craniectomy.  True or False,200427,0,TRUE,0
9732,Elearning-0000-942,2021 REHAB NSC NEUROSURGERY,n13488,60375,4,EVD does not have to be clamped prior to mobilization of patient following craniotomy or craniectomy.  True or False,200428,1,FALSE,1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60378,0,The 4 Red Rules at NSH include all of following except,200434,0,"a.	2-Patient Identifiers",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60378,0,The 4 Red Rules at NSH include all of following except,200435,1,"b.	Specimen Packaging and Management/ Line Reconciliation",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60378,0,The 4 Red Rules at NSH include all of following except,200436,2,"c.	Hand-off communication",1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60378,0,The 4 Red Rules at NSH include all of following except,200437,3,"d.	Line Reconciliation",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60378,0,The 4 Red Rules at NSH include all of following except,200438,4,"e.	Time-Out",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60379,1,Red Rules are used at NSH to,200439,0,"a.	Ensure that staff are supported in speaking up when a critical rule is not followed",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60379,1,Red Rules are used at NSH to,200440,1,"b.	Punish employees who not follow the policies and procedures as outlined",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60379,1,Red Rules are used at NSH to,200441,2,"c.	Support staff for making safe choices",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60379,1,Red Rules are used at NSH to,200442,3,"d.	a, b, & C",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60379,1,Red Rules are used at NSH to,200443,4,"e.	a & c",1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60380,2,"When a Red Rule is violated, staff are expected to speak up and ""stop the line""ù to ensure that patient safety is made a priority",200444,0,a. True,1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60380,2,"When a Red Rule is violated, staff are expected to speak up and ""stop the line""ù to ensure that patient safety is made a priority",200445,1,b. False,0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60381,3,Staff expectations in a Culture of Accountability include all of the following except:,200446,0,"a.	Implementing the chain-of-command when things are not proceeding as planned",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60381,3,Staff expectations in a Culture of Accountability include all of the following except:,200447,1,"b.	Completing Incident/ Verge report for all actual events as well as potential and ""near misses""ù as well as concerns",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60381,3,Staff expectations in a Culture of Accountability include all of the following except:,200448,2,"c.	Following policies and procedures",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60381,3,Staff expectations in a Culture of Accountability include all of the following except:,200449,3,"d.	Focusing on what you are doing and not paying attention to those around you",1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60381,3,Staff expectations in a Culture of Accountability include all of the following except:,200450,4,"e.	Never signing for something that was not done",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60382,4,"When an error or deviation occurs, staff will be interviewed by their supervisor/ manager to understand the source of the errors in order to enhance our learning environment.",200451,0,a. True,1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60382,4,"When an error or deviation occurs, staff will be interviewed by their supervisor/ manager to understand the source of the errors in order to enhance our learning environment.",200452,1,b. False,0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60383,5,Errors are evaluated under a culture of accountability.  An error that occurs as a result of a slip or lapse in practice would be considered a,200453,0,"a.	Human Error",1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60383,5,Errors are evaluated under a culture of accountability.  An error that occurs as a result of a slip or lapse in practice would be considered a,200454,1,"b.	At-Risk Behavior",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60383,5,Errors are evaluated under a culture of accountability.  An error that occurs as a result of a slip or lapse in practice would be considered a,200455,2,"c.	Reckless Behavior",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60384,6,Errors are evaluated under a culture of accountability.  An error that occurs when an employee believes the risk in not following policy is justified under the circumstances would be considered,200456,0,"a.	Human Error",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60384,6,Errors are evaluated under a culture of accountability.  An error that occurs when an employee believes the risk in not following policy is justified under the circumstances would be considered,200457,1,"b.	At-Risk Behavior",1
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60384,6,Errors are evaluated under a culture of accountability.  An error that occurs when an employee believes the risk in not following policy is justified under the circumstances would be considered,200458,2,"c.	Reckless Behavior",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60385,7,Errors are evaluated under a culture of accountability.  An error that occurs as a result of an intentional violation of policy and /or practice would be considered a,200459,0,"a.	Human Error",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60385,7,Errors are evaluated under a culture of accountability.  An error that occurs as a result of an intentional violation of policy and /or practice would be considered a,200460,1,"b.	At-Risk Behavior",0
9654,Elearning-0000-871,NORTHSIDE HOSPITAL RED RULES AND CULTURE OF ACCOUNTABILITY - 2021,n13491,60385,7,Errors are evaluated under a culture of accountability.  An error that occurs as a result of an intentional violation of policy and /or practice would be considered a,200461,2,"c.	Reckless Behavior",1
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60419,0,Patients must have:,200558,0,"a)	AML or MDS with high-risk of relapse",0
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60419,0,Patients must have:,200559,1,"b)	AML in CR, Cri, or MLFS",0
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60419,0,Patients must have:,200560,2,"c)	Relapsed/refractory AML",0
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60419,0,Patients must have:,200561,3,"d)	Relapsed/refractory NHL",0
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60419,0,Patients must have:,200562,4,"e)	Both A and B",1
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60420,1,Patients must be receiving a matched-related donor allo transplant only.,200563,0,TRUE,0
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60420,1,Patients must be receiving a matched-related donor allo transplant only.,200564,1,FALSE,1
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60421,2,K-NK002 will be given:,200565,0,"a)	On Day +1 after transplant",0
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60421,2,K-NK002 will be given:,200566,1,"b)	In 2 doses given 28-days apart",0
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60421,2,K-NK002 will be given:,200567,2,"c)	In 3 doses given on Days -2, +7, and +28",1
9515,Elearning-0000-745,C-394 BMT CTN 1803 NK CELL,n13499,60421,2,K-NK002 will be given:,200568,3,"d)	During HD chemotherapy days prior to transplant",0
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60422,0,Patients must have:,200569,0,"a)	Had an allo transplant between 21 days and 1 year ago",0
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60422,0,Patients must have:,200570,1,"b)	Confirmed myeloid engraftment",0
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60422,0,Patients must have:,200571,2,"c)	Diagnosed with hemorrhagic cystits",0
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60422,0,Patients must have:,200572,3,"d)	All of the above",1
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60423,1,"Patients will receive Viralym-M or placebo in 2 separate infusion, 14 days apart.",200573,0,TRUE,1
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60423,1,"Patients will receive Viralym-M or placebo in 2 separate infusion, 14 days apart.",200574,1,FALSE,0
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60424,2,Patients who experience GVHD Grade >2 or worsening of GVHD (relative to baseline) at the time before the second infusion will not be permitted to receive the 2nd infusion.,200575,0,TRUE,1
9512,Elearning-0000-742,C-429 ALLOVIR HC,n13500,60424,2,Patients who experience GVHD Grade >2 or worsening of GVHD (relative to baseline) at the time before the second infusion will not be permitted to receive the 2nd infusion.,200576,1,FALSE,0
8333,Elearning-0000-121,TRAUMATIC HEMORRHAGE AND HEMORRHAGIC STROKE,n13501,60425,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Traumatic Hemorrhage and Hemorrhagic Stroke CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",200577,0,TRUE,1
8333,Elearning-0000-121,TRAUMATIC HEMORRHAGE AND HEMORRHAGIC STROKE,n13501,60425,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Traumatic Hemorrhage and Hemorrhagic Stroke CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",200578,1,FALSE,0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60426,0,"The purpose of Northside Hospital Fall and Injury Prevention Policy is to provide a safe environment of care, to prevent patient falls, and to manage falls that do occur.",200579,0,TRUE,1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60426,0,"The purpose of Northside Hospital Fall and Injury Prevention Policy is to provide a safe environment of care, to prevent patient falls, and to manage falls that do occur.",200580,1,FALSE,0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60631,1,A patient is found on the floor by the bed. The patient has an abrasion to the leg. The Fall severity would be labeled as,201322,0,"a.	None",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60631,1,A patient is found on the floor by the bed. The patient has an abrasion to the leg. The Fall severity would be labeled as,201323,1,"b.	Minor",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60631,1,A patient is found on the floor by the bed. The patient has an abrasion to the leg. The Fall severity would be labeled as,201324,2,"c.	Moderate",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60631,1,A patient is found on the floor by the bed. The patient has an abrasion to the leg. The Fall severity would be labeled as,201325,3,"d.	Major",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60632,2,A patient has a fall risk score of 30. The Fall Interventions would include:,201326,0,"a.	 Implementing the Universal Safety precautions",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60632,2,A patient has a fall risk score of 30. The Fall Interventions would include:,201327,1,"b.	Yellow armband, yellow non-skid slippers, yellow falling star at door",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60632,2,A patient has a fall risk score of 30. The Fall Interventions would include:,201328,2,"c.	Mandatory Sitter at bedside",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60632,2,A patient has a fall risk score of 30. The Fall Interventions would include:,201329,3,"d.	A and B",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60632,2,A patient has a fall risk score of 30. The Fall Interventions would include:,201330,4,"e.	A, B, and C",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60633,3,There are 3 Zones to set the bed alarm to specific need of a patient. The patient is at risk to fall. Which zone would you select for the patient?,201331,0,"a.	Zone 1",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60633,3,There are 3 Zones to set the bed alarm to specific need of a patient. The patient is at risk to fall. Which zone would you select for the patient?,201332,1,"b.	Zone 2",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60633,3,There are 3 Zones to set the bed alarm to specific need of a patient. The patient is at risk to fall. Which zone would you select for the patient?,201333,2,"c.	Zone 3",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60633,3,There are 3 Zones to set the bed alarm to specific need of a patient. The patient is at risk to fall. Which zone would you select for the patient?,201334,3,"d.	None of the above",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60634,4,"Before you set the bed with any parameters, you must zero the bed scale.",201335,0,TRUE,1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60634,4,"Before you set the bed with any parameters, you must zero the bed scale.",201336,1,FALSE,0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60635,5,The light on footboard is blinking amber. What does this indicate?,201337,0,"a.	The brake is not set",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60635,5,The light on footboard is blinking amber. What does this indicate?,201338,1,"b.	The bed alarm has not been activated",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60635,5,The light on footboard is blinking amber. What does this indicate?,201339,2,"c.	The parameters you have set have been compromised",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60635,5,The light on footboard is blinking amber. What does this indicate?,201340,3,"d.	A and B",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60636,6,Your patient had a fall. After you have cared for the patient you need to:,201341,0,"a.	Complete the HOSP Post Fall Guideline Orders in Cerner",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60636,6,Your patient had a fall. After you have cared for the patient you need to:,201342,1,"b.	Notify admitting MD and manager",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60636,6,Your patient had a fall. After you have cared for the patient you need to:,201343,2,"c.	Complete Post Fall Evaluation Powerform in Cerner,  debriefing tool and an Incident report",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60636,6,Your patient had a fall. After you have cared for the patient you need to:,201344,3,"d.	All the above",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60637,7,The light on footboard is green. What does this indicate?,201345,0,"a.	The brake is on",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60637,7,The light on footboard is green. What does this indicate?,201346,1,"b.	The bed alarm is activated",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60637,7,The light on footboard is green. What does this indicate?,201347,2,"c.	The bed has been set to the parameters  specific to the patient and not compromised",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60637,7,The light on footboard is green. What does this indicate?,201348,3,"d.	B and C",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60638,8,The light at foot of bed is green: you know the bed exit alarm is activated.,201349,0,TRUE,0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60638,8,The light at foot of bed is green: you know the bed exit alarm is activated.,201350,1,FALSE,1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60639,9,Patient does not want the bed alarm on. What should you do?,201351,0,"a.	Provide education about the bed alarm",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60639,9,Patient does not want the bed alarm on. What should you do?,201352,1,"b.	Encourage the patient that you want to be there to assist them",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60639,9,Patient does not want the bed alarm on. What should you do?,201353,2,"c.	Tell them that they cannot have what they want",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60639,9,Patient does not want the bed alarm on. What should you do?,201354,3,"d.	A and B",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60640,10,Your patient is a Fall Risk. What is the appropriate zone for the patient?,201355,0,"a.	Zone 1",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60640,10,Your patient is a Fall Risk. What is the appropriate zone for the patient?,201356,1,"b.	Zone 2",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60640,10,Your patient is a Fall Risk. What is the appropriate zone for the patient?,201357,2,"c.	Zone 3",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60640,10,Your patient is a Fall Risk. What is the appropriate zone for the patient?,201358,3,"d.	Does not matter as long as the bed exit alarm is on.",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60641,11,All Falls are to be reported into the Incident Reporting System,201359,0,TRUE,1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60641,11,All Falls are to be reported into the Incident Reporting System,201360,1,FALSE,0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60642,12,The bed should be set so that the Bed Brake alarms when off except:,201361,0,"a.	During transport",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60642,12,The bed should be set so that the Bed Brake alarms when off except:,201362,1,"b.	At HS",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60642,12,The bed should be set so that the Bed Brake alarms when off except:,201363,2,"c.	When patient in BR",0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60642,12,The bed should be set so that the Bed Brake alarms when off except:,201364,3,"d.	None of the above",1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60643,13,PCU Goal is to have No Falls on the unit.,201365,0,TRUE,1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60643,13,PCU Goal is to have No Falls on the unit.,201366,1,FALSE,0
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60644,14,After this CBL and Check-off you will be able to use the functions to full capacity on the Stryker iBed.,201367,0,a. Yes,1
282,SCORM-0000-92,PCU FALL PREVENTION AND IBED AWARENESS,n13502,60644,14,After this CBL and Check-off you will be able to use the functions to full capacity on the Stryker iBed.,201368,1,b. No,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60427,0,At the end of the MTP the Lead Nurse must complete and/ or participate in the following <b><u>except</u><b>,200581,0,A. An Incident Report,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60427,0,At the end of the MTP the Lead Nurse must complete and/ or participate in the following <b><u>except</u><b>,200582,1,B. Blood Transfusion Request Form,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60427,0,At the end of the MTP the Lead Nurse must complete and/ or participate in the following <b><u>except</u><b>,200583,2,C. All three required documentations and submit to leadership in red MTP folder,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60427,0,At the end of the MTP the Lead Nurse must complete and/ or participate in the following <b><u>except</u><b>,200584,3,D. MTP Debrief,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60428,1,Who must be involved in the debriefing of the MTP?,200585,0,"A. Surgeon, Anesthesiologist and Lead RN",0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60428,1,Who must be involved in the debriefing of the MTP?,200586,1,B. Lead RN and Recorder,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60428,1,Who must be involved in the debriefing of the MTP?,200587,2,C. All who are involved in the MTP,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60428,1,Who must be involved in the debriefing of the MTP?,200588,3,"D. Anesthesiologist, Lead RN, and Scrub Tech",0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60429,2,Which form must be completed for each parcel pick up?,200589,0,A Blood Product Utilization Form,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60429,2,Which form must be completed for each parcel pick up?,200590,1,B Incident Report,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60429,2,Which form must be completed for each parcel pick up?,200591,2,C Blood Product Issue Request Form,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60429,2,Which form must be completed for each parcel pick up?,200592,3,D MTP Debrief Quality Tool,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60430,3,The Recorder must document parcels administered to the patient on the ___________________?,200593,0,A. Blood Product Utilization Form,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60430,3,The Recorder must document parcels administered to the patient on the ___________________?,200594,1,B. Incident Report,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60430,3,The Recorder must document parcels administered to the patient on the ___________________?,200595,2,C. Blood product Issue Request Form,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60430,3,The Recorder must document parcels administered to the patient on the ___________________?,200596,3,D. MTP Debriefing Quality Tool,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60431,4,The Blood Product Utilization Form is part of the patient's Medical Record?,200597,0,TRUE,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60431,4,The Blood Product Utilization Form is part of the patient's Medical Record?,200598,1,FALSE,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60432,5,Who initiates the MTP?,200599,0,A. Anesthesiologist,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60432,5,Who initiates the MTP?,200600,1,B. Lead RN,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60432,5,Who initiates the MTP?,200601,2,C. Surgeon,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60432,5,Who initiates the MTP?,200602,3,D. A and or C,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60433,6,"At the conclusion of an MTP, the MD/ Anesthesiologist will announce ""Stop MTP""ù and the Lead Nurse will do all the following immediately <b><u>except</u></b>?",200603,0,A. Catch up on charting,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60433,6,"At the conclusion of an MTP, the MD/ Anesthesiologist will announce ""Stop MTP""ù and the Lead Nurse will do all the following immediately <b><u>except</u></b>?",200604,1,"B. Confirm ""We are Stopping MTP on Patient Name and MRN#""ù",0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60433,6,"At the conclusion of an MTP, the MD/ Anesthesiologist will announce ""Stop MTP""ù and the Lead Nurse will do all the following immediately <b><u>except</u></b>?",200605,2,C. Call Charge Nurse and communicate stop to MTP,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60433,6,"At the conclusion of an MTP, the MD/ Anesthesiologist will announce ""Stop MTP""ù and the Lead Nurse will do all the following immediately <b><u>except</u></b>?",200606,3,D. Call Blood Bank and communicate stop to MTP,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60434,7,Which of the following are duties of the Runner ?,200607,0,A. Provides Communication to and from the Blood Bank.,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60434,7,Which of the following are duties of the Runner ?,200608,1,B. Picks up blood parcels (Provide Blood Product Issue Request for to Blood Bank),0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60434,7,Which of the following are duties of the Runner ?,200609,2,"C. Returns to Blood Bank, once each parcel is delivered to the OR.",0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60434,7,Which of the following are duties of the Runner ?,200610,3,"D. Delivers Lab Specimens, e.g. Stat ABGs",0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60434,7,Which of the following are duties of the Runner ?,200611,4,E. All of the Above,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60435,8,"If staffing allows for a <b>Runner #2, Runner #1 and #2</b> will share duties?",200612,0,TRUE,1
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60435,8,"If staffing allows for a <b>Runner #2, Runner #1 and #2</b> will share duties?",200613,1,FALSE,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60436,9,It is required to send the Blood Consent with the Blood Product Issue Request to Blood Bank when the Runner is picking up MTP parcels?,200614,0,TRUE,0
9162,Elearning-0000-424,FY2021 MASSIVE TRANSFUSION PROTOCOL (MTP): SURGICAL SERVICES,n13503,60436,9,It is required to send the Blood Consent with the Blood Product Issue Request to Blood Bank when the Runner is picking up MTP parcels?,200615,1,FALSE,1
2373,ILT-0000-10920,INFUSION CENTER STAFF MEETING MARCH 2021,n13504,60437,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Infusion Center Staff meeting March 2021 CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",200616,0,TRUE,1
2373,ILT-0000-10920,INFUSION CENTER STAFF MEETING MARCH 2021,n13504,60437,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Infusion Center Staff meeting March 2021 CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",200617,1,FALSE,0
4487,ILT-0000-20384,TEST CBL ARCHIVE PROCESS,n13506,60438,0,"I acknowledge that I have read and understand the ""TEST CBL"".",200618,0,TRUE,1
4487,ILT-0000-20384,TEST CBL ARCHIVE PROCESS,n13506,60438,0,"I acknowledge that I have read and understand the ""TEST CBL"".",200619,1,FALSE,0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60439,0,"1.	If the newborn fails the first test, in what time frame can the test be repeated?",200620,0,"a.	3-4 hours",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60439,0,"1.	If the newborn fails the first test, in what time frame can the test be repeated?",200621,1,"b.	Immediately",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60439,0,"1.	If the newborn fails the first test, in what time frame can the test be repeated?",200622,2,"c.	6-8 hours",1
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60439,0,"1.	If the newborn fails the first test, in what time frame can the test be repeated?",200623,3,"d.	30 minutes",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60440,1,"2.	The car seat needs to be visualized and documented against for all newborns discharging from FCC.",200624,0,TRUE,1
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60440,1,"2.	The car seat needs to be visualized and documented against for all newborns discharging from FCC.",200625,1,FALSE,0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60441,2,"3.	Parents should be educated about car seat safety and given the educational flyer on admission to FCC and throughout the stay until discharge.",200626,0,TRUE,1
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60441,2,"3.	Parents should be educated about car seat safety and given the educational flyer on admission to FCC and throughout the stay until discharge.",200627,1,FALSE,0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60442,3,"4.	The Angle Tolerance test should be completed on the following newborns",200628,0,"a.	Less than 37 weeks gestation",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60442,3,"4.	The Angle Tolerance test should be completed on the following newborns",200629,1,"b.	Birthweight less than or equal to 2500 grams",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60442,3,"4.	The Angle Tolerance test should be completed on the following newborns",200630,2,"c.	Down Syndrome",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60442,3,"4.	The Angle Tolerance test should be completed on the following newborns",200631,3,"d.	Per provider order for hypotonic newborns",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60442,3,"4.	The Angle Tolerance test should be completed on the following newborns",200632,4,"e.	All of the above",1
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60442,3,"4.	The Angle Tolerance test should be completed on the following newborns",200633,5,"f.	A and B only",0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60443,4,"5.	The Angle Tolerance Test should be completed when the newborn is greater than 24 hours of age, regardless of delivery method.",200634,0,TRUE,1
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60443,4,"5.	The Angle Tolerance Test should be completed when the newborn is greater than 24 hours of age, regardless of delivery method.",200635,1,FALSE,0
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60444,5,"6.	If the discharging location is further than 90 minutes away from the hospital, the Angle Tolerance test must be completed for 120 minutes to ensure newborn stability.",200636,0,TRUE,1
9143,Elearning-0000-407,FCC NEWBORN CAR SEAT CHANGES 2021,n13507,60444,5,"6.	If the discharging location is further than 90 minutes away from the hospital, the Angle Tolerance test must be completed for 120 minutes to ensure newborn stability.",200637,1,FALSE,0
9626,Elearning-0000-846,FY2021 STERILITY VERIFICATION,n13508,60445,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Sterility Verification"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",200638,0,TRUE,1
9626,Elearning-0000-846,FY2021 STERILITY VERIFICATION,n13508,60445,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Sterility Verification"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",200639,1,FALSE,0
202,SCORM-0000-28,DEVELOPING BEHAVIORAL HEALTH CHAMPIONS,n13510,60451,0,I have read and understood the content within the Developing Behavioral Health Champions CBL.,200650,0,TRUE,1
202,SCORM-0000-28,DEVELOPING BEHAVIORAL HEALTH CHAMPIONS,n13510,60451,0,I have read and understood the content within the Developing Behavioral Health Champions CBL.,200651,1,FALSE,0
9463,Elearning-0000-698,5 CENTRAL CODE BLUE EDUCATION 2021,n13512,60453,0,I have read and understand the responsibilities during a CODE BLUE at Northside Hospital. I understand the content and will ask my leadership any questions that I may have.,200654,0,TRUE,1
9463,Elearning-0000-698,5 CENTRAL CODE BLUE EDUCATION 2021,n13512,60453,0,I have read and understand the responsibilities during a CODE BLUE at Northside Hospital. I understand the content and will ask my leadership any questions that I may have.,200655,1,FALSE,0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60454,0,True/False: The Impella device does not require any anticoagulation,200656,0,TRUE,0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60454,0,True/False: The Impella device does not require any anticoagulation,200657,1,FALSE,1
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60455,1,The preferred method of monitoring anticoagulation status is:,200658,0,"a)	Anti-Xa",0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60455,1,The preferred method of monitoring anticoagulation status is:,200659,1,"b)	PTT",0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60455,1,The preferred method of monitoring anticoagulation status is:,200660,2,"c)	INR",0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60455,1,The preferred method of monitoring anticoagulation status is:,200661,3,"d)	ACT",1
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60456,2,True/False: The purge solution must include a dextrose base solution,200662,0,TRUE,1
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60456,2,True/False: The purge solution must include a dextrose base solution,200663,1,FALSE,0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60457,3,True/False: Providers may choose between two different ACT therapeutic ranges: 160 - 180 or 180 - 200.,200664,0,TRUE,1
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60457,3,True/False: Providers may choose between two different ACT therapeutic ranges: 160 - 180 or 180 - 200.,200665,1,FALSE,0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60458,4,"True/False: Intravenous heparin infusion may be started, in addition to heparin purge solution, if post-insertion ACT falls below upper limit of therapeutic range.",200666,0,TRUE,1
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60458,4,"True/False: Intravenous heparin infusion may be started, in addition to heparin purge solution, if post-insertion ACT falls below upper limit of therapeutic range.",200667,1,FALSE,0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60459,5,True/False: Impella Heparin dosing is recorded on the same flowsheet used for standard heparin infusions,200668,0,TRUE,0
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60459,5,True/False: Impella Heparin dosing is recorded on the same flowsheet used for standard heparin infusions,200669,1,FALSE,1
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60460,6,True/False: All heparin infusion calculations require an MD/PharmD double check,200670,0,TRUE,1
9321,Elearning-0000-569,FY2021 IMPELLA PHARMACY EDUCATION,n13513,60460,6,True/False: All heparin infusion calculations require an MD/PharmD double check,200671,1,FALSE,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60462,0,Please list the location for this activity.,200674,0,Atlanta,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60462,0,Please list the location for this activity.,200675,1,Forsyth,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60462,0,Please list the location for this activity.,200676,2,Cherokee,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60462,0,Please list the location for this activity.,200677,3,Other,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60463,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",200678,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60463,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",200679,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60463,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",200680,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60463,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",200681,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60463,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",200682,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60464,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",200683,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60464,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",200684,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60464,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",200685,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60464,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",200686,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60464,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",200687,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60465,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",200688,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60465,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",200689,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60465,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",200690,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60465,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",200691,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60465,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",200692,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60466,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",200693,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60466,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",200694,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60466,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",200695,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60466,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",200696,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60466,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",200697,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60467,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",200698,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60467,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",200699,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60467,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",200700,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60467,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",200701,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60467,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",200702,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60468,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",200703,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60468,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",200704,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60468,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",200705,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60468,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",200706,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60468,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",200707,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60469,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",200708,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60469,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",200709,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60469,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",200710,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60469,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",200711,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60469,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",200712,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60470,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,200713,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60470,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,200714,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60470,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,200715,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60470,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,200716,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60470,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,200717,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60471,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,200718,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60471,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,200719,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60471,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,200720,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60471,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,200721,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60471,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,200722,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60472,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,200723,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60472,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,200724,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60472,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,200725,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60472,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,200726,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60472,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,200727,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60473,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",200728,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60473,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",200729,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60473,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",200730,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60473,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",200731,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60473,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",200732,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60474,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",200733,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60474,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",200734,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60474,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",200735,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60474,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",200736,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60474,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",200737,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60475,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,200738,0,Strongly Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60475,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,200739,1,Agree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60475,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,200740,2,No Opinion,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60475,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,200741,3,Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60475,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,200742,4,Strongly Disagree,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60476,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",200743,0,Excellent,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60476,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",200744,1,Very Good,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60476,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",200745,2,Good,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60476,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",200746,3,Fair,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60476,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",200747,4,Poor,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60477,15,"Overall, this activity was:",200748,0,Excellent,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60477,15,"Overall, this activity was:",200749,1,Very Good,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60477,15,"Overall, this activity was:",200750,2,Good,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60477,15,"Overall, this activity was:",200751,3,Fair,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60477,15,"Overall, this activity was:",200752,4,Poor,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60478,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",200753,0,Yes,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60478,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",200754,1,No,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60478,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",200755,2,N/A,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60481,19,How would you improve this class?,200756,0,Reduce content covered in class,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60481,19,How would you improve this class?,200757,1,Increase content covered in class,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60481,19,How would you improve this class?,200758,2,Update content covered in class,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60481,19,How would you improve this class?,200759,3,Improve the instructional methods,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60481,19,How would you improve this class?,200760,4,Make course activities more stimulating,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60481,19,How would you improve this class?,200761,5,Slow the pace of the class,0
9921,Questions-0000-55,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 3.29.21,n13515,60481,19,How would you improve this class?,201206,6,"No recommendation for improvement (appropriate content, speaker, etc.)",0
273,SCORM-0000-83,NURSING AND PAIN MANAGEMENT,n13522,60593,0,I have read and understood the content within the Nursing and Pain Management CBL.,201198,0,TRUE,1
273,SCORM-0000-83,NURSING AND PAIN MANAGEMENT,n13522,60593,0,I have read and understood the content within the Nursing and Pain Management CBL.,201199,1,FALSE,0
275,SCORM-0000-85,ONCOLOGY FELLOWSHIP: KSU PRECEPTOR WELCOME,n13523,60594,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201200,0,TRUE,1
275,SCORM-0000-85,ONCOLOGY FELLOWSHIP: KSU PRECEPTOR WELCOME,n13523,60594,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201201,1,FALSE,0
277,SCORM-0000-87,ONCOLOGY FELLOWSHIP: PRECEPTOR TRAINING,n13524,60595,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201202,0,TRUE,1
277,SCORM-0000-87,ONCOLOGY FELLOWSHIP: PRECEPTOR TRAINING,n13524,60595,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201203,1,FALSE,0
276,SCORM-0000-86,ONCOLOGY FELLOWSHIP: MERCER PRECEPTOR WELCOME,n13525,60596,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201204,0,TRUE,1
276,SCORM-0000-86,ONCOLOGY FELLOWSHIP: MERCER PRECEPTOR WELCOME,n13525,60596,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201205,1,FALSE,0
9698,Elearning-0000-911,CODE PINK: IT'S EVERYONE'S RESPONSIBILITY UPDATED,n13530,60646,0,"I acknowledge that I have read and understand CBL CODE PINK: IT'S EVERYONE'S RESPONSIBILITY UPDATED. I understand my role in CODE PINK and Infant safety. If I have any questions, I will see my supervisor to help me understand my role.",201371,0,TRUE,1
9698,Elearning-0000-911,CODE PINK: IT'S EVERYONE'S RESPONSIBILITY UPDATED,n13530,60646,0,"I acknowledge that I have read and understand CBL CODE PINK: IT'S EVERYONE'S RESPONSIBILITY UPDATED. I understand my role in CODE PINK and Infant safety. If I have any questions, I will see my supervisor to help me understand my role.",201372,1,FALSE,0
9597,Elearning-0000-82,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q2,n13531,60647,0,Please vote for one of the following staff members for the Clinical Excellence Award FY 21 Q 2,201373,0,Megan Cooper,0
9597,Elearning-0000-82,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q2,n13531,60647,0,Please vote for one of the following staff members for the Clinical Excellence Award FY 21 Q 2,201374,1,Josephine Roberson,0
9597,Elearning-0000-82,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q2,n13531,60648,1,Please vote for one of the following staff members for the Unit star FY 21 Q 2,201375,0,Angie Dixon,0
9597,Elearning-0000-82,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q2,n13531,60648,1,Please vote for one of the following staff members for the Unit star FY 21 Q 2,201376,1,Shameka Bostick,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60650,0,Please list the location for this activity.,201379,0,Atlanta,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60650,0,Please list the location for this activity.,201380,1,Forsyth,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60650,0,Please list the location for this activity.,201381,2,Cherokee,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60650,0,Please list the location for this activity.,201382,3,Other,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60651,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",201383,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60651,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",201384,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60651,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",201385,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60651,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",201386,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60651,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",201387,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60652,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia.</ol>",201388,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60652,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia.</ol>",201389,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60652,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia.</ol>",201390,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60652,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia.</ol>",201391,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60652,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia.</ol>",201392,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60653,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",201393,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60653,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",201394,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60653,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",201395,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60653,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",201396,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60653,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",201397,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60654,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",201398,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60654,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",201399,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60654,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",201400,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60654,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",201401,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60654,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",201402,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60655,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",201403,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60655,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",201404,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60655,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",201405,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60655,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",201406,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60655,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",201407,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60656,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",201408,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60656,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",201409,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60656,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",201410,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60656,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",201411,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60656,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",201412,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60657,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",201413,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60657,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",201414,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60657,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",201415,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60657,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",201416,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60657,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",201417,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60658,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",201418,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60658,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",201419,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60658,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",201420,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60658,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",201421,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60658,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",201422,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60659,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",201423,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60659,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",201424,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60659,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",201425,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60659,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",201426,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60659,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",201427,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60660,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",201428,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60660,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",201429,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60660,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",201430,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60660,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",201431,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60660,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",201432,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60661,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection. Speaker - Coleen Poirier </ol>",201433,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60661,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection. Speaker - Coleen Poirier </ol>",201434,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60661,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection. Speaker - Coleen Poirier </ol>",201435,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60661,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection. Speaker - Coleen Poirier </ol>",201436,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60661,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection. Speaker - Coleen Poirier </ol>",201437,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60662,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",201438,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60662,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",201439,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60662,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",201440,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60662,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",201441,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60662,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",201442,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60663,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",201443,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60663,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",201444,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60663,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",201445,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60663,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",201446,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60663,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",201447,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60664,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",201448,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60664,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",201449,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60664,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",201450,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60664,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",201451,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60664,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",201452,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60665,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,201453,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60665,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,201454,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60665,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,201455,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60665,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,201456,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60665,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,201457,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60666,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,201458,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60666,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,201459,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60666,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,201460,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60666,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,201461,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60666,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,201462,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60667,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201463,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60667,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201464,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60667,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201465,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60667,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201466,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60667,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201467,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60668,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201468,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60668,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201469,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60668,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201470,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60668,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201471,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60668,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201472,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60669,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201473,0,Strongly Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60669,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201474,1,Agree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60669,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201475,2,No Opinion,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60669,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201476,3,Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60669,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201477,4,Strongly Disagree,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60670,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,201478,0,Excellent,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60670,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,201479,1,Very Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60670,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,201480,2,Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60670,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,201481,3,Fair,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60670,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,201482,4,Poor,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60671,23,"Overall, this activity was:",201483,0,Excellent,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60671,23,"Overall, this activity was:",201484,1,Very Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60671,23,"Overall, this activity was:",201485,2,Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60671,23,"Overall, this activity was:",201486,3,Fair,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60671,23,"Overall, this activity was:",201487,4,Poor,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60672,24,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",201488,0,Yes,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60672,24,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",201489,1,No,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60672,24,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",201490,2,N/A,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60675,27,How would you improve this class?,201491,0,Reduce content covered in class,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60675,27,How would you improve this class?,201492,1,Increase content covered in class,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60675,27,How would you improve this class?,201493,2,Update content covered in class,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60675,27,How would you improve this class?,201494,3,Improve the instructional methods,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60675,27,How would you improve this class?,201495,4,Make course activities more stimulating,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60675,27,How would you improve this class?,201496,5,Slow the pace of the class,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60675,27,How would you improve this class?,201497,6,"No Suggestions for improvement ( right content, speakers, location, etc.)",0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60678,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Carolyn Ford, RN</ol>",201498,0,Excellent,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60678,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Carolyn Ford, RN</ol>",201499,1,Very Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60678,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Carolyn Ford, RN</ol>",201500,2,Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60678,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Carolyn Ford, RN</ol>",201501,3,Fair,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60678,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Carolyn Ford, RN</ol>",201502,4,Poor,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60679,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Coleen Poirier</ol>,201503,0,Excellent,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60679,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Coleen Poirier</ol>,201504,1,Very Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60679,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Coleen Poirier</ol>,201505,2,Good,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60679,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Coleen Poirier</ol>,201506,3,Fair,0
9867,Questions-0000-157,STABLE PROGRAM (EVALUATION SURVEY) NSA  3.31.21,n13533,60679,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Coleen Poirier</ol>,201507,4,Poor,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60685,0,Please list the location for this activity.,201524,0,Atlanta,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60685,0,Please list the location for this activity.,201525,1,Cherokee,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60685,0,Please list the location for this activity.,201526,2,Forsyth,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60685,0,Please list the location for this activity.,201527,3,Other,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60686,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify key components of patient education for patients receiving oral anticancer agents.</ol>",201528,0,Strongly Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60686,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify key components of patient education for patients receiving oral anticancer agents.</ol>",201529,1,Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60686,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify key components of patient education for patients receiving oral anticancer agents.</ol>",201530,2,No Opinion,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60686,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify key components of patient education for patients receiving oral anticancer agents.</ol>",201531,3,Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60686,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify key components of patient education for patients receiving oral anticancer agents.</ol>",201532,4,Strongly Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60687,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201533,0,Strongly Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60687,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201534,1,Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60687,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201535,2,No Opinion,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60687,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201536,3,Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60687,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",201537,4,Strongly Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60688,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,201538,0,Strongly Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60688,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,201539,1,Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60688,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,201540,2,No Opinion,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60688,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,201541,3,Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60688,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,201542,4,Strongly Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60689,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,201543,0,Strongly Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60689,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,201544,1,Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60689,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,201545,2,No Opinion,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60689,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,201546,3,Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60689,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,201547,4,Strongly Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60690,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201548,0,Strongly Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60690,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201549,1,Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60690,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201550,2,No Opinion,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60690,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201551,3,Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60690,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",201552,4,Strongly Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60691,6,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201553,0,Strongly Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60691,6,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201554,1,Agree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60691,6,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201555,2,No Opinion,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60691,6,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201556,3,Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60691,6,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,201557,4,Strongly Disagree,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60692,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",201558,0,Excellent,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60692,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",201559,1,Very Good,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60692,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",201560,2,Good,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60692,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",201561,3,Fair,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60692,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",201562,4,Poor,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60693,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",201563,0,Excellent,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60693,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",201564,1,Very Good,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60693,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",201565,2,Good,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60693,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",201566,3,Fair,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60693,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",201567,4,Poor,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60694,9,"Overall, this activity was:",201568,0,Excellent,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60694,9,"Overall, this activity was:",201569,1,Very Good,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60694,9,"Overall, this activity was:",201570,2,Good,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60694,9,"Overall, this activity was:",201571,3,Fair,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60694,9,"Overall, this activity was:",201572,4,Poor,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60695,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",201573,0,Yes,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60695,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",201574,1,No,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60695,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",201575,2,N/A,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60698,13,How would you improve this class?,201576,0,Reduce content covered in class,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60698,13,How would you improve this class?,201577,1,Increase content covered in class,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60698,13,How would you improve this class?,201578,2,Update content covered in class,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60698,13,How would you improve this class?,201579,3,Improve the instructional methods,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60698,13,How would you improve this class?,201580,4,Make course activities more stimulating,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60698,13,How would you improve this class?,201581,5,Slow the pace of the class,0
9943,Questions-0000-77,"NSF INFUSION CENTER JOURNAL CLUB - APRIL 1ST, 2021 (EVALUATION SURVEY)",n13535,60698,13,How would you improve this class?,201582,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60748,0,"The parent provided car seat is appropriate to their infant's weight and height. Despite proper positioning,    there is still slack in the harness straps. (You can pinch the harness strap at the collarbone). Discharge is  tomorrow and they are unwilling to provide another car seat. You educate the parents (and document)      about the danger and liability in using the seat with slack in the harness straps. They sign the CSC statement of understanding saying ""We'll be careful""ù. What do you do?",201776,0,A)  Place blankets under and behind the infant to take up the slack in the harness straps then begin the car seat challenge.,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60748,0,"The parent provided car seat is appropriate to their infant's weight and height. Despite proper positioning,    there is still slack in the harness straps. (You can pinch the harness strap at the collarbone). Discharge is  tomorrow and they are unwilling to provide another car seat. You educate the parents (and document)      about the danger and liability in using the seat with slack in the harness straps. They sign the CSC statement of understanding saying ""We'll be careful""ù. What do you do?",201777,1,B) Contact Care Coordination for a DCFS referral as these parents are knowingly endangering their    infant.,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60748,0,"The parent provided car seat is appropriate to their infant's weight and height. Despite proper positioning,    there is still slack in the harness straps. (You can pinch the harness strap at the collarbone). Discharge is  tomorrow and they are unwilling to provide another car seat. You educate the parents (and document)      about the danger and liability in using the seat with slack in the harness straps. They sign the CSC statement of understanding saying ""We'll be careful""ù. What do you do?",201778,2,C) Have the parent initial both statements and then sign the Release of Liability for Child Safety Seat  (#NH0725) and proceed with the car seat challenge.,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60748,0,"The parent provided car seat is appropriate to their infant's weight and height. Despite proper positioning,    there is still slack in the harness straps. (You can pinch the harness strap at the collarbone). Discharge is  tomorrow and they are unwilling to provide another car seat. You educate the parents (and document)      about the danger and liability in using the seat with slack in the harness straps. They sign the CSC statement of understanding saying ""We'll be careful""ù. What do you do?",201779,3,"D) Check the ""YES""ù box for noncompliance and document that the parents verbalize understanding of the danger of the observed noncompliance with the manufacturer's instructions -slack in  the harness straps- in the comments section of the EMR and proceed with the car seat challenge.",1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60749,1,An infant previously receiving caffeine will have the car seat challenge deferred for at least,201780,0,A)  7 days,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60749,1,An infant previously receiving caffeine will have the car seat challenge deferred for at least,201781,1,B)  3 days,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60749,1,An infant previously receiving caffeine will have the car seat challenge deferred for at least,201782,2,C) 5 days,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60749,1,An infant previously receiving caffeine will have the car seat challenge deferred for at least,201783,3,D)  10 days,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60750,2,You are caring for an infant being discharged using medical equipment. How do you educate the caregiver to secure these items while traveling in a vehicle?,201784,0,A)  Instruct them to wedge it with blankets,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60750,2,You are caring for an infant being discharged using medical equipment. How do you educate the caregiver to secure these items while traveling in a vehicle?,201785,1,B)  Instruct them to seat belt it to an unoccupied seat,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60750,2,You are caring for an infant being discharged using medical equipment. How do you educate the caregiver to secure these items while traveling in a vehicle?,201786,2,C)  Instruct them to wedge it with pillows or foam,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60750,2,You are caring for an infant being discharged using medical equipment. How do you educate the caregiver to secure these items while traveling in a vehicle?,201787,3,D)  Any of the above,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60751,3,The mom arrives on the day of discharge with a car seat she borrowed. She does not have the instruction manual and does not know how to adjust the harness straps. What do you do?,201788,0,A)  Order a car seat from Central Distribution,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60751,3,The mom arrives on the day of discharge with a car seat she borrowed. She does not have the instruction manual and does not know how to adjust the harness straps. What do you do?,201789,1,B)  Ask a staff member who has used a car seat to show mom how to adjust the harness straps,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60751,3,The mom arrives on the day of discharge with a car seat she borrowed. She does not have the instruction manual and does not know how to adjust the harness straps. What do you do?,201790,2,C)  Look on the label or give the parent the list from the SCN Parent information folder for the manufacturer's toll free numbers and websites (or) to download/view the instruction manual,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60751,3,The mom arrives on the day of discharge with a car seat she borrowed. She does not have the instruction manual and does not know how to adjust the harness straps. What do you do?,201791,3,D)  Ask a CPST to adjust the harness straps,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60752,4,You provided the parent with the car seat challenge education information. What else do you tell the parents about the car seat challenge?,201792,0,A) Read the car seat instruction manual (or view the video on the car seat manufacturer's  website) prior to the challenge and practice adjusting the harness straps,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60752,4,You provided the parent with the car seat challenge education information. What else do you tell the parents about the car seat challenge?,201793,1,"B) Bring the car seat, base and the instruction manual to the bedside when the infant is completing 4 or more PO feedings",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60752,4,You provided the parent with the car seat challenge education information. What else do you tell the parents about the car seat challenge?,201794,2,"C)	They will need to review and sign the car seat challenge statement and remain at the bedside for the first 15 minutes of the test in case repositioning is needed",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60752,4,You provided the parent with the car seat challenge education information. What else do you tell the parents about the car seat challenge?,201795,3,D)  All of the above,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60753,5,When you sell a car seat or car bed from Central Distribution the parent must sign what  additional paperwork ?,201796,0,A)  Agreement for purchase of child safety seat,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60753,5,When you sell a car seat or car bed from Central Distribution the parent must sign what  additional paperwork ?,201797,1,B)  Medicaid reimbursement form,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60753,5,When you sell a car seat or car bed from Central Distribution the parent must sign what  additional paperwork ?,201798,2,C) Release of liability for child safety seat,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60753,5,When you sell a car seat or car bed from Central Distribution the parent must sign what  additional paperwork ?,201799,3,D)  B & C,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60754,6,"The shoulder harness straps are in the lowest position on the car seat. The infant is positioned with its back flat against the back of the car seat, yet the infants shoulders are still slightly ( º""ù) below the lowest shoulder harness slot. The harness straps are snug (pass the ""pinch test""ù). The parent has signed the CSC statement and is unwilling to bring   another car seat. What do you do?",201800,0,A)  The straps are snug so there is not a compliance issue. Begin the car seat challenge,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60754,6,"The shoulder harness straps are in the lowest position on the car seat. The infant is positioned with its back flat against the back of the car seat, yet the infants shoulders are still slightly ( º""ù) below the lowest shoulder harness slot. The harness straps are snug (pass the ""pinch test""ù). The parent has signed the CSC statement and is unwilling to bring   another car seat. What do you do?",201801,1,"B)  Check the manufacturer's instructions. If the harness height is allowed to be slightly above the shoulders, check the ""NO""ù box for compliance issues and begin the car seat challenge but note that the harness height was allowed to be above the   shoulders in the comments box.",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60754,6,"The shoulder harness straps are in the lowest position on the car seat. The infant is positioned with its back flat against the back of the car seat, yet the infants shoulders are still slightly ( º""ù) below the lowest shoulder harness slot. The harness straps are snug (pass the ""pinch test""ù). The parent has signed the CSC statement and is unwilling to bring   another car seat. What do you do?",201802,2,"C)  Check the manufacturer's instructions. If the manufacturer does NOT allow  the shoulder harness to be above the  infants shoulders, check the ""YES""ù box, describe the non-compliance issue (harness height above the infants shoulders),   indicate that the parents verbalized understanding of the danger of the misuse in the  comment box in the EMR and education record, then begin the car seat challenge",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60754,6,"The shoulder harness straps are in the lowest position on the car seat. The infant is positioned with its back flat against the back of the car seat, yet the infants shoulders are still slightly ( º""ù) below the lowest shoulder harness slot. The harness straps are snug (pass the ""pinch test""ù). The parent has signed the CSC statement and is unwilling to bring   another car seat. What do you do?",201803,3,D)  B & C,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60755,7,What is the current AAP recommendation for how long an infant should ride rear-facing in a child safety seat?,201804,0,A) The infant should ride rear-facing until it is both #20 lbs. and one year past the original due date,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60755,7,What is the current AAP recommendation for how long an infant should ride rear-facing in a child safety seat?,201805,1,B) The infant should ride rear-facing until it is either 2 years old or #30 lbs.,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60755,7,What is the current AAP recommendation for how long an infant should ride rear-facing in a child safety seat?,201806,2,C) The infant should ride rear-facing until the harness straps are at the highest level on a rear-facing seat,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60755,7,What is the current AAP recommendation for how long an infant should ride rear-facing in a child safety seat?,201807,3,D) The infant should ride rear facing until they reach the highest weight or height allowed by their child safety seat's manufacturer,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60756,8,It is the day of discharge. The parents did not bring the car seat base and are unable to go back home for the base. Can you do the car seat challenge without the base?,201808,0,A) NO - if the car seat has a base you must do the test with the car seat in the base to verify the correct angle,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60756,8,It is the day of discharge. The parents did not bring the car seat base and are unable to go back home for the base. Can you do the car seat challenge without the base?,201809,1,"B) YES - as long the car seat label indicates the car seat can be used without  the base, you are able to simulate the angle as recommended by the manufacturer, and you document that the base was not used in the comments box  in the EMR",1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60757,9,The infant has a desaturation to 89% for 5 seconds after 40 minutes of the car seat challenge. How do you document this?,201810,0,A) No documentation is needed at 40 minutes. Documentation is done at 0-30-60 & 90 minutes,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60757,9,The infant has a desaturation to 89% for 5 seconds after 40 minutes of the car seat challenge. How do you document this?,201811,1,B) The desaturation did not last 10 seconds and therefore is not documented,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60757,9,The infant has a desaturation to 89% for 5 seconds after 40 minutes of the car seat challenge. How do you document this?,201812,2,C)  Stop the car seat challenge and document it as failed,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60757,9,The infant has a desaturation to 89% for 5 seconds after 40 minutes of the car seat challenge. How do you document this?,201813,3,"D)  Events outside the parameters during car seat challenge are documented in events box under ""Other""ù  but this is not a failed car seat  challenge",1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60758,10,The parent has brought a convertible seat for their infant's car seat challenge. What should you tell them?,201814,0,A) Convertible seats are for toddlers. A car seat challenge can only be done in a rear-facing only car seat,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60758,10,The parent has brought a convertible seat for their infant's car seat challenge. What should you tell them?,201815,1,B)  The car seat challenge can be done in a convertible seat if the infant fits and the angle of recline can be obtained.,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60758,10,The parent has brought a convertible seat for their infant's car seat challenge. What should you tell them?,201816,2,C)  The convertible seat does not have a level indicator so you are unable to do the car seat    challenge in a convertible seat,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60758,10,The parent has brought a convertible seat for their infant's car seat challenge. What should you tell them?,201817,3,D)  A & C,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60759,11,"What are the ""fail""ù criteria during the 90 - 120 minute car seat challenge?",201818,0,"A) A heart rate  < 80 for greater than 10 seconds, OR oxygen saturation < 88% for greater than 10 seconds; OR apnea for greater than 20 seconds",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60759,11,"What are the ""fail""ù criteria during the 90 - 120 minute car seat challenge?",201819,1,B)  A heart rate < 80 OR an oxygen saturation < 90% regardless of the duration,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60759,11,"What are the ""fail""ù criteria during the 90 - 120 minute car seat challenge?",201820,2,"C)  Any oxygen saturation < 85%, regardless of duration",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60759,11,"What are the ""fail""ù criteria during the 90 - 120 minute car seat challenge?",201821,3,D) Apnea for greater than 20 seconds OR oxygen saturation < 90% for greater than 10 seconds OR heart rate less than 80 for greater than 10 seconds,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60760,12,Where is the level indicator on the rear-facing car seat when used without the base?,201822,0,"A) The level indicator is only on the base, not on the car seat",0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60760,12,Where is the level indicator on the rear-facing car seat when used without the base?,201823,1,B) The level indicator is on a sticker on the side of the car seat,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60760,12,Where is the level indicator on the rear-facing car seat when used without the base?,201824,2,C) The level indicator is a line molded into the plastic on the side of the car seat,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60760,12,Where is the level indicator on the rear-facing car seat when used without the base?,201825,3,D) B & C,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60761,13,"The infant had been completing 4-6 PO feedings but by the time the parent brings the car seat to the bedside,  the infant is no longer completing 4 PO feedings. When can you do the car seat challenge?",201826,0,A. You must wait until the infant is completing 4-6 feedings again,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60761,13,"The infant had been completing 4-6 PO feedings but by the time the parent brings the car seat to the bedside,  the infant is no longer completing 4 PO feedings. When can you do the car seat challenge?",201827,1,B.  The provider must write for an order regarding timing of car seat challenge,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60761,13,"The infant had been completing 4-6 PO feedings but by the time the parent brings the car seat to the bedside,  the infant is no longer completing 4 PO feedings. When can you do the car seat challenge?",201828,2,C. Now since the infant had met requirements and should have had the car seat challenge done at that time,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60761,13,"The infant had been completing 4-6 PO feedings but by the time the parent brings the car seat to the bedside,  the infant is no longer completing 4 PO feedings. When can you do the car seat challenge?",201829,3,D. Once the infant is completing 3 PO feedings,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60762,14,"The car seat challenge cannot be done if the infant is having ""events""ù",201830,0,TRUE,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60762,14,"The car seat challenge cannot be done if the infant is having ""events""ù",201831,1,FALSE,1
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60763,15,You must wait at least 24 hours after respiratory support is discontinued to do the car seat challenge.,201832,0,TRUE,0
9722,Elearning-0000-933,2021 SCN INFANT CAR SEAT,n13538,60763,15,You must wait at least 24 hours after respiratory support is discontinued to do the car seat challenge.,201833,1,FALSE,1
9049,Elearning-0000-321,NSH1224 AMENDMENT 7,n13540,60765,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201836,0,TRUE,1
9049,Elearning-0000-321,NSH1224 AMENDMENT 7,n13540,60765,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201837,1,FALSE,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60767,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications and supplies needed during a postpartum hemorrhage,201840,0,TRUE,1
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60767,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications and supplies needed during a postpartum hemorrhage,201841,1,FALSE,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60768,1,Hemorrhage carts will be located:,201842,0,FCC,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60768,1,Hemorrhage carts will be located:,201843,1,HRP,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60768,1,Hemorrhage carts will be located:,201844,2,L&D,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60768,1,Hemorrhage carts will be located:,201845,3,All of the above,1
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60769,2,The OB Hemorrhage Cart is secured by:,201846,0,A zip tie,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60769,2,The OB Hemorrhage Cart is secured by:,201847,1,2 Digital locks,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60769,2,The OB Hemorrhage Cart is secured by:,201848,2,Red security seal,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60769,2,The OB Hemorrhage Cart is secured by:,201849,3,B and C,1
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60769,2,The OB Hemorrhage Cart is secured by:,201850,4,All of the above,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60770,3,Medications are stored in the OB Hemorrhage Cart,201851,0,TRUE,1
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60770,3,Medications are stored in the OB Hemorrhage Cart,201852,1,FALSE,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60771,4,What color seal should be placed over the lock bar on the cart to indicate it has been opened and cannot be used?,201853,0,Green,1
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60771,4,What color seal should be placed over the lock bar on the cart to indicate it has been opened and cannot be used?,201854,1,Red,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60771,4,What color seal should be placed over the lock bar on the cart to indicate it has been opened and cannot be used?,201855,2,Yellow,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60772,5,How frequently should the cart thermometer be checked?,201856,0,Once a day,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60772,5,How frequently should the cart thermometer be checked?,201857,1,Every shift,1
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60772,5,How frequently should the cart thermometer be checked?,201858,2,Once a week,0
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60773,6,"If a patient is transferred during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",201859,0,TRUE,1
9037,Elearning-0000-310,OB HEMORRHAGE CART,n13542,60773,6,"If a patient is transferred during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",201860,1,FALSE,0
9090,Elearning-0000-359,NSH1226 AMENDMENT 5,n13541,60766,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201838,0,TRUE,1
9090,Elearning-0000-359,NSH1226 AMENDMENT 5,n13541,60766,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201839,1,FALSE,0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60775,0,What is Northside's empiric treatment for CAP?,201863,0,"a.	Azithromycin 500mg IVPO q24hrs x 5 days",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60775,0,What is Northside's empiric treatment for CAP?,201864,1,"b.	Ceftriaxone 2g IV q24hrs",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60775,0,What is Northside's empiric treatment for CAP?,201865,2,"c.	Zosyn 4.5g IV q8h extended infusion",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60775,0,What is Northside's empiric treatment for CAP?,201866,3,"d.	Ceftriaxone 2g IV q24h + Azithromycin 500mg IV/PO Q24hrs",1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60776,1,What is the duration of therapy for HAP/VAP in a patient clinical improvement?,201867,0,"a.	It depends on the organism isolated",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60776,1,What is the duration of therapy for HAP/VAP in a patient clinical improvement?,201868,1,"b.	7 days of antibiotic treatment",1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60776,1,What is the duration of therapy for HAP/VAP in a patient clinical improvement?,201869,2,"c.	10 days of antibiotic treatment",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60776,1,What is the duration of therapy for HAP/VAP in a patient clinical improvement?,201870,3,"d.	14 days of antibiotic treatment",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60777,2,What is Northside's empiric treatment for HAP/VAP?,201871,0,"a.	Cefepime 2g IV q8h",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60777,2,What is Northside's empiric treatment for HAP/VAP?,201872,1,"b.	Zosyn 4.5g IV q8h extended infusion",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60777,2,What is Northside's empiric treatment for HAP/VAP?,201873,2,"c.	Meropenem 2g IV q8h",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60777,2,What is Northside's empiric treatment for HAP/VAP?,201874,3,"d.	Ceftazidime 2g IV q8h + Vancomycin pharmacy to dose",1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60778,3,Which antibiotic has the highest Pseudomonas coverage per Northside's Antibiogram?,201875,0,"a.	Cefepime 2g IV q8h",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60778,3,Which antibiotic has the highest Pseudomonas coverage per Northside's Antibiogram?,201876,1,"b.	Meropenem 2g IV q8h",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60778,3,Which antibiotic has the highest Pseudomonas coverage per Northside's Antibiogram?,201877,2,"c.	Ceftazidime 2g IV q8h",1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60778,3,Which antibiotic has the highest Pseudomonas coverage per Northside's Antibiogram?,201878,3,"d.	Levaquin 750mg IV q24h",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60779,4,Pharmacists should order MRSA nasal PCR when vancomycin is ordered for Pneumonia indication,201879,0,TRUE,1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60779,4,Pharmacists should order MRSA nasal PCR when vancomycin is ordered for Pneumonia indication,201880,1,FALSE,0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60780,5,Aztreonam does not have any gram positive coverage.,201881,0,TRUE,1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60780,5,Aztreonam does not have any gram positive coverage.,201882,1,FALSE,0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60781,6,What is Northside's Aspiration pneumonia empiric treatment,201883,0,"a.	Ceftriaxone 2g IV q24h",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60781,6,What is Northside's Aspiration pneumonia empiric treatment,201884,1,"b.	Unasyn 3g IV q24h if empyema/abscess suspected",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60781,6,What is Northside's Aspiration pneumonia empiric treatment,201885,2,"c.	Ceftriaxone 2g IV q24h + metronidazole 500mg IV q8h if empyema/abscess suspected",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60781,6,What is Northside's Aspiration pneumonia empiric treatment,201886,3,"d.	A, B, and C are all possible choices for aspiration pneumonia",1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60782,7,Patients with septic shock should not have antibiotics withheld based on a normal initial procalcitonin,201887,0,TRUE,1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60782,7,Patients with septic shock should not have antibiotics withheld based on a normal initial procalcitonin,201888,1,FALSE,0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60783,8,"Procalcitonin levels usually do not increase in response to infection with organisms that lack a cell wall (Mycoplasma, Chlamydia, Atypcial organisms)",201889,0,TRUE,1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60783,8,"Procalcitonin levels usually do not increase in response to infection with organisms that lack a cell wall (Mycoplasma, Chlamydia, Atypcial organisms)",201890,1,FALSE,0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60784,9,Antibiotics are strongly encouraged when Procalcitonin > 0.5ng/mL in LRTI infections.,201891,0,TRUE,1
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60784,9,Antibiotics are strongly encouraged when Procalcitonin > 0.5ng/mL in LRTI infections.,201892,1,FALSE,0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60785,10,Nonbacterial causes of procalcitonin elevation include:,201893,0,"a.	Severe trauma, cardiogenic shock, burns",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60785,10,Nonbacterial causes of procalcitonin elevation include:,201894,1,"b.	Intra-abdominal surgery",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60785,10,Nonbacterial causes of procalcitonin elevation include:,201895,2,"c.	Renal failure including ESRD/HD",0
9751,Elearning-0000-96,FY2021 PHARMACY PNEUMONIA COMPETENCY,n13544,60785,10,Nonbacterial causes of procalcitonin elevation include:,201896,3,"d.	All of the above",1
2449,ILT-0000-11290,IP ONCOLOGY STAFF MEETING MARCH 2021,n13545,60786,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201897,0,TRUE,1
2449,ILT-0000-11290,IP ONCOLOGY STAFF MEETING MARCH 2021,n13545,60786,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201898,1,FALSE,0
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60787,0,Nurses are allowed to use the emergency ad hoc administration tool for all medications,201899,0,TRUE,0
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60787,0,Nurses are allowed to use the emergency ad hoc administration tool for all medications,201900,1,FALSE,1
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60788,1,Ad Hoc administration can be used for medications administered by anesthesia,201901,0,TRUE,0
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60788,1,Ad Hoc administration can be used for medications administered by anesthesia,201902,1,FALSE,1
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60789,2,How often will a report be run to determine if the ad hoc button is being used for unauthorized medications?,201903,0,Every day,0
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60789,2,How often will a report be run to determine if the ad hoc button is being used for unauthorized medications?,201904,1,Every week,1
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60789,2,How often will a report be run to determine if the ad hoc button is being used for unauthorized medications?,201905,2,Every month,0
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60790,3,Disciplinary actions will occur for staff members using the ad hoc administration tool for unapproved medications,201906,0,TRUE,1
9718,Elearning-0000-93,WOMEN'S SERVICES AD HOC MEDICATION ADMINISTRATION,n13546,60790,3,Disciplinary actions will occur for staff members using the ad hoc administration tool for unapproved medications,201907,1,FALSE,0
9676,Elearning-0000-891,HAPI PREVENTION EDUCATION - APRIL 2021 - PRESSURE INJURY STAGING,n13548,60792,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention Education - April 2021 - Pressure Injury Staging"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201910,0,TRUE,1
9676,Elearning-0000-891,HAPI PREVENTION EDUCATION - APRIL 2021 - PRESSURE INJURY STAGING,n13548,60792,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention Education - April 2021 - Pressure Injury Staging"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201911,1,FALSE,0
249,SCORM-0000-59,JADA INSERVICE VIDEO,n13551,60795,0,I have read and understood the content within the JADA Inservice Video.,201916,0,TRUE,1
249,SCORM-0000-59,JADA INSERVICE VIDEO,n13551,60795,0,I have read and understood the content within the JADA Inservice Video.,201917,1,FALSE,0
9623,Elearning-0000-843,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT,n13695,61665,0,"BEFAST means: Balance, Eyes, Face, Arms, Speech, Time.",205001,0,TRUE,1
9623,Elearning-0000-843,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT,n13695,61665,0,"BEFAST means: Balance, Eyes, Face, Arms, Speech, Time.",205002,1,FALSE,0
9623,Elearning-0000-843,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT,n13695,61666,1,It is important to know the last known well (LKW) of the patient.,205003,0,TRUE,1
9623,Elearning-0000-843,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT,n13695,61666,1,It is important to know the last known well (LKW) of the patient.,205004,1,FALSE,0
9623,Elearning-0000-843,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT,n13695,61667,2,"You can help to decrease your personal risk factors with diet, exercise, tobacco free life, and taking your prescribed medications.",205005,0,TRUE,1
9623,Elearning-0000-843,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NON-NURSING PT CONTACT,n13695,61667,2,"You can help to decrease your personal risk factors with diet, exercise, tobacco free life, and taking your prescribed medications.",205006,1,FALSE,0
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,60799,0,"BEFAST means: Balance, Eyes, Face, Arms, Speech, Time.",201924,0,TRUE,1
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,60799,0,"BEFAST means: Balance, Eyes, Face, Arms, Speech, Time.",201925,1,FALSE,0
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61650,1,"Primary RN responsibilities include: Determine, Last Known Well, Call telemetry, treat hypoglycemia, review medications, and labs, establish IV, remain with patient and work with rapid response for next steps.",204971,0,TRUE,1
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61650,1,"Primary RN responsibilities include: Determine, Last Known Well, Call telemetry, treat hypoglycemia, review medications, and labs, establish IV, remain with patient and work with rapid response for next steps.",204972,1,FALSE,0
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61651,2,SBAR should be used to communicate during a Stroke alert.,204973,0,TRUE,1
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61651,2,SBAR should be used to communicate during a Stroke alert.,204974,1,FALSE,0
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61652,3,There is a powerplan in Cerner that requires the ordering neurologist to sign off.,204975,0,TRUE,1
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61652,3,There is a powerplan in Cerner that requires the ordering neurologist to sign off.,204976,1,FALSE,0
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61653,4,The primary RN should assist with the NIHSS during Telestroke.,204977,0,TRUE,1
9624,Elearning-0000-844,FY2021 NORTHSIDE HOSPITAL STROKE ALERT: NURSING,n13555,61653,4,The primary RN should assist with the NIHSS during Telestroke.,204978,1,FALSE,0
9637,Elearning-0000-856,FY2021 NPSG MULTI-DRUG RESISTANT ORGANISMS (MDRO): PATIENT CARE,n13557,60801,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG MULTI-DRUG RESISTANT ORGANISMS (MDRO): PATIENT CARE CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201928,0,TRUE,1
9637,Elearning-0000-856,FY2021 NPSG MULTI-DRUG RESISTANT ORGANISMS (MDRO): PATIENT CARE,n13557,60801,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG MULTI-DRUG RESISTANT ORGANISMS (MDRO): PATIENT CARE CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201929,1,FALSE,0
9618,Elearning-0000-839,FY2021 NPSG.07.05.01 - PREVENTION OF SURGICAL SITE INFECTIONS,n13558,60802,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.05.01 - PREVENTION OF SURGICAL SITE INFECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201930,0,TRUE,1
9618,Elearning-0000-839,FY2021 NPSG.07.05.01 - PREVENTION OF SURGICAL SITE INFECTIONS,n13558,60802,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.05.01 - PREVENTION OF SURGICAL SITE INFECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201931,1,FALSE,0
9638,Elearning-0000-857,FY2021 NPSG.07.04.01 - PREVENTION OF CENTRAL LINE ASSOCIATED INFECTIONS,n13560,60804,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.04.01 - PREVENTION OF CENTRAL LINE ASSOCIATED INFECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201934,0,TRUE,1
9638,Elearning-0000-857,FY2021 NPSG.07.04.01 - PREVENTION OF CENTRAL LINE ASSOCIATED INFECTIONS,n13560,60804,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.04.01 - PREVENTION OF CENTRAL LINE ASSOCIATED INFECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201935,1,FALSE,0
9682,Elearning-0000-897,FY2021 NPSG.07.01.01 - HAND HYGIENE PRINCIPLES,n13559,60803,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.01.01 - HAND HYGIENE PRINCIPLES CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201932,0,TRUE,1
9682,Elearning-0000-897,FY2021 NPSG.07.01.01 - HAND HYGIENE PRINCIPLES,n13559,60803,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.01.01 - HAND HYGIENE PRINCIPLES CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201933,1,FALSE,0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,60805,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201936,0,TRUE,1
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,60805,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",201937,1,FALSE,0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61976,1,What percentage of hospital-acquired UTIs are linked to indwelling urinary catheter use?,206099,0,"a.	30%",0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61976,1,What percentage of hospital-acquired UTIs are linked to indwelling urinary catheter use?,206100,1,"b.	50%",0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61976,1,What percentage of hospital-acquired UTIs are linked to indwelling urinary catheter use?,206101,2,"c.	60%",0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61976,1,What percentage of hospital-acquired UTIs are linked to indwelling urinary catheter use?,206102,3,"d.	80%",1
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61977,2,Complications of CAUTI include:,206103,0,"a.	Increased length of stay by 2-4 days",0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61977,2,Complications of CAUTI include:,206104,1,"b.	Discomfort and pain to the patient",0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61977,2,Complications of CAUTI include:,206105,2,"c.	Increased risk of mortality for the patient",0
9639,Elearning-0000-858,FY2021 NPSG.07.06.01 - PREVENTION OF URINARY CATHETER ASSOCIATED INFECTIONS,n13561,61977,2,Complications of CAUTI include:,206106,3,"d.	All of the above",1
9308,Elearning-0000-557,FY2021 UPDATED ELECTROLYTE REPLACEMENT ORDERS,n13563,60807,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 Updated Electrolyte Replacement Orders CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201940,0,TRUE,1
9308,Elearning-0000-557,FY2021 UPDATED ELECTROLYTE REPLACEMENT ORDERS,n13563,60807,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 Updated Electrolyte Replacement Orders CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",201941,1,FALSE,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60808,0,Please list the location for this activity.,201942,0,Atlanta,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60808,0,Please list the location for this activity.,201943,1,Forsyth,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60808,0,Please list the location for this activity.,201944,2,Cherokee,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60808,0,Please list the location for this activity.,201945,3,Other,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60809,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",201946,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60809,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",201947,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60809,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",201948,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60809,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",201949,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60809,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",201950,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60810,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",201951,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60810,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",201952,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60810,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",201953,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60810,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",201954,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60810,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",201955,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60811,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",201956,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60811,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",201957,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60811,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",201958,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60811,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",201959,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60811,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",201960,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60812,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",201961,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60812,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",201962,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60812,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",201963,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60812,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",201964,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60812,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",201965,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60813,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",201966,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60813,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",201967,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60813,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",201968,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60813,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",201969,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60813,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",201970,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60814,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",201971,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60814,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",201972,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60814,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",201973,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60814,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",201974,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60814,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",201975,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60815,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",201976,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60815,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",201977,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60815,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",201978,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60815,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",201979,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60815,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",201980,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60816,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",201981,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60816,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",201982,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60816,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",201983,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60816,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",201984,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60816,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",201985,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60817,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",201986,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60817,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",201987,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60817,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",201988,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60817,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",201989,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60817,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",201990,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60818,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",201991,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60818,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",201992,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60818,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",201993,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60818,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",201994,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60818,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",201995,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60819,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",201996,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60819,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",201997,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60819,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",201998,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60819,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",201999,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60819,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",202000,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60820,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,202001,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60820,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,202002,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60820,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,202003,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60820,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,202004,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60820,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,202005,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60821,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,202006,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60821,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,202007,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60821,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,202008,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60821,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,202009,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60821,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,202010,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60822,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",202011,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60822,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",202012,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60822,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",202013,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60822,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",202014,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60822,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",202015,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60823,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",202016,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60823,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",202017,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60823,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",202018,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60823,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",202019,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60823,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",202020,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60824,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,202021,0,Strongly Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60824,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,202022,1,Agree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60824,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,202023,2,No Opinion,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60824,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,202024,3,Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60824,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,202025,4,Strongly Disagree,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60825,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN</ol>",202026,0,Excellent,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60825,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN</ol>",202027,1,Very Good,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60825,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN</ol>",202028,2,Good,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60825,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN</ol>",202029,3,Fair,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60825,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN</ol>",202030,4,Poor,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60826,18,"Overall, this activity was:",202031,0,Excellent,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60826,18,"Overall, this activity was:",202032,1,Very Good,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60826,18,"Overall, this activity was:",202033,2,Good,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60826,18,"Overall, this activity was:",202034,3,Fair,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60826,18,"Overall, this activity was:",202035,4,Poor,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60827,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",202036,0,Yes,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60827,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",202037,1,No,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60827,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",202038,2,N/A,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60830,22,How would you improve this class?,202039,0,Reduce content covered in class,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60830,22,How would you improve this class?,202040,1,Increase content covered in class,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60830,22,How would you improve this class?,202041,2,Update content covered in class,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60830,22,How would you improve this class?,202042,3,Improve the instructional methods,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60830,22,How would you improve this class?,202043,4,Make course activities more stimulating,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60830,22,How would you improve this class?,202044,5,Slow the pace of the class,0
9888,Questions-0000-22,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 4-12-21,n13564,60830,22,How would you improve this class?,202045,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60905,0,The application that MUST be utilized to help prevent the creation of duplicate medical records is:,202325,0,"a.	QuadraMed SmartID",1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60905,0,The application that MUST be utilized to help prevent the creation of duplicate medical records is:,202326,1,"b.	Powerchart",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60905,0,The application that MUST be utilized to help prevent the creation of duplicate medical records is:,202327,2,"c.	WQM",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60905,0,The application that MUST be utilized to help prevent the creation of duplicate medical records is:,202328,3,"d.	One Chart",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60906,1,"If a duplicate MRN is discovered by Patient Access at the time of registration, the team member should contact Centralized Scheduling (404.851.6577) to have the patient rescheduled under the appropriate MRN.",202329,0,TRUE,1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60906,1,"If a duplicate MRN is discovered by Patient Access at the time of registration, the team member should contact Centralized Scheduling (404.851.6577) to have the patient rescheduled under the appropriate MRN.",202330,1,FALSE,0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60907,2,The email address used to report multiple MRNs is:,202331,0,"a.	DuplicateFINs@northside.com",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60907,2,The email address used to report multiple MRNs is:,202332,1,"b.	NSHDuplicateMRNs@northside.com",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60907,2,The email address used to report multiple MRNs is:,202333,2,"c.	DuplicateMRNNotifications@northside.com",1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60907,2,The email address used to report multiple MRNs is:,202334,3,"d.	PrecertLeadership@northside.com",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60908,3,"Tara Daley needs to schedule an appointment at Hamilton Mill Imaging.  When you search for the patient, SmartID populates two green results: one affiliated to NSH Atlanta and the other affiliated to a physician practice.  Which medical record should you schedule the new appointment to according to the images below?",202335,0,"a.	MRN 958563",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60908,3,"Tara Daley needs to schedule an appointment at Hamilton Mill Imaging.  When you search for the patient, SmartID populates two green results: one affiliated to NSH Atlanta and the other affiliated to a physician practice.  Which medical record should you schedule the new appointment to according to the images below?",202336,1,"b.	MRN 2248562",1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60908,3,"Tara Daley needs to schedule an appointment at Hamilton Mill Imaging.  When you search for the patient, SmartID populates two green results: one affiliated to NSH Atlanta and the other affiliated to a physician practice.  Which medical record should you schedule the new appointment to according to the images below?",202337,2,"c.	MRN 1015909",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60908,3,"Tara Daley needs to schedule an appointment at Hamilton Mill Imaging.  When you search for the patient, SmartID populates two green results: one affiliated to NSH Atlanta and the other affiliated to a physician practice.  Which medical record should you schedule the new appointment to according to the images below?",202344,3,"d.	Create New",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60909,4,"Submitting the duplicate MRN notification will result in the patient's entire medical history, such as documentation, financials, images, etc, being merged.",202338,0,TRUE,0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60909,4,"Submitting the duplicate MRN notification will result in the patient's entire medical history, such as documentation, financials, images, etc, being merged.",202339,1,FALSE,1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60910,5,"Ben Woods would like to schedule a CT scan at 1100 Forsyth.  When you search the system for him using name, DOB and gender, all of the results come back red.  What does this mean?",202340,0,a. You entered incorrect search criteria,0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60910,5,"Ben Woods would like to schedule a CT scan at 1100 Forsyth.  When you search the system for him using name, DOB and gender, all of the results come back red.  What does this mean?",202341,1,"b.	You need to create a new patient because he has never been to any of our facilities",1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60910,5,"Ben Woods would like to schedule a CT scan at 1100 Forsyth.  When you search the system for him using name, DOB and gender, all of the results come back red.  What does this mean?",202342,2,"c.	These are all duplicate MRNs that need to be merged.",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60910,5,"Ben Woods would like to schedule a CT scan at 1100 Forsyth.  When you search the system for him using name, DOB and gender, all of the results come back red.  What does this mean?",202343,3,"d.	Both a and c",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60911,6,"It is not necessary to follow-up on your merge request.  If you sent it, it will be done.",202345,0,TRUE,0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60911,6,"It is not necessary to follow-up on your merge request.  If you sent it, it will be done.",202346,1,FALSE,1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60912,7,While scheduling Miranda Pennyworth you notice that she has multiple MRNs.  How do you communicate that these duplicates exist?,202347,0,"a.	You complete the Duplicate MRN form or send an email to @Duplicate MRN Notifications",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60912,7,While scheduling Miranda Pennyworth you notice that she has multiple MRNs.  How do you communicate that these duplicates exist?,202348,1,"b.	You notate Scheduling Comments with Duplicate MRN found, Merge Request Initiated",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60912,7,While scheduling Miranda Pennyworth you notice that she has multiple MRNs.  How do you communicate that these duplicates exist?,202349,2,"c.	You carbon copy the Supervisor of the site where the patient is scheduled on the Duplicate merge email",0
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60912,7,While scheduling Miranda Pennyworth you notice that she has multiple MRNs.  How do you communicate that these duplicates exist?,202350,3,"d.	All of the above",1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60913,8,Philip Wesley is requesting to schedule at NSH Cherokee.  He has established history at NSH Atlanta and NSH Gwinnett when you search for him.  It is appropriate for you to schedule to this medical record.,202351,0,TRUE,1
9415,Elearning-0000-654,DUPLICATE MRNS:  HOW TO IDENTIFY AND RESOLVE THEM,n13571,60913,8,Philip Wesley is requesting to schedule at NSH Cherokee.  He has established history at NSH Atlanta and NSH Gwinnett when you search for him.  It is appropriate for you to schedule to this medical record.,202352,1,FALSE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60924,0,Modifier ML is affixed to a charge to communicate the absence of a physician's involvement during a patient encounter.,202381,0,TRUE,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60924,0,Modifier ML is affixed to a charge to communicate the absence of a physician's involvement during a patient encounter.,202382,1,FALSE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60925,1,Another name for a Mid-Level Provider is:,202383,0,A) Medical Doctor,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60925,1,Another name for a Mid-Level Provider is:,202384,1,B) Medical Assistant,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60925,1,Another name for a Mid-Level Provider is:,202385,2,C) Advanced Practice Provider,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60925,1,Another name for a Mid-Level Provider is:,202386,3,D) All of the above,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60925,1,Another name for a Mid-Level Provider is:,202387,4,E) C only,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60926,2,The ML modifier dictates how a claim is reimbursed by a payer.,202388,0,TRUE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60926,2,The ML modifier dictates how a claim is reimbursed by a payer.,202389,1,FALSE,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60927,3,Modifier ML is relied upon by the following departments:,202390,0,A) Revenue Integrity and Compensation,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60927,3,Modifier ML is relied upon by the following departments:,202391,1,B) Contracting and Productivity Management,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60927,3,Modifier ML is relied upon by the following departments:,202392,2,C) Professional Billing Services,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60927,3,Modifier ML is relied upon by the following departments:,202393,3,D) A and C,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60927,3,Modifier ML is relied upon by the following departments:,202394,4,E) All of the above,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60928,4,Advance Practice Provider (APP) sees patient in conjunction with MD.  APP documents all elements of encounter with signature.  MD attests to a face to face encounter and documents substantive portion of the visit with signature.  Modifier ML should not be appended.,202395,0,TRUE,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60928,4,Advance Practice Provider (APP) sees patient in conjunction with MD.  APP documents all elements of encounter with signature.  MD attests to a face to face encounter and documents substantive portion of the visit with signature.  Modifier ML should not be appended.,202396,1,FALSE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60929,5,There are no RCx rules established for modifier ML to stop charges needing additional Charge Entry review before submission.,202397,0,TRUE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60929,5,There are no RCx rules established for modifier ML to stop charges needing additional Charge Entry review before submission.,202398,1,FALSE,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60930,6,Advanced Practice Provider (APP) sees patient alone and documents all elements of the encounter with signature.  The MD reviews the note and signs.  Modifier ML should not be appended.,202399,0,TRUE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60930,6,Advanced Practice Provider (APP) sees patient alone and documents all elements of the encounter with signature.  The MD reviews the note and signs.  Modifier ML should not be appended.,202400,1,FALSE,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60931,7,"If the Advanced Practice Provider (APP) is involved in the care of a patient, the APP is always entered as the Rendering and the MD as the Supervising.",202401,0,TRUE,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60931,7,"If the Advanced Practice Provider (APP) is involved in the care of a patient, the APP is always entered as the Rendering and the MD as the Supervising.",202402,1,FALSE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60932,8,It is not necessary for the Physician (MD) to document their face to face services.,202403,0,TRUE,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60932,8,It is not necessary for the Physician (MD) to document their face to face services.,202404,1,FALSE,1
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60933,9,Which credential(s) represent an Advance Practice Provider:,202405,0,A) PA,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60933,9,Which credential(s) represent an Advance Practice Provider:,202406,1,B) MA,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60933,9,Which credential(s) represent an Advance Practice Provider:,202407,2,C) NP,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60933,9,Which credential(s) represent an Advance Practice Provider:,202408,3,D) A or B,0
9734,Elearning-0000-944,REV INT - MODIFIER ML USE & CHARGE ENTRY GUIDE,n13576,60933,9,Which credential(s) represent an Advance Practice Provider:,202409,4,E) A or C,1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60940,0,If Advance Directive Form has checked: I have not executed an Advance Directive and do not wish to discuss it further at this time. The nurse will do .....,202435,0,Nothing needed to do at this time.,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60940,0,If Advance Directive Form has checked: I have not executed an Advance Directive and do not wish to discuss it further at this time. The nurse will do .....,202436,1,"Sign, date, and time to signify final review has been completed at the bottom of the form.",1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60940,0,If Advance Directive Form has checked: I have not executed an Advance Directive and do not wish to discuss it further at this time. The nurse will do .....,202437,2,Ask the patient for a copy of their Advance Directive.,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60940,0,If Advance Directive Form has checked: I have not executed an Advance Directive and do not wish to discuss it further at this time. The nurse will do .....,202438,3,Call the family and as for copy of Advance Directive.,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60941,1,If the patient has executed an Advance Directive and says they will provide a copy to Northside Hospital the nurse should make two attempts to get the copy from patient and/or family and document under communications. After two attempts have been documented the nurse will sign the bottom of the Advance Directive form in the chart that it is completed.,202439,0,TRUE,1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60941,1,If the patient has executed an Advance Directive and says they will provide a copy to Northside Hospital the nurse should make two attempts to get the copy from patient and/or family and document under communications. After two attempts have been documented the nurse will sign the bottom of the Advance Directive form in the chart that it is completed.,202440,1,FALSE,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60942,2,"If the Advance Directive form is marked that an Advance Directive was provided on a previous admission to Northside Hospital the nurse is required to print a copy of this form, notify the physician that the copy is on the chart and document on the form that the physician was notified.",202441,0,TRUE,1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60942,2,"If the Advance Directive form is marked that an Advance Directive was provided on a previous admission to Northside Hospital the nurse is required to print a copy of this form, notify the physician that the copy is on the chart and document on the form that the physician was notified.",202442,1,FALSE,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60943,3,The Advance Directive form in the chart should be reviewed by the nurse during chart check every shift for completion. The form is completed when you see a nurse signature at the bottom of the form.,202443,0,TRUE,1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60943,3,The Advance Directive form in the chart should be reviewed by the nurse during chart check every shift for completion. The form is completed when you see a nurse signature at the bottom of the form.,202444,1,FALSE,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60944,4,If a patient is unable to answer any questions about their advance directives the nurse should:,202445,0,Contact the legal family member if the patient has an advance directive.,1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60944,4,If a patient is unable to answer any questions about their advance directives the nurse should:,202446,1,Chart unable to complete this information.,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60945,5,"When a patient has an Advance Directive, the Advance Directive Acknowledgement form must be completed and on the chart along with a copy of the Advance Directive, in order for the Advance Directive Checklist to be complete.",202447,0,TRUE,1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60945,5,"When a patient has an Advance Directive, the Advance Directive Acknowledgement form must be completed and on the chart along with a copy of the Advance Directive, in order for the Advance Directive Checklist to be complete.",202448,1,FALSE,0
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60946,6,Every patient should have an Advance Directive Checklist in the chart and completed.,202449,0,TRUE,1
9582,Elearning-0000-806,ADVANCE DIRECTIVE APRIL 2021,n13579,60946,6,Every patient should have an Advance Directive Checklist in the chart and completed.,202450,1,FALSE,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60947,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage,202451,0,TRUE,1
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60947,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage,202452,1,FALSE,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60948,1,The OB Hemorrhage Cart is secured by:,202453,0,A zip tie,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60948,1,The OB Hemorrhage Cart is secured by:,202454,1,2 Digital locks,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60948,1,The OB Hemorrhage Cart is secured by:,202455,2,Red security seal,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60948,1,The OB Hemorrhage Cart is secured by:,202456,3,B and C,1
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60948,1,The OB Hemorrhage Cart is secured by:,202457,4,All of the above,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60949,2,Medications are stored in the OB Hemorrhage Cart,202458,0,TRUE,1
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60949,2,Medications are stored in the OB Hemorrhage Cart,202459,1,FALSE,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60950,3,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,202460,0,Red,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60950,3,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,202461,1,Yellow,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60950,3,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,202462,2,Green,1
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60951,4,How frequently should the cart thermometer be checked?,202463,0,Once a day,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60951,4,How frequently should the cart thermometer be checked?,202464,1,Every shift,1
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60951,4,How frequently should the cart thermometer be checked?,202465,2,Once a week,0
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60952,5,"If a patient is transferred to a higher level of care during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",202466,0,TRUE,1
9038,Elearning-0000-311,NSC OB HEMORRHAGE CART 2021,n13580,60952,5,"If a patient is transferred to a higher level of care during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",202467,1,FALSE,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,60998,0,"You are caring for a nulliparous woman in labor that has been AROM 3 hours ago.  She has remained 4 cm during this time. There is a Cat I FHR tracing.  She has been augmented with Pitocin for 2 1/2 hours.  The provider mentioned at the nurse's station that if she does not have cervical change, that she will need a C/S.   Does the patient meet the criteria for having labor dystocia?",202645,0,Yes,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,60998,0,"You are caring for a nulliparous woman in labor that has been AROM 3 hours ago.  She has remained 4 cm during this time. There is a Cat I FHR tracing.  She has been augmented with Pitocin for 2 1/2 hours.  The provider mentioned at the nurse's station that if she does not have cervical change, that she will need a C/S.   Does the patient meet the criteria for having labor dystocia?",202646,1,No,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,60999,1,"Your patient, J.F., G1 P0, has been admitted for elective induction of labor with Pitocin.   Her admitting cervical exam was 3/80/-1, soft and anterior.  Her membranes were ruptured 18 hours ago and she has been on Pitocin for over 24 hours.  There is a CAT I FHR tracing, and the patient remains afebrile. The provider has diagnosed her as a Failed Elective Induction.  Do you agree?",202647,0,Yes,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,60999,1,"Your patient, J.F., G1 P0, has been admitted for elective induction of labor with Pitocin.   Her admitting cervical exam was 3/80/-1, soft and anterior.  Her membranes were ruptured 18 hours ago and she has been on Pitocin for over 24 hours.  There is a CAT I FHR tracing, and the patient remains afebrile. The provider has diagnosed her as a Failed Elective Induction.  Do you agree?",202648,1,No,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61000,2,Only mothers with Category III FHR tracings should have a C/S for Fetal Intolerance.,202649,0,TRUE,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61000,2,Only mothers with Category III FHR tracings should have a C/S for Fetal Intolerance.,202650,1,FALSE,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61001,3,What category is this FHR tracing?,202651,0,Category I,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61001,3,What category is this FHR tracing?,202652,1,Category II,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61001,3,What category is this FHR tracing?,202653,2,Category III,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61002,4,What is the FHR variability in this tracing?,202654,0,Absent,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61002,4,What is the FHR variability in this tracing?,202655,1,Minimal,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61002,4,What is the FHR variability in this tracing?,202656,2,Moderate,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61002,4,What is the FHR variability in this tracing?,202657,3,Marked,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61003,5,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",202658,0,No corrective measures necessary due to moderate FHRV,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61003,5,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",202659,1,"Maternal position change, 300-500 ml IVF bolus, and push in the lateral position.",0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61003,5,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",202660,2,Administer terbutaline,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61003,5,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",202661,3,Call the provider,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61003,5,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",202662,4,Both B&C,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61003,5,"Patient is G1P0, C/C/+1 and is starting to push.  Her temperature is now 37.7 C. (99.9F). Based on the pattern, what conservative corrective measures will you perform?",202663,5,Both B&D,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61004,6,"Are there ""Clinically Significant decelerations""ù = 50% of contractions?",202664,0,Yes,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61004,6,"Are there ""Clinically Significant decelerations""ù = 50% of contractions?",202665,1,No,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61005,7,"As long as the patient is progressing normally in the second stage, we can observe and continue to push.",202666,0,TRUE,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61005,7,"As long as the patient is progressing normally in the second stage, we can observe and continue to push.",202667,1,FALSE,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61006,8,"The patent is G2P1 admitted for early labor. Her SVE is 2-3/70/-2.  There is no known maternal or fetal risk factors noted upon admission.  Her last delivery was a NSVD. In the tracing below, is there moderate FHRV or accelerations?",202668,0,Yes,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61006,8,"The patent is G2P1 admitted for early labor. Her SVE is 2-3/70/-2.  There is no known maternal or fetal risk factors noted upon admission.  Her last delivery was a NSVD. In the tracing below, is there moderate FHRV or accelerations?",202669,1,No,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61007,9,"In the tracing below, are there clinically significant decelerations with = 50% of contractions?",202670,0,Yes,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61007,9,"In the tracing below, are there clinically significant decelerations with = 50% of contractions?",202671,1,No,1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61008,10,Would you perform and conservative corrective measures for this tracing?,202672,0,"Yes, that is an appropriate action at this point.",1
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61008,10,Would you perform and conservative corrective measures for this tracing?,202673,1,"No, this is a category III tracing and she should be delivered as soon as possible.",0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61009,11,"After performing conservative corrective measures, the pattern below persists for an hour. What should the plan of care be?",202674,0,Observe for an additional hour since she is a multip,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61009,11,"After performing conservative corrective measures, the pattern below persists for an hour. What should the plan of care be?",202675,1,Observe for 30 additional minutes since there are no decels,0
9222,Elearning-0000-479,LD FY 2021 NTSV INITIATIVE EDUCATION,n13584,61009,11,"After performing conservative corrective measures, the pattern below persists for an hour. What should the plan of care be?",202676,2,Move towards cesarean delivery,1
9075,Elearning-0000-345,NSH1287 AMENDMENT 11,n13585,61010,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",202677,0,TRUE,1
9075,Elearning-0000-345,NSH1287 AMENDMENT 11,n13585,61010,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",202678,1,FALSE,0
9667,Elearning-0000-883,KRONOS TIME AND ATTENDANCE FOR NEW TIMEKEEPERS,n13587,61012,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""KRONOS Time and Attendance for New Timekeepers"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",202681,0,TRUE,1
9667,Elearning-0000-883,KRONOS TIME AND ATTENDANCE FOR NEW TIMEKEEPERS,n13587,61012,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""KRONOS Time and Attendance for New Timekeepers"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",202682,1,FALSE,0
9349,Elearning-0000-594,FY2020-2021 STERILIZER LOAD STICKER & PACKAGE LABELS,n13589,61014,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",202685,0,TRUE,1
9349,Elearning-0000-594,FY2020-2021 STERILIZER LOAD STICKER & PACKAGE LABELS,n13589,61014,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",202686,1,FALSE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61017,1,"VS, Aldrete Score, and End Tidal CO2 must be assessed q5 minutes during the procedure and 30 minutes post sedation",202691,0,TRUE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61017,1,"VS, Aldrete Score, and End Tidal CO2 must be assessed q5 minutes during the procedure and 30 minutes post sedation",202692,1,FALSE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61018,0,A large total dose is ordered initially to be given in smaller doses over the entire procedure,202693,0,TRUE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61018,0,A large total dose is ordered initially to be given in smaller doses over the entire procedure,202694,1,FALSE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61019,2,The RN may administer Propofol pushes when ordered in the procedural sedation power plan,202695,0,TRUE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61019,2,The RN may administer Propofol pushes when ordered in the procedural sedation power plan,202696,1,FALSE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61020,3,ICU Moderate Sedation Band is where procedural sedation is documented,202697,0,TRUE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61020,3,ICU Moderate Sedation Band is where procedural sedation is documented,202698,1,FALSE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61021,4,The recovery Aldrete score should be 9 or the patients baseline Aldrete score,202699,0,TRUE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61021,4,The recovery Aldrete score should be 9 or the patients baseline Aldrete score,202700,1,FALSE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61022,5,The RN must scan each individual dose of Fentanyl during the procedure,202701,0,TRUE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61022,5,The RN must scan each individual dose of Fentanyl during the procedure,202702,1,FALSE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61023,6,"When Propofol is documented in the MAR, ""performed by"" needs to remain the NAME OF the RN",202703,0,TRUE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61023,6,"When Propofol is documented in the MAR, ""performed by"" needs to remain the NAME OF the RN",202704,1,FALSE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61024,7,Only some procedures require universal protocol,202705,0,TRUE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61024,7,Only some procedures require universal protocol,202706,1,FALSE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61025,8,Procedural/Moderate sedation meds should be administered as soon as the powerplan is ordered,202707,0,TRUE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61025,8,Procedural/Moderate sedation meds should be administered as soon as the powerplan is ordered,202708,1,FALSE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61026,9,"when a patient is on a sedating IV continuous drip, the provider can give an order for the rate to be changed for the procedure",202709,0,TRUE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61026,9,"when a patient is on a sedating IV continuous drip, the provider can give an order for the rate to be changed for the procedure",202710,1,FALSE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61027,10,"The Aldrete scale is composed of Activity, Respiration, Circulation, Consciousness, and Oxygen Saturation",202711,0,TRUE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61027,10,"The Aldrete scale is composed of Activity, Respiration, Circulation, Consciousness, and Oxygen Saturation",202712,1,FALSE,0
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61028,11,I have viewed the ICU Moderate Sedation Power Point and workflow video and understand the information presented to me.  I understand that I can go to a Clinician or Leadership team member with questions.,202713,0,TRUE,1
9270,Elearning-0000-522,NSC ICU PROCEDURAL MODERATE SEDATION,n13591,61028,11,I have viewed the ICU Moderate Sedation Power Point and workflow video and understand the information presented to me.  I understand that I can go to a Clinician or Leadership team member with questions.,202714,1,FALSE,0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61049,0,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,202782,0,TRUE,1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61049,0,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,202783,1,FALSE,0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61050,1,Mitten(s) are NOT a type of physical restraint,202784,0,TRUE,1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61050,1,Mitten(s) are NOT a type of physical restraint,202785,1,FALSE,0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61051,2,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,202786,0,TRUE,0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61051,2,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,202787,1,FALSE,1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61052,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",202788,0,"a.	A patient with an emotional disorder poses a physical threat to other patients.",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61052,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",202789,1,"b.	A patient is pulling at his Foley catheter and demonstrates lack of understanding to comply with safety directions.",1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61052,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",202790,2,"c.	A patient with an emotional disorder is attempting to cause physical harm to himself.",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61052,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",202791,3,"d.	A patient with a behavioral disorder poses a threat to the staff.",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61053,4,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,202792,0,TRUE,1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61053,4,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,202793,1,FALSE,0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61054,5,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",202794,0,TRUE,1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61054,5,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",202795,1,FALSE,0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61055,6,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",202796,0,TRUE,0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61055,6,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",202797,1,FALSE,1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61056,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",202798,0,"a.	Patient is pulling at lines",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61056,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",202799,1,"b.	Patient is pulling at tubes",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61056,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",202800,2,"c.	Patient wants to get out of bed unattended",1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61056,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",202801,3,"d.	Patient demonstrates lack of understanding to comply with safety directions",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61057,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,202802,0,"a.	Used the right-sized restraint",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61057,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,202803,1,"b.	Applied the restraints according to manufacturer's directions",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61057,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,202804,2,"c.	Secured the restraints to the siderails",1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61057,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,202805,3,"d.	Tied knots so they can be quickly released",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61058,9,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",202806,0,"a.	Patient is an imminent risk of intentional harm to self",0
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61058,9,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",202807,1,"b.	Patient is verbally abusive to staff",1
9306,Elearning-0000-555,FY21 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION FOR INPATIENT REHABILITATIVE SERVICES,n13595,61058,9,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",202808,2,"c.	Patient is an imminent risk of intentional harm to others",0
9118,Elearning-0000-384,NSC FCC EXCLUSIVE BREASTFEEDING ROUNDING,n13601,61133,0,I acknowledge that I have read and understand the information provided in the NSC FCC Exclusive Breastfeeding Rounding CBL.,203110,0,TRUE,1
9118,Elearning-0000-384,NSC FCC EXCLUSIVE BREASTFEEDING ROUNDING,n13601,61133,0,I acknowledge that I have read and understand the information provided in the NSC FCC Exclusive Breastfeeding Rounding CBL.,203111,1,FALSE,0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61150,2,What is considered the normal range for the PR interval?,203176,0,"a.	0.12- 0.20 minutes",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61150,2,What is considered the normal range for the PR interval?,203177,1,"b.	0.06- 0.10 minutes",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61150,2,What is considered the normal range for the PR interval?,203179,2,"c.	0.12- 0.20 seconds",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61150,2,What is considered the normal range for the PR interval?,203178,3,"d.	0.06- 0.10 seconds",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61151,3,The most appropriate treatment for Torsades de pointes is,203180,0,"a.	BLS, epinephrine",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61151,3,The most appropriate treatment for Torsades de pointes is,203181,1,"b.	Transcutaneous pacing or atropine",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61151,3,The most appropriate treatment for Torsades de pointes is,203182,2,"c.	BLS, defibrillation, epinephrine, amiodarone",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61151,3,The most appropriate treatment for Torsades de pointes is,203183,3,"d.	Magnesium, overdrive pacing, isoproterenol",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61152,9,What is considered the normal range for the QT interval?,203187,0,"a.	0.36- 0.44 seconds",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61152,9,What is considered the normal range for the QT interval?,203184,1,"b.	0.20- 0.50 seconds",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61152,9,What is considered the normal range for the QT interval?,203185,2,"c.	0.50- 0.75 seconds",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61152,9,What is considered the normal range for the QT interval?,203186,3,"d.	0.12- 0.20 seconds",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61153,10,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",203188,0,"a.	Lead II",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61153,10,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",203189,1,"b.	Lead I",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61153,10,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",203191,2,"c.	Lead VI",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61153,10,"According to Evidence-Based Practice for bedside cardiac monitoring , the primary arrhythmia monitoring lead is",203190,3,"d.	Lead aVF",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61154,11,A QRS complex represents,203192,0,"a.	Atrial depolarization",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61154,11,A QRS complex represents,203193,1,"b.	Atrial repolarization",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61154,11,A QRS complex represents,203195,2,"c.	Ventricular depolarization",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61154,11,A QRS complex represents,203194,3,"d.	Ventricular repolarization",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61155,16,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",203196,0,"a.	Sinus bradycardia",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61155,16,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",203199,1,"b.	Pulseless electrical activity",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61155,16,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",203197,2,"c.	Second degree heart block type II",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61155,16,"You have completed 2 minutes of CPR.  The ECG monitor displays the lead II rhythm shown below, and the patient has no pulse.  What best characterizes this patient's rhythm?",203198,3,"d.	Third degree heart block",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61156,17,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",203203,0,"a.	Unstable supraventricular tachycardia",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61156,17,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",203200,1,"b.	Stable supraventricular tachycardia",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61156,17,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",203201,2,"c.	Ventricular tachycardia",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61156,17,"A patient is admitted with a history of congestive heart failure.  The patient is experiencing shortness of breath, a blood pressure of 72/50 mmHg, and a heart rate of 190 beats per minute.  The patient's lead II ECG is displayed below.  What best characterizes the patient's rhythm?",203202,3,"d.	Sinus tachycardia",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61157,22,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,203204,0,"a.	Failure to fire",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61157,22,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,203207,1,"b.	Failure to capture",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61157,22,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,203205,2,"c.	Failure to sense",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61157,22,You are caring for a patient with a temporary Transvenous pacemaker.  What best characterizes the Lead II ECG displayed?,203206,3,"d.	Oversensing",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61158,23,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,203211,0,"a.	Defibrillation",1
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61158,23,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,203208,1,"b.	Synchronized cardioversion",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61158,23,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,203209,2,"c.	Administration of adenosine 12 mg IV push",0
9927,Questions-0000-61,FY2021 NSF ICU EKG INTERPRETATION ASSESSMENT CBL,n13602,61158,23,A patient has no pulse and is a witnessed loss of consciousness.  The lead II ECG reveals this rhythm.  Which is the appropriate treatment for the rhythm displayed?,203210,3,"d.	Administration of atropine 0.5mg IV push",0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61164,0,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,203220,0,Labor or Antepartum Order Sets,0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61164,0,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,203221,1,Labor and Delivery Nurse Initiated Standing Orders,1
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61164,0,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,203222,2,Hypertensive Regimen Orders,0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61164,0,What types of orders should be placed on ALL patients at admission and do not require a provider to give the orders first?,203223,3,HIV communication orders,0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61165,1,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",203224,0,Verbal,0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61165,1,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",203225,1,Telephone,1
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61165,1,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",203226,2,Protocol,0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61165,1,"Your patient has a BP 167/92. Fifteen minutes later, you repeat her BP and the result is 174/98. You call the provider at home and she orders the Hydralazine regimen. What order type will you put for this order?",203227,3,Standing,0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61166,2,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",203228,0,Telephone (because that's how the provider placed the initial communication order in the order set),0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61166,2,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",203229,1,Protocol (because it's already been ordered by the provider and this order is completing the protocol),1
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61166,2,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",203230,2,Standing (because the order is already standing and we are just activating it),0
9365,Elearning-0000-609,LD FY 2021 ORDER TYPES CLARIFICATION,n13604,61166,2,"Your patient is a walk in with no prenatal care and has the ""OB Labor Admission Acute NSH"" order set placed in Cerner. When you are drawing her bloodwork, you draw a Hepatitis B lab per the communication order in the order set. When you enter the order for ""Hepatitis B Surface Antigen,"" what order type will you place this under?",203231,3,Verbal (because it's first on the list and any type is fine in this case),0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61172,0,I have read and understood the content within the FCC Postpartum Hemorrhage Education CBL.,203246,0,TRUE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61172,0,I have read and understood the content within the FCC Postpartum Hemorrhage Education CBL.,203247,1,FALSE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61214,1,"1.	The location where all of the carts will be include:",203410,0,"a)	1st floor",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61214,1,"1.	The location where all of the carts will be include:",203411,1,"b)	4th floor",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61214,1,"1.	The location where all of the carts will be include:",203412,2,"c)	5th floor",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61214,1,"1.	The location where all of the carts will be include:",203413,3,"d)	6th floor",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61214,1,"1.	The location where all of the carts will be include:",203414,4,"e)	FCC, HRP, and L&D",1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61215,2,"2.	The Jada system and BT Balloon will be used in all of Women's Services:",203415,0,TRUE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61215,2,"2.	The Jada system and BT Balloon will be used in all of Women's Services:",203416,1,FALSE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61216,3,"3.	Bleach and hydrogen peroxide wipe can be used to clean the hemorrhage cart:",203417,0,TRUE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61216,3,"3.	Bleach and hydrogen peroxide wipe can be used to clean the hemorrhage cart:",203418,1,FALSE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61217,4,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",203419,0,"a)	Once a day",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61217,4,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",203420,1,"b)	Every shift",1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61217,4,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",203421,2,"c)	Once a month",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61217,4,"4.	 The hemorrhage cart checklist should be complete how often by the supervisor or charge nurse:",203422,3,"d)	Once a week",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61218,5,"5.	You can lock the QBL scale drawer open by:",203423,0,"a)	Pulling the red latch up",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61218,5,"5.	You can lock the QBL scale drawer open by:",203424,1,"b)	Pushing the red latch down",1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61218,5,"5.	You can lock the QBL scale drawer open by:",203425,2,"c)	Leaving the red latch alone",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61219,6,"6.	Drawer 2 contains which medical items:",203426,0,"a)	Refrigerated medications- Methergine and Hemabate",1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61219,6,"6.	Drawer 2 contains which medical items:",203427,1,"b)	IV start kits and needles",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61219,6,"6.	Drawer 2 contains which medical items:",203428,2,"c)	IV tubing",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61219,6,"6.	Drawer 2 contains which medical items:",203429,3,"d)	Straight catheter, Foley catheter, and BT catheter",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61220,7,"7.	Drawer 7 contains which medical items:",203430,0,"a)	IV tubing",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61220,7,"7.	Drawer 7 contains which medical items:",203431,1,"b)	Straight catheter, Foley catheter, and BT catheter",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61220,7,"7.	Drawer 7 contains which medical items:",203432,2,"c)	Blue Chux pads, Linens bags, biohazard bags, surgical gowns, and pads",1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61220,7,"7.	Drawer 7 contains which medical items:",203433,3,"d)	JADA system",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61221,8,"8.	Every OB hemorrhage Cart will have cart number that goes along with a binder, that's at sits on the top of the cart:",203434,0,TRUE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61221,8,"8.	Every OB hemorrhage Cart will have cart number that goes along with a binder, that's at sits on the top of the cart:",203435,1,FALSE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61222,9,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",203436,0,"a)	Pounds",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61222,9,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",203437,1,"b)	Grams",1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61222,9,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",203438,2,"c)	Kilograms",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61222,9,"9.	The QBL scale will measured in Kg but will need to be calculated in ____ for the QBL calculator:",203439,3,"d)	Liters",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61223,10,"10.	All bloody items will be placed in the Joey Pouch for measurement and then placed in a linen bag or a biohazard bag:",203440,0,TRUE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61223,10,"10.	All bloody items will be placed in the Joey Pouch for measurement and then placed in a linen bag or a biohazard bag:",203441,1,FALSE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61224,11,"11.	Green used tape will be placed over the lock bar when returning the cart to Central Distribution:",203442,0,TRUE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61224,11,"11.	Green used tape will be placed over the lock bar when returning the cart to Central Distribution:",203443,1,FALSE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61225,12,"12.	FCC will be responsible for contacting Central Distribution to obtain a new cart for the unit:",203444,0,TRUE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61225,12,"12.	FCC will be responsible for contacting Central Distribution to obtain a new cart for the unit:",203445,1,FALSE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61226,13,"13.	Hemorrhage carts should be plugged into a regular outlet when not in use on the units:",203446,0,TRUE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61226,13,"13.	Hemorrhage carts should be plugged into a regular outlet when not in use on the units:",203447,1,FALSE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61227,14,"14.	All carts will be secured with  red security seal tape, which indicates it's a new, unused cart:",203448,0,TRUE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61227,14,"14.	All carts will be secured with  red security seal tape, which indicates it's a new, unused cart:",203449,1,FALSE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61228,15,"15.	If the  patient is transferred to another unit(mainly L&D) the cart will be transferred to L&D with the patient:",203450,0,TRUE,1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61228,15,"15.	If the  patient is transferred to another unit(mainly L&D) the cart will be transferred to L&D with the patient:",203451,1,FALSE,0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61229,16,"16.	A medication charge sheet will be placed in which drawer:",203452,0,"a)	Drawer 1",1
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61229,16,"16.	A medication charge sheet will be placed in which drawer:",203453,1,"b)	Drawer 2",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61229,16,"16.	A medication charge sheet will be placed in which drawer:",203454,2,"c)	Drawer 3",0
226,SCORM-0000-32,FCC POSTPARTUM HEMORRHAGE CART EDUCATION,n13608,61229,16,"16.	A medication charge sheet will be placed in which drawer:",203455,3,"d)	Drawer 4",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61251,0,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,203540,0,"a.	Hypotension",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61251,0,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,203541,1,"b.	Excessive sweating",1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61251,0,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,203542,2,"c.	Fatigue",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61251,0,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,203543,3,"d.	Hair Loss",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61251,0,Immune-related endocrinopathies caused by checkpoint inhibitor immunotherapy typically present with nonspecific symptoms. These may include all of the follow except:,203544,4,"e.	Abnormal thyroid test",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61252,1,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,203545,0,"a.	Discontinue nivolumab and consult Gastroenterology",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61252,1,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,203546,1,"b.	Initiate high dose steroids followed by infliximab",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61252,1,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,203547,2,"c.	Initiate prednisone 1-2mg/kg/day follow by corticosteroid taper and consider mycophenolate for persistent severe hepatitis despite high dose corticosteroids.",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61252,1,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,203548,3,"d.	A and C only",1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61252,1,A patient with advanced renal cell carcinoma presents to your clinic for treatment today. The patient has been receiving nivolumab 240mg IV q 2 weeks for the past 20 weeks. You observe that the patient's AST/ALT have risen by more than 5 x ULN and you inform the provider. Which of the following are all appropriate for management of this potential immune-mediated adverse reaction to nivolumab?,203549,4,"e.	All of the above",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61253,2,Diarrhea is a more common complaint with the use of CTLA-4 inhibitor versus an anti-PD1.,203550,0,TRUE,1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61253,2,Diarrhea is a more common complaint with the use of CTLA-4 inhibitor versus an anti-PD1.,203551,1,FALSE,0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61255,3,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,203554,0,"a.	At baseline and then every 12 weeks during immunotherapy",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61255,3,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,203555,1,"b.	Prior to initiating immunotherapy only",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61255,3,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,203556,2,"c.	At baseline and every 4-6 weeks for all immunotherapy",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61255,3,How often should TSH and FT4 be monitored while a patient is receiving immunotherapy,203557,3,"d.	At baseline and with each dose of ipilimumab",1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61256,4,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,203558,0,"a.	Cough and SOB",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61256,4,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,203559,1,"b.	Radiographic changes",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61256,4,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,203560,2,"c.	Chest pain",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61256,4,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,203561,3,"d.	Fever",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61256,4,Pneumonitis is an uncommon but potentially fatal complication of treatment with checkpoint inhibitor immunotherapy. Signs and symptoms of pneumonitis may include:,203562,4,"e.	All of the above",1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61257,5,Most immune-related adverse events associated with checkpoint inhibitor immunotherapy occur immediately after the first dose.,203563,0,TRUE,0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61257,5,Most immune-related adverse events associated with checkpoint inhibitor immunotherapy occur immediately after the first dose.,203564,1,FALSE,1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61258,6,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",203565,0,"a.	Hold pembrolizumab and initiate IV methylprednisolone 1mg/kg/day",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61258,6,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",203566,1,"b.	If there is no response after starting IV steroids in 2-3 days, may increase dose to 2mg/kg/day. Change to prednisone when appropriate",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61258,6,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",203567,2,"c.	Treat with steroids until symptoms improve to Grade 1 or less. Permanently discontinue pembrolizumab.",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61258,6,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",203568,3,"d.	Never treat gastrointestinal adverse events with infliximab.",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61258,6,"A 65 year old female patient with metastatic gastric cancer presents to your clinic for evaluation due to complaints of frequent diarrhea. After further questioning, she reports approximately 4 loose stools each day beginning three days ago. She is receiving treatment with pembrolizumab 200mg every 3 weeks with the last treatment date being one week ago. What is the most appropriate management of this Grade 2 irAE?",203569,4,"e.	A and B",1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61259,7,Ocular toxicity is the most common immune-related adverse event associated with checkpoint inhibitors.,203570,0,TRUE,0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61259,7,Ocular toxicity is the most common immune-related adverse event associated with checkpoint inhibitors.,203571,1,FALSE,1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61260,8,Successful management of immune checkpoint inhibitor toxicities require:,203572,0,"a.	Excellent patient-provider communication, early diagnosis, and rapid use of corticosteroids.",1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61260,8,Successful management of immune checkpoint inhibitor toxicities require:,203573,1,"b.	Premedication in the form of a corticosteroid prior to administration of any checkpoint inhibitor immunotherapy.",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61260,8,Successful management of immune checkpoint inhibitor toxicities require:,203574,2,"c.	Patients to report symptoms of potential toxicities once the patient does not show any improvement after 5 days of those specific symptoms",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61260,8,Successful management of immune checkpoint inhibitor toxicities require:,203575,3,"d.	None of the above.",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61261,9,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,203576,0,"a.	Pharmacokinetics",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61261,9,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,203577,1,"b.	Mechanism of Action",1
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61261,9,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,203578,2,"c.	Dosing",0
9736,Elearning-0000-946,2021 MANAGEMENT OF IMMUNOTHERAPY RELATED TOXICITIES,n13614,61261,9,Adverse events from immunotherapy differ from conventional chemotherapy and can affect one or several different organ systems. This is due to the differences between immunotherapy and cytotoxic chemotherapy___________.,203579,3,"d.	Administration",0
9642,Elearning-0000-860,FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION,n13615,61254,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",203552,0,TRUE,1
9642,Elearning-0000-860,FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION,n13615,61254,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES: PRESSURE INJURY PREVENTION"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",203553,1,FALSE,0
9185,Elearning-0000-445,FY2021 SURGICAL SERVICES MH FOR NON RN SURGICAL SERVICES,n13619,61318,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 Surgical Services MH For Non RN Surgical Services  CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",203817,0,TRUE,1
9185,Elearning-0000-445,FY2021 SURGICAL SERVICES MH FOR NON RN SURGICAL SERVICES,n13619,61318,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 Surgical Services MH For Non RN Surgical Services  CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",203818,1,FALSE,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61319,0,Please list the location for this activity.,203819,0,Atlanta,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61319,0,Please list the location for this activity.,203820,1,Cherokee,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61319,0,Please list the location for this activity.,203821,2,Forsyth,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61319,0,Please list the location for this activity.,203822,3,Other,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61320,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",203823,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61320,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",203824,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61320,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",203825,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61320,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",203826,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61320,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand the importance of creating a special and sacred experience for a bereaved family.</ol>",203827,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61321,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",203828,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61321,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",203829,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61321,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",203830,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61321,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",203831,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61321,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of a caregiver's hands, as well as the work that they do.</ol>",203832,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61322,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",203833,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61322,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",203834,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61322,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",203835,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61322,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",203836,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61322,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list reasons why keepsakes and photography are an important part of the healing journey.</ol>",203837,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61323,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",203838,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61323,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",203839,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61323,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",203840,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61323,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",203841,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61323,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand policies and procedures regarding paperwork needed following a perinatal loss.</ol>",203842,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61324,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203843,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61324,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203844,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61324,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203845,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61324,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203846,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61324,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203847,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61325,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203848,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61325,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203849,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61325,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203850,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61325,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203851,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61325,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate ways to create an environment that is conducive to keepsake and photography collection.</ol>",203852,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61326,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",203853,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61326,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",203854,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61326,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",203855,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61326,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",203856,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61326,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state reasons why bereavement photography is important to bereaved families and understand NSH policies and procedures related to bereavement photography.</ol>",203857,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61327,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",203858,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61327,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",203859,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61327,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",203860,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61327,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",203861,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61327,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand of the perspective of a bereaved parent.</ol>",203862,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61328,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",203863,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61328,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",203864,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61328,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",203865,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61328,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",203866,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61328,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the importance of working as a team in providing quality patient care.</ol>",203867,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61329,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,203868,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61329,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,203869,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61329,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,203870,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61329,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,203871,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61329,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,203872,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61330,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,203873,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61330,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,203874,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61330,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,203875,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61330,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,203876,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61330,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge base related to perinatal bereavement care. </OL>,203877,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61331,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,203878,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61331,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,203879,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61331,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,203880,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61331,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,203881,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61331,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my comfort level when caring for families experiencing a perinatal loss.</OL>,203882,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61332,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",203883,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61332,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",203884,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61332,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",203885,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61332,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",203886,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61332,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",203887,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61333,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",203888,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61333,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",203889,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61333,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",203890,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61333,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",203891,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61333,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",203892,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61334,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,203893,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61334,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,203894,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61334,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,203895,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61334,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,203896,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61334,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,203897,4,Strongly Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61335,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,203898,0,Excellent,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61335,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,203899,1,Very Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61335,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,203900,2,Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61335,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,203901,3,Fair,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61335,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Melissa Peterson</ol>,203902,4,Poor,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61336,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",203903,0,Excellent,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61336,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",203904,1,Very Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61336,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",203905,2,Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61336,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",203906,3,Fair,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61336,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Brigette Harbour, MSN, RN</ol>",203907,4,Poor,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61337,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,203908,0,Excellent,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61337,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,203909,1,Very Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61337,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,203910,2,Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61337,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,203911,3,Fair,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61337,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Sandra Cramer</ol>,203912,4,Poor,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61338,20,"Overall, this activity was:",203913,0,Excellent,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61338,20,"Overall, this activity was:",203914,1,Very Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61338,20,"Overall, this activity was:",203915,2,Good,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61338,20,"Overall, this activity was:",203916,3,Fair,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61338,20,"Overall, this activity was:",203917,4,Poor,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61339,21,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",203918,0,Yes,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61339,21,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",203919,1,No,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61339,21,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",203920,2,N/A,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61342,24,How would you improve this class?,203921,0,Reduce content covered in class,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61342,24,How would you improve this class?,203922,1,Increase content covered in class,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61342,24,How would you improve this class?,203923,2,Update content covered in class,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61342,24,How would you improve this class?,203924,3,Improve the instructional methods,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61342,24,How would you improve this class?,203925,4,Make course activities more stimulating,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61342,24,How would you improve this class?,203926,5,Slow the pace of the class,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61342,24,How would you improve this class?,203927,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61345,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",203928,0,Strongly Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61345,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",203929,1,Agree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61345,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",203930,2,No Opinion,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61345,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",203931,3,Disagree,0
9850,Questions-0000-141,SACRED WORK: THE BEAUTY OF CARING FOR PERINATAL LOSS FAMILIES_ 2021 (EVALUATION SURVEY)  4.27.21,n13620,61345,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper preparation of a baby for the morgue, as well as for retrieval of a baby for viewing.</ol>",203932,4,Strongly Disagree,0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61346,0,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,203933,0,"A.	200m & 800mg",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61346,0,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,203934,1,"B.	100mg & 900mg",1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61346,0,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,203935,2,"C.	600mg & 400mg",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61346,0,Patient MS was diagnosed with Chronic Lymphocytic Leukemia and is in to receive her 1st treatment of GAZYVA. How much of the 1000mg will she be given on days 1 & 2 respectively?,203936,3,"D.	300mg & 700mg",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61347,1,YERVOY is available in MDV sizes of 50 mg and 200mg.,203937,0,TRUE,0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61347,1,YERVOY is available in MDV sizes of 50 mg and 200mg.,203938,1,FALSE,1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61348,2,All of the following medications are available as RTU (ready to use) except:,203939,0,"A.	Empliciti",1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61348,2,All of the following medications are available as RTU (ready to use) except:,203940,1,"B.	Perjeta",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61348,2,All of the following medications are available as RTU (ready to use) except:,203941,2,"C.	Bavencio",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61348,2,All of the following medications are available as RTU (ready to use) except:,203942,3,"D.	Darzalex",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61349,3,A loading dose is required by Herceptin Hylecta?,203943,0,TRUE,0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61349,3,A loading dose is required by Herceptin Hylecta?,203944,1,FALSE,1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61350,4,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,203945,0,"A.	None",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61350,4,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,203946,1,"B.	70mLs",1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61350,4,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,203947,2,"C.	45mLs",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61350,4,Physician orders Cyramza 700 mg IV in NS 250ml for a patient.  How much fluid should the IA withdraw from the IV bag before adding the Cyramza?,203948,3,"D.	15mls",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61351,5,Pharmacy received an order for Darzalex in D5W for IV infusion for a patient that is diabetic. Why does the Pharmacist need to call Physician to change order?,203949,0,"A.	Diabetic patients can NOT receive D5W infusion due to risk of high blood sugar after Infusion.",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61351,5,Pharmacy received an order for Darzalex in D5W for IV infusion for a patient that is diabetic. Why does the Pharmacist need to call Physician to change order?,203950,1,"B.	Darzalex can only be mixed with 0.9% NS.",1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61351,5,Pharmacy received an order for Darzalex in D5W for IV infusion for a patient that is diabetic. Why does the Pharmacist need to call Physician to change order?,203951,2,"C.	Pharmacist does not have to call Physician for any of the above reasons.",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61352,6,Which is the following statements is NOT correct about Imfinzi ?,203952,0,"a.	It requires an in-line filter for Infusion",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61352,6,Which is the following statements is NOT correct about Imfinzi ?,203953,1,"b.	It is stable for 24 hours at room temperature after dilution",1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61352,6,Which is the following statements is NOT correct about Imfinzi ?,203954,2,"c.	Imfinzi vials should be kept refrigerated and in original package until dilution",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61352,6,Which is the following statements is NOT correct about Imfinzi ?,203955,3,"d.	It comes in 2 vials sizes of 120 and 500 mg",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61353,7,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,203956,0,"a.	Keytruda",1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61353,7,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,203957,1,"b.	Imfinzi",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61353,7,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,203958,2,"c.	Bavencio",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61353,7,Which checkpoint inhibitor is NOT an anti-PDL1 medication?,203959,3,"d.	Tecentriq",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61354,8,Which checkpoint inhibitor does not require a filter?,203960,0,"a.	Keytruda",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61354,8,Which checkpoint inhibitor does not require a filter?,203961,1,"b.	Opdivo",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61354,8,Which checkpoint inhibitor does not require a filter?,203962,2,"c.	Tecentriq",1
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61354,8,Which checkpoint inhibitor does not require a filter?,203963,3,"d.	Libtayo",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61355,9,Adcetris is,203964,0,"a.	Available as SDV of 50mg lyophilized powder",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61355,9,Adcetris is,203965,1,"b.	Indicated for Hodgkin's lymphoma",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61355,9,Adcetris is,203966,2,"c.	Mixed in Normal Saline",0
9737,Elearning-0000-947,2021 IMMUNOTHERAPY FROM THE IA PERSPECTIVE,n13622,61355,9,Adcetris is,203967,3,"d.	All of the above",1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61356,0,It is acceptable to return cold medication stock to the GCS annex on Fridays.,203968,0,TRUE,0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61356,0,It is acceptable to return cold medication stock to the GCS annex on Fridays.,203968,0,TRUE,0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61356,0,It is acceptable to return cold medication stock to the GCS annex on Fridays.,203969,1,FALSE,1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61356,0,It is acceptable to return cold medication stock to the GCS annex on Fridays.,203969,1,FALSE,1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203970,0,"a.	Day",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203970,0,"a.	Day",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203971,1,"b.	Other month",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203971,1,"b.	Other month",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203972,2,"c.	Month",1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203972,2,"c.	Month",1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203973,3,"d.	Year",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61357,1,Pharmacy technician should complete a full Nucleus inventory of all medications at minimum every ______.,203973,3,"d.	Year",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203974,0,"a.	Decreased inventory cost",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203974,0,"a.	Decreased inventory cost",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203975,1,"b.	Minimizing drug waste",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203975,1,"b.	Minimizing drug waste",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203976,2,"c.	Increased inventory turnover",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203976,2,"c.	Increased inventory turnover",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203977,3,"d.	Increased quantity of expired drugs",1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61358,2,Which is not a benefit of managing inventory?,203977,3,"d.	Increased quantity of expired drugs",1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203978,0,"a.	3",1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203978,0,"a.	3",1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203979,1,"b.	2",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203979,1,"b.	2",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203980,2,"c.	6",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203980,2,"c.	6",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203981,3,"d.	4",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61359,3,"Drugs that will expire in _____ months or less with no current patient needs should be sent back to annex ( GCS) or redistributed ( ACC, NGDC, SHOA)",203981,3,"d.	4",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61360,4,Irinotecan 250mg dose is ordered.  Which is the optimal vial size combination to minimize waste?,203982,0,"a.	2 x 100mg + 2 x 40mg",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61360,4,Irinotecan 250mg dose is ordered.  Which is the optimal vial size combination to minimize waste?,203982,0,"a.	2 x 100mg + 2 x 40mg",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61360,4,Irinotecan 250mg dose is ordered.  Which is the optimal vial size combination to minimize waste?,203983,1,"b.	1 x 100mg + 4 x 40mg",1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61360,4,Irinotecan 250mg dose is ordered.  Which is the optimal vial size combination to minimize waste?,203983,1,"b.	1 x 100mg + 4 x 40mg",1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61361,5,The product expiration report may be used to identify expiring items within 3 months.,203984,0,TRUE,1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61361,5,The product expiration report may be used to identify expiring items within 3 months.,203984,0,TRUE,1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61361,5,The product expiration report may be used to identify expiring items within 3 months.,203985,1,FALSE,0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61361,5,The product expiration report may be used to identify expiring items within 3 months.,203985,1,FALSE,0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61362,6,"Medication should be ordered 5 days prior to treatment for GCS and 2 days prior to treatment for ACC, NGDC, and SHOA.",203986,0,TRUE,0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61362,6,"Medication should be ordered 5 days prior to treatment for GCS and 2 days prior to treatment for ACC, NGDC, and SHOA.",203986,0,TRUE,0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61362,6,"Medication should be ordered 5 days prior to treatment for GCS and 2 days prior to treatment for ACC, NGDC, and SHOA.",203987,1,FALSE,1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61362,6,"Medication should be ordered 5 days prior to treatment for GCS and 2 days prior to treatment for ACC, NGDC, and SHOA.",203987,1,FALSE,1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61363,7,Pharmacy staff should plan 3-4 additional days out for holiday closures and inclement weather and other shipping delays.,203988,0,TRUE,1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61363,7,Pharmacy staff should plan 3-4 additional days out for holiday closures and inclement weather and other shipping delays.,203988,0,TRUE,1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61363,7,Pharmacy staff should plan 3-4 additional days out for holiday closures and inclement weather and other shipping delays.,203989,1,FALSE,0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61363,7,Pharmacy staff should plan 3-4 additional days out for holiday closures and inclement weather and other shipping delays.,203989,1,FALSE,0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61364,8,Auto reorder is a useful tool for managing fast moving items.,203990,0,TRUE,1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61364,8,Auto reorder is a useful tool for managing fast moving items.,203990,0,TRUE,1
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61364,8,Auto reorder is a useful tool for managing fast moving items.,203991,1,FALSE,0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61364,8,Auto reorder is a useful tool for managing fast moving items.,203991,1,FALSE,0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203992,0,"a.	NDC#",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203992,0,"a.	NDC#",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203993,1,"b.	Lot #",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203993,1,"b.	Lot #",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203994,2,"c.	Expiration date",0
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203994,2,"c.	Expiration date",0
9726,Elearning-0000-937,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203995,3,"d.	All the above",1
10080,Elearning-0000-1851,2021 RX TECH INVENTORY MANAGEMENT AND AVOIDABLE WASTE,n13623,61365,9,"When restocking and dispensing medication, pharmacy technician should verify:",203995,3,"d.	All the above",1
9309,Elearning-0000-558,FY2021 SURGICAL SERVICES: ISOLATION - ANESTHESIA TECHS,n13626,61372,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES ISOLATION - ANESTHESIA TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204008,0,TRUE,1
9309,Elearning-0000-558,FY2021 SURGICAL SERVICES: ISOLATION - ANESTHESIA TECHS,n13626,61372,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 SURGICAL SERVICES ISOLATION - ANESTHESIA TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204009,1,FALSE,0
9620,Elearning-0000-840,"FY2021 SURGICAL SERVICES: TEMPERATURE, HUMIDITY AND AIRFLOW",n13627,61373,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Temperature, Humidity and Airflow"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204010,0,TRUE,1
9620,Elearning-0000-840,"FY2021 SURGICAL SERVICES: TEMPERATURE, HUMIDITY AND AIRFLOW",n13627,61373,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Temperature, Humidity and Airflow"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204011,1,FALSE,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61379,0,Please list the location for this activity.,204025,0,Atlanta,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61379,0,Please list the location for this activity.,204026,1,Cherokee,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61379,0,Please list the location for this activity.,204027,2,Forsyth,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61379,0,Please list the location for this activity.,204028,3,Other,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61380,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",204029,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61380,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",204030,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61380,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",204031,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61380,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",204032,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61380,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the role and importance of the mental health champion.</ol>",204033,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61381,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",204034,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61381,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",204035,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61381,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",204036,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61381,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",204037,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61381,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify 1013/2013 protocols and educate patients, families and others on the team of the importance of adhering to these protocols for patient safety and care.</ol>",204038,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61382,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",204039,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61382,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",204040,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61382,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",204041,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61382,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",204042,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61382,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to effectively communicate the importance of proper and compassionate care of patients/families who are high risk for self-harm or harm of others, exhibiting poor judgement and have behavioral concerns.</ol>",204043,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61383,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",204044,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61383,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",204045,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61383,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",204046,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61383,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",204047,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61383,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to educate patients, families and other members of the interdisciplinary team in working with patients who have mental health disorders and are in need of care.</ol>",204048,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61384,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204049,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61384,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204050,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61384,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204051,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61384,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204052,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61384,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204053,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61385,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",204054,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61385,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",204055,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61385,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",204056,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61385,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",204057,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61385,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to promoting comprehensive, integrated and responsive mental health and social care services to families of infants in the NICU nursery during times of stress.<OL>",204058,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61386,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to""ù person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",204059,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61386,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to""ù person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",204060,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61386,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to""ù person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",204061,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61386,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to""ù person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",204062,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61386,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates to being equipped for the role of the ""go-to""ù person to support others in comfortably and effectively managing behavioral and mental health family needs and issues related to this population.<OL>",204063,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61387,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",204064,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61387,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",204065,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61387,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",204066,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61387,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",204067,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61387,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",204068,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61388,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204069,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61388,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204070,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61388,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204071,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61388,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204072,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61388,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204073,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61389,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,204074,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61389,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,204075,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61389,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,204076,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61389,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,204077,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61389,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented for contact hours was free of commercial bias.</ol>,204078,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61390,11,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,204079,0,Strongly Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61390,11,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,204080,1,Agree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61390,11,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,204081,2,No Opinion,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61390,11,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,204082,3,Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61390,11,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,204083,4,Strongly Disagree,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61391,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",204084,0,Excellent,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61391,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",204085,1,Very Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61391,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",204086,2,Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61391,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",204087,3,Fair,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61391,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Stephanie Siegel, MSW</ol>",204088,4,Poor,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61392,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",204089,0,Excellent,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61392,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",204090,1,Very Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61392,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",204091,2,Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61392,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",204092,3,Fair,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61392,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lisa Mize, LCSW</ol>",204093,4,Poor,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61393,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",204094,0,Excellent,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61393,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",204095,1,Very Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61393,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",204096,2,Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61393,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",204097,3,Fair,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61393,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amanda Thomas, LPC</ol>",204098,4,Poor,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61394,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",204099,0,Excellent,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61394,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",204100,1,Very Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61394,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",204101,2,Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61394,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",204102,3,Fair,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61394,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Owens, LPC</ol>",204103,4,Poor,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61395,16,"Overall, this activity was:",204104,0,Excellent,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61395,16,"Overall, this activity was:",204105,1,Very Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61395,16,"Overall, this activity was:",204106,2,Good,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61395,16,"Overall, this activity was:",204107,3,Fair,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61395,16,"Overall, this activity was:",204108,4,Poor,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61396,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204109,0,Yes,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61396,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204110,1,No,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61396,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204111,2,N/A,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61399,20,How would you improve this class?,204112,0,Reduce content covered in class,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61399,20,How would you improve this class?,204113,1,Increase content covered in class,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61399,20,How would you improve this class?,204114,2,Update content covered in class,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61399,20,How would you improve this class?,204115,3,Improve the instructional methods,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61399,20,How would you improve this class?,204116,4,Make course activities more stimulating,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61399,20,How would you improve this class?,204117,5,Slow the pace of the class,0
9851,Questions-0000-142,SCN BEHAVIORAL HEALTH CHAMPION PROGRAM (EVALUATION SURVEY) 4.28.21,n13629,61399,20,How would you improve this class?,204118,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61433,0,Please list the location for this activity.,204226,0,Atlanta,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61433,0,Please list the location for this activity.,204227,1,Forsyth,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61433,0,Please list the location for this activity.,204228,2,Cherokee,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61433,0,Please list the location for this activity.,204229,3,Other,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61434,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",204230,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61434,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",204231,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61434,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",204232,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61434,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",204233,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61434,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research at Northside Hospital.</ol>",204234,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61435,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",204235,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61435,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",204236,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61435,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",204237,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61435,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",204238,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61435,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss clinical research, its components, types & importance.</ol>",204239,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61436,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",204240,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61436,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",204241,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61436,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",204242,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61436,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",204243,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61436,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe phases of investigational drug trials & medical devices approval process.</ol>",204244,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61437,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",204245,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61437,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",204246,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61437,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",204247,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61437,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",204248,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61437,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss governance of research and the Institutional Review board.</ol>",204249,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61438,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",204250,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61438,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",204251,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61438,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",204252,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61438,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",204253,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61438,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the Clinical Trial Management Research System.</ol>",204254,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61439,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",204255,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61439,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",204256,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61439,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",204257,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61439,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",204258,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61439,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the basic structure of research protocols.</ol>",204259,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61440,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",204260,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61440,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",204261,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61440,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",204262,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61440,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",204263,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61440,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the types of sponsors and protocol selection process.</ol>",204264,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61441,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",204265,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61441,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",204266,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61441,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",204267,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61441,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",204268,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61441,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe steps taken to implement a research protocol and staff roles.</ol>",204269,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61442,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",204270,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61442,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",204271,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61442,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",204272,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61442,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",204273,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61442,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the process utilized to conduct clinical trials and staff responsibilities.</ol>",204274,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61443,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",204275,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61443,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",204276,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61443,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",204277,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61443,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",204278,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61443,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe process to close protocols.</ol>",204279,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61444,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",204280,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61444,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",204281,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61444,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",204282,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61444,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",204283,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61444,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe expectations as it relates to role specific training.</ol>",204284,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61445,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204285,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61445,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204286,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61445,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204287,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61445,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204288,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61445,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204289,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61446,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,204290,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61446,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,204291,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61446,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,204292,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61446,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,204293,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61446,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has extended my knowledge of medical clinical research at Northside Hospital and filled a professional practice gap. </OL>,204294,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61447,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,204295,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61447,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,204296,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61447,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,204297,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61447,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,204298,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61447,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to discuss the structure of a research protocol.</OL>,204299,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61448,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,204300,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61448,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,204301,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61448,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,204302,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61448,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,204303,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61448,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to describe my role in protocol initiation & protocol closure.</ol>,204304,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61449,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,204305,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61449,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,204306,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61449,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,204307,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61449,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,204308,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61449,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,204309,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61450,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204310,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61450,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204311,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61450,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204312,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61450,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204313,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61450,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204314,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61451,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204315,0,Strongly Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61451,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204316,1,Agree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61451,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204317,2,No Opinion,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61451,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204318,3,Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61451,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204319,4,Strongly Disagree,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61452,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,204320,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61452,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,204321,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61452,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,204322,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61452,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,204323,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61452,19,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Margaret Ferreira</ol>,204324,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61453,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,204325,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61453,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,204326,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61453,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,204327,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61453,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,204328,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61453,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Andrea Patterson</ol>,204329,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61454,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,204330,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61454,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,204331,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61454,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,204332,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61454,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,204333,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61454,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michael Bohannon</ol>,204334,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61455,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,204335,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61455,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,204336,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61455,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,204337,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61455,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,204338,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61455,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patrick Mikkelsen </ol>,204339,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61456,24,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,204340,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61456,24,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,204341,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61456,24,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,204342,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61456,24,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,204343,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61456,24,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katherine Moore</ol>,204344,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61457,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,204345,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61457,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,204346,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61457,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,204347,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61457,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,204348,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61457,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Hema Mody </ol>,204349,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61458,25,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,204350,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61458,25,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,204351,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61458,25,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,204352,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61458,25,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,204353,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61458,25,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Anila Lokhandwala</ol>,204354,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61459,26,"Overall, this activity was:",204355,0,Excellent,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61459,26,"Overall, this activity was:",204356,1,Very Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61459,26,"Overall, this activity was:",204357,2,Good,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61459,26,"Overall, this activity was:",204358,3,Fair,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61459,26,"Overall, this activity was:",204359,4,Poor,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61460,27,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204360,0,Yes,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61460,27,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204361,1,No,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61460,27,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204362,2,N/A,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61463,30,How would you improve this class?,204363,0,Reduce content covered in class,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61463,30,How would you improve this class?,204364,1,Increase content covered in class,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61463,30,How would you improve this class?,204365,2,Update content covered in class,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61463,30,How would you improve this class?,204366,3,Improve the instructional methods,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61463,30,How would you improve this class?,204367,4,Make course activities more stimulating,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61463,30,How would you improve this class?,204368,5,Slow the pace of the class,0
9849,Questions-0000-140,"RESEARCH 101 (EVALUATION SURVEY) NSA APRIL 29 & 30, 2021",n13640,61463,30,How would you improve this class?,204369,6,"No improvement needed (appropriate content, handout, setting, etc.)",0
9330,Elearning-0000-577,FY2021 5 C POST CARDIAC CATH DOCUMENTATION IN ONECHART,n13650,61491,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",204451,0,TRUE,1
9330,Elearning-0000-577,FY2021 5 C POST CARDIAC CATH DOCUMENTATION IN ONECHART,n13650,61491,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",204452,1,FALSE,0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61493,0,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,204455,0,TRUE,1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61493,0,Attempting less restrictive alternatives prior to applying restraints or placing a patient in seclusion is one strategy utilized at Northside Hospital to maintain the patient's rights and dignity?,204456,1,FALSE,0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61494,1,Mitten(s) are NOT a type of physical restraint,204457,0,TRUE,1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61494,1,Mitten(s) are NOT a type of physical restraint,204458,1,FALSE,0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61495,2,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,204459,0,TRUE,0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61495,2,The use of restraints or seclusion is not associated with any potential physical or psychological risk?,204460,1,FALSE,1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61496,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",204461,0,"a.	A patient with an emotional disorder poses a physical threat to other patients.",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61496,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",204462,1,"b.	A patient is pulling at his Foley catheter and demonstrates lack of understanding to comply with safety directions.",1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61496,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",204463,2,"c.	A patient with an emotional disorder is attempting to cause physical harm to himself.",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61496,3,"Which situation is a Non-Violent, Non-Self-Destructive indication for restraint use?",204464,3,"d.	A patient with a behavioral disorder poses a threat to the staff.",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61497,4,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,204465,0,TRUE,1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61497,4,Seclusion is defined as: A patient is involuntarily confined in a room or area from which the patient is physically prevented from leaving AND is alone.,204466,1,FALSE,0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61498,5,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",204467,0,TRUE,1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61498,5,"If restraints are removed and staff leave the room, a new order is required to reapply the restraints?",204468,1,FALSE,0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61499,6,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",204469,0,TRUE,0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61499,6,"If a patient is temporarily released from restraints or seclusion for the purpose of caring for the patient's needs (i.e. toileting, feeding, bathing, and/or range of motion), a new restraint order is required to resume restraints or seclusion?",204470,1,FALSE,1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61500,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",204471,0,"a.	Patient is pulling at lines",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61500,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",204472,1,"b.	Patient is pulling at tubes",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61500,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",204473,2,"c.	Patient wants to get out of bed unattended",1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61500,7,"Which is NOT criteria for initiating Non-Violent, Non-Self-Destructive patient restraints?",204474,3,"d.	Patient demonstrates lack of understanding to comply with safety directions",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61501,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,204475,0,"a.	Used the right-sized restraint",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61501,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,204476,1,"b.	Applied the restraints according to manufacturer's directions",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61501,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,204477,2,"c.	Secured the restraints to the siderails",1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61501,8,You are applying soft limb restraints. Which finding indicates that you have NOT safely applied the restraints?,204478,3,"d.	Tied knots so they can be quickly released",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61502,9,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",204479,0,"a.	Patient is an imminent risk of intentional harm to self",0
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61502,9,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",204480,1,"b.	Patient is verbally abusive to staff",1
9307,Elearning-0000-556,FY2021 MANAGEMENT OF THE PATIENT AT RISK FOR RESTRAINT AND SECLUSION: ANCILLARY STAFF,n13652,61502,9,"Which is NOT criteria for initiating Violent, Self-Destructive patient restraints or seclusion?",204481,2,"c.	Patient is an imminent risk of intentional harm to others",0
9483,Elearning-0000-716,NSH 1282 JCAR017 EAP,n13654,61504,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",204484,0,TRUE,1
9483,Elearning-0000-716,NSH 1282 JCAR017 EAP,n13654,61504,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",204485,1,FALSE,0
9482,Elearning-0000-715,NSH 1298 BB2121 EAP,n13655,61505,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",204486,0,TRUE,1
9482,Elearning-0000-715,NSH 1298 BB2121 EAP,n13655,61505,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",204487,1,FALSE,0
9219,Elearning-0000-476,NSC L&D TEAM LEADER CLASS 2021,n13656,61506,0,I acknowledge that I have read and understand the information provided in the NSC L&D Team Leader Class 2021 CBL,204488,0,TRUE,1
9219,Elearning-0000-476,NSC L&D TEAM LEADER CLASS 2021,n13656,61506,0,I acknowledge that I have read and understand the information provided in the NSC L&D Team Leader Class 2021 CBL,204489,1,FALSE,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61507,0,Which of the following is not true?,204490,0,a. person dies by suicide every 12 minutes.,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61507,0,Which of the following is not true?,204491,1,"b. Over 40,000 people die by suicide each year.",0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61507,0,Which of the following is not true?,204492,2,c. Highest risk age group is 30-45,1
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61507,0,Which of the following is not true?,204493,3,d. 45% of people who died by suicide saw their primary care provider within a month of their death.,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61508,1,What are the key contributing factors to suicide?,204494,0,a. Psychological pain,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61508,1,What are the key contributing factors to suicide?,204495,1,b. Wish to Escape,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61508,1,What are the key contributing factors to suicide?,204496,2,c. Seeking a Solution,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61508,1,What are the key contributing factors to suicide?,204497,3,d. Ambivalence,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61508,1,What are the key contributing factors to suicide?,204498,4,e. All of the Above,1
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61509,2,"True or False: The Columbia Protocol, also known as the Columbia Suicide-Severity Rating Scale, supports suicide risk assessment through a series of simple, plain-language questions that anyone can ask.",204499,0,TRUE,1
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61509,2,"True or False: The Columbia Protocol, also known as the Columbia Suicide-Severity Rating Scale, supports suicide risk assessment through a series of simple, plain-language questions that anyone can ask.",204500,1,FALSE,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61510,3,Which of the following is not a good example of how to ask someone if they are suicidal?,204501,0,a. Have you wished you were dead or wished you could go to sleep and not wake up?,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61510,3,Which of the following is not a good example of how to ask someone if they are suicidal?,204502,1,b. Have you been thinking about how you might kill yourself?,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61510,3,Which of the following is not a good example of how to ask someone if they are suicidal?,204503,2,c. You aren't thinking of suicide are you?,1
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61511,4,Why should nurses ask about suicide risk?,204504,0,a. Nurses spend more time with patients than other healthcare providers.,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61511,4,Why should nurses ask about suicide risk?,204505,1,b. Nurses see every patient.,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61511,4,Why should nurses ask about suicide risk?,204506,2,c. Nurses already screen for other safety/risk factors.,0
9457,Elearning-0000-692,FY2021 - COLUMBIA SUICIDE SEVERITY RATING SCALE (CSSRS),n13657,61511,4,Why should nurses ask about suicide risk?,204507,3,d. All of the above.,1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61512,0,Which of the following is true in regards to intraosseous administration of medications?,204508,0,"a.	Most meds that can be given IV can also be given IO",1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61512,0,Which of the following is true in regards to intraosseous administration of medications?,204509,1,"b.	The dose for most IO meds are twice (2x) the amount of IV doses",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61512,0,Which of the following is true in regards to intraosseous administration of medications?,204510,2,"c.	Endotracheal route is preferred over IO route for med administration during codes",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61512,0,Which of the following is true in regards to intraosseous administration of medications?,204511,3,"d.	IO can only be considered peripheral access",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61513,1,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,204512,0,"a.	Epinephrine 1mg IVP q3-5mins",1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61513,1,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,204513,1,"b.	Lidocaine 1-1.5mg/kg IVP",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61513,1,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,204514,2,"c.	Defibrillation after first round of chest compressions",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61513,1,PEA/asystolic arrests are associated with poor outcomes.  Which of the following strategies would be appropriate in managing a patient in PEA/asystole?,204515,3,"d.	Amiodarone 300mg IVP",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61514,2,"Drawer 5 in the Adult Code Cart contains Respiratory Supplies, and Drawer 6 in the Adult Code Cart contains general miscellaneous supplies.",204516,0,TRUE,1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61514,2,"Drawer 5 in the Adult Code Cart contains Respiratory Supplies, and Drawer 6 in the Adult Code Cart contains general miscellaneous supplies.",204517,1,FALSE,0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61515,3,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm""ù - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",204518,0,"a.	Suggest epinephrine 1mg IVP if the patient remains hypotensive",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61515,3,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm""ù - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",204519,1,"b.	Check the patient's IV pole to see if a dobutamine drip is really hanging as it is not in the code cart",1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61515,3,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm""ù - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",204520,2,"c.	Breathe a sigh of relief that the code was not real and walk away",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61515,3,"You're working in main pharmacy and a code blue was called.  You arrive at the patient's room with an auxiliary box and it was a ""false alarm""ù - patient had a pulse.  The team leader tells you that they already opened the code cart and obtained a dobutamine drip and hung it on the patient.  You -",204521,3,"d.	Suggest an amiodarone drip at 1mg/min for 6 hrs, then 0.5mg/min for 18 hrs thereafter",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61516,4,Options for treating symptomatic bradycardia includes all of the following except:,204522,0,"a.	Atropine 1 mg IVP",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61516,4,Options for treating symptomatic bradycardia includes all of the following except:,204523,1,"b.	Dobutamine drip 5mcg/kg/min",1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61516,4,Options for treating symptomatic bradycardia includes all of the following except:,204524,2,"c.	Dopamine drip 5-20mcg/kg/min",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61516,4,Options for treating symptomatic bradycardia includes all of the following except:,204525,3,"d.	Epinephrine 2-10mcg/min",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61517,5,There are no controlled medications in the adult code cart.,204526,0,TRUE,1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61517,5,There are no controlled medications in the adult code cart.,204527,1,FALSE,0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61518,6,Which of the following drug-location pairs are matched incorrectly?,204528,0,"a.	Flumazenil 0.5mg/5mLvial - adult code cart 2nd drawer",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61518,6,Which of the following drug-location pairs are matched incorrectly?,204529,1,"b.	Normal saline 1000mL IV bags - adult code cart 3rd drawer",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61518,6,Which of the following drug-location pairs are matched incorrectly?,204530,2,"c.	Sodium bicarbonate 50mEq/50mL abbojects - adult code cart 1st drawer",1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61518,6,Which of the following drug-location pairs are matched incorrectly?,204531,3,"d.	Succinylcholine 100mg/ 5ml- pharmacy auxiliary box",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61519,7,Which of the following medications would you never give via IV push?,204532,0,"a.	Epinephrine",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61519,7,Which of the following medications would you never give via IV push?,204533,1,"b.	Sodium bicarbonate",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61519,7,Which of the following medications would you never give via IV push?,204534,2,"c.	Dopamine",1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61519,7,Which of the following medications would you never give via IV push?,204535,3,"d.	Lidocaine",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61520,8,There are no medications for Rapid Sequence Intubation in the pharmacy auxiliary box.,204536,0,TRUE,0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61520,8,There are no medications for Rapid Sequence Intubation in the pharmacy auxiliary box.,204537,1,FALSE,1
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61521,9,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",204538,0,"a.	The pharmacist should remove the amiodarone bolus bag 1 from tray 1 of the adult code cart and prepare a 300mg bolus syringe for IV push.",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61521,9,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",204539,1,"b.	The pharmacist should remove the amiodarone bolus bag 2 from tray 1 of the adult code cart and prepare a 150mg bolus syringe for IV push.",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61521,9,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",204540,2,"c.	The pharmacist should disregard the bolus order and hand the nurse the premixed drip from drawer 1 of the code cart, instructing the RN to bolus from the bag.",0
9583,Elearning-0000-807,FY2021 PHARMACY CODE BLUE AND EMERGENCY CART COMPETENCY,n13659,61521,9,"A patient on the cardiac unit with episodes of non sustained ventricular tachycardia loses pulse and a code blue event is called on the unit. The patient's rhythm is quickly identified as ventricular tachycardia and the patient is successfully defibrillated, returning to NSR with a pulse. The physician requests an amiodarone bolus be given stat and a drip initiated. Which of the following is true?",204541,3,"d.	The pharmacist should obtain a stat amiodarone 150mg/ 100ml IVPB which is not in the adult code cart to infuse over 10 minutes, (not IV push, as the patient now has a pulse), then proceed with the premixed drip at 1mg/ minute.",1
9679,Elearning-0000-894,HAPI PREVENTION EDUCATION - MAY 2021 - BRADEN SCALE RISK FACTORS,n13662,61537,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention Education - May 2021 - Braden Scale Risk Factors"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204554,0,TRUE,1
9679,Elearning-0000-894,HAPI PREVENTION EDUCATION - MAY 2021 - BRADEN SCALE RISK FACTORS,n13662,61537,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention Education - May 2021 - Braden Scale Risk Factors"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204555,1,FALSE,0
9616,Elearning-0000-837,FY2021 SURGICAL SERVICES: ESOPHAGECTOMY PATIENT CARE,n13666,61541,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Esophagectomy Patient Care"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204562,0,TRUE,1
9616,Elearning-0000-837,FY2021 SURGICAL SERVICES: ESOPHAGECTOMY PATIENT CARE,n13666,61541,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Esophagectomy Patient Care"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",204563,1,FALSE,0
121,SCORM-0000-201,TRALIANT_LMS_TEST_COURSE_072220_SCORM12,n13668,61578,0,I'm able to view this CBL successfully.,204715,0,a. True,1
121,SCORM-0000-201,TRALIANT_LMS_TEST_COURSE_072220_SCORM12,n13668,61578,0,I'm able to view this CBL successfully.,204716,1,b. False,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61579,0,Please list the location for this activity.,204717,0,Atlanta,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61579,0,Please list the location for this activity.,204718,1,Cherokee,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61579,0,Please list the location for this activity.,204719,2,Forsyth,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61579,0,Please list the location for this activity.,204720,3,Other,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61580,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",204721,0,Strongly Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61580,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",204722,1,Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61580,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",204723,2,No Opinion,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61580,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",204724,3,Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61580,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss treatment-related toxicities experienced by patients receiving PARP inhibitor therapy.</ol>",204725,4,Strongly Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61581,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204726,0,Strongly Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61581,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204727,1,Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61581,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204728,2,No Opinion,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61581,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204729,3,Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61581,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204730,4,Strongly Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61582,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,204731,0,Strongly Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61582,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,204732,1,Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61582,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,204733,2,No Opinion,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61582,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,204734,3,Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61582,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,204735,4,Strongly Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61583,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,204736,0,Strongly Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61583,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,204737,1,Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61583,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,204738,2,No Opinion,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61583,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,204739,3,Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61583,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,204740,4,Strongly Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61584,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204741,0,Strongly Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61584,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204742,1,Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61584,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204743,2,No Opinion,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61584,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204744,3,Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61584,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204745,4,Strongly Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61585,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204746,0,Strongly Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61585,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204747,1,Agree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61585,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204748,2,No Opinion,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61585,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204749,3,Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61585,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204750,4,Strongly Disagree,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61586,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",204751,0,Excellent,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61586,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",204752,1,Very Good,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61586,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",204753,2,Good,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61586,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",204754,3,Fair,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61586,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",204755,4,Poor,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61587,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",204756,0,Excellent,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61587,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",204757,1,Very Good,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61587,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",204758,2,Good,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61587,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",204759,3,Fair,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61587,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",204760,4,Poor,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61588,9,"Overall, this activity was:",204761,0,Excellent,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61588,9,"Overall, this activity was:",204762,1,Very Good,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61588,9,"Overall, this activity was:",204763,2,Good,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61588,9,"Overall, this activity was:",204764,3,Fair,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61588,9,"Overall, this activity was:",204765,4,Poor,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61589,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204766,0,Yes,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61589,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204767,1,No,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61589,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204768,2,N/A,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61592,13,How would you improve this class?,204769,0,Reduce content covered in class,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61592,13,How would you improve this class?,204770,1,Increase content covered in class,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61592,13,How would you improve this class?,204771,2,Update content covered in class,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61592,13,How would you improve this class?,204772,3,Improve the instructional methods,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61592,13,How would you improve this class?,204773,4,Make course activities more stimulating,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61592,13,How would you improve this class?,204774,5,Slow the pace of the class,0
9947,Questions-0000-81,"NSF INFUSION CENTER JOURNAL CLUB - MAY 6TH, 2021 (EVALUATION SURVEY)",n13669,61592,13,How would you improve this class?,204775,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9653,Elearning-0000-870,NURSE PRECEPTOR CLASS REGISTRATION PROCESS,n13674,61595,0,I have read the attached preceptor flyer.  I understand that I need to take my Net learning transcript and class date to my manager/manager designee to enroll in the Preceptor Development Part B classes.,205483,0,Yes,1
9653,Elearning-0000-870,NURSE PRECEPTOR CLASS REGISTRATION PROCESS,n13674,61595,0,I have read the attached preceptor flyer.  I understand that I need to take my Net learning transcript and class date to my manager/manager designee to enroll in the Preceptor Development Part B classes.,205484,1,No,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61596,0,Please list the location for this activity.,204778,0,Atlanta,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61596,0,Please list the location for this activity.,204779,1,Forsyth,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61596,0,Please list the location for this activity.,204780,2,Cherokee,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61596,0,Please list the location for this activity.,204781,3,Other,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61597,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",204782,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61597,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",204783,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61597,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",204784,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61597,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",204785,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61597,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",204786,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61598,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",204787,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61598,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",204788,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61598,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",204789,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61598,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",204790,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61598,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",204791,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61599,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",204792,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61599,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",204793,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61599,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",204794,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61599,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",204795,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61599,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",204796,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61600,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",204797,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61600,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",204798,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61600,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",204799,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61600,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",204800,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61600,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",204801,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61601,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",204802,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61601,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",204803,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61601,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",204804,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61601,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",204805,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61601,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",204806,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61602,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",204807,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61602,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",204808,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61602,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",204809,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61602,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",204810,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61602,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",204811,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61603,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",204812,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61603,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",204813,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61603,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",204814,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61603,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",204815,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61603,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",204816,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61604,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",204817,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61604,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",204818,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61604,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",204819,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61604,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",204820,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61604,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",204821,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61605,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",204822,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61605,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",204823,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61605,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",204824,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61605,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",204825,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61605,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",204826,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61606,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",204827,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61606,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",204828,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61606,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",204829,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61606,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",204830,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61606,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",204831,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61607,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",204832,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61607,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",204833,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61607,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",204834,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61607,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",204835,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61607,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",204836,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61608,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204837,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61608,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204838,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61608,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204839,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61608,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204840,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61608,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204841,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61609,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,204842,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61609,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,204843,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61609,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,204844,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61609,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,204845,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61609,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,204846,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61610,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204847,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61610,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204848,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61610,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204849,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61610,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204850,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61610,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204851,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61611,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204852,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61611,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204853,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61611,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204854,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61611,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204855,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61611,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",204856,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61612,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204857,0,Strongly Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61612,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204858,1,Agree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61612,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204859,2,No Opinion,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61612,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204860,3,Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61612,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,204861,4,Strongly Disagree,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61613,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",204862,0,Excellent,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61613,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",204863,1,Very Good,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61613,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",204864,2,Good,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61613,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",204865,3,Fair,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61613,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",204866,4,Poor,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61614,18,"Overall, this activity was:",204867,0,Excellent,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61614,18,"Overall, this activity was:",204868,1,Very Good,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61614,18,"Overall, this activity was:",204869,2,Good,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61614,18,"Overall, this activity was:",204870,3,Fair,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61614,18,"Overall, this activity was:",204871,4,Poor,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61615,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204872,0,Yes,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61615,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204873,1,No,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61615,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204874,2,N/A,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61618,22,How would you improve this class?,204875,0,Reduce content covered in class,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61618,22,How would you improve this class?,204876,1,Increase content covered in class,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61618,22,How would you improve this class?,204877,2,Update content covered in class,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61618,22,How would you improve this class?,204878,3,Improve the instructional methods,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61618,22,How would you improve this class?,204879,4,Make course activities more stimulating,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61618,22,How would you improve this class?,204880,5,Slow the pace of the class,0
9889,Questions-0000-23,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-10-21,n13675,61618,22,How would you improve this class?,204881,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61632,0,Please list the location for this activity.,204902,0,Atlanta,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61632,0,Please list the location for this activity.,204903,1,Forsyth,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61632,0,Please list the location for this activity.,204904,2,Cherokee,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61632,0,Please list the location for this activity.,204905,3,Other,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61633,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",204906,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61633,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",204907,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61633,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",204908,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61633,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",204909,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61633,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify which patient populations are most at risk for NEC.</ol>",204910,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61634,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",204911,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61634,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",204912,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61634,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",204913,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61634,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",204914,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61634,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe best practices for prevention of NEC.</ol>",204915,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204916,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204917,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204918,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204919,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61635,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,204920,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61636,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204921,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61636,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204922,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61636,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204923,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61636,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204924,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61636,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204925,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61637,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,204926,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61637,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,204927,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61637,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,204928,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61637,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,204929,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61637,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my nursing knowledge as it relates to the Impact of human milk in preventing adverse conditions in preterm infants.</OL>,204930,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61638,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204931,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61638,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204932,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61638,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204933,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61638,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204934,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61638,7,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",204935,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61639,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,204936,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61639,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,204937,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61639,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,204938,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61639,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,204939,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61639,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in providing patients with education related to the use of donor milk for the preterm infant.</ol>,204940,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61640,9,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204941,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61640,9,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204942,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61640,9,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204943,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61640,9,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204944,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61640,9,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,204945,4,Strongly Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61641,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",204946,0,Excellent,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61641,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",204947,1,Very Good,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61641,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",204948,2,Good,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61641,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",204949,3,Fair,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61641,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Katie Joyner, BSN, RNC-NIC</ol>",204950,4,Poor,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61642,11,"Overall, this activity was:",204951,0,Excellent,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61642,11,"Overall, this activity was:",204952,1,Very Good,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61642,11,"Overall, this activity was:",204953,2,Good,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61642,11,"Overall, this activity was:",204954,3,Fair,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61642,11,"Overall, this activity was:",204955,4,Poor,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61643,12,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204956,0,Yes,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61643,12,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204957,1,No,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61643,12,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",204958,2,N/A,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61646,15,How would you improve this class?,204959,0,Reduce content covered in class,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61646,15,How would you improve this class?,204960,1,Increase content covered in class,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61646,15,How would you improve this class?,204961,2,Update content covered in class,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61646,15,How would you improve this class?,204962,3,Improve the instructional methods,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61646,15,How would you improve this class?,204963,4,Make course activities more stimulating,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61646,15,How would you improve this class?,204964,5,Slow the pace of the class,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61646,15,How would you improve this class?,204965,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61649,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",204966,0,Strongly Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61649,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",204967,1,Agree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61649,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",204968,2,No Opinion,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61649,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",204969,3,Disagree,0
9896,Questions-0000-30,BENEFITS OF HUMAN MILK & NEC PREVENTION (EVALUATION SURVEY) 5.11.21,n13679,61649,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the benefits of human milk for the preterm baby.</ol>",204970,4,Strongly Disagree,0
9622,Elearning-0000-842,FY2021 CPG STROKE EDUCATION,n13696,61672,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 CPG Stroke Education"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",205015,0,TRUE,1
9622,Elearning-0000-842,FY2021 CPG STROKE EDUCATION,n13696,61672,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 CPG Stroke Education"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",205016,1,FALSE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61735,0,All new Shiley Flex tubes come with a tapered percutaneous tip.,205271,0,TRUE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61735,0,All new Shiley Flex tubes come with a tapered percutaneous tip.,205272,1,FALSE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61856,1,The Shiley Flex tube flange is rigid and will not conform to the patient's anatomy.,205676,0,TRUE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61856,1,The Shiley Flex tube flange is rigid and will not conform to the patient's anatomy.,205677,1,FALSE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61857,2,"The new Shiley Flex tubes have a built in 15 mm connector, so the inner cannula is not required for manual ventilation.",205678,0,TRUE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61857,2,"The new Shiley Flex tubes have a built in 15 mm connector, so the inner cannula is not required for manual ventilation.",205679,1,FALSE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61858,3,The inner cannulas for the Legacy Shiley and the new Shiley Flex tubes are not compatible and cannot be interchanged.,205680,0,TRUE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61858,3,The inner cannulas for the Legacy Shiley and the new Shiley Flex tubes are not compatible and cannot be interchanged.,205681,1,FALSE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61859,4,The Shiley Flex inner cannula does not need to be changed unless it is visibly soiled.,205682,0,TRUE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61859,4,The Shiley Flex inner cannula does not need to be changed unless it is visibly soiled.,205683,1,FALSE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61860,5,The recommended cuff pressure for the Shiley Flex taperguard cuff is,205684,0,(A) 15 cmH2O,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61860,5,The recommended cuff pressure for the Shiley Flex taperguard cuff is,205685,1,(B) 20 cmH2O,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61860,5,The recommended cuff pressure for the Shiley Flex taperguard cuff is,205686,2,(C) 25 cmH2O,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61860,5,The recommended cuff pressure for the Shiley Flex taperguard cuff is,205687,3,(D) 35 cmH2O,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61861,6,You do not need to place a laminated sign at the head of the patient's bed if a legacy Shiley trach tube is in use.,205688,0,TRUE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61861,6,You do not need to place a laminated sign at the head of the patient's bed if a legacy Shiley trach tube is in use.,205689,1,FALSE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61862,7,"Whenever a trach tube is downsized, the new obturator must be placed at the head of the bed and the old one discarded.",205690,0,TRUE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61862,7,"Whenever a trach tube is downsized, the new obturator must be placed at the head of the bed and the old one discarded.",205691,1,FALSE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61863,8,The transparent and flexible design of the Shiley Flex flange results in 80% less pressure injuries compared to the Shiley Legacy.,205692,0,TRUE,1
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61863,8,The transparent and flexible design of the Shiley Flex flange results in 80% less pressure injuries compared to the Shiley Legacy.,205693,1,FALSE,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61864,9,"If your product reference code is 8CN85H, your trach size is",205694,0,(A) non-disposable 8.5 cuffed tracheostomy tube,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61864,9,"If your product reference code is 8CN85H, your trach size is",205695,1,(B) disposable 8.5 cuffless tracheostomy tube,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61864,9,"If your product reference code is 8CN85H, your trach size is",205696,2,(C) non-disposable 8 cuffed tracheostomy tube,0
92,SCORM-0000-174,SHILEY FLEXIBLE ADULT TRACHEOSTOMY TUBES,n13697,61864,9,"If your product reference code is 8CN85H, your trach size is",205697,3,(D) disposable 8 cuffed tracheostomy tube,1
9707,Elearning-0000-92,FY2021 AD HOC MEDICATION ADMINISTRATION FOR EMERGENT AND INTRAOPERATIVE USE,n13699,61741,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",205273,0,TRUE,1
9707,Elearning-0000-92,FY2021 AD HOC MEDICATION ADMINISTRATION FOR EMERGENT AND INTRAOPERATIVE USE,n13699,61741,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",205274,1,FALSE,0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61742,0,Why is the Distress Screening completed?,205275,0,"a)	We are told to do it",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61742,0,Why is the Distress Screening completed?,205276,1,"b)	To remain accredited with COC, providing a high standard of care",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61742,0,Why is the Distress Screening completed?,205277,2,"c)	To assess level of distress of patients, identify their needs and establish quality care and assistance",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61742,0,Why is the Distress Screening completed?,205278,3,"d)	Both B and C",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61743,1,When would it be more appropriate to use a 2013 versus 1013?,205279,0,"a)	The patient is incapacitated by alcohol, drugs or other substance on a re-occurring basis and present as a substantial risk of imminent harm to self and/or others if left untreated",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61743,1,When would it be more appropriate to use a 2013 versus 1013?,205280,1,"b)	The patient has mental illness and presents as a substantial risk of harm to self or others",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61743,1,When would it be more appropriate to use a 2013 versus 1013?,205281,2,"c)	The patient has only mental illness and presents substantial risk of imminent harm to self or others with no primary diagnosis of alcoholism or other substance abuse nor dependency, he/she presents as a substantial risk of imminent harm to self or others.",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61743,1,When would it be more appropriate to use a 2013 versus 1013?,205282,3,"d)	Patient is unable to care for his/her own physical health or safety as to create an imminently life-threatening crisis",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61744,2,If a patient score 4-7,205283,0,"a)	Review and sign form, assess patient for any immediate needs/concerns",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61744,2,If a patient score 4-7,205284,1,"b)	RN signs form, which is scanned into EMR",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61744,2,If a patient score 4-7,205285,2,"c)	Email distress screening tool to OCSW",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61744,2,If a patient score 4-7,205286,3,"d)	Notify patient that they will receive call from Social Worker",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61744,2,If a patient score 4-7,205287,4,"e)	All of the above",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61745,3,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",205288,0,"a)	Keep the patient on the phone",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61745,3,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",205289,1,"b)	Notify the supervisor or another staff member to locate the patient's address",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61745,3,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",205290,2,"c)	Call 911 to go to the patient's location",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61745,3,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",205291,3,"d)	Do not document in patient's medical chart since the patient is not in the office.",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61745,3,"In handling a patient, who is expressing suicidal /homicidal ideation, but is on the phone, which of the following is not part of the protocol?",205292,4,"e)	Submit an incident report",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61746,4,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,205293,0,"a)	Follow the Chain of Command Communication for your area and notify OSW/Behavioral Health Services, notify MD if available",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61746,4,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,205294,1,"b)	Do not leave patient alone",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61746,4,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,205295,2,"c)	Call 911 first, then call security, if available, to make aware of the situation.",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61746,4,Which of the following processes would be different in handling a  type 2 patients  versus  handling type  1 patients?,205296,3,"d)	Document facts of the event in the patient ""òs medical chart and complete an incident report",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61747,5,"In handling type 1 patients, which of the following processes should be utilized?",205297,0,"a)	Follow the chain of command for your area and notify the OSW/Behavioral Health Services",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61747,5,"In handling type 1 patients, which of the following processes should be utilized?",205298,1,"b)	Call Security for your respective location; patient should not be left alone",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61747,5,"In handling type 1 patients, which of the following processes should be utilized?",205299,2,"c)	If OSW does not respond within a reasonable timeframe, call the Psych-Oncology Coordinator, respective Supervisor/ Lead OSW, or BHS, notify MD, if available.",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61747,5,"In handling type 1 patients, which of the following processes should be utilized?",205300,3,"d)	Initiate a 1013 and transfer process with appropriate documentation",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61747,5,"In handling type 1 patients, which of the following processes should be utilized?",205301,4,"e)	All of the above",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61748,6,Why is the Distress Screening completed?,205302,0,"a)	We are told to do it",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61748,6,Why is the Distress Screening completed?,205303,1,"b)	To remain accredited with COC, providing a high standard of care",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61748,6,Why is the Distress Screening completed?,205304,2,"c)	To assess level of distress of patients, identify their needs and establish quality care and assistance",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61748,6,Why is the Distress Screening completed?,205305,3,"d)	Both B and C",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61749,7,If a patient scores 8-10,205306,0,"a)	Review form with patient, assess for immediate needs/concerns, call/text OCSW/Behavioral Health for immediate assessment (in-person or telephone);",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61749,7,If a patient scores 8-10,205307,1,"b)	Input data into EMR",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61749,7,If a patient scores 8-10,205308,2,"c)	Email to OSW's email",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61749,7,If a patient scores 8-10,205309,3,"d)	All of the above",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61750,8,Patient scores 0-3,205310,0,"a)	Review form with patient, assess for immediate needs/concerns",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61750,8,Patient scores 0-3,205311,1,"b)	Input form in EMR, making sure to input score and check box ""reviewed by RN""ù",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61750,8,Patient scores 0-3,205312,2,"c)	Educate patient on availability of psychosocial services. Handout accompanies distress tool",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61750,8,Patient scores 0-3,205313,3,"d)	All of the above",1
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61751,9,When should patient be screen in order to remain in compliance with the distress screening guidelines?,205314,0,"a)	Give distress screen whenever you want",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61751,9,When should patient be screen in order to remain in compliance with the distress screening guidelines?,205315,1,"b)	1st, 2nd or no later than 3rd visit",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61751,9,When should patient be screen in order to remain in compliance with the distress screening guidelines?,205316,2,"c)	Whenever there is a regimen change",0
9492,Elearning-0000-724,FY2021 DISTRESS SCREENING AND MANAGEMENT OF THE PATIENT NEEDING A 1013 ORDER,n13700,61751,9,When should patient be screen in order to remain in compliance with the distress screening guidelines?,205317,3,"d)	B & C",1
102,SCORM-0000-184,TIMELESS 101: INTRODUCTION,n13703,61756,0,I have read and understood the content within the Timeless 101: Introduction CBL.,205326,0,TRUE,1
102,SCORM-0000-184,TIMELESS 101: INTRODUCTION,n13703,61756,0,I have read and understood the content within the Timeless 101: Introduction CBL.,205327,1,FALSE,0
103,SCORM-0000-185,TIMELESS 102: LABEL PRINTING,n13704,61757,0,I have read and understood the content within the Timeless 102: Label Printing CBL.,205328,0,TRUE,1
103,SCORM-0000-185,TIMELESS 102: LABEL PRINTING,n13704,61757,0,I have read and understood the content within the Timeless 102: Label Printing CBL.,205329,1,FALSE,0
104,SCORM-0000-186,TIMELESS 103: RECEIVE MILK/PRODUCTS,n13705,61792,0,I have read and understood the content within the Timeless 103: Receive Milk/Products CBL.,205461,0,TRUE,1
104,SCORM-0000-186,TIMELESS 103: RECEIVE MILK/PRODUCTS,n13705,61792,0,I have read and understood the content within the Timeless 103: Receive Milk/Products CBL.,205462,1,FALSE,0
105,SCORM-0000-187,TIMELESS 104: SIMPLE PREPARE,n13706,61793,0,I have read and understood the content within the Timeless 104: Simple Prepare CBL.,205463,0,TRUE,1
105,SCORM-0000-187,TIMELESS 104: SIMPLE PREPARE,n13706,61793,0,I have read and understood the content within the Timeless 104: Simple Prepare CBL.,205464,1,FALSE,0
106,SCORM-0000-188,TIMELESS 105: ADVANCED PREPARE INTRODUCTION,n13707,61794,0,I have read and understood the content within the Timeless 105: Advanced Prepare Introduction CBL.,205465,0,TRUE,1
106,SCORM-0000-188,TIMELESS 105: ADVANCED PREPARE INTRODUCTION,n13707,61794,0,I have read and understood the content within the Timeless 105: Advanced Prepare Introduction CBL.,205466,1,FALSE,0
107,SCORM-0000-189,TIMELESS 106: ADVANCED PREPARE,n13708,61795,0,I have read and understood the content within the Timeless 106: Advanced Prepare CBL.,205467,0,TRUE,1
107,SCORM-0000-189,TIMELESS 106: ADVANCED PREPARE,n13708,61795,0,I have read and understood the content within the Timeless 106: Advanced Prepare CBL.,205468,1,FALSE,0
109,SCORM-0000-190,TIMELESS 107: FEEDING,n13709,61796,0,I have read and understood the content within the Timeless 107: Feeding CBL.,205469,0,TRUE,1
109,SCORM-0000-190,TIMELESS 107: FEEDING,n13709,61796,0,I have read and understood the content within the Timeless 107: Feeding CBL.,205470,1,FALSE,0
110,SCORM-0000-191,TIMELESS 108: MOVE BOTTLES/PRODUCT,n13711,61797,0,I have read and understood the content within the Timeless 108: Move Bottles/Products CBL.,205471,0,TRUE,1
110,SCORM-0000-191,TIMELESS 108: MOVE BOTTLES/PRODUCT,n13711,61797,0,I have read and understood the content within the Timeless 108: Move Bottles/Products CBL.,205472,1,FALSE,0
117,SCORM-0000-198,TIMELESS 115: PRODUCT MANAGEMENT,n13712,61758,0,I have read and understood the content within the Timeless 115: Product Management CBL.,205330,0,TRUE,1
117,SCORM-0000-198,TIMELESS 115: PRODUCT MANAGEMENT,n13712,61758,0,I have read and understood the content within the Timeless 115: Product Management CBL.,205331,1,FALSE,0
9328,Elearning-0000-575,FY2021 PHARMACY BIOSIMILAR EDUCATION,n13716,61755,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",205324,0,TRUE,1
9328,Elearning-0000-575,FY2021 PHARMACY BIOSIMILAR EDUCATION,n13716,61755,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",205325,1,FALSE,0
111,SCORM-0000-192,TIMELESS 109: MILK/PRODUCT DISPOSAL AND DISCHARGE,n13713,61798,0,I have read and understood the content within the Timeless 109: Milk/Product Disposal and Discharge CBL.,205473,0,TRUE,1
111,SCORM-0000-192,TIMELESS 109: MILK/PRODUCT DISPOSAL AND DISCHARGE,n13713,61798,0,I have read and understood the content within the Timeless 109: Milk/Product Disposal and Discharge CBL.,205474,1,FALSE,0
116,SCORM-0000-197,TIMELESS 114: ADMIN MANAGEMENT,n13714,61759,0,I have read and understood the content within the Timeless 114: Admin Management CBL.,205332,0,TRUE,1
116,SCORM-0000-197,TIMELESS 114: ADMIN MANAGEMENT,n13714,61759,0,I have read and understood the content within the Timeless 114: Admin Management CBL.,205333,1,FALSE,0
115,SCORM-0000-196,TIMELESS 113: MANAGE COMMUNITY ORDER,n13715,61788,0,I have read and understood the content within the Timeless 113: Manage Community Order CBL.,205453,0,TRUE,1
115,SCORM-0000-196,TIMELESS 113: MANAGE COMMUNITY ORDER,n13715,61788,0,I have read and understood the content within the Timeless 113: Manage Community Order CBL.,205454,1,FALSE,0
112,SCORM-0000-193,TIMELESS 110: BAGS/BINS,n13717,61791,0,I have read and understood the content within the Timeless 110: Bags/Bins CBL.,205459,0,TRUE,1
112,SCORM-0000-193,TIMELESS 110: BAGS/BINS,n13717,61791,0,I have read and understood the content within the Timeless 110: Bags/Bins CBL.,205460,1,FALSE,0
113,SCORM-0000-194,TIMELESS 111: MOTHER FEATURES,n13718,61790,0,I have read and understood the content within the Timeless 111: Mother's Features CBL.,205457,0,TRUE,1
113,SCORM-0000-194,TIMELESS 111: MOTHER FEATURES,n13718,61790,0,I have read and understood the content within the Timeless 111: Mother's Features CBL.,205458,1,FALSE,0
114,SCORM-0000-195,TIMELESS 112: FEED CONSENTS,n13719,61789,0,I have read and understood the content within the Timeless 112: Feed Consents CBL.,205455,0,TRUE,1
114,SCORM-0000-195,TIMELESS 112: FEED CONSENTS,n13719,61789,0,I have read and understood the content within the Timeless 112: Feed Consents CBL.,205456,1,FALSE,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61760,0,Please list the location for this activity.,205334,0,Atlanta,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61760,0,Please list the location for this activity.,205335,1,Cherokee,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61760,0,Please list the location for this activity.,205336,2,Forsyth,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61760,0,Please list the location for this activity.,205337,3,Other,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61761,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",205338,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61761,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",205339,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61761,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",205340,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61761,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",205341,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61761,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes and pathophysiology of sepsis in the obstetric patient. </ol>",205342,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61762,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",205343,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61762,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",205344,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61762,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",205345,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61762,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",205346,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61762,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment findings, common lab tests and best practice treatments for women with sepsis. </ol>",205347,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61763,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",205348,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61763,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",205349,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61763,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",205350,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61763,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",205351,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61763,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the causes and pathophysiology of cardiomyopathy.</ol>",205352,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61764,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",205353,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61764,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",205354,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61764,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",205355,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61764,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",205356,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61764,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the physical assessment including the radiographic and laboratory findings consistent with cardiomyopathy and describe treatment options. </ol>",205357,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61765,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",205358,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61765,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",205359,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61765,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",205360,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61765,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",205361,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61765,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify causes of hemorrhage in the obstetric patient and discuss recommendations for treatment. </ol>",205362,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61766,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",205363,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61766,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",205364,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61766,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",205365,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61766,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",205366,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61766,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe reasons for delays in the treatment of the hemorrhaging patient and nursing actions to reduce these delays.</ol>",205367,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61767,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",205368,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61767,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",205369,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61767,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",205370,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61767,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",205371,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61767,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic and pharmacologic methods for treating hemorrhage and prevent coagulopathies in the hemorrhaging woman.</ol>",205372,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61768,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",205373,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61768,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",205374,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61768,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",205375,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61768,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",205376,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61768,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathophysiology of hypertension in obstetrics and discuss best practice recommendations for treatment.</ol>",205377,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61769,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",205378,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61769,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",205379,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61769,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",205380,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61769,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",205381,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61769,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify treatment protocols and medications to treat hypertension in pregnancy.</ol>",205382,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61770,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",205383,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61770,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",205384,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61770,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",205385,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61770,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",205386,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61770,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss typical and atypical clinical presentations of hypertension in pregnancy.</ol>",205387,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61771,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",205388,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61771,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",205389,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61771,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",205390,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61771,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",205391,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61771,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss risk factors for pulmonary edema and its effects on the pregnant and postpartum woman.</ol>",205392,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61772,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",205393,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61772,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",205394,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61772,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",205395,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61772,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",205396,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61772,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify conditions that may lead to pulmonary edema.</ol>",205397,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61773,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",205398,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61773,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",205399,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61773,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",205400,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61773,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",205401,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61773,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how pulmonary edema leads to decreased perfusion in the pregnant patient and its potential effects on the mother and fetus. </ol>",205402,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61774,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,205403,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61774,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,205404,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61774,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,205405,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61774,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,205406,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61774,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,205407,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61775,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",205408,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61775,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",205409,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61775,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",205410,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61775,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",205411,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61775,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.<OL>",205412,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61776,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,205413,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61776,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,205414,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61776,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,205415,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61776,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,205416,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61776,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge related to recognition and management of comorbid diseases during pregnancy.<OL>,205417,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61777,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",205418,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61777,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",205419,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61777,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",205420,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61777,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",205421,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61777,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",205422,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61778,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,205423,0,Strongly Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61778,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,205424,1,Agree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61778,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,205425,2,No Opinion,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61778,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,205426,3,Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61778,18,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,205427,4,Strongly Disagree,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61779,19,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",205428,0,Excellent,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61779,19,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",205429,1,Very Good,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61779,19,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",205430,2,Good,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61779,19,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",205431,3,Fair,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61779,19,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, CNM, RN </ol>",205432,4,Poor,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61780,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",205433,0,Excellent,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61780,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",205434,1,Very Good,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61780,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",205435,2,Good,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61780,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",205436,3,Fair,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61780,20,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",205437,4,Poor,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61781,21,"Overall, this activity was:",205438,0,Excellent,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61781,21,"Overall, this activity was:",205439,1,Very Good,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61781,21,"Overall, this activity was:",205440,2,Good,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61781,21,"Overall, this activity was:",205441,3,Fair,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61781,21,"Overall, this activity was:",205442,4,Poor,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61782,22,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",205443,0,Yes,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61782,22,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",205444,1,No,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61782,22,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",205445,2,N/A,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61785,25,How would you improve this class?,205446,0,Reduce content covered in class,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61785,25,How would you improve this class?,205447,1,Increase content covered in class,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61785,25,How would you improve this class?,205448,2,Update content covered in class,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61785,25,How would you improve this class?,205449,3,Improve the instructional methods,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61785,25,How would you improve this class?,205450,4,Make course activities more stimulating,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61785,25,How would you improve this class?,205451,5,Slow the pace of the class,0
9956,Questions-0000-90,OBSTETRICAL COMPLICATIONS (EVALUATION SURVEY) ONLINE 5.5.21,n13720,61785,25,How would you improve this class?,205452,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61823,0,How often should DTR's be assessed and documented per policy?,205564,0,"a.	Every 30 minutes",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61823,0,How often should DTR's be assessed and documented per policy?,205565,1,"b.	Every hour",1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61823,0,How often should DTR's be assessed and documented per policy?,205566,2,"c.	Every 2 hours",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61823,0,How often should DTR's be assessed and documented per policy?,205567,3,"d.	Every 15 minutes",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61824,1,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",205568,0,"a.	6.4 mg/dl",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61824,1,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",205569,1,"b.	7.4 mg/dl",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61824,1,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",205570,2,"c.	8.4 mg/dl",1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61824,1,"2.	If the Magnesium level is greater than which of the following values, the physician should be notified and the therapy discontinued pending further orders?",205571,3,"d.	9.4 mg/dl",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61825,2,"3.	How long do you have to communicate a critical value with the physician?",205572,0,"a.	5 minutes",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61825,2,"3.	How long do you have to communicate a critical value with the physician?",205573,1,"b.	15 minutes",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61825,2,"3.	How long do you have to communicate a critical value with the physician?",205574,2,"c.	1 hour",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61825,2,"3.	How long do you have to communicate a critical value with the physician?",205575,3,"d.	30 minutes",1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61826,3,"4.	How often should urine output be assessed and documented per policy?",205576,0,"a.	Every hour",1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61826,3,"4.	How often should urine output be assessed and documented per policy?",205577,1,"b.	Every 2 hours",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61826,3,"4.	How often should urine output be assessed and documented per policy?",205578,2,"c.	Every 4 hours",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61826,3,"4.	How often should urine output be assessed and documented per policy?",205579,3,"d.	Every 8 hours",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61827,4,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",205580,0,"a.	Every hour",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61827,4,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",205581,1,"b.	Every 5 min",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61827,4,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",205582,2,"c.	Every 15 min",1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61827,4,"5.	During a loading dose of magnesium sulfate, how often should VS be assessed and documented?",205583,3,"d.	Every 30 min",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61828,5,". During magnesium maintenance infusion, VS should be assessed and documented every hour",205584,0,TRUE,1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61828,5,". During magnesium maintenance infusion, VS should be assessed and documented every hour",205585,1,FALSE,0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61829,6,Initiation and maintenance of magnesium sulfate does not require verification by 2 RN's.,205586,0,TRUE,0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61829,6,Initiation and maintenance of magnesium sulfate does not require verification by 2 RN's.,205587,1,FALSE,1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61830,7,"8.	Which of the following is the antagonist of magnesium sulfate?",205588,0,"a.	Calcium Carbonate",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61830,7,"8.	Which of the following is the antagonist of magnesium sulfate?",205589,1,"b.	Calcium Gluconate",1
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61830,7,"8.	Which of the following is the antagonist of magnesium sulfate?",205590,2,"c.	Sodium Chloride",0
9204,Elearning-0000-462,NSC ICU MAG SULFATE POLICY,n13726,61830,7,"8.	Which of the following is the antagonist of magnesium sulfate?",205591,3,"d.	Magnesium Sulfate does not have an antagonist",0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61831,0,True or false- (Malignant Hyperthermia) MH and Local Anesthetic Toxicity (LAST) should be treated as an emergency,205592,0,TRUE,1
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61831,0,True or false- (Malignant Hyperthermia) MH and Local Anesthetic Toxicity (LAST) should be treated as an emergency,205593,1,FALSE,0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61832,1,True or false- MH only occurs immediately after a triggering agent is administered.,205594,0,TRUE,0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61832,1,True or false- MH only occurs immediately after a triggering agent is administered.,205595,1,FALSE,1
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61833,2,What medications can cause LAST?,205596,0,A)      Exparel,0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61833,2,What medications can cause LAST?,205597,1,B)      Bupivacaine,0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61833,2,What medications can cause LAST?,205598,2,C)      Ropivacaine,0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61833,2,What medications can cause LAST?,205599,3,D)      Lidocaine,0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61833,2,What medications can cause LAST?,205600,4,E)      A&B only,0
8529,Elearning-0000-140,FY2021 PHARMACY SURGICAL EMERGENCIES COMPETENCY,n13727,61833,2,What medications can cause LAST?,205601,5,F)       All of the above,1
9603,Elearning-0000-825,DIALYSIS COMMUNICATION UPDATE  MAY 2021(2),n13731,61866,0,I have read and understand the CBL Dialysis Communication Update May 2021(2) and the subsequent expectations for compliance.,205700,0,TRUE,1
9603,Elearning-0000-825,DIALYSIS COMMUNICATION UPDATE  MAY 2021(2),n13731,61866,0,I have read and understand the CBL Dialysis Communication Update May 2021(2) and the subsequent expectations for compliance.,205701,1,FALSE,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61978,0,Please list the location for this activity.,206140,0,Atlanta,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61978,0,Please list the location for this activity.,206141,1,Forsyth,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61978,0,Please list the location for this activity.,206142,2,Cherokee,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61978,0,Please list the location for this activity.,206143,3,Other,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61979,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",206144,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61979,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",206145,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61979,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",206146,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61979,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",206147,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61979,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",206148,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61980,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",206149,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61980,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",206150,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61980,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",206151,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61980,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",206152,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61980,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",206153,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61981,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",206154,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61981,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",206155,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61981,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",206156,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61981,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",206157,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61981,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",206158,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61982,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",206159,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61982,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",206160,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61982,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",206161,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61982,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",206162,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61982,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",206163,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61983,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",206164,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61983,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",206165,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61983,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",206166,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61983,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",206167,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61983,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",206168,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61984,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",206169,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61984,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",206170,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61984,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",206171,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61984,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",206172,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61984,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",206173,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61985,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",206174,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61985,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",206175,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61985,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",206176,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61985,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",206177,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61985,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",206178,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61986,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",206179,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61986,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",206180,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61986,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",206181,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61986,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",206182,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61986,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",206183,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61987,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",206184,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61987,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",206185,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61987,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",206186,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61987,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",206187,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61987,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",206188,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61988,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",206189,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61988,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",206190,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61988,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",206191,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61988,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",206192,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61988,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",206193,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61989,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",206194,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61989,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",206195,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61989,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",206196,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61989,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",206197,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61989,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",206198,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61990,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,206199,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61990,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,206200,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61990,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,206201,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61990,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,206202,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61990,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,206203,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61991,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,206204,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61991,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,206205,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61991,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,206206,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61991,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,206207,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61991,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,206208,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61992,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",206209,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61992,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",206210,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61992,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",206211,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61992,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",206212,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61992,13,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",206213,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61993,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",206214,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61993,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",206215,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61993,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",206216,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61993,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",206217,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61993,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",206218,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61994,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,206219,0,Strongly Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61994,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,206220,1,Agree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61994,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,206221,2,No Opinion,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61994,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,206222,3,Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61994,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,206223,4,Strongly Disagree,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61995,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",206224,0,Excellent,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61995,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",206225,1,Very Good,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61995,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",206226,2,Good,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61995,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",206227,3,Fair,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61995,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN </ol>",206228,4,Poor,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61996,18,"Overall, this activity was:",206229,0,Excellent,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61996,18,"Overall, this activity was:",206230,1,Very Good,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61996,18,"Overall, this activity was:",206231,2,Good,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61996,18,"Overall, this activity was:",206232,3,Fair,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61996,18,"Overall, this activity was:",206233,4,Poor,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61997,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",206234,0,Yes,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61997,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",206235,1,No,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,61997,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",206236,2,N/A,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,62000,22,How would you improve this class?,206237,0,Reduce content covered in class,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,62000,22,How would you improve this class?,206238,1,Increase content covered in class,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,62000,22,How would you improve this class?,206239,2,Update content covered in class,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,62000,22,How would you improve this class?,206240,3,Improve the instructional methods,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,62000,22,How would you improve this class?,206241,4,Make course activities more stimulating,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,62000,22,How would you improve this class?,206242,5,Slow the pace of the class,0
9890,Questions-0000-24,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 5-17-21,n13737,62000,22,How would you improve this class?,206243,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62003,0,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",206244,0,"a.	Patients are NPO immediately post-op",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62003,0,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",206245,1,"b.	Once cleared by the Surgeon, all medications will be given via the J-tube",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62003,0,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",206246,2,"c.	The provider will evaluate the patient for utilization of the J-tube about 48 hours post-operatively",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62003,0,"1.	Post-operative orders for patients that are S/P Esophagogastrectomy include",206247,3,"d.	All of the above",1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62004,1,"2.	Post-operatively, do not manipulate, move, or discontinue the patient's NG tube without permission from the Surgeon.",206248,0,TRUE,1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62004,1,"2.	Post-operatively, do not manipulate, move, or discontinue the patient's NG tube without permission from the Surgeon.",206249,1,FALSE,0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62005,2,"3.	Medications may be given via the NG Tube post-operatively.",206250,0,TRUE,0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62005,2,"3.	Medications may be given via the NG Tube post-operatively.",206251,1,FALSE,1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62006,3,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",206252,0,"a.	In 4 hours",1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62006,3,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",206253,1,"b.	In 8 hours",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62006,3,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",206254,2,"c.	In 12 hours",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62006,3,"4.	Notify the Thoracic Surgeon if there is no NG Tube output post-operatively",206255,3,"d.	All of the above",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62007,4,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",206256,0,"a.	The surgery severs 2 of the 3 major arteries supplying the stomach.",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62007,4,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",206257,1,"b.	Abdominal distention can cut off the existing blood supply and cause ischemia to occur.",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62007,4,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",206258,2,"c.	The patient is high risk for aspiration.",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62007,4,"5.	Decompression of the stomach post-esophagogastrectomy is essential because",206259,3,"d.	All of the above",1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62008,5,"6.	You should report white milky-colored drainage from the JP chest drain to the Thoracic Surgeon immediately since this can be an indication of a Chyle leak related to lymphatic system injury.",206260,0,TRUE,1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62008,5,"6.	You should report white milky-colored drainage from the JP chest drain to the Thoracic Surgeon immediately since this can be an indication of a Chyle leak related to lymphatic system injury.",206261,1,FALSE,0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62009,6,"7.	I have read the CBL in its entirety and understand that I am responsible for this information.",206262,0,TRUE,1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62009,6,"7.	I have read the CBL in its entirety and understand that I am responsible for this information.",206263,1,FALSE,0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62010,7,"8.	I have listened to the video in its entirety and understand that I am responsible for this information.",206264,0,TRUE,1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62010,7,"8.	I have listened to the video in its entirety and understand that I am responsible for this information.",206265,1,FALSE,0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62011,8,"9.	Oral care is essential for these patients in order to prevent",206266,0,"a.	HAP",1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62011,8,"9.	Oral care is essential for these patients in order to prevent",206267,1,"b.	CAP",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62011,8,"9.	Oral care is essential for these patients in order to prevent",206268,2,"c.	VAP",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62011,8,"9.	Oral care is essential for these patients in order to prevent",206269,3,"d.	None of the above",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62012,9,"10.	A potential complication for this surgery that has a high mortality rate is",206270,0,"a.	Pneumonia and ARDS",1
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62012,9,"10.	A potential complication for this surgery that has a high mortality rate is",206271,1,"b.	Unresolved pain",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62012,9,"10.	A potential complication for this surgery that has a high mortality rate is",206272,2,"c.	J tube complications",0
9116,Elearning-0000-382,NSC ICU ESOPHAGOGASTRECTOMY SURGERY,n13738,62012,9,"10.	A potential complication for this surgery that has a high mortality rate is",206273,3,"d.	None of the above",0
9072,Elearning-0000-342,NSH1297 AMENDMENT 4,n13742,62018,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",206290,0,TRUE,1
9072,Elearning-0000-342,NSH1297 AMENDMENT 4,n13742,62018,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",206291,1,FALSE,0
9094,Elearning-0000-362,NSH1208 AMENDMENT 3,n13744,62041,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",206381,0,TRUE,1
9094,Elearning-0000-362,NSH1208 AMENDMENT 3,n13744,62041,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",206382,1,FALSE,0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62042,0,Which of the definitions below is CORRECT?,206383,0,"a.	Neonate refers to a person from birth to 28 days of age",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62042,0,Which of the definitions below is CORRECT?,206384,1,"b.	Infant refers to a child who is >28 days to 1 year of age",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62042,0,Which of the definitions below is CORRECT?,206385,2,"c.	Pediatric refers to children from 1 year to 11 years",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62042,0,Which of the definitions below is CORRECT?,206386,3,"d.	Adolescent refers to a person who is 12-17 years",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62042,0,Which of the definitions below is CORRECT?,206387,4,"e.	Adult refers to a person who is 18 years or greater",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62042,0,Which of the definitions below is CORRECT?,206388,5,"f.	All of the above are correct",1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62043,1,Which of the following statements is INCORRECT?,206389,0,"a.	Neonatal code carts are located in Special Care Nursery, L&D, and FCC, and are used to resuscitate neonates and infants after birth until discharge.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62043,1,Which of the following statements is INCORRECT?,206390,1,"b.	Neonatal carts are located in ED and are used to Resuscitate Neonates and Infants up to 1 year of age.",1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62043,1,Which of the following statements is INCORRECT?,206391,2,"c.	Broselow carts are located in ED and Surgery and are used for resuscitation of children in those areas (Infants and pediatrics).",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62043,1,Which of the following statements is INCORRECT?,206392,3,"d.	Adult Code Carts contain a drawer (drawer 4) which contains medications and references for Infant and Pediatric Resuscitation.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62044,2,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,206393,0,"a.	The ED will call the Neonatal evaluation team and use the Neonatal Code Cart and NRP algorithms for resuscitation",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62044,2,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,206394,1,"b.	The ED will use the Broselow Code Cart and PALS algorithms for resuscitation",1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62044,2,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,206395,2,"c.	The ED will use the Adult Code Cart and ACLS algorithms for resuscitation",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62044,2,A five month old baby is brought into the Emergency Department with no respirations and no pulse. Which of the following is CORRECT related to resuscitation of this Infant?,206396,3,"d.	None of the above is correct",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62045,3,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",206397,0,"a.	Neonatal Code Carts have reference binders on each cart with dosing sheets to calculate exact doses of medications based on weight or gestational age as applicable.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62045,3,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",206398,1,"b.	Broselow Carts have color coded weight based PALS Pediatric Dosing Sheets in the medication drawer that correspond to drawer color and medication concentrations, and should be used to determine exact doses of medications based on weight.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62045,3,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",206399,2,"c.	At Northside Hospital, the Broselow Tape in the Pediatric Medication Drawer should only be used to obtain an estimated weight range of a pediatric patient by measuring height / length if actual weight is not known.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62045,3,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",206400,3,"d.	Adult Code Carts have weight based Pediatric Dosing Sheets located in the Pediatric Drawer (Drawer 4), which is identical to the Broselow Code Cart medication drawer.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62045,3,"Which is CORRECT regarding dosing references associated with Neonatal, Broselow, and Adult Code Carts?",206401,4,"e.	All of the above are correct.",1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62046,4,"True or false? The PALS dosing reference indicates initial dosing and rate for epinephrine and dopamine drips, and a weight based titration chart has been added for drip titration.",206402,0,TRUE,1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62046,4,"True or false? The PALS dosing reference indicates initial dosing and rate for epinephrine and dopamine drips, and a weight based titration chart has been added for drip titration.",206403,1,FALSE,0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62047,5,Which of the below is INCORRECT regarding the preferred way to administer 0.01mg/ kg epinephrine dose for PEA to a 9 kg infant in the ED:,206404,0,"a.	Use the PALS dosing sheet in the pediatric medication tray of the Broselow Code Cart to verify the correct exact dose in mg and mL based on the patient's weight",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62047,5,Which of the below is INCORRECT regarding the preferred way to administer 0.01mg/ kg epinephrine dose for PEA to a 9 kg infant in the ED:,206405,1,"b.	Using the 1mg/ 10mL epinephrine Abboject in the pediatric medication drawer, withdraw 0.9ml (0.09mg) epinephrine into a syringe with appropriate markings of measurement using a transfer device (Rapidfill connector or stopcock)",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62047,5,Which of the below is INCORRECT regarding the preferred way to administer 0.01mg/ kg epinephrine dose for PEA to a 9 kg infant in the ED:,206406,2,"c.	Using the 1mg/ 10mL epinephrine Abboject in the pediatric medication drawer, inject  0.9ml (0.09mg) epinephrine dose into the infant's IV or IO access directly from the 1mg/ 10ml epinephrine Abboject syringe.",1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62048,6,Which of the following is CORRECT regarding Neonatal Resuscitation?,206407,0,"a.	Epinephrine is the primary pharmacologic treatment in NRP algorithm for neonatal resuscitation",1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62048,6,Which of the following is CORRECT regarding Neonatal Resuscitation?,206408,1,"b.	Lidocaine and amiodarone are the primary treatment options for pulseless ventricular fibrillation and ventricular tachycardia in NRP the algorithm.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62048,6,Which of the following is CORRECT regarding Neonatal Resuscitation?,206409,2,"c.	The NRP algorithm includes defibrillation for pulseless ventricular fibrillation and ventricular tachycardia.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62049,7,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,206410,0,"a.	Epinephrine is the only pharmacologic treatment in the PALS algorithms for infant and pediatric resuscitation",1
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62049,7,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,206411,1,"b.	Epinephrine and Atropine are both options for symptomatic bradycardia in the PALS bradycardia algorithm.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62049,7,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,206412,2,"c.	Lidocaine and amiodarone are antiarrhythmic treatment options for pulseless ventricular fibrillation and ventricular tachycardia in the PALS Cardiac Arrest algorithm.",0
9159,Elearning-0000-421,FY2021 PHARMACY NEONATAL INFANT PEDIATRIC RESUSCITATION COMPETENCY,n13745,62049,7,Which of the following is INCORRECT regarding Infant and Pediatric Resuscitation using PALS?,206413,3,"d.	The PALS algorithm includes defibrillation for pulseless ventricular fibrillation and ventricular tachycardia.",0
9446,Elearning-0000-682,CONSTANT OBSERVER CASE STUDY CBL,n13749,62076,0,I have read the contents of this CBL in its entirety and I have filled out a Constant Observer Flowsheet and submitted it in Tara's mailbox.,206510,0,TRUE,1
9446,Elearning-0000-682,CONSTANT OBSERVER CASE STUDY CBL,n13749,62076,0,I have read the contents of this CBL in its entirety and I have filled out a Constant Observer Flowsheet and submitted it in Tara's mailbox.,206511,1,FALSE,0
9608,Elearning-0000-83,WSU BHS COMPETENCY 2021,n13753,62080,0,"I have completed my updated Constant Observer Sheet using the Case Study provided in this CBL, filled out the top section of my Behavioral Health Annual Competency Form and signed the back, and placed these two forms in the Clinician's box.",206518,0,TRUE,1
9608,Elearning-0000-83,WSU BHS COMPETENCY 2021,n13753,62080,0,"I have completed my updated Constant Observer Sheet using the Case Study provided in this CBL, filled out the top section of my Behavioral Health Annual Competency Form and signed the back, and placed these two forms in the Clinician's box.",206519,1,FALSE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62081,0,"1.	Radiation Oncology price estimates consist of what two types of estimates?",206520,0,"a.	Profee and Technical",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62081,0,"1.	Radiation Oncology price estimates consist of what two types of estimates?",206521,1,"b.	Technical only",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62081,0,"1.	Radiation Oncology price estimates consist of what two types of estimates?",206522,2,"c.	Profee only",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62082,1,2. The Oncology Financial Resource Specialist should create a _____________ and ______________ estimate for employed physicians.,206523,0,"a.	Professional and Contracted",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62082,1,2. The Oncology Financial Resource Specialist should create a _____________ and ______________ estimate for employed physicians.,206524,1,"b.	Professional and Technical",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62082,1,2. The Oncology Financial Resource Specialist should create a _____________ and ______________ estimate for employed physicians.,206525,2,"c.	Technical and Commercial",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62083,2,"3.	The Oncology Financial Resource Specialist should create a _____________ ________ only for contracted physicians.",206526,0,"a.	Technical estimate",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62083,2,"3.	The Oncology Financial Resource Specialist should create a _____________ ________ only for contracted physicians.",206527,1,"b.	Insurance estimate",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62083,2,"3.	The Oncology Financial Resource Specialist should create a _____________ ________ only for contracted physicians.",206528,2,"c.	Contracted estimate",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62084,3,"4.	If the patient has a Profee and a technical estimate, which should be generated first?",206529,0,"a.	Either one - it does not matter which order they are created in",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62084,3,"4.	If the patient has a Profee and a technical estimate, which should be generated first?",206530,1,"b.	Technical",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62084,3,"4.	If the patient has a Profee and a technical estimate, which should be generated first?",206531,2,"c.	Profee",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62085,4,"5.	The Oncology Financial Resource Specialist should review previous accounts for outstanding balances and bad debt. This should be included in the FET as it is the total patient financial responsibility.",206532,0,TRUE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62085,4,"5.	The Oncology Financial Resource Specialist should review previous accounts for outstanding balances and bad debt. This should be included in the FET as it is the total patient financial responsibility.",206533,1,FALSE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62086,5,"6.	When creating the technical estimate, it is not necessary to deduct the Profee estimate from the remaining insurance benefits.",206534,0,TRUE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62086,5,"6.	When creating the technical estimate, it is not necessary to deduct the Profee estimate from the remaining insurance benefits.",206535,1,FALSE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62087,6,"7.	What is the first step in preparation for creating a Radiation Oncology price estimate?",206536,0,"a.	Access STAR ILE and locate Modality Treatment Plan",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62087,6,"7.	What is the first step in preparation for creating a Radiation Oncology price estimate?",206537,1,"b.	Access STAR to obtain insurance benefits",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62087,6,"7.	What is the first step in preparation for creating a Radiation Oncology price estimate?",206538,2,"c.	Log into the FET Tool",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62088,7,"8.	What is the name of the tool used by the Oncology Financial Resource Specialist to calculate the technical fees listed on the Modality Treatment Plan?",206539,0,"a.	Estimation Workbook",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62088,7,"8.	What is the name of the tool used by the Oncology Financial Resource Specialist to calculate the technical fees listed on the Modality Treatment Plan?",206540,1,"b.	FET",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62088,7,"8.	What is the name of the tool used by the Oncology Financial Resource Specialist to calculate the technical fees listed on the Modality Treatment Plan?",206541,2,"c.	Technical Workbook",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62089,8,9. A standard note code must be added to each account to notate the financial outcome.,206542,0,TRUE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62089,8,9. A standard note code must be added to each account to notate the financial outcome.,206543,1,FALSE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62090,9,10. A financial clearance/ non-clearance email will be sent to the appropriate email distribution list after the Oncology Financial Resource Specialist works each account.,206544,0,TRUE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62090,9,10. A financial clearance/ non-clearance email will be sent to the appropriate email distribution list after the Oncology Financial Resource Specialist works each account.,206545,1,FALSE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62091,10,"11.	The Modality Treatment plan specifies the quantities of CPT codes and differentiates which codes are Profee versus technical.",206546,0,TRUE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62091,10,"11.	The Modality Treatment plan specifies the quantities of CPT codes and differentiates which codes are Profee versus technical.",206547,1,FALSE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62092,11,"12.	When creating the technical estimate, the Oncology Financial Resource Specialist will refer to the standard processes and procedures via the Financial Estimation Tool.",206548,0,TRUE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62092,11,"12.	When creating the technical estimate, the Oncology Financial Resource Specialist will refer to the standard processes and procedures via the Financial Estimation Tool.",206549,1,FALSE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62093,12,"13.	Each treatment plan has either 3 days or 5 days listed at the top. What does the Oncology Financial Resource Specialist use this for?",206550,0,"a.	This does not indicate anything",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62093,12,"13.	Each treatment plan has either 3 days or 5 days listed at the top. What does the Oncology Financial Resource Specialist use this for?",206551,1,"b.	The number of treatments",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62093,12,"13.	Each treatment plan has either 3 days or 5 days listed at the top. What does the Oncology Financial Resource Specialist use this for?",206552,2,"c.	The number of business days to financially clear the patient",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62094,13,"14. If an ABN is located in STAR, the Oncology Financial Resource Specialist should create a self-pay estimate for the applicable non-covered CPT codes?",206553,0,TRUE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62094,13,"14. If an ABN is located in STAR, the Oncology Financial Resource Specialist should create a self-pay estimate for the applicable non-covered CPT codes?",206554,1,FALSE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62095,14,"15.	 Once the Oncology Financial Resource Specialist completes the ABN, the completed document should be scanned into what ILE folder?",206555,0,"a.	PFS: Primary Insurance",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62095,14,"15.	 Once the Oncology Financial Resource Specialist completes the ABN, the completed document should be scanned into what ILE folder?",206556,1,"b.	PFS: Insurance Information",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62095,14,"15.	 Once the Oncology Financial Resource Specialist completes the ABN, the completed document should be scanned into what ILE folder?",206557,2,"c.	PFS: ABN",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62096,15,"16.	The Intake team will write ________________ across the top of the treatment plan when a patient's care must begin immediately.",206558,0,"a.	Hurry Up",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62096,15,"16.	The Intake team will write ________________ across the top of the treatment plan when a patient's care must begin immediately.",206559,1,"b.	Emergency",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62096,15,"16.	The Intake team will write ________________ across the top of the treatment plan when a patient's care must begin immediately.",206560,2,"c.	ASAP",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62097,16,"17.	 If an emergency patient is unable to make a suitable payment arrangement or qualify for financial assistance, their appointment ______ _______ be postponed.",206561,0,"a.	Will",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62097,16,"17.	 If an emergency patient is unable to make a suitable payment arrangement or qualify for financial assistance, their appointment ______ _______ be postponed.",206562,1,"b.	Will not",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62097,16,"17.	 If an emergency patient is unable to make a suitable payment arrangement or qualify for financial assistance, their appointment ______ _______ be postponed.",206563,2,"c.	May be",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62098,17,"18.	 The Oncology Financial Resource Specialist fills out the Patient Tracker on each patient worked.",206564,0,TRUE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62098,17,"18.	 The Oncology Financial Resource Specialist fills out the Patient Tracker on each patient worked.",206565,1,FALSE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62099,18,"19. If a non-emergency patient cannot make a suitable payment arrangement or qualify for financial assistance, the treatment is  ____________________",206566,0,"a.	Postponed/rescheduled",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62099,18,"19. If a non-emergency patient cannot make a suitable payment arrangement or qualify for financial assistance, the treatment is  ____________________",206567,1,"b.	Continued",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62099,18,"19. If a non-emergency patient cannot make a suitable payment arrangement or qualify for financial assistance, the treatment is  ____________________",206599,2,"c.	Cancelled",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62100,19,"20.	Generic Treatment Plans will be created for patients that do not have an estimated amount due for radiation oncology treatment but may have _______________",206568,0,"a.	Outstanding balances and/or bad debt",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62100,19,"20.	Generic Treatment Plans will be created for patients that do not have an estimated amount due for radiation oncology treatment but may have _______________",206569,1,"b.	A regularly scheduled appointment",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62100,19,"20.	Generic Treatment Plans will be created for patients that do not have an estimated amount due for radiation oncology treatment but may have _______________",206570,2,"c.	Paperwork that needs to be updated",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62101,20,21. The Radiation Oncology Estimation Workbook is located in what folder?,206571,0,"a.	Patient Access All - Radiation Oncology Estimator Worksheet",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62101,20,21. The Radiation Oncology Estimation Workbook is located in what folder?,206572,1,"b.	Patient Access All - Rad Onc Profee Worksheet",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62101,20,21. The Radiation Oncology Estimation Workbook is located in what folder?,206573,2,"c.	Patient Access All - Profee Workbook",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62102,21,"22.	When saving an estimate letter in the Radiation Oncology Estimation Workbook, the following process is followed:",206574,0,"a.	While on the letter tab, hit the save button",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62102,21,"22.	When saving an estimate letter in the Radiation Oncology Estimation Workbook, the following process is followed:",206575,1,"b.	While on the letter tab, do ""file, save as""ù and save letter to desktop",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62102,21,"22.	When saving an estimate letter in the Radiation Oncology Estimation Workbook, the following process is followed:",206576,2,"c.	Return to the patient tab and hit the gray save button at the top",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62103,22,"23.	 By selecting the gray ""SAVE""    button on the Patient Form tab of the Radiation Oncology Estimation Workbook, the estimate letter is:",206577,0,"a.	Automatically saved to the Galen folder",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62103,22,"23.	 By selecting the gray ""SAVE""    button on the Patient Form tab of the Radiation Oncology Estimation Workbook, the estimate letter is:",206578,1,"b.	Automatically saved to the desktop",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62103,22,"23.	 By selecting the gray ""SAVE""    button on the Patient Form tab of the Radiation Oncology Estimation Workbook, the estimate letter is:",206579,2,"c.	Automatically sent to the patient",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62104,23,"24.	 Once the Profee estimate letter is saved on the Galen drive, the Oncology Financial Resource Specialist should access the Galen drive and",206580,0,"a.	Open the excel workbook, access the estimate letter and change to a PDF format",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62104,23,"24.	 Once the Profee estimate letter is saved on the Galen drive, the Oncology Financial Resource Specialist should access the Galen drive and",206581,1,"b.	Open the excel workbook and delete the estimate letter",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62104,23,"24.	 Once the Profee estimate letter is saved on the Galen drive, the Oncology Financial Resource Specialist should access the Galen drive and",206582,2,"c.	Do nothing.  Galen does not need the letter",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62105,24,"25.	 Profee and technical payments are applied to the same outlet in Wells Fargo.",206583,0,TRUE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62105,24,"25.	 Profee and technical payments are applied to the same outlet in Wells Fargo.",206584,1,FALSE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62106,25,"26.	 What two steps have to be done in order to create the Profee Financial Estimate letter once the Oncology Financial Resource Specialist accesses the Radiation Oncology Estimation Workbook?",206585,0,"a.	Fill in the insurance benefits on the Patient Form and review the Detailed Bill Estimate tab",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62106,25,"26.	 What two steps have to be done in order to create the Profee Financial Estimate letter once the Oncology Financial Resource Specialist accesses the Radiation Oncology Estimation Workbook?",206586,1,"b.	Fill in the insurance benefits on the Patient Form tab and save to the desktop",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62106,25,"26.	 What two steps have to be done in order to create the Profee Financial Estimate letter once the Oncology Financial Resource Specialist accesses the Radiation Oncology Estimation Workbook?",206587,2,"c.	Fill in the insurance benefits on the Patient Form tab and compare the Treatment Plan CPT Codes and Quantities to the ones listed on the Template List tab and update as needed",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62107,26,"27.	 If an Oncology Financial Resource Specialist is unable to reach a patient to provide an estimate prior to treatment, the patient is considered financially cleared.",206588,0,TRUE,0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62107,26,"27.	 If an Oncology Financial Resource Specialist is unable to reach a patient to provide an estimate prior to treatment, the patient is considered financially cleared.",206589,1,FALSE,1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62108,27,"28.	 When should the Oncology Financial Resource Specialist run eligibility through RevRunner (if applicable) to see if the patient has met more of their deductible or out of pocket prior to creating the estimate letter?",206590,0,"a.	Only if benefits were verified by the Intake Team within the past two weeks",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62108,27,"28.	 When should the Oncology Financial Resource Specialist run eligibility through RevRunner (if applicable) to see if the patient has met more of their deductible or out of pocket prior to creating the estimate letter?",206591,1,"b.	Only if benefits were verified by the Intake Team within the past week",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62108,27,"28.	 When should the Oncology Financial Resource Specialist run eligibility through RevRunner (if applicable) to see if the patient has met more of their deductible or out of pocket prior to creating the estimate letter?",206592,2,"c.	Prior to every estimate",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62109,28,"29.	 The Oncology Financial Resource Specialist should scan both the profee and technical estimate letters to what folder in ILE?",206593,0,"a.	PFS:  POS COLLECTIONS DOCUMENTS",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62109,28,"29.	 The Oncology Financial Resource Specialist should scan both the profee and technical estimate letters to what folder in ILE?",206594,1,"b.	PFS:  PRICE ESTIMATE LETTERS",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62109,28,"29.	 The Oncology Financial Resource Specialist should scan both the profee and technical estimate letters to what folder in ILE?",206595,2,"c.	PFS:  COLLECTIONS LETTERS",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62110,29,"30.	  If a patient pays more than the required 1/3 down deposit the Oncology Financial Resource Specialist should use what form located on the Revenue Cycle Website?",206596,0,"a.	Generic FET Letter",1
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62110,29,"30.	  If a patient pays more than the required 1/3 down deposit the Oncology Financial Resource Specialist should use what form located on the Revenue Cycle Website?",206597,1,"b.	Copay FET Letter",0
8952,Elearning-0000-233,RADIATION ONCOLOGY TRAINING FOR PROFESSIONAL AND TECHNICAL PRICE ESTIMATES_2021,n13754,62110,29,"30.	  If a patient pays more than the required 1/3 down deposit the Oncology Financial Resource Specialist should use what form located on the Revenue Cycle Website?",206598,2,"c.	1/3 Down/Copay Only FET Letter",0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62111,0,Vasopressors increase vasoconstriction which can increase perfusion to distal tissue like the skin,206600,0,TRUE,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62111,0,Vasopressors increase vasoconstriction which can increase perfusion to distal tissue like the skin,206601,1,FALSE,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62112,1,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,206602,0,1. Titrating gtts every time a MAP is outside of ordered range,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62112,1,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,206603,1,2.  2 consecutive MAPs> ordered upper parameter without decreasing the vasopressor gtt,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62112,1,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,206604,2,"3,  Titrating gtt when MAP is within ordered range",0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62112,1,What is the most common mistake made in regards to not completing titrations correctly (may result in putting patients at higher risk for skin breakdown)?,206605,3,4.  All of the above,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62113,2,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",206606,0,1.  Titrate the vasopressor up by the ordered dose,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62113,2,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",206607,1,2.  Titrate vasopressor down by ordered dose,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62113,2,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",206608,2,"3.  Continue to monitor VS every 15 minutes until 2 consecutive MAP's are out of range, then titrate according to order",1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62113,2,"MAP ordered range is to maintain MAP 65-80, patient has a MAP of 64 followed by a MAP of 65, what should you do? (best answer)",206609,3,4.  None of the above,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62114,3,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",206610,0,1.  MAP 65-70 for the majority of patients,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62114,3,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",206611,1,"2.  MAP 70-80, higher is better",0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62114,3,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",206612,2,3.  MAP 60-50,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62114,3,"To aggressively wean vasopressor gtts, what is the recommended MAP range?",206613,3,4. MAP 75-85,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62115,4,It is best to complete all titrations through the MAR,206614,0,TRUE,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62115,4,It is best to complete all titrations through the MAR,206615,1,FALSE,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62116,5,"At the beginning of every shift, the oncoming RN should enter gtt rates in iVIEW gtt section during handoff for verification of line reconciliation and to ensure baseline rate for all gtt titrations for the shift",206616,0,TRUE,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62116,5,"At the beginning of every shift, the oncoming RN should enter gtt rates in iVIEW gtt section during handoff for verification of line reconciliation and to ensure baseline rate for all gtt titrations for the shift",206617,1,FALSE,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62117,6,If a patient has 2 VS sources (Cuff pressure and Aline)- both sources must be documented in the EMR every 15 minutes for the duration of all vasoactive gtts.,206618,0,TRUE,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62117,6,If a patient has 2 VS sources (Cuff pressure and Aline)- both sources must be documented in the EMR every 15 minutes for the duration of all vasoactive gtts.,206619,1,FALSE,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62118,7,Communications orders should only be used for 1 time events,206620,0,TRUE,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62118,7,Communications orders should only be used for 1 time events,206621,1,FALSE,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62119,8,"It is ok to titrate vasoactive gtts when VS are within ordered range (example:  MAP is 75, order is to maintain MAP of 60-80)",206622,0,TRUE,0
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62119,8,"It is ok to titrate vasoactive gtts when VS are within ordered range (example:  MAP is 75, order is to maintain MAP of 60-80)",206623,1,FALSE,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62120,9,"I have read and understand the content of the CBL entitled FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION, understand that I am responsible for the content contained herein, and proper vasoactive gtt titrations following provider orders.  I will seek assistance or further education as needed.",206624,0,TRUE,1
9315,Elearning-0000-563,FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION,n13755,62120,9,"I have read and understand the content of the CBL entitled FY2021 NSF ICU VASOACTIVE GTT TITRATION EDUCATION, understand that I am responsible for the content contained herein, and proper vasoactive gtt titrations following provider orders.  I will seek assistance or further education as needed.",206625,1,FALSE,0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62121,0,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",206626,0,"a.	High-alert medications",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62121,0,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",206627,1,"b.	Low-alert medications",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62121,0,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",206628,2,"c.	Highly addictive medications",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62121,0,"According to ISMP, heparin, argatroban, and all IV anticoagulants are:",206629,3,"d.	None of the above",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62122,1,Potential adverse effects of heparin include:,206630,0,"a.	Systemic bleeding",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62122,1,Potential adverse effects of heparin include:,206631,1,"b.	Heparin-induced thrombocytopenia",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62122,1,Potential adverse effects of heparin include:,206632,2,"c.	Heparin-induced osteopenia",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62122,1,Potential adverse effects of heparin include:,206633,3,"d.	All of the above",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62123,2,Heparin is indicated for:,206634,0,"a.	Prophylaxis for DVT/PE",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62123,2,Heparin is indicated for:,206635,1,"b.	Treatment of DVT/PE",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62123,2,Heparin is indicated for:,206636,2,"c.	Acute Coronary Syndrome",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62123,2,Heparin is indicated for:,206637,3,"d.	All of the above",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62124,3,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",206638,0,"a.	The patient has an increased risk of bleeding due to their anti-Xa and concurrent anti-platelet therapy.",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62124,3,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",206639,1,"b.	The heparin drip should be held and the physician contacted for orders.",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62124,3,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",206640,2,"c.	The headache and elevated BP could be an indication of an impending serious adverse drug event",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62124,3,"You are caring for an elderly patient (85 years old) who is on a heparin drip at 850 units per hour.  The admitting diagnosis is rule out DVT in left lower extremity.  The patient's home medications include aspirin and Plavix.  BP with routine vitals is 190/95 mmHg.  The patient is awake, but their mental status has noticeably declined since the last assessment and they are requesting something for a severe headache.  The patient's 6 hour anti-Xa result was just received from the lab and is > 2.  Which of the following statements are true:",206641,3,"d.	All of the above are true.",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62125,4,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,206642,0,"a.	6160 units",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62125,4,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,206643,1,"b.	6000 units",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62125,4,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,206644,2,"c.	5000 units",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62125,4,CC is a 62 year old male admitted to the medical unit with a deep vein thrombosis in his left lower leg.  His admitting physician initiates the weight-based heparin order set based on the following parameters:  80 units/kg bolus followed by 18 units/kg/hour infusion.  CC weighs 77kg.  His baseline PTT is 27.  CC's initial bolus dose will be:,206645,3,"d.	10,000 units",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62126,5,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",206646,0,"a.	2 ml",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62126,5,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",206647,1,"b.	4 ml",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62126,5,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",206648,2,"c.	6 ml",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62126,5,"The pharmacy dispensed heparin 10,000 units/ 10 ml vial for administration of the bolus.  The correct volume to be administered is:",206649,3,"d.	8 ml",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62127,6,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",206650,0,"a.	1400 units/hour",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62127,6,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",206651,1,"b.	1402.2 units/hour",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62127,6,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",206652,2,"c.	1387 units/hour",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62127,6,"The orders specify the patient will receive 18 units/kg/hour via continuous infusion.  Again, the patient's dosing weight is 77.9 kg.  How many units per hour will CC receive?  Units/hour = (units/kg/hour) x (patient's weight) = units/hour (DO NOT ROUND).",206653,3,"d.	1500 units/hour",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62128,7,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",206654,0,"a.	28 ml/hour",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62128,7,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",206655,1,"b.	28.1 ml/hour",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62128,7,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",206656,2,"c.	27 ml/hour",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62128,7,"In order to deliver 1402.2 units/hour of heparin, the infusion pump should be set to deliver how many ml/hour?  The heparin drip dispensed from pharmacy is 25,000 units in 500 mL with a concentration of 50 units/mL. Round to the nearest 0.1mL per pump capabilities.",206657,3,"d.	30 ml/hour",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62129,8,"Prior to administration of a heparin bolus dose, the nurse should",206658,0,"a.	Verify the bolus dose calculations with a pharmacist or physician",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62129,8,"Prior to administration of a heparin bolus dose, the nurse should",206659,1,"b.	Read the medication label three times (drug name, concentration, and vial size)",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62129,8,"Prior to administration of a heparin bolus dose, the nurse should",206660,2,"c.	Confirm the amount in the syringe (both the dose in units, and volume in ml) with a second RN",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62129,8,"Prior to administration of a heparin bolus dose, the nurse should",206661,3,"d.	All of the above",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62130,9,Argatroban can be used in patients with Heparin-Induced Thrombocytopenia (HIT),206662,0,TRUE,1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62130,9,Argatroban can be used in patients with Heparin-Induced Thrombocytopenia (HIT),206663,1,FALSE,0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62131,10,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",206664,0,"a.	8000 mcg/hr",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62131,10,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",206665,1,"b.	9000 mcg/hr",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62131,10,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",206666,2,"c.	8220 mcg/hr",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62131,10,"11.	AA is a 55 year old female on a heparin infusion who develops severe thrombocytopenia with concern for HIT.  Her discontinues heparin and orders an argatroban infusion to begin 2 hours later. Her baseline anticoagulation labs are within normal limits and she has normal liver function. CC weighs 68.5kg and her initial argatroban infusion dose is 2 mcg/kg/min.  What is her initial infusion rate in mcg/hr (do not round)? Argatroban infusion rate ______ mcg/kg/min x ______kg x 60 = rate in mcg/hr",206667,3,"d.	8550 mcg/hr",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62175,11,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",206809,0,"a.	9 mL/hr",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62175,11,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",206810,1,"b.	8.5 mL/hr",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62175,11,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",206811,2,"c.	8.3 mL/hr",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62175,11,"In order to deliver 8220 mcg/hr of argatroban, the infusion pump should be set to deliver how many mL/hour?  The argatroban drip dispensed from pharmacy is 250mg in 250 mL with a concentration of 1000 mcg/mL. Round to the nearest 0.1mL per pump capabilities.",206812,3,"d.	8.2 mL.hr",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62176,12,The initials of the nurse performing calculations and the pharmacist (or physician) performing the independent double check must be recorded on the heparin or argatroban flow sheet.,206813,0,TRUE,1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62176,12,The initials of the nurse performing calculations and the pharmacist (or physician) performing the independent double check must be recorded on the heparin or argatroban flow sheet.,206814,1,FALSE,0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62177,13,"Pump settings must be verified and documented at all of the following except""¶",206815,0,"a.	Infusion initiation",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62177,13,"Pump settings must be verified and documented at all of the following except""¶",206816,1,"b.	Bag changes",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62177,13,"Pump settings must be verified and documented at all of the following except""¶",206817,2,"c.	Tubing changes",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62177,13,"Pump settings must be verified and documented at all of the following except""¶",206818,3,"d.	Rate changes",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62177,13,"Pump settings must be verified and documented at all of the following except""¶",206819,4,"e.	Shift changes",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62177,13,"Pump settings must be verified and documented at all of the following except""¶",206820,5,"f.	Therapeutic Anti-Xa/PTT values",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62178,14,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",206821,0,"a.	Contact the physician for additional instructions/orders",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62178,14,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",206822,1,"b.	Stop the infusion and recheck level in 6 hours",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62178,14,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",206823,2,"c.	Decrease the rate by  Ω and contact the physician",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62178,14,"If titration via the nomogram for heparin or argatroban cause the rate to decrease to 0 ml/hour, which of the following is the correct action?",206824,3,"d.	Continue the current rate and recheck level in 6 hours",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62179,15,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,206825,0,"a.	Take no action, no change is required to the infusion rate",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62179,15,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,206826,1,"b.	Document the correct dosing weight in the EMR and notify pharmacy",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62179,15,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,206827,2,"c.	Print a new flowsheet, write the correct dosing weight and re-calculate the infusion rate",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62179,15,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,206828,3,"d.	Cross out the incorrect weight on the current flowsheet and write the correct weight.",0
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62179,15,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,206829,4,"e.	B and C",1
9324,Elearning-0000-571,FY2021 HEPARIN AND ARGATROBAN INFUSION EDUCATION: NURSING AND PHARMACY,n13756,62179,15,A patient on a heparin or argatroban infusion is found to have an error in their dosing weight of 10kg. Which of the following is the correct action?,206830,5,"f.	B and D",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62132,0,"According to current Northside policy, which age group requires all medication orders to be double checked?",206668,0,"A.	< 1 year old",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62132,0,"According to current Northside policy, which age group requires all medication orders to be double checked?",206669,1,"B.	11 years and younger",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62132,0,"According to current Northside policy, which age group requires all medication orders to be double checked?",206670,2,"C.	12 years and younger",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62132,0,"According to current Northside policy, which age group requires all medication orders to be double checked?",206671,3,"D.	18 years and younger",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62133,1,What is the most common source of pediatric patient harm during medical treatment?,206672,0,"A.	Procedural technique errors",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62133,1,What is the most common source of pediatric patient harm during medical treatment?,206673,1,"B.	Delays in therapeutic management",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62133,1,What is the most common source of pediatric patient harm during medical treatment?,206674,2,"C.	Medication errors",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62133,1,What is the most common source of pediatric patient harm during medical treatment?,206675,3,"D.	Lack of clinical guidelines",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62134,2,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,206676,0,A. Surgery patients,1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62134,2,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,206677,1,B. ED patients,0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62134,2,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,206678,2,C. ICU patients,0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62134,2,Which pediatric patient group is NOT identified as being at the highest risk of experiencing a medication error?,206679,3,D. < 2 years old,0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62135,3,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",206680,0,"A.	2",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62135,3,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",206681,1,"B.	3",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62135,3,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",206682,2,"C.	4",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62135,3,"In one study, pediatric patients were at risk of a potentially dangerous prescribing error that was _____ times greater than adult patients.",206683,3,"D.	5",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62136,4,Which of the following is true about independent double checks?,206684,0,"A.	When done appropriately, double checks can decrease errors by 80%",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62136,4,Which of the following is true about independent double checks?,206685,1,"B.	Every situation requires two pharmacists to perform a double check",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62136,4,Which of the following is true about independent double checks?,206686,2,"C.	Only high risk medications require a double check",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62136,4,Which of the following is true about independent double checks?,206687,3,"D.	The first practitioner should not communicate their findings to the 2nd practitioner",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62137,5,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,206688,0,"A.	Some medications are not commercially available as a liquid",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62137,5,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,206689,1,"B.	Some commercially available products have unfavorable excipients",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62137,5,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,206690,2,"C.	Some commercially available products are too concentrated for smaller patients and infants",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62137,5,Which of the following contributes to concerns of providing pediatric patients with medications in liquid form?,206691,3,"D.	All of the above",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62138,6,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",206692,0,"A.	Acetaminophen",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62138,6,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",206693,1,"B.	Adrenals, corticosteroids",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62138,6,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",206694,2,"C.	Insulin",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62138,6,"Based on multiple studies, pediatric patients in the emergency department are at particularly high risk of errors related to:",206695,3,"D.	Opioids",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62139,7,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,206696,0,"A.	Adult and pediatric medications stored together",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62139,7,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,206697,1,"B.	Crowded pharmacy",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62139,7,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,206698,2,"C.	Staff distracted by their cell phone",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62139,7,Which of the following factors is thought to contribute to the medication error in the Emily Jerry case?,206699,3,"D.	New electronic medical record implementation",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62140,8,Which medication does Northside NICU further dilute to improve measurability?,206700,0,"A.	Carvedilol",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62140,8,Which medication does Northside NICU further dilute to improve measurability?,206701,1,"B.	Omeprazole",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62140,8,Which medication does Northside NICU further dilute to improve measurability?,206702,2,"C.	Baclofen",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62140,8,Which medication does Northside NICU further dilute to improve measurability?,206703,3,"D.	Propranolol",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62141,9,"What patient areas are excluded from the ""Pediatric Patient Alert""ù?",206704,0,"A.	NICU and Well Baby Nursery",1
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62141,9,"What patient areas are excluded from the ""Pediatric Patient Alert""ù?",206705,1,"B.	Main OR",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62141,9,"What patient areas are excluded from the ""Pediatric Patient Alert""ù?",206706,2,"C.	Labor and Delivery",0
9006,Elearning-0000-282,FY2021 PHARMACY NEONATAL AND PEDIATRIC MEDICATION COMPETENCY,n13757,62141,9,"What patient areas are excluded from the ""Pediatric Patient Alert""ù?",206707,3,"D.	Emergency Department",0
9021,Elearning-0000-296,ON-Q PUMP EDUCATION WSU FY21,n13763,62158,0,I have read and understand the FY21 On-Q Pump Education CBL.,206762,0,TRUE,1
9021,Elearning-0000-296,ON-Q PUMP EDUCATION WSU FY21,n13763,62158,0,I have read and understand the FY21 On-Q Pump Education CBL.,206763,1,FALSE,0
9549,Elearning-0000-776,NSC ICU BBRAUN 400 ES PUMP UPDATE,n13764,62159,0,"I have read the CBL in it's entirety.  I understand that if I have questions, I can contact a leadership team member.",206764,0,TRUE,1
9549,Elearning-0000-776,NSC ICU BBRAUN 400 ES PUMP UPDATE,n13764,62159,0,"I have read the CBL in it's entirety.  I understand that if I have questions, I can contact a leadership team member.",206765,1,FALSE,0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62160,0,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusing""¶",206766,0,"a.	The ICU nurse will see a task on Care Compass. b.	The task serves as a reminder to follow through with the new workflow c.	Do not complete the task until the infusion is complete and the end time is documented in the MAR.  d.	All of the above.",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62160,0,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusing""¶",206767,1,"b.	The task serves as a reminder to follow through with the new workflow",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62160,0,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusing""¶",206768,2,"c.	Do not complete the task until the infusion is complete and the end time is documented in the MAR.",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62160,0,"1.	Per the new workflow, when a patient arrives from the ED to the ICU with a sepsis bolus infusing""¶",206769,3,"d.	All of the above.",1
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62161,1,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusion""¶ a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)""ù box c.	Click Apply d.	Click on the blue ""Pending""ù box e.	Ensure that the ""to""ù time is updated for the end-time of the infusion bag",206770,0,"i.	a, b, c, d, e",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62161,1,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusion""¶ a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)""ù box c.	Click Apply d.	Click on the blue ""Pending""ù box e.	Ensure that the ""to""ù time is updated for the end-time of the infusion bag",206771,1,"ii.	a, d, b, e, c",1
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62161,1,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusion""¶ a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)""ù box c.	Click Apply d.	Click on the blue ""Pending""ù box e.	Ensure that the ""to""ù time is updated for the end-time of the infusion bag",206772,2,"iii.	a, c, b, d, e",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62161,1,"2.	Select the correct order of actions:  When the sepsis bolus that was begun in the ED is complete, to end the infusion""¶ a.	Go to the MAR and find your sepsis bolus order b.	Select the Infuse square and document the infused volume in the ""infuse volume (mL)""ù box c.	Click Apply d.	Click on the blue ""Pending""ù box e.	Ensure that the ""to""ù time is updated for the end-time of the infusion bag",206773,3,"iv.	a, e, d, b, c",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62162,2,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in either""¶",206774,0,"a.	Pre-Arrival IV fluid amount",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62162,2,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in either""¶",206775,1,"b.	Sepsis Bolus Continuous infusion",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62162,2,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in either""¶",206776,2,"c.	A and b",1
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62162,2,"3.	If the volume infused by the ED is not documented in I & O, document the volume of the sepsis bolus from the ED in either""¶",206777,3,"d.	None of the above",0
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62163,3,"4.	If a patient requires subsequent infusions to complete the total sepsis bolus dose, return to the normal process-start the bag in MAW and document the end time in Infusion Billing and the infused volume in I & O.",206778,0,TRUE,1
8902,Elearning-0000-188,NSC ICU SEPSIS BOLUS FROM THE ED TO ICU,n13765,62163,3,"4.	If a patient requires subsequent infusions to complete the total sepsis bolus dose, return to the normal process-start the bag in MAW and document the end time in Infusion Billing and the infused volume in I & O.",206779,1,FALSE,0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62164,0,"1.	The new standard maximum drip rate for Fentanyl is",206780,0,"a.	450 mcg/hr.",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62164,0,"1.	The new standard maximum drip rate for Fentanyl is",206781,1,"b.	250 mcg/hr.",1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62164,0,"1.	The new standard maximum drip rate for Fentanyl is",206782,2,"c.	500 mcg/hr.",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62164,0,"1.	The new standard maximum drip rate for Fentanyl is",206783,3,"d.	None of the above",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62165,1,"2.	Providers may modify drip max to allow for higher maximum to meet individual patient needs on either analgesic or sedative continuous infusions.",206784,0,TRUE,1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62165,1,"2.	Providers may modify drip max to allow for higher maximum to meet individual patient needs on either analgesic or sedative continuous infusions.",206785,1,FALSE,0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62166,2,"3.	You should contact the patient's provider if the patient is not at PAYEN or RASS goal and is at/approaching maximum rate to discuss changing maximum or adding other therapy.",206786,0,TRUE,1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62166,2,"3.	You should contact the patient's provider if the patient is not at PAYEN or RASS goal and is at/approaching maximum rate to discuss changing maximum or adding other therapy.",206787,1,FALSE,0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62167,3,"4.	The new standard maximum drip rate for Midazolam is",206788,0,"a.	250mcg/hr.",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62167,3,"4.	The new standard maximum drip rate for Midazolam is",206789,1,"b.	20mg/hr.",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62167,3,"4.	The new standard maximum drip rate for Midazolam is",206790,2,"c.	10mg/hr.",1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62167,3,"4.	The new standard maximum drip rate for Midazolam is",206791,3,"d.	None of the above",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62168,4,"5.	For patients that are on analgesic and sedative infusions, a Ketamine loading dose may not be required.",206792,0,TRUE,1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62168,4,"5.	For patients that are on analgesic and sedative infusions, a Ketamine loading dose may not be required.",206793,1,FALSE,0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62169,5,"6.	All Ketamine drips will be linked to an order for Midazolam for emergence reactions.",206794,0,TRUE,1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62169,5,"6.	All Ketamine drips will be linked to an order for Midazolam for emergence reactions.",206795,1,FALSE,0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62170,6,"7.	Per the new orders, a physician may not choose between",206796,0,"a.	Fixed rate infusion of Ketamine",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62170,6,"7.	Per the new orders, a physician may not choose between",206797,1,"b.	Titratable infusion of Ketamine",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62170,6,"7.	Per the new orders, a physician may not choose between",206798,2,"c.	All of the above",1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62171,7,"8.	If titratable ketamine infusion is ordered, stop titrating all previously ordered infusions for that same indication.",206799,0,TRUE,1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62171,7,"8.	If titratable ketamine infusion is ordered, stop titrating all previously ordered infusions for that same indication.",206800,1,FALSE,0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62172,8,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",206801,0,"a.	Hallucinations",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62172,8,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",206802,1,"b.	Confusion, delirium",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62172,8,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",206803,2,"c.	Combativeness, irrational behavior",0
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62172,8,"9.	Psychotomimetic effects induced by the emergence from Ketamine (e.g. downward titration of a ketamine infusion) include",206804,3,"d.	All of the above",1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62173,9,"10.	I have read the information on ICU Sedative and Analgesic Drip Updates in its entirety.  I understand that if I have questions, I can ask an ICU leadership team member.",206805,0,TRUE,1
9250,Elearning-0000-504,NSC ICU KETAMINE INFUSIONS AND NEW SEDATIVE ANALGESIA DRIP MAXES 2021,n13766,62173,9,"10.	I have read the information on ICU Sedative and Analgesic Drip Updates in its entirety.  I understand that if I have questions, I can ask an ICU leadership team member.",206806,1,FALSE,0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62180,0,What is the maximum amount of time a Bronchoscope should soak?,206831,0,"a.	2 hours",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62180,0,What is the maximum amount of time a Bronchoscope should soak?,206832,1,"b.	1 hour",1
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62180,0,What is the maximum amount of time a Bronchoscope should soak?,206833,2,"c.	24 hours",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62180,0,What is the maximum amount of time a Bronchoscope should soak?,206834,3,"d.	30 minutes",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62181,1,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,206835,0,"a.	To help document the time it took to finished the procedure",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62181,1,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,206836,1,"b.	To document the time it took to do the pre-cleaning",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62181,1,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,206837,2,"c.	There is no point to put the time on the bag.",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62181,1,What is the purpose of writing the time of pre-cleaning on the top of the dirty scope bag?,206838,3,"d.	To help ensure the scope is reprocessed with the 60 minute window per the FDA in order the minimize risk of infection for patients?",1
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62182,2,What is the minimum amount of time an ERCP scope should be soaked?,206839,0,"a.	 2 hours",1
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62182,2,What is the minimum amount of time an ERCP scope should be soaked?,206840,1,"b.	10 hours",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62182,2,What is the minimum amount of time an ERCP scope should be soaked?,206841,2,"c.	1 hours",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62182,2,What is the minimum amount of time an ERCP scope should be soaked?,206842,3,"d.	24 hours",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62183,3,What is the maximum of amount time any scope should be soaked?,206843,0,"a.	2 hours",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62183,3,What is the maximum of amount time any scope should be soaked?,206844,1,"b.	10 hours",1
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62183,3,What is the maximum of amount time any scope should be soaked?,206845,2,"c.	1 hour",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62183,3,What is the maximum of amount time any scope should be soaked?,206846,3,"d.	24 hours",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62184,4,What does intercept foam do?,206847,0,"a.	Intercept foam cleans the scope",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62184,4,What does intercept foam do?,206848,1,"b.	Intercept foam kill the bacteria?",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62184,4,What does intercept foam do?,206849,2,"c.	Intercept foam replaces the pre-cleaning process?",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62184,4,What does intercept foam do?,206850,3,"d.	Intercept foam used according to the IFU's protects the inside and outside of the scope from the formation of Biofilm up to 72 hours.",1
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62185,5,What is the correct product to soak the scope in for delayed reprocessing?,206851,0,"a.	Water",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62185,5,What is the correct product to soak the scope in for delayed reprocessing?,206852,1,"b.	Cidex",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62185,5,What is the correct product to soak the scope in for delayed reprocessing?,206853,2,"c.	Cotton Candy",0
9427,Elearning-0000-665,DELAYED REPROCESSING,n13768,62185,5,What is the correct product to soak the scope in for delayed reprocessing?,206854,3,"d.	Diluted Enzol",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62187,0,Acute Coronary Syndrome include all the following except:,206857,0,"a.	STEMI",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62187,0,Acute Coronary Syndrome include all the following except:,206858,1,"b.	Aortic Dissection",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62187,0,Acute Coronary Syndrome include all the following except:,206859,2,"c.	NSTEMI",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62187,0,Acute Coronary Syndrome include all the following except:,206860,3,"d.	Unstable Angina",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62188,1,True/False: In hospital STEMI results in improved outcomes vs outpatient STEMI's.,206861,0,TRUE,0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62188,1,True/False: In hospital STEMI results in improved outcomes vs outpatient STEMI's.,206862,1,FALSE,1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62189,2,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,206863,0,"a.	Coronary plaque erosion",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62189,2,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,206864,1,"b.	Coronary plaque rupture (plaque rupture and plaque erosion can result in thrombosis. STEMI is most often from coronary thrombosis after plaque rupture and less often from fixed obstruction)",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62189,2,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,206865,2,"c.	Coronary plaque progression causing progressive stenosis",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62189,2,Which of the following best describes the most common pathophysiologic mechanism present during ST segment elevation myocardial infarction?,206866,3,"d.	Coronary Vasospasm",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62190,3,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",206867,0,"a.	Start an IV",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62190,3,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",206868,1,"b.	Call the physician",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62190,3,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",206869,2,"c. 	Obtain a 12 lead ECG",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62190,3,"Your patient presents with nagging epigastric pain that has worsened over the day without relieve from Tums.  Your patient is female, no other symptoms reported and has diabetes.  What is the most important next steps?",206870,3,"d.	Obtain Vital Signs",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62191,4,True/False: A New left bundle branch block (LBBB) may be considered a STEMI,206871,0,TRUE,1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62191,4,True/False: A New left bundle branch block (LBBB) may be considered a STEMI,206872,1,FALSE,0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62192,5,NSTEMI may present with ST depression including T wave inversion which means?,206873,0,"a.	Partial occlusion of major coronary artery",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62192,5,NSTEMI may present with ST depression including T wave inversion which means?,206874,1,"b.	Complete occlusion of major coronary artery",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62192,5,NSTEMI may present with ST depression including T wave inversion which means?,206875,2,"c.	Sustained Coronary Spasms",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62192,5,NSTEMI may present with ST depression including T wave inversion which means?,206876,3,"d.	Normal coronary artery flow",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62193,6,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,206877,0,"a.	Septal Wall",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62193,6,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,206878,1,"b.	Inferior Wall",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62193,6,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,206879,2,"c.	Anterior Wall",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62193,6,Your patient is showing ECG changes in Leads V3 - V6.  Which walls of the heart are being affected?,206880,3,"d.	Anterior/Lateral Wall",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62194,7,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,206881,0,"a.	120 minutes",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62194,7,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,206882,1,"b.	60 minutes",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62194,7,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,206883,2,"c.	90 minutes",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62194,7,A patient presents to the ED and is a confirmed STEMI.  What is the standard time for FMC to Balloon?,206884,3,"d.	75 minutes",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62195,8,True/False: A patient comes to the ED with chest pain but the 12 ECG does not show a STEMI.  This is conclusive that there is no further evaluation needed.,206885,0,TRUE,0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62195,8,True/False: A patient comes to the ED with chest pain but the 12 ECG does not show a STEMI.  This is conclusive that there is no further evaluation needed.,206886,1,FALSE,1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62196,9,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,206887,0,"a.	Heart Failure Clinic Referral",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62196,9,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,206888,1,"b.	Cardiac Rehab Referral",1
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62196,9,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,206889,2,"c.	Coumadin Clinic Referral",0
9744,Elearning-0000-953,FY2021 ACUTE CORONARY SYNDROME,n13770,62196,9,Based on American Heart Get with the Guidelines - CAD; patient who have had a STEMI with PCI should go home with:,206890,3,"d.	Cardiology Referral",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62246,0,Which two leads would reveal an anterior wall MI?,207088,0,"a.	V1 and V2",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62246,0,Which two leads would reveal an anterior wall MI?,207089,1,"b.	Leads I, II and AVF",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62246,0,Which two leads would reveal an anterior wall MI?,207090,2,"c.	V3 and V4",1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62246,0,Which two leads would reveal an anterior wall MI?,207091,3,"d.	V5 and V6",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62247,1,Any metformin containing medication must be held only for 3 days post procedure.,207092,0,a. True,0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62247,1,Any metformin containing medication must be held only for 3 days post procedure.,207093,1,b. False,1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62248,2,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",207094,0,"a.	Vasovagal",1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62248,2,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",207095,1,"b.	Retroperitoneal bleed",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62248,2,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",207096,2,"c.	Dehydration",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62248,2,"The sheath has just been pulled and your patient has become very diaphoretic, BP and HR has dropped.  What is the most likely cause:",207097,3,"d.	Ventricular arrhythmia",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62249,3,When should ACE inhibitors be prescribed for PCI patients:,207098,0,"a.	Indefinitely with heart failure, LV dysfunction with LVEF <40%, hypertension, or diabetes",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62249,3,When should ACE inhibitors be prescribed for PCI patients:,207099,1,"b.	Absence of LV dysfunction, hypertension or diabetes",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62249,3,When should ACE inhibitors be prescribed for PCI patients:,207100,2,"c.	HF with LVEF of >40%",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62249,3,When should ACE inhibitors be prescribed for PCI patients:,207101,3,"d.	All of the above",1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62250,4,Reversal for heparin,207102,0,"a.	Platelet infusion",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62250,4,Reversal for heparin,207103,1,"b.	Protamine",1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62250,4,Reversal for heparin,207104,2,"c.	No available reversal agent",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62250,4,Reversal for heparin,207105,3,"d.	Naloxone",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62251,5,Reopro (abciximab) can be administered up to 8 hours post PCI procedure.,207106,0,a. True,0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62251,5,Reopro (abciximab) can be administered up to 8 hours post PCI procedure.,207107,1,b. False,1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62252,6,Heparin is compatible with amiodarone and can be infused through the same IV line.,207108,0,a. True,0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62252,6,Heparin is compatible with amiodarone and can be infused through the same IV line.,207109,1,b. False,1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62253,7,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,207110,0,"a.	Continue to monitor",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62253,7,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,207111,1,"b.	Get a 12-lead ECG",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62253,7,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,207112,2,"c.	Perform more frequent VS",0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62253,7,The patient has unrelieved Chest Pain post PCI despite analgesia; the nurse should:,207113,3,"d.	Notify the Medical Team",1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62254,8,A pseudoaneurysm is typically associated with Inadequate compression after sheath removal and hemostasis,207114,0,a. True,1
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62254,8,A pseudoaneurysm is typically associated with Inadequate compression after sheath removal and hemostasis,207115,1,b. False,0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62255,9,"Upon Discharge, it is important that the patient receive the following information",207116,0,a. Test result,0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62255,9,"Upon Discharge, it is important that the patient receive the following information",207117,1,b. Follow up appointment(s),0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62255,9,"Upon Discharge, it is important that the patient receive the following information",207118,2,c. Aware of smoking risk,0
9700,Elearning-0000-913,CARE OF THE PATIENT PRE AND POST CARDIAC CATHETERIZATION AND PCI,n13775,62255,9,"Upon Discharge, it is important that the patient receive the following information",207119,3,d. All of the above,1
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62314,0,Please list the location for this activity.,207347,0,Atlanta,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62314,0,Please list the location for this activity.,207348,1,Cherokee,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62314,0,Please list the location for this activity.,207349,2,Forsyth,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62314,0,Please list the location for this activity.,207350,3,Other,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62315,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",207351,0,Strongly Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62315,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",207352,1,Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62315,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",207353,2,No Opinion,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62315,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",207354,3,Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62315,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",207355,4,Strongly Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62316,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207356,0,Strongly Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62316,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207357,1,Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62316,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207358,2,No Opinion,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62316,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207359,3,Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62316,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207360,4,Strongly Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62317,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,207361,0,Strongly Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62317,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,207362,1,Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62317,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,207363,2,No Opinion,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62317,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,207364,3,Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62317,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,207365,4,Strongly Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62318,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,207366,0,Strongly Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62318,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,207367,1,Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62318,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,207368,2,No Opinion,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62318,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,207369,3,Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62318,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,207370,4,Strongly Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62319,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207371,0,Strongly Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62319,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207372,1,Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62319,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207373,2,No Opinion,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62319,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207374,3,Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62319,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207375,4,Strongly Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62320,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207376,0,Strongly Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62320,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207377,1,Agree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62320,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207378,2,No Opinion,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62320,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207379,3,Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62320,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207380,4,Strongly Disagree,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62321,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",207381,0,Excellent,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62321,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",207382,1,Very Good,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62321,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",207383,2,Good,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62321,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",207384,3,Fair,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62321,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",207385,4,Poor,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62322,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",207386,0,Excellent,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62322,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",207387,1,Very Good,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62322,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",207388,2,Good,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62322,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",207389,3,Fair,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62322,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",207390,4,Poor,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62323,9,"Overall, this activity was:",207391,0,Excellent,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62323,9,"Overall, this activity was:",207392,1,Very Good,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62323,9,"Overall, this activity was:",207393,2,Good,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62323,9,"Overall, this activity was:",207394,3,Fair,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62323,9,"Overall, this activity was:",207395,4,Poor,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62324,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207396,0,Yes,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62324,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207397,1,No,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62324,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207398,2,N/A,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62327,13,How would you improve this class?,207399,0,Reduce content covered in class,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62327,13,How would you improve this class?,207400,1,Increase content covered in class,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62327,13,How would you improve this class?,207401,2,Update content covered in class,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62327,13,How would you improve this class?,207402,3,Improve the instructional methods,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62327,13,How would you improve this class?,207403,4,Make course activities more stimulating,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62327,13,How would you improve this class?,207404,5,Slow the pace of the class,0
9946,Questions-0000-80,"NSF INFUSION CENTER JOURNAL CLUB - JUNE 3RD, 2021 (EVALUATION SURVEY)",n13779,62327,13,How would you improve this class?,207405,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9613,Elearning-0000-834,FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS,n13780,62330,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207406,0,TRUE,1
9613,Elearning-0000-834,FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS,n13780,62330,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR NURSING AND MONITOR TECHS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207407,1,FALSE,0
9671,Elearning-0000-887,FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE,n13781,62331,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207408,0,TRUE,1
9671,Elearning-0000-887,FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE,n13781,62331,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 TELEMETRY AND ALARMS FOR THE ICU NURSE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207409,1,FALSE,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62332,0,Please list the location for this activity.,207410,0,Atlanta,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62332,0,Please list the location for this activity.,207411,1,Forsyth,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62332,0,Please list the location for this activity.,207412,2,Cherokee,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62332,0,Please list the location for this activity.,207413,3,Other,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62333,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",207414,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62333,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",207415,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62333,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",207416,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62333,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",207417,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62333,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",207418,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62334,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",207419,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62334,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",207420,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62334,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",207421,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62334,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",207422,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62334,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",207423,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62335,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",207424,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62335,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",207425,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62335,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",207426,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62335,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",207427,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62335,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",207428,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62336,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",207429,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62336,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",207430,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62336,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",207431,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62336,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",207432,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62336,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",207433,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62337,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",207434,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62337,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",207435,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62337,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",207436,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62337,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",207437,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62337,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",207438,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62338,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",207439,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62338,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",207440,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62338,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",207441,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62338,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",207442,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62338,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",207443,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62339,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",207444,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62339,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",207445,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62339,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",207446,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62339,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",207447,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62339,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",207448,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62340,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207449,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62340,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207450,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62340,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207451,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62340,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207452,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62340,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207453,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62341,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,207454,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62341,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,207455,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62341,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,207456,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62341,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,207457,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62341,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,207458,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62342,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207459,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62342,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207460,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62342,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207461,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62342,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207462,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62342,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207463,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62343,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207464,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62343,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207465,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62343,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207466,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62343,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207467,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62343,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",207468,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62344,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,207469,0,Strongly Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62344,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,207470,1,Agree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62344,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,207471,2,No Opinion,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62344,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,207472,3,Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62344,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,207473,4,Strongly Disagree,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62345,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",207474,0,Excellent,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62345,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",207475,1,Very Good,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62345,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",207476,2,Good,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62345,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",207477,3,Fair,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62345,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",207478,4,Poor,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62346,14,"Overall, this activity was:",207479,0,Excellent,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62346,14,"Overall, this activity was:",207480,1,Very Good,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62346,14,"Overall, this activity was:",207481,2,Good,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62346,14,"Overall, this activity was:",207482,3,Fair,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62346,14,"Overall, this activity was:",207483,4,Poor,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62347,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207484,0,Yes,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62347,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207485,1,No,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62347,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207486,2,N/A,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62350,18,How would you improve this class?,207487,0,Reduce content covered in class,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62350,18,How would you improve this class?,207488,1,Increase content covered in class,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62350,18,How would you improve this class?,207489,2,Update content covered in class,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62350,18,How would you improve this class?,207490,3,Improve the instructional methods,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62350,18,How would you improve this class?,207491,4,Make course activities more stimulating,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62350,18,How would you improve this class?,207492,5,Slow the pace of the class,0
9951,Questions-0000-85,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-9-21,n13782,62350,18,How would you improve this class?,207493,6,"Nothing: (appropriate content, speaker, setting, setting.)",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62353,0,"True/False - Complex Regional Pain Syndrome (CRPS) is a form of chronic pain that usually affects an arm or a leg. It typically happens after an injury, surgery, stroke, or hear attack.",207495,0,TRUE,1
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62353,0,"True/False - Complex Regional Pain Syndrome (CRPS) is a form of chronic pain that usually affects an arm or a leg. It typically happens after an injury, surgery, stroke, or hear attack.",207494,1,FALSE,0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62354,1,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,207496,0,"a.	CRPS I occurs after an illness or injury that directly damaged the nerves in the affected limb",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62354,1,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,207499,1,"b.	CRPS II occurs after an illness or injury that directly damaged the nerves in the affected limb",1
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62354,1,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,207497,2,"c.	CRPS I only occurs at birth",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62354,1,CRPS is classified into two categories: CRPS-I and CRPS-II. The main difference between the two categories is:,207498,3,"d.	CRPS II only occurs later in life",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62355,2,True/False - Every patient with CRPS presents with the same symptoms and follows the same treatment plan.,207500,0,TRUE,0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62355,2,True/False - Every patient with CRPS presents with the same symptoms and follows the same treatment plan.,207501,1,FALSE,1
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62356,3,"True/False - Prior to surgery, the surgeon should discuss the pain management plan with the patient and document in the H&P.",207503,0,TRUE,1
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62356,3,"True/False - Prior to surgery, the surgeon should discuss the pain management plan with the patient and document in the H&P.",207502,1,FALSE,0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207504,0,"a.	Medications (e.g. NSAIDS, oioids, corticosteroids, antidepressants, etc.)",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207505,1,"b.	Heat therapy",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207506,2,"c.	Cold therapy",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207507,3,"d.	Physical therapy",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207508,4,"e.	There are no treatment options for CRPS",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207509,5,"f.	All of the above",0
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207511,6,"g.	A, B, D only",1
9449,Elearning-0000-685,FY2021 COMPLEX REGIONAL PAIN SYNDROME: NURSING,n13783,62357,4,Treatment options for CRPS include:,207510,7,"h.	A, B, C, D only",0
9414,Elearning-0000-653,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13786,62360,0,ECMO is a new support system and has only been around for 10 years.,207516,0,TRUE,0
9414,Elearning-0000-653,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13786,62360,0,ECMO is a new support system and has only been around for 10 years.,207517,1,FALSE,1
9414,Elearning-0000-653,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13786,62361,1,Venovenous (VV) ECMO only supports the heart.,207518,0,TRUE,0
9414,Elearning-0000-653,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13786,62361,1,Venovenous (VV) ECMO only supports the heart.,207519,1,FALSE,1
9414,Elearning-0000-653,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13786,62362,2,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",207520,0,TRUE,1
9414,Elearning-0000-653,FY2021 ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13786,62362,2,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",207521,1,FALSE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62363,0,"Two random controlled trials have been utilized to justify the efficacy of ECMO in the adult respiratory population, those are called the CESAR and EOLIA Trials.",207522,0,TRUE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62363,0,"Two random controlled trials have been utilized to justify the efficacy of ECMO in the adult respiratory population, those are called the CESAR and EOLIA Trials.",207523,1,FALSE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62364,1,"A patient with a PaO2 of 160, Murray score of 2, and peep of 5 would make a good candidate for ECMO.",207524,0,TRUE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62364,1,"A patient with a PaO2 of 160, Murray score of 2, and peep of 5 would make a good candidate for ECMO.",207525,1,FALSE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62365,2,There are no absolute contraindications to ECLS.,207526,0,TRUE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62365,2,There are no absolute contraindications to ECLS.,207527,1,FALSE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62366,3,The basic goal(s) of VV ECMO management include:,207528,0,"Using High peep, High Oxygen, and the use of iNO",0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62366,3,The basic goal(s) of VV ECMO management include:,207529,1,"Decrease further lung damage, Reduce oxygen toxicity, and provide lung rest",1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62366,3,The basic goal(s) of VV ECMO management include:,207530,2,Use very high ECMO flows to support the work of the heart,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62367,4,Optimal ventilator while on VV ECMO are:,207531,0,"Rate=15, PIP=30, PEEP=10, FiO2=40%",0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62367,4,Optimal ventilator while on VV ECMO are:,207532,1,"Rate=25, PIP=25, Peep=20, FiO2=30%",0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62367,4,Optimal ventilator while on VV ECMO are:,207533,2,"Rate=10, PIP=15, Peep=15, FiO2=21%",0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62367,4,Optimal ventilator while on VV ECMO are:,207534,3,"Rate=10, PIP=10, Peep=10, Fio2=40%",1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62368,5,A SaO2 of 85% and a PaO2 of 50 is acceptable on VV ECMO.,207535,0,TRUE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62368,5,A SaO2 of 85% and a PaO2 of 50 is acceptable on VV ECMO.,207536,1,FALSE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62369,6,"Depending on the patient's condition, the patient will not always be on ""rest vent settings""ù while on VA ECMO.",207537,0,TRUE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62369,6,"Depending on the patient's condition, the patient will not always be on ""rest vent settings""ù while on VA ECMO.",207538,1,FALSE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62370,7,"While on ECMO, CO2 removal is controlled by the ECMO blood flow.",207539,0,TRUE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62370,7,"While on ECMO, CO2 removal is controlled by the ECMO blood flow.",207540,1,FALSE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62371,8,"While on ECMO, Oxygenation is controlled by the ECMO Sweep gas.",207541,0,TRUE,0
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62371,8,"While on ECMO, Oxygenation is controlled by the ECMO Sweep gas.",207542,1,FALSE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62372,9,Routine ventilator changes are not made unless ECMO and Critical Care Physicians are notified.,207543,0,TRUE,1
9412,Elearning-0000-651,FY2021 ECMO RESPIRATORY CARE SPECIFIC,n13788,62372,9,Routine ventilator changes are not made unless ECMO and Critical Care Physicians are notified.,207544,1,FALSE,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62378,0,I have read and understood the content within the Philips Monitor IntelliVue Education CBL.,207563,0,TRUE,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62378,0,I have read and understood the content within the Philips Monitor IntelliVue Education CBL.,207564,1,FALSE,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62384,1,The X3 (small brain) on the back of the monitors can be undocked to utilize as a handheld monitor.,207575,0,TRUE,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62384,1,The X3 (small brain) on the back of the monitors can be undocked to utilize as a handheld monitor.,207576,1,FALSE,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62385,2,Sheila is performing a CSAT and gets a phone call from Admission team. She can barely hear what the nurse is saying on the phone. Sheila should turn the volume down on the Philips Monitor.,207577,0,TRUE,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62385,2,Sheila is performing a CSAT and gets a phone call from Admission team. She can barely hear what the nurse is saying on the phone. Sheila should turn the volume down on the Philips Monitor.,207578,1,FALSE,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62386,3,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",207579,0,1,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62386,3,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",207580,1,2,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62386,3,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",207581,2,3,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62386,3,"Baby Girl Williams has a heart rate of 77. The Philips Monitor starts alarming and Vanessa, the anchor, silences the alarm. The monitor will alarm again in ______ minute(s) if the event continues.",207582,3,5,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62387,4,The Philips Monitor defaults as Profile ______ .,207583,0,Neo,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62387,4,The Philips Monitor defaults as Profile ______ .,207584,1,Car,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62387,4,The Philips Monitor defaults as Profile ______ .,207585,2,Pedi,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62387,4,The Philips Monitor defaults as Profile ______ .,207586,3,CCHD,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62388,5,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",207587,0,"Click ""Stop Car""ù and allow Monique to utilize the Philips Monitor.",0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62388,5,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",207588,1,"Click ""End Case""ù, obtain vitals, and allow Monique to utilize the Philips Monitor.",0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62388,5,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",207589,2,"Obtain vitals, click ""End Case""ù, and allow Monique to utilize the Philips Monitor.",1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62388,5,"Sarah, 5WA Anchor, has just completed the CSAT on Baby Boy Brown, but has not documented vitals in Cerner. Monique, 5WB Anchor, asks for the Philips Monitor to complete a CSAT on a baby. What should Sarah do?",207590,3,Allow Monique to utilize the Philips Monitor and obtain vitals afterwards.,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62389,6,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207591,0,Main Setup,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62389,6,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207592,1,Vitals Trend,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62389,6,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207593,2,Event Review,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62389,6,Anchor Nurse Tiffany wants to see all vitals (normal and abnormal) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207594,3,Profiles,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62390,7,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207595,0,Main Setup,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62390,7,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207596,1,Vitals Trend,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62390,7,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207597,2,Event Review,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62390,7,Anchor Nurse Carmen wants to see only abnormal vitals (life-threatening and non-life-threatening) that has occurred the past 30 minutes. What Smart Key should Tiffany utilize to access this feature?,207598,3,Profiles,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62391,8,"The Smart Key ""Start Car""ù defaults as ______ minutes duration.",207599,0,30,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62391,8,"The Smart Key ""Start Car""ù defaults as ______ minutes duration.",207600,1,60,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62391,8,"The Smart Key ""Start Car""ù defaults as ______ minutes duration.",207601,2,90,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62391,8,"The Smart Key ""Start Car""ù defaults as ______ minutes duration.",207602,3,120,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62392,9,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car""ù Smart Key?",207603,0,Ensure that the Profile is set to Profile Car.,1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62392,9,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car""ù Smart Key?",207604,1,Ensure that the alarm volume has been reduced to 3.,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62392,9,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car""ù Smart Key?",207605,2,Ensure that the Profile is set to Profile Neo.,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62392,9,"Anchor Nurse Maria is getting ready to begin a CSAT. What is the FIRST thing she should do before initiating the ""Start Car""ù Smart Key?",207606,3,Ensure that the timer is set to 60 minutes.,0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62393,10,What is the indicator for each alarm?,207607,0,Yellow (inoperable); red (life-threatening events); blue (non-life-threatening events),0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62393,10,What is the indicator for each alarm?,207608,1,Yellow (non-life-threatening events); red (life-threatening events); blue (inoperable),1
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62393,10,What is the indicator for each alarm?,207609,2,Yellow (life-threatening events); red (non-life-threatening events); blue (inoperable),0
284,SCORM-0000-94,PHILIPS MONITOR INTELLIVUE EDUCATION,n13787,62393,10,What is the indicator for each alarm?,207610,3,Yellow (non-life-threatening events); red (inoperable); blue (life-threatening events),0
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62379,0,ECMO is a new support system and has only been around for 10 years.,207565,0,TRUE,0
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62379,0,ECMO is a new support system and has only been around for 10 years.,207566,1,FALSE,1
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62380,1,Venovenous (VV) ECMO only supports the heart.,207567,0,TRUE,0
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62380,1,Venovenous (VV) ECMO only supports the heart.,207568,1,FALSE,1
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62381,2,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",207569,0,TRUE,1
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62381,2,"There are many different indications for ECMO, including but not limited to: Flu, Covid-19, Asthma, Heart Attack, Cardiogenic Shock, and Septic Shock",207570,1,FALSE,0
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62382,3,The ICU nurse will be responsible for documenting the head to toe assessment as well as documenting on the ECMO flowsheet.,207571,0,TRUE,0
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62382,3,The ICU nurse will be responsible for documenting the head to toe assessment as well as documenting on the ECMO flowsheet.,207572,1,FALSE,1
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62383,4,There will always be an ECMO designee at the bedside and an ECMO physician in close proximity to the patient.,207573,0,TRUE,1
9413,Elearning-0000-652,FY2021 ICU ECMO: EXTRACORPOREAL MEMBRANE OXYGENATION,n13789,62383,4,There will always be an ECMO designee at the bedside and an ECMO physician in close proximity to the patient.,207574,1,FALSE,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62628,0,Please list the location for this activity.,208491,0,Atlanta,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62628,0,Please list the location for this activity.,208492,1,Cherokee,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62628,0,Please list the location for this activity.,208493,2,Forsyth,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62628,0,Please list the location for this activity.,208494,3,Other,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62629,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208495,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62629,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208496,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62629,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208497,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62629,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208498,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62629,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208499,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62630,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208500,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62630,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208501,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62630,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208502,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62630,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208503,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62630,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208504,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62631,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208505,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62631,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208506,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62631,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208507,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62631,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208508,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62631,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208509,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62632,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208510,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62632,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208511,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62632,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208512,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62632,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208513,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62632,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208514,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62633,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208515,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62633,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208516,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62633,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208517,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62633,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208518,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62633,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208519,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62634,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208520,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62634,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208521,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62634,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208522,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62634,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208523,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62634,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208524,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62635,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208525,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62635,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208526,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62635,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208527,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62635,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208528,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62635,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208529,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62636,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208530,0,Strongly Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62636,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208531,1,Agree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62636,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208532,2,No Opinion,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62636,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208533,3,Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62636,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208534,4,Strongly Disagree,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62637,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",208535,0,Excellent,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62637,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",208536,1,Very Good,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62637,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",208537,2,Good,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62637,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",208538,3,Fair,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62637,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",208539,4,Poor,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62637,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",208540,5,N/A,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62638,10,"Overall, this activity was:",208541,0,Excellent,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62638,10,"Overall, this activity was:",208542,1,Very Good,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62638,10,"Overall, this activity was:",208543,2,Good,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62638,10,"Overall, this activity was:",208544,3,Fair,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62638,10,"Overall, this activity was:",208545,4,Poor,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62639,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208546,0,Yes,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62639,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208547,1,No,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62639,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208548,2,N/A,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62642,14,How would you improve this class (check all that apply)?,208549,0,Reduce content covered in class,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62642,14,How would you improve this class (check all that apply)?,208550,1,Increase content covered in class,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62642,14,How would you improve this class (check all that apply)?,208551,2,Update content covered in class,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62642,14,How would you improve this class (check all that apply)?,208552,3,Improve the instructional methods,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62642,14,How would you improve this class (check all that apply)?,208553,4,Make course activities more stimulating,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62642,14,How would you improve this class (check all that apply)?,208554,5,Slow the pace of the class,0
9901,Questions-0000-35,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 5-28-21,n13847,62642,14,How would you improve this class (check all that apply)?,208555,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9513,Elearning-0000-743,C-401 VERSION 3.0,n13792,62404,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",207634,0,TRUE,1
9513,Elearning-0000-743,C-401 VERSION 3.0,n13792,62404,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",207635,1,FALSE,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62445,0,Please list the location for this activity.,207796,0,Atlanta,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62445,0,Please list the location for this activity.,207797,1,Cherokee,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62445,0,Please list the location for this activity.,207798,2,Forsyth,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62445,0,Please list the location for this activity.,207799,3,Other,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62446,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207800,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62446,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207801,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62446,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207802,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62446,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207803,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62446,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207804,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62447,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207805,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62447,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207806,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62447,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207807,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62447,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207808,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62447,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207809,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62448,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207810,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62448,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207811,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62448,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207812,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62448,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207813,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62448,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207814,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62449,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207815,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62449,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207816,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62449,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207817,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62449,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207818,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62449,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207819,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62450,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207820,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62450,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207821,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62450,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207822,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62450,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207823,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62450,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207824,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62451,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207825,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62451,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207826,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62451,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207827,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62451,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207828,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62451,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207829,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62452,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207830,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62452,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207831,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62452,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207832,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62452,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207833,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62452,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207834,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62453,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207835,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62453,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207836,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62453,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207837,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62453,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207838,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62453,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207839,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62454,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207840,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62454,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207841,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62454,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207842,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62454,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207843,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62454,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207844,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62455,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,207845,0,Strongly Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62455,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,207846,1,Agree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62455,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,207847,2,No Opinion,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62455,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,207848,3,Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62455,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,207849,4,Strongly Disagree,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62456,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207851,0,Very Good,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62456,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207852,1,Good,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62456,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207853,2,Fair,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62456,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207854,3,Poor,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62456,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207850,4,Excellent,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62456,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207855,5,N/A,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62457,12,"Overall, this activity was:",207856,0,Excellent,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62457,12,"Overall, this activity was:",207857,1,Very Good,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62457,12,"Overall, this activity was:",207858,2,Good,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62457,12,"Overall, this activity was:",207859,3,Fair,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62457,12,"Overall, this activity was:",207860,4,Poor,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62458,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207861,0,Yes,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62458,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207862,1,No,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62458,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207863,2,N/A,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62461,16,How would you improve this class (check all that apply)?,207864,0,Reduce content covered in class,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62461,16,How would you improve this class (check all that apply)?,207865,1,Increase content covered in class,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62461,16,How would you improve this class (check all that apply)?,207866,2,Update content covered in class,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62461,16,How would you improve this class (check all that apply)?,207867,3,Improve the instructional methods,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62461,16,How would you improve this class (check all that apply)?,207868,4,Make course activities more stimulating,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62461,16,How would you improve this class (check all that apply)?,207869,5,Slow the pace of the class,0
9914,Questions-0000-48,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 5-28-21",n13795,62461,16,How would you improve this class (check all that apply)?,207870,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62405,0,Please list the location for this activity.,207636,0,Atlanta,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62405,0,Please list the location for this activity.,207637,1,Cherokee,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62405,0,Please list the location for this activity.,207638,2,Forsyth,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62405,0,Please list the location for this activity.,207639,3,Other,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62406,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207640,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62406,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207641,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62406,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207642,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62406,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207643,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62406,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",207644,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62407,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207645,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62407,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207646,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62407,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207647,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62407,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207648,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62407,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",207649,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62408,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207650,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62408,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207651,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62408,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207652,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62408,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207653,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62408,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",207654,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62409,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207655,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62409,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207656,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62409,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207657,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62409,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207658,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62409,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",207659,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62410,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",207660,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62410,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",207661,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62410,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",207662,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62410,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",207663,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62410,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",207664,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62411,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",207665,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62411,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",207666,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62411,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",207667,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62411,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",207668,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62411,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",207669,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62412,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",207670,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62412,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",207671,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62412,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",207672,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62412,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",207673,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62412,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",207674,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62413,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",207675,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62413,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",207676,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62413,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",207677,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62413,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",207678,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62413,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",207679,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62414,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207680,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62414,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207681,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62414,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207682,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62414,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207683,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62414,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207684,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62415,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207685,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62415,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207686,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62415,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207687,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62415,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207688,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62415,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",207689,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62416,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207690,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62416,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207691,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62416,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207692,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62416,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207693,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62416,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,207694,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62417,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207695,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62417,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207696,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62417,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207697,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62417,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207698,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62417,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,207699,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62418,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207700,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62418,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207701,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62418,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207702,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62418,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207703,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62418,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,207704,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62419,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,207705,0,Strongly Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62419,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,207706,1,Agree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62419,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,207707,2,No Opinion,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62419,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,207708,3,Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62419,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,207709,4,Strongly Disagree,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62420,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207710,0,Excellent,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62420,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207711,1,Very Good,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62420,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207712,2,Good,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62420,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207713,3,Fair,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62420,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207714,4,Poor,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62420,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",207715,5,N/A,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62421,16,"Overall, this activity was:",207716,0,Excellent,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62421,16,"Overall, this activity was:",207717,1,Very Good,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62421,16,"Overall, this activity was:",207718,2,Good,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62421,16,"Overall, this activity was:",207719,3,Fair,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62421,16,"Overall, this activity was:",207720,4,Poor,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62422,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207721,0,Yes,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62422,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207722,1,No,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62422,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207723,2,N/A,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62425,20,How would you improve this class (check all that apply)?,207724,0,Reduce content covered in class,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62425,20,How would you improve this class (check all that apply)?,207725,1,Increase content covered in class,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62425,20,How would you improve this class (check all that apply)?,207726,2,Update content covered in class,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62425,20,How would you improve this class (check all that apply)?,207727,3,Improve the instructional methods,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62425,20,How would you improve this class (check all that apply)?,207728,4,Make course activities more stimulating,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62425,20,How would you improve this class (check all that apply)?,207729,5,Slow the pace of the class,0
9908,Questions-0000-42,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 5-28-21,n13793,62425,20,How would you improve this class (check all that apply)?,207730,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9660,Elearning-0000-877,FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS,n13797,62465,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207873,0,TRUE,1
9660,Elearning-0000-877,FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS,n13797,62465,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 MOCK SURVEY FINDINGS - PCT.CCA.UCS"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207874,1,FALSE,0
8907,Elearning-0000-192,TIPS FOR HIGH QUALITY HAND-OFFS,n13799,62467,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",207877,0,TRUE,1
8907,Elearning-0000-192,TIPS FOR HIGH QUALITY HAND-OFFS,n13799,62467,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the <CBL Name> CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",207878,1,FALSE,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62475,0,Please list the location for this activity.,207895,0,Atlanta,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62475,0,Please list the location for this activity.,207896,1,Cherokee,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62475,0,Please list the location for this activity.,207897,2,Forsyth,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62475,0,Please list the location for this activity.,207898,3,Other,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62476,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",207899,0,Strongly Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62476,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",207900,1,Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62476,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",207901,2,No Opinion,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62476,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",207902,3,Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62476,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",207903,4,Strongly Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62477,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",207904,0,Strongly Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62477,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",207905,1,Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62477,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",207906,2,No Opinion,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62477,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",207907,3,Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62477,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",207908,4,Strongly Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62478,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",207909,0,Strongly Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62478,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",207910,1,Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62478,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",207911,2,No Opinion,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62478,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",207912,3,Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62478,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",207913,4,Strongly Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62479,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207914,0,Strongly Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62479,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207915,1,Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62479,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207916,2,No Opinion,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62479,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207917,3,Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62479,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,207918,4,Strongly Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62480,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,207919,0,Strongly Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62480,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,207920,1,Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62480,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,207921,2,No Opinion,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62480,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,207922,3,Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62480,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,207923,4,Strongly Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62481,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",207924,0,Strongly Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62481,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",207925,1,Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62481,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",207926,2,No Opinion,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62481,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",207927,3,Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62481,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",207928,4,Strongly Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62482,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207929,0,Strongly Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62482,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207930,1,Agree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62482,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207931,2,No Opinion,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62482,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207932,3,Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62482,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,207933,4,Strongly Disagree,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62483,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",207934,0,Excellent,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62483,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",207935,1,Very Good,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62483,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",207936,2,Good,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62483,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",207937,3,Fair,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62483,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",207938,4,Poor,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62483,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",207939,5,N/A,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62484,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",207940,0,Excellent,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62484,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",207941,1,Very Good,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62484,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",207942,2,Good,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62484,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",207943,3,Fair,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62484,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",207944,4,Poor,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62484,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",207945,5,N/A,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62485,10,"Overall, this activity was:",207946,0,Excellent,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62485,10,"Overall, this activity was:",207947,1,Very Good,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62485,10,"Overall, this activity was:",207948,2,Good,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62485,10,"Overall, this activity was:",207949,3,Fair,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62485,10,"Overall, this activity was:",207950,4,Poor,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62486,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207951,0,Yes,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62486,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207952,1,No,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62486,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",207953,2,N/A,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62489,14,How would you improve this class (check all that apply)?,207954,0,Reduce content covered in class,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62489,14,How would you improve this class (check all that apply)?,207955,1,Increase content covered in class,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62489,14,How would you improve this class (check all that apply)?,207956,2,Update content covered in class,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62489,14,How would you improve this class (check all that apply)?,207957,3,Improve the instructional methods,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62489,14,How would you improve this class (check all that apply)?,207958,4,Make course activities more stimulating,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62489,14,How would you improve this class (check all that apply)?,207959,5,Slow the pace of the class,0
9940,Questions-0000-74,MIND THE GAP (EVALUATION SURVEY) 6-8-21,n13803,62489,14,How would you improve this class (check all that apply)?,207960,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62499,0,Please list the location for this activity.,207983,0,Atlanta,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62499,0,Please list the location for this activity.,207984,1,Cherokee,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62499,0,Please list the location for this activity.,207985,2,Forsyth,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62499,0,Please list the location for this activity.,207986,3,Other,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62500,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",207987,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62500,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",207988,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62500,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",207989,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62500,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",207990,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62500,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",207991,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62501,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",207992,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62501,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",207993,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62501,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",207994,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62501,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",207995,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62501,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",207996,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62502,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",207997,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62502,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",207998,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62502,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",207999,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62502,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",208000,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62502,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",208001,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62503,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",208002,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62503,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",208003,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62503,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",208004,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62503,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",208005,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62503,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",208006,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62504,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",208007,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62504,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",208008,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62504,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",208009,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62504,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",208010,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62504,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",208011,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62505,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",208012,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62505,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",208013,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62505,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",208014,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62505,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",208015,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62505,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",208016,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62506,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208017,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62506,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208018,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62506,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208019,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62506,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208020,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62506,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208021,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62507,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208022,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62507,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208023,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62507,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208024,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62507,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208025,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62507,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208026,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62508,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208027,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62508,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208028,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62508,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208029,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62508,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208030,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62508,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208031,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62509,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208032,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62509,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208033,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62509,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208034,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62509,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208035,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62509,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,208036,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62510,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,208037,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62510,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,208038,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62510,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,208039,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62510,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,208040,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62510,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,208041,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62511,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208042,0,Strongly Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62511,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208043,1,Agree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62511,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208044,2,No Opinion,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62511,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208045,3,Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62511,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208046,4,Strongly Disagree,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62512,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",208047,0,Excellent,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62512,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",208048,1,Very Good,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62512,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",208049,2,Good,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62512,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",208050,3,Fair,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62512,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",208051,4,Poor,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62513,14,"Overall, this activity was:",208052,0,Excellent,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62513,14,"Overall, this activity was:",208053,1,Very Good,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62513,14,"Overall, this activity was:",208054,2,Good,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62513,14,"Overall, this activity was:",208055,3,Fair,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62513,14,"Overall, this activity was:",208056,4,Poor,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62514,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208057,0,Yes,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62514,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208058,1,No,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62514,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208059,2,N/A,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62517,18,How would you improve this class?,208060,0,Reduce content covered in class,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62517,18,How would you improve this class?,208061,1,Increase content covered in class,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62517,18,How would you improve this class?,208062,2,Update content covered in class,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62517,18,How would you improve this class?,208063,3,Improve the instructional methods,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62517,18,How would you improve this class?,208064,4,Make course activities more stimulating,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62517,18,How would you improve this class?,208065,5,Slow the pace of the class,0
9806,Questions-0000-101,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 06-9-21,n13805,62517,18,How would you improve this class?,208066,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
95,SCORM-0000-177,SUCCESSFACTORS SYSTEM TRAINING 2021,n13807,62521,0,I have read and understood the content within the SuccessFactors System Training 2021 CBL.,208069,0,TRUE,1
95,SCORM-0000-177,SUCCESSFACTORS SYSTEM TRAINING 2021,n13807,62521,0,I have read and understood the content within the SuccessFactors System Training 2021 CBL.,208070,1,FALSE,0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62522,0,"1.	Post-Intensive Care Syndrome is a constellation of new or worsening impairments in cognition, physical ability and/or psychological well-being for individuals who have survived critical illness requiring intensive care. a.	TRUE  b.	FALSE",208074,0,TRUE,1
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62522,0,"1.	Post-Intensive Care Syndrome is a constellation of new or worsening impairments in cognition, physical ability and/or psychological well-being for individuals who have survived critical illness requiring intensive care. a.	TRUE  b.	FALSE",208075,1,FALSE,0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62523,1,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",208076,0,"a.	Cancer",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62523,1,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",208077,1,"b.	Stroke",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62523,1,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",208078,2,"c.	Sepsis",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62523,1,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",208079,3,"d.	Respiratory Distress/ARDS",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62523,1,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",208080,4,"e.	COVID-19",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62523,1,"2.	The following illnesses and conditions that require ICU care can lead to PICS: a.	Cancer b.	Stroke  c.	Sepsis d.	Respiratory Distress/ARDS e.	COVID-19 f.	All of the above",208081,5,"f.	All of the above",1
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62524,2,"3.	Patients who develop PICS can have cognitive impairment, physical impairments, and psychiatric illness that can last for years after their hospitalization. a.	TRUE  b.	FALSE",208082,0,TRUE,1
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62524,2,"3.	Patients who develop PICS can have cognitive impairment, physical impairments, and psychiatric illness that can last for years after their hospitalization. a.	TRUE  b.	FALSE",208083,1,FALSE,0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62525,3,"4.	When a Speech Pathologist evaluates a PICS patient, they only need to address dysphagia, and not cognition and/or dysphonia. a.	TRUE b.	FALSE",208084,0,TRUE,0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62525,3,"4.	When a Speech Pathologist evaluates a PICS patient, they only need to address dysphagia, and not cognition and/or dysphonia. a.	TRUE b.	FALSE",208085,1,FALSE,1
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62526,4,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",208086,0,"a.	Pain",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62526,4,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",208087,1,"b.	Respiratory, Core, and Limb Muscle Strength",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62526,4,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",208088,2,"c.	Activity Limitations",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62526,4,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",208089,3,"d.	None of the above",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62526,4,"5.	When an Occupational and/or Physical Therapist evaluates a PICS patient, they are treating: a.	Pain b.	Respiratory, Core, and Limb Muscle Strength c.	Activity Limitations d.	None of the above e.	A,B, and C",208090,4,"e.	A,B, and C",1
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62527,5,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",208091,0,"a.	at all Out-Patient locations",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62527,5,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",208092,1,"b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62527,5,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",208093,2,"c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated",0
8983,Elearning-0000-261,PICS FOR ACUTE CARE REHAB,n13808,62527,5,"6.	Northside Hospital has a PICS Clinic: a.	at all Out-Patient locations b.	where therapists have received specific education regarding PICS, and follow discipline specific guidelines c.	where all PICS patients are screened for behavioral health needs, and are referred as indicated d.	all of the above",208094,3,"d.	all of the above",1
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62534,0,Patients must be:,208114,0,"a)	Eligible for high dose chemotherapy and autologous stem cell transplant.",0
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62534,0,Patients must be:,208115,1,"b)	HIV+ but with the viral load below the limit of detection by standard commercial assay.",0
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62534,0,Patients must be:,208116,2,"c)	Diagnosed with relapsed/refractory DLBCL having received 2-3 prior regimens.",0
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62534,0,Patients must be:,208117,3,"d)	All of the above",1
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62535,1,Patients will receive the HST-NEETs on Day +1 (the day after autologous stem cell transplant).,208118,0,TRUE,0
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62535,1,Patients will receive the HST-NEETs on Day +1 (the day after autologous stem cell transplant).,208119,1,FALSE,1
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62536,2,A universal donor will be used for HST-NEET manufacturing that will occur 1 week prior to autologous stem cell transplant.,208120,0,TRUE,0
9493,Elearning-0000-725,C-459 BMT CTN 1903,n13810,62536,2,A universal donor will be used for HST-NEET manufacturing that will occur 1 week prior to autologous stem cell transplant.,208121,1,FALSE,1
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62584,0,I acknowledge that I have read and understood the FY2021 Interdisciplinary Plan of Care for Dialysis Patients: Nursing CBL in its entirety.,208320,0,TRUE,1
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62584,0,I acknowledge that I have read and understood the FY2021 Interdisciplinary Plan of Care for Dialysis Patients: Nursing CBL in its entirety.,208321,1,FALSE,0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62585,1,What is the purpose of a persistent note (yellow highlighted text) in the IPOC?,208322,0,"a.	Persistent notes have no real purpose. You can choose to use them if you want.",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62585,1,What is the purpose of a persistent note (yellow highlighted text) in the IPOC?,208323,1,"b.	Persistent notes provide important information such as guidance in selecting appropriate goals/outcomes and interventions based on a patient's individual needs and condition",1
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62585,1,What is the purpose of a persistent note (yellow highlighted text) in the IPOC?,208324,2,"c.	Persistent notes are reminders on issues to follow up with the MD",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62586,2,Where do you find the reference document with the list of applicable IPOCS,208325,0,"a.	OneChart Central: Job Aids: Clinical Care tab and Women's Health tab",1
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62586,2,Where do you find the reference document with the list of applicable IPOCS,208326,1,"b.	Pdrive: IPOCs",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62586,2,Where do you find the reference document with the list of applicable IPOCS,208327,2,"c.	Under Orders in OneChart",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62587,3,You can add Patient Specific Goals and Patient Specific Interventions to any IPOC if the built in elements do not meet the patient's needs.,208328,0,TRUE,1
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62587,3,You can add Patient Specific Goals and Patient Specific Interventions to any IPOC if the built in elements do not meet the patient's needs.,208329,1,FALSE,0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62588,4,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,208330,0,"a.	Fluid Volume Excess Prevention and Management",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62588,4,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,208331,1,"b.	Nutritional Deficit",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62588,4,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,208332,2,"c.	Fluid Volume Deficit",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62588,4,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,208333,3,"d.	Infection Prevention and Management: CLABSI phase",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62588,4,The following IPOCs are appropriate for patients with Renal Dysfunction / Dialysis,208334,4,"e.	Any of the above may be appropriate according to patient condition and need",1
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62589,5,"What should you do with ""Suggested Plans""ù before the end of your shift?",208335,0,"a.	Nothing, they are just suggestions",0
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62589,5,"What should you do with ""Suggested Plans""ù before the end of your shift?",208336,1,"b.	""Accept/Initiate""ù plans that are appropriate and ""reject""ù plans that are not appropriate, based on patient condition and need",1
9481,Elearning-0000-714,FY2021 INTERDISCIPLINARY PLAN OF CARE FOR DIALYSIS PATIENTS: NURSING,n13813,62589,5,"What should you do with ""Suggested Plans""ù before the end of your shift?",208337,2,"c.	""Accept""ù all plans",0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62590,0,Please list the location for this activity.,208338,0,Atlanta,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62590,0,Please list the location for this activity.,208339,1,Forsyth,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62590,0,Please list the location for this activity.,208340,2,Cherokee,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62590,0,Please list the location for this activity.,208341,3,Other,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62591,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",208342,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62591,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",208343,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62591,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",208344,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62591,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",208345,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62591,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify issues of patient safety and error reduction in the delivery of healthcare to Infants.</ol>",208346,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62592,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",208347,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62592,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",208348,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62592,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",208349,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62592,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",208350,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62592,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of hypoglycemia .</ol>",208351,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62593,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",208352,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62593,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",208353,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62593,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",208354,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62593,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",208355,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62593,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe infants at risk for hypothermia.</ol>",208356,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62594,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",208357,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62594,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",208358,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62594,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",208359,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62594,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",208360,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62594,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state 3 precautions to minimize heat loss in the delivery room.</ol>",208361,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62595,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",208362,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62595,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",208363,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62595,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",208364,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62595,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",208365,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62595,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to distinguish between mild, moderate, and severe respiratory distress.</ol>",208366,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62596,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",208367,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62596,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",208368,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62596,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",208369,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62596,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",208370,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62596,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to interpret Blood Gases for respiratory and metabolic acidosis.</ol>",208371,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62597,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",208372,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62597,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",208373,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62597,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",208374,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62597,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",208375,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62597,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list the 3 major types of shock seen in infants.</ol>",208376,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62598,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",208377,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62598,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",208378,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62598,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",208379,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62598,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",208380,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62598,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify factors that can impair cardiac output.</ol>",208381,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62599,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",208382,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62599,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",208383,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62599,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",208384,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62599,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",208385,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62599,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to define the term Shock.</ol>",208386,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62600,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",208387,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62600,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",208388,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62600,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",208389,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62600,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",208390,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62600,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the clinical signs of neonatal sepsis.</ol>",208391,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62601,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",208392,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62601,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",208393,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62601,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",208394,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62601,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",208395,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62601,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list perinatal and postnatal risk factors that predispose the infant to infection.</ol>",208396,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62602,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",208397,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62602,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",208398,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62602,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",208399,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62602,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",208400,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62602,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify methods to obtain lab specimens to rule out sepsis.</ol>",208401,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62603,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",208402,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62603,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",208403,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62603,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",208404,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62603,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",208405,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62603,13,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to list 2 ways healthcare providers can support parents of sick infants.</ol>",208406,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62604,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",208407,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62604,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",208408,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62604,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",208409,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62604,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",208410,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62604,14,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize the importance of reducing errors to improve outcome.<ol>",208411,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62605,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208412,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62605,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208413,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62605,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208414,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62605,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208415,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62605,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208416,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62606,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,208417,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62606,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,208418,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62606,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,208419,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62606,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,208420,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62606,16,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence level for organizing the myriad of details and interventions necessary for stabilizing a sick infant. </OL>,208421,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62607,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208422,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62607,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208423,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62607,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208424,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62607,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208425,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62607,17,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208426,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62608,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",208427,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62608,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",208428,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62608,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",208429,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62608,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",208430,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62608,18,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",208431,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62609,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208432,0,Strongly Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62609,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208433,1,Agree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62609,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208434,2,No Opinion,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62609,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208435,3,Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62609,19,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208436,4,Strongly Disagree,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62610,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,208437,0,Excellent,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62610,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,208438,1,Very Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62610,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,208439,2,Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62610,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,208440,3,Fair,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62610,20,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Erica Miller</ol>,208441,4,Poor,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62611,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,208442,0,Excellent,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62611,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,208443,1,Very Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62611,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,208444,2,Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62611,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,208445,3,Fair,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62611,23,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Leann Vanlandingham  </ol>,208446,4,Poor,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62612,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,208447,0,Excellent,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62612,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,208448,1,Very Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62612,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,208449,2,Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62612,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,208450,3,Fair,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62612,21,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dana Gopal </ol>,208451,4,Poor,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62613,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,208452,0,Excellent,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62613,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,208453,1,Very Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62613,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,208454,2,Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62613,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,208455,3,Fair,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62613,22,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Maggie Jones</ol>,208456,4,Poor,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62614,24,"Overall, this activity was:",208457,0,Excellent,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62614,24,"Overall, this activity was:",208458,1,Very Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62614,24,"Overall, this activity was:",208459,2,Good,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62614,24,"Overall, this activity was:",208460,3,Fair,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62614,24,"Overall, this activity was:",208461,4,Poor,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62615,25,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208462,0,Yes,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62615,25,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208463,1,No,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62615,25,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208464,2,N/A,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62618,28,How would you improve this class?,208465,0,Reduce content covered in class,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62618,28,How would you improve this class?,208466,1,Increase content covered in class,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62618,28,How would you improve this class?,208467,2,Update content covered in class,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62618,28,How would you improve this class?,208468,3,Improve the instructional methods,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62618,28,How would you improve this class?,208469,4,Make course activities more stimulating,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62618,28,How would you improve this class?,208470,5,Slow the pace of the class,0
9869,Questions-0000-159,STABLE PROGRAM (EVALUATION SURVEY) NSF 6.07.21,n13844,62618,28,How would you improve this class?,208471,6,"No Suggestions for improvement ( right content, speakers, location, etc.)",0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62622,0,Multiple patient deaths and injuries have occurred due to lack of line reconciliation being done.,208474,0,TRUE,1
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62622,0,Multiple patient deaths and injuries have occurred due to lack of line reconciliation being done.,208475,1,FALSE,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62623,1,The following lines should be reconciled at the change of shift:,208476,0,Tube feedings,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62623,1,The following lines should be reconciled at the change of shift:,208477,1,Urinary Catheters,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62623,1,The following lines should be reconciled at the change of shift:,208478,2,JP drains,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62623,1,The following lines should be reconciled at the change of shift:,208479,3,All the above,1
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62624,2,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,208480,0,Ask the last shift nurse to label it.,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62624,2,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,208481,1,Discard the entire IV set-up.,1
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62624,2,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,208482,2,Assume it was from the admission date.,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62624,2,When checking an IV line during shift change and you find there is not sticker for tubing change you should:,208483,3,Nothing,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62625,3,Line Reconciliation process should be done the following times:,208484,0,"Hand-off communication, patient returns from procedure",1
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62625,3,Line Reconciliation process should be done the following times:,208485,1,"Prior to initiating any new infusion, before patient returns from procedure",0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62625,3,Line Reconciliation process should be done the following times:,208486,2,"When assuming care of a patient, within one hour of transferring to the unit.",0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62626,4,Line reconciliation should be documented in cerner only one time a shift.,208487,0,TRUE,0
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62626,4,Line reconciliation should be documented in cerner only one time a shift.,208488,1,FALSE,1
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62627,5,Patients with suction hook-up in room should have line reconciliation done.,208489,0,TRUE,1
9210,Elearning-0000-468,FY2021 LINE RECONCILIATION,n13846,62627,5,Patients with suction hook-up in room should have line reconciliation done.,208490,1,FALSE,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62645,0,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",208556,0,"every 15 minutes x 4, every 30 minutes x 4, then every hour x 4",0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62645,0,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",208557,1,"every 5 minutes x 4, every 15 minutes x 4, then every hour x 4",0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62645,0,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",208558,2,"every 15 minutes x 4, every 30 minutes x 2, then every hour x 4",1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62645,0,"After sheath is removed and patient establishes hemostasis, Vital signs should be done:",208559,3,Vital signs are done in Cath lab.,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62646,1,"After a cardiac catheter is completed the nurse should assess for pain, pallor, pulse, paresthesia, and paralysis.",208560,0,TRUE,1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62646,1,"After a cardiac catheter is completed the nurse should assess for pain, pallor, pulse, paresthesia, and paralysis.",208561,1,FALSE,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62647,2,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,208562,0,Patient Assessment,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62647,2,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,208563,1,Adult Systems Assessment,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62647,2,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,208564,2,Cardiovascular Post-Procedure Monitoring,1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62647,2,Documentation for a patient returning from a Cardiac Catheter should be included in Cerner under:,208565,3,Adult Education,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62648,3,Patients post-cardiac catheter should position head of bed at 40 degrees.,208566,0,TRUE,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62648,3,Patients post-cardiac catheter should position head of bed at 40 degrees.,208567,1,FALSE,1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62649,4,Complications associated with Femoral Access post catheter procedure include all except:,208568,0,"Neural damage, Death",0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62649,4,Complications associated with Femoral Access post catheter procedure include all except:,208569,1,"Thrombosis, Free bleeding",0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62649,4,Complications associated with Femoral Access post catheter procedure include all except:,208570,2,"Hematoma, Venous thrombosis",0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62649,4,Complications associated with Femoral Access post catheter procedure include all except:,208571,3,"itching to skin, hypothermia",1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62650,5,If complications occur after a cardiac catheter it is best to call rapid response team.,208572,0,TRUE,1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62650,5,If complications occur after a cardiac catheter it is best to call rapid response team.,208573,1,FALSE,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62651,6,Complications that can occur after a radial post catheter procedure can include:,208574,0,itching,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62651,6,Complications that can occur after a radial post catheter procedure can include:,208575,1,Bleeding and spasms,1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62651,6,Complications that can occur after a radial post catheter procedure can include:,208576,2,Retroperitoneal hemorrage,0
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62652,7,"I understand my responsibilities as a nurse to monitor a cardiac catheter patient as instructed in this training, that charting will be in real time and completed with all details under the Cardiovascular Post-Procedure Monitoring tab in Cerner. I also understand the complications that can occur for both a",208577,0,TRUE,1
8360,Elearning-0000-1234,FY2021 POST CARDIAC CATHETERIZATION MANAGEMENT,n13848,62652,7,"I understand my responsibilities as a nurse to monitor a cardiac catheter patient as instructed in this training, that charting will be in real time and completed with all details under the Cardiovascular Post-Procedure Monitoring tab in Cerner. I also understand the complications that can occur for both a",208578,1,FALSE,0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62653,0,"1.	If a code purple is announced you should""¶",208579,0,"a.	Remain at nurses station",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62653,0,"1.	If a code purple is announced you should""¶",208580,1,"b.	Answer call lights and phones",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62653,0,"1.	If a code purple is announced you should""¶",208581,2,"c.	Direct traffic",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62653,0,"1.	If a code purple is announced you should""¶",208582,3,"d.	All the above",1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62654,1,"2.	If you should happen to see a patient matching the description called over the intercom and/or wearing a purple armband is observed call security and keep patient in sight",208583,0,TRUE,1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62654,1,"2.	If you should happen to see a patient matching the description called over the intercom and/or wearing a purple armband is observed call security and keep patient in sight",208584,1,FALSE,0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62655,2,"3.	If a Bomb threat (code orange) is called in via the phone you should""¶",208585,0,"a.	Attempt to keep caller talking and try to get as much as information as possible",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62655,2,"3.	If a Bomb threat (code orange) is called in via the phone you should""¶",208586,1,"b.	Complete bomb threat checklist located in Lucidoc",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62655,2,"3.	If a Bomb threat (code orange) is called in via the phone you should""¶",208587,2,"c.	Alert nearby employee and have them contact security",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62655,2,"3.	If a Bomb threat (code orange) is called in via the phone you should""¶",208588,3,"d.	All the above",1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62656,3,"4.	If a Bomb threat (code orange) is a written message you should, handle the message as little as possible, notify security and place message in a clean plastic bag",208589,0,TRUE,1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62656,3,"4.	If a Bomb threat (code orange) is a written message you should, handle the message as little as possible, notify security and place message in a clean plastic bag",208590,1,FALSE,0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62657,4,"5.	If a code Brown is activated you can expect to""¶",208591,0,"a.	Evacuate horizontally from one smoke compartment to another and place the patient's medical records in a pillow case to move with the patient",1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62657,4,"5.	If a code Brown is activated you can expect to""¶",208592,1,"b.	To find a person wandering the halls",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62657,4,"5.	If a code Brown is activated you can expect to""¶",208593,2,"c.	Get under the desk",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62657,4,"5.	If a code Brown is activated you can expect to""¶",208594,3,"d.	Scream for help",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62658,5,"6.	For a code Grey, you would do all EXCEPT""¶",208595,0,"a.	Remain at nurses station",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62658,5,"6.	For a code Grey, you would do all EXCEPT""¶",208596,1,"b.	Answer call lights and phones",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62658,5,"6.	For a code Grey, you would do all EXCEPT""¶",208597,2,"c.	Direct traffic",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62658,5,"6.	For a code Grey, you would do all EXCEPT""¶",208598,3,"d.	Take shelter under desks",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62658,5,"6.	For a code Grey, you would do all EXCEPT""¶",208599,4,"e.	Scream for help",1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62659,6,"7.	If you notice discolored water or low water pressure (code dry) you should notify""¶",208600,0,"a.	Biomed",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62659,6,"7.	If you notice discolored water or low water pressure (code dry) you should notify""¶",208601,1,"b.	Engineering",1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62659,6,"7.	If you notice discolored water or low water pressure (code dry) you should notify""¶",208602,2,"c.	MD",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62659,6,"7.	If you notice discolored water or low water pressure (code dry) you should notify""¶",208603,3,"d.	No one",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62660,7,"8.	It is important to obtain the name and number of a caller reporting a victim contaminated with hazardous material (code yellow) before transferring the caller to the ED in case of disconnection",208604,0,TRUE,1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62660,7,"8.	It is important to obtain the name and number of a caller reporting a victim contaminated with hazardous material (code yellow) before transferring the caller to the ED in case of disconnection",208605,1,FALSE,0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62661,8,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",208606,0,"a.	Call 8911",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62661,8,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",208607,1,"b.	Remain at nurses station",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62661,8,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",208608,2,"c.	Answer call lights and phones",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62661,8,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",208609,3,"d.	Make calls as directed by RN and/or charge nurse, call MD as directed",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62661,8,"9.	During a Code Blue (Cardiopulmonary Arrest)  the UCS should",208610,4,"e.	All the above",1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62662,9,"10.	During a code pink, stop any visitor or employee that passes through with any item large enough to fit an infant in. Say ""we have an infant alert and I notice you have an object that could conceal an infant, I apologize for the delay but would you mind opening the (item) so that we can clear you to leave the hospital?""ù If no infant seen thank them, apologize for any delay and ask them to wait for security to avoid being stopped again. If they refuse to let you look in object notify security immediately. Alert other employees to help you. A staff member may follow them at a safe distance. Do not attempt to detain them",208611,0,TRUE,1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62662,9,"10.	During a code pink, stop any visitor or employee that passes through with any item large enough to fit an infant in. Say ""we have an infant alert and I notice you have an object that could conceal an infant, I apologize for the delay but would you mind opening the (item) so that we can clear you to leave the hospital?""ù If no infant seen thank them, apologize for any delay and ask them to wait for security to avoid being stopped again. If they refuse to let you look in object notify security immediately. Alert other employees to help you. A staff member may follow them at a safe distance. Do not attempt to detain them",208612,1,FALSE,0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62663,10,"11.	If there is an active shooter (code silver) in the hospital you should""¶",208613,0,"a.	Try to remain calm",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62663,10,"11.	If there is an active shooter (code silver) in the hospital you should""¶",208614,1,"b.	Try not to provoke the threat",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62663,10,"11.	If there is an active shooter (code silver) in the hospital you should""¶",208615,2,"c.	Shelter in place by barricading a room, turn off lights, close blinds, and silence cell phones",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62663,10,"11.	If there is an active shooter (code silver) in the hospital you should""¶",208616,3,"d.	You should only make the personal choice to attempt to negotiate with or overpower the shooter if it is a last resort and there is no possibility of escape",0
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62663,10,"11.	If there is an active shooter (code silver) in the hospital you should""¶",208617,4,"e.	All the above",1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62664,11,"12.	You should remain at the nurses station, answer call lights and phones, and direction traffic during a code red",208618,0,TRUE,1
9575,Elearning-0000-80,WSU EMERGENCY CODES _UCS,n13850,62664,11,"12.	You should remain at the nurses station, answer call lights and phones, and direction traffic during a code red",208619,1,FALSE,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62702,0,Please list the location for this activity.,208762,0,Atlanta,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62702,0,Please list the location for this activity.,208763,1,Cherokee,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62702,0,Please list the location for this activity.,208764,2,Forsyth,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62702,0,Please list the location for this activity.,208765,3,Other,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62703,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208766,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62703,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208767,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62703,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208768,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62703,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208769,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62703,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208770,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62704,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208771,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62704,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208772,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62704,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208773,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62704,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208774,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62704,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208775,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62705,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208776,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62705,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208777,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62705,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208778,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62705,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208779,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62705,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208780,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62706,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208781,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62706,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208782,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62706,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208783,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62706,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208784,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62706,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208785,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62707,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",208786,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62707,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",208787,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62707,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",208788,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62707,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",208789,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62707,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",208790,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62708,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",208791,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62708,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",208792,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62708,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",208793,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62708,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",208794,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62708,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",208795,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62709,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",208796,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62709,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",208797,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62709,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",208798,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62709,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",208799,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62709,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",208800,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62710,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",208801,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62710,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",208802,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62710,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",208803,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62710,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",208804,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62710,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",208805,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62711,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208806,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62711,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208807,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62711,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208808,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62711,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208809,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62711,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208810,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62712,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208811,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62712,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208812,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62712,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208813,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62712,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208814,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62712,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208815,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62713,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208816,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62713,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208817,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62713,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208818,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62713,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208819,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62713,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208820,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62714,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208821,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62714,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208822,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62714,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208823,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62714,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208824,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62714,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208825,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62715,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208826,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62715,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208827,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62715,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208828,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62715,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208829,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62715,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208830,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62716,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208831,0,Strongly Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62716,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208832,1,Agree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62716,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208833,2,No Opinion,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62716,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208834,3,Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62716,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,208835,4,Strongly Disagree,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62717,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208836,0,Excellent,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62717,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208837,1,Very Good,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62717,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208838,2,Good,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62717,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208839,3,Fair,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62717,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208840,4,Poor,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62717,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208841,5,N/A,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62718,16,"Overall, this activity was:",208842,0,Excellent,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62718,16,"Overall, this activity was:",208843,1,Very Good,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62718,16,"Overall, this activity was:",208844,2,Good,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62718,16,"Overall, this activity was:",208845,3,Fair,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62718,16,"Overall, this activity was:",208846,4,Poor,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62719,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208847,0,Yes,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62719,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208848,1,No,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62719,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208849,2,N/A,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62722,20,How would you improve this class (check all that apply)?,208850,0,Reduce content covered in class,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62722,20,How would you improve this class (check all that apply)?,208851,1,Increase content covered in class,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62722,20,How would you improve this class (check all that apply)?,208852,2,Update content covered in class,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62722,20,How would you improve this class (check all that apply)?,208853,3,Improve the instructional methods,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62722,20,How would you improve this class (check all that apply)?,208854,4,Make course activities more stimulating,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62722,20,How would you improve this class (check all that apply)?,208855,5,Slow the pace of the class,0
9909,Questions-0000-43,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-11-21,n13854,62722,20,How would you improve this class (check all that apply)?,208856,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62683,0,Please list the location for this activity.,208687,0,Atlanta,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62683,0,Please list the location for this activity.,208688,1,Cherokee,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62683,0,Please list the location for this activity.,208689,2,Forsyth,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62683,0,Please list the location for this activity.,208690,3,Other,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62684,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208691,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62684,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208692,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62684,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208693,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62684,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208694,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62684,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208695,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62685,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208696,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62685,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208697,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62685,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208698,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62685,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208699,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62685,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208700,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62686,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208701,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62686,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208702,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62686,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208703,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62686,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208704,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62686,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",208705,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62687,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208706,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62687,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208707,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62687,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208708,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62687,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208709,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62687,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",208710,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62688,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208711,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62688,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208712,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62688,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208713,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62688,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208714,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62688,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208715,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62689,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208716,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62689,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208717,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62689,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208718,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62689,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208719,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62689,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208720,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62690,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208721,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62690,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208722,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62690,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208723,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62690,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208724,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62690,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208725,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62691,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208726,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62691,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208727,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62691,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208728,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62691,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208729,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62691,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208730,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62692,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208731,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62692,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208732,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62692,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208733,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62692,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208734,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62692,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208735,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62693,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,208736,0,Strongly Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62693,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,208737,1,Agree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62693,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,208738,2,No Opinion,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62693,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,208739,3,Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62693,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,208740,4,Strongly Disagree,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62694,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208742,0,Very Good,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62694,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208743,1,Good,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62694,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208744,2,Fair,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62694,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208745,3,Poor,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62694,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208741,4,Excellent,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62694,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208746,5,N/A,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62695,12,"Overall, this activity was:",208747,0,Excellent,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62695,12,"Overall, this activity was:",208748,1,Very Good,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62695,12,"Overall, this activity was:",208749,2,Good,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62695,12,"Overall, this activity was:",208750,3,Fair,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62695,12,"Overall, this activity was:",208751,4,Poor,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62696,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208752,0,Yes,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62696,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208753,1,No,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62696,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208754,2,N/A,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62699,16,How would you improve this class (check all that apply)?,208755,0,Reduce content covered in class,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62699,16,How would you improve this class (check all that apply)?,208756,1,Increase content covered in class,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62699,16,How would you improve this class (check all that apply)?,208757,2,Update content covered in class,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62699,16,How would you improve this class (check all that apply)?,208758,3,Improve the instructional methods,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62699,16,How would you improve this class (check all that apply)?,208759,4,Make course activities more stimulating,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62699,16,How would you improve this class (check all that apply)?,208760,5,Slow the pace of the class,0
9915,Questions-0000-49,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-11-21",n13853,62699,16,How would you improve this class (check all that apply)?,208761,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62666,0,Please list the location for this activity.,208622,0,Atlanta,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62666,0,Please list the location for this activity.,208623,1,Cherokee,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62666,0,Please list the location for this activity.,208624,2,Forsyth,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62666,0,Please list the location for this activity.,208625,3,Other,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62667,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208626,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62667,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208627,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62667,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208628,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62667,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208629,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62667,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",208630,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62668,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208631,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62668,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208632,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62668,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208633,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62668,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208634,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62668,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",208635,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62669,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208636,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62669,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208637,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62669,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208638,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62669,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208639,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62669,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,208640,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62670,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208641,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62670,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208642,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62670,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208643,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62670,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208644,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62670,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",208645,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62671,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208646,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62671,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208647,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62671,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208648,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62671,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208649,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62671,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,208650,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62672,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208651,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62672,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208652,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62672,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208653,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62672,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208654,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62672,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,208655,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62673,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208656,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62673,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208657,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62673,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208658,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62673,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208659,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62673,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,208660,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62674,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208661,0,Strongly Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62674,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208662,1,Agree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62674,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208663,2,No Opinion,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62674,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208664,3,Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62674,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,208665,4,Strongly Disagree,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62675,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208666,0,Excellent,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62675,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208667,1,Very Good,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62675,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208668,2,Good,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62675,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208669,3,Fair,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62675,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208670,4,Poor,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62675,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, RN-C, BSN, CCRN</ol>",208671,5,N/A,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62676,10,"Overall, this activity was:",208672,0,Excellent,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62676,10,"Overall, this activity was:",208673,1,Very Good,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62676,10,"Overall, this activity was:",208674,2,Good,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62676,10,"Overall, this activity was:",208675,3,Fair,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62676,10,"Overall, this activity was:",208676,4,Poor,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62677,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208677,0,Yes,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62677,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208678,1,No,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62677,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",208679,2,N/A,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62680,14,How would you improve this class (check all that apply)?,208680,0,Reduce content covered in class,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62680,14,How would you improve this class (check all that apply)?,208681,1,Increase content covered in class,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62680,14,How would you improve this class (check all that apply)?,208682,2,Update content covered in class,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62680,14,How would you improve this class (check all that apply)?,208683,3,Improve the instructional methods,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62680,14,How would you improve this class (check all that apply)?,208684,4,Make course activities more stimulating,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62680,14,How would you improve this class (check all that apply)?,208685,5,Slow the pace of the class,0
9902,Questions-0000-36,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-11-21,n13852,62680,14,How would you improve this class (check all that apply)?,208686,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
243,SCORM-0000-49,FY2021 SURGICAL SERVICES: LUMBAR DRAIN MANAGEMENT FOR PACU,n13856,62726,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 Surgical Services: Lumbar Drain Management for PACU CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",208859,0,TRUE,1
243,SCORM-0000-49,FY2021 SURGICAL SERVICES: LUMBAR DRAIN MANAGEMENT FOR PACU,n13856,62726,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the FY2021 Surgical Services: Lumbar Drain Management for PACU CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",208860,1,FALSE,0
9634,Elearning-0000-853,2021 PULMONARY HYPERTENSION FOR RT CBL,n13857,62727,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Pulmonary Hypertension for RT CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",208861,0,TRUE,1
9996,Elearning-0000-1767,2021 PULMONARY HYPERTENSION FOR RT CBL,n13857,62727,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Pulmonary Hypertension for RT CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",208861,0,TRUE,1
9634,Elearning-0000-853,2021 PULMONARY HYPERTENSION FOR RT CBL,n13857,62727,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Pulmonary Hypertension for RT CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",208862,1,FALSE,0
9996,Elearning-0000-1767,2021 PULMONARY HYPERTENSION FOR RT CBL,n13857,62727,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Pulmonary Hypertension for RT CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",208862,1,FALSE,0
9643,Elearning-0000-861,2021 PNEUMONIA DSC FOR RT CBL,n13858,62728,0,What are the 4 indicators we are measuring for Pneumonia DSC?,208863,0,"1. Nursing documentation of SMI, progressive mobility, antibiotic stewardship, pneumonia vaccination",0
9643,Elearning-0000-861,2021 PNEUMONIA DSC FOR RT CBL,n13858,62728,0,What are the 4 indicators we are measuring for Pneumonia DSC?,208864,1,"2. Oral care, progressive mobility, diet reconciliation, oxygen weaning",0
9643,Elearning-0000-861,2021 PNEUMONIA DSC FOR RT CBL,n13858,62728,0,What are the 4 indicators we are measuring for Pneumonia DSC?,208865,2,"3. Oxygen weaning, nursing documentation of SMI, progressive mobility, diet reconciliation",1
9643,Elearning-0000-861,2021 PNEUMONIA DSC FOR RT CBL,n13858,62728,0,What are the 4 indicators we are measuring for Pneumonia DSC?,208866,3,"4. Hand hygiene, oxygen weaning, oral care, progressive mobility",0
9662,Elearning-0000-879,2021 LUNG CANCER DSC FOR RT CBL,n13859,62729,0,What are 4 of the indicators we are measuring?,208867,0,"1. Oral Care Provided; toothbrush BID, PT consult, Pain Goal met, Nodal Stations and Length of stay.",0
9662,Elearning-0000-879,2021 LUNG CANCER DSC FOR RT CBL,n13859,62729,0,What are 4 of the indicators we are measuring?,208868,1,"2. Patient Education, SLP consult, Documentation of Nodal Stations and Length of stay.",0
9662,Elearning-0000-879,2021 LUNG CANCER DSC FOR RT CBL,n13859,62729,0,What are 4 of the indicators we are measuring?,208869,2,"3. Ambulation initiation by nursing, Nursing documentation of Incentive Spirometry, Prehab Referrals, and Speech Therapy optimization of safe swallow function.",1
9662,Elearning-0000-879,2021 LUNG CANCER DSC FOR RT CBL,n13859,62729,0,What are 4 of the indicators we are measuring?,208870,3,"4. Patients up out of bed on day of surgery, Oral Care Provided; toothbrush BID, OT consult, Length of stay.",0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62730,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage,208871,0,TRUE,1
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62730,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage,208872,1,FALSE,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62731,1,The OB Hemorrhage Cart is secured by:,208873,0,A zip tie,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62731,1,The OB Hemorrhage Cart is secured by:,208874,1,2 Digital locks,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62731,1,The OB Hemorrhage Cart is secured by:,208875,2,Red security seal,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62731,1,The OB Hemorrhage Cart is secured by:,208876,3,B and C,1
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62731,1,The OB Hemorrhage Cart is secured by:,208877,4,All of the above,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62732,2,Medications are stored in the OB Hemorrhage Cart,208878,0,TRUE,1
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62732,2,Medications are stored in the OB Hemorrhage Cart,208879,1,FALSE,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62733,3,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,208880,0,Red,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62733,3,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,208881,1,Yellow,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62733,3,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,208882,2,Green,1
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62734,4,How frequently should the cart thermometer be checked?,208883,0,Once a day,0
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62734,4,How frequently should the cart thermometer be checked?,208884,1,Every shift,1
9110,Elearning-0000-377,NSC HEMORRHAGE CART,n13860,62734,4,How frequently should the cart thermometer be checked?,208885,2,Once a week,0
9625,Elearning-0000-845,2021 STROKE FOR RT CBL,n13866,62764,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""2021 STROKE FOR RT CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209000,0,TRUE,1
9625,Elearning-0000-845,2021 STROKE FOR RT CBL,n13866,62764,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""2021 STROKE FOR RT CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209001,1,FALSE,0
9695,Elearning-0000-909,2021 COPD FOR RT CBL,n13865,62763,0,What are the 4 indicators we are measuring for COPD DSC?,208996,0,"1. Smoking cessation, mobility, incentive spirometry, COPD action plan documentation",0
9695,Elearning-0000-909,2021 COPD FOR RT CBL,n13865,62763,0,What are the 4 indicators we are measuring for COPD DSC?,208997,1,"2. COPD action plan documentation, CUN7 (follow up visit with PCP/pulmonologist within 7 days), speech therapy consult, RT discharge topic education",1
9695,Elearning-0000-909,2021 COPD FOR RT CBL,n13865,62763,0,What are the 4 indicators we are measuring for COPD DSC?,208998,2,"3. RT discharge topic education, pneumonia vaccine, mobility, smoking cessation",0
9695,Elearning-0000-909,2021 COPD FOR RT CBL,n13865,62763,0,What are the 4 indicators we are measuring for COPD DSC?,208999,3,"4. Physical therapy consult, mobility, CUN7 (follow up visit with PCP/pulmonologist within 7 days), RT discharge topic education",0
8404,Elearning-0000-1274,REV INT - INTRO TO PRO FEE CARDIOLOGY CODING,n13867,62765,0,I have reviewed the Revenue Integrity Intro to Pro Fee Cardiology Coding CBL and acknowledge that I am responsible for understanding the content therein.  I also understand that I should stop in the face of uncertainty and ask for clarification.  I know where and how to get my questions answered about this topic.,209002,0,TRUE,1
8404,Elearning-0000-1274,REV INT - INTRO TO PRO FEE CARDIOLOGY CODING,n13867,62765,0,I have reviewed the Revenue Integrity Intro to Pro Fee Cardiology Coding CBL and acknowledge that I am responsible for understanding the content therein.  I also understand that I should stop in the face of uncertainty and ask for clarification.  I know where and how to get my questions answered about this topic.,209003,1,FALSE,0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62766,0,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",209004,0,"a.	Urinary Dysfunction",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62766,0,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",209005,1,"b.	No new IPOC needed as Knowledge Deficit addresses change in condition, admission diagnosis and discharge planning",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62766,0,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",209006,2,"c.	Nausea Management and/or Pain Management Acute",1
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62766,0,"<b>CASE STUDY</b><br> Mr. Jones is a 68 year-old male admitted for a left total hip replacement.  He has a history of Type 2 Diabetes, Hypertension and Gout.  The discharge plan is to go home with his care partner. The patient has just returned from the PACU and is experiencing mild pain and some nausea but vital signs are stable.<br><br>  Using C.H.A.D.S., you have addressed the following areas of the POC.  What would be an appropriate plan(s) for Change in condition?<br><br>  <b>Change in Condition - ________________________</b><br> <b>High-Risk Comorbidities - </b>Therapeutic Regimen Management (r/t DM and HTN)<br> <b>Admission Diagnosis -</b> Knowledge Deficit<br> <b>Discharge Planning - </b>Knowledge Deficit<br> <b>Safety - </b>At Risk to Fall<br><br>",209007,3,"d.	Change in condition is not important",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62767,1,"A ""High-Risk Comorbidity""ù is a condition that, if left untreated during the hospital stay, would be problematic for the patient.",209008,0,TRUE,1
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62767,1,"A ""High-Risk Comorbidity""ù is a condition that, if left untreated during the hospital stay, would be problematic for the patient.",209009,1,FALSE,0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62768,2,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",209010,0,"a.	All outcome target dates should be set for the anticipated date of discharge",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62768,2,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",209011,1,"b.	When setting target dates, nursing should consider the patient condition and expected progress toward discharge so that (s)he can set a reasonable time-frame for each outcome",1
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62768,2,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",209012,2,"c.	All target dates should be about 24-48 hours from the time they are initiated",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62768,2,"When establishing target dates for IPOC outcomes, which of the following statements about is true?",209013,3,"d.	The target dates are unimportant and thus all target dates should be set for the same date and time",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62769,3,How often should the IPOC be updated/evaluated?,209014,0,"a.	Every 4 hours",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62769,3,How often should the IPOC be updated/evaluated?,209015,1,"b.	At least once per shift",1
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62769,3,How often should the IPOC be updated/evaluated?,209016,2,"c.	Only when something changes with the patient",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62769,3,How often should the IPOC be updated/evaluated?,209017,3,"d.	Just before discharge",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62770,4,"What should you do with ""Suggested Plans""ù before the end of your shift?",209018,0,"a.	Nothing, they are just suggestions",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62770,4,"What should you do with ""Suggested Plans""ù before the end of your shift?",209019,1,"b.	""Accept""ù plans that are appropriate and ""reject""ù plans that are not",1
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62770,4,"What should you do with ""Suggested Plans""ù before the end of your shift?",209020,2,"c.	""Accept""ù all suggested plans",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62770,4,"What should you do with ""Suggested Plans""ù before the end of your shift?",209021,3,"d.	Reject all plans as the system is suggesting them unnecessarily",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62771,5,"Each patient should have an <b>individualized</b> plan of care based upon patient history, reason for admission, provider orders, nursing assessment, and Peratrend or other early warning system.",209022,0,TRUE,1
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62771,5,"Each patient should have an <b>individualized</b> plan of care based upon patient history, reason for admission, provider orders, nursing assessment, and Peratrend or other early warning system.",209023,1,FALSE,0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62772,6,How can the IPOC be individualized for a particular patient?,209024,0,"a.	No IPOC can be individualized because they are standardized bundles of care that cannot be altered.",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62772,6,How can the IPOC be individualized for a particular patient?,209025,1,"b.	By applying target dates to outcomes/goals in consideration of patient needs and condition.",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62772,6,How can the IPOC be individualized for a particular patient?,209026,2,"c.	By adding built-in components that are not default preselects but are appropriate to patient need and condition.",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62772,6,How can the IPOC be individualized for a particular patient?,209027,3,"d.	By adding patient specific outcomes or patient specific interventions.",0
240,SCORM-0000-46,FY2021 INTERDISCIPLINARY PLAN OF CARE: NURSING,n13868,62772,6,How can the IPOC be individualized for a particular patient?,209028,4,"e.	b, c, and d are all ways that an IPOC can be individualized for a particular patient",1
9602,Elearning-0000-824,FORSYTH FCC ECD,n13871,62775,0,The new ECD changes are only in the maternal chart. The newborn changes will happen at a later date.,209033,0,TRUE,1
9602,Elearning-0000-824,FORSYTH FCC ECD,n13871,62775,0,The new ECD changes are only in the maternal chart. The newborn changes will happen at a later date.,209034,1,FALSE,0
9602,Elearning-0000-824,FORSYTH FCC ECD,n13871,62776,1,The ECD changes will help streamline charting.,209035,0,TRUE,1
9602,Elearning-0000-824,FORSYTH FCC ECD,n13871,62776,1,The ECD changes will help streamline charting.,209036,1,FALSE,0
9602,Elearning-0000-824,FORSYTH FCC ECD,n13871,62777,2,I have read and understood the content of this module.,209037,0,TRUE,1
9602,Elearning-0000-824,FORSYTH FCC ECD,n13871,62777,2,I have read and understood the content of this module.,209038,1,FALSE,0
242,SCORM-0000-48,FY2021 SURGICAL SERVICES: END OF CASE SURGICAL DEBRIEF,n13872,62358,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the SURGICAL SERVICES: FY2021 END OF CASE SURGICAL DEBRIEF CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207512,0,TRUE,1
242,SCORM-0000-48,FY2021 SURGICAL SERVICES: END OF CASE SURGICAL DEBRIEF,n13872,62358,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the SURGICAL SERVICES: FY2021 END OF CASE SURGICAL DEBRIEF CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",207513,1,FALSE,0
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62779,0,What are the benefits of positioning?,209058,0,a. Promotes improved rest and neurobehavioral organization.,0
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62779,0,What are the benefits of positioning?,209059,1,b. Guides normal fetal neuromotor and musculoskeletal development.,0
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62779,0,What are the benefits of positioning?,209060,2,c. Protects skin integrity.,0
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62779,0,What are the benefits of positioning?,209061,3,d. Assist in thermoregulation.,0
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62779,0,What are the benefits of positioning?,209062,4,e. All of the above,1
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62780,1,All infants admitted to the NICU under 33 weeks are positioned in a Z-Flo.,209063,0,TRUE,0
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62780,1,All infants admitted to the NICU under 33 weeks are positioned in a Z-Flo.,209064,1,FALSE,1
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62781,2,"In all positions, the infant should be in a midline flexed position with containment.",209065,0,TRUE,1
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62781,2,"In all positions, the infant should be in a midline flexed position with containment.",209066,1,FALSE,0
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62782,3,"I acknowledge that I have read and understand the information provided in the ""Positioning and Zflo in the NICU"" CBL.",209067,0,TRUE,1
8975,Elearning-0000-254,POSITIONING AND ZFLO IN THE NICU,n13873,62782,3,"I acknowledge that I have read and understand the information provided in the ""Positioning and Zflo in the NICU"" CBL.",209068,1,FALSE,0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62783,0,True or False?  KINDER1 falls screening is used for both adult and pediatric patients.,209069,0,TRUE,1
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62783,0,True or False?  KINDER1 falls screening is used for both adult and pediatric patients.,209070,1,FALSE,0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62784,1,Which of the following patients are at risk to fall?,209071,0,"a.	A 30-year-old who came to the ED because of a fall",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62784,1,Which of the following patients are at risk to fall?,209072,1,"b.	An intoxicated patient",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62784,1,Which of the following patients are at risk to fall?,209073,2,"c.	A 10-month old infant who cannot walk",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62784,1,Which of the following patients are at risk to fall?,209074,3,"d.	All of the above",1
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62785,2,True or False?  Patients identified as at risk to fall do not need to have a safety plan documented.,209075,0,TRUE,0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62785,2,True or False?  Patients identified as at risk to fall do not need to have a safety plan documented.,209076,1,FALSE,1
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62786,3,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",209077,0,"a.	Assist the patient to bed, notify the provider, and address immediate medical needs",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62786,3,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",209078,1,"b.	Complete a new KINDER1 falls screening via Ad Hoc Forms and implement a safety plan",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62786,3,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",209079,2,"c.	Complete an incident report",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62786,3,"A patient was identified as NOT at risk to fall in triage.  Later in their ED visit, the patient falls while using the restroom.  What should the ED nurse do?",209080,3,"d.	All of the above",1
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62787,4,Which falls scale will be used for Admission Holds in the ED?,209081,0,"a.	KINDER1",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62787,4,Which falls scale will be used for Admission Holds in the ED?,209082,1,"b.	Morse Fall Scale",1
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62787,4,Which falls scale will be used for Admission Holds in the ED?,209083,2,"c.	Falls Risk Assessment Tool",0
9693,Elearning-0000-907,ED KINDER1 FALLS SCREENING,n13875,62787,4,Which falls scale will be used for Admission Holds in the ED?,209084,3,"d.	None of the above",0
9627,Elearning-0000-847,"FY2021 SURGICAL SERVICES: CULTURE OF SAFETY, ACCOUNTABILITY, AND PROFESSIONALISM",n13876,62788,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Culture of Safety, Accountability and Professionalism"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209085,0,TRUE,1
9627,Elearning-0000-847,"FY2021 SURGICAL SERVICES: CULTURE OF SAFETY, ACCOUNTABILITY, AND PROFESSIONALISM",n13876,62788,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""FY2021 Surgical Services: Culture of Safety, Accountability and Professionalism"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209086,1,FALSE,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62789,0,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,209087,0,TRUE,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62789,0,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,209088,1,FALSE,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62790,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209089,0,A) 10 minutes,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62790,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209090,1,B) 2 minutes,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62790,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209091,2,C) 1 minute,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62790,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209092,3,D) 1 hour,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62791,2,"True or False? <br><br> You receive a patient while Alteplase is infusing.<br><br> The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",209093,0,TRUE,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62791,2,"True or False? <br><br> You receive a patient while Alteplase is infusing.<br><br> The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",209094,1,FALSE,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62792,3,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br><ul> <li>Every 15 minutes for 2 hours, then""¶</li> <li>Every 30 minutes for 6 hours, then""¶</li> <li>Every hour for __ hours.</li> </ul>",209095,0,A. 10 hrs,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62792,3,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br><ul> <li>Every 15 minutes for 2 hours, then""¶</li> <li>Every 30 minutes for 6 hours, then""¶</li> <li>Every hour for __ hours.</li> </ul>",209096,1,B. 24 hrs,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62792,3,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br><ul> <li>Every 15 minutes for 2 hours, then""¶</li> <li>Every 30 minutes for 6 hours, then""¶</li> <li>Every hour for __ hours.</li> </ul>",209097,2,C. 16 hrs,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62793,4,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,209098,0,A. Turn off Alteplase infusion,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62793,4,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,209099,1,B. Give prn Labetalol as per the Alteplase order set,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62793,4,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,209100,2,C. Do a stat EKG,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62794,5,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",209101,0,A) 56.4 mg,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62794,5,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",209102,1,B)  50 mg,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62794,5,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",209103,2,C)  63 mg,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62795,6,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",209104,0,A) 56.4 mg,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62795,6,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",209105,1,B) 50 mg,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62795,6,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",209106,2,C) 37 mg,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62796,7,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",209107,0,A)  6.3 mg,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62796,7,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",209108,1,B)  5 mg,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62796,7,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",209109,2,C) 5.6 mg,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62797,8,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",209110,0,A) 6.3 mg,0
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62797,8,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",209111,1,B) 56.7 mg,1
9709,Elearning-0000-921,ALTEPLASE EDUCATION FOR CRITICAL CARE,n13877,62797,8,"<u><b>Alteplase Dosing</b></u><br><br> Total Dose formula:	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:   Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",209112,2,C) 53.8 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62798,0,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,209113,0,TRUE,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62798,0,True or False?  It is appropriate to get an approximate weight to save on time when giving Alteplase?,209114,1,FALSE,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62799,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209115,0,A) 10 minutes,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62799,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209116,1,B) 2 minutes,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62799,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209117,2,C) 1 minute,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62799,1,Alteplase bolus should be 10% of total calculated dose and should be administered over:,209118,3,C) 1 hour,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62800,2,"True or False? <br> You receive a patient while Alteplase is infusing.  The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",209119,0,TRUE,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62800,2,"True or False? <br> You receive a patient while Alteplase is infusing.  The transferring nurse and receiving nurse perform a bedside NIHSS together and the transferring nurse should report the last completed vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment as documented on the flowsheet and the next time the ordered assessments are due.",209120,1,FALSE,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62801,3,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br> <ul> <li>Every 15 minutes for 2 hours, then""¶</li> <li>Every 30 minutes for 6 hours, then""¶</li> <li>Every hour for __ hours.</li> </ul>",209121,0,A. 10 hrs,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62801,3,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br> <ul> <li>Every 15 minutes for 2 hours, then""¶</li> <li>Every 30 minutes for 6 hours, then""¶</li> <li>Every hour for __ hours.</li> </ul>",209122,1,B. 24 hrs,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62801,3,"Patients who receive Alteplase must have vitals, cardiac rhythm, NIHSS and bleeding/angioedema assessment documented:<br> <ul> <li>Every 15 minutes for 2 hours, then""¶</li> <li>Every 30 minutes for 6 hours, then""¶</li> <li>Every hour for __ hours.</li> </ul>",209123,2,C. 16 hrs,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62802,4,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,209124,0,A. Turn off Alteplase infusion,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62802,4,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,209125,1,B. Give prn Labetalol as per the Alteplase order set,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62802,4,Your patient has been receiving Alteplase for 30 minutes when his B/P goes up to 191/115. What is your next step?,209126,2,C. Do a stat EKG,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62803,5,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",209127,0,A) 56.4 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62803,5,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",209128,1,B)  50 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62803,5,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Total Dose is:</b>",209129,2,C)  63 mg,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62804,6,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",209130,0,A) 56.4 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62804,6,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",209131,1,B) 50 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62804,6,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Discard amount is:</b>",209132,2,C) 37 mg,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62805,7,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",209133,0,A)  6.3 mg,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62805,7,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",209134,1,B)  5 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62805,7,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Bolus dose is:</b>",209135,2,C) 5.6 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62806,8,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",209136,0,A) 6.3 mg,0
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62806,8,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",209137,1,B) 56.7 mg,1
9708,Elearning-0000-920,ALTEPLASE EDUCATION FOR RRT,n13878,62806,8,"<b>Alteplase Dosing</b><br><br> Total Dose formula: 	   0.9 mg/kg x _____kg = ____mg (max dose 90mg).<br> Bolus dose formula: 	   Total dose x 0.1 = ____ mg<br> Infusion dose formula:    Total dose - bolus dose = ____ mg / 1 mg/mL / 1 hour = infusion rate = ____mL/hr<br> Amount to discard formula:   100mg - Total dose = ____ mg (discard prior to administration)<br> Patient Weight = 70kg<br><br> <b>Infusion dose is:</b>",209138,2,C) 53.8 mg,0
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62807,0,Patients must have:,209139,0,"a)	Relapsed/refractory Multiple Myeloma",1
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62807,0,Patients must have:,209140,1,"b)	Relapsed/refractory AML",0
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62807,0,Patients must have:,209141,2,"c)	Relapsed/refractory NHL",0
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62807,0,Patients must have:,209142,3,"d)	None of the above",0
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62808,1,Patients will be randomized to receive either bb2121 CAR-T cells or a standard of care combination therapy.,209143,0,"a)	True",0
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62808,1,Patients will be randomized to receive either bb2121 CAR-T cells or a standard of care combination therapy.,209144,1,"b)	False",1
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62809,2,Patients must have achieved a minimal response or better to at least 1 prior regimen to be eligible.,209145,0,a) True,1
9655,Elearning-0000-872,NSH 1304 KARMMA-7,n13879,62809,2,Patients must have achieved a minimal response or better to at least 1 prior regimen to be eligible.,209146,1,b) False,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62810,0,State and federal law require hospitals to provide appropriate medical screening exams and stabilizing treatment to any patient who comes to the hospital requesting examination or treatment?,209147,0,a. True,1
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62810,0,State and federal law require hospitals to provide appropriate medical screening exams and stabilizing treatment to any patient who comes to the hospital requesting examination or treatment?,209148,1,b. False,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62811,1,Who may perform a screening examination?,209149,0,a. Physician Assistant,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62811,1,Who may perform a screening examination?,209150,1,b. Certified Nurse Midwife,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62811,1,Who may perform a screening examination?,209151,2,c. Advanced Practice RN,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62811,1,Who may perform a screening examination?,209152,3,d. MD,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62811,1,Who may perform a screening examination?,209153,4,e. All of the above,1
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62812,2,"Northside hospital personnel should <u>not</u> advise parents to go to ""Children's Hospital""ù before the screening exam is completed?",209154,0,a. True,1
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62812,2,"Northside hospital personnel should <u>not</u> advise parents to go to ""Children's Hospital""ù before the screening exam is completed?",209155,1,b. False,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62813,3,Triage assessment by a RN is considered a medical screening exam?,209156,0,a. True,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62813,3,Triage assessment by a RN is considered a medical screening exam?,209157,1,b. False,1
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62814,4,Concerns regarding possible violations of the EMTALA policy should be referred to the,209158,0,a. ED Supervisor,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62814,4,Concerns regarding possible violations of the EMTALA policy should be referred to the,209159,1,b. House Coordinator/ PSC,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62814,4,Concerns regarding possible violations of the EMTALA policy should be referred to the,209160,2,c. Risk Management,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62814,4,Concerns regarding possible violations of the EMTALA policy should be referred to the,209161,3,d. either b or c,1
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62815,5,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",209162,0,a. ED Supervisor,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62815,5,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",209163,1,b. House Coordinator/ PSC/ Transfer Line for Gwinnett,1
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62815,5,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",209164,2,c. ED Physician,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62815,5,"Requests to transfer patients <u>from other facilities, including</u> other Northside facilities, will be referred to the  ________________  who is responsible for determining whether the Hospital has sufficient capacity to treat the patient at the time the transfer is requested.",209165,3,d. Risk Management,0
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62816,6,"Patients  who leave from the ED or L&D prior to the medical screening being completed should be provided the form called ""Leaving Against Medical Advice""ù to sign after review the content.",209166,0,a. True,1
9691,Elearning-0000-905,EMTALA ANNUAL EDUCATION FOR THE ED AND L&D STAFF,n13880,62816,6,"Patients  who leave from the ED or L&D prior to the medical screening being completed should be provided the form called ""Leaving Against Medical Advice""ù to sign after review the content.",209167,1,b. False,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63304,0,Please list the location for this activity.,211010,0,Atlanta,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63304,0,Please list the location for this activity.,211011,1,Cherokee,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63304,0,Please list the location for this activity.,211012,2,Forsyth,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63304,0,Please list the location for this activity.,211013,3,Other,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63305,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",211014,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63305,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",211015,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63305,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",211016,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63305,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",211017,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63305,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",211018,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63306,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",211019,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63306,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",211020,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63306,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",211021,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63306,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",211022,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63306,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",211023,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63307,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",211024,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63307,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",211025,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63307,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",211026,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63307,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",211027,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63307,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",211028,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63308,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",211029,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63308,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",211030,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63308,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",211031,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63308,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",211032,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63308,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",211033,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63309,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",211034,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63309,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",211035,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63309,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",211036,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63309,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",211037,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63309,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",211038,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63310,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",211039,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63310,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",211040,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63310,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",211041,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63310,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",211042,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63310,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",211043,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63311,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211044,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63311,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211045,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63311,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211046,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63311,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211047,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63311,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211048,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63312,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211049,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63312,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211050,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63312,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211051,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63312,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211052,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63312,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211053,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63313,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211054,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63313,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211055,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63313,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211056,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63313,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211057,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63313,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211058,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63314,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211059,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63314,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211060,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63314,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211061,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63314,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211062,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63314,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,211063,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63315,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,211064,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63315,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,211065,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63315,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,211066,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63315,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,211067,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63315,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,211068,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63316,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211069,0,Strongly Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63316,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211070,1,Agree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63316,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211071,2,No Opinion,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63316,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211072,3,Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63316,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211073,4,Strongly Disagree,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63317,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",211074,0,Excellent,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63317,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",211075,1,Very Good,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63317,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",211076,2,Good,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63317,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",211077,3,Fair,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63317,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Bailey Ray, RN, BSN, OCN</ol>",211078,4,Poor,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63318,14,"Overall, this activity was:",211079,0,Excellent,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63318,14,"Overall, this activity was:",211080,1,Very Good,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63318,14,"Overall, this activity was:",211081,2,Good,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63318,14,"Overall, this activity was:",211082,3,Fair,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63318,14,"Overall, this activity was:",211083,4,Poor,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63319,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211084,0,Yes,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63319,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211085,1,No,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63319,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211086,2,N/A,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63322,18,How would you improve this class?,211087,0,Reduce content covered in class,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63322,18,How would you improve this class?,211088,1,Increase content covered in class,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63322,18,How would you improve this class?,211089,2,Update content covered in class,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63322,18,How would you improve this class?,211090,3,Improve the instructional methods,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63322,18,How would you improve this class?,211091,4,Make course activities more stimulating,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63322,18,How would you improve this class?,211092,5,Slow the pace of the class,0
9808,Questions-0000-103,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSC 07-9-21,n13938,63322,18,How would you improve this class?,211093,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62864,0,Please list the location for this activity.,209361,0,Atlanta,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62864,0,Please list the location for this activity.,209362,1,Cherokee,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62864,0,Please list the location for this activity.,209363,2,Forsyth,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62864,0,Please list the location for this activity.,209364,3,Other,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62865,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",209365,0,Strongly Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62865,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",209366,1,Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62865,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",209367,2,No Opinion,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62865,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",209368,3,Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62865,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state the difference between gap identification and needs assessment.</ol>",209369,4,Strongly Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62866,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",209370,0,Strongly Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62866,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",209371,1,Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62866,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",209372,2,No Opinion,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62866,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",209373,3,Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62866,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the differences between a knowledge gap vs a skills gap vs a practice gap.</ol>",209374,4,Strongly Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62867,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",209375,0,Strongly Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62867,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",209376,1,Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62867,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",209377,2,No Opinion,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62867,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",209378,3,Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62867,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe tools and strategies that can be utilized for gap identification and validation.</ol>",209379,4,Strongly Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62868,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209380,0,Strongly Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62868,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209381,1,Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62868,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209382,2,No Opinion,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62868,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209383,3,Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62868,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209384,4,Strongly Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62869,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,209385,0,Strongly Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62869,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,209386,1,Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62869,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,209387,2,No Opinion,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62869,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,209388,3,Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62869,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence as it relates to incorporating gap identification and gap validation strategies/tools into my education design process.</OL>,209389,4,Strongly Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62870,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",209390,0,Strongly Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62870,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",209391,1,Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62870,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",209392,2,No Opinion,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62870,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",209393,3,Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62870,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.<ol>",209394,4,Strongly Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62871,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,209395,0,Strongly Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62871,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,209396,1,Agree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62871,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,209397,2,No Opinion,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62871,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,209398,3,Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62871,7,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,209399,4,Strongly Disagree,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62872,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",209400,0,Excellent,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62872,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",209401,1,Very Good,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62872,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",209402,2,Good,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62872,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",209403,3,Fair,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62872,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",209404,4,Poor,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62872,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Pamela Noonan, MS, BSN, NPD-BC</ol>",209405,5,N/A,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62873,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",209406,0,Excellent,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62873,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",209407,1,Very Good,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62873,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",209408,2,Good,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62873,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",209409,3,Fair,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62873,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",209410,4,Poor,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62873,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Natasha Melbourne, MSN, RN</ol>",209411,5,N/A,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62874,10,"Overall, this activity was:",209412,0,Excellent,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62874,10,"Overall, this activity was:",209413,1,Very Good,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62874,10,"Overall, this activity was:",209414,2,Good,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62874,10,"Overall, this activity was:",209415,3,Fair,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62874,10,"Overall, this activity was:",209416,4,Poor,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62875,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209417,0,Yes,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62875,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209418,1,No,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62875,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209419,2,N/A,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62878,14,How would you improve this class (check all that apply)?,209420,0,Reduce content covered in class,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62878,14,How would you improve this class (check all that apply)?,209421,1,Increase content covered in class,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62878,14,How would you improve this class (check all that apply)?,209422,2,Update content covered in class,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62878,14,How would you improve this class (check all that apply)?,209423,3,Improve the instructional methods,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62878,14,How would you improve this class (check all that apply)?,209424,4,Make course activities more stimulating,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62878,14,How would you improve this class (check all that apply)?,209425,5,Slow the pace of the class,0
9939,Questions-0000-73,MIND THE GAP (EVALUATION SURVEY) 6-17-21,n13884,62878,14,How would you improve this class (check all that apply)?,209426,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62881,0,Please list the location for this activity.,209427,0,Atlanta,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62881,0,Please list the location for this activity.,209428,1,Cherokee,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62881,0,Please list the location for this activity.,209429,2,Forsyth,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62881,0,Please list the location for this activity.,209430,3,Other,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62882,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",209431,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62882,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",209432,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62882,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",209433,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62882,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",209434,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62882,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",209435,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62883,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",209436,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62883,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",209437,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62883,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",209438,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62883,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",209439,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62883,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",209440,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62884,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",209441,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62884,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",209442,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62884,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",209443,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62884,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",209444,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62884,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",209445,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62885,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",209446,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62885,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",209447,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62885,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",209448,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62885,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",209449,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62885,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",209450,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62886,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",209451,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62886,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",209452,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62886,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",209453,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62886,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",209454,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62886,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",209455,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62887,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",209456,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62887,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",209457,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62887,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",209458,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62887,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",209459,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62887,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",209460,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62888,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209461,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62888,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209462,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62888,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209463,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62888,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209464,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62888,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209465,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62889,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209466,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62889,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209467,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62889,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209468,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62889,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209469,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62889,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209470,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62890,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209471,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62890,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209472,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62890,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209473,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62890,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209474,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62890,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209475,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62891,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209476,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62891,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209477,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62891,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209478,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62891,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209479,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62891,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,209480,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62892,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,209481,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62892,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,209482,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62892,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,209483,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62892,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,209484,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62892,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,209485,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62893,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209486,0,Strongly Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62893,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209487,1,Agree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62893,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209488,2,No Opinion,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62893,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209489,3,Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62893,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209490,4,Strongly Disagree,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62894,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",209491,0,Excellent,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62894,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",209492,1,Very Good,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62894,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",209493,2,Good,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62894,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",209494,3,Fair,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62894,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Patricia Thompson, MSN, RN, OCN</ol>",209495,4,Poor,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62895,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",209496,0,Excellent,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62895,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",209497,1,Very Good,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62895,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",209498,2,Good,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62895,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",209499,3,Fair,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62895,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Laura Stanley, BSN, RN, BMTCN</ol>",209500,4,Poor,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62896,15,"Overall, this activity was:",209501,0,Excellent,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62896,15,"Overall, this activity was:",209502,1,Very Good,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62896,15,"Overall, this activity was:",209503,2,Good,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62896,15,"Overall, this activity was:",209504,3,Fair,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62896,15,"Overall, this activity was:",209505,4,Poor,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62897,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209506,0,Yes,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62897,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209507,1,No,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62897,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209508,2,N/A,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62900,19,How would you improve this class?,209509,0,Reduce content covered in class,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62900,19,How would you improve this class?,209510,1,Increase content covered in class,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62900,19,How would you improve this class?,209511,2,Update content covered in class,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62900,19,How would you improve this class?,209512,3,Improve the instructional methods,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62900,19,How would you improve this class?,209513,4,Make course activities more stimulating,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62900,19,How would you improve this class?,209514,5,Slow the pace of the class,0
9809,Questions-0000-104,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSF 06-22-21,n13885,62900,19,How would you improve this class?,209515,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62905,0,Please list the location for this activity.,209520,0,Atlanta,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62905,0,Please list the location for this activity.,209521,1,Forsyth,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62905,0,Please list the location for this activity.,209522,2,Cherokee,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62905,0,Please list the location for this activity.,209523,3,Other,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62906,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",209524,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62906,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",209525,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62906,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",209526,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62906,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",209527,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62906,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",209528,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62907,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",209529,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62907,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",209530,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62907,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",209531,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62907,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",209532,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62907,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",209533,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62908,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",209534,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62908,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",209535,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62908,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",209536,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62908,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",209537,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62908,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",209538,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62909,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",209539,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62909,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",209540,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62909,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",209541,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62909,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",209542,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62909,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",209543,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62910,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",209544,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62910,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",209545,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62910,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",209546,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62910,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",209547,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62910,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",209548,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62911,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",209549,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62911,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",209550,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62911,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",209551,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62911,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",209552,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62911,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",209553,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62912,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",209554,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62912,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",209555,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62912,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",209556,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62912,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",209557,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62912,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",209558,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62913,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209559,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62913,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209560,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62913,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209561,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62913,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209562,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62913,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209563,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62914,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,209564,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62914,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,209565,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62914,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,209566,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62914,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,209567,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62914,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,209568,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62915,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209569,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62915,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209570,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62915,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209571,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62915,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209572,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62915,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209573,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62916,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",209574,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62916,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",209575,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62916,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",209576,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62916,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",209577,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62916,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",209578,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62917,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209579,0,Strongly Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62917,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209580,1,Agree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62917,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209581,2,No Opinion,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62917,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209582,3,Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62917,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,209583,4,Strongly Disagree,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62918,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",209584,0,Excellent,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62918,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",209585,1,Very Good,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62918,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",209586,2,Good,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62918,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",209587,3,Fair,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62918,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",209588,4,Poor,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62919,14,"Overall, this activity was:",209589,0,Excellent,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62919,14,"Overall, this activity was:",209590,1,Very Good,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62919,14,"Overall, this activity was:",209591,2,Good,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62919,14,"Overall, this activity was:",209592,3,Fair,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62919,14,"Overall, this activity was:",209593,4,Poor,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62920,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209594,0,Yes,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62920,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209595,1,No,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62920,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209596,2,N/A,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62923,18,How would you improve this class?,209597,0,Reduce content covered in class,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62923,18,How would you improve this class?,209598,1,Increase content covered in class,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62923,18,How would you improve this class?,209599,2,Update content covered in class,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62923,18,How would you improve this class?,209600,3,Improve the instructional methods,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62923,18,How would you improve this class?,209601,4,Make course activities more stimulating,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62923,18,How would you improve this class?,209602,5,Slow the pace of the class,0
9950,Questions-0000-84,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 6-23-21,n13888,62923,18,How would you improve this class?,209603,6,"Nothing: (appropriate content, speaker, setting, setting.)",0
9358,Elearning-0000-602,CONTINUOUS READINESS: FIRE SAFETY EDUCATION,n13891,62928,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Continuous Readiness: Fire Safety Education CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",209608,0,TRUE,1
9358,Elearning-0000-602,CONTINUOUS READINESS: FIRE SAFETY EDUCATION,n13891,62928,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Continuous Readiness: Fire Safety Education CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",209609,1,FALSE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62929,0,A Bronch Wash is any volume less than 20ml,209610,0,TRUE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62929,0,A Bronch Wash is any volume less than 20ml,209611,1,FALSE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62930,1,A Bronchial Alveolar Lavage is any volume 20ml or greater,209612,0,TRUE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62930,1,A Bronchial Alveolar Lavage is any volume 20ml or greater,209613,1,FALSE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62931,2,What do you need to be aware of before giving Phenylephrine,209614,0,1. It can decrease blood pressure,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62931,2,What do you need to be aware of before giving Phenylephrine,209615,1,2. It can increase blood pressure,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62931,2,What do you need to be aware of before giving Phenylephrine,209616,2,3. It can cause a fast/irregular heartbeat,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62931,2,What do you need to be aware of before giving Phenylephrine,209617,3,4. It can increase the blood pressure and cause a fast/irregular heartbeat.,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62932,3,Correct mixture for Phenylephrine is,209618,0,1. 10ml mixed with 1ml of 0.9% Sodium Chloride,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62932,3,Correct mixture for Phenylephrine is,209619,1,2. 1ml mixed with 9ml of 0.9% Sodium Chloride,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62932,3,Correct mixture for Phenylephrine is,209620,2,3. 1ml mixed with 9ml of 0.9% Sodium Bicarb,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62933,4,What is the best way to achieve hemostasis in the lung,209621,0,1. CPAP,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62933,4,What is the best way to achieve hemostasis in the lung,209622,1,2. Iced normal saline lavage,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62933,4,What is the best way to achieve hemostasis in the lung,209623,2,3. Hold pressure with the bronchoscope,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62934,5,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",209624,0,1. 10%,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62934,5,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",209625,1,2. 1%,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62934,5,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",209626,2,3. 5%,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62934,5,"When prepping nares for a bronchoscopy, what% viscous lidocaine should be used",209627,3,4. 2%,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62935,6,"When prepping a patient for a bronchoscopy, with platelets less than 50, you should prep the mouth instead of the nares",209628,0,TRUE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62935,6,"When prepping a patient for a bronchoscopy, with platelets less than 50, you should prep the mouth instead of the nares",209629,1,FALSE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62936,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,209630,0,1. Formaldehyde,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62936,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,209631,1,2. Alcohol,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62936,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,209632,2,3. Peroxide,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62936,7,Cytology brushings are fixed on slides and sprayed with what fixative spray?,209633,3,4. Hairspray,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62937,8,You should always wear gloves when touching a bronchoscope?,209634,0,TRUE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62937,8,You should always wear gloves when touching a bronchoscope?,209635,1,FALSE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62938,9,The Medication sheet should be:,209636,0,1. Signed and dated only,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62938,9,The Medication sheet should be:,209637,1,2. Noted and timed only,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62938,9,The Medication sheet should be:,209638,2,"3. Signed, dated, timed, and noted",1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62938,9,The Medication sheet should be:,209639,3,4. None of the above,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62939,10,The bedside pre-clean of the bronchoscope can be done after you take the samples to the lab,209640,0,TRUE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62939,10,The bedside pre-clean of the bronchoscope can be done after you take the samples to the lab,209641,1,FALSE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62940,11,The enzymatic sponge is utilized during the bedside pre-clean,209642,0,TRUE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62940,11,The enzymatic sponge is utilized during the bedside pre-clean,209643,1,FALSE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62941,12,You should transport a bronchoscope in a closed bin,209644,0,TRUE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62941,12,You should transport a bronchoscope in a closed bin,209645,1,FALSE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62942,13,It is ok if a clean bronchoscope touches another clean bronchoscope while stored in gi lab,209646,0,TRUE,0
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62942,13,It is ok if a clean bronchoscope touches another clean bronchoscope while stored in gi lab,209647,1,FALSE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62943,14,Physicians are responsible for placing bronch orders in to cerner,209648,0,TRUE,1
9569,Elearning-0000-794,2021 ANNUAL BRONCH TEST,n13892,62943,14,Physicians are responsible for placing bronch orders in to cerner,209649,1,FALSE,0
9472,Elearning-0000-706,CHEROKEE PNUEMONIA DSC FOR RT 2021,n13894,62944,0,What are the 4 indicators we are measuring for Pneumonia DSC?,209650,0,"1. Nursing documentation of SMI, progressive mobility, antibiotic stewardship, pneumonia vaccination",0
9472,Elearning-0000-706,CHEROKEE PNUEMONIA DSC FOR RT 2021,n13894,62944,0,What are the 4 indicators we are measuring for Pneumonia DSC?,209651,1,"2. Oral care, progressive mobility, diet reconciliation, oxygen weaning",0
9472,Elearning-0000-706,CHEROKEE PNUEMONIA DSC FOR RT 2021,n13894,62944,0,What are the 4 indicators we are measuring for Pneumonia DSC?,209652,2,"3. Oxygen weaning, nursing documentation of SMI, progressive mobility, % of follow up appointment within 7days of discharge with PCP or Pulmonologist",1
9472,Elearning-0000-706,CHEROKEE PNUEMONIA DSC FOR RT 2021,n13894,62944,0,What are the 4 indicators we are measuring for Pneumonia DSC?,209653,3,"4. Hand hygiene, oxygen weaning, oral care, progressive mobility",0
9647,Elearning-0000-865,POLICY & PROCEDURE UPDATES FOR ONCOLOGY NURSING,n13896,62946,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Policy & Procedure Updates for Oncology Nursing"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209656,0,TRUE,1
9647,Elearning-0000-865,POLICY & PROCEDURE UPDATES FOR ONCOLOGY NURSING,n13896,62946,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Policy & Procedure Updates for Oncology Nursing"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209657,1,FALSE,0
260,SCORM-0000-70,NEUROSURGERY SPINE LECTURE - 6TH FLOOR NSC,n13897,49408,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Neurosurgery Spine Lecture - 6th Floor NSC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",161829,0,TRUE,1
260,SCORM-0000-70,NEUROSURGERY SPINE LECTURE - 6TH FLOOR NSC,n13897,49408,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Neurosurgery Spine Lecture - 6th Floor NSC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",161830,1,FALSE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62947,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",209658,0,TRUE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62947,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",209659,1,FALSE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62948,1,Which one of the following hazardous medication list grouping is incorrect?,209660,0,"a.	Group 2 - Hazardous agents (primarily reproductive risk)",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62948,1,Which one of the following hazardous medication list grouping is incorrect?,209661,1,"b.	Group 1 - Hazardous agents (cytotoxic antineoplastic/reproductive risks)",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62948,1,Which one of the following hazardous medication list grouping is incorrect?,209662,2,"c.	Group 2A - Non-hazardous antineoplastic agents",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62948,1,Which one of the following hazardous medication list grouping is incorrect?,209663,3,"d.	Appendix D - Excluded drugs based on NSH risk assessment",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62949,2,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",209664,0,TRUE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62949,2,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",209665,1,FALSE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62950,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",209666,0,"a.	Decontamination",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62950,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",209667,1,"b.	Cleaning",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62950,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",209668,2,"c.	Disinfection",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62950,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",209669,3,"d.	Deactivate",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62950,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",209670,4,"e.	All of the above",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62951,4,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",209671,0,TRUE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62951,4,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",209672,1,FALSE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62952,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,209673,0,"a.	Protective Gown",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62952,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,209674,1,"b.	Eye/Face protection",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62952,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,209675,2,"c.	Respiratory protection",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62952,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,209676,3,"d.	Footwear",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62952,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,209677,4,"e.	Gloves",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62952,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,209678,5,"f.	All of the above",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62953,6,The spill response team is activated for any spills that is not contained by the following:,209679,0,"a.	Two Spill Kits",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62953,6,The spill response team is activated for any spills that is not contained by the following:,209680,1,"b.	Single Spill Kit",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62953,6,The spill response team is activated for any spills that is not contained by the following:,209681,2,"c.	Three Spill Kits",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62953,6,The spill response team is activated for any spills that is not contained by the following:,209682,3,"d.	Any spill in patient care area",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62953,6,The spill response team is activated for any spills that is not contained by the following:,209683,4,"e.	Any spill in pharmacy area",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62954,7,Gloves used in the preparation of HDs must be:,209684,0,"a.	Disposable",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62954,7,Gloves used in the preparation of HDs must be:,209685,1,"b.	Powdered to facilitate removal",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62954,7,Gloves used in the preparation of HDs must be:,209686,2,"c.	Specified as ASTM-tested chemotherapy gloves",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62954,7,Gloves used in the preparation of HDs must be:,209687,3,"d.	A and C",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62955,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",209688,0,"a.	Filter needles",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62955,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",209689,1,"b.	Leur-Lock syringes",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62955,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",209690,2,"c.	Closed-system transfer devices (CSTDs)",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62955,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",209691,3,"d.	None of the above",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62956,9,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,209692,0,TRUE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62956,9,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,209693,1,FALSE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62957,10,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,209694,0,"a.	Biological safety cabinet (BSC)",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62957,10,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,209695,1,"b.	Horizontal laminar air flow workbench",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62957,10,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,209696,2,"c.	Compounding aseptic containment isolator (CACI)",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62957,10,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,209697,3,"d.	A and C",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62958,11,Spill kits:,209698,0,"a.	May be obtained from Central Supply when needed",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62958,11,Spill kits:,209699,1,"b.	Are kept wherever HDs and chemotherapy agents are handled",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62958,11,Spill kits:,209700,2,"c.	Contain supplies needed to clean a HD spill",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62958,11,Spill kits:,209701,3,"d.	All of the above",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62959,12,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",209702,0,TRUE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62959,12,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",209703,1,FALSE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62960,13,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",209704,0,TRUE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62960,13,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",209705,1,FALSE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62961,14,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",209706,0,TRUE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62961,14,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",209707,1,FALSE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62962,15,How often do you have to change the gown during hazardous drug compounding?,209708,0,"a.	At least every 12 hours",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62962,15,How often do you have to change the gown during hazardous drug compounding?,209709,1,"b.	At least every 24 hours",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62962,15,How often do you have to change the gown during hazardous drug compounding?,209710,2,"c.	At least every 3 hours",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62962,15,How often do you have to change the gown during hazardous drug compounding?,209711,3,"d.	 At shift change",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62963,16,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,209712,0,TRUE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62963,16,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,209713,1,FALSE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62964,17,Which statement is true?,209714,0,"a.	Cytotoxic chemotherapy doses maybe rounded down or up to the nearest vials size within < 5% of the calculated dose",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62964,17,Which statement is true?,209715,1,"b.	Cytotoxic chemotherapy doses maybe rounded down to the nearest vials size within < 5% of the calculated dose",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62964,17,Which statement is true?,209716,2,"c.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 10% of the calculated dose.",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62964,17,Which statement is true?,209717,3,"d.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 5% of the calculated dose.",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62964,17,Which statement is true?,209718,4,"e.	a & c",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62964,17,Which statement is true?,209719,5,"f.	b & c",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62965,18,PA or NP may sign C1D1 chemotherapy orders.,209720,0,TRUE,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62965,18,PA or NP may sign C1D1 chemotherapy orders.,209721,1,FALSE,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62966,19,Which statement is false?,209722,0,a. Verbal and telephone orders to initiate chemotherapy will not be accepted,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62966,19,Which statement is false?,209723,1,b. A physician must sign C1D1 chemotherapy orders,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62966,19,Which statement is false?,209724,2,c. Pregnancy screening is required at baseline and then at least once a week while the patient is on therapy,1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62966,19,Which statement is false?,209725,3,d. Treating physicians are responsible for monitoring cumulative anthracycline doses,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62969,20,How often do you have to change the outer gloves during hazardous drug sterile compounding?,209730,0,"a.	At least every 8 hours",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62969,20,How often do you have to change the outer gloves during hazardous drug sterile compounding?,209731,1,"b.	At least every 3  hours",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62969,20,How often do you have to change the outer gloves during hazardous drug sterile compounding?,209732,2,"c.	At least every 30 minutes",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62969,20,How often do you have to change the outer gloves during hazardous drug sterile compounding?,209733,3,At shift change,0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62970,21,When wearing double gloves:,209734,0,"a.	The gown cuffs should be tucked over both gloves",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62970,21,When wearing double gloves:,209735,1,"b.	The gown cuffs should be tucked under both gloves",0
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62970,21,When wearing double gloves:,209736,2,"c.	The inner glove should be worn under the cuff and the outer glove should be worn over the gown cuff",1
9251,Elearning-0000-505,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION,n13899,62970,21,When wearing double gloves:,209737,3,"d.	It makes no difference if gown cuffs are worn over or under the gloves",0
8388,Elearning-0000-126,TELESTROKE EDUCATION TRAINING FOR RRT AND HC,n13901,62968,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Telestroke Education Training For RRT and HC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",209728,0,TRUE,1
8388,Elearning-0000-126,TELESTROKE EDUCATION TRAINING FOR RRT AND HC,n13901,62968,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Telestroke Education Training For RRT and HC CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",209729,1,FALSE,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62974,0,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",209744,0,Repeat BP in 5 minutes,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62974,0,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",209745,1,Repeat BP in 15 minutes,1
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62974,0,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",209746,2,Administer an extra dose of labetalol 300 mg PO,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62974,0,"Ms. Jones is a 19 year old G1PO patient that delivered a 36 week baby girl by C section. The patient had a c section related to severe preeclampsia. The patient was on magnesium sulfate for 24 hours after delivery. She is prescribed labetalol 300 mg PO TID. Her blood pressures have ranged 130s-150s/70s-90s since admission.   At 48 hours postpartum, the patient's blood pressure is 176/97.  What is your next nursing action?",209747,3,Notify the provider,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62975,1,The patient's blood pressure 15 minutes later is 159/110 and she is now complaining of a headache.  What is your next nursing action?,209748,0,Wait 30 minutes and recheck the blood pressure again to make sure it was a valid blood pressure reading,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62975,1,The patient's blood pressure 15 minutes later is 159/110 and she is now complaining of a headache.  What is your next nursing action?,209749,1,Call the provider to determine what regimen to initiate,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62975,1,The patient's blood pressure 15 minutes later is 159/110 and she is now complaining of a headache.  What is your next nursing action?,209750,2,Review the admission orders to determine which regimen was selected in the communication order,1
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62976,2,"The patient has a communication order to initiate the IV hydralazine regimen for severe, sustained hypertension.  What is your next nursing action?",209751,0,Place an order for the hydralazine regimen via the OB Hypertension Acute NSH orders as a standing order,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62976,2,"The patient has a communication order to initiate the IV hydralazine regimen for severe, sustained hypertension.  What is your next nursing action?",209752,1,Place an order for the hydralazine OB regimen via the Hypertension Acute NSH orders as a protocol order,1
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62976,2,"The patient has a communication order to initiate the IV hydralazine regimen for severe, sustained hypertension.  What is your next nursing action?",209753,2,Place an order for the hydralazine regimen via the OB Hypertension Acute NSH orders as a telephone order,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62977,3,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",209754,0,Repeat the BP in 15 minutes,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62977,3,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",209755,1,Call the provider to obtain a new order for treatment,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62977,3,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",209756,2,Administer the second dose of hydralazine 10 mg IV per the regimen,1
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62977,3,"Hydralazine 10 mg x 1 dose is administered and the patient achieves a target blood pressure of 148/99.  You begin monitoring her blood pressure q 10 min per the orders.  30 minutes after her last dose of hydralazine, the patient's BP is 168/90.  What is your next nursing action?",209757,3,Administer labetalol 20 mg IV,0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62978,4,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",209758,0,Repeat BP in 15 minutes,1
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62978,4,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",209759,1,"Administer Hydralazine 10 mg IV, and notify provider",0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62978,4,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",209760,2,"Administer Labetalol 20 mg IV, and notify provider",0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62978,4,"The second dose of hydralazine 10mg IV is not effective.  You continue to the next dose in the hydralazine regimen and administer labetalol 20 mg IV.  The patient achieves a target blood pressure and maintains target range for the following 4 hours.  During hourly blood pressure monitoring, her blood pressure elevates to 174/90.  What is your next nursing action?",209761,3,"Administer Labetalol 40 mg IV, and notify provider",0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62979,5,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,209762,0,"Administer Hydralazine 10 mg IV, and notify provider",1
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62979,5,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,209763,1,"Administer Labetalol 20 mg IV, and notify provider",0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62979,5,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,209764,2,"Administer Labetalol 40 mg IV, and notify provider",0
9477,Elearning-0000-710,CHANGES TO OB ANTIHYPERTENSIVE MEDICATION ORDERS,n13906,62979,5,15 minutes later the patient's blood pressure is 168/105.  What is your next nursing action?,209765,3,Call the provider to obtain a new order for treatment,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62980,0,"If a patient is not experiencing pain when you assess for it, you should still document at least once per shift that the patient is not experiencing pain.",209766,0,TRUE,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62980,0,"If a patient is not experiencing pain when you assess for it, you should still document at least once per shift that the patient is not experiencing pain.",209767,1,FALSE,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62981,1,Within what time frame do you need to reassess a patient's pain after treatment?,209768,0,a.  3 hours,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62981,1,Within what time frame do you need to reassess a patient's pain after treatment?,209769,1,b. 1 hour,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62981,1,Within what time frame do you need to reassess a patient's pain after treatment?,209770,2,c. 2 hours,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62981,1,Within what time frame do you need to reassess a patient's pain after treatment?,209771,3,d. 4 hours,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62982,2,"When assessing pain you always need to be sure to document Pain rating (0-10), Pain goal, Site, Characteristics, Duration, Sedation, and Interventions.",209772,0,TRUE,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62982,2,"When assessing pain you always need to be sure to document Pain rating (0-10), Pain goal, Site, Characteristics, Duration, Sedation, and Interventions.",209773,1,FALSE,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62983,3,"You need to document all non-pharmacological pain management interventions provided, and reassessment of those interventions as well.",209774,0,TRUE,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62983,3,"You need to document all non-pharmacological pain management interventions provided, and reassessment of those interventions as well.",209775,1,FALSE,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62984,4,What are non-pharmacological pain management interventions?,209776,0,a. Ice,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62984,4,What are non-pharmacological pain management interventions?,209777,1,b. Heat,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62984,4,What are non-pharmacological pain management interventions?,209778,2,c. Massage,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62984,4,What are non-pharmacological pain management interventions?,209779,3,d. Repositioning,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62984,4,What are non-pharmacological pain management interventions?,209780,4,"e. a, b, c, d",1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62985,5,What pain score range is mild pain?,209781,0,a. 1-4,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62985,5,What pain score range is mild pain?,209782,1,b. 1-3,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62985,5,What pain score range is mild pain?,209783,2,c. 1-2,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62985,5,What pain score range is mild pain?,209784,3,d. 1-5,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62986,6,What pain score range is moderate pain?,209785,0,a. 2-6,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62986,6,What pain score range is moderate pain?,209786,1,b. 3-6,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62986,6,What pain score range is moderate pain?,209787,2,c. 4-6,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62986,6,What pain score range is moderate pain?,209788,3,d. 4-5,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62987,7,What pain score range is severe pain?,209789,0,a. 7-10,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62987,7,What pain score range is severe pain?,209790,1,b. 6-10,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62987,7,What pain score range is severe pain?,209791,2,c. 5-10,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62987,7,What pain score range is severe pain?,209792,3,d. 8-10,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62988,8,"Pain treatment should be based off of the patient's pain score dosing range, and you should always check orders to ensure that the treatment aligns with the patients pain score.",209793,0,TRUE,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62988,8,"Pain treatment should be based off of the patient's pain score dosing range, and you should always check orders to ensure that the treatment aligns with the patients pain score.",209794,1,FALSE,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62989,9,Pain should be included in the patients IPOC when they are experiencing pain.,209795,0,TRUE,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62989,9,Pain should be included in the patients IPOC when they are experiencing pain.,209796,1,FALSE,0
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62990,10,The Patient Preference Pain Management Standing order should be utilized when the patient requests pain medication which is in a lower category than what they score their pain as. The medication must be on the patient's medication list.,209797,0,TRUE,1
9645,Elearning-0000-863,PAIN MANAGEMENT - CARDIAC MED/SURG,n13907,62990,10,The Patient Preference Pain Management Standing order should be utilized when the patient requests pain medication which is in a lower category than what they score their pain as. The medication must be on the patient's medication list.,209798,1,FALSE,0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63074,0,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",210115,0,"a.	Patient is not having a major, life-threatening bleed; Hold Rivaroxaban, provide supportive care and control bleeding site until the drug is out his system.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63074,0,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",210116,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63074,0,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",210117,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63074,0,"75 year-old male on Rivaroxaban 15mg daily for atrial fibrillation (CHA2DS2VASc=6) presents to the ED with dizziness, hypotension (BP 80/50), and black tarry stools. Hgb=7, Hct=22.1, plt=193, SCr=2.46 (baseline 1.7). His last dose of Rivaroxaban was 6 hours ago.  The ED provider asks for your recommendation on reversal of Rivaroxaban. Using the NSH reference guide, what will you recommend?",210118,3,"d.	Patient is having a major, life-threatening bleed; administer idarucizumab 5g IV as 2 consecutive doses of 2.5mg each",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63075,1,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",210119,0,"a.	Bleeding at a critical site such as intracranial hemorrhage, CNS bleeds (intraocular, spinal), thoracic, intra-abdominal (not including intraluminal GI bleeding)",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63075,1,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",210120,1,"b.	Bleeding that results in hemodynamic instability such as hypotension (SBP <90 mmHg or a drop in SBP >40 mmHg from baseline), tachycardia, or makers of poor organ perfusion (ex. UOP < 0.5mL/kg/hr)",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63075,1,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",210121,2,"c.	Overt bleeding resulting in hemoglobin drop of 2 g/dL or more from baseline",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63075,1,"Due to their high risk for thrombotic events, anticoagulant reversal agents should only be used to treat major, life-threatening bleeding events. Which of the following are considered a major, life-threatening bleed?",210122,3,"d.	All of the above",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63076,2,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210123,0,"a.	Patient is not having a major, life-threatening bleed; Hold Apixaban, provide supportive care and control bleeding site until the drug is out her system.",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63076,2,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210124,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63076,2,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210125,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63076,2,"83 year-old patient on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 110/70 (normal for her baseline), Hbg=10, Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210126,3,"d.	Patient is having a major, life-threatening bleed; administer idarucizumab 5g IV as 2 consecutive doses of 2.5mg each",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63077,3,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210127,0,"a.	Patient is not having a major, life-threatening bleed; Hold Apixaban, provide supportive care and control bleeding site until the drug is out her system.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63077,3,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210128,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63077,3,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210129,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63077,3,"83 year-old female on Apixaban 5mg BID for atrial fibrillation presents to the ED with bright red blood per rectum x 2 days. Blood pressure is 80/50 (baseline 110/80), Hbg=7 (baseline 10), Hct=28, plt=145, SCr=0.8 (baseline 0.9). Her lase dose of Apixaban was 10 hours ago. The ED provider asks for your recommendation on reversal of Apixaban. Using the NSH reference guide, what will you recommend?",210130,3,"d.	Patient is having a major, life-threatening bleed; administer idarucizumab 5g IV as 2 consecutive doses of 2.5mg each",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63078,4,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",210131,0,"a.	Patient is not having a major, life-threatening bleed; Hold Edoxaban, provide supportive care and control bleeding site until the drug is out his system.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63078,4,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",210132,1,"b.	Patient is having a major, life-threatening bleed; administer high dose andexanet alfa: 800mg IV bolus followed by continuous infusion of 8mg/min for up to 120 minutes",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63078,4,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",210133,2,"c.	Patient is having a major, life-threatening bleed; administer low dose andexanet alfa: 400mg IV bolus followed by continuous infusion of 4mg/min for up to 120 minutes",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63078,4,"67 year-old male on Edoxaban 60mg daily for atrial fibrillation presents to the ED after a ground level fall in which he hit his head. Per the patient's wife, his mental status is altered from baseline and she is concerned he has a concussion. CT of the head reveals severe intracranial hemorrhage. The ED providers asks for your recommendation on reversal of Edoxaban, using the NSH reference guide, what will you recommend?",210134,3,"d.	Patient is having a major, life-threatening bleed; however, andexanet alfa is not indicated for reversal of Edoxaban. Administer 4PCC (Kcentra) 50units/kg.",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63079,5,What factors should be considered in the perioperative management of anticoagulant therapy?,210135,0,"a.	Drug specific details including dose, elimination half-life, and method of drug elimination/excretion",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63079,5,What factors should be considered in the perioperative management of anticoagulant therapy?,210136,1,"b.	Procedure specific risk for major bleeding",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63079,5,What factors should be considered in the perioperative management of anticoagulant therapy?,210137,2,"c.	Patient risk factors for perioperative thrombotic events",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63079,5,What factors should be considered in the perioperative management of anticoagulant therapy?,210138,3,"d.	All of the above",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63080,6,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",210139,0,"a.	Hold Apixaban for 1 to 2 days prior to procedure",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63080,6,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",210140,1,"b.	Hold Apixaban for 2 to 3 days prior to procedure",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63080,6,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",210141,2,"c.	Consider using prophylactic doses of unfractionated heparin or enoxaparin while apixban is being held",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63080,6,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",210142,3,"d.	Both A and C",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63080,6,"A 70 year-old female who takes Apixaban 5mg BID for atrial fibrillation is scheduled for a knee replacement in the coming weeks due to chronic osteoarthritis. You are working in surgery pharmacy and the surgeon calls to ask for your recommendation on the perioperative management of her Apixaban. The surgeon is concerned for bleeding during the procedure but is also hesitant to hold anticoagulation very long due to recent history (<3 months ago) of a stroke while taking a different anticoagulant. Using labs from the most recent pre-op blood work, you calculate the patient's estimated creatinine clearance to be 65mL/min Using the NSH reference guide, what will you recommend?",210143,4,"e.	Both B and C",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63081,7,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",210144,0,"a.	This is a low bleed risk procedure; hold warfarin for 5 days or until INR <2 and it is not required to hold aspirin. The patient has a high risk for perioperative VTE, consider prophylactic heparin or enoxaparin while warfarin is being held.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63081,7,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",210145,1,"b.	This is a minimal bleed risk procedure that may not require holding warfarin or aspirin. The patient has a high risk for perioperative VTE, and if the provider does wish to hold anticoagulation, consider prophylactic heparin or enoxaparin while warfarin is being held.",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63081,7,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",210146,2,"c.	This is a low bleed risk procedure; hold warfarin for 5 days or until INR < 2 and it is not required to hold aspirin. There is no need to consider prophylactic anticoagulants while warfarin is being held.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63081,7,"68 year-old male is taking warfarin 5mg daily and aspirin 81mg daily for prophylaxis due to a mechanical mitral valve. The physician asks for your recommendation on how long to hold warfarin and aspirin prior to squamous cell skin cancer excision. Using the NSH reference guide, what will you recommend?",210147,3,"d.	This is a minimal bleed risk procedure; hold warfarin for 2-3 days and it is not required to hold aspirin.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63082,8,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",210148,0,"a.	This is a high bleed risk procedure, delay surgery for 5 days from the last dose of clopidogrel to allow for recovery of platelet function.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63082,8,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",210149,1,"b.	The patient may be taken to surgery right away, it is not recommended to delay urgent or emergent surgery due to antiplatelet use alone.",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63082,8,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",210150,2,"c.	This is a high bleed risk procedure, delay surgery for 7 days from the last dose of clopidogrel to allow for recovery of platelet function.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63082,8,"A 72 year old male presents to the ED after a fall. The patient is determined to have a severe hip fracture and the ortho surgeon consulted would like to perform emergent hip replacement surgery. The patient is taking Clopidogrel 75mg daily for a history of NSTEMI that occurred 12 months ago. The last dose of clopidogrel was taken 10 hours ago. The surgeon asks how long they should delay surgery to allow for recovery of platelet function. Using the NSH reference guide, what will you recommend?",210151,3,"d.	This is a low bleed risk procedure and it is not required to hold antiplatelet agents.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63083,9,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",210152,0,"a.	Hold Rivaroxaban for 3 days prior to surgery, consider using prophylactic heparin or enoxaparin while Rivaroxaban is being held.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63083,9,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",210153,1,"b.	Hold Rivaroxaban for 2 days prior to surgery, patient has a low risk for perioperative VTE and prophylactic heparin or enoxaparin may not be needed while Rivaroxaban is being held.",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63083,9,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",210154,2,"c.	Hold Rivaroxaban for 2 days prior to surgery and consider using prophylactic heparin or enoxaparin while Rivaroxaban is being held.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63083,9,"A patient who takes Rivaroxaban 10mg daily for secondary DVT prophylaxis status post an unprovoked DVT 13 months ago is scheduled to undergo a total abdominal hysterectomy. You are asked how long it is recommended to hold Rivaroxaban prior to surgery. CrCl= 45mL/min. Using the NSH reference guide, what will you recommend?",210155,3,"d.	Hold Rivaroxaban for 1 day prior to surgery, patient has a low risk for perioperative VTE and prophylactic heparin or enoxaparin may not be needed while Rivaroxaban is being held.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63084,10,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,210156,0,"a.	Do not hold",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63084,10,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,210157,1,"b.	Hold 12 hours/Resume in 6 hr",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63084,10,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,210158,2,"c.	Hold 24 hours/Resume in 6 hr",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63084,10,A patient who is takes Enoxaparin for treatment of a PE is scheduled to undergo initial placement of a nephrostomy tube. You are asked how long to hold Enoxaparin prior to the procedure and how long after the procedure to resume the medication. All labs are WNL.,210159,3,"d.	Hold 24 hours/Resume in 48 hr",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63085,11,T/F Anesthesia should always be contacted when anticoagulant or antiplatelet agents and an epidural or intrathecal are ordered concurrently.,210160,0,TRUE,1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63085,11,T/F Anesthesia should always be contacted when anticoagulant or antiplatelet agents and an epidural or intrathecal are ordered concurrently.,210161,1,FALSE,0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63086,12,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",210162,0,"a.	8 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63086,12,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",210163,1,"b.	12 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63086,12,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",210164,2,"c.	6 hours",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63086,12,"The minimum time between the last dose of Heparin 5,000 units SQ every 12 hours and the placement of an epidural catheter is ________.",210165,3,"d.	24 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63087,13,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",210166,0,"a.	6 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63087,13,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",210167,1,"b.	12 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63087,13,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",210168,2,"c.	1 hour",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63087,13,"The minimum time between the removal of an epidural catheter and the first dose of Heparin 5,000 units SQ every 12 hours is  ________.",210169,3,"d.	8 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63088,14,The first dose of enoxaparin 40mg daily may be given _________.,210484,0,"a.	&#8805 12 hours after removal of epidural catheter.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63088,14,The first dose of enoxaparin 40mg daily may be given _________.,210485,1,"b..	&#8805   4 hours after removal of epidural catheter.",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63088,14,The first dose of enoxaparin 40mg daily may be given _________.,210486,2,"c.	&#8805   4 hours after removal of AND &#8805 12 hours after initial placement of epidural catheter; whichever is longer",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63088,14,The first dose of enoxaparin 40mg daily may be given _________.,210487,3,"d.	&#8805 12 hours after removal of AND &#8805  24 hours after initial placement of epidural catheter; whichever is longer",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63089,15,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,210174,0,"a.	12 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63089,15,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,210175,1,"b.	24 hours",1
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63089,15,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,210176,2,"c.	8 hours",0
9302,Elearning-0000-551,FY2021 PHARMACY ANTICOAGULATION REVERSAL AND PERIPROCEDURAL MANAGEMENT,n13918,63089,15,The minimum time between the last dose of enoxaparin 1mg/kg BID and the placement of an epidural catheter is ______.,210177,3,"d.	6 hours",0
9593,Elearning-0000-816,HAPI PREVENTION EDUCATION - JULY 2021 - PRESSURE INJURY PREVENTION OFFLOADING,n13909,62992,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention - July 2021 - Pressure Injury Prevention Offloading"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209801,0,TRUE,1
9593,Elearning-0000-816,HAPI PREVENTION EDUCATION - JULY 2021 - PRESSURE INJURY PREVENTION OFFLOADING,n13909,62992,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""HAPI Prevention - July 2021 - Pressure Injury Prevention Offloading"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209802,1,FALSE,0
9644,Elearning-0000-862,PEOPLEFLUENT FOR HIRING MANAGERS CBL,n13910,62993,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""PeopleFluent For Hiring Managers CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209803,0,TRUE,1
9644,Elearning-0000-862,PEOPLEFLUENT FOR HIRING MANAGERS CBL,n13910,62993,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""PeopleFluent For Hiring Managers CBL"" content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",209804,1,FALSE,0
9683,Elearning-0000-898,GI LAB NSF: STERILE SUPPLY STORAGE,n13915,63060,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""GI LAB NSF: STERILE SUPPLY STORAGE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",210063,0,TRUE,1
9683,Elearning-0000-898,GI LAB NSF: STERILE SUPPLY STORAGE,n13915,63060,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""GI LAB NSF: STERILE SUPPLY STORAGE"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",210064,1,FALSE,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63043,0,Please list the location for this activity.,209998,0,Atlanta,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63043,0,Please list the location for this activity.,209999,1,Cherokee,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63043,0,Please list the location for this activity.,210000,2,Forsyth,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63043,0,Please list the location for this activity.,210001,3,Other,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63044,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",210002,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63044,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",210003,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63044,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",210004,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63044,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",210005,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63044,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",210006,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63045,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",210007,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63045,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",210008,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63045,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",210009,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63045,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",210010,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63045,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",210011,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63046,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210012,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63046,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210013,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63046,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210014,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63046,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210015,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63046,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210016,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63047,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210017,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63047,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210018,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63047,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210019,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63047,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210020,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63047,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210021,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63048,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,210022,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63048,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,210023,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63048,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,210024,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63048,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,210025,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63048,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,210026,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63049,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,210027,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63049,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,210028,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63049,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,210029,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63049,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,210030,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63049,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,210031,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63050,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,210032,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63050,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,210033,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63050,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,210034,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63050,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,210035,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63050,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,210036,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63051,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210037,0,Strongly Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63051,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210038,1,Agree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63051,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210039,2,No Opinion,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63051,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210040,3,Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63051,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210041,4,Strongly Disagree,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63052,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",210042,0,Excellent,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63052,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",210043,1,Very Good,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63052,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",210044,2,Good,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63052,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",210045,3,Fair,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63052,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",210046,4,Poor,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63052,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",210047,5,N/A,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63053,10,"Overall, this activity was:",210048,0,Excellent,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63053,10,"Overall, this activity was:",210049,1,Very Good,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63053,10,"Overall, this activity was:",210050,2,Good,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63053,10,"Overall, this activity was:",210051,3,Fair,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63053,10,"Overall, this activity was:",210052,4,Poor,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63054,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210053,0,Yes,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63054,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210054,1,No,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63054,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210055,2,N/A,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63057,14,How would you improve this class (check all that apply)?,210056,0,Reduce content covered in class,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63057,14,How would you improve this class (check all that apply)?,210057,1,Increase content covered in class,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63057,14,How would you improve this class (check all that apply)?,210058,2,Update content covered in class,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63057,14,How would you improve this class (check all that apply)?,210059,3,Improve the instructional methods,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63057,14,How would you improve this class (check all that apply)?,210060,4,Make course activities more stimulating,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63057,14,How would you improve this class (check all that apply)?,210061,5,Slow the pace of the class,0
9903,Questions-0000-37,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 6-25-21,n13914,63057,14,How would you improve this class (check all that apply)?,210062,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63024,0,Please list the location for this activity.,209923,0,Atlanta,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63024,0,Please list the location for this activity.,209924,1,Cherokee,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63024,0,Please list the location for this activity.,209925,2,Forsyth,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63024,0,Please list the location for this activity.,209926,3,Other,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63025,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209927,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63025,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209928,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63025,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209929,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63025,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209930,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63025,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209931,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63026,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209932,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63026,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209933,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63026,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209934,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63026,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209935,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63026,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209936,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63027,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209937,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63027,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209938,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63027,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209939,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63027,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209940,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63027,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209941,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63028,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209942,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63028,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209943,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63028,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209944,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63028,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209945,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63028,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209946,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63029,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209947,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63029,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209948,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63029,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209949,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63029,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209950,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63029,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209951,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63030,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209952,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63030,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209953,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63030,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209954,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63030,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209955,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63030,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209956,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63031,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209957,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63031,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209958,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63031,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209959,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63031,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209960,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63031,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209961,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63032,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209962,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63032,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209963,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63032,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209964,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63032,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209965,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63032,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209966,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63033,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209967,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63033,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209968,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63033,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209969,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63033,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209970,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63033,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209971,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63034,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,209972,0,Strongly Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63034,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,209973,1,Agree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63034,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,209974,2,No Opinion,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63034,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,209975,3,Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63034,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,209976,4,Strongly Disagree,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63035,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209978,0,Very Good,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63035,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209979,1,Good,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63035,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209980,2,Fair,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63035,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209981,3,Poor,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63035,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209977,4,Excellent,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63035,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209982,5,N/A,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63036,12,"Overall, this activity was:",209983,0,Excellent,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63036,12,"Overall, this activity was:",209984,1,Very Good,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63036,12,"Overall, this activity was:",209985,2,Good,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63036,12,"Overall, this activity was:",209986,3,Fair,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63036,12,"Overall, this activity was:",209987,4,Poor,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63037,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209988,0,Yes,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63037,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209989,1,No,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63037,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209990,2,N/A,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63040,16,How would you improve this class (check all that apply)?,209991,0,Reduce content covered in class,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63040,16,How would you improve this class (check all that apply)?,209992,1,Increase content covered in class,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63040,16,How would you improve this class (check all that apply)?,209993,2,Update content covered in class,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63040,16,How would you improve this class (check all that apply)?,209994,3,Improve the instructional methods,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63040,16,How would you improve this class (check all that apply)?,209995,4,Make course activities more stimulating,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63040,16,How would you improve this class (check all that apply)?,209996,5,Slow the pace of the class,0
9916,Questions-0000-50,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 6-25-21",n13913,63040,16,How would you improve this class (check all that apply)?,209997,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63001,0,Please list the location for this activity.,209828,0,Atlanta,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63001,0,Please list the location for this activity.,209829,1,Cherokee,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63001,0,Please list the location for this activity.,209830,2,Forsyth,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63001,0,Please list the location for this activity.,209831,3,Other,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63002,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209832,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63002,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209833,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63002,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209834,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63002,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209835,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63002,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",209836,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63003,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209837,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63003,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209838,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63003,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209839,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63003,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209840,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63003,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",209841,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63004,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209842,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63004,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209843,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63004,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209844,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63004,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209845,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63004,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",209846,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63005,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209847,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63005,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209848,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63005,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209849,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63005,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209850,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63005,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",209851,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63006,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",209852,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63006,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",209853,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63006,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",209854,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63006,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",209855,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63006,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",209856,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63007,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",209857,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63007,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",209858,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63007,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",209859,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63007,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",209860,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63007,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",209861,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63008,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",209862,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63008,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",209863,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63008,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",209864,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63008,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",209865,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63008,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",209866,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63009,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",209867,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63009,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",209868,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63009,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",209869,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63009,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",209870,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63009,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",209871,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63010,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209872,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63010,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209873,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63010,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209874,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63010,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209875,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63010,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,209876,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63011,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209877,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63011,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209878,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63011,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209879,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63011,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209880,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63011,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",209881,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63012,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209882,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63012,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209883,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63012,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209884,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63012,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209885,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63012,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,209886,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63013,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209887,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63013,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209888,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63013,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209889,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63013,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209890,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63013,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,209891,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63014,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209892,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63014,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209893,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63014,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209894,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63014,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209895,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63014,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,209896,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63015,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,209897,0,Strongly Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63015,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,209898,1,Agree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63015,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,209899,2,No Opinion,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63015,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,209900,3,Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63015,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,209901,4,Strongly Disagree,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63016,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209902,0,Excellent,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63016,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209903,1,Very Good,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63016,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209904,2,Good,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63016,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209905,3,Fair,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63016,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209906,4,Poor,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63016,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN, CCRN -K</ol>",209907,5,N/A,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63017,16,"Overall, this activity was:",209908,0,Excellent,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63017,16,"Overall, this activity was:",209909,1,Very Good,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63017,16,"Overall, this activity was:",209910,2,Good,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63017,16,"Overall, this activity was:",209911,3,Fair,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63017,16,"Overall, this activity was:",209912,4,Poor,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63018,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209913,0,Yes,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63018,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209914,1,No,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63018,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",209915,2,N/A,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63021,20,How would you improve this class (check all that apply)?,209916,0,Reduce content covered in class,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63021,20,How would you improve this class (check all that apply)?,209917,1,Increase content covered in class,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63021,20,How would you improve this class (check all that apply)?,209918,2,Update content covered in class,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63021,20,How would you improve this class (check all that apply)?,209919,3,Improve the instructional methods,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63021,20,How would you improve this class (check all that apply)?,209920,4,Make course activities more stimulating,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63021,20,How would you improve this class (check all that apply)?,209921,5,Slow the pace of the class,0
9910,Questions-0000-44,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 6-25-21,n13912,63021,20,How would you improve this class (check all that apply)?,209922,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63061,0,When can you drawn an ABG per RT Protocol?,210065,0,A. Any patient who is in distress or has had a change in status,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63061,0,When can you drawn an ABG per RT Protocol?,210066,1,B. Any patient suddenly requiring greater than or equal to 50% FIO2,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63061,0,When can you drawn an ABG per RT Protocol?,210067,2,C. Any patient with an exacerbation of their medical condition where their acid/base balance is questioned,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63061,0,When can you drawn an ABG per RT Protocol?,210068,3,D. Any patient in which oximetry results are questionable,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63061,0,When can you drawn an ABG per RT Protocol?,210069,4,E. ABGs may be obtained on a PRN basis based on the clinical presentation of the patient on the ventilator,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63061,0,When can you drawn an ABG per RT Protocol?,210070,5,"F. A, B, and C Only",0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63061,0,When can you drawn an ABG per RT Protocol?,210071,6,G. All of the above,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63062,1,Which statement is not true about AM ABGs in the ICU?,210072,0,ABGs in the ICU are always a Complete Panel unless ordered otherwise,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63062,1,Which statement is not true about AM ABGs in the ICU?,210073,1,Am ABGs in the ICU are only done if there is an active order in Cerner,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63062,1,Which statement is not true about AM ABGs in the ICU?,210074,2,Am ABGs are done daily on all Vented patients,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63063,2,"You must take an ABG machine to the bedside, but in the event you cannot, what process is most appropriate?",210075,0,"A. Pt sticker can be taken to the lab after verifying the Pt's name, FIN number, and DOB on the Patient's arm band",1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63063,2,"You must take an ABG machine to the bedside, but in the event you cannot, what process is most appropriate?",210076,1,B. Pt sticker can be taken to the lab after verifying Pt's correct room number,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63063,2,"You must take an ABG machine to the bedside, but in the event you cannot, what process is most appropriate?",210077,2,C. Pt sticker can be taken to the lab after verifying one patient identifier,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",210078,0,A. Expired sample,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",210079,1,B. Analyze time is before the draw time,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",210080,2,C. Wrong patient sticker,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",210081,3,D. No order entered in Cerner,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",210082,4,"E. A, B, C",0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",210083,5,F. A  and B,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63064,3,"When running a sample, what are the reasons you might see question marks instead of results on the results page?",210084,6,G. All of the above,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63065,4,"If the patients armband or sticker doesn't scan, you will have to manually enter ""AC""ù followed by the patients FIN number. If entered correctly what should happen next?",210085,0,A. Therapist will also manually enter Pt's full name and DOB,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63065,4,"If the patients armband or sticker doesn't scan, you will have to manually enter ""AC""ù followed by the patients FIN number. If entered correctly what should happen next?",210086,1,B. A gray demographics box will appear for the therapist to confirm correct Pt information was entered,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63065,4,"If the patients armband or sticker doesn't scan, you will have to manually enter ""AC""ù followed by the patients FIN number. If entered correctly what should happen next?",210087,2,C. None of the above,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63066,5,Which statement is true?,210088,0,A. You do not have to have an ABG to wean,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63066,5,Which statement is true?,210089,1,B. Use both SpO2 and EtCO2 to wean as long at they are correlating with previous gasses,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63066,5,Which statement is true?,210090,2,C. None are true,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63066,5,Which statement is true?,210091,3,D. A and B are true,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63067,6,Which statement is true regarding notification of critical ABG results?,210092,0,A. Therapist must document under critical notification tab in Cerner,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63067,6,Which statement is true regarding notification of critical ABG results?,210093,1,B. Therapist must document last name and credential. For example: Dr. Boyce,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63067,6,Which statement is true regarding notification of critical ABG results?,210094,2,"C. Therapist must document first initial, last name, and credential. For example: P. Boyce MD",0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63067,6,Which statement is true regarding notification of critical ABG results?,210095,3,D. Results can be given to a licensed health care professional,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63067,6,Which statement is true regarding notification of critical ABG results?,210096,4,E. A and D are true,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63067,6,Which statement is true regarding notification of critical ABG results?,210097,5,F. C and D are true,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63068,7,"If collateral circulation cannot be verified as a positive Allen's Test on either hand, you can do a brachial stick per protocol?",210098,0,A. True,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63068,7,"If collateral circulation cannot be verified as a positive Allen's Test on either hand, you can do a brachial stick per protocol?",210099,1,B. False,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63069,8,What is not considered a MANDATORY field when running an ABG?,210100,0,"A. Correct Patient Name, Fin #, and DOB",0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63069,8,What is not considered a MANDATORY field when running an ABG?,210101,1,B. Draw time,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63069,8,What is not considered a MANDATORY field when running an ABG?,210102,2,C. Ordering MD,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63069,8,What is not considered a MANDATORY field when running an ABG?,210103,3,D. Sample type,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63069,8,What is not considered a MANDATORY field when running an ABG?,210104,4,E. Oxygen device,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63070,9,"Verification of orders, correct patient identification, proper technique in obtaining and prepping the blood sample, confirmation of demographic information, pertinent date entry, and reporting of critical values are all integral parts of the quality assurance process in ABG analysis.",210105,0,A. True,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63070,9,"Verification of orders, correct patient identification, proper technique in obtaining and prepping the blood sample, confirmation of demographic information, pertinent date entry, and reporting of critical values are all integral parts of the quality assurance process in ABG analysis.",210106,1,B. False,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63071,10,The image shows the correct charging of additional test when running a complete panel?,210107,0,A. True,1
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63071,10,The image shows the correct charging of additional test when running a complete panel?,210108,1,B. False,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63072,11,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,210109,0,A. Red Rules are not reported if the Therapist self reports,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63072,11,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,210110,1,B. Red Rules are not reported if the Nurse hands you the incorrect sticker during a CODE/Rapid Response,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63072,11,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,210111,2,C. Red Rules are not reported if we catch the mistake immediately after the sample is approved,0
9713,Elearning-0000-925,2021 RESPIRATORY ABG COMPETENCY CBL,n13916,63072,11,Which statement is true regarding Red Rule violations when scanning the wrong patient information?,210112,3,D. All Red Rules are reported. It is your responsibility to report results on the correct patient,1
9581,Elearning-0000-805,HEART FAILURE DISEASE MANAGAMENT CLINIC CHEROKEE,n13917,63073,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Heart Failure Disease Managament Clinic Cherokee CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",210113,0,TRUE,1
9581,Elearning-0000-805,HEART FAILURE DISEASE MANAGAMENT CLINIC CHEROKEE,n13917,63073,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the Heart Failure Disease Managament Clinic Cherokee CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",210114,1,FALSE,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63093,0,Please list the location for this activity.,210189,0,Atlanta,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63093,0,Please list the location for this activity.,210190,1,Forsyth,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63093,0,Please list the location for this activity.,210191,2,Cherokee,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63093,0,Please list the location for this activity.,210192,3,Other,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63094,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",210193,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63094,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",210194,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63094,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",210195,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63094,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",210196,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63094,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",210197,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63095,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",210198,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63095,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",210199,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63095,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",210200,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63095,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",210201,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63095,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",210202,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63096,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",210203,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63096,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",210204,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63096,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",210205,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63096,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",210206,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63096,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",210207,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63097,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",210208,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63097,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",210209,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63097,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",210210,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63097,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",210211,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63097,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",210212,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63098,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",210213,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63098,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",210214,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63098,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",210215,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63098,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",210216,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63098,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",210217,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63099,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",210218,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63099,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",210219,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63099,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",210220,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63099,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",210221,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63099,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",210222,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63100,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",210223,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63100,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",210224,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63100,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",210225,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63100,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",210226,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63100,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",210227,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63101,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",210228,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63101,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",210229,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63101,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",210230,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63101,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",210231,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63101,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",210232,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63102,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",210233,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63102,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",210234,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63102,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",210235,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63102,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",210236,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63102,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",210237,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63103,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",210238,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63103,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",210239,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63103,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",210240,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63103,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",210241,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63103,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",210242,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63104,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",210243,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63104,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",210244,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63104,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",210245,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63104,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",210246,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63104,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",210247,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63105,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210248,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63105,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210249,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63105,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210250,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63105,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210251,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63105,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210252,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63106,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,210253,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63106,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,210254,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63106,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,210255,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63106,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,210256,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63106,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,210257,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63107,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210258,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63107,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210259,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63107,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210260,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63107,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210261,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63107,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210262,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63108,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210263,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63108,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210264,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63108,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210265,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63108,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210266,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63108,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210267,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63109,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,210268,0,Strongly Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63109,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,210269,1,Agree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63109,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,210270,2,No Opinion,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63109,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,210271,3,Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63109,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,210272,4,Strongly Disagree,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63110,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",210273,0,Excellent,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63110,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",210274,1,Very Good,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63110,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",210275,2,Good,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63110,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",210276,3,Fair,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63110,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",210277,4,Poor,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63111,18,"Overall, this activity was:",210278,0,Excellent,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63111,18,"Overall, this activity was:",210279,1,Very Good,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63111,18,"Overall, this activity was:",210280,2,Good,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63111,18,"Overall, this activity was:",210281,3,Fair,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63111,18,"Overall, this activity was:",210282,4,Poor,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63112,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210283,0,Yes,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63112,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210284,1,No,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63112,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210285,2,N/A,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63115,22,How would you improve this class?,210286,0,Reduce content covered in class,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63115,22,How would you improve this class?,210287,1,Increase content covered in class,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63115,22,How would you improve this class?,210288,2,Update content covered in class,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63115,22,How would you improve this class?,210289,3,Improve the instructional methods,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63115,22,How would you improve this class?,210290,4,Make course activities more stimulating,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63115,22,How would you improve this class?,210291,5,Slow the pace of the class,0
9891,Questions-0000-25,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 6-28-21,n13920,63115,22,How would you improve this class?,210292,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63138,0,Please list the location for this activity.,210363,0,Atlanta,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63138,0,Please list the location for this activity.,210364,1,Forsyth,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63138,0,Please list the location for this activity.,210365,2,Cherokee,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63138,0,Please list the location for this activity.,210366,3,Other,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63139,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210367,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63139,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210368,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63139,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210369,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63139,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210370,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63139,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210371,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63140,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210372,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63140,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210373,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63140,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210374,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63140,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210375,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63140,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210376,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63141,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210377,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63141,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210378,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63141,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210379,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63141,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210380,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63141,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210381,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63142,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210382,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63142,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210383,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63142,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210384,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63142,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210385,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63142,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210386,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63143,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210387,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63143,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210388,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63143,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210389,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63143,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210390,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63143,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210391,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63144,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210392,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63144,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210393,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63144,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210394,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63144,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210395,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63144,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210396,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63145,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210397,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63145,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210398,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63145,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210399,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63145,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210400,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63145,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210401,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63146,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210402,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63146,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210403,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63146,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210404,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63146,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210405,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63146,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210406,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63147,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210407,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63147,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210408,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63147,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210409,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63147,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210410,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63147,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210411,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63148,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210412,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63148,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210413,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63148,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210414,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63148,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210415,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63148,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210416,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63149,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210417,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63149,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210418,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63149,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210419,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63149,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210420,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63149,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210421,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63150,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210422,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63150,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210423,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63150,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210424,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63150,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210425,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63150,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210426,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63151,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210427,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63151,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210428,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63151,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210429,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63151,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210430,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63151,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210431,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63152,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210432,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63152,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210433,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63152,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210434,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63152,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210435,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63152,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210436,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63153,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210437,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63153,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210438,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63153,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210439,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63153,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210440,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63153,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210441,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63154,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210442,0,Strongly Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63154,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210443,1,Agree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63154,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210444,2,No Opinion,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63154,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210445,3,Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63154,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210446,4,Strongly Disagree,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63155,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,210447,0,Excellent,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63155,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,210448,1,Very Good,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63155,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,210449,2,Good,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63155,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,210450,3,Fair,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63155,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Alex McKeithan</ol>,210451,4,Poor,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63156,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210452,0,Excellent,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63156,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210453,1,Very Good,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63156,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210454,2,Good,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63156,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210455,3,Fair,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63156,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210456,4,Poor,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63157,19,"Overall, this activity was:",210457,0,Excellent,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63157,19,"Overall, this activity was:",210458,1,Very Good,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63157,19,"Overall, this activity was:",210459,2,Good,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63157,19,"Overall, this activity was:",210460,3,Fair,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63157,19,"Overall, this activity was:",210461,4,Poor,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63158,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210462,0,Yes,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63158,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210463,1,No,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63158,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210464,2,N/A,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63161,23,How would you improve this class?,210465,0,Reduce content covered in class,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63161,23,How would you improve this class?,210466,1,Increase content covered in class,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63161,23,How would you improve this class?,210467,2,Update content covered in class,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63161,23,How would you improve this class?,210468,3,Improve the instructional methods,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63161,23,How would you improve this class?,210469,4,Make course activities more stimulating,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63161,23,How would you improve this class?,210470,5,Slow the pace of the class,0
9932,Questions-0000-66,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 6.30.21,n13924,63161,23,How would you improve this class?,210471,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63119,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",210295,0,TRUE,1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63119,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",210296,1,FALSE,0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63120,1,Which one of the following hazardous medication list grouping is incorrect?,210297,0,"a.	Group 2 - Hazardous agents (primarily reproductive risk)",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63120,1,Which one of the following hazardous medication list grouping is incorrect?,210298,1,"b.	Group 1 - Hazardous agents (cytotoxic antineoplastic/reproductive risks)",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63120,1,Which one of the following hazardous medication list grouping is incorrect?,210299,2,"c.	Group 2A - Non-hazardous antineoplastic agents",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63120,1,Which one of the following hazardous medication list grouping is incorrect?,210300,3,"d.	Appendix D - Excluded drugs based on NSH risk assessment",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63121,2,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",210301,0,TRUE,1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63121,2,"New Hazardous Drug Alerts fire in PowerChart and PharmNet for all Group 1 and 2 HDs with NON-PARENTERAL routes, when ordered, to ensure that safe handling procedures and appropriate patient monitoring is in place.",210302,1,FALSE,0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63122,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",210303,0,"a.	Decontamination",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63122,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",210304,1,"b.	Cleaning",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63122,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",210305,2,"c.	Disinfection",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63122,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",210306,3,"d.	Deactivate",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63122,3,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",210307,4,"e.	All of the above",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63123,4,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",210308,0,TRUE,1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63123,4,"For hazardous medications (group 1 or 2), any manipulations of tablets/capsules such as splitting or crushing will be performed inside a BSC or CACI and dispensed in final dosage form for administration",210309,1,FALSE,0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63124,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,210310,0,"a.	Protective Gown",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63124,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,210311,1,"b.	Eye/Face protection",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63124,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,210312,2,"c.	Respiratory protection",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63124,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,210313,3,"d.	Footwear",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63124,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,210314,4,"e.	Gloves",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63124,5,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,210315,5,"f.	All of the above",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63125,6,The spill response team is activated for any spills that is not contained by the following:,210316,0,"a.	Two Spill Kits",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63125,6,The spill response team is activated for any spills that is not contained by the following:,210317,1,"b.	Single Spill Kit",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63125,6,The spill response team is activated for any spills that is not contained by the following:,210318,2,"c.	Three Spill Kits",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63125,6,The spill response team is activated for any spills that is not contained by the following:,210319,3,"d.	Any spill in patient care area",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63125,6,The spill response team is activated for any spills that is not contained by the following:,210320,4,"e.	Any spill in pharmacy area",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63126,7,Gloves used in the preparation of HDs must be:,210321,0,"a.	Disposable",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63126,7,Gloves used in the preparation of HDs must be:,210322,1,"b.	Powdered to facilitate removal",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63126,7,Gloves used in the preparation of HDs must be:,210323,2,"c.	Specified as ASTM-tested chemotherapy gloves",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63126,7,Gloves used in the preparation of HDs must be:,210324,3,"d.	A and C",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63127,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",210325,0,"a.	Filter needles",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63127,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",210326,1,"b.	Leur-Lock syringes",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63127,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",210327,2,"c.	Closed-system transfer devices (CSTDs)",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63127,8,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",210328,3,"d.	None of the above",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63128,9,When wearing double gloves:,210329,0,"a.	The gown cuffs should be tucked over both gloves",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63128,9,When wearing double gloves:,210330,1,"b.	The gown cuffs should be tucked under both gloves",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63128,9,When wearing double gloves:,210331,2,"c.	The inner glove should be worn under the cuff and the outer glove should be worn over the gown cuff",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63128,9,When wearing double gloves:,210332,3,"d.	It makes no difference if gown cuffs are worn over or under the gloves",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63129,10,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,210333,0,TRUE,0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63129,10,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,210334,1,FALSE,1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63130,11,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,210335,0,"a.	Biological safety cabinet (BSC)",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63130,11,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,210336,1,"b.	Horizontal laminar air flow workbench",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63130,11,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,210337,2,"c.	Compounding aseptic containment isolator (CACI)",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63130,11,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,210338,3,"d.	A and C",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63131,12,Spill kits:,210339,0,"a.	May be obtained from Central Supply when needed",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63131,12,Spill kits:,210340,1,"b.	Are kept wherever HDs and chemotherapy agents are handled",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63131,12,Spill kits:,210341,2,"c.	Contain supplies needed to clean a HD spill",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63131,12,Spill kits:,210342,3,"d.	All of the above",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63132,13,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",210343,0,TRUE,0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63132,13,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",210344,1,FALSE,1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63133,14,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",210345,0,TRUE,1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63133,14,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",210346,1,FALSE,0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63134,15,How often do you have to change the gown during hazardous drug compounding?,210347,0,"a.	At least every 12 hours",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63134,15,How often do you have to change the gown during hazardous drug compounding?,210348,1,"b.	At least every 24 hours",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63134,15,How often do you have to change the gown during hazardous drug compounding?,210349,2,"c.	At least every 3 hours",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63134,15,How often do you have to change the gown during hazardous drug compounding?,210350,3,"d.	At least every 8 hours",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63135,16,How often do you have to change the outer gloves during hazardous drug sterile compounding?,210351,0,"a.	At least every 8 hours",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63135,16,How often do you have to change the outer gloves during hazardous drug sterile compounding?,210352,1,"b.	At least every 3  hours",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63135,16,How often do you have to change the outer gloves during hazardous drug sterile compounding?,210353,2,"c.	At least every 30 minutes",1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63135,16,How often do you have to change the outer gloves during hazardous drug sterile compounding?,210354,3,"d.	 At shift change",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63136,17,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,210355,0,TRUE,1
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63136,17,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,210356,1,FALSE,0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63137,18,Which statement is true?,210357,0,"a.	Cytotoxic chemotherapy doses maybe rounded down or up to the nearest vials size within < 5% of the calculated dose",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63137,18,Which statement is true?,210358,1,"b.	Cytotoxic chemotherapy doses maybe rounded down to the nearest vials size within < 5% of the calculated dose",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63137,18,Which statement is true?,210359,2,"c.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 10% of the calculated dose.",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63137,18,Which statement is true?,210360,3,"d.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 5% of the calculated dose.",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63137,18,Which statement is true?,210361,4,"e.	a & c",0
9252,Elearning-0000-506,FY2021 PHARMACY HAZARDOUS DRUGS / CHEMOTHERAPEUTICS (K-5) POLICY EDUCATION TECHNICIANS,n13923,63137,18,Which statement is true?,210362,5,"f.	b & c",1
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63164,0,Which of the following are true statements,210472,0,"a.	Veno-venous ECMO provides respiratory support for critically ill patients",0
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63164,0,Which of the following are true statements,210473,1,"b.	Veno-arterial ECMO provides both cardiac and respiratory support for critically ill patients",0
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63164,0,Which of the following are true statements,210474,2,"c.	ECMO is NOT a cure for respiratory or cardiac failure but can be used as short term therapy until organ function is recovered",0
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63164,0,Which of the following are true statements,210475,3,"d.	All of the above",1
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63165,1,True or False: ECMO cannot be used in patients that have an absolute contraindication to anticoagulation,210476,0,TRUE,1
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63165,1,True or False: ECMO cannot be used in patients that have an absolute contraindication to anticoagulation,210477,1,FALSE,0
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63166,2,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,210478,0,"a.	All ECMO heparin drips are monitoring with ACT",0
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63166,2,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,210479,1,"b.	Heparin drips should be dosed using actual body weight with no weight cap",0
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63166,2,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,210480,2,"c.	ECMO heparin drips should be titrated using the ECMO specific nomogram and all dose changes should be recorded on the ECMO heparin flowsheet",1
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63166,2,Heparin is the preferred anticoagulant in ECMO. Which of the following statements is TRUE about heparin orders for ECMO:,210481,3,"d.	No double check is required for ECMO heparin drips due to the frequency of lab checks",0
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63167,3,"True or False: ECMO orders include concentrated options of sedation, analgesic, neuromuscular blocker, and vasopressor drips, when available, to limit fluid volumes",210482,0,TRUE,1
9325,Elearning-0000-572,FY2021 PHARMACY ECMO EDUCATION,n13925,63167,3,"True or False: ECMO orders include concentrated options of sedation, analgesic, neuromuscular blocker, and vasopressor drips, when available, to limit fluid volumes",210483,1,FALSE,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63191,1,Normal Axillary Temp in the newborn should be between 36.1 degrees Celcius and 36.4 Celcious?,210579,0,TRUE,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63191,1,Normal Axillary Temp in the newborn should be between 36.1 degrees Celcius and 36.4 Celcious?,210580,1,FALSE,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63192,0,Conduction is the method of heat loss when what occurs?,210581,0,a. Airflow carrying heat to or away from an object occurs,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63192,0,Conduction is the method of heat loss when what occurs?,210582,1,b.  Heat exchange between objects in direct contact with each other,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63192,0,Conduction is the method of heat loss when what occurs?,210583,2,c.  Radiant energy exchange between tow objects not in contact with each other,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63192,0,Conduction is the method of heat loss when what occurs?,210584,3,"d.  Thermal energy turns liquid into vapor, removing energy (heat) away from the object",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63193,2,Three characteristics that put newborns at a greater risk for heat loss is:,210585,0,"a.  a smaller surface area to body mass ratio, decreased subcutaneous fat and greater body water content",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63193,2,Three characteristics that put newborns at a greater risk for heat loss is:,210586,1,"b. having greater body water content, larger surface area to body mass ratio and ability to shiver",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63193,2,Three characteristics that put newborns at a greater risk for heat loss is:,210587,2,"c.  having greater body water content, larger surface area to body mass ratio and not able to shiver",1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63193,2,Three characteristics that put newborns at a greater risk for heat loss is:,210588,3,"d. decreased subcutaneous fat, peripheral cyanosis and skin that is mature leading to increased evaporative water and heat losses",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63194,3,Signs and symptoms of hypothermia include:,210589,0,"a. acryocyanosis, cool mottled or pale skin",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63194,3,Signs and symptoms of hypothermia include:,210590,1,"b. hypoglycemia, poor feeder, week or feeble cry",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63194,3,Signs and symptoms of hypothermia include:,210591,2,"c. decreased activity, lethergy, hypotonia",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63194,3,Signs and symptoms of hypothermia include:,210592,3,"d. bradycardia, tachypnea, respirtory distress, poor weight gain",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63194,3,Signs and symptoms of hypothermia include:,210593,4,e. all of the above,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63195,4,True or False if left untreated hypothermia may lead to life theatening complications,210594,0,TRUE,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63195,4,True or False if left untreated hypothermia may lead to life theatening complications,210595,1,FALSE,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63196,5,Care activities to help prevent hypothermia include which of the following?,210596,0,"a. Skin to skin, increase room temperature, and dress in clothes and place hat on infant",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63196,5,Care activities to help prevent hypothermia include which of the following?,210597,1,b. place infant under radiant warmer with temp probe and set on manual,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63196,5,Care activities to help prevent hypothermia include which of the following?,210598,2,"c. place infant under radiant warmer with temp probe and set on ""baby""",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63196,5,Care activities to help prevent hypothermia include which of the following?,210599,3,d. a and c,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63196,5,Care activities to help prevent hypothermia include which of the following?,210600,4,e. all of the above,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63197,6,Signs and symptoms of hyperthermia in the newborn include:,210601,0,"a. tachycardia, tachypnea, apnea",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63197,6,Signs and symptoms of hyperthermia in the newborn include:,210602,1,"b.lethargy, hypotonia,and irritibility",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63197,6,Signs and symptoms of hyperthermia in the newborn include:,210603,2,"c. poor feeding, weak cry and warm extremities",0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63197,6,Signs and symptoms of hyperthermia in the newborn include:,210604,3,"d. a, b and c",1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63197,6,Signs and symptoms of hyperthermia in the newborn include:,210605,4,e. non of the above,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63198,7,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,210606,0,a. take infant to nursery and place under radiant warmer with temp probe set to baby,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63198,7,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,210607,1,"b. place skin to skin with mother, S. O. or other family member",1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63198,7,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,210608,2,c. use heel warmers to warm infant 36.3 is too cold,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63198,7,You are getting VS on Baby North who just came to the floor. Baby North's temp is 36.3 C. What is the first step you should do?,210609,3,d. do nothing this is an acceptable temperature.,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63199,8,When should you recheck Baby North's Temperature after initiating the first intervention?,210610,0,a. in 1 hour,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63199,8,When should you recheck Baby North's Temperature after initiating the first intervention?,210611,1,b. it does not need to be rechecked as it was within normal range,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63199,8,When should you recheck Baby North's Temperature after initiating the first intervention?,210612,2,c. 30 minutes,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63199,8,When should you recheck Baby North's Temperature after initiating the first intervention?,210613,3,d. with the next set of VS in 4 hours,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63200,9,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,210614,0,"a. place infant on radiant warmer with skin probe set at 36.5 in ""baby"" mode",1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63200,9,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,210615,1,b. do nothing temp is WNL,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63200,9,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,210616,2,c. call SCN/TCN to transfer infant,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63200,9,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,210617,3,d. call the provider,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63200,9,When you recheck Baby North's temperature (1st 30 min check) it is not rising. Your next step is to :,210618,4,e. warm blankets in microwave and swaddle infant,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63201,10,Baby North needed to go to the nursery to be placed on a radiant warmer for rewarming protocol.  Baby North has now had two consecutive temperatures 30 mins apart and each was 36.8  and 36.9 so she may return to her mother.,210619,0,TRUE,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63201,10,Baby North needed to go to the nursery to be placed on a radiant warmer for rewarming protocol.  Baby North has now had two consecutive temperatures 30 mins apart and each was 36.8  and 36.9 so she may return to her mother.,210620,1,FALSE,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63202,11,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",210621,0,a. Her temperature was normal and does not need rechecking,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63202,11,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",210622,1,b. Every 30 mins times 4,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63202,11,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",210623,2,c. Recheck temperature every hour times 2,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63202,11,"Baby North has been returned to her mother in an open crib swaddled in blankets, diaper, clothes and hat.  How often should her temperature be rechecked?",210624,3,d. Recheck temperature every 30 mins time 2 then every hour times 4 then may return to every 4 hours,0
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63203,12,"Policies frequently change and are updated.  If I am in doubt of what, how and or when procedures or processes should be done I should always look at the policy in Lucidoc and review and follow my policy.",210625,0,TRUE,1
9117,Elearning-0000-383,NSC FCC NEWBORN THERMOREGULATION COMPETENCY 2021,n13927,63203,12,"Policies frequently change and are updated.  If I am in doubt of what, how and or when procedures or processes should be done I should always look at the policy in Lucidoc and review and follow my policy.",210626,1,FALSE,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63168,0,Please list the location for this activity.,210488,0,Atlanta,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63168,0,Please list the location for this activity.,210489,1,Cherokee,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63168,0,Please list the location for this activity.,210490,2,Forsyth,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63168,0,Please list the location for this activity.,210491,3,Other,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63169,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",210492,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63169,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",210493,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63169,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",210494,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63169,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",210495,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63169,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state elements of the universal characteristics of the preceptor role.</ol>",210496,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63170,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",210497,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63170,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",210498,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63170,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",210499,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63170,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",210500,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63170,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state opportunities for self-improvement related to people skills, self-knowledge, technical and teaching skills</ol>",210501,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63171,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",210502,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63171,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",210503,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63171,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",210504,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63171,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",210505,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63171,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify adult learning principles.</ol>",210506,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63172,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",210507,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63172,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",210508,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63172,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",210509,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63172,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",210510,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63172,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine how people learn and how to balance comfort with discomfort.</ol>",210511,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63173,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",210512,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63173,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",210513,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63173,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",210514,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63173,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",210515,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63173,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe current models for quick assessment of learner knowledge and use of daily objectives.</ol>",210516,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63174,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",210517,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63174,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",210518,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63174,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",210519,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63174,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",210520,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63174,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the benefits of debriefing and determine how and when to fit it in during the daily work assignment.</ol>",210521,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63175,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210522,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63175,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210523,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63175,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210524,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63175,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210525,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63175,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210526,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63176,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210527,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63176,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210528,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63176,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210529,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63176,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210530,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63176,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210531,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63177,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,210532,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63177,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,210533,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63177,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,210534,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63177,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,210535,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63177,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to my role as a preceptor in the Surgical Services Department.</OL>,210536,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63178,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,210537,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63178,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,210538,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63178,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,210539,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63178,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,210540,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63178,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to function in the role of Surgical Services Preceptor.OL>,210541,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63179,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210542,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63179,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210543,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63179,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210544,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63179,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210545,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63179,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210546,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63180,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210547,0,Strongly Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63180,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210548,1,Agree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63180,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210549,2,No Opinion,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63180,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210550,3,Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63180,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210551,4,Strongly Disagree,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63181,13,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,210552,0,Excellent,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63181,13,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,210553,1,Very Good,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63181,13,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,210554,2,Good,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63181,13,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,210555,3,Fair,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63181,13,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Vanessa Jones</ol>,210556,4,Poor,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63182,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",210557,0,Excellent,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63182,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",210558,1,Very Good,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63182,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",210559,2,Good,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63182,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",210560,3,Fair,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63182,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Scarborough, BSN, RN</ol>",210561,4,Poor,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63183,15,"Overall, this activity was:",210562,0,Excellent,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63183,15,"Overall, this activity was:",210563,1,Very Good,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63183,15,"Overall, this activity was:",210564,2,Good,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63183,15,"Overall, this activity was:",210565,3,Fair,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63183,15,"Overall, this activity was:",210566,4,Poor,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63184,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210567,0,Yes,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63184,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210568,1,No,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63184,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210569,2,N/A,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63187,19,How would you improve this class?,210570,0,Reduce content covered in class,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63187,19,How would you improve this class?,210571,1,Increase content covered in class,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63187,19,How would you improve this class?,210572,2,Update content covered in class,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63187,19,How would you improve this class?,210573,3,Improve the instructional methods,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63187,19,How would you improve this class?,210574,4,Make course activities more stimulating,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63187,19,How would you improve this class?,210575,5,Slow the pace of the class,0
9871,Questions-0000-160,SURGICAL SERVICES PRECEPTOR LIVE (EVALUATION SURVEY) NSF 6.30.21,n13926,63187,19,How would you improve this class?,210576,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63206,0,A device that is intended to be used on patient's mucous membranes is classified as:,210633,0,A.  Non-critical,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63206,0,A device that is intended to be used on patient's mucous membranes is classified as:,210634,1,B.  Semi-critical,1
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63206,0,A device that is intended to be used on patient's mucous membranes is classified as:,210635,2,C.  Critical,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63207,1,What is the minimum reprocessing requirement for devices used in semi-critical applications?,210636,0,A.  High level disinfection,1
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63207,1,What is the minimum reprocessing requirement for devices used in semi-critical applications?,210637,1,B.  Low level disinfection,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63207,1,What is the minimum reprocessing requirement for devices used in semi-critical applications?,210638,2,C.  Sterilization,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63208,2,Warnings/precautions regarding high level disinfectant chemicals common to all include:,210639,0,"A.  Avoidance of contact with eyes, skin, clothing, food, fumes/vapors",0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63208,2,Warnings/precautions regarding high level disinfectant chemicals common to all include:,210640,1,B.  Provision of adequate ventilation,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63208,2,Warnings/precautions regarding high level disinfectant chemicals common to all include:,210641,2,C.  Attention to device rinsing per manufacturer's IFU,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63208,2,Warnings/precautions regarding high level disinfectant chemicals common to all include:,210642,3,D.  Do not use on flexible endoscopes,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63208,2,Warnings/precautions regarding high level disinfectant chemicals common to all include:,210643,4,"E.  A, B, C",1
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63208,2,Warnings/precautions regarding high level disinfectant chemicals common to all include:,210644,5,F.  All of the above,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63209,3,"When considering the choice of the ideal high level disinfectant, one quality that does not make the list is:",210645,0,A.  Act slowly,1
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63209,3,"When considering the choice of the ideal high level disinfectant, one quality that does not make the list is:",210646,1,B.  Cost effective,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63209,3,"When considering the choice of the ideal high level disinfectant, one quality that does not make the list is:",210647,2,C.  Be odorless and non-staining,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63210,4,What must be done prior to high level disinfection in order for it to be effective?,210648,0,A.  Allow instruments to air dry,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63210,4,What must be done prior to high level disinfection in order for it to be effective?,210649,1,B.  Clean instruments according to IFU to remove fluids or debris,1
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63210,4,What must be done prior to high level disinfection in order for it to be effective?,210650,2,C.  Wipe instruments with a paper towel,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63211,5,How often must reusable high level disinfectant chemicals be tested using product specific indicators (test strips/discs)?,210651,0,A.  Daily,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63211,5,How often must reusable high level disinfectant chemicals be tested using product specific indicators (test strips/discs)?,210652,1,B.  Monthly,0
9567,Elearning-0000-792,FY21 ANNUAL HLD UPDATE,n13929,63211,5,How often must reusable high level disinfectant chemicals be tested using product specific indicators (test strips/discs)?,210653,2,C.  Prior to each use,1
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63219,0,Please list the location for this activity.,210669,0,Atlanta,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63219,0,Please list the location for this activity.,210670,1,Cherokee,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63219,0,Please list the location for this activity.,210671,2,Forsyth,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63219,0,Please list the location for this activity.,210672,3,Other,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63220,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",210673,0,Strongly Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63220,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",210674,1,Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63220,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",210675,2,No Opinion,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63220,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",210676,3,Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63220,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the effects of intermittent fasting on health, aging, and disease.</ol>",210677,4,Strongly Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63221,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210678,0,Strongly Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63221,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210679,1,Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63221,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210680,2,No Opinion,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63221,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210681,3,Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63221,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210682,4,Strongly Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63222,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,210683,0,Strongly Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63222,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,210684,1,Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63222,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,210685,2,No Opinion,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63222,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,210686,3,Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63222,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,210687,4,Strongly Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63223,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,210688,0,Strongly Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63223,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,210689,1,Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63223,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,210690,2,No Opinion,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63223,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,210691,3,Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63223,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,210692,4,Strongly Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63224,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210693,0,Strongly Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63224,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210694,1,Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63224,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210695,2,No Opinion,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63224,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210696,3,Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63224,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210697,4,Strongly Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63225,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,210698,0,Strongly Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63225,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,210699,1,Agree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63225,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,210700,2,No Opinion,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63225,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,210701,3,Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63225,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,210702,4,Strongly Disagree,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63226,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",210703,0,Excellent,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63226,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",210704,1,Very Good,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63226,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",210705,2,Good,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63226,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",210706,3,Fair,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63226,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",210707,4,Poor,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63227,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",210708,0,Excellent,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63227,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",210709,1,Very Good,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63227,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",210710,2,Good,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63227,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",210711,3,Fair,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63227,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",210712,4,Poor,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63228,9,"Overall, this activity was:",210713,0,Excellent,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63228,9,"Overall, this activity was:",210714,1,Very Good,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63228,9,"Overall, this activity was:",210715,2,Good,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63228,9,"Overall, this activity was:",210716,3,Fair,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63228,9,"Overall, this activity was:",210717,4,Poor,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63229,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210718,0,Yes,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63229,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210719,1,No,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63229,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210720,2,N/A,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63232,13,How would you improve this class?,210721,0,Reduce content covered in class,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63232,13,How would you improve this class?,210722,1,Increase content covered in class,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63232,13,How would you improve this class?,210723,2,Update content covered in class,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63232,13,How would you improve this class?,210724,3,Improve the instructional methods,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63232,13,How would you improve this class?,210725,4,Make course activities more stimulating,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63232,13,How would you improve this class?,210726,5,Slow the pace of the class,0
9945,Questions-0000-79,"NSF INFUSION CENTER JOURNAL CLUB - JULY 1ST, 2021 (EVALUATION SURVEY)",n13932,63232,13,How would you improve this class?,210727,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63235,0,Please list the location for this activity.,210728,0,Atlanta,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63235,0,Please list the location for this activity.,210729,1,Forsyth,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63235,0,Please list the location for this activity.,210730,2,Cherokee,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63235,0,Please list the location for this activity.,210731,3,Other,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63236,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210732,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63236,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210733,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63236,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210734,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63236,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210735,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63236,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss crash dynamics related to injury prevention.</ol>",210736,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63237,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210737,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63237,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210738,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63237,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210739,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63237,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210740,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63237,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize Georgia's and AAP's recommendations for child safety seat use.</ol>",210741,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63238,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210742,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63238,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210743,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63238,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210744,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63238,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210745,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63238,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand rationale for rear facing car seats.</ol>",210746,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63239,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210747,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63239,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210748,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63239,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210749,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63239,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210750,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63239,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize car safety recommendations for growing infants and children.</ol>",210751,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63240,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210752,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63240,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210753,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63240,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210754,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63240,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210755,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63240,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify infants at risk for airway obstruction.</ol>",210756,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63241,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210757,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63241,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210758,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63241,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210759,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63241,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210760,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63241,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe safe travel options for infants who fail the car seat challenge/angle tolerance test.</ol>",210761,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63242,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210762,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63242,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210763,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63242,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210764,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63242,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210765,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63242,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to utilize the recall list to identify if a car seat has a recall.</ol>",210766,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63243,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210767,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63243,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210768,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63243,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210769,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63243,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210770,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63243,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the dangers of air bags and car seats.</ol>",210771,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63244,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210772,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63244,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210773,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63244,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210774,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63244,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210775,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63244,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe car seat cleaning practices.</ol>",210776,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63245,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210777,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63245,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210778,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63245,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210779,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63245,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210780,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63245,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to State corrections needed when viewing pictures of children in car seats at car seat check events.</ol>",210781,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63246,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210782,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63246,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210783,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63246,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210784,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63246,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210785,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63246,11,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify simulated car seat misuses and discuss corrective actions.</ol>",210786,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63247,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210787,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63247,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210788,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63247,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210789,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63247,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210790,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63247,12,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to determine qualities and qualifications for becoming CPST.</ol>",210791,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63248,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210792,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63248,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210793,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63248,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210794,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63248,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210795,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63248,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve parent education.</OL>,210796,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63249,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210797,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63249,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210798,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63249,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210799,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63249,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210800,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63249,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.OL>",210801,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63250,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210802,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63250,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210803,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63250,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210804,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63250,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210805,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63250,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210806,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63251,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210807,0,Strongly Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63251,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210808,1,Agree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63251,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210809,2,No Opinion,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63251,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210810,3,Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63251,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210811,4,Strongly Disagree,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63252,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,210812,0,Excellent,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63252,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,210813,1,Very Good,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63252,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,210814,2,Good,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63252,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,210815,3,Fair,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63252,17,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Allison Craig</ol>,210816,4,Poor,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63253,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210817,0,Excellent,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63253,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210818,1,Very Good,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63253,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210819,2,Good,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63253,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210820,3,Fair,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63253,18,<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kathy Cunningham</ol>,210821,4,Poor,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63254,19,"Overall, this activity was:",210822,0,Excellent,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63254,19,"Overall, this activity was:",210823,1,Very Good,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63254,19,"Overall, this activity was:",210824,2,Good,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63254,19,"Overall, this activity was:",210825,3,Fair,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63254,19,"Overall, this activity was:",210826,4,Poor,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63255,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210827,0,Yes,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63255,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210828,1,No,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63255,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210829,2,N/A,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63258,23,How would you improve this class?,210830,0,Reduce content covered in class,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63258,23,How would you improve this class?,210831,1,Increase content covered in class,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63258,23,How would you improve this class?,210832,2,Update content covered in class,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63258,23,How would you improve this class?,210833,3,Improve the instructional methods,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63258,23,How would you improve this class?,210834,4,Make course activities more stimulating,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63258,23,How would you improve this class?,210835,5,Slow the pace of the class,0
9933,Questions-0000-67,KEEPING KIDS SAFE (EVALUATION SURVEY) NSA 7.7.21,n13933,63258,23,How would you improve this class?,210836,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63261,0,Please list the location for this activity.,210837,0,Atlanta,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63261,0,Please list the location for this activity.,210838,1,Forsyth,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63261,0,Please list the location for this activity.,210839,2,Cherokee,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63261,0,Please list the location for this activity.,210840,3,Other,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63262,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",210841,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63262,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",210842,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63262,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",210843,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63262,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",210844,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63262,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",210845,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63263,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",210846,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63263,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",210847,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63263,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",210848,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63263,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",210849,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63263,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",210850,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63264,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",210851,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63264,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",210852,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63264,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",210853,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63264,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",210854,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63264,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",210855,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63265,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",210856,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63265,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",210857,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63265,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",210858,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63265,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",210859,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63265,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",210860,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63266,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",210861,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63266,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",210862,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63266,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",210863,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63266,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",210864,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63266,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",210865,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63267,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",210866,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63267,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",210867,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63267,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",210868,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63267,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",210869,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63267,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",210870,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63268,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",210871,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63268,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",210872,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63268,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",210873,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63268,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",210874,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63268,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",210875,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63269,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210876,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63269,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210877,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63269,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210878,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63269,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210879,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63269,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210880,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63270,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,210881,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63270,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,210882,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63270,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,210883,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63270,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,210884,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63270,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,210885,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63271,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210886,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63271,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210887,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63271,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210888,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63271,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210889,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63271,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210890,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63272,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210891,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63272,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210892,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63272,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210893,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63272,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210894,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63272,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210895,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63273,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210896,0,Strongly Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63273,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210897,1,Agree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63273,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210898,2,No Opinion,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63273,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210899,3,Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63273,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,210900,4,Strongly Disagree,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63274,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",210901,0,Excellent,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63274,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",210902,1,Very Good,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63274,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",210903,2,Good,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63274,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",210904,3,Fair,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63274,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",210905,4,Poor,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63275,14,"Overall, this activity was:",210906,0,Excellent,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63275,14,"Overall, this activity was:",210907,1,Very Good,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63275,14,"Overall, this activity was:",210908,2,Good,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63275,14,"Overall, this activity was:",210909,3,Fair,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63275,14,"Overall, this activity was:",210910,4,Poor,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63276,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210911,0,Yes,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63276,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210912,1,No,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63276,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",210913,2,N/A,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63279,18,How would you improve this class?,210914,0,Reduce content covered in class,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63279,18,How would you improve this class?,210915,1,Increase content covered in class,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63279,18,How would you improve this class?,210916,2,Update content covered in class,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63279,18,How would you improve this class?,210917,3,Improve the instructional methods,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63279,18,How would you improve this class?,210918,4,Make course activities more stimulating,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63279,18,How would you improve this class?,210919,5,Slow the pace of the class,0
9953,Questions-0000-87,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-7-21,n13936,63279,18,How would you improve this class?,210920,6,"Nothing: (appropriate content, speaker, setting, setting.)",0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63282,0,Please list the location for this activity.,210921,0,Atlanta,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63282,0,Please list the location for this activity.,210922,1,Forsyth,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63282,0,Please list the location for this activity.,210923,2,Cherokee,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63282,0,Please list the location for this activity.,210924,3,Other,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63283,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",210925,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63283,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",210926,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63283,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",210927,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63283,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",210928,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63283,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart.</ol>",210929,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63284,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",210930,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63284,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",210931,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63284,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",210932,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63284,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",210933,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63284,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the examination of leads and significance.</ol>",210934,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63285,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",210935,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63285,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",210936,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63285,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",210937,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63285,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",210938,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63285,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify appropriate electrode placements for each individual lead on a 12 lead EKG. </ol>",210939,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63286,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",210940,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63286,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",210941,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63286,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",210942,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63286,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",210943,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63286,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the pathological difference between myocardial ischemia, injury and infarction.</ol>",210944,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63287,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",210945,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63287,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",210946,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63287,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",210947,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63287,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",210948,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63287,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to plot an axis on the 12 lead EKG & discuss conditions that cause axis deviation.</ol>",210949,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63288,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",210950,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63288,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",210951,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63288,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",210952,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63288,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",210953,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63288,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of right and left bundle branch blocks on 12 lead EKG.</ol>",210954,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63289,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",210955,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63289,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",210956,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63289,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",210957,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63289,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",210958,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63289,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify QT prolongation on 12-Lead EKG </ol>",210959,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63290,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210960,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63290,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210961,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63290,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210962,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63290,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210963,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63290,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,210964,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63291,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,210965,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63291,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,210966,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63291,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,210967,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63291,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,210968,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63291,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to identification of changes in the 12 Lead EKG associated with conditions that have potential life threatening implications.</OL>,210969,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63292,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,210970,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63292,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,210971,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63292,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,210972,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63292,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,210973,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63292,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in effectively communicating my findings to physicians to aid in the managing my patients medical conditions.</OL>,210974,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63293,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210975,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63293,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210976,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63293,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210977,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63293,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210978,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63293,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",210979,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63294,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210980,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63294,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210981,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63294,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210982,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63294,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210983,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63294,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",210984,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63295,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210985,0,Strongly Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63295,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210986,1,Agree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63295,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210987,2,No Opinion,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63295,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210988,3,Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63295,13,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,210989,4,Strongly Disagree,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63296,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",210990,0,Excellent,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63296,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",210991,1,Very Good,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63296,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",210992,2,Good,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63296,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",210993,3,Fair,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63296,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Cindy White, MSN, RN, CCRN</ol>",210994,4,Poor,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63297,15,"Overall, this activity was:",210995,0,Excellent,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63297,15,"Overall, this activity was:",210996,1,Very Good,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63297,15,"Overall, this activity was:",210997,2,Good,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63297,15,"Overall, this activity was:",210998,3,Fair,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63297,15,"Overall, this activity was:",210999,4,Poor,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63298,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211000,0,Yes,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63298,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211001,1,No,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63298,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211002,2,N/A,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63301,19,How would you improve this class?,211003,0,Reduce content covered in class,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63301,19,How would you improve this class?,211004,1,Increase content covered in class,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63301,19,How would you improve this class?,211005,2,Update content covered in class,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63301,19,How would you improve this class?,211006,3,Improve the instructional methods,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63301,19,How would you improve this class?,211007,4,Make course activities more stimulating,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63301,19,How would you improve this class?,211008,5,Slow the pace of the class,0
9922,Questions-0000-56,FUNDAMENTALS OF 12 LEAD EKG ( EVALUATION SURVEY) 7.8.21,n13937,63301,19,How would you improve this class?,211009,6,"No recommendation for improvement (appropriate content, speaker, etc.)",0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63361,0,Please list the location for this activity.,211234,0,Atlanta,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63361,0,Please list the location for this activity.,211235,1,Cherokee,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63361,0,Please list the location for this activity.,211236,2,Forsyth,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63361,0,Please list the location for this activity.,211237,3,Other,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63362,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211238,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63362,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211239,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63362,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211240,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63362,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211241,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63362,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211242,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63363,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211243,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63363,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211244,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63363,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211245,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63363,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211246,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63363,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211247,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63364,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211248,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63364,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211249,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63364,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211250,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63364,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211251,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63364,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211252,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63365,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211253,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63365,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211254,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63365,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211255,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63365,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211256,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63365,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211257,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63366,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",211258,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63366,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",211259,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63366,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",211260,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63366,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",211261,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63366,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",211262,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63367,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",211263,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63367,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",211264,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63367,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",211265,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63367,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",211266,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63367,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",211267,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63368,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",211268,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63368,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",211269,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63368,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",211270,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63368,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",211271,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63368,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",211272,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63369,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",211273,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63369,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",211274,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63369,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",211275,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63369,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",211276,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63369,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",211277,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63370,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211278,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63370,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211279,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63370,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211280,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63370,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211281,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63370,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211282,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63371,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211283,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63371,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211284,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63371,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211285,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63371,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211286,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63371,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211287,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63372,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211288,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63372,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211289,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63372,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211290,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63372,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211291,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63372,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211292,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63373,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211293,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63373,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211294,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63373,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211295,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63373,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211296,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63373,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211297,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63374,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211298,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63374,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211299,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63374,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211300,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63374,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211301,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63374,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211302,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63375,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211303,0,Strongly Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63375,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211304,1,Agree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63375,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211305,2,No Opinion,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63375,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211306,3,Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63375,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,211307,4,Strongly Disagree,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63376,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211308,0,Excellent,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63376,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211309,1,Very Good,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63376,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211310,2,Good,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63376,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211311,3,Fair,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63376,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211312,4,Poor,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63376,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211313,5,N/A,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63377,16,"Overall, this activity was:",211314,0,Excellent,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63377,16,"Overall, this activity was:",211315,1,Very Good,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63377,16,"Overall, this activity was:",211316,2,Good,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63377,16,"Overall, this activity was:",211317,3,Fair,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63377,16,"Overall, this activity was:",211318,4,Poor,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63378,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211319,0,Yes,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63378,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211320,1,No,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63378,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211321,2,N/A,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63381,20,How would you improve this class (check all that apply)?,211322,0,Reduce content covered in class,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63381,20,How would you improve this class (check all that apply)?,211323,1,Increase content covered in class,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63381,20,How would you improve this class (check all that apply)?,211324,2,Update content covered in class,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63381,20,How would you improve this class (check all that apply)?,211325,3,Improve the instructional methods,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63381,20,How would you improve this class (check all that apply)?,211326,4,Make course activities more stimulating,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63381,20,How would you improve this class (check all that apply)?,211327,5,Slow the pace of the class,0
9912,Questions-0000-46,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-9-21,n13941,63381,20,How would you improve this class (check all that apply)?,211328,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63342,0,Please list the location for this activity.,211159,0,Atlanta,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63342,0,Please list the location for this activity.,211160,1,Cherokee,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63342,0,Please list the location for this activity.,211161,2,Forsyth,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63342,0,Please list the location for this activity.,211162,3,Other,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63343,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211163,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63343,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211164,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63343,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211165,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63343,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211166,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63343,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211167,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63344,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211168,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63344,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211169,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63344,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211170,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63344,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211171,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63344,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211172,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63345,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211173,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63345,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211174,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63345,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211175,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63345,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211176,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63345,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",211177,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63346,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211178,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63346,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211179,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63346,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211180,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63346,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211181,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63346,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",211182,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63347,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211183,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63347,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211184,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63347,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211185,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63347,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211186,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63347,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211187,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63348,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211188,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63348,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211189,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63348,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211190,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63348,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211191,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63348,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211192,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63349,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211193,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63349,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211194,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63349,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211195,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63349,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211196,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63349,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211197,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63350,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211198,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63350,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211199,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63350,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211200,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63350,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211201,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63350,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211202,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63351,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211203,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63351,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211204,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63351,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211205,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63351,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211206,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63351,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211207,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63352,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,211208,0,Strongly Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63352,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,211209,1,Agree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63352,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,211210,2,No Opinion,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63352,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,211211,3,Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63352,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,211212,4,Strongly Disagree,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63353,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211214,0,Very Good,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63353,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211215,1,Good,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63353,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211216,2,Fair,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63353,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211217,3,Poor,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63353,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211213,4,Excellent,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63353,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211218,5,N/A,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63354,12,"Overall, this activity was:",211219,0,Excellent,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63354,12,"Overall, this activity was:",211220,1,Very Good,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63354,12,"Overall, this activity was:",211221,2,Good,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63354,12,"Overall, this activity was:",211222,3,Fair,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63354,12,"Overall, this activity was:",211223,4,Poor,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63355,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211224,0,Yes,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63355,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211225,1,No,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63355,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211226,2,N/A,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63358,16,How would you improve this class (check all that apply)?,211227,0,Reduce content covered in class,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63358,16,How would you improve this class (check all that apply)?,211228,1,Increase content covered in class,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63358,16,How would you improve this class (check all that apply)?,211229,2,Update content covered in class,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63358,16,How would you improve this class (check all that apply)?,211230,3,Improve the instructional methods,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63358,16,How would you improve this class (check all that apply)?,211231,4,Make course activities more stimulating,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63358,16,How would you improve this class (check all that apply)?,211232,5,Slow the pace of the class,0
9918,Questions-0000-52,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-9-21",n13940,63358,16,How would you improve this class (check all that apply)?,211233,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63325,0,Please list the location for this activity.,211094,0,Atlanta,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63325,0,Please list the location for this activity.,211095,1,Cherokee,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63325,0,Please list the location for this activity.,211096,2,Forsyth,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63325,0,Please list the location for this activity.,211097,3,Other,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63326,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211098,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63326,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211099,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63326,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211100,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63326,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211101,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63326,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",211102,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63327,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211103,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63327,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211104,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63327,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211105,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63327,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211106,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63327,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",211107,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63328,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211108,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63328,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211109,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63328,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211110,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63328,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211111,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63328,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211112,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63329,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211113,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63329,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211114,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63329,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211115,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63329,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211116,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63329,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211117,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63330,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211118,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63330,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211119,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63330,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211120,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63330,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211121,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63330,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,211122,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63331,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211123,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63331,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211124,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63331,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211125,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63331,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211126,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63331,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,211127,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63332,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211128,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63332,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211129,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63332,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211130,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63332,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211131,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63332,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,211132,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63333,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,211133,0,Strongly Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63333,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,211134,1,Agree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63333,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,211135,2,No Opinion,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63333,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,211136,3,Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63333,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,211137,4,Strongly Disagree,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63334,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211138,0,Excellent,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63334,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211139,1,Very Good,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63334,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211140,2,Good,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63334,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211141,3,Fair,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63334,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211142,4,Poor,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63334,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",211143,5,N/A,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63335,10,"Overall, this activity was:",211144,0,Excellent,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63335,10,"Overall, this activity was:",211145,1,Very Good,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63335,10,"Overall, this activity was:",211146,2,Good,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63335,10,"Overall, this activity was:",211147,3,Fair,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63335,10,"Overall, this activity was:",211148,4,Poor,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63336,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211149,0,Yes,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63336,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211150,1,No,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63336,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211151,2,N/A,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63339,14,How would you improve this class (check all that apply)?,211152,0,Reduce content covered in class,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63339,14,How would you improve this class (check all that apply)?,211153,1,Increase content covered in class,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63339,14,How would you improve this class (check all that apply)?,211154,2,Update content covered in class,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63339,14,How would you improve this class (check all that apply)?,211155,3,Improve the instructional methods,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63339,14,How would you improve this class (check all that apply)?,211156,4,Make course activities more stimulating,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63339,14,How would you improve this class (check all that apply)?,211157,5,Slow the pace of the class,0
9905,Questions-0000-39,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-9-21,n13939,63339,14,How would you improve this class (check all that apply)?,211158,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9316,Elearning-0000-564,FY2021 NSF ICU POST CATH DOCUMENTATION EDUCATION,n13942,63384,0,I have read and understand the education surrounding post cath assessment and re assessment.  I attest to demonstrate assessment and documentation of assessment per provider orders,211329,0,TRUE,1
9316,Elearning-0000-564,FY2021 NSF ICU POST CATH DOCUMENTATION EDUCATION,n13942,63384,0,I have read and understand the education surrounding post cath assessment and re assessment.  I attest to demonstrate assessment and documentation of assessment per provider orders,211330,1,FALSE,0
225,SCORM-0000-31,ETIME TIMEKEEPER TRAINING,n13943,63385,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the eTime Timekeeper Training CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",211331,0,TRUE,1
225,SCORM-0000-31,ETIME TIMEKEEPER TRAINING,n13943,63385,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the eTime Timekeeper Training CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",211332,1,FALSE,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63395,0,Number 1 root cause for Sentinel Events is,211360,0,A.  Poor Communication,1
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63395,0,Number 1 root cause for Sentinel Events is,211361,1,B. Inexperience of Staff,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63395,0,Number 1 root cause for Sentinel Events is,211362,2,C. Distractions,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63395,0,Number 1 root cause for Sentinel Events is,211363,3,D. Fatigue,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63396,1,Successful HOC occurs when there is,211364,0,A.  Active Listening and Interactive Communication between both parties,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63396,1,Successful HOC occurs when there is,211365,1,B.  Time allotted for Questions and Verbal Verification of Received Information,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63396,1,Successful HOC occurs when there is,211366,2,C. Limit to Interruptions during HOC,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63396,1,Successful HOC occurs when there is,211367,3,D. All the above,1
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63397,2,True or False HOC should only be completed during permanent relief?,211368,0,A. True,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63397,2,True or False HOC should only be completed during permanent relief?,211369,1,B. False,1
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63398,3,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,211370,0,A. Scrub Tech to Scrub Tech,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63398,3,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,211371,1,B. Support Tech to Primary RN,1
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63398,3,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,211372,2,C. Primary Nurse to Relief Nurse,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63398,3,All individuals are responsible for  HOC during relief <b><u>EXCEPT</u></b>,211373,3,D. All the above,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63399,4,When <b><u>MUST</u></b> a nurse document HOC?,211374,0,A. Breaks,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63399,4,When <b><u>MUST</u></b> a nurse document HOC?,211375,1,B. Meals Breaks,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63399,4,When <b><u>MUST</u></b> a nurse document HOC?,211376,2,C. Permanent Relief,1
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63399,4,When <b><u>MUST</u></b> a nurse document HOC?,211377,3,D. All the Above,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63400,5,Some of the elements that must be covered in HOC include?,211378,0,"A. Time Out (patient name, date of birth, procedure, allergies)",0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63400,5,Some of the elements that must be covered in HOC include?,211379,1,B. Medications on the field and amount administered to patient,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63400,5,Some of the elements that must be covered in HOC include?,211380,2,C. Specimen Status,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63400,5,Some of the elements that must be covered in HOC include?,211381,3,D. All the Above,1
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63401,6,Who is responsible for the patients care and well being after HOC?,211382,0,A. Surgeon,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63401,6,Who is responsible for the patients care and well being after HOC?,211383,1,B. Reporting RN and reporting Surgical Technologist,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63401,6,Who is responsible for the patients care and well being after HOC?,211384,2,C. Receiving RN and receiving Surgical Technologist,1
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63401,6,Who is responsible for the patients care and well being after HOC?,211385,3,D. First Assist,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63402,7,The use of a HOC checklist as a memory aid serves what purpose(s)?,211386,0,A. Ensures that critical information necessary for patient care is not omitted,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63402,7,The use of a HOC checklist as a memory aid serves what purpose(s)?,211387,1,B. Provides a consistent order in which information should be communicated from care provider to care provider,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63402,7,The use of a HOC checklist as a memory aid serves what purpose(s)?,211388,2,C. Provides a visual guide for individuals to use during HOC,0
241,SCORM-0000-47,FY2021 SURGICAL SERVICES INTRAOPERATIVE  RN HAND-OFF COMMUNICATION,n13945,63402,7,The use of a HOC checklist as a memory aid serves what purpose(s)?,211389,3,D. All the Above,1
9686,Elearning-0000-900,SCN FEEDING WORKFLOW UPDATE,n13948,63403,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""SCN Feeding Workflow Update"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",211390,0,TRUE,1
9686,Elearning-0000-900,SCN FEEDING WORKFLOW UPDATE,n13948,63403,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""SCN Feeding Workflow Update"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",211391,1,FALSE,0
125,SCORM-0000-205,WAVE ONBOARDING REPORT TUTORIAL,n13949,63404,0,I have read and understood the content within the WAVE Onboarding Report Tutorial CBL.,211392,0,TRUE,1
125,SCORM-0000-205,WAVE ONBOARDING REPORT TUTORIAL,n13949,63404,0,I have read and understood the content within the WAVE Onboarding Report Tutorial CBL.,211393,1,FALSE,0
9329,Elearning-0000-576,FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD),n13950,63405,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD) CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",211394,0,TRUE,1
9329,Elearning-0000-576,FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD),n13950,63405,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the FY2021 BBRAUN ONGUARD CLOSED SYSTEM TRANSFER DEVICE (CSTD) CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",211395,1,FALSE,0
9130,Elearning-0000-395,ONS CONGRESS 2021 REFLECTIONS,n13953,63408,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ONS CONGRESS 2021 REFLECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",211400,0,TRUE,1
9130,Elearning-0000-395,ONS CONGRESS 2021 REFLECTIONS,n13953,63408,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ONS CONGRESS 2021 REFLECTIONS CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",211401,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63409,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",211402,0,1. All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63409,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",211403,1,2. A and C,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63409,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",211404,2,"3. A, C, D",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63410,1,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",211405,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63410,1,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",211406,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63411,2,"Which statement about ASV mode is FALSE?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",211407,0,1. All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63411,2,"Which statement about ASV mode is FALSE?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",211408,1,2. A and C,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63411,2,"Which statement about ASV mode is FALSE?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours. B. IPPB PIP of 15cmH20. C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness) D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",211409,2,"3. A, C, D",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63412,56,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",211410,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63412,56,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",211411,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63413,3,Which statement about ASV mode is FALSE?,211412,0,1. ASV maintains an operator-preset minimum minute ventilation independent of the patient's activity.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63413,3,Which statement about ASV mode is FALSE?,211413,1,"2. On the G5, the maximum pressure set by ASV is always 10 cmH2O below the maximum pressure limit, thus the maximum pressure and the ASV limit co-vary.",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63413,3,Which statement about ASV mode is FALSE?,211414,2,"3. The lowest Minute Volume % to be used in ASV mode is 100%.  Per protocol, the RT may set the MV% to 80% without a Physican's order for patients with a diagnosis of COPD.",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63413,3,Which statement about ASV mode is FALSE?,211415,3,"4. When started, the device delivers 3 test breaths in synchronized intermittent mandatory pressure ventilation mode.",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63414,4,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",211416,0,"1. A, B, C, D",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63414,4,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",211417,1,2. A and C,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63414,4,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",211418,2,"3. B, C, F",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63414,4,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",211419,3,"4. A, B, C",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63414,4,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV. A. Patient Height B. Gender C. % Minute Volume D. PEEP E. Trigger F. ETS (Expiratory Trigger Sensitivity)",211420,4,5. All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63415,5,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",211421,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63415,5,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",211422,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63416,6,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,211423,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63416,6,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,211424,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63417,7,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",211425,0,1. A only,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63417,7,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",211426,1,2. C and D,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63417,7,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",211427,2,"3. B, C, D",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63417,7,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14, PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.  All pain medications are PRN.   Patient is awake and follows commands. AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.   What is the next appropriate course of action?<br> A. Report the ABG to the physician and make changes only if ordered. B. Decrease the set rate to 12bpm.  C. Decrease Fi02  D. Decrease the Vt to 450mL. E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR",211428,3,4. C and E,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63418,8,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",211429,0,A. 255mL - 395mL,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63418,8,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",211430,1,B. 280mL - 420mL,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63418,8,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",211431,2,C. 300mL - 440mL,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63418,8,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",211432,3,D. 320mL - 460mL,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63419,9,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,211433,0,1. A and B,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63419,9,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,211434,1,"2. B, C, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63419,9,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,211435,2,3. B and D,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63419,9,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,211436,3,"4. A, B, D, E",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63419,9,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,211437,4,"5. C, D, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63419,9,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.  The Pa02 is 52mmHg on a Fi02 of 85%.   CXR shows dense bilateral infiltrates  Select the following strategies you might include in the management of this ventilated patient.<br> A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP B. Increase Fi02  C. Change modes from APV-CMV to ASV for improved ventilator synchrony D. Adjust Vt to achieve 4-6mL/kg IBW E. Consider Prone position or Nitric oxide,211438,5,6. All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63420,10,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",211439,0,1. A and C,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63420,10,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",211440,1,2. A and D,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63420,10,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",211441,2,"3. A, B, C",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63420,10,"In P-CMV mode, what factor may affect the delivered Vt? A. Changes in the respiratory system compliance B. Administration of bronchodilators C. Patient's respiratory activity D. Changes to the pressure control level",211442,3,4. All of the above,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63421,11,Which of these statements regarding Spontaneous mode is FALSE?,211443,0,"a. When pressure support is set to zero, the mode functions like  a conventional CPAP system.",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63421,11,Which of these statements regarding Spontaneous mode is FALSE?,211444,1,b. The patient determines the breath timing and may be either flow or  pressure triggered.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63421,11,Which of these statements regarding Spontaneous mode is FALSE?,211445,2,"c. The settings in this mode include: Psupport, P-ramp, ETS, PEEP,  Fi02 and Trigger.",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63421,11,Which of these statements regarding Spontaneous mode is FALSE?,211446,3,"d. If the back up mode is selected, the vent will transition from SPONT to APV-CMV mode when the apnea alarm is triggered.",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63422,12,"The vent weaning readiness criteria includes a PEEP =  8 cmH20, Fi02 = 50%, spontaneous respirations and a patient that follows commands.",211447,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63422,12,"The vent weaning readiness criteria includes a PEEP =  8 cmH20, Fi02 = 50%, spontaneous respirations and a patient that follows commands.",211448,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63423,13,Which statement regarding the Spontaneous Breathing Trial is FALSE?,211449,0,A. The SBT should not exceed 120 minutes unless ordered by MD or midlevel.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63423,13,Which statement regarding the Spontaneous Breathing Trial is FALSE?,211450,1,"B. If at any time the patient because unstable or has an increased RR > 35bpm, the mode should be changed to achieve the pre-trial minute volume.",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63423,13,Which statement regarding the Spontaneous Breathing Trial is FALSE?,211451,2,C. ASV at 100%MV or CPAP/PS mode may be used.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63423,13,Which statement regarding the Spontaneous Breathing Trial is FALSE?,211452,3,"D. ASV at 100%MV may be used and the Pinsp should be < 15cmH20 to be considered in a ""weaning""ù mode.",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63423,13,Which statement regarding the Spontaneous Breathing Trial is FALSE?,211453,4,"E. If the patient is on pressors, the RT and RN must confirm that the physician is aware of the type and dose of pressors before a weaning trial is conducted.",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63424,14,The red alarm cable connected should be documented with every Q4h vent check while confirmation of the audible and visual alarms should be documented with every vent check.,211454,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63424,14,The red alarm cable connected should be documented with every Q4h vent check while confirmation of the audible and visual alarms should be documented with every vent check.,211455,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63425,15,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,211456,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63425,15,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,211457,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63426,16,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,211458,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63426,16,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,211459,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63427,17,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,211460,0,1. All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63427,17,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,211461,1,"2. A, C, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63427,17,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,211462,2,3. B and C,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63427,17,Physician orders are needed for which of the following?<br> A. BiPAP use B. Brachial ABG C. Use of a bite block D. Changing vent modes to start the SBT E. Extubation,211463,3,"4. A, B, C, E",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63428,18,"When patients are placed in the prone position, which of the following tube holders are acceptable?",211464,0,A. Hollister,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63428,18,"When patients are placed in the prone position, which of the following tube holders are acceptable?",211465,1,B. Silk tape then Stabiltube,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63428,18,"When patients are placed in the prone position, which of the following tube holders are acceptable?",211466,2,C. Hollister with Physician's order,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63428,18,"When patients are placed in the prone position, which of the following tube holders are acceptable?",211467,3,D.  B and C,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63429,19,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",211468,0,"A. Increased I-time, decreased E-time",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63429,19,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",211469,1,"B. Decreased I-time, increased E-time",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63429,19,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",211470,2,"C. Decreased I-time, decreased E-time",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63429,19,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",211471,3,D. None of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63430,20,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",211472,0,A. Only the G5 can utilize Heliox.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63430,20,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",211473,1,B. The G5 flow sensor must be recalibrated with Heliox prior to starting the therapy.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63430,20,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",211474,2,C. The circuit must first be changed from a single limb with a HME to a heated wire circuit prior to starting Heliox therapy,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63431,21,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",211475,0,A. 68,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63431,21,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",211476,1,B.  70,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63431,21,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",211477,2,C.  66,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63431,21,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP<br> 10cmH20, Fi02 85%.  Sp02 90%.<br> ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",211478,3,D.  49,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63432,22,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",211479,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63432,22,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",211480,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63433,23,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,211481,0,A. Peak airway pressure,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63433,23,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,211482,1,B. Optimal PEEP,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63433,23,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,211483,2,C. Dynamic lung compliance,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63433,23,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,211484,3,D. Plateau pressure,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63434,24,The Hamilton ventilator will display which of the following calculations and measurements?,211485,0,A. Lung compliance,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63434,24,The Hamilton ventilator will display which of the following calculations and measurements?,211486,1,B. AutoPEEP,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63434,24,The Hamilton ventilator will display which of the following calculations and measurements?,211487,2,C. Rapid shallow breathing index,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63434,24,The Hamilton ventilator will display which of the following calculations and measurements?,211488,3,D. Airway resistance,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63434,24,The Hamilton ventilator will display which of the following calculations and measurements?,211489,4,"E. A, C, D",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63434,24,The Hamilton ventilator will display which of the following calculations and measurements?,211490,5,F. All of the above,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63435,25,"Hamilton C2-C3 in NIV-ST mode<br>   Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",211491,0,A.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63435,25,"Hamilton C2-C3 in NIV-ST mode<br>   Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",211492,1,B.,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63435,25,"Hamilton C2-C3 in NIV-ST mode<br>   Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",211493,2,C.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63436,26,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,211494,0,"1. A, D, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63436,26,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,211495,1,"2. B, C, D",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63436,26,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,211496,2,"3. A, B, D, E",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63436,26,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,211497,3,4. A and E,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63436,26,BiPAP is contraindicated in which of the following cases:<br> A.  Actively vomiting B.  Inability to protect the airway; severely obtunded C.  Hypercapnia with spontaneous respiratory effort D.  Trauma or burns involving the face E.   Apnea or respiratory arrest,211498,4,5. All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63437,27,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",211499,0,"1. A, B, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63437,27,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",211500,1,"2.   B, C and E",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63437,27,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",211501,2,"3. C, D, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63437,27,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22. ABG 7.28 / 72 / 63 / 31 / 4.9 Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation. B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation. C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve. D. Increasing the set rate to 20 will improve ventilation. E. Increasing IPAP will improve ventilation.",211502,3,4. All statements are true,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63438,28,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",211503,0,a.   NIV-ST,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63438,28,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",211504,1,b.   Spontaneous,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63438,28,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",211505,2,c.   NIV,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63438,28,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",211506,3,d.   NIPPV,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63439,29,"Per protocol, what are the initial HFO settings?",211507,0,"a.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 50%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 35 lpm",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63439,29,"Per protocol, what are the initial HFO settings?",211508,1,"b.  Hz 5, Power 5 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20 above mean pressure on conventional vent, Bias Flow 35 lpm",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63439,29,"Per protocol, what are the initial HFO settings?",211509,2,"c.  Hz 3, Power 5 - adjusting for adequate chest wiggle, Ti 40%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 25 lpm",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63439,29,"Per protocol, what are the initial HFO settings?",211510,3,"d.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20  below mean pressure on conventional vent, Bias Flow 45 lpm",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63440,30,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,211511,0,1.  All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63440,30,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,211512,1,2.  A and B,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63440,30,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,211513,2,"3.  A, B, C",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63440,30,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg C.  Greater than 12 hours since start of HFO D.  Fi02 less than 75%,211514,3,4.  B and C,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63441,31,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",211515,0,a.   Frequency,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63441,31,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",211516,1,b.   Cuff Leak,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63441,31,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",211517,2,c.    I Time,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63441,31,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",211518,3,d. Amplitude,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63441,31,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",211519,4,e. A and B only,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63441,31,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",211520,5,"f. A, B, C, D",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63442,32,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",211521,0,a.   MAP,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63442,32,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",211522,1,b.   FiO2,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63442,32,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",211523,2,c. Amplitude,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63442,32,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",211524,3,d. A and B only,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63442,32,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",211525,4,"e. A, B, C",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63443,33,"Per protocol, which changes could correct the following ABG using the HFO 3100B? pH 7.24 - PaC02 68 - Pa02 80 - HCO3 29 - BE 3.9<br> A. Increase Hz, Decrease Power B. Increase Power, Increase Hz C. Decreased Hz, Increase Power D. Cuff leak",211526,0,"1.  A, D, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63443,33,"Per protocol, which changes could correct the following ABG using the HFO 3100B? pH 7.24 - PaC02 68 - Pa02 80 - HCO3 29 - BE 3.9<br> A. Increase Hz, Decrease Power B. Increase Power, Increase Hz C. Decreased Hz, Increase Power D. Cuff leak",211527,1,2.  B and D,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63443,33,"Per protocol, which changes could correct the following ABG using the HFO 3100B? pH 7.24 - PaC02 68 - Pa02 80 - HCO3 29 - BE 3.9<br> A. Increase Hz, Decrease Power B. Increase Power, Increase Hz C. Decreased Hz, Increase Power D. Cuff leak",211528,2,3.  C and D,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63444,34,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",211529,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63444,34,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",211530,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63445,35,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,211531,0,a.  5 PPM,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63445,35,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,211532,1,b.  10 PPM,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63445,35,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,211533,2,c.  Therapist discretion,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63445,35,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,211534,3,d.  20 PPM,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63446,36,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,211535,0,a. 20ppm,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63446,36,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,211536,1,b. 30ppm,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63446,36,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,211537,2,c. 40ppm,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63446,36,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,211538,3,d. 60ppm,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63447,37,When should you consider changing the Nitric oxide filter and sample line?,211539,0,A. When you see fluid in the sample line,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63447,37,When should you consider changing the Nitric oxide filter and sample line?,211540,1,B. When the measured Nitric oxide and Fi02 is inaccurate,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63447,37,When should you consider changing the Nitric oxide filter and sample line?,211541,2,"C. After medications like Tobramycin, Mucomyst or Colistin are nebulized inline",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63447,37,When should you consider changing the Nitric oxide filter and sample line?,211542,3,D. All of the above,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63448,38,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,211543,0,1. All of the above,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63448,38,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,211544,1,"2. A, B, D",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63448,38,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,211545,2,3. A and B only,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63448,38,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices  B. McGrath intubation handles C. EMMA capnography devices D. Personal stethoscopes E. A Vision BiPAP used for a patient with C. diff,211546,3,"4. A, C, D",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63449,39,Components of the Fresh Trach protocol include?,211547,0,A. Signage on the door with the date and time the 48 hour observation ends,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63449,39,Components of the Fresh Trach protocol include?,211548,1,B.  ETC02 Q4  and breath sounds documentation with any patient repositioning during the first 48 hours,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63449,39,Components of the Fresh Trach protocol include?,211549,2,C.  Same size trach and one size smaller at bedside,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63449,39,Components of the Fresh Trach protocol include?,211550,3,D.  Obturator at the HOB,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63449,39,Components of the Fresh Trach protocol include?,211551,4,E.  Airway box at bedside,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63449,39,Components of the Fresh Trach protocol include?,211552,5,F.  Ambu bag and mask at bedside,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63449,39,Components of the Fresh Trach protocol include?,211553,6,G.  All of the above,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63450,40,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",211554,0,"1. A, B, C, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63450,40,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",211555,1,"2. B, C, D",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63450,40,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",211556,2,3. A and E,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63450,40,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br> A. Obturator B. Same size trach tube, both cuffed and cuffless C. A cuffed tube one size smaller D. A cuffless tube one size smaller E. Ambu bag and mask",211557,3,4. All of the above,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63453,41,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",211562,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63453,41,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",211563,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63454,42,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,211564,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63454,42,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,211565,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63455,43,"49 F, 5'5""ù, with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",211566,0,"A. ASV 140%, PEEP 10, Fi02 100%.  Target 8lpm.",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63455,43,"49 F, 5'5""ù, with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",211567,1,"B. P-CMV, PC 20cmH20, RR 16, PEEP 8, Fi02 85%, exh Vt 570mL",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63455,43,"49 F, 5'5""ù, with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",211568,2,"C. APV-CMV Vt 400, RR 20, PEEP 10, Fi02 100%",1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63456,44,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,211569,0,"1. B, C, D, E",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63456,44,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,211570,1,"2. A, B, C, D",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63456,44,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,211571,2,3. C and E,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63456,44,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br> A. ICP > 20 B. Patient on Dopamine > 5 mcg/kg/min C. Patient on Norepinephrine > 2 mcg/kg/min D. Patient on Neosynephrine > 100 mcg/min E. Patient on Vasopressin - any dose,211572,3,4. All of the above,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63457,45,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",211573,0,1. All statements are true,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63457,45,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",211574,1,2. A and D,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63457,45,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",211575,2,3. B and C,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63457,45,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.  Which statements regarding skin breakdown are TRUE?<br> A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.  B. An incident report must be logged, a physician promptly notified and Progress Note written.  C. Notify the RN to consult wound care and document the skin breakdown in Cerner. D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",211576,3,4. B and D,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63458,46,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",211577,0,"1. B, D, E, G",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63458,46,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",211578,1,"2. A, D, G, H",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63458,46,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",211579,2,"3. B, C, F, G,",0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63458,46,"Progress note topics include which of the following?<br> A. Fi02 increase > 10% B. SBT start and stop time with mode and settings, including the reason why SBT is stopped C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow D. All intubations and extubations E. Changes of airway type, vent mode or PEEP F. Codes and Rapid Response G. ICU shift summaries H. RT evaluation and treat consults",211580,3,4. All of the above,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63459,47,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,211581,0,1. Cover the laryngectomy stoma with your hand or gauze and bag through the mouth with the AMBU bag.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63459,47,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,211582,1,2. Use an adult AMBU bag and a pediatric mask over the laryngectomy stoma to provide ventilation.,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63459,47,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,211583,2,3. Intubate through the mouth with an ETT and provide ventilation with the AMBU bag.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63459,47,Laryngectomy patients<br> What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,211584,3,4. Do not use an AMBU bag for laryngectomy patients.,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63460,48,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Visual content only - Reviewed.,211585,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63460,48,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Visual content only - Reviewed.,211586,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63461,49,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater   Visual content only - Reviewed.",211587,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63461,49,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater   Visual content only - Reviewed.",211588,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63462,51,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Visual content only - Reviewed.",211589,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63462,51,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Visual content only - Reviewed.",211590,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63463,52,Heliox<br> G5 with Heliox: connection (we have 3 G5)  Visual content only - Reviewed.,211591,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63463,52,Heliox<br> G5 with Heliox: connection (we have 3 G5)  Visual content only - Reviewed.,211592,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63464,53,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox  Visual conten only - Reviewed.,211593,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63464,53,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox  Visual conten only - Reviewed.,211594,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63465,54,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.  Visual content only - Reviewed.",211595,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63465,54,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.  Visual content only - Reviewed.",211596,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63466,55,Skin Co-Signature for ETT's<br> (When The Tube holder is changed)  Visual content only - Reviewed.,211597,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63466,55,Skin Co-Signature for ETT's<br> (When The Tube holder is changed)  Visual content only - Reviewed.,211598,1,FALSE,0
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63467,50,"Heliox<br> The Heliox mask, attach the Aerogen spacer and nebulizer using elbow  Visual content only - Reviewed.",211599,0,TRUE,1
9730,Elearning-0000-940,2021 RESPIRATORY ICU COMPETENCY,n13954,63467,50,"Heliox<br> The Heliox mask, attach the Aerogen spacer and nebulizer using elbow  Visual content only - Reviewed.",211600,1,FALSE,0
9681,Elearning-0000-896,HAND OFF COMMUNICATION PERIOPERATIVE COMMUNICATION,n13956,63452,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Hand Off Communication Perioperative Communication"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",211560,0,TRUE,1
9681,Elearning-0000-896,HAND OFF COMMUNICATION PERIOPERATIVE COMMUNICATION,n13956,63452,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Hand Off Communication Perioperative Communication"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",211561,1,FALSE,0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63469,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",211603,0,a. True,1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63469,0,"NSH K-5 Policy provides guidelines for the handling of hazardous drugs (HDs) in conformance with USP, OSHA, NIOSH and EPA standards to protect NSH staff from unintended HD exposure.",211604,1,b. False,0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63470,1,Which one of the following hazardous medication list grouping is incorrect?,211605,0,"a.	Group 2 - Hazardous agents (primarily reproductive risk)",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63470,1,Which one of the following hazardous medication list grouping is incorrect?,211606,1,"b.	Group 1 - Hazardous agents (cytotoxic antineoplastic/reproductive risks)",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63470,1,Which one of the following hazardous medication list grouping is incorrect?,211607,2,"c.	Group 2A - Non-hazardous antineoplastic agents",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63470,1,Which one of the following hazardous medication list grouping is incorrect?,211608,3,"d.	Appendix D - Excluded drugs based on NSH risk assessment",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63471,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",211609,0,"a.	Decontamination",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63471,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",211610,1,"b.	Cleaning",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63471,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",211611,2,"c.	Disinfection",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63471,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",211612,3,"d.	Deactivate",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63471,2,"All sterile compounding areas and devices where hazardous drugs are handled must following the following cleaning steps per pharmacy policies, cleaning logs, and standard operating procedures using approved products:",211613,4,"e.	All of the above",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63472,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,211614,0,"a.	Protective Gown",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63472,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,211615,1,"b.	Eye/Face protection",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63472,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,211616,2,"c.	Respiratory protection",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63472,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,211617,3,"d.	Footwear",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63472,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,211618,4,"e.	Gloves",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63472,3,The following Personal Protective Equipment is utilized for handling various dosage forms of hazardous drugs:,211619,5,"f.	All of the above",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63473,4,The spill response team is activated for any spills that is not contained by the following:,211620,0,"a.	Two Spill Kits",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63473,4,The spill response team is activated for any spills that is not contained by the following:,211621,1,"b.	Single Spill Kit",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63473,4,The spill response team is activated for any spills that is not contained by the following:,211622,2,"c.	Three Spill Kits",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63473,4,The spill response team is activated for any spills that is not contained by the following:,211623,3,"d.	Any spill in patient care area",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63473,4,The spill response team is activated for any spills that is not contained by the following:,211624,4,"e.	Any spill in pharmacy area",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63474,5,Gloves used in the preparation of HDs must be:,211625,0,"a.	Disposable",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63474,5,Gloves used in the preparation of HDs must be:,211626,1,"b.	Powdered to facilitate removal",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63474,5,Gloves used in the preparation of HDs must be:,211627,2,"c.	Specified as ASTM-tested chemotherapy gloves",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63474,5,Gloves used in the preparation of HDs must be:,211628,3,"d.	A and C",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63475,6,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",211629,0,"a.	Filter needles",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63475,6,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",211630,1,"b.	Leur-Lock syringes",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63475,6,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",211631,2,"c.	Closed-system transfer devices (CSTDs)",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63475,6,"When reconstituting and withdrawing chemotherapy medications from vials, aerosol droplets may be generated. This can be minimized or eliminated by using:",211632,3,"d.	None of the above",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63476,7,When wearing double gloves:,211633,0,"a.	The gown cuffs should be tucked over both gloves",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63476,7,When wearing double gloves:,211634,1,"b.	The gown cuffs should be tucked under both gloves",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63476,7,When wearing double gloves:,211635,2,"c.	The inner glove should be worn under the cuff and the outer glove should be worn over the gown cuff",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63476,7,When wearing double gloves:,211636,3,"d.	It makes no difference if gown cuffs are worn over or under the gloves",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63477,8,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,211637,0,"a.	True",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63477,8,Gowns and gloves worn while working in the HD preparation area can be worn while working in other medication preparation areas.,211638,1,"b.	False",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63478,9,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,211639,0,"a.	Biological safety cabinet (BSC)",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63478,9,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,211640,1,"b.	Horizontal laminar air flow workbench",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63478,9,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,211641,2,"c.	Compounding aseptic containment isolator (CACI)",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63478,9,Which of the following types of containment primary engineering controls (C-PECs) can be used for preparing sterile HDs?,211642,3,"d.	A and C",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63479,10,Spill kits:,211643,0,"a.	May be obtained from Central Supply when needed",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63479,10,Spill kits:,211644,1,"b.	Are kept wherever HDs and chemotherapy agents are handled",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63479,10,Spill kits:,211645,2,"c.	Contain supplies needed to clean a HD spill",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63479,10,Spill kits:,211646,3,"d.	All of the above",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63480,11,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",211647,0,"a.	True",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63480,11,"Hazardous drugs (Group 1 and 2) that require manipulation or compounding may be stored in areas with non-hazardous drugs; however, they must be stored above other drugs on higher medication shelves.",211648,1,"b.	False",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63481,12,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",211649,0,"a.	True",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63481,12,"Group 1 HDs in final dosage forms (tablets, capsules, pre-filled syringes) may not be stored in patient medication drawers with non-hazardous drugs or in unit-based automated dispensing cabinets.",211650,1,"b.	False",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63482,13,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",211651,0,a. True,1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63482,13,"With the exception of hormonal agents, an Informed Consent for Drug Therapy is required for the initiation of any Group 1 or 2 HD prescribed for an oncology indication. The consent must be fully completed, with all applicable sections addressed.",211652,1,b. False,0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63483,14,How often do you have to change the gown during hazardous drug compounding?,211653,0,"a.	At least every 12 hours",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63483,14,How often do you have to change the gown during hazardous drug compounding?,211654,1,"b.	At least every 24 hours",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63483,14,How often do you have to change the gown during hazardous drug compounding?,211655,2,"c.	At least every 3 hours",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63483,14,How often do you have to change the gown during hazardous drug compounding?,211656,3,"d.	At least every 8 hours",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63484,15,How often do you have to change the outer gloves during hazardous drug sterile compounding?,211657,0,"a.	At least every 8 hours",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63484,15,How often do you have to change the outer gloves during hazardous drug sterile compounding?,211658,1,"b.	At least every 3  hours",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63484,15,How often do you have to change the outer gloves during hazardous drug sterile compounding?,211659,2,"c.	At least every 30 minutes",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63484,15,How often do you have to change the outer gloves during hazardous drug sterile compounding?,211660,3,"d.	 At shift change",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63485,16,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,211661,0,"a.	True",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63485,16,Cytotoxic chemotherapy dispensed in a syringe must not take up more than 80% of the total volume of the syringe.,211662,1,"b.	False",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63486,17,Which statement is true?,211663,0,"a.	Cytotoxic chemotherapy doses maybe rounded down or up to the nearest vials size within < 5% of the calculated dose",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63486,17,Which statement is true?,211664,1,"b.	Cytotoxic chemotherapy doses maybe rounded down to the nearest vials size within < 5% of the calculated dose",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63486,17,Which statement is true?,211665,2,"c.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 10% of the calculated dose.",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63486,17,Which statement is true?,211666,3,"d.	Monoclonal antibodies and other biologic agents may be dose rounded down or up to the nearest vial size within = 5% of the calculated dose.",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63486,17,Which statement is true?,211667,4,"e.	a & c",0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63486,17,Which statement is true?,211668,5,"f.	b & c",1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63487,18,PA or NP may sign C1D1 chemotherapy orders.,211669,0,a. True,0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63487,18,PA or NP may sign C1D1 chemotherapy orders.,211670,1,b. False,1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63488,19,Which statement is false?,211671,0,a. Verbal and telephone orders to initiate chemotherapy will not be accepted,0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63488,19,Which statement is false?,211672,1,b. A physician must sign C1D1 chemotherapy orders,0
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63488,19,Which statement is false?,211673,2,c. Pregnancy screening is required at baseline and then at least once a week while the patient is on therapy,1
9675,Elearning-0000-890,HAZARDOUS DRUGS (K-5) POLICY OBIC PHARMACY EDUCATION,n13959,63488,19,Which statement is false?,211674,3,d. Treating physicians are responsible for monitoring cumulative anthracycline doses,0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63489,0,All fresh trachs performed by Atlanta Head and Neck Associates (AHNA) will use the fresh trach protocol without any changes.,211675,0,TRUE,0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63489,0,All fresh trachs performed by Atlanta Head and Neck Associates (AHNA) will use the fresh trach protocol without any changes.,211676,1,FALSE,1
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63490,1,What will dictate the care of the fresh trachs done by AHNA?,211677,0,"a.	The surgeons will write specific orders that may change from patient-to-patient.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63490,1,What will dictate the care of the fresh trachs done by AHNA?,211678,1,"b.	The nurse, the doctor and the RT must communicate to develop an appropriate plan of care.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63490,1,What will dictate the care of the fresh trachs done by AHNA?,211679,2,"c.	Patients that do not have specific orders from the surgeon will follow the Fresh Trach Protocol with additional instructions.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63490,1,What will dictate the care of the fresh trachs done by AHNA?,211680,3,"d.	All of the above",1
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63491,2,What considerations should be taken for patients with a reconstructive flap?,211681,0,"a.	No trach ties or elastic bands can be used around the neck.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63491,2,What considerations should be taken for patients with a reconstructive flap?,211682,1,"b.	Suctioning is done Q2 hours.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63491,2,What considerations should be taken for patients with a reconstructive flap?,211683,2,"c.	The patients MUST have a humidification device as mucus plugging is common.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63491,2,What considerations should be taken for patients with a reconstructive flap?,211684,3,"d.	A ""Head and Neck Flap""ù sign should be present at the HOB until the patient leaves the ICU.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63491,2,What considerations should be taken for patients with a reconstructive flap?,211685,4,"e.	A and B only.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63491,2,What considerations should be taken for patients with a reconstructive flap?,211686,5,"f.	All of the above",1
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63492,3,How is humidification secured for patients with a reconstructive flap?,211687,0,"a.	Safety pins attach the trach collar to tape on the patient's chest.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63492,3,How is humidification secured for patients with a reconstructive flap?,211688,1,"b.	The green elastic strap goes behind the patient's neck to secure the trach collar.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63492,3,How is humidification secured for patients with a reconstructive flap?,211689,2,"c.	If tape will not stick to the patient's chest, a towel may go behind the patient's neck and the safety pins should secure the trach collar to the towel",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63492,3,How is humidification secured for patients with a reconstructive flap?,211690,3,"d.	No humidification is needed for patients with reconstructive neck flaps.",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63492,3,How is humidification secured for patients with a reconstructive flap?,211691,4,"e.	A and C only",1
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63492,3,How is humidification secured for patients with a reconstructive flap?,211692,5,"f.	All of the above",0
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63493,4,Can the RT remove sutures after 5 day for AHNA trach patients?,211693,0,"a.	NO. The sutures can only be removed by the surgeon.",1
9558,Elearning-0000-784,ATLANTA HEAD AND NECK ASSOCIATES,n13960,63493,4,Can the RT remove sutures after 5 day for AHNA trach patients?,211694,1,"b.	YES. The RT can remove the sutures after seeking physician approval.",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63526,0,"Per protocol, you can obtain ABGs when a patient is on _____ or greater FiO2 and then contact the physician with the results.",211793,0,"a.	30%",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63526,0,"Per protocol, you can obtain ABGs when a patient is on _____ or greater FiO2 and then contact the physician with the results.",211794,1,"b.	40%",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63526,0,"Per protocol, you can obtain ABGs when a patient is on _____ or greater FiO2 and then contact the physician with the results.",211795,2,"c.	50%",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63527,1,Which probe goes with the Capnography monitor?,211796,0,"a.	Adult Respiratory Sensor with SpO2 and RR",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63527,1,Which probe goes with the Capnography monitor?,211797,1,"b.	Neonatal-Adult SpO2 Sensor",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63528,2,Which statement about CPAP documentation is False?,211798,0,a. the patient does not have to sign a release of liability to use their home CPAP,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63528,2,Which statement about CPAP documentation is False?,211799,1,b. Home CPAP units will be checked Qshift,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63528,2,Which statement about CPAP documentation is False?,211800,2,c. CPAP documentation includes the documentation of skin integrity,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63529,3,How often do you change an inner cannula?,211801,0,A. BID and as needed,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63529,3,How often do you change an inner cannula?,211802,1,B. Q24 on dayshift and as needed,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63529,3,How often do you change an inner cannula?,211803,2,C. Q24 on nightshift and as needed,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63529,3,How often do you change an inner cannula?,211804,3,D. Not during the 48 hour fresh trach protocol,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63530,4,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,211805,0,"a.	If room air Sp02 at rest is < 89%, place patient on oxygen to get their Sp02 > or = 89%. If able to ambulate, see what 02 is needed to keep Sp02 > 88% on exertion)",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63530,4,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,211806,1,"b.	If room air Sp02 is > or = to 89% at rest, you need to do a room air Sp02 with exertion",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63530,4,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,211807,2,"c.	If exertional Sp02 is lower than < 89%, you need to document how much 02 is needed to keep Sp02 > 89%. Please relay to RN and Case Management",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63530,4,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,211808,3,"d.	None of the above",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63530,4,Home oxygen assessment includes documenting under respiratory assessment tab during which of the following:,211809,4,"e.	All of the above",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63531,5,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",211810,0,"A.	A, B, and E",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63531,5,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",211811,1,"B.	D",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63531,5,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",211812,2,"C.	A, B, C, D, E",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63531,5,"BioMed work order, found on the Intranet under Requests, should include which of the following information?  A. Facility B. Tag C. Patient name and DOB D. Problem  E. Location /Room",211813,3,"D.	A, B, D, E",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63532,6,Which of the following is not a component of the fresh trach protocol?,211814,0,"a.	Signage on the door with the date and time the 48 hour observations ends",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63532,6,Which of the following is not a component of the fresh trach protocol?,211815,1,"b.	Same size trach and one size smaller",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63532,6,Which of the following is not a component of the fresh trach protocol?,211816,2,"c.	Speaking Valve in Room",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63532,6,Which of the following is not a component of the fresh trach protocol?,211817,3,"d.	Obturator at the HOB",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63532,6,Which of the following is not a component of the fresh trach protocol?,211818,4,"e.	Airway box at bedside",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63532,6,Which of the following is not a component of the fresh trach protocol?,211819,5,"f.	Ambu bag at bedside",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63533,7,Any Trach patient outside the ICU needs to be placed on Remote monitoring.,211820,0,TRUE,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63533,7,Any Trach patient outside the ICU needs to be placed on Remote monitoring.,211821,1,FALSE,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63534,8,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",211822,0,"i.	A and B",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63534,8,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",211823,1,"ii.	C only",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63534,8,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",211824,2,"iii.	A and C",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63534,8,"The Respiratory Therapist will attend the transport of a patient when: a.	The fiO2> 50% b.	The patient has a tracheostomy tube and is on Oxygen c.	The patient is intubated and mechanically ventilated d.	On high flow nasal cannula",211825,3,"iv.	A, B, C and D",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63535,9,When should you consider weaning your patient off of optiflow?,211826,0,"a.	At the earliest appropriate time",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63535,9,When should you consider weaning your patient off of optiflow?,211827,1,"b.	When the fio2 is less than or equal to 50%",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63535,9,When should you consider weaning your patient off of optiflow?,211828,2,"c.	Per physician order",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63535,9,When should you consider weaning your patient off of optiflow?,211829,3,"d.	All of the above",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63536,10,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order",211830,0,TRUE,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63536,10,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order",211831,1,FALSE,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63537,11,"If an order reads, ""CPAP per RT protocol""ù, you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",211832,0,"i.	A. only",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63537,11,"If an order reads, ""CPAP per RT protocol""ù, you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",211833,1,"ii.	B. only",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63537,11,"If an order reads, ""CPAP per RT protocol""ù, you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",211834,2,"iii.	A and C",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63537,11,"If an order reads, ""CPAP per RT protocol""ù, you should set up: a.	The Remstar, Lumis or Airsense10 in the Auto mode  b.	Fixed CPAP of 15CM c.	If O2 is needed you can bleed in up to 4 L/min d.	If O2 is needed you can bleed in up to 15 L/min",211835,3,"iv.	A and D",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63538,12,When a Trach patient on the floor is de-cannulated you must:,211836,0,"a.	Stay in the room with the patient for 24 hours",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63538,12,When a Trach patient on the floor is de-cannulated you must:,211837,1,"b.	Place on a remote pulse ox for 24 hours per policy",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63538,12,When a Trach patient on the floor is de-cannulated you must:,211838,2,"c.	Place on a remote Capnography for 24 hours",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63538,12,When a Trach patient on the floor is de-cannulated you must:,211839,3,"d.	B or C",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63538,12,When a Trach patient on the floor is de-cannulated you must:,211840,4,"e.	A and B",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63539,13,"Per CPAP/BiPAP protocol, the physician will be contacted when:",211841,0,"a.	Heart rate increases or decreases to >20 from the pre therapy heart rate",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63539,13,"Per CPAP/BiPAP protocol, the physician will be contacted when:",211842,1,"b.	Therapist is unable to achieve an adequate mask seal",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63539,13,"Per CPAP/BiPAP protocol, the physician will be contacted when:",211843,2,"c.	Tach dysrhythmias or Brach arrhythmias Occur",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63539,13,"Per CPAP/BiPAP protocol, the physician will be contacted when:",211844,3,"d.	All of the above",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63540,14,"When using the C1 or C3 in Non-invasive mode, it is important to set the following:",211845,0,"a.	I-time lower than I time Max and ETS at least 50% to help compensate for leaks in the mask",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63540,14,"When using the C1 or C3 in Non-invasive mode, it is important to set the following:",211846,1,"b.	I-time needs to be higher than I time Max and ETS at 25%",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63541,15,On the code sheet you should ALWAYS make sure the airway/Etco2 section is filled out correctly before signing the sheet,211847,0,TRUE,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63541,15,On the code sheet you should ALWAYS make sure the airway/Etco2 section is filled out correctly before signing the sheet,211848,1,FALSE,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63542,16,"What should you do when a patient is not compliant with CPAP, home or Hospital unit?",211849,0,"a.	It's okay, they have the right to refuse treatment",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63542,16,"What should you do when a patient is not compliant with CPAP, home or Hospital unit?",211850,1,"b.	Notify the physician, place them on a capnography remote monitor and educate on why it is needed.",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63542,16,"What should you do when a patient is not compliant with CPAP, home or Hospital unit?",211851,2,"c.	Place them on 3L nc",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63543,17,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",211852,0,"i.	A and C",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63543,17,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",211853,1,"ii.	B and C",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63543,17,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",211854,2,"iii.	A, B, C",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63543,17,"Which are the indicators for continuous pulse oximetry? a.	All Post-operative patients on a PCA pump or epidural. b.	Tracheostomy patients located outside ICU and those recently decannulated <24 hrs. c.	Floor patient with a PaO2 <65",211855,3,"iv.	B only",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63544,18,"Remote monitors placed per protocol may be discontinued one hour after the PCA/Epidural has been discontinued, BIPAP/CPAP usage has been discontinued, or a repeat ABG results in a PaO2 > 65mmHg.",211856,0,TRUE,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63544,18,"Remote monitors placed per protocol may be discontinued one hour after the PCA/Epidural has been discontinued, BIPAP/CPAP usage has been discontinued, or a repeat ABG results in a PaO2 > 65mmHg.",211857,1,FALSE,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63545,19,"Patients on CPAP, home or Hospital Unit that require more than 40% / 5lpm FiO2 bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",211858,0,"a.	Remote capnography",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63545,19,"Patients on CPAP, home or Hospital Unit that require more than 40% / 5lpm FiO2 bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",211859,1,"b.	Remote Pulse Oximeter",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63546,20,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",211860,0,"i.	A and C",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63546,20,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",211861,1,"ii.	A, B, and C",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63546,20,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",211862,2,"iii.	A,D,E",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63546,20,"Per Bronchodilator Therapy, the therapist can order the following medications: a.	Albuterol b.	Levalbuterol (Xopenex) c.	Ipratropium (Atrovent) d.	Brovana e.	Pulmicort",211863,3,"iv.	All of the above",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63547,21,A patient may be on the floor with a cuffed Trach.,211864,0,TRUE,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63547,21,A patient may be on the floor with a cuffed Trach.,211865,1,FALSE,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63548,22,Which of the following patient type needs to be monitored by remote pulse oximetry,211866,0,"a.	Patients with a PaO2 65 or less",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63548,22,Which of the following patient type needs to be monitored by remote pulse oximetry,211867,1,"b.	Patients on comfort care",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63548,22,Which of the following patient type needs to be monitored by remote pulse oximetry,211868,2,"c.	Any patient requiring more than 6l of oxygen to maintain their SpO2 greater than 92%",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63549,23,Patients on high flow device requiring an FiO2of 50% or greater to maintain a SpO2 of 92% or patients that have had a FiO2 increase of 10% or greater over 1-2 hours should have a pulmonary or critical care consult for management and to determine appropriate  hospital unit placement.,211869,0,TRUE,1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63549,23,Patients on high flow device requiring an FiO2of 50% or greater to maintain a SpO2 of 92% or patients that have had a FiO2 increase of 10% or greater over 1-2 hours should have a pulmonary or critical care consult for management and to determine appropriate  hospital unit placement.,211870,1,FALSE,0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63550,24,"If the therapist receives an order for a Bipap device from a provider other than Critical Care, they will stabilize the patient then:",211871,0,"a.	Personally contact the critical care doc on call to notify them of the patient",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63550,24,"If the therapist receives an order for a Bipap device from a provider other than Critical Care, they will stabilize the patient then:",211872,1,"b.	Communicate with the ordering physician that Critical Care must be consulted for further evaluation",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63551,25,When setting up a MetaNeb treatment on a patient which of the following is not set:,211873,0,"a.	Oscillations",0
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63551,25,When setting up a MetaNeb treatment on a patient which of the following is not set:,211874,1,"b.	Pressure",1
9739,Elearning-0000-949,2021 CHEROKEE RESPIRATORY ADULT FLOOR COMPETENCY,n13964,63551,25,When setting up a MetaNeb treatment on a patient which of the following is not set:,211875,2,"c.	Resistance",0
274,SCORM-0000-84,OCCUPATIONAL THERAPY AND HEART FAILURE,n13963,63525,0,I have read and understood the content within the Occupational Therapy and Heart Failure CBL.,211791,0,TRUE,1
274,SCORM-0000-84,OCCUPATIONAL THERAPY AND HEART FAILURE,n13963,63525,0,I have read and understood the content within the Occupational Therapy and Heart Failure CBL.,211792,1,FALSE,0
9611,Elearning-0000-832,TIMELESS 116: MOTHERS KIOSK,n13968,63562,0,I acknowledge that I have read and understand the Timeless 116: Mothers Kiosk CBL in its entirety.,211898,0,TRUE,1
9611,Elearning-0000-832,TIMELESS 116: MOTHERS KIOSK,n13968,63562,0,I acknowledge that I have read and understand the Timeless 116: Mothers Kiosk CBL in its entirety.,211899,1,FALSE,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63563,0,Please list the location for this activity.,211900,0,Atlanta,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63563,0,Please list the location for this activity.,211901,1,Forsyth,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63563,0,Please list the location for this activity.,211902,2,Cherokee,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63563,0,Please list the location for this activity.,211903,3,Other,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63564,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",211904,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63564,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",211905,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63564,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",211906,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63564,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",211907,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63564,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",211908,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63565,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",211909,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63565,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",211910,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63565,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",211911,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63565,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",211912,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63565,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",211913,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63566,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",211914,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63566,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",211915,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63566,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",211916,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63566,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",211917,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63566,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",211918,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63567,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",211919,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63567,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",211920,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63567,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",211921,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63567,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",211922,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63567,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",211923,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63568,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",211924,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63568,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",211925,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63568,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",211926,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63568,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",211927,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63568,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",211928,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63569,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",211929,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63569,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",211930,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63569,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",211931,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63569,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",211932,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63569,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",211933,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63570,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",211934,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63570,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",211935,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63570,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",211936,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63570,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",211937,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63570,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",211938,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63571,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",211939,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63571,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",211940,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63571,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",211941,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63571,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",211942,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63571,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",211943,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63572,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",211944,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63572,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",211945,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63572,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",211946,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63572,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",211947,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63572,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",211948,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63573,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",211949,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63573,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",211950,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63573,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",211951,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63573,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",211952,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63573,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",211953,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63574,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",211954,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63574,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",211955,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63574,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",211956,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63574,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",211957,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63574,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",211958,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63575,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211959,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63575,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211960,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63575,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211961,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63575,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211962,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63575,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,211963,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63576,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,211964,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63576,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,211965,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63576,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,211966,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63576,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,211967,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63576,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,211968,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63577,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211969,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63577,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211970,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63577,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211971,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63577,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211972,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63577,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",211973,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63578,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",211974,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63578,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",211975,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63578,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",211976,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63578,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",211977,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63578,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",211978,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63579,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,211979,0,Strongly Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63579,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,211980,1,Agree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63579,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,211981,2,No Opinion,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63579,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,211982,3,Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63579,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,211983,4,Strongly Disagree,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63580,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",211984,0,Excellent,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63580,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",211985,1,Very Good,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63580,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",211986,2,Good,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63580,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",211987,3,Fair,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63580,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",211988,4,Poor,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63581,18,"Overall, this activity was:",211989,0,Excellent,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63581,18,"Overall, this activity was:",211990,1,Very Good,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63581,18,"Overall, this activity was:",211991,2,Good,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63581,18,"Overall, this activity was:",211992,3,Fair,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63581,18,"Overall, this activity was:",211993,4,Poor,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63582,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211994,0,Yes,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63582,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211995,1,No,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63582,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",211996,2,N/A,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63585,22,How would you improve this class?,211997,0,Reduce content covered in class,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63585,22,How would you improve this class?,211998,1,Increase content covered in class,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63585,22,How would you improve this class?,211999,2,Update content covered in class,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63585,22,How would you improve this class?,212000,3,Improve the instructional methods,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63585,22,How would you improve this class?,212001,4,Make course activities more stimulating,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63585,22,How would you improve this class?,212002,5,Slow the pace of the class,0
9892,Questions-0000-26,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-12-21,n13969,63585,22,How would you improve this class?,212003,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63610,0,Please list the location for this activity.,212098,0,Atlanta,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63610,0,Please list the location for this activity.,212099,1,Forsyth,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63610,0,Please list the location for this activity.,212100,2,Cherokee,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63610,0,Please list the location for this activity.,212101,3,Other,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63611,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",212102,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63611,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",212103,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63611,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",212104,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63611,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",212105,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63611,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe internal structures and function of the heart along with cardiac conduction.</ol>",212106,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63612,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",212107,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63612,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",212108,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63612,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",212109,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63612,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",212110,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63612,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specialized properties of cardiac cells.</ol>",212111,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63613,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",212112,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63613,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",212113,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63613,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",212114,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63613,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",212115,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63613,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal ECG measurements.</ol>",212116,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63614,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",212117,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63614,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",212118,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63614,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",212119,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63614,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",212120,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63614,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe flow of electricity through the heart based on lead placement.</ol>",212121,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63615,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",212122,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63615,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",212123,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63615,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",212124,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63615,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",212125,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63615,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state how to calculate heart rate using estimation and exact method given a 6 second strip. </ol>",212126,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63616,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",212127,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63616,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",212128,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63616,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",212129,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63616,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",212130,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63616,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to explore ECG graph paper and its use systematic approach to ECG rhythm interpretation.</ol>",212131,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63617,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",212132,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63617,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",212133,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63617,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",212134,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63617,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",212135,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63617,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state ECG characteristics for Normal Sinus Rhythm.</ol>",212136,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63618,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",212137,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63618,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",212138,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63618,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",212139,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63618,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",212140,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63618,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify dysrhythmias originating from selected areas of the cardiac conduction system (SA node, atria, ventricle, AV node, etc.) to include ECG criteria for each along with principles of management. </ol>",212141,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63619,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",212142,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63619,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",212143,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63619,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",212144,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63619,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",212145,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63619,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify different types of heart blocks to include ECG criteria for each and principles of management.</ol>",212146,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63620,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",212147,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63620,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",212148,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63620,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",212149,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63620,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",212150,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63620,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe and identify ECG criteria for asystole and PEA.</ol>",212151,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63621,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212152,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63621,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212153,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63621,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212154,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63621,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212155,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63621,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212156,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63622,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212157,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63622,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212158,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63622,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212159,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63622,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212160,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63622,12,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212161,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63623,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,212162,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63623,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,212163,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63623,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,212164,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63623,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,212165,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63623,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge/skills of life threating EKG rhythm recognition along with principles of management..</OL>,212166,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63624,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,212167,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63624,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,212168,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63624,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,212169,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63624,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,212170,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63624,14,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered will assist me in passing the ACLS megacode & test.<OL>,212171,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63625,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212172,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63625,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212173,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63625,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212174,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63625,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212175,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63625,15,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212176,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63626,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,212177,0,Strongly Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63626,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,212178,1,Agree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63626,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,212179,2,No Opinion,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63626,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,212180,3,Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63626,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,212181,4,Strongly Disagree,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63627,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",212182,0,Excellent,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63627,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",212183,1,Very Good,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63627,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",212184,2,Good,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63627,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",212185,3,Fair,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63627,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN </ol>",212186,4,Poor,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63628,18,"Overall, this activity was:",212187,0,Excellent,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63628,18,"Overall, this activity was:",212188,1,Very Good,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63628,18,"Overall, this activity was:",212189,2,Good,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63628,18,"Overall, this activity was:",212190,3,Fair,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63628,18,"Overall, this activity was:",212191,4,Poor,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63629,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212192,0,Yes,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63629,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212193,1,No,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63629,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212194,2,N/A,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63632,22,How would you improve this class?,212195,0,Reduce content covered in class,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63632,22,How would you improve this class?,212196,1,Increase content covered in class,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63632,22,How would you improve this class?,212197,2,Update content covered in class,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63632,22,How would you improve this class?,212198,3,Improve the instructional methods,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63632,22,How would you improve this class?,212199,4,Make course activities more stimulating,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63632,22,How would you improve this class?,212200,5,Slow the pace of the class,0
9938,Questions-0000-72,LIFE THREATENING EKG RECOGNITION (EVALUATION SURVEY) ONLINE 7.14.21,n13971,63632,22,How would you improve this class?,212201,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63635,0,"If patient is complaining of pain and burning at the IV site, the nurse should consider extravasation and stop infusion and assess site immediately.",212202,0,TRUE,1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63635,0,"If patient is complaining of pain and burning at the IV site, the nurse should consider extravasation and stop infusion and assess site immediately.",212203,1,FALSE,0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63636,1,"If IV access has visible blood return, the nurse should consider IV is patent and there is no need to flush IV access.",212204,0,TRUE,0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63636,1,"If IV access has visible blood return, the nurse should consider IV is patent and there is no need to flush IV access.",212205,1,FALSE,1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63637,2,It is possible that Vesicant drugs could leak at the insertion site causing extravasation without the vein wall being punctured.,212206,0,TRUE,1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63637,2,It is possible that Vesicant drugs could leak at the insertion site causing extravasation without the vein wall being punctured.,212207,1,FALSE,0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63638,3,"A cold or warm compress should be applied on extravasation site for 20minutes, 4 times per day for the first 48hrs.",212208,0,TRUE,1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63638,3,"A cold or warm compress should be applied on extravasation site for 20minutes, 4 times per day for the first 48hrs.",212209,1,FALSE,0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63639,4,"When administering Amiodarone, an inline filter should always be used.",212210,0,TRUE,1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63639,4,"When administering Amiodarone, an inline filter should always be used.",212211,1,FALSE,0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63640,5,Which of the following are early signs/symptoms of extravasation?,212212,0,"a.	Local blistering",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63640,5,Which of the following are early signs/symptoms of extravasation?,212213,1,"b.	Loss of blood return",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63640,5,Which of the following are early signs/symptoms of extravasation?,212214,2,"c.	Mild burning and discomfort  on IV site",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63640,5,Which of the following are early signs/symptoms of extravasation?,212215,3,"d.	Increased pain",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63640,5,Which of the following are early signs/symptoms of extravasation?,212216,4,"e.	Ulceration",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63640,5,Which of the following are early signs/symptoms of extravasation?,212217,5,"f.	Increased swelling",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63640,5,Which of the following are early signs/symptoms of extravasation?,212218,6,"g.	B,C",1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63641,6,What is the ideal time to administer extravasation antidotes to get the maximum effects?,212219,0,"a.	Within 4hrs of extravasation",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63641,6,What is the ideal time to administer extravasation antidotes to get the maximum effects?,212220,1,"b.	Within one hour",1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63641,6,What is the ideal time to administer extravasation antidotes to get the maximum effects?,212221,2,"c.	It can be administered any time",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63641,6,What is the ideal time to administer extravasation antidotes to get the maximum effects?,212222,3,"d.	Within 24hrs",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63642,7,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,212223,0,"a.	2,3,1,4",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63642,7,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,212224,1,"b.	2,1,3,4",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63642,7,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,212225,2,"c.	2,4,3,1",1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63642,7,What is the correct sequence of events that should happen at the first suspicion of an extravasation? 1. Remove IV access 2.stop infusion 3.attempt to aspirate drug from the IV device 4. Disconnect IV tubing,212226,3,"d.	1,2,3,4",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63643,8,Which medication requires a warm compress?,212227,0,"a.	Amiodarone",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63643,8,Which medication requires a warm compress?,212228,1,"b.	Dobutamine",1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63643,8,Which medication requires a warm compress?,212229,2,"c.	TPN",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63643,8,Which medication requires a warm compress?,212230,3,"d.	Potassium Chloride",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63644,9,Hyalurondase should be administered,212231,0,"a.	In a series of five 0.2ml injection in a clock wise manner around the circumference of the extravasation.",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63644,9,Hyalurondase should be administered,212232,1,"b.	Using a new 25 gauge needle for each injection",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63644,9,Hyalurondase should be administered,212233,2,"c.	A total dose of 1ml dose subcutaneously",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63644,9,Hyalurondase should be administered,212234,3,"d.	All of the above",1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63645,10,Phentolamine should be administered,212235,0,"a.	In a series of ten injections in a clock wise manner around the circumference of the extravasation",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63645,10,Phentolamine should be administered,212236,1,"b.	Total dose should not exceed 0.2mg/kg or 5mg.",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63645,10,Phentolamine should be administered,212237,2,"c.	Using a 25 gauge needle for each injection subcutaneously",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63645,10,Phentolamine should be administered,212238,3,"d.	All of the above",1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63646,11,How often should the RN assess and document IV access while infusing Vesicant drugs,212239,0,"a.	Once per shift and as needed",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63646,11,How often should the RN assess and document IV access while infusing Vesicant drugs,212240,1,"b.	Twice a shift",0
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63646,11,How often should the RN assess and document IV access while infusing Vesicant drugs,212241,2,"c.	A minimum of every 2hrs",1
9689,Elearning-0000-903,EXTRAVASATION MANAGEMENT OF NON-CHOMOTHERAPY MEDICATION,n13972,63646,11,How often should the RN assess and document IV access while infusing Vesicant drugs,212242,3,"d.	Once per shift",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63655,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours.<br> B. IPPB PIP of 15cmH20.<br> C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness)<br> D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",212259,0,1. All of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63655,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours.<br> B. IPPB PIP of 15cmH20.<br> C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness)<br> D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",212260,1,2. A and C,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63655,0,"Which of the following are components of the Thoracic Surgery protocol?<br> A. Institute SMI and IPPB on all patients with a unit dose of Albuterol (2.5mg) and Ipratroprium Bromide (0.5mg) at a frequency of every 8 hours for 24 hours.<br> B. IPPB PIP of 15cmH20.<br> C. Patient assessment including pre and post vital signs (heart and respiratory rate, breath sounds, sputum production, Sp02 and level of consciousness)<br> D. After 24 hours, if the bronchodilator is not indicated, it may be changed to PRN.",212261,2,"3. A, C, D",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63656,1,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",212262,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63656,1,"Contraindications for IPPB therapy include presence of ICP > 20, recent facial/oral surgery or trauma, esophageal surgery, untreated pneumothorax, hemodynamic instability, acute sinusitis and acute hemoptysis or nausea.",212263,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63657,2,Which statement about ASV mode is FALSE?,212264,0,1. ASV maintains an operator-preset minimum minute ventilation independent of the patient's activity.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63657,2,Which statement about ASV mode is FALSE?,212265,1,"2. On the G5, the maximum pressure set by ASV is always 10 cmH2O below the maximum pressure limit, thus the maximum pressure and the ASV limit co-vary.",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63657,2,Which statement about ASV mode is FALSE?,212266,2,"3. The lowest Minute Volume % to be used in ASV mode is 100%.  Per protocol, the RT may set the MV% to 80% without a Physican's order for patients with a diagnosis of COPD.",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63657,2,Which statement about ASV mode is FALSE?,212267,3,"4. When started, the device delivers 3 test breaths in synchronized intermittent mandatory pressure ventilation mode.",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63658,3,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",212268,0,"1. A, B, C, D",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63658,3,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",212269,1,2. A and C,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63658,3,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",212270,2,"3. B, C, F",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63658,3,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",212271,3,"4. A, B, C",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63658,3,"In ASV mode, adjustment to which of the following settings will affect delivered Vt and MV.<br> A. Patient Height<br> B. Gender<br> C. % Minute Volume<br> D. PEEP<br> E. Trigger<br> F. ETS (Expiratory Trigger Sensitivity)",212272,4,5. All of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63659,4,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",212273,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63659,4,"Pinsp is a direct correlation to the Pressure Support level the patient is requiring in ASV, and should be documented every vent check under invasive ventilation - Pinsp.",212274,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63660,5,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,212275,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63660,5,APV-CMV functions similar to the conventional pressure-controlled modes with the exception that a target volume may be delivered.,212276,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63661,6,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",212277,0,1. A only,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63661,6,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",212278,1,2. C and D,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63661,6,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",212279,2,"3. B, C, D",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63661,6,"Your patient remains intubated in APV-CMV mode after surgery: Vt 500mL, RR 14,<br> PEEP 5. Fi02 50%. Exh Vt 515mL, Total RR 16, Sp02 99%. No pressors, no sedation.<br> All pain medications are PRN.   Patient is awake and follows commands.<br> AM ABG results:  7.47 / 30 / 105 / 25 / 1.8.  EtC02 31.<br> What is the next appropriate course of action?<br>  A. Report the ABG to the physician and make changes only if ordered.<br> B. Decrease the set rate to 12bpm.<br>  C. Decrease Fi02<br>  D. Decrease the Vt to 450mL.<br> E. Start the SBT using either ASV 100%MV or CPAP/PS, notify the physician and RN and document in the EMR   .",212280,3,4. C and E,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63662,7,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",212281,0,A. 255mL - 395mL,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63662,7,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",212282,1,B. 280mL - 420mL,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63662,7,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",212283,2,C. 300mL - 440mL,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63662,7,"Per the Mechanical Ventilator protocol, select the appropriate Vt for a male patient with ARDS - Height 5'8""ù",212284,3,D. 320mL - 460mL,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63663,8,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,212285,0,1. A and B,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63663,8,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,212286,1,"2. B, C, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63663,8,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,212287,2,3. B and D,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63663,8,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,212288,3,"4. A, B, D, E",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63663,8,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,212289,4,"5. C, D, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63663,8,68 y/old male is intubated for hypoxic respiratory failure secondary to COVID PNA.<br> The Pa02 is 52mmHg on a Fi02 of 85%<br>  CXR shows dense bilateral infiltrates.<br> Select the following strategies you might include in the management of this ventilated patient.<br>  A. Use the P/V tool to screen for a recruitment maneuver and to set optimal PEEP<br> B. Increase Fi02<br>  C. Change modes from APV-CMV to ASV for improved ventilator synchrony<br> D. Adjust Vt to achieve 4-6mL/kg IBW<br> E. Consider Prone position or Nitric oxide,212290,5,6. All of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63664,9,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",212291,0,1. A and C,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63664,9,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",212292,1,2. A and D,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63664,9,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",212293,2,"3. A, B, C",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63664,9,"In P-CMV mode, what factor may affect the delivered Vt?<br> A. Changes in the respiratory system compliance<br> B. Administration of bronchodilators<br> C. Patient's respiratory activity<br> D. Changes to the pressure control level",212294,3,4. All of the above,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63665,10,Which of these statements regarding Spontaneous mode is FALSE?,212295,0,"a. When pressure support is set to zero, the mode functions like  a conventional CPAP system.",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63665,10,Which of these statements regarding Spontaneous mode is FALSE?,212296,1,b. The patient determines the breath timing and may be either flow or  pressure triggered.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63665,10,Which of these statements regarding Spontaneous mode is FALSE?,212297,2,"c. The settings in this mode include: Psupport, P-ramp, ETS, PEEP,  Fi02 and Trigger.",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63665,10,Which of these statements regarding Spontaneous mode is FALSE?,212298,3,"d. If the back up mode is selected, the vent will transition from SPONT to APV-CMV mode when the apnea alarm is triggered.",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63666,11,"The vent weaning readiness criteria includes a PEEP = 8 cmH20, Fi02 = 50%, effective cough, manageable secretions, the patient is awake and alert.",212299,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63666,11,"The vent weaning readiness criteria includes a PEEP = 8 cmH20, Fi02 = 50%, effective cough, manageable secretions, the patient is awake and alert.",212300,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63667,12,Which statement regarding the Spontaneous Breathing Trial is FALSE?,212301,0,A. The SBT should not exceed 120 minutes unless ordered by MD or midlevel.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63667,12,Which statement regarding the Spontaneous Breathing Trial is FALSE?,212302,1,"B. If at any time the patient because unstable or has an increased RR > 35bpm, the mode should be changed to achieve the pre-trial minute volume.",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63667,12,Which statement regarding the Spontaneous Breathing Trial is FALSE?,212303,2,C. ASV at 100%MV or CPAP/PS mode may be used.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63667,12,Which statement regarding the Spontaneous Breathing Trial is FALSE?,212304,3,"D. ASV at 100%MV may be used and the Pinsp should be < 15cmH20 to be considered in a ""weaning""ù mode.",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63667,12,Which statement regarding the Spontaneous Breathing Trial is FALSE?,212305,4,"E. If the patient is on pressors, the RT and RN must confirm that the physician is aware of the type and dose of pressors before a weaning trial is conducted.",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63668,13,The connection of the red alarm cable should be documented with every Q4h vent check as well as the audible and visual alarms.,212306,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63668,13,The connection of the red alarm cable should be documented with every Q4h vent check as well as the audible and visual alarms.,212307,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63669,14,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,212308,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63669,14,Oral care and tube movement  is performed Q2 and is a shared responsibility between Nursing and Respiratory Therapy.   Night shift should consult the RN prior to performing mouth care/tube movement to ensure undisturbed sleep time.,212309,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63670,15,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,212310,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63670,15,Hollister tube holders should be labeled with the date and time of application to ensure they are changed Q72h and PRN.Skin assessment co-signature is required on ALL tube holder changes.,212311,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63671,16,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,212312,0,1. All of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63671,16,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,212313,1,"2. A, C, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63671,16,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,212314,2,3. B and C,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63671,16,Physician orders are needed for which of the following?<br> A. BiPAP use<br> B. Brachial ABG<br> C. Use of a bite block<br> D. Changing vent modes to start the SBT<br> E. Extubation,212315,3,"4. A, B, C, E",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63672,17,"When patients are placed in the prone position, which of the following tube holders are acceptable?",212316,0,A. Hollister,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63672,17,"When patients are placed in the prone position, which of the following tube holders are acceptable?",212317,1,B. Silk tape then Stabiltube,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63672,17,"When patients are placed in the prone position, which of the following tube holders are acceptable?",212318,2,C. Hollister with Physician's order,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63672,17,"When patients are placed in the prone position, which of the following tube holders are acceptable?",212319,3,D.  B and C,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63673,18,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",212320,0,"A. Increased I-time, decreased E-time",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63673,18,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",212321,1,"B. Decreased I-time, increased E-time",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63673,18,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",212322,2,"C. Decreased I-time, decreased E-time",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63673,18,"ETS (expiratory trigger sensitivity), represents the percent of peak inspiratory flow at which the ventilator cycles from inspiration to exhalation.  The normal default ETS is 25%.  An intubated patient with COPD or air trapping would benefit from an increase of ETS to 40%.  What effect does this have on the I:E ratio?",212323,3,D. None of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63674,19,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",212324,0,A. Only the G5 can utilize Heliox.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63674,19,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",212325,1,B. The G5 flow sensor must be recalibrated with Heliox prior to starting the therapy.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63674,19,"In regards to Heliox via the Hamilton G5, which of these statements is FALSE?",212326,2,C. The circuit must first be changed from a single limb with a  HME to a heated wire circuit prior to starting Heliox therapy.,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63675,20,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",212327,0,A.  68,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63675,20,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",212328,1,B.  70,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63675,20,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",212329,2,C.  66,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63675,20,"An ARDS patient is intubated in APV-CMV mode: Vt 380mL, Rate 22bpm, PEEP 10cmH20, Fi02 85%.  Sp02 90%. <br>  ABG results:  pH 7.32, PaC02 49, Pa02 57.8, HC03 26, BE +2.5.<br> What is the P/F ratio?",212330,3,D.  49,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63676,21,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",212331,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63676,21,"Complications of inverse I:E ratio include, but are not limited to, excessive gas trapping, adverse hemodynamic effects, and the need for sedation",212332,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63677,22,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,212333,0,A. Peak airway pressure,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63677,22,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,212334,1,B. Optimal PEEP,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63677,22,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,212335,2,C. Dynamic lung compliance,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63677,22,Performing an Inspiratory hold on the Hamilton ventilator allows for the measurement of which parameter?,212336,3,D. Plateau pressure,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63678,23,The Hamilton ventilator will display which of the following calculations and measurements?,212337,0,A. Lung compliance,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63678,23,The Hamilton ventilator will display which of the following calculations and measurements?,212338,1,B. AutoPEEP,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63678,23,The Hamilton ventilator will display which of the following calculations and measurements?,212339,2,C. Rapid shallow breathing index,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63678,23,The Hamilton ventilator will display which of the following calculations and measurements?,212340,3,D. Airway resistance,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63678,23,The Hamilton ventilator will display which of the following calculations and measurements?,212341,4,"E. A, C, D",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63678,23,The Hamilton ventilator will display which of the following calculations and measurements?,212342,5,F. All of the above,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63680,24,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,212346,0,"1. A, D, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63680,24,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,212347,1,"2. B, C, D",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63680,24,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,212348,2,"3. A, B, D, E",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63680,24,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,212349,3,4. A and E,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63680,24,BiPAP is contraindicated in which of the following cases:<br>  A.  Actively vomiting<br> B.  Inability to protect the airway; severely obtunded<br> C.  Hypercapnia with spontaneous respiratory effort<br> D.  Trauma or burns involving the face<br> E.   Apnea or respiratory arrest,212350,4,5. All of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63681,26,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",212351,0,"1. A, B, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63681,26,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",212352,1,"2.   B, C and E",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63681,26,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",212353,2,"3. C, D, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63681,26,"Vision BiPAP settings:  IPAP 12,  EPAP 6, RR 12, Fi02 50%, Sp02 95%.  Exh Vt 300mL, total RR 22<br> ABG 7.28 / 72 / 63 / 31 / 4.9<br> Which statement regarding changes to the settings is TRUE?<br>  A. Increasing the EPAP will improve both ventilation and oxygenation.<br> B. Increasing EPAP alone may improve oxygenation but will adversely affect ventilation.<br> C. An increase in EPAP must be accompanied by an increase in IPAP for ventilation to remain constant or improve.<br> D. Increasing the set rate to 20 will improve ventilation.<br> E. Increasing IPAP will improve ventilation.",212354,3,4. All statements are true,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63682,27,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",212355,0,a.   NIV-ST,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63682,27,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",212356,1,b.   Spontaneous,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63682,27,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",212357,2,c.   NIV,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63682,27,"If a patient is trached and needs to be on BIPAP, which mode is to be used on the G5/C2/C3 or transport vent?",212358,3,d.   NIPPV,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63683,28,"Per protocol, what are the initial HFO settings?",212359,0,"a.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 50%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 35 lpm",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63683,28,"Per protocol, what are the initial HFO settings?",212360,1,"b.  Hz 5, Power 5 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20 above mean pressure on conventional vent, Bias Flow 35 lpm",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63683,28,"Per protocol, what are the initial HFO settings?",212361,2,"c.  Hz 3, Power 5 - adjusting for adequate chest wiggle, Ti 40%, Fi02 same as conventional vent, MAP set to same as conventional vent, Bias Flow 25 lpm",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63683,28,"Per protocol, what are the initial HFO settings?",212362,3,"d.  Hz 5, Power 8 - adjusting for adequate chest wiggle, Ti 33%, Fi02 100%, MAP set to 5cmH20  below mean pressure on conventional vent, Bias Flow 45 lpm",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63684,29,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,212363,0,1.  All of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63684,29,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,212364,1,2.  A and B,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63684,29,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,212365,2,"3.  A, B, C",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63684,29,Contraindications for the HFO recruitment maneuver include:<br> A.  Pneumothorax with active air leak<br> B.  Hemodynamic instability:  Mean arterial pressure < 60mmHg<br> C.  Greater than 12 hours since start of HFO<br> D.  Fi02 less than 75%,212366,3,4.  B and C,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63685,30,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",212367,0,a.   Frequency,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63685,30,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",212368,1,b.   Cuff Leak,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63685,30,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",212369,2,c.    I Time,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63685,30,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",212370,3,d. Amplitude,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63685,30,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",212371,4,e. A and B only,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63685,30,"On the Sensormedics Oscillator, what parameter could be changed to improve ventilation?",212372,5,"f. A, B, C, D",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63686,31,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",212373,0,a. MAP,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63686,31,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",212374,1,b.   FiO2,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63686,31,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",212375,2,c. Amplitude,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63686,31,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",212376,3,d. A and B only,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63686,31,"On the Sensormedics Oscillator, what parameters could be changed to improve oxygenation?",212377,4,"e. A, B, C",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63687,32,"Per protocol, which changes could correct the following ABG using the HFO 3100B?<br>  pH 7.24<br> - PaC02 68 - Pa02 80<br> - HCO3 29<br> - BE 3.9<br>  A. Increase Hz, Decrease Power<br> B. Increase Power, Increase Hz<br> C. Decreased Hz, Increase Power<br> D. Cuff leak",212378,0,"1.  A, D, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63687,32,"Per protocol, which changes could correct the following ABG using the HFO 3100B?<br>  pH 7.24<br> - PaC02 68 - Pa02 80<br> - HCO3 29<br> - BE 3.9<br>  A. Increase Hz, Decrease Power<br> B. Increase Power, Increase Hz<br> C. Decreased Hz, Increase Power<br> D. Cuff leak",212379,1,2.  B and D,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63687,32,"Per protocol, which changes could correct the following ABG using the HFO 3100B?<br>  pH 7.24<br> - PaC02 68 - Pa02 80<br> - HCO3 29<br> - BE 3.9<br>  A. Increase Hz, Decrease Power<br> B. Increase Power, Increase Hz<br> C. Decreased Hz, Increase Power<br> D. Cuff leak",212380,2,3.  C and D,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63688,54,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",212381,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63688,54,"Consider transition to conventional ventilation when the Fi02 is </= 50% and the mPaw is < 25cmH20, or you are not able to ventilate the patient despite all the appropriate changes.",212382,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63689,33,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,212383,0,a.  5 PPM,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63689,33,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,212384,1,b.  10 PPM,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63689,33,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,212385,2,c.  Therapist discretion,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63689,33,Under the Respiratory Protocol for Nitric Oxide:  What  level should the patient  initially be started on?,212386,3,d.  20 PPM,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63690,34,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,212387,0,a. 20ppm,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63690,34,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,212388,1,b. 30ppm,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63690,34,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,212389,2,c. 40ppm,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63690,34,Under the Respiratory Protocol for Nitric Oxide: What is the highest level a patient should be on?,212390,3,d. 60ppm,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63691,25,"Hamilton C2-C3 in NIV-ST mode<br> Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",212391,0,A.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63691,25,"Hamilton C2-C3 in NIV-ST mode<br> Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",212392,1,B.,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63691,25,"Hamilton C2-C3 in NIV-ST mode<br> Your patient is currently on a Vision BiPAP.  Ordered settings: IPAP 15, EPAP 8, Rate 14, Fi02 50%.  You need to transport the patient using a Hamilton C2.  Which picture shows the correct settings for the Hamilton device?",212393,2,C.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63692,35,When should you consider changing the Nitric oxide filter and sample line?,212394,0,A. When you see fluid in the sample line,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63692,35,When should you consider changing the Nitric oxide filter and sample line?,212395,1,B. When the measured Nitric oxide and Fi02 is inaccurate,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63692,35,When should you consider changing the Nitric oxide filter and sample line?,212396,2,"C. After medications like Tobramycin, Mucomyst or Colistin are nebulized inline",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63692,35,When should you consider changing the Nitric oxide filter and sample line?,212397,3,D. All of the above,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63693,36,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,212398,0,1. All of the above,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63693,36,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,212399,1,"2. A, B, D",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63693,36,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,212400,2,3. A and B only,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63693,36,A hydrogen peroxide wipe is used to clean which pieces of equipment?<br> A. ALL Hamilton devices<br>  B. McGrath intubation handles<br> C. EMMA capnography devices<br> D. Personal stethoscopes<br> E. A Vision BiPAP used for a patient with C. diff,212401,3,"4. A, C, D",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63694,37,Components of the Fresh Trach protocol include?,212402,0,A. Signage on the door with the date and time the 48 hour observation ends,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63694,37,Components of the Fresh Trach protocol include?,212403,1,B.  ETC02 Q4  and breath sounds documentation with any patient repositioning during the first 48 hours,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63694,37,Components of the Fresh Trach protocol include?,212404,2,C.  Same size trach and one size smaller at bedside,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63694,37,Components of the Fresh Trach protocol include?,212405,3,D.  Obturator at the HOB,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63694,37,Components of the Fresh Trach protocol include?,212406,4,E.  Airway box at bedside,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63694,37,Components of the Fresh Trach protocol include?,212407,5,F.  Ambu bag and mask at bedside,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63694,37,Components of the Fresh Trach protocol include?,212408,6,G.  All of the above,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63695,38,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",212409,0,"1. A, B, C, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63695,38,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",212410,1,"2. B, C, D",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63695,38,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",212411,2,3. A and E,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63695,38,"For a trach patient with a cuffless tube, what supplies do you need at bedside?<br>  A. Obturator<br> B. Same size trach tube, both cuffed and cuffless<br> C. A cuffed tube one size smaller<br> D. A cuffless tube one size smaller<br> E. Ambu bag and mask",212412,3,4. All of the above,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63696,39,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",212413,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63696,39,"The radiant infant warmer with supplies is located across from ED Room 11, just in front of the ambulance entrance to the ED.",212414,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63697,40,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,212415,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63697,40,There are two supply rooms for respiratory equipment in the ED:  One supply room across from Care Team 3 and the other is the respiratory equipment room housing the ABG analyzer and C2.,212416,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63698,41,"49 F, 5'5""ù, with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",212417,0,"A. APV-CMV Vt 500, RR 18, PEEP 12, Fi02 75%",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63698,41,"49 F, 5'5""ù, with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",212418,1,"B. ASV 140%, PEEP 10, Fi02 100%.  Target 8lpm.",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63698,41,"49 F, 5'5""ù, with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",212419,2,"C. P-CMV, PC 20cmH20, RR 16, PEEP 8, Fi02 85%, exh Vt 570mL",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63698,41,"49 F, 5'5""ù, with a history of chronic renal failure, CHF, pulmonary edema, morbid obesity, and HTN is admitted to the ICU after having missed her dialysis treatment.  She arrives on the unit wearing a NRB mask at 15lpm, Sp02 92%.  She presents with crackles throughout, labored breathing in a tripod position.  CXR shows pulmonary edema.  ABG results on current settings: 7.29/54/69/29/3.1.  HR 100.  B/P 115/69.  The decision is made to intubate and sedate.  Per protocol, what initial mode and settings would be most appropriate?",212420,3,"D. APV-CMV Vt 400, RR 20, PEEP 10, Fi02 100%",1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63699,42,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,212421,0,"1. B, C, D, E",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63699,42,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,212422,1,"2. A, B, C, D",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63699,42,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,212423,2,3. C and E,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63699,42,Spontaneous Breathing Trial Reason Not Done includes which of the following?<br>  A. ICP > 20<br> B. Patient on Dopamine > 5 mcg/kg/min<br> C. Patient on Norepinephrine > 2 mcg/kg/min<br> D. Patient on Neosynephrine > 100 mcg/min<br> E. Patient on Vasopressin - any dose,212424,3,4. All of the above,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63700,43,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",212425,0,1. All statements are true,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63700,43,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",212426,1,2. A and D,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63700,43,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",212427,2,3. B and C,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63700,43,"It is day 3 after trach tube placement in the OR.  There is no skin barrier in place, sutures remain intact, and you notice skin breakdown below the flange.<br>  Which statements regarding skin breakdown are TRUE?<br>  A. Trach sutures may be removed prior to 5 days when new skin breakdown occurs.  Notify the physician once sutures are removed, place a skin barrier and write a Progress note.<br>  B. An incident report must be logged, a physician promptly notified and Progress Note written.<br>  C. Notify the RN to consult wound care and document the skin breakdown in Cerner.<br> D. If ointment is at bedside, RT may scan the medication before applying it when scheduled trach care is done.",212428,3,4. B and D,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63701,44,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",212429,0,"1. B, D, E, G",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63701,44,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",212430,1,"2. A, D, G, H",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63701,44,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",212431,2,"3. B, C, F, G,",0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63701,44,"Progress note topics include which of the following?<br>   A. Fi02 increase > 10%<br> B. SBT start and stop time with mode and settings, including the reason why SBT is stopped<br> C. Clinical changes requiring additional support, like the initiation of BiPAP or Optiflow<br> D. All intubations and extubations<br> E. Changes of airway type, vent mode or PEEP<br> F. Codes and Rapid Response<br> G. ICU shift summaries<br> H. RT evaluation and treat consults",212432,3,4. All of the above,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63702,45,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,212433,0,1. Cover the laryngectomy stoma with your hand or gauze and bag through the mouth with the AMBU bag.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63702,45,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,212434,1,2. Use an adult AMBU bag and a pediatric mask over the laryngectomy stoma to provide ventilation.,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63702,45,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,212435,2,3. Intubate through the mouth with an ETT and provide ventilation with the AMBU bag.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63702,45,Laryngectomy patients<br>  What is the appropriate way to ventilate with a bag/mask for a laryngectomy patient without an artificial airway?,212436,3,4. Do not use an AMBU bag for laryngectomy patients.,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63703,46,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Acknowledge this slide was reviewed.,212437,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63703,46,Nitric with C2/C3<br> C2/C3 with Nitric oxide: use heated wire circuit<br>  Acknowledge this slide was reviewed.,212438,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63704,47,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater<br>  Acknowledge slide was reviewed.",212439,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63704,47,"Nitric with Transport Vent<br> Transport vent with Nitric oxide : Use heated wire circuit, bypass heater<br>  Acknowledge slide was reviewed.",212440,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63705,48,Heliox<br> The Heliox mask; attach the Aerogen spacer and nebulizer using elbow<br>  Acknowledge slide was reviewed.,212441,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63705,48,Heliox<br> The Heliox mask; attach the Aerogen spacer and nebulizer using elbow<br>  Acknowledge slide was reviewed.,212442,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63706,49,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Acknowledge slide was reviewed.",212443,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63706,49,"Heliox<br> Heliox tank, regulator, hose for G5 connection<br>  Acknowledge slide was reviewed.",212444,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63707,50,Heliox<br> G5 with Heliox: connection (we have 3 G5)<br>  Acknowledge slide was reviewed.,212445,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63707,50,Heliox<br> G5 with Heliox: connection (we have 3 G5)<br>  Acknowledge slide was reviewed.,212446,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63708,51,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox<br> You must calibrate the flowsensor with the Heliox***<br>  Acknowledge slide was reviewed.,212447,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63708,51,Heliox with G-5<br> G5 screenshots: select gas source then calibrate on Heliox<br> You must calibrate the flowsensor with the Heliox***<br>  Acknowledge slide was reviewed.,212448,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63709,52,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.<br>  Acknowledge slide was reviewed.",212449,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63709,52,"Prone positioning: Silk tape, then Stabiltube. Hollister only per MD order. Skin assessment co-signature is required on ALL tube holder changes.<br>  Acknowledge slide was reviewed.",212450,1,FALSE,0
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63710,53,Skin Co-Signature for ETT's <br> (When The Tube holder is changed)<br>  Acknowledge slide was reviewed.,212451,0,TRUE,1
9727,Elearning-0000-938,2021 RESPIRATORY ADULT ICU COMPETENCY,n13985,63710,53,Skin Co-Signature for ETT's <br> (When The Tube holder is changed)<br>  Acknowledge slide was reviewed.,212452,1,FALSE,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2111,1,The normal oxygen saturation for a healthy adult is about:,2126,0,97 % - 98 %,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2111,1,The normal oxygen saturation for a healthy adult is about:,2127,1,92 % - 96 %,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2111,1,The normal oxygen saturation for a healthy adult is about:,2128,2,91 % - 93 %,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2111,1,The normal oxygen saturation for a healthy adult is about:,2129,3,88 % - 90 %,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2115,5,"The physician orders the opiate Fentanyl (Sublimaze) 25 mcg and Midazolam (Versed) 2 mg to be given IV. You draw up and administer the drugs as prescribed. All of the following statements are true about Benzodiazipines (Valium, Versed) EXC EPT:",2130,0,They are used to relieve pain.,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2115,5,"The physician orders the opiate Fentanyl (Sublimaze) 25 mcg and Midazolam (Versed) 2 mg to be given IV. You draw up and administer the drugs as prescribed. All of the following statements are true about Benzodiazipines (Valium, Versed) EXC EPT:",2131,1,They generally relieve nervousness or tension.,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2115,5,"The physician orders the opiate Fentanyl (Sublimaze) 25 mcg and Midazolam (Versed) 2 mg to be given IV. You draw up and administer the drugs as prescribed. All of the following statements are true about Benzodiazipines (Valium, Versed) EXC EPT:",2132,2,The dosage is usually lower when given with an opioid.,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2115,5,"The physician orders the opiate Fentanyl (Sublimaze) 25 mcg and Midazolam (Versed) 2 mg to be given IV. You draw up and administer the drugs as prescribed. All of the following statements are true about Benzodiazipines (Valium, Versed) EXC EPT:",2133,3,They may cause respiratory depression.,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2116,6,"Opiates (fentanyl, morphine, meperidine) can cause all of the following side effects EXCEPT:",2134,0,Hypotension,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2116,6,"Opiates (fentanyl, morphine, meperidine) can cause all of the following side effects EXCEPT:",2135,1,Apnea,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2116,6,"Opiates (fentanyl, morphine, meperidine) can cause all of the following side effects EXCEPT:",2136,2,Hypoglycemia,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2116,6,"Opiates (fentanyl, morphine, meperidine) can cause all of the following side effects EXCEPT:",2137,3,Respiratory depression,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2120,10,When administering Flumazeril (Romazicon) you should monitor the patient for all of the following EXCEPT:,2138,0,Resedation / respiratory depression,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2120,10,When administering Flumazeril (Romazicon) you should monitor the patient for all of the following EXCEPT:,2139,1,Seizures,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2120,10,When administering Flumazeril (Romazicon) you should monitor the patient for all of the following EXCEPT:,2140,2,"Withdrawal symptoms (sweating, nausea, vomiting, etc)",0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2120,10,When administering Flumazeril (Romazicon) you should monitor the patient for all of the following EXCEPT:,2141,3,Retrograde amnesia (recent memory loss before/during procedure),1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2121,11,"After receiving the Flumazenil (Romazicon), Mrs. N. becomes less anxious; her oxygen saturation quickly returns to 98%, pulse 80, BP 110/70. Mrs. N. appears adequately sedated and the MD wishes to begin the case. Which one of the following  observations would alert you if Mrs. N. became over sedated?",2142,0,Slurred speech,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2121,11,"After receiving the Flumazenil (Romazicon), Mrs. N. becomes less anxious; her oxygen saturation quickly returns to 98%, pulse 80, BP 110/70. Mrs. N. appears adequately sedated and the MD wishes to begin the case. Which one of the following  observations would alert you if Mrs. N. became over sedated?",2143,1,Turns head and responds to a loud noise,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2121,11,"After receiving the Flumazenil (Romazicon), Mrs. N. becomes less anxious; her oxygen saturation quickly returns to 98%, pulse 80, BP 110/70. Mrs. N. appears adequately sedated and the MD wishes to begin the case. Which one of the following  observations would alert you if Mrs. N. became over sedated?",2144,2,Drowsy,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2121,11,"After receiving the Flumazenil (Romazicon), Mrs. N. becomes less anxious; her oxygen saturation quickly returns to 98%, pulse 80, BP 110/70. Mrs. N. appears adequately sedated and the MD wishes to begin the case. Which one of the following  observations would alert you if Mrs. N. became over sedated?",2145,3,"Cold, clammy skin",1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2122,12,The procedure is nearly over when Mrs. N.'s blood pessure suddenly drops to 75/55. You should consider all of the following actions EXCEPT:,2146,0,Place the patient in the Trendelenburg position,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2122,12,The procedure is nearly over when Mrs. N.'s blood pessure suddenly drops to 75/55. You should consider all of the following actions EXCEPT:,2147,1,Give Versed 0.5 mg IV push,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2122,12,The procedure is nearly over when Mrs. N.'s blood pessure suddenly drops to 75/55. You should consider all of the following actions EXCEPT:,2148,2,Increase the IV fluids,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2122,12,The procedure is nearly over when Mrs. N.'s blood pessure suddenly drops to 75/55. You should consider all of the following actions EXCEPT:,2149,3,Notify the MD,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2123,13,Possible causes of hypotension during moderate sedation include all of the following EXCEPT:,2150,0,Slow heart rate,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2123,13,Possible causes of hypotension during moderate sedation include all of the following EXCEPT:,2151,1,Arrhythmia,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2123,13,Possible causes of hypotension during moderate sedation include all of the following EXCEPT:,2152,2,Pain,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2123,13,Possible causes of hypotension during moderate sedation include all of the following EXCEPT:,2153,3,Acute hypoxia,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2124,14,"In vasovagal syncope, you would expect to see all of the following EXCEPT:",2154,0,Bradycardia,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2124,14,"In vasovagal syncope, you would expect to see all of the following EXCEPT:",2155,1,Dizziness/loss of consciousness,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2124,14,"In vasovagal syncope, you would expect to see all of the following EXCEPT:",2156,2,Nausea,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2124,14,"In vasovagal syncope, you would expect to see all of the following EXCEPT:",2157,3,Respiratory distress,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2125,15,Bradycardia is defined as a heart rate of under:,2158,0,80 beats/minutes,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2125,15,Bradycardia is defined as a heart rate of under:,2159,1,60 beats/minute,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2125,15,Bradycardia is defined as a heart rate of under:,2160,2,50 beats/minute,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2125,15,Bradycardia is defined as a heart rate of under:,2161,3,40 beats/minute,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2129,19,Intravenous moderate sedation is produced by administration of drugs for:,2162,0,Anxiety and combative behavior,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2129,19,Intravenous moderate sedation is produced by administration of drugs for:,2163,1,The performance of brief diagnostic procedures or therapeutic interventions,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2129,19,Intravenous moderate sedation is produced by administration of drugs for:,2164,2,Acute onset pain,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2129,19,Intravenous moderate sedation is produced by administration of drugs for:,2165,3,All of the above,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2130,20,While under moderate sedation a patient has a depressed level of consciousness but:,2166,0,Retains the ability to maintain a patent airway,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2130,20,While under moderate sedation a patient has a depressed level of consciousness but:,2167,1,Responds appropriately to physical stimulation,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2130,20,While under moderate sedation a patient has a depressed level of consciousness but:,2168,2,Follows verbal commands,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2130,20,While under moderate sedation a patient has a depressed level of consciousness but:,2169,3,All of the above,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2131,21,Deep sedation exists when the patient:,2170,0,Has a decreased level of consciousness,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2131,21,Deep sedation exists when the patient:,2171,1,A partial or complete loss of protective reflexes,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2131,21,Deep sedation exists when the patient:,2172,2,Can no longer respond to verbal stimuli,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2131,21,Deep sedation exists when the patient:,2173,3,All of the above,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2132,22,The most common adverse reaction from medications used for IV sedation is:,2174,0,Respiratory depression,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2132,22,The most common adverse reaction from medications used for IV sedation is:,2175,1,Respiratory arrest,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2132,22,The most common adverse reaction from medications used for IV sedation is:,2176,2,Extrapyramidal symptoms,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2132,22,The most common adverse reaction from medications used for IV sedation is:,2177,3,Drug addiction,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2135,25,Minimal monitoring requirements for moderate sedation include all of the following EXCEPT:,2178,0,Heart rate,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2135,25,Minimal monitoring requirements for moderate sedation include all of the following EXCEPT:,2179,1,Blood pressure,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2135,25,Minimal monitoring requirements for moderate sedation include all of the following EXCEPT:,2180,2,Respirations,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2135,25,Minimal monitoring requirements for moderate sedation include all of the following EXCEPT:,2181,3,O2 saturation,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2135,25,Minimal monitoring requirements for moderate sedation include all of the following EXCEPT:,2182,4,Blood gases & End Tidal O2,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2136,26,"Once IV sedation is given during a procedure, vital signs and O2 saturation must be monitored and recorded every:",2183,0,Q 2 hours,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2136,26,"Once IV sedation is given during a procedure, vital signs and O2 saturation must be monitored and recorded every:",2184,1,Q 30 minutes,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2136,26,"Once IV sedation is given during a procedure, vital signs and O2 saturation must be monitored and recorded every:",2185,2,Q15 minutes,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,2136,26,"Once IV sedation is given during a procedure, vital signs and O2 saturation must be monitored and recorded every:",2186,3,Q 5 minutes,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6226,0,"Read the following scenario and then proceed to the test questions.  Mrs. N. is having an outpatient procedure early in the morning that requires receiving moderate sedation.  She is a cooperative, alert, 63-year old woman weighing 90 pou nds (41 kg).  She has been a diabetic under good control for the last 10 years by diet.  She is not on insulin.  She had a mild case of osteoarthritis in her spine, but otherwise no significant prior health history or conditions.  Vital signs on admission are BP 100/80, Pulse 88, and Respirations 16.  Her initial pulse oximetry reading on room air is 97%.  Fentanyl (Sublimaze) and Midazolam (Versed) will be used for sedation during the procedure.   All of the following conditions except_________ suggest that Mrs. N may need a lower than usual dose of sedation medications.",13106,0,A.  Age,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6226,0,"Read the following scenario and then proceed to the test questions.  Mrs. N. is having an outpatient procedure early in the morning that requires receiving moderate sedation.  She is a cooperative, alert, 63-year old woman weighing 90 pou nds (41 kg).  She has been a diabetic under good control for the last 10 years by diet.  She is not on insulin.  She had a mild case of osteoarthritis in her spine, but otherwise no significant prior health history or conditions.  Vital signs on admission are BP 100/80, Pulse 88, and Respirations 16.  Her initial pulse oximetry reading on room air is 97%.  Fentanyl (Sublimaze) and Midazolam (Versed) will be used for sedation during the procedure.   All of the following conditions except_________ suggest that Mrs. N may need a lower than usual dose of sedation medications.",13107,1,B.  Weight,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6226,0,"Read the following scenario and then proceed to the test questions.  Mrs. N. is having an outpatient procedure early in the morning that requires receiving moderate sedation.  She is a cooperative, alert, 63-year old woman weighing 90 pou nds (41 kg).  She has been a diabetic under good control for the last 10 years by diet.  She is not on insulin.  She had a mild case of osteoarthritis in her spine, but otherwise no significant prior health history or conditions.  Vital signs on admission are BP 100/80, Pulse 88, and Respirations 16.  Her initial pulse oximetry reading on room air is 97%.  Fentanyl (Sublimaze) and Midazolam (Versed) will be used for sedation during the procedure.   All of the following conditions except_________ suggest that Mrs. N may need a lower than usual dose of sedation medications.",13108,2,C.  Renal Failure,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6226,0,"Read the following scenario and then proceed to the test questions.  Mrs. N. is having an outpatient procedure early in the morning that requires receiving moderate sedation.  She is a cooperative, alert, 63-year old woman weighing 90 pou nds (41 kg).  She has been a diabetic under good control for the last 10 years by diet.  She is not on insulin.  She had a mild case of osteoarthritis in her spine, but otherwise no significant prior health history or conditions.  Vital signs on admission are BP 100/80, Pulse 88, and Respirations 16.  Her initial pulse oximetry reading on room air is 97%.  Fentanyl (Sublimaze) and Midazolam (Versed) will be used for sedation during the procedure.   All of the following conditions except_________ suggest that Mrs. N may need a lower than usual dose of sedation medications.",13109,3,D.  Osteoarthritis,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6239,2,At the beginning of the procedure you place the pulse oximetry device on Mrs. N's finger  and observe a reading of 70%.  All of the following factors except_________ may affect the ability to get an accurate pulse oximetry reading.,13110,0,A.  Skin moisture,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6239,2,At the beginning of the procedure you place the pulse oximetry device on Mrs. N's finger  and observe a reading of 70%.  All of the following factors except_________ may affect the ability to get an accurate pulse oximetry reading.,13111,1,B.  Skin pigment,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6239,2,At the beginning of the procedure you place the pulse oximetry device on Mrs. N's finger  and observe a reading of 70%.  All of the following factors except_________ may affect the ability to get an accurate pulse oximetry reading.,13112,2,C.  Fingernail polish,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6239,2,At the beginning of the procedure you place the pulse oximetry device on Mrs. N's finger  and observe a reading of 70%.  All of the following factors except_________ may affect the ability to get an accurate pulse oximetry reading.,13113,3,D.  Hypotension,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6240,3,"Prior to the procedure and the administration of sedation, which of the following should be obtained and documented?",13114,0,"A.  Vital sign including BP, heart rate, respiratory rate and pain level",0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6240,3,"Prior to the procedure and the administration of sedation, which of the following should be obtained and documented?",13115,1,B.  Level of consciousness,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6240,3,"Prior to the procedure and the administration of sedation, which of the following should be obtained and documented?",13116,2,"C.  Verification of correct patient, procedure, side/site, National Patient Safety Goal, Universal Protocol",0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6240,3,"Prior to the procedure and the administration of sedation, which of the following should be obtained and documented?",13117,3,D.  All of the above,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6241,4,Initial signs and symptoms of hypoxia include all of the following except:,13118,0,A.  Anxiety,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6241,4,Initial signs and symptoms of hypoxia include all of the following except:,13119,1,B.  Increased pulse,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6241,4,Initial signs and symptoms of hypoxia include all of the following except:,13120,2,C.  Decreased blood pressure,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6241,4,Initial signs and symptoms of hypoxia include all of the following except:,13121,3,D.  Sweating,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6241,4,Initial signs and symptoms of hypoxia include all of the following except:,13122,4,E.  Pallor,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6242,7,Which patient in general may require a higher dose of sedation medications than usual?,13123,0,A.  A disoriented patient,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6242,7,Which patient in general may require a higher dose of sedation medications than usual?,13124,1,B.  A patient with a drug abuse history,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6242,7,Which patient in general may require a higher dose of sedation medications than usual?,13125,2,C.  An elderly patient,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6242,7,Which patient in general may require a higher dose of sedation medications than usual?,13126,3,D.  A patient who has a history of seizures,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6243,8,"Following administration of sedation medications, you continue to open supplies for the procedure.  Hearing the oximetry alarm and observing the pulse oximetry reading, you immediately assess Mrs. N. and find her to be somewhat restless, wi th a heart rate of 108, blood pressure 130/85, respirations 10/minute and oxygen saturation at 85% (baseline vital signs were heart rate 88, blood pressure 100/80, respirations 16/minute, pulse oximetry 97% and 0 pain). The most probable cause of Mrs. N's symptoms is",13127,0,A.  Angina,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6243,8,"Following administration of sedation medications, you continue to open supplies for the procedure.  Hearing the oximetry alarm and observing the pulse oximetry reading, you immediately assess Mrs. N. and find her to be somewhat restless, wi th a heart rate of 108, blood pressure 130/85, respirations 10/minute and oxygen saturation at 85% (baseline vital signs were heart rate 88, blood pressure 100/80, respirations 16/minute, pulse oximetry 97% and 0 pain). The most probable cause of Mrs. N's symptoms is",13128,1,B.  Hypoxia,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6243,8,"Following administration of sedation medications, you continue to open supplies for the procedure.  Hearing the oximetry alarm and observing the pulse oximetry reading, you immediately assess Mrs. N. and find her to be somewhat restless, wi th a heart rate of 108, blood pressure 130/85, respirations 10/minute and oxygen saturation at 85% (baseline vital signs were heart rate 88, blood pressure 100/80, respirations 16/minute, pulse oximetry 97% and 0 pain). The most probable cause of Mrs. N's symptoms is",13129,2,C.  Hypoglycemia,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6243,8,"Following administration of sedation medications, you continue to open supplies for the procedure.  Hearing the oximetry alarm and observing the pulse oximetry reading, you immediately assess Mrs. N. and find her to be somewhat restless, wi th a heart rate of 108, blood pressure 130/85, respirations 10/minute and oxygen saturation at 85% (baseline vital signs were heart rate 88, blood pressure 100/80, respirations 16/minute, pulse oximetry 97% and 0 pain). The most probable cause of Mrs. N's symptoms is",13130,3,D.  Pulmonary edema,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6244,9,You report your findings to the physician who orders Flumazenil (Romazicon) 0.2 mg IV push. You have a syringe labeled 0.5 mg Flumazenil in 5 cc's.  How many ml's should you administer?,13131,0,A.  1 ml,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6244,9,You report your findings to the physician who orders Flumazenil (Romazicon) 0.2 mg IV push. You have a syringe labeled 0.5 mg Flumazenil in 5 cc's.  How many ml's should you administer?,13132,1,B.  2 mls,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6244,9,You report your findings to the physician who orders Flumazenil (Romazicon) 0.2 mg IV push. You have a syringe labeled 0.5 mg Flumazenil in 5 cc's.  How many ml's should you administer?,13133,2,C.  0.5 mls,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6244,9,You report your findings to the physician who orders Flumazenil (Romazicon) 0.2 mg IV push. You have a syringe labeled 0.5 mg Flumazenil in 5 cc's.  How many ml's should you administer?,13134,3,D.  0.2 mls,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6245,16,"If Mrs. N were to have a sudden drop in her heart rate to 35 beats/minute, which would be the most appropriate medication to give first?",13135,0,A.  Atropine 0.5-1 mg IV push,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6245,16,"If Mrs. N were to have a sudden drop in her heart rate to 35 beats/minute, which would be the most appropriate medication to give first?",13136,1,B.  Epinephrine ( Adrenaline) 3-5 mg IV push,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6245,16,"If Mrs. N were to have a sudden drop in her heart rate to 35 beats/minute, which would be the most appropriate medication to give first?",13137,2,C.  Lidocaine 40 mg IV push,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6245,16,"If Mrs. N were to have a sudden drop in her heart rate to 35 beats/minute, which would be the most appropriate medication to give first?",13138,3,D.  Naloxone ( Narcan) 0.1 - 0.2 mg IV push,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6246,17,"The most commonly used antagonist (reversing agent) for opiates (Fentanyl, Morphine, and Demerol) is:",13139,0,A.  Flumazenil ( Romazicon),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6246,17,"The most commonly used antagonist (reversing agent) for opiates (Fentanyl, Morphine, and Demerol) is:",13140,1,B.  Naloxone ( Narcan),1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6246,17,"The most commonly used antagonist (reversing agent) for opiates (Fentanyl, Morphine, and Demerol) is:",13141,2,C.  Midazolam (Versed),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6246,17,"The most commonly used antagonist (reversing agent) for opiates (Fentanyl, Morphine, and Demerol) is:",13142,3,D.  Atropine,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6247,18,"Mrs. N. completes the procedure without further incident.  She is being prepared for discharge.  Which of the following situations best meets the hospital criteria to discharge Mrs. N. after sedation?   Note: baseline vital signs are blood pressure (BP) 100/80, heart rate (P)88, respirations/minute (R)16, and oxygen saturation (O2 Sat) 97%",13143,0,"A.  BP 150/80, P 78/min, R 16, O2 Sat 94%",0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6247,18,"Mrs. N. completes the procedure without further incident.  She is being prepared for discharge.  Which of the following situations best meets the hospital criteria to discharge Mrs. N. after sedation?   Note: baseline vital signs are blood pressure (BP) 100/80, heart rate (P)88, respirations/minute (R)16, and oxygen saturation (O2 Sat) 97%",13144,1,"B.  BP 90/60, P 80/min, R 14, O2 Sat 90%",0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6247,18,"Mrs. N. completes the procedure without further incident.  She is being prepared for discharge.  Which of the following situations best meets the hospital criteria to discharge Mrs. N. after sedation?   Note: baseline vital signs are blood pressure (BP) 100/80, heart rate (P)88, respirations/minute (R)16, and oxygen saturation (O2 Sat) 97%",13145,2,"C.  BP 90/60, P 120/min, R 18, O2 Sat 97%",0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6247,18,"Mrs. N. completes the procedure without further incident.  She is being prepared for discharge.  Which of the following situations best meets the hospital criteria to discharge Mrs. N. after sedation?   Note: baseline vital signs are blood pressure (BP) 100/80, heart rate (P)88, respirations/minute (R)16, and oxygen saturation (O2 Sat) 97%",13146,3,"D.  BP 105/70, P 90/min, R 14, O2 Sat 97%",1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6248,23,"The following agent used for IV sedation is contraindicated in patients receiving MAO inhibitors ( Marplan, Nardil, Parnate, etc.)",13147,0,A.  Morphine Sulfate,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6248,23,"The following agent used for IV sedation is contraindicated in patients receiving MAO inhibitors ( Marplan, Nardil, Parnate, etc.)",13148,1,B.  Demerol ( Meperidine),1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6248,23,"The following agent used for IV sedation is contraindicated in patients receiving MAO inhibitors ( Marplan, Nardil, Parnate, etc.)",13149,2,C.  Fentanyl,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6248,23,"The following agent used for IV sedation is contraindicated in patients receiving MAO inhibitors ( Marplan, Nardil, Parnate, etc.)",13150,3,D.  Ativan (Lorazepam),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6249,24,The following benzodiazepine can safely be used during pregnancy:,13151,0,A.  Versed ( Midazolam),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6249,24,The following benzodiazepine can safely be used during pregnancy:,13152,1,B.  Valium ( Diazepam),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6249,24,The following benzodiazepine can safely be used during pregnancy:,13153,2,C.  Didrex ( Benzphetamine),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6249,24,The following benzodiazepine can safely be used during pregnancy:,13154,3,D.  Xanax (Alprazolam),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6249,24,The following benzodiazepine can safely be used during pregnancy:,13155,4,E.  None of the above,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6250,27,The following drugs may be administered by an RN for sedation except:,13156,0,A.  Ativan  (Lorazepam),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6250,27,The following drugs may be administered by an RN for sedation except:,13157,1,B.  Demerol (Meperedine),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6250,27,The following drugs may be administered by an RN for sedation except:,13158,2,C.  Benadryl ( Diphenhydramine),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6250,27,The following drugs may be administered by an RN for sedation except:,13159,3,D.  Morphine,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6250,27,The following drugs may be administered by an RN for sedation except:,13160,4,E.  Propofol (Dipravin) and Ketamine ( Ketalar),1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6250,27,The following drugs may be administered by an RN for sedation except:,13161,5,F.  Versed (Midazolam),0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6251,28,"When a patient receives a reversal agent, either during the procedure or in the recovery area:",13162,0,A.  The recovery does not change and the patient may be discharged according to recovery criteria,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6251,28,"When a patient receives a reversal agent, either during the procedure or in the recovery area:",13163,1,B.  The recovery time is extended a minimum of 90 minutes and the patient is assessed during the recovery period.,1
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6251,28,"When a patient receives a reversal agent, either during the procedure or in the recovery area:",13164,2,C.  The patient must be admitted to the PACU,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6251,28,"When a patient receives a reversal agent, either during the procedure or in the recovery area:",13165,3,D.  None of the above,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6252,29,Patients may be discharged after sedation:,13166,0,A.  When fully awake,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6252,29,Patients may be discharged after sedation:,13167,1,B.  Thirty minutes after recovery time,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6252,29,Patients may be discharged after sedation:,13168,2,C.  When the MD's discharge orders are written,0
9659,Elearning-0000-876,FY2021 MODERATE SEDATION: NURSING,n13986,6252,29,Patients may be discharged after sedation:,13169,3,D.  Vital signs are stable. The patient's documented Aldrete score is 9-10 or baseline and it has been a minimum of thirty minutes since the last dose of sedation.,1
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63716,0,Please list the location for this activity.,212470,0,Atlanta,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63716,0,Please list the location for this activity.,212471,1,Cherokee,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63716,0,Please list the location for this activity.,212472,2,Forsyth,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63716,0,Please list the location for this activity.,212473,3,Other,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63717,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",212474,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63717,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",212475,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63717,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",212476,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63717,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",212477,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63717,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe normal vs abnormal cardiac findings in pregnancy.</ol>",212478,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63718,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",212479,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63718,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",212480,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63718,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",212481,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63718,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",212482,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63718,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to recognize pulmonary changes of pregnancy.</ol>",212483,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63719,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",212484,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63719,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",212485,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63719,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",212486,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63719,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",212487,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63719,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe neurologic alterations of pregnancy.</ol>",212488,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63720,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",212489,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63720,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",212490,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63720,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",212491,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63720,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",212492,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63720,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss hematologic changes of pregnancy.</ol>",212493,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63721,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",212494,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63721,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",212495,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63721,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",212496,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63721,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",212497,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63721,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss lab changes and recognize expected laboratory variations in pregnancy.</ol>",212498,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63722,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",212499,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63722,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",212500,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63722,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",212501,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63722,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",212502,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63722,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe how normal physiologic changes of pregnancy impact clinical presentation.<ol>",212503,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63723,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",212504,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63723,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",212505,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63723,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",212506,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63723,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",212507,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63723,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the 4Ps of Labor (Power, Passenger, Passage, Psyche).</ol>",212508,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63724,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",212509,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63724,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",212510,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63724,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",212511,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63724,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",212512,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63724,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss why changing positions enhances labor and describe actions for labor nurses to take to improve vaginal birth.</ol>",212513,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63725,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",212514,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63725,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",212515,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63725,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",212516,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63725,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",212517,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63725,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss non-pharmacologic pain relief methods in labor.</ol>",212518,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63726,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",212519,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63726,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",212520,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63726,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",212521,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63726,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",212522,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63726,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss fetal monitoring and labor progression for nullipars.</ol>",212523,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63727,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212524,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63727,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212525,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63727,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212526,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63727,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212527,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63727,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212528,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63728,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,212529,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63728,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,212530,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63728,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,212531,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63728,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,212532,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63728,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the normal physiologic changes of pregnancy.</OL>,212533,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63729,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,212534,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63729,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,212535,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63729,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,212536,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63729,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,212537,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63729,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence as it relates recognizing normal changes vs abnormal changes in pregnancy & postpartum.</OL>,212538,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63730,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212539,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63730,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212540,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63730,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212541,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63730,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212542,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63730,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212543,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63731,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212544,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63731,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212545,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63731,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212546,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63731,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212547,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63731,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212548,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63732,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212549,0,Strongly Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63732,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212550,1,Agree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63732,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212551,2,No Opinion,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63732,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212552,3,Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63732,16,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212553,4,Strongly Disagree,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63733,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",212554,0,Excellent,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63733,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",212555,1,Very Good,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63733,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",212556,2,Good,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63733,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",212557,3,Fair,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63733,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, DNP, RNC</ol>",212558,4,Poor,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63734,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",212559,0,Excellent,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63734,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",212560,1,Very Good,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63734,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",212561,2,Good,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63734,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",212562,3,Fair,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63734,18,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Lauren Schwartz, MSN, RN</ol>",212563,4,Poor,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63735,19,"Overall, this activity was:",212564,0,Excellent,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63735,19,"Overall, this activity was:",212565,1,Very Good,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63735,19,"Overall, this activity was:",212566,2,Good,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63735,19,"Overall, this activity was:",212567,3,Fair,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63735,19,"Overall, this activity was:",212568,4,Poor,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63736,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212569,0,Yes,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63736,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212570,1,No,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63736,20,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212571,2,N/A,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63739,23,How would you improve this class?,212572,0,Reduce content covered in class,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63739,23,How would you improve this class?,212573,1,Increase content covered in class,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63739,23,How would you improve this class?,212574,2,Update content covered in class,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63739,23,How would you improve this class?,212575,3,Improve the instructional methods,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63739,23,How would you improve this class?,212576,4,Make course activities more stimulating,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63739,23,How would you improve this class?,212577,5,Slow the pace of the class,0
9886,Questions-0000-20,BACK TO BASICS: IMPROVING VAGINAL BIRTH ONLINE (EVALUATION SURVEY) 7-20-21,n13988,63739,23,How would you improve this class?,212578,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63742,0,Please list the location for this activity.,212579,0,Atlanta,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63742,0,Please list the location for this activity.,212580,1,Forsyth,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63742,0,Please list the location for this activity.,212581,2,Cherokee,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63742,0,Please list the location for this activity.,212582,3,Other,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63743,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",212583,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63743,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",212584,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63743,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",212585,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63743,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",212586,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63743,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",212587,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63744,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",212588,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63744,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",212589,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63744,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",212590,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63744,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",212591,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63744,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",212592,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63745,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",212593,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63745,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",212594,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63745,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",212595,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63745,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",212596,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63745,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",212597,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63746,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",212598,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63746,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",212599,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63746,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",212600,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63746,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",212601,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63746,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",212602,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63747,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",212603,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63747,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",212604,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63747,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",212605,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63747,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",212606,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63747,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",212607,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63748,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",212608,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63748,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",212609,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63748,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",212610,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63748,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",212611,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63748,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",212612,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63749,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",212613,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63749,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",212614,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63749,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",212615,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63749,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",212616,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63749,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",212617,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63750,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212618,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63750,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212619,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63750,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212620,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63750,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212621,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63750,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212622,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63751,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,212623,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63751,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,212624,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63751,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,212625,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63751,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,212626,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63751,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,212627,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63752,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212628,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63752,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212629,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63752,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212630,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63752,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212631,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63752,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212632,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63753,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212633,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63753,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212634,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63753,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212635,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63753,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212636,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63753,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",212637,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63754,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212638,0,Strongly Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63754,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212639,1,Agree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63754,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212640,2,No Opinion,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63754,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212641,3,Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63754,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212642,4,Strongly Disagree,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63755,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",212643,0,Excellent,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63755,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",212644,1,Very Good,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63755,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",212645,2,Good,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63755,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",212646,3,Fair,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63755,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN, PCCN</ol>",212647,4,Poor,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63756,14,"Overall, this activity was:",212648,0,Excellent,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63756,14,"Overall, this activity was:",212649,1,Very Good,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63756,14,"Overall, this activity was:",212650,2,Good,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63756,14,"Overall, this activity was:",212651,3,Fair,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63756,14,"Overall, this activity was:",212652,4,Poor,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63757,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212653,0,Yes,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63757,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212654,1,No,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63757,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212655,2,N/A,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63760,18,How would you improve this class?,212656,0,Reduce content covered in class,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63760,18,How would you improve this class?,212657,1,Increase content covered in class,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63760,18,How would you improve this class?,212658,2,Update content covered in class,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63760,18,How would you improve this class?,212659,3,Improve the instructional methods,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63760,18,How would you improve this class?,212660,4,Make course activities more stimulating,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63760,18,How would you improve this class?,212661,5,Slow the pace of the class,0
9952,Questions-0000-86,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 7-20-21,n13989,63760,18,How would you improve this class?,212662,6,"Nothing: (appropriate content, speaker, setting, setting.)",0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63763,0,Please list the location for this activity.,212663,0,Atlanta,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63763,0,Please list the location for this activity.,212664,1,Cherokee,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63763,0,Please list the location for this activity.,212665,2,Forsyth,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63763,0,Please list the location for this activity.,212666,3,Other,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63764,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",212667,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63764,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",212668,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63764,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",212669,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63764,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",212670,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63764,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify key differences in how chemotherapy, biotherapy, immunotherapy and targeted therapy work to treat cancer.</ol>",212671,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63765,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",212672,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63765,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",212673,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63765,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",212674,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63765,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",212675,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63765,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the concept of ""targeted therapy""ù and identify specific mechanisms of action for commonly prescribed drugs.</ol>",212676,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63766,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",212677,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63766,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",212678,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63766,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",212679,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63766,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",212680,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63766,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the mechanisms of action for commonly prescribed agents.</ol>",212681,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63767,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",212682,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63767,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",212683,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63767,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",212684,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63767,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",212685,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63767,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify common side effects associated with commonly prescribed agents.</ol>",212686,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63768,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",212687,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63768,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",212688,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63768,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",212689,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63768,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",212690,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63768,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to state key principles associated with safe handling and administration of hazardous medications.</ol>",212691,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63769,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",212692,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63769,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",212693,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63769,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",212694,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63769,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",212695,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63769,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate the skills associated with safe handling and administration of chemotherapy and biotherapy agents.</ol>",212696,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63770,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212697,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63770,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212698,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63770,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212699,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63770,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212700,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63770,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212701,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63771,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212702,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63771,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212703,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63771,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212704,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63771,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212705,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63771,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212706,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63772,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212707,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63772,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212708,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63772,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212709,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63772,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212710,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63772,9,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212711,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63773,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212712,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63773,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212713,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63773,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212714,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63773,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212715,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63773,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my confidence in performing skills related to safe administration and handling of chemotherapy and biotherapy medications for oncology indications.</OL>,212716,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63774,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,212717,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63774,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,212718,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63774,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,212719,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63774,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,212720,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63774,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,212721,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63775,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212722,0,Strongly Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63775,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212723,1,Agree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63775,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212724,2,No Opinion,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63775,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212725,3,Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63775,12,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212726,4,Strongly Disagree,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63776,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",212727,0,Excellent,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63776,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",212728,1,Very Good,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63776,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",212729,2,Good,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63776,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",212730,3,Fair,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63776,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Punita Panchal, BSN, RN, BMTCN</ol>",212731,4,Poor,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63777,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",212732,0,Excellent,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63777,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",212733,1,Very Good,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63777,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",212734,2,Good,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63777,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",212735,3,Fair,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63777,14,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Christina Happeny, BSN, RN, OCN </ol>",212736,4,Poor,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63778,15,"Overall, this activity was:",212737,0,Excellent,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63778,15,"Overall, this activity was:",212738,1,Very Good,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63778,15,"Overall, this activity was:",212739,2,Good,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63778,15,"Overall, this activity was:",212740,3,Fair,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63778,15,"Overall, this activity was:",212741,4,Poor,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63779,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212742,0,Yes,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63779,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212743,1,No,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63779,16,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212744,2,N/A,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63782,19,How would you improve this class?,212745,0,Reduce content covered in class,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63782,19,How would you improve this class?,212746,1,Increase content covered in class,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63782,19,How would you improve this class?,212747,2,Update content covered in class,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63782,19,How would you improve this class?,212748,3,Improve the instructional methods,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63782,19,How would you improve this class?,212749,4,Make course activities more stimulating,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63782,19,How would you improve this class?,212750,5,Slow the pace of the class,0
9807,Questions-0000-102,PRINCIPLES OF CHEMOTHERAPY & BIOTHERAPY (EVALUATION SURVEY) NSA 07-20-21,n13990,63782,19,How would you improve this class?,212751,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51747,0,Laser eye protection should be worn to prevent injury to the _________ and/or ________ which can cause temporary or permanent vision loss.,170133,0,"a.	Cornea / Retina",1
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51747,0,Laser eye protection should be worn to prevent injury to the _________ and/or ________ which can cause temporary or permanent vision loss.,170134,1,"b.	Retina / Eye Lid",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51747,0,Laser eye protection should be worn to prevent injury to the _________ and/or ________ which can cause temporary or permanent vision loss.,170135,2,"c.	Iris / Pupil",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51748,1,"Which of the following about Laser eye protection is NOT true?<br><br> 1)	Labeled with optical density and wavelength (appropriate for laser being used). <br> 2)	Available for all staff and patients in the Operating Room with right comfort and fit.<br> 3)	Due to the special coating, the glasses do not have to be LLD after each use.<br> 4)	Available outside on the Operating Room door for those who need to enter the room.<br> 5)	There is no need for someone who wears glasses or contacts to use safety glasses as these provide adequate protection. <br>",170136,0,"a.	1 and 3",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51748,1,"Which of the following about Laser eye protection is NOT true?<br><br> 1)	Labeled with optical density and wavelength (appropriate for laser being used). <br> 2)	Available for all staff and patients in the Operating Room with right comfort and fit.<br> 3)	Due to the special coating, the glasses do not have to be LLD after each use.<br> 4)	Available outside on the Operating Room door for those who need to enter the room.<br> 5)	There is no need for someone who wears glasses or contacts to use safety glasses as these provide adequate protection. <br>",170137,1,"b.	2 and 5",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51748,1,"Which of the following about Laser eye protection is NOT true?<br><br> 1)	Labeled with optical density and wavelength (appropriate for laser being used). <br> 2)	Available for all staff and patients in the Operating Room with right comfort and fit.<br> 3)	Due to the special coating, the glasses do not have to be LLD after each use.<br> 4)	Available outside on the Operating Room door for those who need to enter the room.<br> 5)	There is no need for someone who wears glasses or contacts to use safety glasses as these provide adequate protection. <br>",170138,2,"c.	3 and 5",1
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51749,2,"Examples of Respiratory Protection include: <br><br> 1)	Smoke Evacuation<br> 2)	Holding your Breath<br> 3)	Level 1 surgical mask<br> 4)	N95 mask<br>",170139,0,"a.	3 and 4",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51749,2,"Examples of Respiratory Protection include: <br><br> 1)	Smoke Evacuation<br> 2)	Holding your Breath<br> 3)	Level 1 surgical mask<br> 4)	N95 mask<br>",170140,1,"b.	2 and 3",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51749,2,"Examples of Respiratory Protection include: <br><br> 1)	Smoke Evacuation<br> 2)	Holding your Breath<br> 3)	Level 1 surgical mask<br> 4)	N95 mask<br>",170141,2,"c.	1 and 4",1
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51750,3,Lasers are considered an ___________ in the Fire Triangle.,170142,0,"a.	Oxidizer",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51750,3,Lasers are considered an ___________ in the Fire Triangle.,170143,1,"b.	Ignition Source",1
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51750,3,Lasers are considered an ___________ in the Fire Triangle.,170144,2,"c.	Fuel",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51751,4,Which of the following statements is TRUE concerning Laser Safety Fire Prevention.,170145,0,"a.	Keep wet towels and saline on the sterile field.  Can be used to douse or smother a fire.",1
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51751,4,Which of the following statements is TRUE concerning Laser Safety Fire Prevention.,170146,1,"b.	Have an ABC Fire Extinguisher available",0
9666,Elearning-0000-882,SURGICAL SERVICES: FY2021 LASER SAFETY EDUCATION,n13992,51751,4,Which of the following statements is TRUE concerning Laser Safety Fire Prevention.,170147,2,"c.	Dry sponges and towels should be used around the incision site.",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63844,0,"When a rapid response is called, you should ALWAYS inform your Charge RT/ 5335 and the nurse taking care of the patient.",212968,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63844,0,"When a rapid response is called, you should ALWAYS inform your Charge RT/ 5335 and the nurse taking care of the patient.",212969,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63845,1,On the code sheet you should ALWAYS make sure the Airway and ETC02 section is filled out correctly before signing the sheet.,212970,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63845,1,On the code sheet you should ALWAYS make sure the Airway and ETC02 section is filled out correctly before signing the sheet.,212971,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63846,2,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,212972,0,1.  5 cm,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63846,2,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,212973,1,2. 10 cm,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63846,2,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,212974,2,3. 15 cm,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63846,2,You are called to the PACU to set up a CPAP on a gastric sleeve patient.  You first confirm the MD order and it states CPAP per RT Protocol.  You would then place the patient on which of the following settings?,212975,3,4. Auto set mode with high pressure limit of 10cm.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63847,3,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",212976,0,1. Do nothing.  The patient has the right to refuse treatment.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63847,3,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",212977,1,2. Notify the Physician and place them on a Capnography Remote Monitor. Document in the EMR and write a Progress Note.,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63847,3,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",212978,2,3.  Place them on 3 l/m nasal oxygen,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63847,3,"What do you do when a patient has a history of OSA but is not complaint with CPAP, Home or Hospital unit?",212979,3,4.  Place them on an Optiflow at 50 l/min & 50% Fio2,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63848,4,"Patients on CPAP, home unit or hospital unit that require more than 40% / >5 lpm bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",212980,0,1. Remote Capnography,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63848,4,"Patients on CPAP, home unit or hospital unit that require more than 40% / >5 lpm bled into the unit to maintain SpO2 within the oxygen policy guidelines will need to be placed on:",212981,1,2. Remote Pulse Ox,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63849,5,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,212982,0,1. A & B,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63849,5,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,212983,1,2. B & C,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63849,5,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,212984,2,3. B only,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63849,5,When do you need to call the MD for a CPAP order?<br> A.   When the patient is requiring 50% FIO2.<br>  B.   When the patient states they are on specific CPAP pressures at home but did not bring their CPAP device<br>  C.   When the patients Sats are < 88% in PACU.,212985,3,4. All of the above,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63850,6,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol""ù, you should set up:",212986,0,"A. Air-sense or Lumis in autoset mode with a minimum pressure of 4cmH20, max of 18cmH20",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63850,6,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol""ù, you should set up:",212987,1,B. Fixed CPAP of 15cmH20,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63850,6,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol""ù, you should set up:",212988,2,C. Up to 15lpm of 02 bled inline,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63850,6,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol""ù, you should set up:",212989,3,D. Up to 4lpm of 02 bled inline,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63850,6,"If an order reads ""Respiratory CPAP (Hospital Owned Device) Therapy Protocol""ù, you should set up:",212990,4,E. A and D,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63851,7,"When using the Hamilton C-2/C-3 for BiPAP, it is important  to set the following :",212991,0,"1. I- time lower than I- time Max and ETS to 50% to compensate for mask leaks, promoting synchrony and patient comfort",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63851,7,"When using the Hamilton C-2/C-3 for BiPAP, it is important  to set the following :",212992,1,2.  I time needs to be higher than I time Max & ETS at 25%,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63852,8,"Per the Oxygen Administration Protocol, you can obtain ABGs when a patient is on 40% or greater FiO2 without a physician order:",212993,0,TRUE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63852,8,"Per the Oxygen Administration Protocol, you can obtain ABGs when a patient is on 40% or greater FiO2 without a physician order:",212994,1,FALSE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63853,9,All post-op thoracic patients for the first 24 hours will receive:,212995,0,1. SMI/Accupap(+10cm)/albuterol and ipratropium bromide Q8,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63853,9,All post-op thoracic patients for the first 24 hours will receive:,212996,1,2. Accupap only Q8,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63853,9,All post-op thoracic patients for the first 24 hours will receive:,212997,2,3. SMI only Q8,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63853,9,All post-op thoracic patients for the first 24 hours will receive:,212998,3,4. Aerosol treatments with Duoneb and Mucomyst Q8,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63854,10,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,212999,0,"a.  If room air sat at rest is < 89, place patient on oxygen to get their sat  >or = 89.  If able to ambulate, see what o2 is needed to keep > 88 on exertion(pt at home might need higher o2 when ambulating)",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63854,10,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,213000,1,"b.  If room air sat is > or = to  89% at rest, you need to do a room air sat with  exertion",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63854,10,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,213001,2,c.  If exertional sat is lower than <89% you need to document how much o2 is needed to keep sat > 89%. Please relay to RN and Case Management,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63854,10,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,213002,3,d.  All of the above,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63854,10,Home oxygen assessment includes documenting under home O2 assessment tab which of the following:,213003,4,e.  None of the above,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63855,11,Any trach outside the ICU needs to be on a remote pulse oximeter:,213004,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63855,11,Any trach outside the ICU needs to be on a remote pulse oximeter:,213005,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63875,12,What is the Jackson size of this trach?,213081,0,1) 8.5,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63875,12,What is the Jackson size of this trach?,213082,1,2) 7.5,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63875,12,What is the Jackson size of this trach?,213083,2,3) 8,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63875,12,What is the Jackson size of this trach?,213084,3,4) 85,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63876,13,When a trach patient on the floor is de-cannulated you must :,213085,0,1.   Stay in room with the patient for 24 hours,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63876,13,When a trach patient on the floor is de-cannulated you must :,213086,1,2.   Keep the patient on a remote pulse ox for 24 hours per policy,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63876,13,When a trach patient on the floor is de-cannulated you must :,213087,2,3.  Place on a remote capnography for 24 hours,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63877,14,The remote therapist will assess monitored patients and document results twice per shift.,213088,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63877,14,The remote therapist will assess monitored patients and document results twice per shift.,213089,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63898,15,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,213160,0,1. Place the patient on a remote Capnography.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63898,15,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,213161,1,2. Call the physician to have the remote monitor d/c'd.,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63898,15,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,213162,2,3. Continue to use the remote pulse ox until the patient is discharged.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63898,15,You have a patient that does not use home O2 at baseline and was placed on a remote monitor for low PaO2 10 days ago.<br> The patient has been on room air for 48 hours and the patient has not had any desat episodes for 24 hours.  What is your next plan of action?,213163,3,4. Place the patient on a nasal cannula.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63899,16,Which of these statements is TRUE regarding the Remote monitors?,213164,0,A.  The Capnography monitor attaches to the probe with blue end,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63899,16,Which of these statements is TRUE regarding the Remote monitors?,213165,1,B.  The Remote Pulse-ox monitor attaches to the probe with the white end,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63899,16,Which of these statements is TRUE regarding the Remote monitors?,213166,2,C.  The sensor with Sp02 and RR attaches to the Remote Pulse-ox monitor,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63899,16,Which of these statements is TRUE regarding the Remote monitors?,213167,3,D.  All statements are true,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63900,17,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order.",213168,0,TRUE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63900,17,"According to the bronchodilator protocol, a patient's home nebulizer or medication regimen can be changed without a MD order.",213169,1,FALSE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63901,18,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,213170,0,"1.  If the frequency is increased or the patient calls more often for a treatment than ordered, the Physician or Mid-level must be contacted by phone to notify them of changes in the patient status.",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63901,18,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,213171,1,2.  Budesonide (Pulmicort) ordered by the physician or mid-level cannot be discontinued or made PRN by the RT.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63901,18,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,213172,2,"3.  If a physician or midlevel enters an order for concurrent therapy with Brovana , Pulmicort, Albuterol and Atrovent, they may be administered per RT discretion or patient preference.",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63901,18,Which Statement regarding the Bronchodilator Therapy Protocol is FALSE?,213173,3,"4.  If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat, the RT may order albuterol 2.5mg at the following frequencies:  Q4, Q6, BID, TID, QID, Q4 w/a or Q6 w/a.",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63902,19,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",213174,0,1. Regular nebulizer,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63902,19,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",213175,1,2. Pep Device,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63902,19,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",213176,2,3. Aerogen,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63902,19,"If a patient is requiring Q4 hour treatments initially, nebulizer treatments are to be given via?",213177,3,4. None of the above,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63903,20,Levalbuterol (Xopenex) 1.25mg may be substituted for albuterol if the physician indicates that or if the patient has an adverse reaction to albuterol.,213178,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63903,20,Levalbuterol (Xopenex) 1.25mg may be substituted for albuterol if the physician indicates that or if the patient has an adverse reaction to albuterol.,213179,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63904,21,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",213180,0,1. B and C,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63904,21,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",213181,1,"2. A, B, C",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63904,21,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",213182,2,3. A and C,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63904,21,"Per the Bronchodilator protocol, when can Respiratory Therapy order Ipratropium (Atrovent 0.5mg)?<br>  A. It may be added to albuterol/Levabuterol therapy at the same frequency if the patient is on home ipratropium therapy<br> B. If the physician does not specify the medications and only writes for Respiratory to Evaluate and Treat for Bronchodilator therapy and the patient has a diagnosis of COPD<br> C. When the patient is in persistent respiratory distress after initial bronchodilator treatment requiring treatments more often than every six hours<br> D. RT cannot order Atrovent 0.5mg.",213183,3,4. B only,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63905,22,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",213184,0,1. Treatment of bronchospasms,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63905,22,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",213185,1,2. Bacterial Pneumonia in cystic fibrosis patients,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63905,22,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",213186,2,3. Prevention of PJP/pneumocystis,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63905,22,"Inhaled Pentamidine, an antiprotozoal agent, is indicated for:",213187,3,4. Treatment of RSV,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63906,23,Ribavirin is approved  for the treatment of:,213188,0,1.  RSV,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63906,23,Ribavirin is approved  for the treatment of:,213189,1,2.  Pneumocystis,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63906,23,Ribavirin is approved  for the treatment of:,213190,2,3.  Pseudomonas,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63907,24,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,213191,0,1. After each treatment,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63907,24,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,213192,1,2. Q12,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63907,24,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,213193,2,3. You don't need to clean,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63907,24,How often are the Parts to the Aerogen Pump/nebulizer to be replaced?,213194,3,4. Between patients only,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63908,25,Where do the parts of the Ribavirin treatment go after each use?,213195,0,1.  In the black chemo bucket in patient room,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63908,25,Where do the parts of the Ribavirin treatment go after each use?,213196,1,2.  In the trash can,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63908,25,Where do the parts of the Ribavirin treatment go after each use?,213197,2,3.  Its reused for 24 hours,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63908,25,Where do the parts of the Ribavirin treatment go after each use?,213198,3,4.  Blue trash bin,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63909,26,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",213199,0,1.   all of the above,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63909,26,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",213200,1,"2.   A, C, & D",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63909,26,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",213201,2,"3.   A, B, & D",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63909,26,"The SMI policy:<br> A.  Instruct patient on use and purpose of incentive spirometer.       Mark goal and 50% with yellow sticker /Place name on unit<br>  B.   Perform Smi: if patient reaches > 75% of their goal, turn over to nursing       and inform them. Inform patient they are to do exercise q2 wa on own.       Perform SMI daily as long as the patient is in the 50-75% range<br>  C.   If patient is less than 50% of predicted value, initiate IPPB with SMI BID  or       with scheduled treatment until they can achieve greater than 50% of their        goal for 2 consecutive visits<br>   D.   Document Education/Document Goal/Document number of attempts",213202,3,"4.   B, C, & D",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63910,27,"When giving an aerosol treatment with Heliox, you should:<br>  A.   Use an 80:20 tank<br> B.   Use the 80:20 regulator(in wire cart in department)<br> C.   Use the heliox adaptable mask with the aerogen nebulizer<br> D.   If oxygen is needed , you can use a nasal cannula under the        mask or you can attach o2 tubing under the aerogen spacer        up to 6 l/min",213203,0,1.    All of the above,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63910,27,"When giving an aerosol treatment with Heliox, you should:<br>  A.   Use an 80:20 tank<br> B.   Use the 80:20 regulator(in wire cart in department)<br> C.   Use the heliox adaptable mask with the aerogen nebulizer<br> D.   If oxygen is needed , you can use a nasal cannula under the        mask or you can attach o2 tubing under the aerogen spacer        up to 6 l/min",213204,1,2.    Only A & B,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63910,27,"When giving an aerosol treatment with Heliox, you should:<br>  A.   Use an 80:20 tank<br> B.   Use the 80:20 regulator(in wire cart in department)<br> C.   Use the heliox adaptable mask with the aerogen nebulizer<br> D.   If oxygen is needed , you can use a nasal cannula under the        mask or you can attach o2 tubing under the aerogen spacer        up to 6 l/min",213205,2,"3.    Only A, B, & C",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63911,28,Heliox:,213206,0,"1. The mixture generates less resistance than atmospheric air when passing  through the airways of the lungs, and thus requires less effort by a patient",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63911,28,Heliox:,213207,1,2.    Heliox is a breathing gas composed of a mixture of helium (He) and           oxygen (O2),0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63911,28,Heliox:,213208,2,"3. Heliox is mainly used in conditions of large airway narrowing (upper airway  obstruction from tumors or foreign bodies and vocal cord dysfunction). There is also some use of heliox in conditions of the medium airways (croup, asthma and chronic obstructive pulmonary disease",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63911,28,Heliox:,213209,3,4. All are true statements,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63911,28,Heliox:,213210,4,5. Only 3 is a true statement,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63912,29,Empty inhalers and leftover Ribavirin medication will be disposed of in the black trash bin.<br>  Partial doses of Albuterol/Xopenex/Atrovent/Pulmicort/Mucomyst may be disposed of In the Blue trash bin,213211,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63912,29,Empty inhalers and leftover Ribavirin medication will be disposed of in the black trash bin.<br>  Partial doses of Albuterol/Xopenex/Atrovent/Pulmicort/Mucomyst may be disposed of In the Blue trash bin,213212,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63913,30,Which statement about CPAP documentation is FALSE?,213213,0,A. A hospital owned CPAP device will be checked Q12 and with any change in settings or status of the patient,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63913,30,Which statement about CPAP documentation is FALSE?,213214,1,B. Home CPAP units will be checked Qshift.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63913,30,Which statement about CPAP documentation is FALSE?,213215,2,C. CPAP documentation includes skin integrity and the use of any skin barrier,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63914,31,"When using a BiPAP, Physician will be notified when:",213216,0,A. Heart rate increases or decreases to > 20% from pre therapy heart rate.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63914,31,"When using a BiPAP, Physician will be notified when:",213217,1,B. Therapist is unable to achieve an adequate mask seal.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63914,31,"When using a BiPAP, Physician will be notified when:",213218,2,C. Tachydysrhythmias or Brachyarrhythmias occur.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63914,31,"When using a BiPAP, Physician will be notified when:",213219,3,D. All of the above,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213220,0,A. Sign on the door with the date and time the 48 hour observation ends.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213221,1,B. ETC02 and breath sounds documentation with any patient repositioning.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213222,2,C. Same size trach and one size smaller.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213223,3,D. Obturator at the HOB.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213224,4,E. Airway box at bedside.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213225,5,F. Ambu bag/mask at bedside.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213226,6,G. Respiratory at the bedside for all repositioning.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63915,32,Which are components of the fresh trach protocol?,213227,7,H. All of the above.,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63916,33,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,213228,0,1. C and D,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63916,33,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,213229,1,2. A and D,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63916,33,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,213230,2,3. B only,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63916,33,How often do you change an inner cannula?<br>  A. Qshift on nightshift and as needed<br> B. BID and as needed<br> C. Q24 on dayshift and as needed<br> D. Not during the 48 hour fresh trach protocol,213231,3,4. C only,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63917,34,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",213232,0,"1. A, B, C ,D",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63917,34,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",213233,1,"2. A, B, D, E",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63917,34,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",213234,2,"3. B, D, E",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63917,34,"A BioMed work order, found on the Intranet under requests, should include which of the following information?<br>  A. Facility<br> B. Tag<br> C. Patient name and DOB<br> D. Problem<br>  E. Location /Room",213235,3,4. All of the above,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63918,35,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,213236,0,1. B and C,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63918,35,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,213237,1,"2. A, B, C",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63918,35,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,213238,2,"3. A, D, E",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63918,35,Which of the following items will you find on the P-drive?<br>  A. How to change a CPAP from variable to fixed.<br> B. Equipment manuals<br> C. Release of liability forms<br> D. Hand hygiene results<br> E. EMMA / Code blue statistics,213239,3,"4. A, B, C, D, E",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63919,36,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",213240,0,"1. A, C, E",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63919,36,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",213241,1,"2. A, B, C, E",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63919,36,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",213242,2,3. B and C,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63919,36,"Lucidoc, found on the Northside Intranet, contains which of the following?<br>  A. Interdisciplinary Professional Practice (IPP) System-wide<br> B. Human Resources Policies<br> C. Respiratory Therapy Protocols<br> D. Centricity Web<br> E. Corporate Compliance",213243,3,4. All of the above,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63920,37,"To place a Remote Pulse ox monitor in standby, you disconnect the pulse ox sensor from the cable then press DISMISS from the drop down menu and silence the alarm.",213244,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63920,37,"To place a Remote Pulse ox monitor in standby, you disconnect the pulse ox sensor from the cable then press DISMISS from the drop down menu and silence the alarm.",213245,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63921,38,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",213246,0,"1. B, C, D, E",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63921,38,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",213247,1,"2. A, B, C, D",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63921,38,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",213248,2,3. All of the above,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63921,38,"Which of the following items are located in every code cart drawer labelled Miscellaneous?<br>  A. 14 Fr suction kit with gloves,<br> B. Suction canister with lid<br> C. Suction tubing both long and short<br> D. Yankauer<br> E. Wall suction regulator",213249,3,4. None of the above,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213250,0,A.   Head or neck injury that has not been stabilized,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213251,1,B.   Active pulmonary hemorrhaging,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213252,2,"C.   Presence of ICP >20, recent facial/oral surgery or trauma",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213253,3,D.   Esophageal surgery and/or gastric sleeve surgery,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213254,4,E.    Neuromuscular disorders,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213255,5,F.    COPD,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213256,6,G.   Post-Op Management of Atelectasis,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213257,7,H. All of the above,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63922,39,All of the following are contraindications of using MetaNeb EXCEPT:,213258,8,"I.  E, F and G",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63923,40,Which statement regarding the delivery of IPV therapy is FALSE?,213259,0,1.   The RT must remain with the patient while therapy is in progress.  Therapy must    be stopped before RT can leave the room.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63923,40,Which statement regarding the delivery of IPV therapy is FALSE?,213260,1,2. Alternate between CPEP and CHFO modes every 2.5 minutes until the treatment is complete and the nebulizer is empty.,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63923,40,Which statement regarding the delivery of IPV therapy is FALSE?,213261,2,"3. IPV facilitates the mobilization of secretions, lung expansion therapy,  and the treatment and prevention of pulmonary atelectasis",0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63923,40,Which statement regarding the delivery of IPV therapy is FALSE?,213262,3,"4. If the physician does not order medications for nebulization, RT will order Duoneb Q6 and document in the EMR",1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63924,41,Respiratory Therapy is NOT responsible for bringing the code cart to any Code Blue in the 980/960 buildings.,213263,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63924,41,Respiratory Therapy is NOT responsible for bringing the code cart to any Code Blue in the 980/960 buildings.,213264,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63925,42,FYI'S: Please read. It's good information  Acknowledge slide review.,213265,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63925,42,FYI'S: Please read. It's good information  Acknowledge slide review.,213266,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63926,43,Home O2 Assessment<br>  Acknowledge slide review.,213267,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63926,43,Home O2 Assessment<br>  Acknowledge slide review.,213268,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63927,44,Smoking Cessation<br>  Acknowledge slide review.,213269,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63927,44,Smoking Cessation<br>  Acknowledge slide review.,213270,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63928,45,Learner Assessment<br>  Acknowledge slide review.,213271,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63928,45,Learner Assessment<br>  Acknowledge slide review.,213272,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63929,46,Provider Notification<br>  Acknowledge slide review.,213273,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63929,46,Provider Notification<br>  Acknowledge slide review.,213274,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63930,47,RT Handoff Notifications,213275,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63930,47,RT Handoff Notifications,213276,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63931,48,Code Blue and Rapid Response<br>  Acknowledge slide review.,213277,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63931,48,Code Blue and Rapid Response<br>  Acknowledge slide review.,213278,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63932,49,MetaNeb<br>  Acknowledge slide review.,213279,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63932,49,MetaNeb<br>  Acknowledge slide review.,213280,1,FALSE,0
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63933,50,Cough Assist<br>  Acknowledge slide review.,213281,0,TRUE,1
9728,Elearning-0000-939,2021 RESPIRATORY ADULT FLOOR COMPETENCY,n13997,63933,50,Cough Assist<br>  Acknowledge slide review.,213282,1,FALSE,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63827,0,Please list the location for this activity.,212903,0,Atlanta,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63827,0,Please list the location for this activity.,212904,1,Cherokee,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63827,0,Please list the location for this activity.,212905,2,Forsyth,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63827,0,Please list the location for this activity.,212906,3,Other,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63828,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212907,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63828,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212908,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63828,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212909,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63828,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212910,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63828,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212911,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63829,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212912,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63829,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212913,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63829,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212914,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63829,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212915,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63829,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212916,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63830,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212917,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63830,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212918,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63830,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212919,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63830,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212920,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63830,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212921,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63831,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212922,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63831,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212923,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63831,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212924,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63831,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212925,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63831,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212926,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63832,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212927,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63832,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212928,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63832,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212929,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63832,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212930,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63832,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212931,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63833,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212932,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63833,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212933,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63833,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212934,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63833,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212935,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63833,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212936,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63834,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212937,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63834,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212938,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63834,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212939,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63834,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212940,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63834,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212941,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63835,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212942,0,Strongly Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63835,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212943,1,Agree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63835,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212944,2,No Opinion,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63835,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212945,3,Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63835,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,212946,4,Strongly Disagree,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63836,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",212947,0,Excellent,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63836,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",212948,1,Very Good,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63836,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",212949,2,Good,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63836,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",212950,3,Fair,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63836,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",212951,4,Poor,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63836,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",212952,5,N/A,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63837,10,"Overall, this activity was:",212953,0,Excellent,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63837,10,"Overall, this activity was:",212954,1,Very Good,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63837,10,"Overall, this activity was:",212955,2,Good,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63837,10,"Overall, this activity was:",212956,3,Fair,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63837,10,"Overall, this activity was:",212957,4,Poor,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63838,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212958,0,Yes,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63838,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212959,1,No,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63838,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212960,2,N/A,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63841,14,How would you improve this class (check all that apply)?,212961,0,Reduce content covered in class,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63841,14,How would you improve this class (check all that apply)?,212962,1,Increase content covered in class,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63841,14,How would you improve this class (check all that apply)?,212963,2,Update content covered in class,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63841,14,How would you improve this class (check all that apply)?,212964,3,Improve the instructional methods,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63841,14,How would you improve this class (check all that apply)?,212965,4,Make course activities more stimulating,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63841,14,How would you improve this class (check all that apply)?,212966,5,Slow the pace of the class,0
9904,Questions-0000-38,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 7-23-21,n13996,63841,14,How would you improve this class (check all that apply)?,212967,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63856,0,Please list the location for this activity.,213006,0,Atlanta,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63856,0,Please list the location for this activity.,213007,1,Cherokee,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63856,0,Please list the location for this activity.,213008,2,Forsyth,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63856,0,Please list the location for this activity.,213009,3,Other,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63857,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",213010,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63857,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",213011,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63857,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",213012,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63857,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",213013,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63857,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",213014,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63858,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",213015,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63858,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",213016,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63858,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",213017,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63858,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",213018,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63858,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",213019,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63859,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",213020,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63859,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",213021,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63859,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",213022,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63859,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",213023,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63859,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",213024,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63860,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",213025,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63860,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",213026,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63860,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",213027,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63860,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",213028,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63860,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",213029,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63861,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213030,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63861,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213031,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63861,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213032,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63861,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213033,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63861,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213034,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63862,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213035,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63862,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213036,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63862,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213037,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63862,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213038,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63862,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213039,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63863,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,213040,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63863,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,213041,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63863,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,213042,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63863,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,213043,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63863,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,213044,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63864,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,213045,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63864,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,213046,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63864,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,213047,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63864,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,213048,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63864,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,213049,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63865,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,213050,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63865,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,213051,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63865,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,213052,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63865,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,213053,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63865,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,213054,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63866,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,213055,0,Strongly Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63866,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,213056,1,Agree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63866,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,213057,2,No Opinion,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63866,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,213058,3,Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63866,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,213059,4,Strongly Disagree,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63867,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",213061,0,Very Good,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63867,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",213062,1,Good,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63867,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",213063,2,Fair,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63867,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",213064,3,Poor,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63867,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",213060,4,Excellent,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63867,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN</ol>",213065,5,N/A,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63868,12,"Overall, this activity was:",213066,0,Excellent,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63868,12,"Overall, this activity was:",213067,1,Very Good,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63868,12,"Overall, this activity was:",213068,2,Good,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63868,12,"Overall, this activity was:",213069,3,Fair,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63868,12,"Overall, this activity was:",213070,4,Poor,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63869,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",213071,0,Yes,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63869,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",213072,1,No,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63869,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",213073,2,N/A,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63872,16,How would you improve this class (check all that apply)?,213074,0,Reduce content covered in class,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63872,16,How would you improve this class (check all that apply)?,213075,1,Increase content covered in class,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63872,16,How would you improve this class (check all that apply)?,213076,2,Update content covered in class,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63872,16,How would you improve this class (check all that apply)?,213077,3,Improve the instructional methods,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63872,16,How would you improve this class (check all that apply)?,213078,4,Make course activities more stimulating,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63872,16,How would you improve this class (check all that apply)?,213079,5,Slow the pace of the class,0
9917,Questions-0000-51,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 7-23-21",n13998,63872,16,How would you improve this class (check all that apply)?,213080,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63804,0,Please list the location for this activity.,212808,0,Atlanta,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63804,0,Please list the location for this activity.,212809,1,Cherokee,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63804,0,Please list the location for this activity.,212810,2,Forsyth,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63804,0,Please list the location for this activity.,212811,3,Other,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63805,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212812,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63805,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212813,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63805,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212814,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63805,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212815,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63805,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",212816,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63806,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212817,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63806,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212818,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63806,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212819,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63806,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212820,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63806,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",212821,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63807,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",212822,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63807,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",212823,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63807,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",212824,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63807,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",212825,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63807,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",212826,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63808,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",212827,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63808,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",212828,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63808,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",212829,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63808,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",212830,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63808,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",212831,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63809,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",212832,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63809,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",212833,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63809,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",212834,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63809,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",212835,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63809,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",212836,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63810,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",212837,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63810,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",212838,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63810,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",212839,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63810,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",212840,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63810,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",212841,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63811,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",212842,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63811,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",212843,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63811,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",212844,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63811,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",212845,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63811,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",212846,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63812,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",212847,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63812,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",212848,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63812,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",212849,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63812,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",212850,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63812,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",212851,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63813,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212852,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63813,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212853,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63813,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212854,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63813,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212855,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63813,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,212856,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63814,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212857,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63814,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212858,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63814,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212859,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63814,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212860,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63814,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",212861,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63815,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212862,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63815,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212863,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63815,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212864,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63815,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212865,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63815,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,212866,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63816,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212867,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63816,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212868,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63816,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212869,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63816,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212870,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63816,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,212871,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63817,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212872,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63817,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212873,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63817,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212874,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63817,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212875,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63817,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,212876,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63818,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212877,0,Strongly Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63818,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212878,1,Agree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63818,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212879,2,No Opinion,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63818,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212880,3,Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63818,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,212881,4,Strongly Disagree,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63819,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",212882,0,Excellent,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63819,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",212883,1,Very Good,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63819,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",212884,2,Good,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63819,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",212885,3,Fair,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63819,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",212886,4,Poor,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63819,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN</ol>",212887,5,N/A,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63820,16,"Overall, this activity was:",212888,0,Excellent,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63820,16,"Overall, this activity was:",212889,1,Very Good,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63820,16,"Overall, this activity was:",212890,2,Good,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63820,16,"Overall, this activity was:",212891,3,Fair,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63820,16,"Overall, this activity was:",212892,4,Poor,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63821,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212893,0,Yes,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63821,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212894,1,No,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63821,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",212895,2,N/A,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63824,20,How would you improve this class (check all that apply)?,212896,0,Reduce content covered in class,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63824,20,How would you improve this class (check all that apply)?,212897,1,Increase content covered in class,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63824,20,How would you improve this class (check all that apply)?,212898,2,Update content covered in class,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63824,20,How would you improve this class (check all that apply)?,212899,3,Improve the instructional methods,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63824,20,How would you improve this class (check all that apply)?,212900,4,Make course activities more stimulating,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63824,20,How would you improve this class (check all that apply)?,212901,5,Slow the pace of the class,0
9911,Questions-0000-45,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 7-23-21,n13995,63824,20,How would you improve this class (check all that apply)?,212902,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
8931,Elearning-0000-214,RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH,n14002,63939,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213295,0,TRUE,1
8931,Elearning-0000-214,RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH,n14002,63939,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the RESPIRATORY PERIPHERAL ARTERIAL SAMPLING CBL 2021 FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213296,1,FALSE,0
9745,Elearning-0000-954,2021 ABG CBL FORSYTH,n14003,63941,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 ABG CBL FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213299,0,TRUE,1
9745,Elearning-0000-954,2021 ABG CBL FORSYTH,n14003,63941,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 ABG CBL FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213300,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63942,0,All intubated babies must have two healthcare providers at the bedside for repositioning to reduce unplanned extubations.,213301,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63942,0,All intubated babies must have two healthcare providers at the bedside for repositioning to reduce unplanned extubations.,213302,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63943,1,What is the primary role of the second person that is needed for repositioning an intubated baby?,213303,0,A. To give the other person some company,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63943,1,What is the primary role of the second person that is needed for repositioning an intubated baby?,213304,1,B. To offer encouragement to the primary caregiver,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63943,1,What is the primary role of the second person that is needed for repositioning an intubated baby?,213305,2,"C. To maintain the airway before, during, and after patient repositioning",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63944,2,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,213306,0,A. When damaged or visibly soiled,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63944,2,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,213307,1,B. After it is used to deliver PPV,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63944,2,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,213308,2,C. When admitting a new patient,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63944,2,When should the bedside bag & mask and/or the t-piece resuscitator circuit be replaced?,213309,3,D. All of the above,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63945,3,"When changing or setting-up the bedside bag and mask and/or t-piece resuscitator, the storage bag should be labeled with the date the equipment was set up.",213310,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63945,3,"When changing or setting-up the bedside bag and mask and/or t-piece resuscitator, the storage bag should be labeled with the date the equipment was set up.",213311,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63946,4,When should the closed suction setup for ET tubes be replaced?,213312,0,A. Every night,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63946,4,When should the closed suction setup for ET tubes be replaced?,213313,1,B. When visibly soiled or damaged,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63946,4,When should the closed suction setup for ET tubes be replaced?,213314,2,C. Weekly on Sunday nights,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63946,4,When should the closed suction setup for ET tubes be replaced?,213315,3,D. None of the above,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63946,4,When should the closed suction setup for ET tubes be replaced?,213316,4,E. B & C,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63947,5,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,213317,0,A. Entering the unit before shift report.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63947,5,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,213318,1,B. Before and after patient contact.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63947,5,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,213319,2,C. Before putting on gloves and after removal of gloves.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63947,5,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,213320,3,D. Before touching anything in the infant's bed space.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63947,5,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,213321,4,E. When moving from a contaminated body site to a clean site during care.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63947,5,Effective hand hygiene is the single most important intervention in decreasing the incidence of infection and disease.  When should proper hand hygiene be performed?,213322,5,F. All of the above.,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63948,6,Which of the following does maintaining NCPAP promote?,213323,0,A.  FRC,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63948,6,Which of the following does maintaining NCPAP promote?,213324,1,B.  Endogenous surfactant production,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63948,6,Which of the following does maintaining NCPAP promote?,213325,2,C.  Oxygenation,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63948,6,Which of the following does maintaining NCPAP promote?,213326,3,D.  All of the above,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63949,7,ALL babies < 30 weeks should have CPAP placed on them immediately in the delivery room.,213327,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63949,7,ALL babies < 30 weeks should have CPAP placed on them immediately in the delivery room.,213328,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63950,8,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,213329,0,A.  Over distention,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63950,8,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,213330,1,B.  Decreased oxygenation,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63950,8,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,213331,2,C.  Atelectasis or loss of FRC,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63950,8,Any interruption of CPAP when admitting a patient to SCN should be avoided.  Which of the following may be caused by interruption of CPAP?,213332,3,D.  B and C,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63951,9,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,213333,0,A. Immediately upon admission to the unit,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63951,9,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,213334,1,B. After lines are placed by the physician,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63951,9,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,213335,2,"C. After 1 hour of continuous, uninterrupted time on CPAP",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63951,9,The initial blood gas for an infant/neonate that is admitted on CPAP should be obtained:,213336,3,"D. After length, head, and chest are measured",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63952,10,"Any nasal redness, bruising, or skin breakdown due to nasal prong therapy requires the MD and RN to be notified and results charted.",213337,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63952,10,"Any nasal redness, bruising, or skin breakdown due to nasal prong therapy requires the MD and RN to be notified and results charted.",213338,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63953,11,How do you determine the correct size nasal prongs for CPAP or NIPPV?,213339,0,A. Use the INCA Nasal Sizing Gauge,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63953,11,How do you determine the correct size nasal prongs for CPAP or NIPPV?,213340,1,B. Use the prong size that fill the nares without dilating or causing blanching,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63953,11,How do you determine the correct size nasal prongs for CPAP or NIPPV?,213341,2,C. Doesn't matter because the Cannulaide provides a seal,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63953,11,How do you determine the correct size nasal prongs for CPAP or NIPPV?,213342,3,D. A & B,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63953,11,How do you determine the correct size nasal prongs for CPAP or NIPPV?,213343,4,E. None of the above,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63954,12,"Normal saline should only be used to clear the in-line suction catheter and NOT instilled down the endotracheal tube as a lavage, UNLESS ordered by a physician.",213344,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63954,12,"Normal saline should only be used to clear the in-line suction catheter and NOT instilled down the endotracheal tube as a lavage, UNLESS ordered by a physician.",213345,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63955,13,"Prior to being placed on a patient, the device check and breathing circuit check must be performed on the Drager VN 500.",213346,0,TRUE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63955,13,"Prior to being placed on a patient, the device check and breathing circuit check must be performed on the Drager VN 500.",213347,1,FALSE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63956,14,Which statement best describes the Volume Guarantee mode?,213348,0,"A.  Set volume, variable pressure",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63956,14,Which statement best describes the Volume Guarantee mode?,213349,1,"B.  Set pressure, variable volume",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63956,14,Which statement best describes the Volume Guarantee mode?,213350,2,"C.  Set volume, set pressure",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63957,15,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",213351,0,A. Increase VG to blow-off CO2,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63957,15,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",213352,1,B. Call MD for high PCO2,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63957,15,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",213353,2,C. Call MD due to max VG,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63957,15,"Your 1000g patient has an arterial PCO2 of 69 and is on the following settings:<br>  PC-AC/VG = 7.0mL, PMAX = 25, PEEP = 5, Ti = 0.4s, Back-up Rate=30, total rate of 60.<br> Based on the ventilator weaning guidelines, what actions should be taken?",213354,3,D. None of the above,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63958,16,"In the PC-SIMV/VG mode, only the set breaths are full ventilator breaths.",213355,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63958,16,"In the PC-SIMV/VG mode, only the set breaths are full ventilator breaths.",213356,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63959,17,"The vent settings are:<br> PC-AC/VG = 3.0mL 	PMAX= 25	 PEEP = 5.Rate = 30 	Set Ti = 0.5 seconds<br>  Your patient requires a PIP of 22 to deliver this volume. How will the delivered PIP change if your patient becomes more compliant?",213357,0,A.  Delivered PIP will increase,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63959,17,"The vent settings are:<br> PC-AC/VG = 3.0mL 	PMAX= 25	 PEEP = 5.Rate = 30 	Set Ti = 0.5 seconds<br>  Your patient requires a PIP of 22 to deliver this volume. How will the delivered PIP change if your patient becomes more compliant?",213358,1,B.  Delivered PIP will decrease.,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63959,17,"The vent settings are:<br> PC-AC/VG = 3.0mL 	PMAX= 25	 PEEP = 5.Rate = 30 	Set Ti = 0.5 seconds<br>  Your patient requires a PIP of 22 to deliver this volume. How will the delivered PIP change if your patient becomes more compliant?",213359,2,C.  No change,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63960,18,Where should the initial flow trigger be set for patients on the Drager VN-500?,213360,0,A.  0.2 for initial setting,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63960,18,Where should the initial flow trigger be set for patients on the Drager VN-500?,213361,1,B.  High enough to stop the patient from being tachypneic,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63960,18,Where should the initial flow trigger be set for patients on the Drager VN-500?,213362,2,"C.  Adjusted to prevent auto-cycling, but allow for easy patient triggering",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63960,18,Where should the initial flow trigger be set for patients on the Drager VN-500?,213363,3,D.  A and C,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63961,19,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",213364,0,A.  Increase the rate to 34,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63961,19,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",213365,1,B.  Wean P Insp to maintain VT  5 to 7 cc per kg,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63961,19,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",213366,2,C.  Extubate to Bubble CPAP,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63961,19,"Your 1000 gram infant is on PC-SIMV with the following settings:<br> P Insp = 22	PEEP = 5 cmH2O	Rate = 30 breaths/min<br>  Ti = 0.4 seconds	Measured Vte = 12 cc	PCO2 on ABG = 40.<br>  What change would you make to the ventilator settings?",213367,3,D.  Decrease rate to 25,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63962,20,The Ventilator Performance Check and Circuit Calibration on the 3100A  needs to be performed:,213368,0,A. Every 500 hours of use,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63962,20,The Ventilator Performance Check and Circuit Calibration on the 3100A  needs to be performed:,213369,1,B. After each patient use,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63962,20,The Ventilator Performance Check and Circuit Calibration on the 3100A  needs to be performed:,213370,2,C. Before setting up for use on a new patient,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63963,21,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",213371,0,A. Decreasing the Hz/Frequency,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63963,21,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",213372,1,B. Increasing the Amps/Power,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63963,21,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",213373,2,C. Increasing the Hz/Frequency,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63963,21,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",213374,3,D. Increasing the MAP,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63963,21,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",213375,4,E. A & B,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63963,21,"If the PCO2 on the blood gas for a baby on HFOV is too high, you can increase ventilation on the HFOV by:",213376,5,F. All of the above,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63964,22,How do you assess adequate lung inflation for babies on HFOV?,213377,0,A.  Auscultate for bilateral and equal breath sounds,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63964,22,How do you assess adequate lung inflation for babies on HFOV?,213378,1,B.  Assess the amount of chest wiggle,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63964,22,How do you assess adequate lung inflation for babies on HFOV?,213379,2,C.  Lung expansion on chest X-ray (diaphragm sits between 8 to 10 ribs),1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63965,23,How do you assess the baby for proper Power/Amplitude on 3100A?,213380,0,A. Chest wiggle to mid-thigh,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63965,23,How do you assess the baby for proper Power/Amplitude on 3100A?,213381,1,B. Chest wiggle to umbilicus,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63965,23,How do you assess the baby for proper Power/Amplitude on 3100A?,213382,2,C. Auscultate for oscillations equally throughout all lobes,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63965,23,How do you assess the baby for proper Power/Amplitude on 3100A?,213383,3,D. Chest X-ray,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63967,24,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,213386,0,A.   When the lung expansion is = 10 ribs.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63967,24,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,213387,1,B.   When the lung expansion is < 8 ribs.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63967,24,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,213388,2,C.   When the MAP is > 30.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63967,24,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,213389,3,D.   All of the above,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63967,24,When would you call the doctor for a baby with a chest x-ray that shows the lungs as under or over inflated?,213390,4,E.   Just A & B,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63968,25,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",213391,0,A. When PCO2 is > 65,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63968,25,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",213392,1,B. When ordered by the MD,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63968,25,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",213393,2,"C. When an ETCO2 or TcCO2 tracing, that has been correlated to a blood gas, trends higher than a stable level",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63968,25,"According to the Ventilator Weaning Guidelines, when should the therapist increase ventilator support?",213394,3,D. All of the above,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63969,27,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",213395,0,A. Decrease alveolar surface tension,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63969,27,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",213396,1,B. Maintain bronchiolar patency,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63969,27,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",213397,2,C. Preferentially improve the surface tension of collapsed alveoli,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63969,27,"A 32 week, 1 day old patient is on BCPAP of +9 cmH2O.  The baby has an increased work of breathing with FiO2 of 75% with SpO2 of 88%.  The RT notifies the physician and is ordered to intubate and give surfactant.  Which of the following is the most likely effect of surfactant administration?",213398,3,D. Increase the pressure needed to keep alveoli open,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63970,28,"The dose number of Curosurf (1st, 2nd, or 3rd dose) should be noted in the comments field of OneChart MAR and Respiratory Therapy iView.",213399,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63970,28,"The dose number of Curosurf (1st, 2nd, or 3rd dose) should be noted in the comments field of OneChart MAR and Respiratory Therapy iView.",213400,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63971,29,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,213401,0,"A. Sterile gloves, clean chux or 4 x 4 gauze, unvented syringe for waste, vented syringe for blood sampling, 4 Site scrubs, heparin flush syringe and Curos green cap.",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63971,29,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,213402,1,"B. Gloves, clean chux or 4 x 4 gauze, vented syringe for waste, vented syringe for blood sampling, 4 Site scrubs, heparin flush syringe and Curos green cap.",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63971,29,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,213403,2,"C. Gloves, clean chux only, vented syringe for waste, vented syringe for blood sampling, 2 Site scrubs, heparin flush syringe and Curos green cap.",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63971,29,What supplies are needed for drawing a blood sample from a Peripheral Arterial Line (PAL)?,213404,3,"D. Gloves, 4 x 4 gauze, unvented syringe for waste, unvented syringe for blood sampling, 4 Site scrubs, heparin flush syringe and Curos green cap.",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63972,30,How much heparin is required to flush an umbilical artery catheter in the SCN?,213405,0,A. 1cc over 30 - 60 seconds,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63972,30,How much heparin is required to flush an umbilical artery catheter in the SCN?,213406,1,B. 0.3 - 0.5cc over 30 - 60 seconds,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63972,30,How much heparin is required to flush an umbilical artery catheter in the SCN?,213407,2,C. 0.5cc rapidly,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63972,30,How much heparin is required to flush an umbilical artery catheter in the SCN?,213408,3,D. Until the line is clear,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63973,31,"There must be a new MD order to use the RAM prongs on a HFNC, BCPAP or NIPPV patient, even if the baby was already on RAM prongs during previous therapies.",213409,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63973,31,"There must be a new MD order to use the RAM prongs on a HFNC, BCPAP or NIPPV patient, even if the baby was already on RAM prongs during previous therapies.",213410,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63974,32,"When RAM prongs are ordered to be used with HFNC, the prongs used should not occlude the nares.",213411,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63974,32,"When RAM prongs are ordered to be used with HFNC, the prongs used should not occlude the nares.",213412,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63975,33,When does an Oxygen Index need to be calculated?,213413,0,A. With every ABG for patients receiving inhaled nitric oxide therapy,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63975,33,When does an Oxygen Index need to be calculated?,213414,1,B. With every patient on HFOV,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63975,33,When does an Oxygen Index need to be calculated?,213415,2,C. Only when the patient is on 100% oxygen,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63975,33,When does an Oxygen Index need to be calculated?,213416,3,D. If ordered by the physician,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63975,33,When does an Oxygen Index need to be calculated?,213417,4,E. A & D,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63976,34,"Calculate the Oxygen Index for a 38 week newborn with confirmed pulmonary hypertension via echocardiogram on Inhaled Nitric Oxide based on the following parameters:,br> MAP = 25	FiO2 = 75%	PaO2 = 50",213418,0,A. 60,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63976,34,"Calculate the Oxygen Index for a 38 week newborn with confirmed pulmonary hypertension via echocardiogram on Inhaled Nitric Oxide based on the following parameters:,br> MAP = 25	FiO2 = 75%	PaO2 = 50",213419,1,B. 55,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63976,34,"Calculate the Oxygen Index for a 38 week newborn with confirmed pulmonary hypertension via echocardiogram on Inhaled Nitric Oxide based on the following parameters:,br> MAP = 25	FiO2 = 75%	PaO2 = 50",213420,2,C. 37.5,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63977,35,What oxygen index requires a call to the MD?,213421,0,A. OI > 20 for babies = 34 weeks,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63977,35,What oxygen index requires a call to the MD?,213422,1,B.  OI > 10 for babies 26 - 33 6/7 weeks,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63977,35,What oxygen index requires a call to the MD?,213423,2,C. None of the above,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63977,35,What oxygen index requires a call to the MD?,213424,3,D. A & B,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63978,36,Which statement best describes the indication for use of inhaled nitric oxide?,213425,0,A. Hypoxic Respiratory Failure associated with clinical or echocardiographic evidence of pulmonary hypertension,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63978,36,Which statement best describes the indication for use of inhaled nitric oxide?,213426,1,B. Meconium Aspiration Syndrome requiring FiO2 > 50%,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63978,36,Which statement best describes the indication for use of inhaled nitric oxide?,213427,2,C. Pulmonary Interstitial Ephysema requiring HFOV,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63979,37,Which of the following shows the correct placement and adaptors for the nitric injector module on a 3100 A/B HFOV?,213428,0,A.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63979,37,Which of the following shows the correct placement and adaptors for the nitric injector module on a 3100 A/B HFOV?,213429,1,B.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63979,37,Which of the following shows the correct placement and adaptors for the nitric injector module on a 3100 A/B HFOV?,213430,2,C.,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63980,38,Which of the following shows the correct placement of the nitric sample line on HFOV? (sample line has a yellow tag),213431,0,A.,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63980,38,Which of the following shows the correct placement of the nitric sample line on HFOV? (sample line has a yellow tag),213432,1,B.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63980,38,Which of the following shows the correct placement of the nitric sample line on HFOV? (sample line has a yellow tag),213433,2,C.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63981,39,Which of the following shows correct placement of the nitric injector module on the Drager VN-500?,213434,0,A.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63981,39,Which of the following shows correct placement of the nitric injector module on the Drager VN-500?,213435,1,B.,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63981,39,Which of the following shows correct placement of the nitric injector module on the Drager VN-500?,213436,2,C.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63982,40,Which of the following shows correct placement of the nitric sampling line for the Drager?,213437,0,A.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63982,40,Which of the following shows correct placement of the nitric sampling line for the Drager?,213438,1,B.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63982,40,Which of the following shows correct placement of the nitric sampling line for the Drager?,213439,2,C.,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63983,41,How often should the orange resus bags be checked for inventory?,213440,0,"A)	Once per shift by the Resus RT",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63983,41,How often should the orange resus bags be checked for inventory?,213441,1,"B)	Once per day by the charge therapist",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63983,41,How often should the orange resus bags be checked for inventory?,213442,2,"C)	After each use, if an item is used",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63983,41,How often should the orange resus bags be checked for inventory?,213443,3,"D)	A & C",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63984,42,All unplanned extubations need to be followed up with an incident report.,213444,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63984,42,All unplanned extubations need to be followed up with an incident report.,213445,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63985,43,What is the proper starting temperature for the TC probe when placing on a neonate?,213446,0,"A)	41 ∞C",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63985,43,What is the proper starting temperature for the TC probe when placing on a neonate?,213447,1,"B)	37 ∞C",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63985,43,What is the proper starting temperature for the TC probe when placing on a neonate?,213448,2,"C)	39 ∞C",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63985,43,What is the proper starting temperature for the TC probe when placing on a neonate?,213449,3,"D)	42 ∞C",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63986,44,What is the maximum temperature for the TC probe on a term neonate?,213450,0,"A)	42 ∞C",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63986,44,What is the maximum temperature for the TC probe on a term neonate?,213451,1,"B)	41 ∞C",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63986,44,What is the maximum temperature for the TC probe on a term neonate?,213452,2,"C)	40 ∞C",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63986,44,What is the maximum temperature for the TC probe on a term neonate?,213453,3,"D)	39 ∞C",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63987,45,"Unless the physician orders to NOT use a TC monitor, EVERY baby on HFOV must have a TC monitor.",213454,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63987,45,"Unless the physician orders to NOT use a TC monitor, EVERY baby on HFOV must have a TC monitor.",213455,1,FALSE,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63988,46,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",213456,0,"A.  If the baby is in an open crib or radiant warmer, remove the unheated portion of the inspiratory limb.",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63988,46,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",213457,1,"B.  If the baby is in a Caleo isolette, remove the unheated portion of the inspiratory limb if the air temperature of the Caleo is < 34 ∞C.",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63988,46,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",213458,2,C.  Make sure temp probes are pushed all the way into the ports.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63988,46,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",213459,3,"D.  If flow is < 5 Lpm, set heater to Non-Invasive.",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63988,46,"If condensation persistently develops in the respiratory circuit, what are the proper steps to be taken?",213460,4,E.  All of the above,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63989,47,"According to NRP, what is the single most effective way to reverse bradycardia?",213461,0,"A.	Chest Compressions",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63989,47,"According to NRP, what is the single most effective way to reverse bradycardia?",213462,1,"B.	Blow-by Therapy",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63989,47,"According to NRP, what is the single most effective way to reverse bradycardia?",213463,2,"C.	Effective PPV confirmed by MRSOPA",1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63989,47,"According to NRP, what is the single most effective way to reverse bradycardia?",213464,3,"D.	CPAP",0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63990,48,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,213465,0,A. Once per day.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63990,48,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,213466,1,B. Every 6 hours.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63990,48,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,213467,2,C. Every 3 to 4 hours.,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63990,48,How often should the Cannulaide be checked on patients who are on BCPAP and NIPPV?,213468,3,D. Once a shift.,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63991,49,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,213469,0,A. P-CMV and orange,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63991,49,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,213470,1,B. P-CPAP and green,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63991,49,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,213471,2,C. P-SIMV and yellow,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,63991,49,What is the correct mode to use when placing a patient on Non Invasive Positive Pressure Ventilation on the Drager VN-500 and what color should be displayed on the monitor?,213472,3,D. P-AC and blue,0
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,64492,26,"Any unopened and unused vials of surfactant should be returned to pharmacy, whereas any used or unused portion of an opened vial or syringe should be discarded appropriately, per policy.",215321,0,TRUE,1
9733,Elearning-0000-943,2021 NICU COMPETENCY EXAM_ NSF,n14004,64492,26,"Any unopened and unused vials of surfactant should be returned to pharmacy, whereas any used or unused portion of an opened vial or syringe should be discarded appropriately, per policy.",215322,1,FALSE,0
8914,Elearning-0000-199,SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH,n14007,63992,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213473,0,TRUE,1
8914,Elearning-0000-199,SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH,n14007,63992,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the SCN HAND HYGIENE  2021 FINAL_RRT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213474,1,FALSE,0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213477,0,"A.	Increase target Vt",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213478,1,"B.	Increase Pmax and Pmin",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213479,2,"C.	Increase EPAP",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213480,3,"D.	Decrease Rate",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213481,4,"E.	Decrease FiO2",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213482,5,"F.	Increase Rate",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213483,6,"G.	A, B, E, F",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213484,7,"H.	Only A & B",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63994,0,"A Covid negative patient is very lethargic and has an ABG result: 7.20/93/150/42.0/100% on 8L HFNC. You place them on BiPAP on AVAPS with settings of target Vt 450, Pmax 15, Pmin 8, EPAP 5 Rate 8, FiO2 50%. An ABG repeated after 1 hour is 7.25/89/130/42/99%. What adjustments could you make?",213485,8,"I.	All of the above",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63995,1,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,213486,0,"A.	Capnostream EtCO2 remote monitor",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63995,1,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,213487,1,"B.	NellCor  remote monitored pulse oximeter",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63995,1,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,213488,2,"C.	Nellcor N65 pulse oximeter",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63995,1,A patient with a PCA pump needs remote monitoring. He has a history of OSA and he is wearing his home CPAP. Which device would be most appropriate?,213489,3,"D.	Floor Dynamap monitor",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63996,2,A patient with a trach transfers from ICU to your floor. What do you need to do?,213490,0,"A.	Verify equipment such as oxygen, humidity therapy, & suction are set up",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63996,2,A patient with a trach transfers from ICU to your floor. What do you need to do?,213491,1,"B.	Verify ambu-bag and extra trachs are at bedside including one of equal size, and one size smaller than the patient's trach size.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63996,2,A patient with a trach transfers from ICU to your floor. What do you need to do?,213492,2,"C.	Set up remote pulse ox on patient and enter patient data and orders into all computer systems",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63996,2,A patient with a trach transfers from ICU to your floor. What do you need to do?,213493,3,"D.	Assess patient and document assessment and recommendations in computer system",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63996,2,A patient with a trach transfers from ICU to your floor. What do you need to do?,213494,4,"E.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63997,3,Which of the following are FALSE concerning Tracheostomy patients during transports?,213495,0,"A.	Respiratory Therapist must accompany the patient during the entire transport (must stay with patient).",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63997,3,Which of the following are FALSE concerning Tracheostomy patients during transports?,213496,1,"B.	A bag valve mask, obturator or spare tracheostomy must also accompany the patient during transport in the event the airway is displaced.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63997,3,Which of the following are FALSE concerning Tracheostomy patients during transports?,213497,2,"C.	If a patient is having an MRI or CT performed, the Respiratory Therapist must stay in the MRI or CT room and be able to access the patient in the event of an emergency at all times.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63997,3,Which of the following are FALSE concerning Tracheostomy patients during transports?,213498,3,"D.	Respiratory Therapist must accompany the patient during transport, and may leave patient (if stable) in area where procedure is to be performed",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63998,4,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",213499,0,"A.	None. These are home meds and we don't recommend changing home meds.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63998,4,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",213500,1,"B.	Keep meds as listed but add 0.5mg Atrovent Q4 and Spiriva 1 puff daily",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63998,4,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",213501,2,"C.	Change Albuterol to Xopenex per interchange policy & add Spiriva 1 puff daily",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63998,4,"Patient has a history of COPD is admitted with Pneumonia. Home meds on MED REC form completed by the nurse include ProAir 2puffs PRN, 0.5mg Pulmicort and 15mcg Brovana BID, 0.5mg Albuterol Q4, and Advair 250/50. What changes would you recommend to the physician?",213502,3,"D.	Recommend discontinuing one of the duplications of inhaled corticosteroid and long-acting beta agonist medications, consider adding 0.5mg Atrovent Q4.",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63999,5,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,213503,0,"A.	75%: Change SMI to PRN for nursing to follow, notify RN & Document in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63999,5,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,213504,1,"B.	50% - 75%: Continue SMI for now, start IPPB in 3 days; Document in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63999,5,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,213505,2,"C.	50%-75%: Start IBBP therapy and discontinue SMI; Document in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63999,5,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,213506,3,"D.	<50%: Start IBBP and continue use of SMI BID or after each IPPB treatment to measure volume improvement until patient can achieve goal >50% for 2 consecutive visits;  Document both in EMR",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,63999,5,A patient admitted with pneumonia has Incentive Spirometry ordered Q2w/a. Predicted Goal is 2750 but patient is only achieving 1300ml at start of therapy.  What is the percentage the patient is achieving and what changes would you make per protocol?,213507,4,"E.	<50%: continue SMI, reassess in 72 hours for need for IPPB; Document in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64000,6,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",213508,0,"A.	Write Goal and start date. Place sticker in chart",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64000,6,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",213509,1,"B.	Write Goal and volume <50%. Place sticker on nebulizer",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64000,6,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",213510,2,"C.	Write Goal and volume <50%. Place sticker just above goal line on SMI",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64000,6,"Patient's SMI Goal is 2500 per the nomogram based on height, age, and gender. What do you put on the yellow SMI sticker and where do you place the sticker?",213511,3,"D.	What yellow sticker?",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213512,0,"A.	Selecting the correct monitor and accessory equipment; putting in a remote monitoring order with start date and time",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213513,1,"B.	Use the pink probe with the Pulse oximeter and the white probe with the Capnostream",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213514,2,"C.	Placing the patient data in Bernoulli using 2 patient identifiers, start date & time and notify Telemetry at 43588",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213515,3,"D.	Chart appropriately in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213516,4,"E.	Completing Log Book in dept. to include patient name, account number, CB#, pager assigned, and device selected.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213517,5,"F.	Patients on >5L O2 are placed on Capnostream EtCO2 monitoring",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213518,6,"G.	A, C, D, E",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64001,7,The proper steps for setting a patient up with Remote monitoring include:,213519,7,"H.	A, B, E, F",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64002,8,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",213520,0,"A.	Start Albuterol nebs Q8 and AccuPAP for 24 hours then d/c therapy",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64002,8,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",213521,1,"B.	Start SMI and 10cmH2O of IPPB therapy with 2.5mg Albuterol and 0.5mg Atrovent Q8 for 24 hours, then reassess.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64002,8,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",213522,2,"C.	Enter start date and goal in SMI order's comment section",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64002,8,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",213523,3,"D.	We don't do respiratory protocol on 5TC patients",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64002,8,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",213524,4,"E.	Place correct orders in EMR and document assessment and therapy in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64002,8,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",213525,5,"F.	B, C, E",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64002,8,"A patient is on 5TC post thoracotomy with orders for Respiratory Therapy. The patient appears without distress, has chest tube present and it is functioning. His only complaint is mild pain at the incision site. What are the appropriate actions?",213526,6,"G.	A & E",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64003,9,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,213527,0,"A.	Set flow at 60Lpm and 100% FiO2 and wean flow first by 5 liters until below 30Lpm before weaning oxygen",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64003,9,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,213528,1,"B.	Set flow at 30Lpm and 50% FiO2; wean FiO2 before flow; follow MD recommendations for titration. Try to get patient in negative pressure room & place STOP sign AGP sign outside patient room.",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64003,9,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,213529,2,"C.	Set flow at 40Lpm and 100% FiO2 and wean flow first by 5% until below 30L before weaning FiO2",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64003,9,You have a Covid positive patient on 10L HFNC who needs to go on Optiflow. Which settings would you recommend?,213530,3,"D.	All of the above",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64004,10,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,213531,0,"A.	Proximal to the machine but after the 1st filter on the machine",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64004,10,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,213532,1,"B.	Proximal to the patient but before the 2nd filter on the mask",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64004,10,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,213533,2,"C.	Distal from the patient, proximal from the machine, but before the 1st filter",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64004,10,Where is correct placement of the Aerogen  or Aerosol nebulizer on the BiPAP/CPAP device?,213534,3,"D.	Proximal to the patient, between the 2nd filter and the mask or on the exhalation port.",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64005,11,Which statements are correct?,213535,0,"A.	All vents in storage areas need to be clean, plugged in, & bagged with disposable supplies packaged with vent.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64005,11,Which statements are correct?,213536,1,"B.	Any equipment that is SET-UP READY for USE, must be stickered with date of setup and RT initials. Set up is good for 2 weeks.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64005,11,Which statements are correct?,213537,2,"C.	Equipment cleaning and set-up is everyone's responsibility",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64005,11,Which statements are correct?,213538,3,"D.	All equipment must be set up and ready to go at all times",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64005,11,Which statements are correct?,213539,4,"E.	A, B, C",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64005,11,Which statements are correct?,213540,5,"F.	All of the above",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64006,12,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",213541,0,"A.	Any patient who requires high flow oxygen > or = to 50%. The attending physician will be notified of the results immediately.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64006,12,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",213542,1,"B.	Any patient with an exacerbation of their pulmonary condition in which their Acid/Base or PCO2 status is questionable.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64006,12,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",213543,2,"C.	Any patient in which oximetry results are questionable",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64006,12,"Per the PDP for Oxygen Therapy, an ABG may be obtained by the RT per policy when:",213544,3,"D.	All of the Above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64007,13,"If an order reads, ""CPAP per RT Protocol""ù you should set up:",213545,0,"A.	Air-sense10 or ResMed S9 in auto mode",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64007,13,"If an order reads, ""CPAP per RT Protocol""ù you should set up:",213546,1,"B.	If O2 is needed, you can bleed in up to 15 L/min",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64007,13,"If an order reads, ""CPAP per RT Protocol""ù you should set up:",213547,2,"C.	If O2 is needed, you can bleed in up to 4 L/min",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64007,13,"If an order reads, ""CPAP per RT Protocol""ù you should set up:",213548,3,"D.	V-60 only if auto CPAP device not available; start with 5 cmH2O. This level may be increased in 2 cmH2O increments Q10minutes to a maximum of 18cmH2O.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64007,13,"If an order reads, ""CPAP per RT Protocol""ù you should set up:",213549,4,"E.	A, B, D",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64007,13,"If an order reads, ""CPAP per RT Protocol""ù you should set up:",213550,5,"F.	A, C, D",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64008,14,Home Oxygen Assessment documentation includes which of the following:,213551,0,"A.	If room air SpO2 at rest is < 89, place patient on oxygen to get SpO2 >= 89%. If able to ambulate, monitor oxygen amount needed to keep SpO2 >88% on exertion",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64008,14,Home Oxygen Assessment documentation includes which of the following:,213552,1,"B.	If room air SpO2 is >=89% at rest, do a room air SpO2 with exertion",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64008,14,Home Oxygen Assessment documentation includes which of the following:,213553,2,"C.	If exertional SpO2 is <89%, document how much oxygen is needed to keep SpO2 > 89%.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64008,14,Home Oxygen Assessment documentation includes which of the following:,213554,3,"D.	A & B",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64008,14,Home Oxygen Assessment documentation includes which of the following:,213555,4,"E.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64009,15,"Per CPAP/BiPAP protocol, the physician will be contacted when:",213556,0,"A.	HR increases or decreases 20% from pre-therapy HR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64009,15,"Per CPAP/BiPAP protocol, the physician will be contacted when:",213557,1,"B.	Therapist is unable to achieve an adequate mask seal",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64009,15,"Per CPAP/BiPAP protocol, the physician will be contacted when:",213558,2,"C.	No improvement within 1 hour after post ABG",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64009,15,"Per CPAP/BiPAP protocol, the physician will be contacted when:",213559,3,"D.	A & C",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64009,15,"Per CPAP/BiPAP protocol, the physician will be contacted when:",213560,4,"E.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64010,16,Which are the components of the fresh trach protocol?,213561,0,"A.	Signage on the door with the date and time the 48 hour observation ends",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64010,16,Which are the components of the fresh trach protocol?,213562,1,"B.	EtCO2 documented Q4",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64010,16,Which are the components of the fresh trach protocol?,213563,2,"C.	Ambu-bag & mask, same size trach, and one size smaller at bedside, Obturator at HOB",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64010,16,Which are the components of the fresh trach protocol?,213564,3,"D.	Respiratory therapist to be at the bedside for all patient turns/movement",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64010,16,Which are the components of the fresh trach protocol?,213565,4,"E.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64011,17,You have an order for an ABG. What is the process for analyzing this test?,213566,0,"A.	Verify order in EMR FIRST! Use 2 patient identifiers (compare sticker to EMR chart)",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64011,17,You have an order for an ABG. What is the process for analyzing this test?,213567,1,"B.	Run sample in analyzer, input data at analyzer including correct panel type",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64011,17,You have an order for an ABG. What is the process for analyzing this test?,213568,2,"C.	Always pick Complete Panel regardless of order",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64011,17,You have an order for an ABG. What is the process for analyzing this test?,213569,3,"D.	Address any critical comments with appropriate documentation, then approve sample,",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64011,17,You have an order for an ABG. What is the process for analyzing this test?,213570,4,"E.	Verify results appear in EMR, complete ABG (Adhoc) collection form & chart Therapist time.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64011,17,You have an order for an ABG. What is the process for analyzing this test?,213571,5,"F.	A, B, D, E",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64011,17,You have an order for an ABG. What is the process for analyzing this test?,213572,6,"G.	A, B, C, D",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64012,18,You have an ABG with critical results. Which of the following statements is FALSE.,213573,0,"A.	You have 30 minutes to contact a licensed provider or MD to report critical values",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64012,18,You have an ABG with critical results. Which of the following statements is FALSE.,213574,1,"B.	You have 60 minutes to contact a licensed provider or MD to report critical values",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64012,18,You have an ABG with critical results. Which of the following statements is FALSE.,213575,2,"C.	You must document in analyzer who you contacted and include first name or initial, full last name, AND credential.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64012,18,You have an ABG with critical results. Which of the following statements is FALSE.,213576,3,"D.	Critical results can only be called to a licensed medical provider.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64013,19,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,213577,0,"A.	ABG form",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64013,19,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,213578,1,"B.	Non-ABG Lab Testing form",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64013,19,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,213579,2,"C.	Blood Gas Sample Collection form",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64013,19,You analyze an ionized calcium sample. Which Adhoc form do you use in Cerner to charge?,213580,3,"D.	ABG-SCN (RT) form",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64014,20,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,213581,0,"A.	Modify the Aerosol Treatment order under Respiratory Orders to change the frequency",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64014,20,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,213582,1,"B.	Cancel & Reorder the Aerosol Treatment order under Respiratory Orders to change frequency",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64014,20,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,213583,2,"C.	Modify the Albuterol order under Medications Orders to change the frequency",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64014,20,You decide to change a patient's albuterol treatments frequency per RT protocol. Which steps are correct for changing medication orders in Cerner?,213584,3,"D.	Cancel & Reorder the Albuterol order under Medication Orders to change the frequency",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64015,21,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,213585,0,"A.	Skin integrity will be assessed with each device check",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64015,21,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,213586,1,"B.	A skin barrier device, such as Protecta-Gel should be used, especially if irritation or redness present, and MD is notified.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64015,21,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,213587,2,"C.	If skin breakdown occurs, a wound consult must be placed and an incident report must be filed",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64015,21,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,213588,3,"D.	Use alternative interface such as ""under-the-nose""ù mask",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64015,21,Your (non-Covid) patient is wearing BiPAP regularly. Which of the following statements are true regarding skin integrity?,213589,4,"E.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64016,22,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",213590,0,"A.	Increase oxygen, notify RN, document Progress note in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64016,22,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",213591,1,"B.	Change to High-Flow NC, titrate to increase SpO2 >= 92%",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64016,22,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",213592,2,"C.	Order and Draw ABG per O2 protocol & notify MD of results",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64016,22,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",213593,3,"D.	Leave oxygen at 6L, SpO2 of 91% is acceptable at rest",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64016,22,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",213594,4,"E.	A, B, C",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64016,22,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",213595,5,"F.	A & B only",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64016,22,"A patient goes from 2L NC to 6L NC during your shift. His SpO2 on 6L is 91%. His WOB is unlabored at rest, but he is SOB with activity. He does not wear home oxygen. What steps should you take?",213596,6,"G.	D only",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64017,23,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",213597,0,"A.	Assess patient in person",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64017,23,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",213598,1,"B.	Decrease IPI Alarm to OFF",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64017,23,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",213599,2,"C.	Verify Capnostream Nasal cannula is on patient and both prongs are in nares",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64017,23,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",213600,3,"D.	Verify RR actual vs monitor reading",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64017,23,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",213601,4,"E.	If patient is on oxygen too, verify flow is < 6L",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64017,23,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",213602,5,"F.	A, C, D, E",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64017,23,"A patient is on Capnography monitoring per MD orders. His IPI is alarming at 3. HR is 80, SpO2 is 92%, RR is 6, EtCO2 is 19. What should you do?",213603,6,"G.	All of the above",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64018,24,Which of the following statements is FALSE?,213604,0,"A.	Notes or comments should be placed in a Progress Note in Cerner",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64018,24,Which of the following statements is FALSE?,213605,1,"B.	Right-click any charting field and place a comment if necessary",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64018,24,Which of the following statements is FALSE?,213606,2,"C.	Chart education on every patient on therapy at least once a shift",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64018,24,Which of the following statements is FALSE?,213607,3,"D.	Smoking cessation education is charted in Social Habits Education section",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64019,25,Which Statements are FALSE about oxygen weaning/titration as NSH?,213608,0,"A.	Once a shift, weaning or titration of oxygen should be attempted for any patient wearing low flow (<7L) oxygen, who does NOT wear oxygen at home, unless they meet certain criteria.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64019,25,Which Statements are FALSE about oxygen weaning/titration as NSH?,213609,1,"B.	If a patient does not qualify for oxygen titration, the RT must select a reason for why patient was not weaned from the REASON NOT TITRATED field in EMR",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64019,25,Which Statements are FALSE about oxygen weaning/titration as NSH?,213610,2,"C.	AMI, Comfort Care, Pt at home level, & SpO2 less than 90% are some of the choices for REASON NOT TITRATED. OTHER is another choice, that opens a free text window, where RT can chart why oxygen weaning not indicated.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64019,25,Which Statements are FALSE about oxygen weaning/titration as NSH?,213611,3,"D.	 Oxygen titration must also be documented on ventilated patients Q shift",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64020,26,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,213612,0,"A.	Skin integrity and airway status will be assessed with each device check, or therapy administered or minimum Qshift.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64020,26,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,213613,1,"B.	A skin barrier device, such as Cavilon swabs, Drawtex drain pads,  Mepilex, or Duoderm,  will be used, especially if irritation or redness present, and MD is notified.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64020,26,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,213614,2,"C.	If skin breakdown occurs, a wound consult must be placed and an incident report must be filed",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64020,26,Which of the following statements are true regarding skin integrity and airway status for a tracheostomy patient?,213615,3,"D.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64021,27,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",213616,0,"A.	Place a Biomed work order for device inspection",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64021,27,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",213617,1,"B.	Have patient sign release of liability form and place in Chart under Consents",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64021,27,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",213618,2,"C.	Verify or place appropriate orders and protocols",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64021,27,"When a patient brings in a home CPAP/BiPAP, the RT must do the following:",213619,3,"D.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64022,28,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",213620,0,"A.	An EtCO2 measurement verifies airway placement in the lungs",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64022,28,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",213621,1,"B.	An EtCO2 < 10mmHg indicates poor circulation and reduces the likelihood of ROSC",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64022,28,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",213622,2,"C.	Adequacy of Chest compressions can be seen by a EtCO2 > 10-15 mmHg",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64022,28,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",213623,3,"D.	A sudden rise in EtCO2 could indicated ROSC and a pulse check should be done",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64022,28,"During a Code Blue, the RT must call out the EtCO2 Q2 minutes. This is because:",213624,4,"E.	All of the above",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64023,29,Which of the following statements are true about remote monitoring?,213625,0,"A.	All patients who need monitoring go on a pulse ox with a pink wrap probe and then get put Bernoulli.",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64023,29,Which of the following statements are true about remote monitoring?,213626,1,"B.	If the patient is on the dynamap on the floor, they don't need to go on remote monitoring",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64023,29,Which of the following statements are true about remote monitoring?,213627,2,"C.	Only PCA patients go on Remote Monitoring and only for 24 hours",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64023,29,Which of the following statements are true about remote monitoring?,213628,3,"D.	The criteria for EtCO2 monitoring is located on the badge cards and includes high risk factors such as COPD, BMI >35, age >80, Sepsis, Respiratory distress (RR <10 or >30);",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64023,29,Which of the following statements are true about remote monitoring?,213629,4,"E.	Patients with PaO2 on ABG <65 mmHg will go on remote pulse ox with RR, per Oxygen PDP",0
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64023,29,Which of the following statements are true about remote monitoring?,213630,5,"F.	D & E",1
9804,Questions-0000-10,2021 RESPIRATORY ADULT EXAM LEVEL I FORSYTH,n14009,64023,29,Which of the following statements are true about remote monitoring?,213631,6,"G.	All of the above",0
8144,Elearning-0000-104,2021 VENTILATOR MODES FOR RT FORSYTH,n14008,63993,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 VENTILATOR MODES FOR RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213475,0,TRUE,1
8144,Elearning-0000-104,2021 VENTILATOR MODES FOR RT FORSYTH,n14008,63993,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the 2021 VENTILATOR MODES FOR RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213476,1,FALSE,0
9560,Elearning-0000-786,ASV-1.1 FOR  RT FORSYTH,n14011,64064,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ASV-1.1 for RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213822,0,TRUE,1
9560,Elearning-0000-786,ASV-1.1 FOR  RT FORSYTH,n14011,64064,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the ASV-1.1 for RT FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213823,1,FALSE,0
9189,Elearning-0000-449,METANEB-IPV FORSYTH,n14012,64065,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the MetaNeb-IPV FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213824,0,TRUE,1
9189,Elearning-0000-449,METANEB-IPV FORSYTH,n14012,64065,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the MetaNeb-IPV FORSYTH CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213825,1,FALSE,0
8634,Elearning-0000-150,CONTINUOUS READINESS SUPPLY STORAGE,n14014,64067,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the CONTINUOUS READINESS SUPPLY STORAGE CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213828,0,TRUE,1
8634,Elearning-0000-150,CONTINUOUS READINESS SUPPLY STORAGE,n14014,64067,0,"For questions about these statements, contact your manager.<br><br>  I have reviewed the CONTINUOUS READINESS SUPPLY STORAGE CBL content.<br> I understand that I am responsible for the information.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br> I know where and how to get my questions answered about this topic.",213829,1,FALSE,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64068,0,Please list the location for this activity.,213830,0,Atlanta,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64068,0,Please list the location for this activity.,213831,1,Forsyth,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64068,0,Please list the location for this activity.,213832,2,Cherokee,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64068,0,Please list the location for this activity.,213833,3,Other,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64069,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",213834,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64069,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",213835,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64069,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",213836,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64069,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",213837,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64069,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",213838,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64070,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",213839,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64070,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",213840,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64070,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",213841,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64070,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",213842,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64070,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",213843,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64071,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",213844,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64071,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",213845,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64071,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",213846,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64071,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",213847,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64071,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",213848,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64072,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",213849,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64072,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",213850,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64072,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",213851,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64072,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",213852,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64072,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",213853,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64073,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",213854,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64073,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",213855,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64073,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",213856,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64073,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",213857,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64073,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",213858,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64074,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",213859,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64074,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",213860,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64074,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",213861,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64074,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",213862,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64074,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",213863,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64075,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",213864,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64075,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",213865,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64075,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",213866,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64075,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",213867,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64075,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",213868,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64076,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",213869,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64076,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",213870,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64076,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",213871,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64076,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",213872,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64076,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",213873,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64077,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",213874,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64077,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",213875,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64077,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",213876,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64077,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",213877,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64077,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",213878,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64078,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",213879,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64078,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",213880,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64078,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",213881,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64078,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",213882,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64078,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",213883,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64079,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",213884,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64079,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",213885,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64079,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",213886,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64079,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",213887,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64079,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",213888,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64080,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213889,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64080,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213890,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64080,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213891,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64080,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213892,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64080,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,213893,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64081,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,213894,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64081,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,213895,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64081,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,213896,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64081,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,213897,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64081,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,213898,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64082,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213899,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64082,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213900,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64082,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213901,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64082,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213902,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64082,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",213903,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64083,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",213904,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64083,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",213905,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64083,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",213906,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64083,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",213907,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64083,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",213908,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64084,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,213909,0,Strongly Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64084,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,213910,1,Agree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64084,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,213911,2,No Opinion,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64084,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,213912,3,Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64084,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,213913,4,Strongly Disagree,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64085,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",213914,0,Excellent,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64085,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",213915,1,Very Good,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64085,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",213916,2,Good,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64085,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",213917,3,Fair,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64085,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Mary King, BSN, RN-C, CCRN</ol>",213918,4,Poor,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64086,18,"Overall, this activity was:",213919,0,Excellent,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64086,18,"Overall, this activity was:",213920,1,Very Good,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64086,18,"Overall, this activity was:",213921,2,Good,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64086,18,"Overall, this activity was:",213922,3,Fair,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64086,18,"Overall, this activity was:",213923,4,Poor,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64087,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",213924,0,Yes,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64087,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",213925,1,No,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64087,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",213926,2,N/A,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64090,22,How would you improve this class?,213927,0,Reduce content covered in class,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64090,22,How would you improve this class?,213928,1,Increase content covered in class,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64090,22,How would you improve this class?,213929,2,Update content covered in class,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64090,22,How would you improve this class?,213930,3,Improve the instructional methods,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64090,22,How would you improve this class?,213931,4,Make course activities more stimulating,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64090,22,How would you improve this class?,213932,5,Slow the pace of the class,0
9893,Questions-0000-27,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 7-26-21,n14015,64090,22,How would you improve this class?,213933,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64115,0,"If a patient has a laryngectomy, the patient can be intubated through the mouth if mechanical ventilation is needed.",213991,0,TRUE,0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64115,0,"If a patient has a laryngectomy, the patient can be intubated through the mouth if mechanical ventilation is needed.",213992,1,FALSE,1
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64126,1,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",214021,0,"a)	All of the above",0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64126,1,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",214022,1,"b)	1, 3, 4",1
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64126,1,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",214023,2,"c)	2, 3, 4",0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64126,1,"Which statements are true for laryngectomy patients:<br> 1)	The patient should have an ETT placed through the neck stoma during a respiratory emergency.<br> 2)	The upper airway maintains communication with the lower airway and the patient may be intubated through the mouth if necessary.<br> 3)	A speaking valve should NEVER be used for a laryngectomy patient.<br> 4)	Bagging can only be performed through the neck with a pediatric mask",214024,3,"d)	1, 3",0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64127,2,"If the patient has a laryngectomy, what should be at the HOB?",214025,0,"a)	Fresh Trach sign",0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64127,2,"If the patient has a laryngectomy, what should be at the HOB?",214026,1,"b)	""I am a neck breather""ù sign",1
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64127,2,"If the patient has a laryngectomy, what should be at the HOB?",214027,2,"c)	Nothing needed at the HOB",0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64128,3,"If mechanical ventilation is necessary, an ETT should be placed through the stoma such that the balloon is nearly visible under the skin.",214028,0,TRUE,1
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64128,3,"If mechanical ventilation is necessary, an ETT should be placed through the stoma such that the balloon is nearly visible under the skin.",214029,1,FALSE,0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64129,4,What should be used to clean around the patient's laryngectomy stoma?,214030,0,"a)	Hydrogen peroxide",0
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64129,4,What should be used to clean around the patient's laryngectomy stoma?,214031,1,"b)	Sterile saline",1
9552,Elearning-0000-779,LARYNGECTOMY,n14023,64129,4,What should be used to clean around the patient's laryngectomy stoma?,214032,2,"c)	Tap water",0
9253,Elearning-0000-507,JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE FOR ACC & GCS,n14024,64130,0,"For questions about these statements, contact your manager or clinical specialist.<br><br>  I have reviewed the JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE for ACC & GCS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",214033,0,TRUE,1
9253,Elearning-0000-507,JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE FOR ACC & GCS,n14024,64130,0,"For questions about these statements, contact your manager or clinical specialist.<br><br>  I have reviewed the JULY 2021 POLICY & PROCEDURE ONCOLOGY NURSING UPDATE for ACC & GCS CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",214034,1,FALSE,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64131,0,Please list the location for this activity.,214035,0,Atlanta,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64131,0,Please list the location for this activity.,214036,1,Forsyth,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64131,0,Please list the location for this activity.,214037,2,Cherokee,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64131,0,Please list the location for this activity.,214038,3,Other,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64132,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",214039,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64132,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",214040,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64132,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",214041,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64132,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",214042,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64132,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to Identify areas of FHR interpretation that have consensus among individuals who interpret FHR tracings.</ol>",214043,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64133,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",214044,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64133,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",214045,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64133,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",214046,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64133,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",214047,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64133,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to outline a standardized approach to intervening for abnormal FHR patterns.</ol>",214048,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64134,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",214049,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64134,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",214050,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64134,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",214051,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64134,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",214052,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64134,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to associate clinical manifestations in conjunction with FHR patterns that hold increased clinical significance based upon the most common acute FHR emergencies.</ol>",214053,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64135,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",214054,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64135,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",214055,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64135,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",214056,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64135,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",214057,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64135,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to summarize key strategies that confirm that the electronic signal is of fetal origin on the fetal heart rate tracing.</ol>",214058,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64136,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",214059,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64136,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",214060,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64136,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",214061,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64136,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",214062,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64136,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe specific features of uterine contractions that determine uteroplacental perfusion and fetal oxygenation.</ol>",214063,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64137,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",214064,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64137,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",214065,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64137,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",214066,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64137,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",214067,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64137,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the relevance of the 30-minute rule in the setting of variant FHR patterns.</ol>",214068,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64138,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214069,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64138,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214070,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64138,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214071,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64138,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214072,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64138,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214073,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64139,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214074,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64139,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214075,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64139,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214076,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64139,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214077,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64139,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214078,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64140,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,214079,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64140,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,214080,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64140,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,214081,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64140,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,214082,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64140,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.</ol>,214083,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64141,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,214084,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64141,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,214085,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64141,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,214086,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64141,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,214087,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64141,10,<OL><B>ACTIVITY CONTENT</B></OL> <OL>I will change my practice as a result of this activity.</ol>,214088,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64142,11,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214089,0,Strongly Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64142,11,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214090,1,Agree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64142,11,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214091,2,No Opinion,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64142,11,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214092,3,Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64142,11,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214093,4,Strongly Disagree,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64143,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",214094,0,Excellent,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64143,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",214095,1,Very Good,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64143,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",214096,2,Good,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64143,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",214097,3,Fair,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64143,12,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Ginny Wurttemberg, MSN, RN </ol>",214098,4,Poor,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64144,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",214099,0,Excellent,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64144,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",214100,1,Very Good,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64144,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",214101,2,Good,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64144,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",214102,3,Fair,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64144,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Kristen Foshee, RNC-OB, CBC </ol>",214103,4,Poor,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64145,14,"Overall, this activity was:",214104,0,Excellent,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64145,14,"Overall, this activity was:",214105,1,Very Good,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64145,14,"Overall, this activity was:",214106,2,Good,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64145,14,"Overall, this activity was:",214107,3,Fair,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64145,14,"Overall, this activity was:",214108,4,Poor,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64146,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214109,0,Yes,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64146,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214110,1,No,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64146,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214111,2,N/A,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64149,18,How would you improve this class?,214112,0,Reduce content covered in class,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64149,18,How would you improve this class?,214113,1,Increase content covered in class,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64149,18,How would you improve this class?,214114,2,Update content covered in class,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64149,18,How would you improve this class?,214115,3,Improve the instructional methods,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64149,18,How would you improve this class?,214116,4,Make course activities more stimulating,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64149,18,How would you improve this class?,214117,5,Slow the pace of the class,0
9884,Questions-0000-18,ADVANCED ELECTRONIC FETAL MONITORING (EFM) (EVALUATION SURVEY)  7.29.21,n14025,64149,18,How would you improve this class?,214118,6,"Nothing: (appropriate speakers, content, setting, etc.)",0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64177,0,Please list the location for this activity.,214223,0,Atlanta,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64177,0,Please list the location for this activity.,214224,1,Forsyth,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64177,0,Please list the location for this activity.,214225,2,Cherokee,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64177,0,Please list the location for this activity.,214226,3,Other,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64178,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",214227,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64178,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",214228,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64178,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",214229,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64178,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",214230,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64178,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the elements of coaching in the new age of leadership.</ol>",214231,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64179,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",214232,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64179,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",214233,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64179,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",214234,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64179,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",214235,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64179,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to articulate the components of coaching.</ol>",214236,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64180,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",214237,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64180,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",214238,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64180,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",214239,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64180,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",214240,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64180,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the value of coaching as a fundamental part of the management process.<ol>",214241,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64181,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",214242,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64181,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",214243,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64181,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",214244,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64181,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",214245,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64181,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",214246,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64182,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214247,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64182,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214248,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64182,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214249,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64182,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214250,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64182,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214251,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64183,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,214252,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64183,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,214253,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64183,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,214254,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64183,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,214255,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64183,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge as it relates to the value of coaching as a fundamental part of the management process.<OL>,214256,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64184,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,214257,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64184,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,214258,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64184,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,214259,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64184,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,214260,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64184,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of confidence in my ability to apply coaching fundamentals to the exercise of leadership at every level of surgical services. </OL>,214261,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64185,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214262,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64185,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214263,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64185,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214264,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64185,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214265,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64185,8,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214266,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64186,9,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214267,0,Strongly Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64186,9,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214268,1,Agree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64186,9,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214269,2,No Opinion,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64186,9,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214270,3,Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64186,9,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214271,4,Strongly Disagree,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64187,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",214272,0,Excellent,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64187,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",214273,1,Very Good,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64187,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",214274,2,Good,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64187,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",214275,3,Fair,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64187,10,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rebecca Roe, MSN-Ed, RN CNOR</ol>",214276,4,Poor,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64188,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",214277,0,Excellent,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64188,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",214278,1,Very Good,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64188,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",214279,2,Good,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64188,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",214280,3,Fair,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64188,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Amy Fischer, BSN, RN</ol>",214281,4,Poor,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64189,12,"Overall, this activity was:",214282,0,Excellent,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64189,12,"Overall, this activity was:",214283,1,Very Good,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64189,12,"Overall, this activity was:",214284,2,Good,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64189,12,"Overall, this activity was:",214285,3,Fair,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64189,12,"Overall, this activity was:",214286,4,Poor,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64190,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214287,0,Yes,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64190,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214288,1,No,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64190,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214289,2,N/A,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64193,16,How would you improve this class?,214290,0,Reduce content covered in class,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64193,16,How would you improve this class?,214291,1,Increase content covered in class,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64193,16,How would you improve this class?,214292,2,Update content covered in class,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64193,16,How would you improve this class?,214293,3,Improve the instructional methods,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64193,16,How would you improve this class?,214294,4,Make course activities more stimulating,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64193,16,How would you improve this class?,214295,5,Slow the pace of the class,0
9873,Questions-0000-162,THE LEADER AS COACH (EVALUATION SURVEY) 8.2.21,n14027,64193,16,How would you improve this class?,214296,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64196,0,Please list the location for this activity.,214297,0,Atlanta,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64196,0,Please list the location for this activity.,214298,1,Cherokee,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64196,0,Please list the location for this activity.,214299,2,Forsyth,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64196,0,Please list the location for this activity.,214300,3,Other,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64197,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",214301,0,Strongly Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64197,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",214302,1,Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64197,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",214303,2,No Opinion,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64197,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",214304,3,Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64197,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to screen patients for the use of CBD-containing products and advise them regarding potential adverse effects.  </ol>",214305,4,Strongly Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64198,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214306,0,Strongly Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64198,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214307,1,Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64198,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214308,2,No Opinion,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64198,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214309,3,Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64198,2,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214310,4,Strongly Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64199,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,214311,0,Strongly Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64199,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,214312,1,Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64199,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,214313,2,No Opinion,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64199,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,214314,3,Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64199,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my level of knowledge as it relates to current cancer research.</OL>,214315,4,Strongly Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64200,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,214316,0,Strongly Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64200,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,214317,1,Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64200,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,214318,2,No Opinion,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64200,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,214319,3,Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64200,4,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my clinical decision-making confidence as it relates to the care of cancer patients.</OL>,214320,4,Strongly Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64201,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214321,0,Strongly Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64201,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214322,1,Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64201,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214323,2,No Opinion,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64201,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214324,3,Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64201,5,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214325,4,Strongly Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64202,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,214326,0,Strongly Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64202,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,214327,1,Agree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64202,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,214328,2,No Opinion,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64202,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,214329,3,Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64202,6,<OL><B>SETTING</B></OL> <OL>Facility or online training platform was appropriate for the activity</ol>,214330,4,Strongly Disagree,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64203,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",214331,0,Excellent,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64203,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",214332,1,Very Good,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64203,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",214333,2,Good,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64203,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",214334,3,Fair,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64203,7,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Rosemary McCabe, BSN, RN, OCN</ol>",214335,4,Poor,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64204,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",214336,0,Excellent,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64204,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",214337,1,Very Good,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64204,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",214338,2,Good,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64204,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",214339,3,Fair,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64204,8,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of  Michelle Homsy, BSN, RN, OCN</ol>",214340,4,Poor,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64205,9,"Overall, this activity was:",214341,0,Excellent,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64205,9,"Overall, this activity was:",214342,1,Very Good,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64205,9,"Overall, this activity was:",214343,2,Good,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64205,9,"Overall, this activity was:",214344,3,Fair,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64205,9,"Overall, this activity was:",214345,4,Poor,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64206,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214346,0,Yes,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64206,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214347,1,No,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64206,10,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214348,2,N/A,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64209,13,How would you improve this class?,214349,0,Reduce content covered in class,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64209,13,How would you improve this class?,214350,1,Increase content covered in class,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64209,13,How would you improve this class?,214351,2,Update content covered in class,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64209,13,How would you improve this class?,214352,3,Improve the instructional methods,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64209,13,How would you improve this class?,214353,4,Make course activities more stimulating,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64209,13,How would you improve this class?,214354,5,Slow the pace of the class,0
9944,Questions-0000-78,"NSF INFUSION CENTER JOURNAL CLUB - AUGUST  4TH, 2021 (EVALUATION SURVEY)",n14028,64209,13,How would you improve this class?,214355,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
8993,Elearning-0000-270,PHILIPS MONITOR INTELLIVUE EDUCATION MX400,n14029,64212,0,"I acknowledge that I have read this CBL in its entirety, and I understand how to properly navigate functionality on the Philips Monitor IntellliVue MX400.",214356,0,TRUE,1
8993,Elearning-0000-270,PHILIPS MONITOR INTELLIVUE EDUCATION MX400,n14029,64212,0,"I acknowledge that I have read this CBL in its entirety, and I understand how to properly navigate functionality on the Philips Monitor IntellliVue MX400.",214357,1,FALSE,0
9586,Elearning-0000-81,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3,n14030,64213,0,"Please vote for one of the following staff members for the Clinical Excellence Award FY 21 Q 3,  Ni Aung or Jummy Kareem",214358,0,Ni Aung,1
9586,Elearning-0000-81,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3,n14030,64213,0,"Please vote for one of the following staff members for the Clinical Excellence Award FY 21 Q 3,  Ni Aung or Jummy Kareem",214359,1,Jummy Kareem,1
9586,Elearning-0000-81,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3,n14030,64214,1,"Please vote for one of the following staff members for the Unit star FY 21 Q 3,  Angie Dixon or Sabrena Sanders",214360,0,Angie Dixon,1
9586,Elearning-0000-81,WSU CLINICAL EXCELLENCE _UNIT STAR AWARDS FY_21_Q3,n14030,64214,1,"Please vote for one of the following staff members for the Unit star FY 21 Q 3,  Angie Dixon or Sabrena Sanders",214361,1,Sabrena Sanders,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64216,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage.,214364,0,TRUE,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64216,0,The OB Hemorrhage Cart is a key component to achieving rapid access to medications supplies needed during a postpartum hemorrhage.,214365,1,FALSE,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64217,1,Hemorrhage carts will be located,214366,0,FCC,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64217,1,Hemorrhage carts will be located,214367,1,L&D,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64217,1,Hemorrhage carts will be located,214368,2,L&D only,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64217,1,Hemorrhage carts will be located,214369,3,Both A&B,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64218,2,The OB Hemorrhage Cart is secured by:,214370,0,A zip tie,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64218,2,The OB Hemorrhage Cart is secured by:,214371,1,2 Digital locks,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64218,2,The OB Hemorrhage Cart is secured by:,214372,2,Red security seal,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64218,2,The OB Hemorrhage Cart is secured by:,214373,3,B and C,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64218,2,The OB Hemorrhage Cart is secured by:,214374,4,All of the above,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64219,3,Medications are stored in the OB Hemorrhage Cart,214375,0,TRUE,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64219,3,Medications are stored in the OB Hemorrhage Cart,214376,1,FALSE,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64220,4,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,214377,0,Red,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64220,4,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,214378,1,Yellow,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64220,4,What color seal should be placed over the lock bar on the cart to indicate is has been opened and cannot be used?,214379,2,Green,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64221,5,How frequently should the cart thermometer be checked?,214380,0,Once a day,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64221,5,How frequently should the cart thermometer be checked?,214381,1,Every shift,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64221,5,How frequently should the cart thermometer be checked?,214382,2,Once a week,0
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64222,6,"If a patient is transferred during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",214383,0,TRUE,1
9651,Elearning-0000-869,FY2021 OB HEMORRHAGE CART - NSF,n14032,64222,6,"If a patient is transferred during use of a hemorrhage cart, the hemorrhage cart should be transferred with the patient.",214384,1,FALSE,0
9601,Elearning-0000-823,HAND HYGIENE ATTESTATION 2021,n14039,64233,0,I have reviewed the hospital Hand Hygiene Policy and this CBL. I attest that I will speak up if I witness any break in proper Hand Hygiene.,214406,0,TRUE,1
9601,Elearning-0000-823,HAND HYGIENE ATTESTATION 2021,n14039,64233,0,I have reviewed the hospital Hand Hygiene Policy and this CBL. I attest that I will speak up if I witness any break in proper Hand Hygiene.,214407,1,FALSE,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64235,0,Rituxan Hycela © is available in:,214410,0,a. 11..7 ml vial,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64235,0,Rituxan Hycela © is available in:,214411,1,b. 13.4 ml vial,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64235,0,Rituxan Hycela © is available in:,214412,2,c. 15.5 ml vial,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64235,0,Rituxan Hycela © is available in:,214413,3,d. a and b,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64236,1,A loading dose is required for Herceptin Hylecta ©,214414,0,a. True,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64236,1,A loading dose is required for Herceptin Hylecta ©,214415,1,b. False,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64237,2,Which of the following is correct about Darzalex Faspro ©?,214416,0,"a. Contains 1800 mg Darzalex/30,000units Hyaluronic acid in 15 ml.",1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64237,2,Which of the following is correct about Darzalex Faspro ©?,214417,1,b. Administration requires an infusion pump.,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64237,2,Which of the following is correct about Darzalex Faspro ©?,214418,2,c. Requires successful completion of a Darzalex © IV dose prior to administration of Darzalex Faspro ©.,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64237,2,Which of the following is correct about Darzalex Faspro ©?,214419,3,"d-	Requires premeds be given at least one hour before dose.",0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64238,3,Which technique is used to increase bioavailability of a subcutaneous combination of biological drug with enzyme rHuPH20 in oncology treatment?,214420,0,"a. The two components are administered sequentially through the same needle, with rHuPH20 introduced first, followed by the immunoglobulin.",0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64238,3,Which technique is used to increase bioavailability of a subcutaneous combination of biological drug with enzyme rHuPH20 in oncology treatment?,214421,1,b. rHuPH20 is co-formulated with the subcutaneous active biotherapeutic.,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64238,3,Which technique is used to increase bioavailability of a subcutaneous combination of biological drug with enzyme rHuPH20 in oncology treatment?,214422,2,c. CADD pump administration allows for continuous SC administration,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64239,4,Fixed dosing for subcutaneous mABs is considered a drawback although it is more efficient and more convenient,214423,0,a. True,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64239,4,Fixed dosing for subcutaneous mABs is considered a drawback although it is more efficient and more convenient,214424,1,b. False,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64240,5,Herceptin Hylecta © is injected SC over:,214425,0,a. 2-5 min,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64240,5,Herceptin Hylecta © is injected SC over:,214426,1,b. 5 min,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64240,5,Herceptin Hylecta © is injected SC over:,214427,2,c. 10-15 min,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64240,5,Herceptin Hylecta © is injected SC over:,214428,3,d. 20-30 min,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64241,6,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",214429,0,a. Cost savings opportunities,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64241,6,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",214430,1,b. Shorter administration time,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64241,6,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",214431,2,c. Decreased patient discomfort,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64241,6,"Although the pharmacokinetic profiles of IV and SC formulations are different, SC formulations are preferred by patients and healthcare providers for the following reasons:",214432,3,d. All of the above,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64242,7,Rituxan Hycela using the new subcutaneous novel administration technique:,214433,0,a. Requires administration of a BSA- adjusted intravenous Rituxan © dose prior to Rituxan Hycela ©.,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64242,7,Rituxan Hycela using the new subcutaneous novel administration technique:,214434,1,b. Requires a 1400mg loading dose for follicular lymphoma.,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64242,7,Rituxan Hycela using the new subcutaneous novel administration technique:,214435,2,c. Has flat 1600mg dose for all indications,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64242,7,Rituxan Hycela using the new subcutaneous novel administration technique:,214436,3,d. Is interchangeable with Rituxan IV,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64243,8,Phesgo 600mg x 2 is interchangeable with Phesgo 1200mg. Either may be used for loading dose.,214437,0,a. True,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64243,8,Phesgo 600mg x 2 is interchangeable with Phesgo 1200mg. Either may be used for loading dose.,214438,1,b. False,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64244,9,Subcutaneous biologics are administered at home for all of the following diseases except:,214439,0,a. Rheumatoid Arthritis,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64244,9,Subcutaneous biologics are administered at home for all of the following diseases except:,214440,1,b. Multiple Sclerosis,0
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64244,9,Subcutaneous biologics are administered at home for all of the following diseases except:,214441,2,c. Cancer,1
9657,Elearning-0000-874,2021 NOVEL SUBCUTANEOUS BIOLOGICS,n14042,64244,9,Subcutaneous biologics are administered at home for all of the following diseases except:,214442,3,d. Diabetes,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64245,0,The magnitude of increase in red blood cell concentration is primarily controlled by the length of time erythropoietin concentrations are maintained.,214443,0,TRUE,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64245,0,The magnitude of increase in red blood cell concentration is primarily controlled by the length of time erythropoietin concentrations are maintained.,214444,1,FALSE,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64246,1,All are appropriate uses of ESAs except,214445,0,a. Anemia of chronic kidney disease,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64246,1,All are appropriate uses of ESAs except,214446,1,b. Myelodysplastic syndrome,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64246,1,All are appropriate uses of ESAs except,214447,2,c. Zidovudine treated HIV+ patients,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64246,1,All are appropriate uses of ESAs except,214448,3,d. Acute renal failure,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64247,2,"Typically, increases in hemoglobin, red blood cells and hematocrit are not seen for 2-6 weeks after beginning therapy.",214449,0,TRUE,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64247,2,"Typically, increases in hemoglobin, red blood cells and hematocrit are not seen for 2-6 weeks after beginning therapy.",214450,1,FALSE,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64248,3,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,214451,0,a. CKD patients on hemodialysis,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64248,3,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,214452,1,b. CKD patients not on hemodialysis,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64248,3,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,214453,2,c. Chemotherapy induced anemia,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64248,3,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,214454,3,d. B and C,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64248,3,ESAs should only be initiated when hemoglobin levels fall below 10g/dl for,214455,4,"e. A, B and C",1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64249,4,Greater biological response to ESAs is not observed at doses exceeding,214456,0,a. 120 units/kg three times weekly,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64249,4,Greater biological response to ESAs is not observed at doses exceeding,214457,1,b. 200 units/kg three times weekly,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64249,4,Greater biological response to ESAs is not observed at doses exceeding,214458,2,c. 300 units/kg three times weekly,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64249,4,Greater biological response to ESAs is not observed at doses exceeding,214459,3,d. 500 units/kg three times weekly,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64250,5,"In almost all published studies, subcutaneous administration of ESAs in chronic kidney disease is associated with a 25-50% EPO dose reduction compared to IV administration.",214460,0,TRUE,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64250,5,"In almost all published studies, subcutaneous administration of ESAs in chronic kidney disease is associated with a 25-50% EPO dose reduction compared to IV administration.",214461,1,FALSE,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64251,6,ESAs have been shown to improve quality of life in patients with chemotherapy induced anemia.,214462,0,TRUE,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64251,6,ESAs have been shown to improve quality of life in patients with chemotherapy induced anemia.,214463,1,FALSE,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64252,7,Administration of iron helps to,214464,0,a. Achieve and maintain goal hemoglobin levels,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64252,7,Administration of iron helps to,214465,1,b. Prevent iron deficiencies,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64252,7,Administration of iron helps to,214466,2,c. Minimize the dose of ESA needed,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64252,7,Administration of iron helps to,214467,3,d. All of the above,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64253,8,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,214468,0,a. Hemoglobin > 12 g/dL,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64253,8,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,214469,1,b. Hemoglobin >11 g/dL,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64253,8,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,214470,2,c. Hemoglobin >10 g/dL,0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64253,8,When would it be appropriate to recommend holding the dose of ESA in a CKD patient not on hemodialysis?,214471,3,d. All of the above,1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64254,9,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,214472,0,"a. fever, chills",0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64254,9,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,214473,1,"b. backache, myalgia",0
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64254,9,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,214474,2,"c. sweating, excessive lacrimation",1
9629,Elearning-0000-849,RPH UPDATE ON RBCGFS 2021,n14043,64254,9,Systemic reactions may occur during or following intravenous iron administration and include all of the following except:,214475,3,"d. dizziness, syncope",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214476,0,A. Ask her about her side effects and tell her to continue the way she is taking them.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214476,0,A. Ask her about her side effects and tell her to continue the way she is taking them.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214477,1,B. Tell her that she must stop immediately and make an appointment to see the MD.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214477,1,B. Tell her that she must stop immediately and make an appointment to see the MD.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214478,2,C. Document your call in EMR and notify the Physician/RN directly.  Instruct the patient to contact the office to discuss dose change with the Physician.,1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214478,2,C. Document your call in EMR and notify the Physician/RN directly.  Instruct the patient to contact the office to discuss dose change with the Physician.,1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214479,3,D. Do nothing because some medication is better than her not taking it at all.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64255,0,Ms Jones has been taking Xeloda for 3 months and her prescription says 4 tablets in the morning and 3 tablets in the evening. During your call she tells you that she has been taking 2 tablets every 12 hours because it doesn't make her feel well. <br><br> What do you do?,214479,3,D. Do nothing because some medication is better than her not taking it at all.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214480,0,"A. Patient name, patient's DOB, doctor's name, and medication",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214480,0,"A. Patient name, patient's DOB, doctor's name, and medication",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214481,1,"B. Patient name, your name, your title, patient's medication, patient's medical record number, and doctor's name, and office location",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214481,1,"B. Patient name, your name, your title, patient's medication, patient's medical record number, and doctor's name, and office location",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214482,2,"C. Patient name, your name, your title, and clinic's name",1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214482,2,"C. Patient name, your name, your title, and clinic's name",1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214483,3,"D. Doctor's name, office location, patient's name, patient's DOB, date of therapy, and name of medication",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64256,1,Mr Depp does not pick up the phone and you would like to leave a message. What information can you leave on the voicemail?,214483,3,"D. Doctor's name, office location, patient's name, patient's DOB, date of therapy, and name of medication",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214484,0,"A. Yes, you can double your dose any time you miss a dose as long as you don't take more than 2 days together.",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214484,0,"A. Yes, you can double your dose any time you miss a dose as long as you don't take more than 2 days together.",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214485,1,"B. No, you should never double the dose of your medication. Skip the missed dose if it's too close to your next dose or take the missed dose as soon as you remember if it's not too close to your next dose.",1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214485,1,"B. No, you should never double the dose of your medication. Skip the missed dose if it's too close to your next dose or take the missed dose as soon as you remember if it's not too close to your next dose.",1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214486,2,"C. Yes, you can take as many doses as needed to get back on schedule.",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214486,2,"C. Yes, you can take as many doses as needed to get back on schedule.",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214487,3,"D. No, don't double the dose. Skip a day as a wash out and start your therapy again from day 1.",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64257,2,Ms Cruise has been on vacation and missed her first day of Gleevec therapy. She asks you if she can take 2 the following day like she used to do with her birth control. What would you recommend?,214487,3,"D. No, don't double the dose. Skip a day as a wash out and start your therapy again from day 1.",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214488,0,A. Counsel her on the side effects of therapy and let her know to call the office with any questions and document your call in EMR.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214488,0,A. Counsel her on the side effects of therapy and let her know to call the office with any questions and document your call in EMR.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214489,1,B. Remind the patient that the medication is most effective when it is taken as prescribed by the physician. Notify the physician and nursing staff she is having financial barriers to therapy and look into potential solutions or financial assistance and document your call in EMR.,1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214489,1,B. Remind the patient that the medication is most effective when it is taken as prescribed by the physician. Notify the physician and nursing staff she is having financial barriers to therapy and look into potential solutions or financial assistance and document your call in EMR.,1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214490,2,"C. Let her know that instead of taking her medication every other day, she can open the capsules and only take half so that it will last her the duration of therapy.",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214490,2,"C. Let her know that instead of taking her medication every other day, she can open the capsules and only take half so that it will last her the duration of therapy.",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214491,3,D. Document her change in therapy in the EMR but don't say anything to the physician or nursing staff.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64258,3,Ms Jackson has just started taking Alecensa and has told you that it's too expensive so she picked up her refill but plans on taking it every other day to make it last longer. <br><br> What do you recommend?,214491,3,D. Document her change in therapy in the EMR but don't say anything to the physician or nursing staff.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214492,0,"A. Advise him that medications should never be shared and he should call the local drug take back center, take it to a local medication drop off unit in the community, or contact the pharmacy for instructions on proper disposal.",1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214492,0,"A. Advise him that medications should never be shared and he should call the local drug take back center, take it to a local medication drop off unit in the community, or contact the pharmacy for instructions on proper disposal.",1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214493,1,B. Tell him it's all right as long as you can call the other patient to verify the dose of his therapy.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214493,1,B. Tell him it's all right as long as you can call the other patient to verify the dose of his therapy.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214494,2,C. Instruct him to bring the medication back to the office and you will dispose of it for him.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214494,2,C. Instruct him to bring the medication back to the office and you will dispose of it for him.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214495,3,"D. Tell him he can choose any of the above options, depending on what suits him the best.",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64259,4,Mr Brown tells you that the physician has changed his therapy and he no longer needs his Cabometyx. He tells you that he met another patient in his support group that is taking the same medication and wants to give him the remaining pills.<br><br> What do you recommend?,214495,3,"D. Tell him he can choose any of the above options, depending on what suits him the best.",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214496,0,A. Make an appointment with her to discuss her medication and counsel her.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214496,0,A. Make an appointment with her to discuss her medication and counsel her.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214497,1,B. Refer her to the retail pharmacy because only certain pharmacists are authorized to counsel a patient on Revlimid due to the REMS program.,1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214497,1,B. Refer her to the retail pharmacy because only certain pharmacists are authorized to counsel a patient on Revlimid due to the REMS program.,1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214498,2,C. Tell her that you cannot speak to her currently but you can set up a date/time to counsel her over the phone.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214498,2,C. Tell her that you cannot speak to her currently but you can set up a date/time to counsel her over the phone.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214499,3,D. Tell her you have a few minutes and can discuss her Revlimid now.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64260,5,Ms Price is currently taking Revlimid and wants to make an appointment with you to counsel her on her medication. <br><br> Which response <u>would not</u> be appropriate?,214499,3,D. Tell her you have a few minutes and can discuss her Revlimid now.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214500,0,"A.	I, II, IV",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214500,0,"A.	I, II, IV",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214501,1,"B.	I, II, III, IV",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214501,1,"B.	I, II, III, IV",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214502,2,"C.	III, IV",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214502,2,"C.	III, IV",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214503,3,"D.	II, III",1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64261,6,"Choose the best type of questions to use when counseling a patient from the questions below.<br><br>  I. ""Are you having any problems with your medication?""ù<br> II. ""What did your provider tell you to expect while on therapy?""ù<br> III. ""What side effects will you be looking out for while on this medication?""ù<br> IV. ""Do you have any questions?""ù<br><br>",214503,3,"D.	II, III",1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214504,0,A. Building a strong pharmacist-patient relationship.,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214504,0,A. Building a strong pharmacist-patient relationship.,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214505,1,"B. Recognizing barriers to therapy such as drug cost, inability to swallow pills, etc.",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214505,1,"B. Recognizing barriers to therapy such as drug cost, inability to swallow pills, etc.",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214506,2,C. Increased potential for drug toxicity,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214506,2,C. Increased potential for drug toxicity,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214507,3,D. A & B,1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214507,3,D. A & B,1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214508,4,E. All of the above,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64262,7,What is the pharmacist's role in oral medication adherence?,214508,4,E. All of the above,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214509,0,"A.  Review patient's past and current course of therapy, identify correct treatment plan, appropriate dose, and need for dose adjustments",0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214509,0,"A.  Review patient's past and current course of therapy, identify correct treatment plan, appropriate dose, and need for dose adjustments",0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214510,1,B. Document the topics that you would like to discuss with the patient,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214510,1,B. Document the topics that you would like to discuss with the patient,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214511,2,C. Familiarize yourself with patient's medication,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214511,2,C. Familiarize yourself with patient's medication,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214512,3,D. A &C,1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214512,3,D. A &C,1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214513,4,E. None of the above,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64263,8,"Prior to calling a patient, make sure to do the following:",214513,4,E. None of the above,0
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64264,9,"True or False: All Adverse events, lack of compliance, or any other issue should be communicated to the physician and/or nursing staff and documented in the EMR.",214514,0,TRUE,1
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64264,9,"True or False: All Adverse events, lack of compliance, or any other issue should be communicated to the physician and/or nursing staff and documented in the EMR.",214514,0,TRUE,1
9631,Elearning-0000-850,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64264,9,"True or False: All Adverse events, lack of compliance, or any other issue should be communicated to the physician and/or nursing staff and documented in the EMR.",214515,1,FALSE,0
9993,Elearning-0000-1764,2021 RPH ORAL CHEMOTHERAPY ADHERENCE CALLS,n14044,64264,9,"True or False: All Adverse events, lack of compliance, or any other issue should be communicated to the physician and/or nursing staff and documented in the EMR.",214515,1,FALSE,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64266,0,Please list the location for this activity.,214518,0,Atlanta,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64266,0,Please list the location for this activity.,214519,1,Forsyth,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64266,0,Please list the location for this activity.,214520,2,Cherokee,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64266,0,Please list the location for this activity.,214521,3,Other,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64267,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",214522,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64267,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",214523,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64267,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",214524,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64267,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",214525,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64267,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the cardiac anatomy and physiology. </ol>",214526,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64268,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",214527,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64268,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",214528,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64268,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",214529,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64268,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",214530,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64268,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to demonstrate proper application of ECG leads.</ol>",214531,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64269,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",214532,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64269,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",214533,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64269,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",214534,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64269,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",214535,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64269,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review Northside Hospitals' Telemetry Monitoring Policies and Procedures.</ol>",214536,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64270,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",214537,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64270,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",214538,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64270,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",214539,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64270,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",214540,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64270,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to review selected-cardiac dysrhythmias and appropriate nursing interventions.</ol>",214541,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64271,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",214542,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64271,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",214543,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64271,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",214544,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64271,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",214545,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64271,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Bundle Branch Blocks and appropriate nursing interventions.</ol>",214546,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64272,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",214547,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64272,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",214548,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64272,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",214549,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64272,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",214550,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64272,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe signs and symptoms of Acute MI and Nursing Interventions.</ol>",214551,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64273,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",214552,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64273,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",214553,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64273,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",214554,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64273,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",214555,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64273,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe Life Threatening Dysthymias and Nursing Interventions. </ol>",214556,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64274,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214557,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64274,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214558,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64274,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214559,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64274,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214560,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64274,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214561,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64275,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,214562,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64275,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,214563,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64275,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,214564,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64275,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,214565,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64275,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge in caring for patients on telemetry cardiac monitoring.</OL>,214566,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64276,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214567,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64276,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214568,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64276,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214569,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64276,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214570,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64276,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214571,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64277,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214572,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64277,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214573,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64277,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214574,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64277,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214575,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64277,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",214576,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64278,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214577,0,Strongly Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64278,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214578,1,Agree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64278,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214579,2,No Opinion,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64278,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214580,3,Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64278,12,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,214581,4,Strongly Disagree,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64279,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",214582,0,Excellent,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64279,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",214583,1,Very Good,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64279,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",214584,2,Good,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64279,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",214585,3,Fair,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64279,13,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, BSN, RN, CCRN_K</ol>",214586,4,Poor,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64280,14,"Overall, this activity was:",214587,0,Excellent,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64280,14,"Overall, this activity was:",214588,1,Very Good,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64280,14,"Overall, this activity was:",214589,2,Good,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64280,14,"Overall, this activity was:",214590,3,Fair,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64280,14,"Overall, this activity was:",214591,4,Poor,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64281,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214592,0,Yes,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64281,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214593,1,No,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64281,15,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214594,2,N/A,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64284,18,How would you improve this class?,214595,0,Reduce content covered in class,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64284,18,How would you improve this class?,214596,1,Increase content covered in class,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64284,18,How would you improve this class?,214597,2,Update content covered in class,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64284,18,How would you improve this class?,214598,3,Improve the instructional methods,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64284,18,How would you improve this class?,214599,4,Make course activities more stimulating,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64284,18,How would you improve this class?,214600,5,Slow the pace of the class,0
9955,Questions-0000-89,NURSING IMPLICATIONS FOR THE PATIENT ON TELEMETRY MONITORING (EVALUATION SURVEY) ONLINE 8-4-21,n14046,64284,18,How would you improve this class?,214601,6,"Nothing: (appropriate content, speaker, setting, setting.)",0
228,SCORM-0000-34,FIRE SAFETY ORIENTATION UPDATED (2021),n14047,47181,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",154286,0,TRUE,1
228,SCORM-0000-34,FIRE SAFETY ORIENTATION UPDATED (2021),n14047,47181,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",154287,1,FALSE,0
228,SCORM-0000-34,FIRE SAFETY ORIENTATION UPDATED (2021),n14047,65073,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation Updated (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",217384,0,TRUE,1
228,SCORM-0000-34,FIRE SAFETY ORIENTATION UPDATED (2021),n14047,65073,1,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the ""Fire Safety Orientation Updated (2021)"" CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",217385,1,FALSE,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64288,0,True or False?  When you come to work you are onstage?,214604,0,TRUE,1
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64288,0,True or False?  When you come to work you are onstage?,214605,1,FALSE,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64289,2,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,214606,0,a. Legendary attention to detail,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64289,2,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,214607,1,b. Exceeding people's expectations,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64289,2,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,214608,2,c. Being customer/patient centered,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64289,2,Good customer service is taking the extra step to help without being asked. It's all about attitude and skills. It includes:,214609,3,d. All of the above,1
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64290,1,When looking for solutions focus on short term solution instead of long term solutions,214610,0,TRUE,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64290,1,When looking for solutions focus on short term solution instead of long term solutions,214611,1,FALSE,1
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64291,3,True or False? Never let backstage come onstage,214612,0,TRUE,1
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64291,3,True or False? Never let backstage come onstage,214613,1,FALSE,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64292,4,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,214614,0,a. 90 seconds,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64292,4,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,214615,1,b. 30 seconds,1
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64292,4,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,214616,2,c. 60 seconds,0
9392,Elearning-0000-633,FCC CHEROKEE ONSTAGE BEHAVIORS-MAKING A GREAT FIRST IMPRESSION 2021,n14049,64292,4,People make judgements in the first ___________ seconds! You only have one Chance to make aGREAT first impression!,214617,3,d. 15 seconds,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64293,0,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,214618,0,"a.	Occupational Safety and Health Administration",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64293,0,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,214619,1,"b.	Environmental Protection Agency",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64293,0,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,214620,2,"c.	U.S. Food and Drug Administration",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64293,0,Chapter 5:  Regulations and Standards<br> Agency which may intervene in a matter of worker protection even if there are no specific regulations covering the situation.,214621,3,"d.	Association of perioperative Registered Nurses",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64294,1,Regulations under the Clean Air Act are administered by the,214622,0,"a.	Occupational Safety and Health Administration",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64294,1,Regulations under the Clean Air Act are administered by the,214623,1,"b.	U.S. Food and Drug Administration",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64294,1,Regulations under the Clean Air Act are administered by the,214624,2,"c.	Environmental Protection Agency",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64294,1,Regulations under the Clean Air Act are administered by the,214625,3,"d.	Association of periOperative Registered Nurses",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64295,2,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,214626,0,"a.	Occupational Safety and Health Administration",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64295,2,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,214627,1,"b.	U.S. Food and Drug Administration",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64295,2,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,214628,2,"c.	Environmental Protection Agency",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64295,2,The agency which imposes very strict labeling requirements on manufacturers of disinfectants used by Central Service departments.,214629,3,"d.	Association for the Advancement of Medical Instrumentation",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64296,3,Healthcare regulations and standards establish,214630,0,"a.	minimal levels of quality and safety",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64296,3,Healthcare regulations and standards establish,214631,1,"b.	equal pay practices",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64296,3,Healthcare regulations and standards establish,214632,2,"c.	productivity time lines",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64296,3,Healthcare regulations and standards establish,214633,3,"d.	all of the above",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64297,4,Chemical indicators are classified as,214634,0,"a.	FDA Class I medical devices",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64297,4,Chemical indicators are classified as,214635,1,"b.	FDA Class II medical devices",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64297,4,Chemical indicators are classified as,214636,2,"c.	FDA Class III medical devices",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64297,4,Chemical indicators are classified as,214637,3,"d.	None, not regulatory by FDA",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64298,5,Heart valves and pacemakers are example of,214638,0,"a.	FDA Class I medical devices",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64298,5,Heart valves and pacemakers are example of,214639,1,"b.	FDA Class II medical devices",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64298,5,Heart valves and pacemakers are example of,214640,2,"c.	FDA Class III medical devices",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64298,5,Heart valves and pacemakers are example of,214641,3,"d.	None, not regulatory by FDA",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64299,6,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",214642,0,"a.	Device manufacturer",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64299,6,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",214643,1,"b.	Hospitals",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64299,6,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",214644,2,"c.	All of the above",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64299,6,"Under current regulations, who is required to report suspected medical device related deaths to the U.S. Food and Drug Administration?",214645,3,"d.	None of the above",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64300,7,Standards and regulations help set levels of ___________________________ in our departments.,214646,0,"a.	quality",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64300,7,Standards and regulations help set levels of ___________________________ in our departments.,214647,1,"b.	safety",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64300,7,Standards and regulations help set levels of ___________________________ in our departments.,214648,2,"c.	efficiency",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64300,7,Standards and regulations help set levels of ___________________________ in our departments.,214649,3,"d.	both quality and safety",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64301,8,Medical device reporting is regulated by the,214650,0,"a.	National Fire Protection Associated",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64301,8,Medical device reporting is regulated by the,214651,1,"b.	Environmental Protection Agency",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64301,8,Medical device reporting is regulated by the,214652,2,"c.	World Health Organization",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64301,8,Medical device reporting is regulated by the,214653,3,"d.	U.S. Food and Drug Administration",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64302,9,The Department of Transportation enforces statutes relating to the,214654,0,"a.	transportation of clean and soiled instruments between facilities",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64302,9,The Department of Transportation enforces statutes relating to the,214655,1,"b.	transportation of medical supplies for emergency use",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64302,9,The Department of Transportation enforces statutes relating to the,214656,2,"c.	transportation of equipment for the decontamination area",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64302,9,The Department of Transportation enforces statutes relating to the,214657,3,"d.	transportation of instrumentation across state lines",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64308,10,"Sometimes state or local regulations differ from Federal regulations and when that happens, the most stringent regulations apply.",214676,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64308,10,"Sometimes state or local regulations differ from Federal regulations and when that happens, the most stringent regulations apply.",214677,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64309,11,It is optional to allow the Occupational Safety and Health Administration's regulation for wearing personal protective equipment in the Central Service decontamination area.,214678,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64309,11,It is optional to allow the Occupational Safety and Health Administration's regulation for wearing personal protective equipment in the Central Service decontamination area.,214679,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64310,12,Third-party reprocessors are regulated by the U.S. Food and Drug Administration.,214680,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64310,12,Third-party reprocessors are regulated by the U.S. Food and Drug Administration.,214681,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64311,13,Recommendations regarding sterilization practices are provided by the Association for the Advancement of Medical Instrumentation.,214682,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64311,13,Recommendations regarding sterilization practices are provided by the Association for the Advancement of Medical Instrumentation.,214683,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64312,14,The Occupational Safety and Health Administration is a voluntary association dedicated to infection control and prevention.,214684,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64312,14,The Occupational Safety and Health Administration is a voluntary association dedicated to infection control and prevention.,214685,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64313,15,Failure to receive accreditation from The Joint Commission can result in the loss of Medicare and Medicaid payments.,214686,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64313,15,Failure to receive accreditation from The Joint Commission can result in the loss of Medicare and Medicaid payments.,214687,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64314,16,The Society of Gastroenterology Nurses and Associates is a source for information about the proper processing of flexible endoscopes.,214688,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64314,16,The Society of Gastroenterology Nurses and Associates is a source for information about the proper processing of flexible endoscopes.,214689,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64315,17,Class III medical devices are identified as high risk.,214690,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64315,17,Class III medical devices are identified as high risk.,214691,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64316,18,Reuse of single use medical devices is less regulated now than it was in the 1990's.,214692,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64316,18,Reuse of single use medical devices is less regulated now than it was in the 1990's.,214693,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64317,19,The U.S. Food and Drug Administration recalls may be either mandatory or voluntary.,214694,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64317,19,The U.S. Food and Drug Administration recalls may be either mandatory or voluntary.,214695,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64318,20,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",214696,0,"a.	placed in an uptight position",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64318,20,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",214697,1,"b.	loaded first",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64318,20,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",214698,2,"c.	placed on edge",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64318,20,"Chapter 14:  High-Temperature Sterilization<br>  When loading a steam sterilizer, basins should be",214699,3,"d.	placed in a wire basket",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64319,21,The higher bioburden on an object,214700,0,"a.	the more difficult it will be to sterilize",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64319,21,The higher bioburden on an object,214701,1,"b.	the less time it will take to sterilize it",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64319,21,The higher bioburden on an object,214702,2,"c.	the more biological tests will be needed in the load",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64319,21,The higher bioburden on an object,214703,3,"d.	the longer it will take to cool after sterilization",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64320,22,"When combining loads, hard goods should be placed on the top shelves to allow for more efficient removal of the condensate.",214704,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64320,22,"When combining loads, hard goods should be placed on the top shelves to allow for more efficient removal of the condensate.",214705,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64321,23,The steam sterilization process can be affected by the design of the medical device being sterilized.,214706,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64321,23,The steam sterilization process can be affected by the design of the medical device being sterilized.,214707,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64322,24,Central Service technicians need to understand the anatomy of a steam sterilizer to,214708,0,"a.	know how to properly clean the chamber",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64322,24,Central Service technicians need to understand the anatomy of a steam sterilizer to,214709,1,"b.	understand how the sterilizer operates",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64322,24,Central Service technicians need to understand the anatomy of a steam sterilizer to,214710,2,"c.	understand how to test the thermostatic trap",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64322,24,Central Service technicians need to understand the anatomy of a steam sterilizer to,214711,3,"d.	know how to properly maintain the jacket",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64323,25,The weakest part of a steam sterilizer is the,214712,0,"a.	jacket",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64323,25,The weakest part of a steam sterilizer is the,214713,1,"b.	gasket",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64323,25,The weakest part of a steam sterilizer is the,214714,2,"c.	door",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64323,25,The weakest part of a steam sterilizer is the,214715,3,"d.	thermostatic valve",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64324,26,Three of the main phases of a terminal steam sterilizer cycle are,214716,0,"a.	gravity, exposure and exhaust",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64324,26,Three of the main phases of a terminal steam sterilizer cycle are,214717,1,"b.	pre-vacuum, exposure and exhaust",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64324,26,Three of the main phases of a terminal steam sterilizer cycle are,214718,2,"c.	exposure, exhaust and dry",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64324,26,Three of the main phases of a terminal steam sterilizer cycle are,214719,3,"d.	conditioning, exposure and exhaust",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64325,27,The most common reason for steam sterilization failure is,214720,0,"a.	lack of steam contact with the instrument",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64325,27,The most common reason for steam sterilization failure is,214721,1,"b.	insufficient temperature",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64325,27,The most common reason for steam sterilization failure is,214722,2,"c.	inadequate exposure time",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64325,27,The most common reason for steam sterilization failure is,214723,3,"d.	drying issues",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64326,28,The coolest place in a steam sterilizer is the,214724,0,"a.	gasket",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64326,28,The coolest place in a steam sterilizer is the,214725,1,"b.	thermostatic trap",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64326,28,The coolest place in a steam sterilizer is the,214726,2,"c.	jacket",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64326,28,The coolest place in a steam sterilizer is the,214727,3,"d.	chamber",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64327,29,Steam flush pressure pulse sterilizers are a type of gravity sterilizers,214728,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64327,29,Steam flush pressure pulse sterilizers are a type of gravity sterilizers,214729,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64328,30,Factors that can cause sterilant contact failure with the instrument are,214730,0,"a.	cleaning, loosely packed load",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64328,30,Factors that can cause sterilant contact failure with the instrument are,214731,1,"b.	conditioning, size and weight of the instrument",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64328,30,Factors that can cause sterilant contact failure with the instrument are,214732,2,"c.	solid bottom containers, exposure time",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64328,30,Factors that can cause sterilant contact failure with the instrument are,214733,3,"d.	crowded loads, clogged drain strainer",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64329,31,One of the most frequent causes of a clogged drain screen is,214734,0,"a.	tape",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64329,31,One of the most frequent causes of a clogged drain screen is,214735,1,"b.	wrapper particles",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64329,31,One of the most frequent causes of a clogged drain screen is,214736,2,"c.	poor stream quality",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64329,31,One of the most frequent causes of a clogged drain screen is,214737,3,"d.	malfunctioning baffle plate",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64330,32,After sterilization the load contents may take two hours or more to cool.,214738,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64330,32,After sterilization the load contents may take two hours or more to cool.,214739,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64331,33,Peel pouches should be placed ________________________________________ for sterilization.,214740,0,"a.	on edge, paper to plastic",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64331,33,Peel pouches should be placed ________________________________________ for sterilization.,214741,1,"b.	on edge, plastic to plastic",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64331,33,Peel pouches should be placed ________________________________________ for sterilization.,214742,2,"c.	placed flat with the plastic side up",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64331,33,Peel pouches should be placed ________________________________________ for sterilization.,214743,3,"d.	placed flat with the paper side up",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64332,34,Items with a standard steam sterilization cycle recommended by the manufacturer can be damaged if run in an extended cycle.,214744,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64332,34,Items with a standard steam sterilization cycle recommended by the manufacturer can be damaged if run in an extended cycle.,214745,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64333,35,How frequently should a sterilizer's strainer be removed and cleaned?,214746,0,"a.	daily",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64333,35,How frequently should a sterilizer's strainer be removed and cleaned?,214747,1,"b.	after each use",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64333,35,How frequently should a sterilizer's strainer be removed and cleaned?,214748,2,"c.	once weekly",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64333,35,How frequently should a sterilizer's strainer be removed and cleaned?,214749,3,"d.	only when the machine's operating control gauge indicates cleaning is necessary",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64334,36,Immediate use steam sterilization is the process to sterilize trays for future use.,214750,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64334,36,Immediate use steam sterilization is the process to sterilize trays for future use.,214751,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64335,37,Wood products should be sterilized in an extended steam cycle.,214752,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64335,37,Wood products should be sterilized in an extended steam cycle.,214753,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64336,38,When water is seen on the outside of a pack after sterilization the pack is considered safe to use if all other packs in the load are dry.,214754,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64336,38,When water is seen on the outside of a pack after sterilization the pack is considered safe to use if all other packs in the load are dry.,214755,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64337,39,Packs that are improperly packaged or loaded on the sterilizer cart frequently become wet packs.,214756,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64337,39,Packs that are improperly packaged or loaded on the sterilizer cart frequently become wet packs.,214757,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64338,40,Chapter 15:  Low-Temperature Sterilization<br> Woven reusable fabrics are the packaging of choice for ozone sterilization.,214758,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64338,40,Chapter 15:  Low-Temperature Sterilization<br> Woven reusable fabrics are the packaging of choice for ozone sterilization.,214759,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64339,41,Ethylene kills microorganisms by a process called oxidation.,214760,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64339,41,Ethylene kills microorganisms by a process called oxidation.,214761,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64340,42,"Ethylene oxide, hydrogen peroxide and ozone sterilization process must all be monitored using chemical, physical and biological monitors.",214762,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64340,42,"Ethylene oxide, hydrogen peroxide and ozone sterilization process must all be monitored using chemical, physical and biological monitors.",214763,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64341,43,"Ethylene oxide, hydrogen peroxide and ozone sterilization can all use the same packaging materials.",214764,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64341,43,"Ethylene oxide, hydrogen peroxide and ozone sterilization can all use the same packaging materials.",214765,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64342,44,Lumens should be moist when using hydrogen peroxide as a sterilizing agent.,214766,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64342,44,Lumens should be moist when using hydrogen peroxide as a sterilizing agent.,214767,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64343,45,Ethylene oxide is a toxic gas.,214768,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64343,45,Ethylene oxide is a toxic gas.,214769,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64344,46,Cellulose-containing packaging materials are not compatible with hydrogen peroxide sterilization.,214770,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64344,46,Cellulose-containing packaging materials are not compatible with hydrogen peroxide sterilization.,214771,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64345,47,Information about a device's compatibility with a specific sterilization process should be obtained from the device's manufacturer.,214772,0,TRUE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64345,47,Information about a device's compatibility with a specific sterilization process should be obtained from the device's manufacturer.,214773,1,FALSE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64346,48,An extended aeration cycle is required for items sterilized in ozone sterilization processes.,214774,0,TRUE,0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64346,48,An extended aeration cycle is required for items sterilized in ozone sterilization processes.,214775,1,FALSE,1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64347,49,Permissible exposure levels for low-temperature sterilization methods are established by the,214776,0,"a.	U.S. Food and Drug Administration",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64347,49,Permissible exposure levels for low-temperature sterilization methods are established by the,214777,1,"b.	Centers for Disease Control",0
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64347,49,Permissible exposure levels for low-temperature sterilization methods are established by the,214778,2,"c.	Occupational Safety and Health Administration",1
9863,Questions-0000-153,"SPD INTERNSHIP: TEST 4 CHAPTERS 5, 14, 15",n14050,64347,49,Permissible exposure levels for low-temperature sterilization methods are established by the,214779,3,"d.	Environmental Protection Agency",0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64303,0,How does the newborn appear on the Circumcision Dashboard?,214658,0,"A. The Admission Team documents ""Yes""ù in the Birth Information Powerform to the parents having plans for their newborn to be circumcised.",0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64303,0,How does the newborn appear on the Circumcision Dashboard?,214659,1,"B. The Anchor Nurse documents in Circumcision in iView ""Yes""ù to the parents having plans for their newborn to be circumcised.",0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64303,0,How does the newborn appear on the Circumcision Dashboard?,214660,2,C. All baby boys will automatically appear on the Circumcision Dashboard.,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64303,0,How does the newborn appear on the Circumcision Dashboard?,214661,3,D. Answers A or B are both correct.,1
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64304,1,"True or False: A newborn has all 8 green check marks on the circumcision dashboard, so the Anchor Nurse can assume the newborn is eligible for circumcision.",214662,0,TRUE,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64304,1,"True or False: A newborn has all 8 green check marks on the circumcision dashboard, so the Anchor Nurse can assume the newborn is eligible for circumcision.",214663,1,FALSE,1
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64305,2,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,214664,0,A. Before the Time-Out Procedure,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64305,2,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,214665,1,B. Each Shift,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64305,2,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,214666,2,C. As the different requirements are met,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64305,2,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,214667,3,D. If newborn's medical status changes,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64305,2,When should the Pre-Circumcision Checklist be reviewed and/or documented in by the Anchor Nurse?,214668,4,E. All the above,1
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64306,3,"It was documented in the Pre-Circumcision Checklist that the newborn was feeding well. Two shifts have since passed, and the newborn is no longer feeding well. The Pediatrician is notified, and writes a ""Hold Circ""ù order. The OB Provider then calls saying that they see the newborn has the 8 required green checks to be eligible for circumcision. What should the Anchor Nurse do?",214669,0,A. Allow the OB Provider to come circumcise the newborn.,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64306,3,"It was documented in the Pre-Circumcision Checklist that the newborn was feeding well. Two shifts have since passed, and the newborn is no longer feeding well. The Pediatrician is notified, and writes a ""Hold Circ""ù order. The OB Provider then calls saying that they see the newborn has the 8 required green checks to be eligible for circumcision. What should the Anchor Nurse do?",214670,1,"B. Inform the Provider that the newborn has a ""Hold Circ""ù order because they are no longer feeding well, and cannot be circumcised at this time.",1
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64306,3,"It was documented in the Pre-Circumcision Checklist that the newborn was feeding well. Two shifts have since passed, and the newborn is no longer feeding well. The Pediatrician is notified, and writes a ""Hold Circ""ù order. The OB Provider then calls saying that they see the newborn has the 8 required green checks to be eligible for circumcision. What should the Anchor Nurse do?",214671,2,C. None of the above,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64307,4,Which of the following is true?,214672,0,A. It is the responsibility of the Mother Baby Nurse to fill out the Pre-Circumcision Checklist.,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64307,4,Which of the following is true?,214673,1,B. It is the responsibility of the Anchor Nurse to fill out the Pre-Circumcision Checklist.,0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64307,4,Which of the following is true?,214674,2,"C. The Mother Baby Nurse is responsible for obtaining signed consent for circumcision procedure and notifying the Anchor Nurse informed consent has been obtained, informing the Anchor Nurse when newborn has their first void and updating the Anchor Nurse with any changes in newborn status.",0
9479,Elearning-0000-712,CERNER CIRCUMCISION DASHBOARD,n14051,64307,4,Which of the following is true?,214675,3,D. B&C,1
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64348,0,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,214780,0,a. Friction,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64348,0,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,214781,1,b. Shear,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64348,0,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,214782,2,c. Pressure,1
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64348,0,The main factors managed by multilayer sacral foam dressings to <u>prevent</u> against pressure injuries include all of the following except:,214783,3,d. Moisture,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64349,1,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,214784,0,a. Moisturize skin daily and right after bathing,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64349,1,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,214785,1,b. Some protectants may be for prevention while others may be for treatment,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64349,1,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,214786,2,c. Avoid rigorous scrubbing or rubbing of skin,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64349,1,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,214787,3,d. Barriers can protect the skin from excessive moisture,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64349,1,Essential steps of skin care to help assist with pressure injury prevention include all of the following except?,214788,4,e. Use cleansing products that are alkaline in nature,1
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64350,2,Skin protectants and liquid cyanoacrylates protect against?,214789,0,a. Adhesive,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64350,2,Skin protectants and liquid cyanoacrylates protect against?,214790,1,b. Friction,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64350,2,Skin protectants and liquid cyanoacrylates protect against?,214791,2,c. Moisture and incontinence,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64350,2,Skin protectants and liquid cyanoacrylates protect against?,214792,3,d. All of the above,1
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64350,2,Skin protectants and liquid cyanoacrylates protect against?,214793,4,e. None of the above,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64351,3,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,214794,0,a. Thorough skin inspection under and around a device is important to preventing these injuries,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64351,3,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,214795,1,b. These pressure injuries cannot be staged,1
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64351,3,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,214796,2,c. Devices should be assessed for proper fit,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64351,3,The Skin Champion Nurse is assessing a patient whose pressure injury is medical device related. Which of the following statements is false?,214797,3,d. Respiratory devices are common sources of injury,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64352,4,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,214798,0,a. The dressing can stay on for as long as it lasts without the skin being assessed,1
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64352,4,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,214799,1,b. The cost associated with the dressing,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64352,4,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,214800,2,c. The size and appropriateness of the dressing,0
9678,Elearning-0000-893,HAPI PREVENTION EDUCATION - AUGUST 2021 - PRESSURE INJURY PREVENTION - DEFENSE,n14052,64352,4,The Skin Champion Nurse is applying a multilayer sacral foam dressing for prevention of pressure injuries. Which is NOT a consideration they should think about?,214801,3,d. The ability of the dressing to manage microclimate and friction,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64395,0,Please list the location for this activity.,214972,0,Atlanta,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64395,0,Please list the location for this activity.,214973,1,Cherokee,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64395,0,Please list the location for this activity.,214974,2,Forsyth,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64395,0,Please list the location for this activity.,214975,3,Other,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64396,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214976,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64396,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214977,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64396,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214978,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64396,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214979,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64396,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214980,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64397,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214981,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64397,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214982,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64397,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214983,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64397,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214984,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64397,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214985,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64398,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214986,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64398,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214987,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64398,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214988,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64398,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214989,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64398,3,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214990,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64399,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214991,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64399,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214992,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64399,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214993,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64399,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214994,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64399,4,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214995,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64400,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214996,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64400,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214997,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64400,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214998,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64400,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214999,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64400,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,215000,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64401,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,215001,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64401,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,215002,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64401,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,215003,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64401,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,215004,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64401,6,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,215005,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64402,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,215006,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64402,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,215007,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64402,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,215008,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64402,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,215009,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64402,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,215010,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64403,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,215011,0,Strongly Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64403,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,215012,1,Agree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64403,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,215013,2,No Opinion,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64403,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,215014,3,Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64403,8,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity.</ol>,215015,4,Strongly Disagree,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64404,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",215016,0,Excellent,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64404,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",215017,1,Very Good,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64404,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",215018,2,Good,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64404,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",215019,3,Fair,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64404,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",215020,4,Poor,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64404,9,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",215021,5,N/A,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64405,10,"Overall, this activity was:",215022,0,Excellent,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64405,10,"Overall, this activity was:",215023,1,Very Good,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64405,10,"Overall, this activity was:",215024,2,Good,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64405,10,"Overall, this activity was:",215025,3,Fair,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64405,10,"Overall, this activity was:",215026,4,Poor,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64406,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",215027,0,Yes,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64406,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",215028,1,No,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64406,11,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",215029,2,N/A,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64409,14,How would you improve this class (check all that apply)?,215030,0,Reduce content covered in class,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64409,14,How would you improve this class (check all that apply)?,215031,1,Increase content covered in class,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64409,14,How would you improve this class (check all that apply)?,215032,2,Update content covered in class,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64409,14,How would you improve this class (check all that apply)?,215033,3,Improve the instructional methods,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64409,14,How would you improve this class (check all that apply)?,215034,4,Make course activities more stimulating,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64409,14,How would you improve this class (check all that apply)?,215035,5,Slow the pace of the class,0
9906,Questions-0000-40,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- BMT ONLY 2.3) 8-6-21,n14055,64409,14,How would you improve this class (check all that apply)?,215036,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64372,0,Please list the location for this activity.,214877,0,Atlanta,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64372,0,Please list the location for this activity.,214878,1,Cherokee,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64372,0,Please list the location for this activity.,214879,2,Forsyth,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64372,0,Please list the location for this activity.,214880,3,Other,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64373,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214881,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64373,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214882,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64373,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214883,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64373,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214884,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64373,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214885,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64374,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214886,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64374,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214887,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64374,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214888,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64374,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214889,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64374,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214890,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64375,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214891,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64375,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214892,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64375,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214893,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64375,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214894,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64375,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214895,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64376,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214896,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64376,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214897,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64376,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214898,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64376,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214899,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64376,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214900,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64377,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",214901,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64377,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",214902,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64377,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",214903,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64377,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",214904,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64377,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasopressors.</ol>",214905,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64378,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",214906,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64378,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",214907,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64378,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",214908,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64378,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",214909,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64378,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasopressors.</ol>",214910,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64379,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",214911,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64379,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",214912,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64379,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",214913,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64379,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",214914,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64379,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for sedatives, hypnotics, paralytics and narcotics.</ol>",214915,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64380,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",214916,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64380,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",214917,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64380,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",214918,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64380,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",214919,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64380,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for sedatives, hypnotics, paralytics and narcotics.</ol>",214920,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64381,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214921,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64381,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214922,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64381,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214923,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64381,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214924,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64381,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214925,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64382,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214926,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64382,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214927,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64382,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214928,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64382,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214929,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64382,10,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214930,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64383,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214931,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64383,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214932,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64383,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214933,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64383,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214934,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64383,11,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214935,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64384,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214936,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64384,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214937,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64384,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214938,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64384,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214939,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64384,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214940,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64385,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214941,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64385,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214942,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64385,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214943,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64385,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214944,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64385,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214945,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64386,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214946,0,Strongly Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64386,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214947,1,Agree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64386,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214948,2,No Opinion,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64386,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214949,3,Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64386,14,<OL><B>SETTING</B></OL> <OL>Facility was appropriate for the activity.</ol>,214950,4,Strongly Disagree,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64387,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214951,0,Excellent,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64387,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214952,1,Very Good,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64387,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214953,2,Good,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64387,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214954,3,Fair,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64387,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214955,4,Poor,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64387,15,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214956,5,N/A,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64388,16,"Overall, this activity was:",214957,0,Excellent,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64388,16,"Overall, this activity was:",214958,1,Very Good,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64388,16,"Overall, this activity was:",214959,2,Good,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64388,16,"Overall, this activity was:",214960,3,Fair,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64388,16,"Overall, this activity was:",214961,4,Poor,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64389,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214962,0,Yes,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64389,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214963,1,No,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64389,17,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214964,2,N/A,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64392,20,How would you improve this class (check all that apply)?,214965,0,Reduce content covered in class,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64392,20,How would you improve this class (check all that apply)?,214966,1,Increase content covered in class,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64392,20,How would you improve this class (check all that apply)?,214967,2,Update content covered in class,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64392,20,How would you improve this class (check all that apply)?,214968,3,Improve the instructional methods,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64392,20,How would you improve this class (check all that apply)?,214969,4,Make course activities more stimulating,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64392,20,How would you improve this class (check all that apply)?,214970,5,Slow the pace of the class,0
9913,Questions-0000-47,DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY- ED & ICU ONLY 5.5) 8-6-21,n14054,64392,20,How would you improve this class (check all that apply)?,214971,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64353,0,Please list the location for this activity.,214802,0,Atlanta,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64353,0,Please list the location for this activity.,214803,1,Cherokee,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64353,0,Please list the location for this activity.,214804,2,Forsyth,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64353,0,Please list the location for this activity.,214805,3,Other,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64354,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214806,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64354,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214807,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64354,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214808,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64354,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214809,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64354,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for Diuretics, anti-arrhythmics and inotropes.</ol>",214810,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64355,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214811,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64355,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214812,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64355,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214813,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64355,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214814,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64355,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for diuretics, anti-arrhythmics and inotropes.</ol>",214815,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64356,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214816,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64356,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214817,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64356,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214818,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64356,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214819,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64356,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to discuss the mechanism of action, indications and normal dosing for vasodilators.</ol>",214820,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64357,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214821,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64357,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214822,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64357,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214823,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64357,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214824,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64357,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe titration, side effects, monitoring parameters and nursing precautions for vasodilators. </ol>",214825,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64358,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214826,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64358,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214827,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64358,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214828,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64358,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214829,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64358,5,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,214830,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64359,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214831,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64359,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214832,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64359,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214833,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64359,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214834,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64359,6,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",214835,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64360,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214836,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64360,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214837,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64360,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214838,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64360,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214839,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64360,7,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to providing care for patients on continuous IV drips.</OL>,214840,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64361,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214841,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64361,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214842,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64361,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214843,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64361,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214844,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64361,8,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered has increased my knowledge and confidence as it relates to monitoring and titrating medications administered via continuous IV drips.</OL>,214845,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64362,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214846,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64362,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214847,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64362,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214848,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64362,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214849,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64362,9,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<ol>,214850,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64363,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,214851,0,Strongly Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64363,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,214852,1,Agree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64363,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,214853,2,No Opinion,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64363,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,214854,3,Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64363,10,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for the activity</ol>,214855,4,Strongly Disagree,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64364,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214857,0,Very Good,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64364,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214858,1,Good,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64364,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214859,2,Fair,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64364,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214860,3,Poor,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64364,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214856,4,Excellent,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64364,11,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Michele Aldoretta, MSN, RN, CCRN</ol>",214861,5,N/A,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64365,12,"Overall, this activity was:",214862,0,Excellent,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64365,12,"Overall, this activity was:",214863,1,Very Good,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64365,12,"Overall, this activity was:",214864,2,Good,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64365,12,"Overall, this activity was:",214865,3,Fair,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64365,12,"Overall, this activity was:",214866,4,Poor,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64366,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214867,0,Yes,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64366,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214868,1,No,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64366,13,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",214869,2,N/A,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64369,16,How would you improve this class (check all that apply)?,214870,0,Reduce content covered in class,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64369,16,How would you improve this class (check all that apply)?,214871,1,Increase content covered in class,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64369,16,How would you improve this class (check all that apply)?,214872,2,Update content covered in class,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64369,16,How would you improve this class (check all that apply)?,214873,3,Improve the instructional methods,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64369,16,How would you improve this class (check all that apply)?,214874,4,Make course activities more stimulating,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64369,16,How would you improve this class (check all that apply)?,214875,5,Slow the pace of the class,0
9919,Questions-0000-53,"DRIP MANAGEMENT FOR SPECIALTY AREAS (EVALUATION SURVEY-PCU, PCCU, PTCU & NPCU ONLY 3.1 ) 8-6-21",n14053,64369,16,How would you improve this class (check all that apply)?,214876,6,"Nothing: (appropriate speakers, content, facility, etc.)",0
9692,Elearning-0000-906,2021 EMOTIONAL SUPPORT FOR STAFF CBL,n14058,64413,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Emotional Support  For Staff CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",215039,0,TRUE,1
9692,Elearning-0000-906,2021 EMOTIONAL SUPPORT FOR STAFF CBL,n14058,64413,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the 2021 Emotional Support  For Staff CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",215040,1,FALSE,0
9699,Elearning-0000-912,CLEANLINESS IN THE MRI ROOM,n14059,64414,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the Cleanliness in the MRI Room CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",215041,0,TRUE,1
9699,Elearning-0000-912,CLEANLINESS IN THE MRI ROOM,n14059,64414,0,"For questions about these statements, contact your manager or clinician.<br><br> I have reviewed the Cleanliness in the MRI Room CBL content.<br> I understand that I am responsible for the information.<br> I know where and how to get my questions answered about this topic.<br> I understand that I should stop in the face of uncertainty and ask for clarification.<br>",215042,1,FALSE,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64464,0,Please list the location for this activity.,215209,0,Atlanta,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64464,0,Please list the location for this activity.,215210,1,Forsyth,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64464,0,Please list the location for this activity.,215211,2,Cherokee,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64464,0,Please list the location for this activity.,215212,3,Other,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64465,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",215213,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64465,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",215214,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64465,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",215215,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64465,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",215216,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64465,1,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to describe the internal structures and functions of the heart. </ol>",215217,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64466,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",215218,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64466,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",215219,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64466,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",215220,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64466,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",215221,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64466,2,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to understand lead placement and its importance in EKG interpretation.</ol>",215222,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64467,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",215223,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64467,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",215224,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64467,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",215225,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64467,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",215226,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64467,3,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to verbalize an organized approach to the assessment of EKG rhythm strip tracings.<ol>",215227,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64468,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",215228,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64468,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",215229,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64468,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",215230,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64468,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",215231,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64468,4,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of normal sinus rhythm. </ol>",215232,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64469,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",215233,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64469,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",215234,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64469,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",215235,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64469,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",215236,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64469,5,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the SA node and nursing implications.</ol>",215237,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64470,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",215238,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64470,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",215239,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64470,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",215240,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64470,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",215241,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64470,6,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the atria and nursing implications.</ol>",215242,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64471,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",215243,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64471,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",215244,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64471,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",215245,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64471,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",215246,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64471,7,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the AV node and nursing implications </ol>",215247,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64472,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",215248,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64472,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",215249,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64472,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",215250,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64472,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",215251,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64472,8,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics of dysrhythmias originating in the ventricles and nursing implications.</ol>",215252,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64473,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",215253,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64473,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",215254,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64473,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",215255,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64473,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",215256,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64473,9,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify the defining characteristics for conduction defects and nursing implications. </ol>",215257,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64474,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",215258,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64474,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",215259,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64474,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",215260,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64474,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",215261,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64474,10,"<ol><b>LEARNING OBJECTIVES</b></ol> <ol>After attending this activity, I am better able to identify pacemaker rhythms on EKG strips.<ol>",215262,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64475,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",215263,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64475,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",215264,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64475,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",215265,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64475,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",215266,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64475,11,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented has increased my knowledge of electrocardiogram monitoring, interpretation and ways to initiate the appropriate nursing and medical response for patients experiencing dysrhythmias.</OL>",215267,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64476,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,215268,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64476,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,215269,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64476,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,215270,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64476,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,215271,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64476,12,<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content presented will help me to improve patient care.</OL>,215272,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64477,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,215273,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64477,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,215274,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64477,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,215275,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64477,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,215276,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64477,13,<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was free of commercial bias.<OL>,215277,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64478,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",215278,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64478,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",215279,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64478,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",215280,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64478,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",215281,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64478,14,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>The content covered is useful, timely, and relevant to my practice.</OL>",215282,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64479,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",215283,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64479,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",215284,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64479,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",215285,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64479,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",215286,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64479,15,"<OL><B>ACTIVITY CONTENT</B></OL> <OL>This activity was balanced, objective and scientifically rigorous.</ol>",215287,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64480,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,215288,0,Strongly Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64480,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,215289,1,Agree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64480,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,215290,2,No Opinion,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64480,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,215291,3,Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64480,16,<OL><B>SETTING</B></OL> <OL>Facility or online platform was appropriate for this activity</ol>,215292,4,Strongly Disagree,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64481,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",215293,0,Excellent,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64481,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",215294,1,Very Good,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64481,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",215295,2,Good,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64481,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",215296,3,Fair,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64481,17,"<ol><b>EFFECTIVENESS OF SPEAKER</B></OL>  <ol>Please rate the effectiveness of Dina McDonald, RN, BSN CCRN-K </ol>",215297,4,Poor,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64482,18,"Overall, this activity was:",215298,0,Excellent,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64482,18,"Overall, this activity was:",215299,1,Very Good,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64482,18,"Overall, this activity was:",215300,2,Good,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64482,18,"Overall, this activity was:",215301,3,Fair,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64482,18,"Overall, this activity was:",215302,4,Poor,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64483,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",215303,0,Yes,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64483,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",215304,1,No,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64483,19,"<ol><b>ACTIVITY OUTCOMES</B></OL> <OL>Has this activity closed gaps in your knowledge, skill, or practice?",215305,2,N/A,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64486,22,How would you improve this class?,215306,0,Reduce content covered in class,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64486,22,How would you improve this class?,215307,1,Increase content covered in class,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64486,22,How would you improve this class?,215308,2,Update content covered in class,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64486,22,How would you improve this class?,215309,3,Improve the instructional methods,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64486,22,How would you improve this class?,215310,4,Make course activities more stimulating,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64486,22,How would you improve this class?,215311,5,Slow the pace of the class,0
9894,Questions-0000-28,BASIC DYSRHYTHMIA INTERPRETATION REFRESHER ( EVALUATION SURVEY) 8-9-21,n14063,64486,22,How would you improve this class?,215312,6,"No improvements needed (appropriate content, instructor, facility, etc.)",0
